IL-2 XX-d NE
gene xxx NE
expression xxx NE
and xxx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
through xxx NE
CD28 XXdd protein
requires xxx NE
reactive xxx NE
oxygen xxx NE
production xxx NE
by xx NE
5-lipoxygenase d-xxx protein
. . NE

Activation Xxxx NE
of xx NE
the xxx NE
CD28 XXdd protein_B
surface xxx protein_M
receptor xxx protein_E
provides xxx NE
a x NE
major xxx NE
costimulatory xxx NE
signal xxx NE
for xxx NE
T X NE
cell xxx NE
activation xxx NE
resulting xxx NE
in xx NE
enhanced xxx NE
production xxx NE
of xx NE
interleukin-2 xxx-d protein
( ( NE
IL-2 XX-d protein
) ) NE
and xxx NE
cell xxx NE
proliferation xxx NE
. . NE

In Xx NE
primary xxx cell_type_B
T X cell_type_M
lymphocytes xxx cell_type_E
we xx NE
show xxx NE
that xxx NE
CD28 XXdd protein
ligation xxx NE
leads xxx NE
to xx NE
the xxx NE
rapid xxx NE
intracellular xxx NE
formation xxx NE
of xx NE
reactive xxx NE
oxygen xxx NE
intermediates xxx NE
( ( NE
ROIs XXXx NE
) ) NE
which xxx NE
are xxx NE
required xxx NE
for xxx NE
CD28 XXdd NE
-mediated -xxx NE
activation xxx NE
of xx NE
the xxx NE
NF-kappa XX-xxx NE
B X NE
/ / NE
CD28 XXdd NE
-responsive -xxx NE
complex xxx NE
and xxx NE
IL-2 XX-d NE
expression xxx NE
. . NE

Delineation Xxxx NE
of xx NE
the xxx NE
CD28 XXdd NE
signaling xxx NE
cascade xxx NE
was xxx NE
found xxx NE
to xx NE
involve xxx NE
protein xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
, , NE
followed xxx NE
by xx NE
the xxx NE
activation xxx NE
of xx NE
phospholipase xxx protein_B
A2 Xd protein_E
and xxx NE
5-lipoxygenase d-xxx protein
. . NE

Our Xxx NE
data xxx NE
suggest xxx NE
that xxx NE
lipoxygenase xxx protein_B
metabolites xxx protein_E
activate xxx NE
ROI XXX NE
formation xxx NE
which xxx NE
then xxx NE
induce xxx NE
IL-2 XX-d protein
expression xxx NE
via xxx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
. . NE

These Xxxx NE
findings xxx NE
should xxx NE
be xx NE
useful xxx NE
for xxx NE
therapeutic xxx NE
strategies xxx NE
and xxx NE
the xxx NE
development xxx NE
of xx NE
immunosuppressants xxx NE
targeting xxx NE
the xxx NE
CD28 XXdd NE
costimulatory xxx NE
pathway xxx NE
. . NE

The Xxx NE
peri-kappa xxx-xxx DNA_B
B X DNA_M
site xxx DNA_E
mediates xxx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
2 d NE
enhancer xxx NE
activation xxx NE
in xx NE
monocytes xxx cell_type
but xxx NE
not xxx NE
in xx NE
T X cell_type_B
cells xxx cell_type_E
. . NE

Human Xxxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
2 d NE
( ( NE
HIV-2 XXX-d NE
) ) NE
, , NE
like xxx NE
HIV-1 XXX-d NE
, , NE
causes xxx NE
AIDS XXXX NE
and xxx NE
is xx NE
associated xxx NE
with xxx NE
AIDS XXXX NE
cases xxx NE
primarily xxx NE
in xx NE
West Xxxx NE
Africa Xxxx NE
. . NE

HIV-1 XXX-d NE
and xxx NE
HIV-2 XXX-d NE
display xxx NE
significant xxx NE
differences xxx NE
in xx NE
nucleic xxx DNA_B
acid xxx DNA_M
sequence xxx DNA_E
and xxx NE
in xx NE
the xxx NE
natural xxx NE
history xxx NE
of xx NE
clinical xxx NE
disease xxx NE
. . NE

Consistent Xxxx NE
with xxx NE
these xxx NE
differences xxx NE
, , NE
we xx NE
have xxx NE
previously xxx NE
demonstrated xxx NE
that xxx NE
the xxx NE
enhancer/promoter xxx/xxx DNA_B
region xxx DNA_E
of xx NE
HIV-2 XXX-d NE
functions xxx NE
quite xxx NE
differently xxx NE
from xxx NE
that xxx NE
of xx NE
HIV-1 XXX-d NE
. . NE

Whereas Xxxx NE
activation xxx NE
of xx NE
the xxx NE
HIV-1 XXX-d DNA_B
enhancer xxx DNA_E
following xxx NE
T-cell X-xxx NE
stimulation xxx NE
is xx NE
mediated xxx NE
largely xxx NE
through xxx NE
binding xxx NE
of xx NE
the xxx NE
transcription xxx protein_B
factor xxx protein_E
NF-kappa XX-xxx protein_B
B X protein_E
to xx NE
two xxx NE
adjacent xxx NE
kappa xxx DNA_B
B X DNA_M
sites xxx DNA_E
in xx NE
the xxx NE
HIV-1 XXX-d DNA_B
long xxx DNA_M
terminal xxx DNA_M
repeat xxx DNA_E
, , NE
activation xxx NE
of xx NE
the xxx NE
HIV-2 XXX-d DNA_B
enhancer xxx DNA_E
in xx NE
monocytes xxx cell_type
and xxx NE
T X cell_type_B
cells xxx cell_type_E
is xx NE
dependent xxx NE
on xx NE
four xxx NE
cis-acting xxx-xxx DNA_B
elements xxx DNA_E
: : NE
a x NE
single xxx NE
kappa xxx DNA_B
B X DNA_M
site xxx DNA_E
, , NE
two xxx NE
purine-rich xxx-xxx DNA_B
binding xxx DNA_M
sites xxx DNA_E
, , NE
PuB1 XxXd DNA
and xxx NE
PuB2 XxXd DNA
, , NE
and xxx NE
a x NE
pets xxx DNA_B
site xxx DNA_E
. . NE

We Xx NE
have xxx NE
now xxx NE
identified xxx NE
a x NE
novel xxx NE
cis-acting xxx-xxx DNA_B
element xxx DNA_E
within xxx NE
the xxx NE
HIV-2 XXX-d DNA_B
enhancer xxx DNA_E
, , NE
immediately xxx NE
upstream xxx NE
of xx NE
the xxx NE
kappa xxx DNA_B
B X DNA_M
site xxx DNA_E
, , NE
designated xxx NE
peri-kappa xxx-xxx DNA_B
B X DNA_E
. . NE

This Xxxx NE
site xxx NE
is xx NE
conserved xxx NE
among xxx NE
isolates xxx NE
of xx NE
HIV-2 XXX-d NE
and xxx NE
the xxx NE
closely xxx NE
related xxx NE
simian xxx NE
immunodeficiency xxx NE
virus xxx NE
, , NE
and xxx NE
transfection xxx NE
assays xxx NE
show xxx NE
this xxx NE
site xxx NE
to xx NE
mediate xxx NE
HIV-2 XXX-d NE
enhancer xxx NE
activation xxx NE
following xxx NE
stimulation xxx NE
of xx NE
monocytic xxx NE
but xxx NE
not xxx NE
T-cell X-xxx NE
lines xxx NE
. . NE

This Xxxx NE
is xx NE
the xxx NE
first xxx NE
description xxx NE
of xx NE
an xx NE
HIV-2 XXX-d DNA_B
enhancer xxx DNA_M
element xxx DNA_E
which xxx NE
displays xxx NE
such xxx NE
monocyte xxx NE
specificity xxx NE
, , NE
and xxx NE
no xx NE
comparable xxx NE
enhancer xxx DNA_B
element xxx DNA_E
has xxx NE
been xxx NE
clearly xxx NE
defined xxx NE
for xxx NE
HIV-1 XXX-d NE
. . NE

While Xxxx NE
a x NE
nuclear xxx protein_B
factor xxx protein_E
(s) (x) NE
from xxx NE
both xxx NE
peripheral xxx cell_type_B
blood xxx cell_type_M
monocytes xxx cell_type_E
and xxx NE
T X cell_type_B
cells xxx cell_type_E
binds xxx NE
the xxx NE
peri-kappa xxx-xxx DNA_B
B X DNA_M
site xxx DNA_E
, , NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assays xxx NE
suggest xxx NE
that xxx NE
either xxx NE
a x NE
different xxx NE
protein xxx NE
binds xxx NE
to xx NE
this xxx NE
site xxx NE
in xx NE
monocytes xxx cell_type
versus xxx NE
T X cell_type_B
cells xxx cell_type_E
or xx NE
that xxx NE
the xxx NE
protein xxx NE
recognizing xxx NE
this xxx NE
enhancer xxx DNA_B
element xxx DNA_E
undergoes xxx NE
differential xxx NE
modification xxx NE
in xx NE
monocytes xxx cell_type
and xxx NE
T X cell_type_B
cells xxx cell_type_E
, , NE
thus xxx NE
supporting xxx NE
the xxx NE
transfection xxx NE
data xxx NE
. . NE

Further Xxxx NE
, , NE
while xxx NE
specific xxx NE
constitutive xxx NE
binding xxx NE
to xx NE
the xxx NE
peri-kappa xxx-xxx DNA_B
B X DNA_M
site xxx DNA_E
is xx NE
seen xxx NE
in xx NE
monocytes xxx cell_type
, , NE
stimulation xxx NE
with xxx NE
phorbol xxx NE
esters xxx NE
induces xxx NE
additional xxx NE
, , NE
specific xxx NE
binding xxx NE
. . NE

Understanding Xxxx NE
the xxx NE
monocyte-specific xxx-xxx NE
function xxx NE
of xx NE
the xxx NE
peri-kappa xxx-xxx protein_B
B X protein_M
factor xxx protein_E
may xxx NE
ultimately xxx NE
provide xxx NE
insight xxx NE
into xxx NE
the xxx NE
different xxx NE
role xxx NE
monocytes xxx cell_type
and xxx NE
T X cell_type_B
cells xxx cell_type_E
play xxx NE
in xx NE
HIV XXX NE
pathogenesis xxx NE
. . NE

E1A XdX NE
gene xxx NE
expression xxx NE
induces xxx NE
susceptibility xxx NE
to xx NE
killing xxx NE
by xx NE
NK XX cell_type_B
cells xxx cell_type_E
following xxx NE
immortalization xxx NE
but xxx NE
not xxx NE
adenovirus xxx NE
infection xxx NE
of xx NE
human xxx cell_type_B
cells xxx cell_type_E
. . NE

Adenovirus Xxxx NE
(Ad) (Xx) NE
infection xxx NE
and xxx NE
E1A XdX NE
transfection xxx NE
were xxx NE
used xxx NE
to xx NE
model xxx NE
changes xxx NE
in xx NE
susceptibility xxx NE
to xx NE
NK XX NE
cell xxx NE
killing xxx NE
caused xxx NE
by xx NE
transient xxx NE
vs xx NE
stable xxx NE
E1A XdX NE
expression xxx NE
in xx NE
human xxx cell_type_B
cells xxx cell_type_E
. . NE

Only Xxxx NE
stably xxx NE
transfected xxx cell_line_B
target xxx cell_line_M
cells xxx cell_line_E
exhibited xxx NE
cytolytic xxx NE
susceptibility xxx NE
, , NE
despite xxx NE
expression xxx NE
of xx NE
equivalent xxx NE
levels xxx NE
of xx NE
E1A XdX protein_B
proteins xxx protein_E
in xx NE
Ad-infected Xx-xxx cell_line_B
targets xxx cell_line_E
. . NE

The Xxx NE
inability xxx NE
of xx NE
E1A XdX DNA_B
gene xxx DNA_E
products xxx NE
to xx NE
induce xxx NE
cytolytic xxx NE
susceptibility xxx NE
during xxx NE
infection xxx NE
was xxx NE
not xxx NE
explained xxx NE
by xx NE
an xx NE
inhibitory xxx NE
effect xxx NE
of xx NE
viral xxx NE
infection xxx NE
on xx NE
otherwise xxx NE
susceptible xxx NE
target xxx cell_type_B
cells xxx cell_type_E
or xx NE
by xx NE
viral xxx DNA_B
gene xxx DNA_E
effects xxx NE
on xx NE
class xxx NE
I X NE
MHC XXX NE
antigen xxx NE
expression xxx NE
on xx NE
target xxx cell_type_B
cells xxx cell_type_E
. . NE

This Xxxx NE
differential xxx NE
effect xxx NE
of xx NE
E1A XdX NE
expression xxx NE
on xx NE
the xxx NE
cytolytic xxx NE
phenotypes xxx NE
of xx NE
infected xxx NE
and xxx NE
stably xxx NE
transfected xxx NE
human xxx cell_type_B
cells xxx cell_type_E
suggests xxx NE
that xxx NE
human xxx cell_type_B
NK XX cell_type_M
cells xxx cell_type_E
provide xxx NE
an xx NE
effective xxx NE
immunologic xxx NE
barrier xxx NE
against xxx NE
the xxx NE
in xx NE
vivo xxx NE
survival xxx NE
and xxx NE
neoplastic xxx NE
progression xxx NE
of xx NE
E1A-immortalized XdX-xxx cell_line_B
cells xxx cell_line_E
that xxx NE
may xxx NE
emerge xxx NE
from xxx NE
the xxx NE
reservoir xxx NE
of xx NE
persistently xxx cell_type_B
infected xxx cell_type_M
cells xxx cell_type_E
in xx NE
the xxx NE
human xxx NE
host xxx NE
. . NE

Distinct Xxxx NE
signaling xxx NE
properties xxx NE
identify xxx NE
functionally xxx NE
different xxx NE
CD4 XXd protein_B
epitopes xxx protein_E
. . NE

The Xxx NE
CD4 XXd protein_B
coreceptor xxx protein_E
interacts xxx NE
with xxx NE
non-polymorphic xxx-xxx protein_B
regions xxx protein_E
of xx NE
major xxx protein_B
histocompatibility xxx protein_M
complex xxx protein_M
class xxx protein_M
II XX protein_M
molecules xxx protein_E
on xx NE
antigen-presenting xxx-xxx cell_type_B
cells xxx cell_type_E
and xxx NE
contributes xxx NE
to xx NE
T X NE
cell xxx NE
activation xxx NE
. . NE

We Xx NE
have xxx NE
investigated xxx NE
the xxx NE
effect xxx NE
of xx NE
CD4 XXd NE
triggering xxx NE
on xx NE
T X NE
cell xxx NE
activating xxx NE
signals xxx NE
in xx NE
a x NE
lymphoma xxx NE
model xxx NE
using xxx NE
monoclonal xxx NE
antibodies xxx NE
( ( NE
mAb xXx NE
) ) NE
which xxx NE
recognize xxx NE
different xxx NE
CD4 XXd NE
epitopes xxx NE
. . NE

We Xx NE
demonstrate xxx NE
that xxx NE
CD4 XXd NE
triggering xxx NE
delivers xxx NE
signals xxx NE
capable xxx NE
of xx NE
activating xxx NE
the xxx NE
NF-AT XX-XX protein_B
transcription xxx protein_M
factor xxx protein_E
which xxx NE
is xx NE
required xxx NE
for xxx NE
interleukin-2 xxx-d NE
gene xxx NE
expression xxx NE
. . NE

Whereas Xxxx NE
different xxx NE
anti-CD4 xxx-XXd protein_B
mAb xXx protein_E
or xx NE
HIV-1 XXX-d protein_B
gp120 xxddd protein_E
could xxx NE
all xxx NE
trigger xxx NE
activation xxx NE
of xx NE
the xxx NE
protein xxx protein_B
tyrosine xxx protein_M
kinases xxx protein_E
p56lck xddxxx protein
and xxx NE
p59fyn xddxxx protein
and xxx NE
phosphorylation xxx NE
of xx NE
the xxx NE
Shc Xxx protein_B
adaptor xxx protein_M
protein xxx protein_E
, , NE
which xxx NE
mediates xxx NE
signals xxx NE
to xx NE
Ras Xxx protein
, , NE
they xxx NE
differed xxx NE
significantly xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
activate xxx NE
NF-AT XX-XX protein
. . NE

Lack Xxxx NE
of xx NE
full xxx NE
activation xxx NE
of xx NE
NF-AT XX-XX protein
could xxx NE
be xx NE
correlated xxx NE
to xx NE
a x NE
dramatically xxx NE
reduced xxx NE
capacity xxx NE
to xx NE
induce xxx NE
calcium xxx NE
flux xxx NE
and xxx NE
could xxx NE
be xx NE
complemented xxx NE
with xxx NE
a x NE
calcium xxx NE
ionophore xxx NE
. . NE

The Xxx NE
results xxx NE
identify xxx NE
functionally xxx NE
distinct xxx NE
epitopes xxx protein
on xx NE
the xxx NE
CD4 XXd protein_B
coreceptor xxx protein_E
involved xxx NE
in xx NE
activation xxx NE
of xx NE
the xxx NE
Ras Xxx NE
/protein /xxx NE
kinase xxx NE
C X NE
and xxx NE
calcium xxx NE
pathways xxx NE
. . NE

Ligand-dependent Xxxx-xxx NE
repression xxx NE
of xx NE
the xxx NE
erythroid xxx protein_B
transcription xxx protein_M
factor xxx protein_E
GATA-1 XXXX-d protein
by xx NE
the xxx NE
estrogen xxx protein_B
receptor xxx protein_E
. . NE

High-dose Xxxx-xxx NE
estrogen xxx NE
administration xxx NE
induces xxx NE
anemia xxx NE
in xx NE
mammals xxx NE
. . NE

In Xx NE
chickens xxx NE
, , NE
estrogens xxx NE
stimulate xxx NE
outgrowth xxx NE
of xx NE
bone xxx cell_type_B
marrow-derived xxx-xxx cell_type_M
erythroid xxx cell_type_M
progenitor xxx cell_type_M
cells xxx cell_type_E
and xxx NE
delay xxx NE
their xxx NE
maturation xxx NE
. . NE

This Xxxx NE
delay xxx NE
is xx NE
associated xxx NE
with xxx NE
down-regulation xxx-xxx NE
of xx NE
many xxx NE
erythroid xxx DNA_B
cell-specific xxx-xxx DNA_M
genes xxx DNA_E
, , NE
including xxx NE
alpha-globin xxx-xxx DNA_B
and xxx DNA_M
beta-globin xxx-xxx DNA_E
H5 Xd NE
. . DNA

We Xx NE
show xxx NE
here xxx NE
that xxx NE
estrogens xxx NE
also xxx NE
reduce xxx NE
the xxx NE
number xxx NE
of xx NE
erythroid xxx cell_type_B
progenitor xxx cell_type_M
cells xxx cell_type_E
in xx NE
primary xxx cell_line_B
human xxx cell_line_M
bone xxx cell_line_M
marrow xxx cell_line_M
cultures xxx cell_line_E
. . NE

To Xx NE
address xxx NE
potential xxx NE
mechanisms xxx NE
by xx NE
which xxx NE
estrogens xxx NE
suppress xxx NE
erythropoiesis xxx NE
, , NE
we xx NE
have xxx NE
examined xxx NE
their xxx NE
effects xxx NE
on xx NE
GATA-1 XXXX-d protein
, , NE
an xx NE
erythroid xxx protein_B
transcription xxx protein_M
factor xxx protein_E
that xxx NE
participates xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
the xxx NE
majority xxx NE
of xx NE
erythroid xxx DNA_B
cell-specific xxx-xxx DNA_M
genes xxx DNA_E
and xxx NE
is xx NE
necessary xxx NE
for xxx NE
full xxx NE
maturation xxx NE
of xx NE
erythrocytes xxx cell_type
. . NE

We Xx NE
demonstrate xxx NE
that xxx NE
the xxx NE
transcriptional xxx NE
activity xxx NE
of xx NE
GATA-1 XXXX-d protein
is xx NE
strongly xxx NE
repressed xxx NE
by xx NE
the xxx NE
estrogen xxx protein_B
receptor xxx protein_E
( ( NE
ER XX protein
) ) NE
in xx NE
a x NE
ligand-dependent xxx-xxx NE
manner xxx NE
and xxx NE
that xxx NE
this xxx NE
repression xxx NE
is xx NE
reversible xxx NE
in xx NE
the xxx NE
presence xxx NE
of xx NE
4-hydroxytamoxifen d-xxx NE
. . NE

ER XX NE
-mediated -xxx NE
repression xxx NE
of xx NE
GATA-1 XXXX-d NE
activity xxx NE
occurs xxx NE
on xx NE
an xx NE
artificial xxx NE
promoter xxx NE
containing xxx NE
a x NE
single xxx NE
GATA-binding XXXX-xxx NE
site xxx NE
, , NE
as xx NE
well xxx NE
as xx NE
in xx NE
the xxx NE
context xxx NE
of xx NE
an xx NE
intact xxx NE
promoter xxx NE
which xxx NE
is xx NE
normally xxx NE
regulated xxx NE
by xx NE
GATA-1 XXXX-d NE
. . NE

GATA-1 XXXX-d protein
and xxx NE
ER XX protein
bind xxx NE
to xx NE
each xxx NE
other xxx NE
in xx NE
vitro xxx NE
in xx NE
the xxx NE
absence xxx NE
of xx NE
DNA XXX NE
. . NE

In Xx NE
coimmunoprecipitation xxx NE
experiments xxx NE
using xxx NE
transfected xxx NE
COS XXX cell_line_B
cells xxx cell_line_E
, , NE
GATA-1 XXXX-d protein
and xxx NE
ER XX protein
associate xxx NE
in xx NE
a x NE
ligand-dependent xxx-xxx NE
manner xxx NE
. . NE

Mapping Xxxx NE
experiments xxx NE
indicate xxx NE
that xxx NE
GATA-1 XXXX-d protein
and xxx NE
the xxx NE
ER XX protein
form xxx NE
at xx NE
least xxx NE
two xxx NE
contacts xxx NE
, , NE
which xxx NE
involve xxx NE
the xxx NE
finger xxx NE
region xxx NE
and xxx NE
the xxx NE
N-terminal X-xxx protein_B
activation xxx protein_M
domain xxx protein_E
of xx NE
GATA-1 XXXX-d protein
. . NE

We Xx NE
speculate xxx NE
that xxx NE
estrogens xxx NE
exert xxx NE
effects xxx NE
on xx NE
erythropoiesis xxx NE
by xx NE
modulating xxx NE
GATA-1 XXXX-d NE
activity xxx NE
through xxx NE
protein-protein xxx-xxx NE
interaction xxx NE
with xxx NE
the xxx NE
ER XX protein
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Mouse Xxxx NE
interleukin-2 xxx-d NE
receptor xxx NE
alpha xxx NE
gene xxx NE
expression xxx NE
. . NE

Interleukin-1 Xxxx-d protein
and xxx NE
interleukin-2 xxx-d protein
control xxx NE
transcription xxx NE
via xxx NE
distinct xxx NE
cis-acting xxx-xxx DNA_B
elements xxx DNA_E
. . NE

We Xx NE
have xxx NE
shown xxx NE
that xxx NE
interleukin-1 xxx-d protein
( ( NE
IL-1 XX-d protein
) ) NE
and xxx NE
IL-2 XX-d protein
control xxx NE
IL-2 XX-d NE
receptor xxx NE
alpha xxx NE
( ( NE
IL-2R XX-dX NE
alpha xxx NE
) ) NE
gene xxx NE
transcription xxx NE
in xx NE
CD4-CD8- XXd-XXd- NE
murine xxx NE
T X NE
lymphocyte xxx NE
precursors xxx NE
. . NE

Here Xxxx NE
we xx NE
map xxx NE
the xxx NE
cis-acting xxx-xxx DNA_B
elements xxx DNA_E
that xxx NE
mediate xxx NE
interleukin xxx NE
responsiveness xxx NE
of xx NE
the xxx NE
mouse xxx DNA_B
IL-2R XX-dX DNA_M
alpha xxx DNA_M
gene xxx DNA_E
using xxx NE
a x NE
thymic xxx cell_line_B
lymphoma-derived xxx-xxx cell_line_M
hybridoma xxx cell_line_E
( ( NE
PC60 XXdd cell_line
) ) NE
. . NE

The Xxx NE
transcriptional xxx NE
response xxx NE
of xx NE
the xxx NE
IL-2R XX-dX DNA_B
alpha xxx DNA_M
gene xxx DNA_E
to xx NE
stimulation xxx NE
by xx NE
IL-1 XX-d protein
+ + NE
IL-2 XX-d protein
is xx NE
biphasic xxx NE
. . NE

IL-1 XX-d protein
induces xxx NE
a x NE
rapid xxx NE
, , NE
protein xxx NE
synthesis-independent xxx-xxx NE
appearance xxx NE
of xx NE
IL-2R XX-dX RNA_B
alpha xxx RNA_M
mRNA xXXX RNA_E
that xxx NE
is xx NE
blocked xxx NE
by xx NE
inhibitors xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
. . NE

It Xx NE
also xxx NE
primes xxx NE
cells xxx NE
to xx NE
become xxx NE
IL-2 XX-d protein
responsive xxx NE
and xxx NE
thereby xxx NE
prepares xxx NE
the xxx NE
second xxx NE
phase xxx NE
, , NE
in xx NE
which xxx NE
IL-2 XX-d protein
induces xxx NE
a x NE
100-fold ddd-xxx NE
further xxx NE
increase xxx NE
in xx NE
IL-2R XX-dX RNA_B
alpha xxx RNA_M
transcripts xxx RNA_E
. . NE

Transient Xxxx NE
transfection xxx NE
experiments xxx NE
show xxx NE
that xxx NE
several xxx NE
elements xxx NE
in xx NE
the xxx NE
promoter-proximal xxx-xxx DNA_B
region xxx DNA_E
of xx NE
the xxx NE
IL-2R XX-dX DNA_B
alpha xxx DNA_M
gene xxx DNA_E
contribute xxx NE
to xx NE
IL-1 XX-d protein
responsiveness xxx NE
, , NE
most xxx NE
importantly xxx NE
an xx NE
NF-kappa XX-xxx DNA_B
B X DNA_M
site xxx DNA_E
conserved xxx NE
in xx NE
the xxx NE
human xxx DNA_B
gene xxx DNA_M
and xxx DNA_M
mouse xxx DNA_M
gene xxx DNA_E

IL-2 XX-d NE
responsiveness xxx NE
, , NE
on xx NE
the xxx NE
other xxx NE
hand xxx NE
, , NE
depends xxx NE
on xx NE
a x NE
78-nucleotide dd-xxx DNA_B
segment xxx DNA_E
1.3 d.d NE
kilobases xxx NE
upstream xxx NE
of xx NE
the xxx NE
major xxx DNA_B
transcription xxx DNA_M
start xxx DNA_M
site xxx DNA_E
. . NE

This Xxxx NE
segment xxx NE
functions xxx NE
as xx NE
an xx NE
IL-2-inducible XX-d-xxx DNA_B
enhancer xxx DNA_E
and xxx NE
lies xxx NE
within xxx NE
a x NE
region xxx NE
that xxx NE
becomes xxx NE
DNase XXxxx NE
I X NE
hypersensitive xxx NE
in xx NE
normal xxx NE
T X cell_type_B
cells xxx cell_type_E
in xx NE
which xxx NE
IL-2R XX-dX NE
alpha xxx NE
expression xxx NE
has xxx NE
been xxx NE
induced xxx NE
. . NE

IL-2 XX-d NE
responsiveness xxx NE
requires xxx NE
three xxx NE
distinct xxx NE
elements xxx DNA
within xxx NE
the xxx NE
enhancer xxx DNA
. . NE

Two Xxx NE
of xx NE
these xxx NE
are xxx NE
potential xxx NE
binding xxx NE
sites xxx NE
for xxx NE
STAT XXXX protein_B
proteins xxx protein_E
. . NE

Hematopoietic Xxxx NE
lineage xxx NE
commitment xxx NE
: : NE
role xxx NE
of xx NE
transcription xxx protein_B
factors xxx protein_E
. . NE

This Xxxx NE
review xxx NE
focuses xxx NE
on xx NE
the xxx NE
roles xxx NE
of xx NE
transcription xxx protein_B
factors xxx protein_E
in xx NE
hematopoietic xxx NE
lineage xxx NE
commitment xxx NE
. . NE

A X NE
brief xxx NE
introduction xxx NE
to xx NE
lineage xxx NE
commitment xxx NE
and xxx NE
asymmetric xxx NE
cell xxx NE
division xxx NE
is xx NE
followed xxx NE
by xx NE
a x NE
discussion xxx NE
of xx NE
several xxx NE
methods xxx NE
used xxx NE
to xx NE
identify xxx NE
transcription xxx protein_B
factors xxx protein_E
important xxx NE
in xx NE
specifying xxx NE
hematopoietic xxx cell_type_B
cell xxx cell_type_M
types xxx cell_type_E
. . NE

Next Xxxx NE
is xx NE
presented xxx NE
a x NE
discussion xxx NE
of xx NE
the xxx NE
use xxx NE
of xx NE
embryonic xxx cell_type_B
stem xxx cell_type_M
cells xxx cell_type_E
in xx NE
the xxx NE
analysis xxx NE
of xx NE
hematopoietic xxx NE
gene xxx NE
expression xxx NE
and xxx NE
the xxx NE
use xxx NE
of xx NE
targeted xxx NE
gene xxx NE
disruption xxx NE
to xx NE
analyze xxx NE
the xxx NE
role xxx NE
of xx NE
transcription xxx protein_B
factors xxx protein_E
in xx NE
hematopoiesis xxx NE
. . NE

Finally Xxxx NE
, , NE
the xxx NE
status xxx NE
of xx NE
our xxx NE
current xxx NE
knowledge xxx NE
concerning xxx NE
the xxx NE
roles xxx NE
of xx NE
transcription xxx protein_B
factors xxx protein_E
in xx NE
the xxx NE
commitment xxx NE
to xx NE
erythroid xxx cell_type_B
cell xxx cell_type_M
type xxx cell_type_M
and xxx cell_type_M
myeloid xxx cell_type_M
cell xxx cell_type_M
type xxx cell_type_M
and xxx cell_type_M
lymphoid xxx cell_type_M
cell xxx cell_type_M
type xxx cell_type_E

Epstein-Barr Xxxx-Xxxx NE
virus xxx NE
replicative xxx NE
gene xxx NE
transcription xxx NE
during xxx NE
de xx NE
novo xxx NE
infection xxx NE
of xx NE
human xxx cell_type_B
thymocytes xxx cell_type_E
: : NE
simultaneous xxx NE
early xxx NE
expression xxx NE
of xx NE
BZLF-1 XXXX-d protein
and xxx NE
its xxx NE
repressor xxx NE
RAZ XXX protein
. . NE

Epstein-Barr Xxxx-Xxxx NE
virus xxx NE
( ( NE
EBV XXX NE
) ) NE
is xx NE
known xxx NE
to xx NE
infect xxx NE
B X cell_type_B
cells xxx cell_type_E
and xxx NE
epithelial xxx cell_type_B
cells xxx cell_type_E
. . NE

We Xx NE
and xxx NE
others xxx NE
have xxx NE
shown xxx NE
that xxx NE
EBV XXX NE
can xxx NE
also xxx NE
infect xxx NE
a x NE
subset xxx NE
of xx NE
thymocytes xxx cell_type
. . NE

Infection Xxxx NE
of xx NE
thymocytes xxx cell_type
was xxx NE
accompanied xxx NE
by xx NE
the xxx NE
appearance xxx NE
of xx NE
linear xxx DNA_B
EBV XXX DNA_M
genome xxx DNA_E
within xxx NE
8 d NE
hr xx NE
of xx NE
infection xxx NE
. . NE

Circularization Xxxx NE
of xx NE
the xxx NE
EBV XXX DNA_B
genome xxx DNA_E
was xxx NE
not xxx NE
detected xxx NE
. . NE

This Xxxx NE
is xx NE
in xx NE
contrast xxx NE
to xx NE
the xxx NE
infection xxx NE
in xx NE
B X cell_type_B
cells xxx cell_type_E
where xxx NE
the xxx NE
genome xxx NE
can xxx NE
circularize xxx NE
within xxx NE
24 dd NE
hr xx NE
of xx NE
infection xxx NE
. . NE

The Xxx NE
appearance xxx NE
of xx NE
the xxx NE
BamHI XxxXX protein_B
ZLF-1 XXX-d protein_M
gene xxx protein_M
product xxx protein_E
, , NE
ZEBRA XXXXX protein
, , NE
by xx NE
RT-PCR XX-XXX NE
, , NE
was xxx NE
observed xxx NE
within xxx NE
8 d NE
hr xx NE
of xx NE
infection xxx NE
. . NE

The Xxx NE
appearance xxx NE
of xx NE
a x NE
novel xxx NE
fusion xxx protein_B
transcript xxx protein_E
( ( NE
RAZ XXX protein
) ) NE
, , NE
which xxx NE
comprised xxx NE
regions xxx NE
of xx NE
the xxx NE
BZLF-1 XXXX-d DNA_B
locus xxx DNA_E
and xxx NE
the xxx NE
adjacent xxx NE
BRLF-1 XXXX-d DNA_B
locus xxx DNA_E
, , NE
was xxx NE
detected xxx NE
by xx NE
RT-PCR XX-XXX NE
. . NE

ZEBRA XXXXX protein_B
protein xxx protein_E
was xxx NE
also xxx NE
identified xxx NE
in xx NE
infected xxx NE
thymocytes xxx cell_type
by xx NE
immunoprecipitation xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
we xx NE
demonstrated xxx NE
that xxx NE
the xxx NE
EBNA-1 XXXX-d DNA_B
gene xxx DNA_E
in xx NE
infected xxx NE
thymocytes xxx cell_type
was xxx NE
transcribed xxx NE
from xxx NE
the xxx NE
Fp Xx DNA_B
promoter xxx DNA_E
, , NE
rather xxx NE
than xxx NE
from xxx NE
the xxx NE
Cp/Wp Xx/Xx DNA_B
promoter xxx DNA_E
which xxx NE
is xx NE
used xxx NE
in xx NE
latently xxx cell_type_B
infected xxx cell_type_M
B X cell_type_M
cells xxx cell_type_E
. . NE

Transcripts Xxxx NE
encoding xxx NE
gp350/220 xxddd/ddd protein
, , NE
the xxx NE
major xxx protein_B
coat xxx protein_M
protein xxx protein_E
of xx NE
EBV XXX NE
, , NE
were xxx NE
identified xxx NE
, , NE
but xxx NE
we xx NE
did xxx NE
not xxx NE
find xxx NE
any xxx NE
evidence xxx NE
of xx NE
transcription xxx NE
from xxx NE
the xxx NE
LMP-2A XXX-dX DNA
or xx NE
EBER-1 XXXX-d DNA_B
loci xxx DNA_E
in xx NE
infected xxx NE
thymocytes xxx cell_type
. . NE

These Xxxx NE
observations xxx NE
suggest xxx NE
that xxx NE
de xx NE
novo xxx NE
EBV XXX NE
infection xxx NE
of xx NE
thymocytes xxx cell_type
differs xxx NE
from xxx NE
infection xxx NE
of xx NE
B X cell_type_B
cells xxx cell_type_E
. . NE

The Xxx NE
main xxx NE
difference xxx NE
is xx NE
that xxx NE
with xxx NE
thymocytes xxx cell_type
, , NE
no xx NE
evidence xxx NE
could xxx NE
be xx NE
found xxx NE
that xxx NE
the xxx NE
virus xxx NE
ever xxx NE
circularizes xxx NE
. . NE

Rather Xxxx NE
, , NE
EBV XXX NE
remains xxx NE
in xx NE
a x NE
linear xxx NE
configuration xxx NE
from xxx NE
which xxx NE
replicative xxx DNA_B
genes xxx DNA_E
are xxx NE
transcribed xxx NE
. . NE

Identification Xxxx NE
and xxx NE
purification xxx NE
of xx NE
human xxx protein_B
Stat Xxxx protein_M
proteins xxx protein_E
activated xxx NE
in xx NE
response xxx NE
to xx NE
interleukin-2 xxx-d protein
. . NE

A X NE
key xxx NE
cytokine xxx protein
induced xxx NE
during xxx NE
the xxx NE
immune xxx NE
response xxx NE
is xx NE
IL-2 XX-d protein
. . NE

Following Xxxx NE
T X NE
cell xxx NE
activation xxx NE
, , NE
the xxx NE
genes xxx NE
encoding xxx NE
IL-2 XX-d protein
and xxx NE
the xxx NE
various xxx NE
chains xxx NE
of xx NE
its xxx NE
receptor xxx NE
are xxx NE
transcriptionally xxx NE
induced xxx NE
. . NE

In Xx NE
turn xxx NE
, , NE
secreted xxx NE
IL-2 XX-d protein
serves xxx NE
to xx NE
stimulate xxx NE
the xxx NE
proliferation xxx NE
and xxx NE
differentiation xxx NE
of xx NE
T X cell_type_B
lymphocytes xxx cell_type_E
. . NE

Several Xxxx NE
recent xxx NE
studies xxx NE
have xxx NE
implicated xxx NE
Jak Xxx NE
kinases xxx NE
in xx NE
the xxx NE
signaling xxx NE
pathway xxx NE
induced xxx NE
by xx NE
IL-2 XX-d protein
. . NE

Following Xxxx NE
this xxx NE
lead xxx NE
, , NE
we xx NE
set xxx NE
out xxx NE
to xx NE
identify xxx NE
transcription xxx protein_B
factors xxx protein_E
induced xxx NE
in xx NE
response xxx NE
to xx NE
IL-2 XX-d protein
. . NE

Human Xxxx cell_type_B
peripheral xxx cell_type_M
blood xxx cell_type_M
lymphocytes xxx cell_type_E
were xxx NE
observed xxx NE
to xx NE
contain xxx NE
several xxx NE
IL-2 XX-d NE
-inducible -xxx NE
DNA XXX NE
binding xxx NE
activities xxx NE
. . NE

Similar Xxxx NE
activities xxx NE
were xxx NE
also xxx NE
observed xxx NE
in xx NE
a x NE
transformed xxx cell_line_B
human xxx cell_line_M
lymphocyte xxx cell_line_M
line xxx cell_line_E
, , NE
termed xxx NE
YT XX cell_line
. . NE

We Xx NE
have xxx NE
purified xxx NE
these xxx NE
activities xxx NE
and xxx NE
found xxx NE
that xxx NE
the xxx NE
principal xxx NE
IL-2 XX-d NE
-inducible -xxx NE
component xxx NE
bears xxx NE
significant xxx NE
relatedness xxx NE
to xx NE
a x NE
prolactin-induced xxx-xxx NE
transcription xxx NE
factor xxx NE
first xxx NE
identified xxx NE
in xx NE
sheep xxx NE
mammary xxx NE
gland xxx NE
tissue xxx NE
. . NE

We Xx NE
hypothesize xxx NE
that xxx NE
activation xxx NE
of xx NE
this xxx NE
protein xxx NE
, , NE
designated xxx NE
hStat5 xXxxxd protein
, , NE
helps xxx NE
govern xxx NE
the xxx NE
biological xxx NE
effects xxx NE
of xx NE
IL-2 XX-d protein
during xxx NE
the xxx NE
immune xxx NE
response xxx NE
. . NE

E2F-1 XdX-d protein
and xxx NE
a x NE
cyclin-like xxx-xxx protein_B
DNA XXX protein_M
repair xxx protein_M
enzyme xxx protein_E
, , NE
uracil-DNA xxx-XXX protein_B
glycosylase xxx protein_E
, , NE
provide xxx NE
evidence xxx NE
for xxx NE
an xx NE
autoregulatory xxx NE
mechanism xxx NE
for xxx NE
transcription xxx NE
. . NE

The Xxx NE
cell xxx protein_B
cycle-dependent xxx-xxx protein_M
transcription xxx protein_M
factor xxx protein_E
, , NE
E2F-1 XdX-d protein
, , NE
regulates xxx NE
the xxx NE
cyclin xxx protein
-like -xxx NE
species xxx NE
of xx NE
the xxx NE
DNA XXX protein_B
repair xxx protein_M
enzyme xxx protein_E
uracil-DNA xxx-XXX NE
glycosylase xxx NE
( ( NE
UDG XXX NE
) ) NE
gene xxx NE
in xx NE
human xxx NE
osteosarcoma xxx NE
( ( NE
Saos-2 Xxxx-d NE
) ) NE
cells xxx NE
. . NE

We Xx NE
demonstrate xxx NE
, , NE
through xxx NE
the xxx NE
deletion xxx NE
of xx NE
the xxx NE
human xxx DNA_B
UDG XXX DNA_M
promoter xxx DNA_M
sequences xxx DNA_E
, , NE
that xxx NE
expression xxx NE
of xx NE
E2F-1 XdX-d protein
activates xxx NE
the xxx NE
UDG XXX DNA_B
promoter xxx DNA_E
through xxx NE
several xxx NE
E2F XdX DNA_B
sites xxx DNA_E
. . NE

The Xxx NE
major xxx DNA_B
putative xxx DNA_M
downstream xxx DNA_M
site xxx DNA_E
for xxx NE
E2F XdX protein
, , NE
located xxx NE
in xx NE
the xxx NE
first xxx DNA_B
exon xxx DNA_E
, , NE
serves xxx NE
as xx NE
a x NE
target xxx NE
for xxx NE
E2F-1/DP1 XdX-d/XXd protein_B
complex xxx protein_E
binding xxx NE
in xx NE
vitro xxx NE
. . NE

We Xx NE
also xxx NE
provide xxx NE
evidence xxx NE
for xxx NE
the xxx NE
functional xxx NE
relationship xxx NE
between xxx NE
the xxx NE
cyclin-like xxx-xxx protein_B
UDG XXX protein_M
gene xxx protein_M
product xxx protein_E
and xxx NE
E2F XdX protein
. . NE

High Xxxx NE
levels xxx NE
of xx NE
UDG XXX NE
expression xxx NE
in xx NE
a x NE
transient xxx NE
transfection xxx NE
assay xxx NE
result xxx NE
in xx NE
the xxx NE
down-regulation xxx-xxx NE
of xx NE
transcriptional xxx NE
activity xxx NE
through xxx NE
elements xxx DNA
specific xxx NE
for xxx NE
E2F XdX NE
-mediated -xxx NE
transcription xxx NE
. . NE

Overexpression Xxxx NE
of xx NE
UDG XXX protein
in xx NE
Saos Xxxx cell_line_B
2 d cell_line_M
cells xxx cell_line_E
was xxx NE
observed xxx NE
to xx NE
delay xxx NE
growth xxx NE
late xxx NE
in xx NE
G1 Xd NE
phase xxx NE
and xxx NE
transiently xxx NE
arrest xxx NE
these xxx NE
cells xxx NE
from xxx NE
progressing xxx NE
into xxx NE
the xxx NE
S X NE
phase xxx NE
. . NE

This Xxxx NE
hypothetical xxx NE
model xxx NE
integrates xxx NE
one xxx NE
mechanism xxx NE
of xx NE
DNA XXX NE
repair xxx NE
with xxx NE
the xxx NE
cell xxx NE
cycle xxx NE
control xxx NE
of xx NE
gene xxx NE
transcription xxx NE
, , NE
likely xxx NE
through xxx NE
E2F XdX protein
. . NE

This Xxxx NE
implicates xxx NE
E2F XdX protein
as xx NE
a x NE
multifunctional xxx NE
target xxx NE
for xxx NE
proteins xxx NE
and xxx NE
enzymes xxx NE
, , NE
possibly xxx NE
, , NE
responsive xxx NE
to xx NE
DNA XXX NE
damage xxx NE
through xxx NE
the xxx NE
negative xxx NE
effect xxx NE
of xx NE
UDG XXX protein
on xx NE
E2F XdX NE
-mediated -xxx NE
transcriptional xxx NE
activity xxx NE
. . NE

Cellular Xxxx NE
mechanism xxx NE
and xxx NE
molecular xxx NE
mechanism xxx NE
of xx NE
IFN-gamma XXX-xxx NE
production xxx NE
induced xxx NE
by xx NE
IL-2 XX-d protein
and xxx NE
IL-12 XX-dd protein
in xx NE
a x NE
human xxx cell_line_B
NK XX cell_line_M
cell xxx cell_line_M
line xxx cell_line_E
. . NE

Interferon-gamma Xxxx-xxx protein
( ( NE
IFN-gamma XXX-xxx protein
) ) NE
is xx NE
an xx NE
important xxx NE
immunoregulatory xxx protein_B
protein xxx protein_E
produced xxx NE
predominantly xxx NE
by xx NE
T X cell_type_B
cells xxx cell_type_E
and xxx NE
large xxx cell_type_B
granular xxx cell_type_M
lymphocytes xxx cell_type_E
( ( NE
LGL XXX cell_type
) ) NE
in xx NE
response xxx NE
to xx NE
different xxx NE
extracellular xxx NE
signals xxx NE
. . NE

In Xx NE
particular xxx NE
, , NE
two xxx NE
interleukins xxx protein
( ( NE
ILs XXx protein
) ) NE
, , NE
IL-2 XX-d protein
and xxx NE
IL-12 XX-dd protein
, , NE
have xxx NE
been xxx NE
shown xxx NE
to xx NE
be xx NE
potent xxx NE
inducers xxx NE
of xx NE
IFN-gamma XXX-xxx NE
gene xxx NE
expression xxx NE
in xx NE
both xxx NE
T X cell_type_B
cells xxx cell_type_E
and xxx NE
LGL XXX cell_type
. . NE

Although Xxxx NE
it xx NE
has xxx NE
been xxx NE
reported xxx NE
that xxx NE
there xxx NE
are xxx NE
some xxx NE
T X cell_line_B
cell xxx cell_line_M
lines xxx cell_line_E
that xxx NE
produce xxx NE
IFN-gamma XXX-xxx protein
in xx NE
response xxx NE
to xx NE
IL-2 XX-d NE
stimulation xxx NE
and xxx NE
IL-12 XX-dd NE
stimulation xxx NE

In Xx NE
this xxx NE
report xxx NE
we xx NE
present xxx NE
evidence xxx NE
that xxx NE
the xxx NE
cell xxx cell_line_B
line xxx cell_line_M
NK3.3 XXd.d cell_line_E
derived xxx NE
from xxx NE
human xxx cell_type_B
NK XX cell_type_M
cells xxx cell_type_E
, , NE
responds xxx NE
to xx NE
both xxx NE
IL-2 XX-d protein
and xxx NE
IL-12 XX-dd protein
, , NE
as xx NE
measured xxx NE
by xx NE
increases xxx NE
in xx NE
IFN-gamma XXX-xxx protein
and xxx NE
granulocyte-macrophage xxx-xxx protein_B
colony-stimulating xxx-xxx protein_M
factor xxx protein_E
( ( NE
GM-CSF XX-XXX protein
) ) NE
cytoplasmic xxx NE
mRNA xXXX NE
expression xxx NE
and xxx NE
cytoplasmic xxx NE
protein xxx NE
expression xxx NE

In Xx NE
addition xxx NE
, , NE
when xxx NE
used xxx NE
together xxx NE
IL-2 XX-d protein
and xxx NE
IL-12 XX-dd protein
synergized xxx NE
in xx NE
the xxx NE
induction xxx NE
of xx NE
IFN-gamma XXX-xxx protein
and xxx NE
GM-CSF XX-XXX protein
and xxx NE
this xxx NE
synergy xxx NE
was xxx NE
attributed xxx NE
to xx NE
an xx NE
increased xxx NE
accumulation xxx NE
and xxx NE
stability xxx NE
of xx NE
the xxx NE
IFN-gamma XXX-xxx RNA_B
and xxx RNA_M
GM-CSF XX-XXX RNA_M
mRNAs xXXXx RNA_E
. . NE

To Xx NE
investigate xxx NE
the xxx NE
signaling xxx NE
pathways xxx NE
involved xxx NE
in xx NE
the xxx NE
gene xxx NE
induction xxx NE
, , NE
five xxx NE
inhibitors xxx NE
, , NE
cyclosporin xxx NE
A X NE
( ( NE
CsA XxX NE
) ) NE
, , NE
transforming xxx protein_B
growth xxx protein_M
factor-beta xxx-xxx protein_E
, , NE
cycloheximide xxx NE
, , NE
genistein xxx NE
, , NE
and xxx NE
staurosporine xxx NE
A X NE
, , NE
were xxx NE
used xxx NE
in xx NE
analyzing xxx NE
the xxx NE
effects xxx NE
of xx NE
IL-2 XX-d protein
and xxx NE
IL-12 XX-dd protein
on xx NE
NK3.3 XXd.d cell_line_B
cells xxx cell_line_E
. . NE

The Xxx NE
results xxx NE
suggest xxx NE
that xxx NE
activation xxx NE
of xx NE
protein xxx protein_B
kinase xxx protein_M
C X protein_E
, , NE
but xxx NE
not xxx NE
new xxx NE
protein xxx NE
synthesis xxx NE
, , NE
is xx NE
required xxx NE
for xxx NE
IL-2 XX-d protein
induction xxx NE
of xx NE
IFN-gamma XXX-xxx RNA_B
cytoplasmic xxx RNA_M
mRNA xXXX RNA_M
and xxx RNA_M
GM-CSF XX-XXX RNA_M
cytoplasmic xxx RNA_M
mRNA xXXX RNA_E

In Xx NE
contrast xxx NE
, , NE
IL-12 XX-dd NE
induction xxx NE
of xx NE
IFN-gamma XXX-xxx RNA_B
cytoplasmic xxx RNA_M
mRNA xXXX RNA_E
appears xxx NE
to xx NE
only xxx NE
partially xxx NE
depend xxx NE
on xx NE
activation xxx NE
of xx NE
protein xxx protein_B
kinase xxx protein_M
C X protein_E
. . NE

Furthermore Xxxx NE
, , NE
both xxx NE
transforming xxx protein_B
growth xxx protein_M
factor-beta xxx-xxx protein_E
and xxx NE
genistein xxx NE
, , NE
a x NE
tyrosine xxx NE
kinase xxx NE
inhibitor xxx NE
, , NE
could xxx NE
suppress xxx NE
IL-2 XX-d protein
and xxx NE
IL-12 XX-dd protein
signaling xxx NE
but xxx NE
CsA XxX NE
was xxx NE
generally xxx NE
inactive xxx NE
. . NE

It Xx NE
also xxx NE
was xxx NE
observed xxx NE
that xxx NE
suppression xxx NE
of xx NE
cytokine xxx NE
gene xxx NE
expression xxx NE
by xx NE
these xxx NE
agents xxx NE
was xxx NE
independent xxx NE
of xx NE
the xxx NE
inhibition xxx NE
of xx NE
proliferation xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
IL-2 XX-d protein
but xxx NE
not xxx NE
IL-12 XX-dd protein
induced xxx NE
nuclear xxx protein_B
factors xxx protein_E
NF-kappa XX-xxx NE
B X NE
and xxx NE
AP1 XXd protein
, , NE
and xxx NE
regulation xxx NE
of xx NE
the xxx NE
nuclear xxx NE
levels xxx NE
of xx NE
these xxx NE
two xxx NE
DNA XXX NE
binding xxx NE
protein xxx NE
complexes xxx NE
is xx NE
correlated xxx NE
with xxx NE
IFN-gamma XXX-xxx NE
gene xxx NE
expression xxx NE
and xxx NE
GM-CSF XX-XXX NE
gene xxx NE
expression xxx NE

These Xxxx NE
data xxx NE
indicate xxx NE
that xxx NE
IL-2 XX-d protein
and xxx NE
IL-12 XX-dd protein
may xxx NE
have xxx NE
distinct xxx NE
signaling xxx NE
pathways xxx NE
leading xxx NE
to xx NE
the xxx NE
induction xxx NE
of xx NE
IFN-gamma XXX-xxx protein
and xxx NE
GM-CSF XX-XXX NE
gene xxx NE
expression xxx NE
, , NE
and xxx NE
that xxx NE
the xxx NE
NK3.3 XXd.d cell_line_B
cell xxx cell_line_M
line xxx cell_line_E
may xxx NE
serve xxx NE
as xx NE
a x NE
novel xxx NE
model xxx NE
for xxx NE
dissecting xxx NE
the xxx NE
biochemical xxx NE
and xxx NE
molecular xxx NE
events xxx NE
involved xxx NE
in xx NE
these xxx NE
pathways xxx NE
. . NE

A X NE
functional xxx NE
T-cell X-xxx NE
receptor xxx NE
signaling xxx NE
pathway xxx NE
is xx NE
required xxx NE
for xxx NE
p95vav xddxxx NE
activity xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
the xxx NE
T-cell X-xxx protein_B
antigen xxx protein_M
receptor xxx protein_E
( ( NE
TCR XXX protein
) ) NE
induces xxx NE
activation xxx NE
of xx NE
multiple xxx NE
tyrosine xxx protein_B
kinases xxx protein_E
, , NE
resulting xxx NE
in xx NE
phosphorylation xxx NE
of xx NE
numerous xxx NE
intracellular xxx NE
substrates xxx NE
. . NE

One Xxx NE
substrate xxx NE
is xx NE
p95vav xddxxx protein
, , NE
which xxx NE
is xx NE
expressed xxx NE
exclusively xxx NE
in xx NE
hematopoietic xxx cell_type_B
cell xxx cell_type_M
and xxx cell_type_M
trophoblast xxx cell_type_M
cell xxx cell_type_E

It Xx NE
contains xxx NE
a x NE
number xxx NE
of xx NE
structural xxx protein_B
motifs xxx protein_E
, , NE
including xxx NE
Src Xxx NE
homology xxx NE
2 d NE
, , NE
Src Xxx NE
homology xxx NE
3 d NE
, , NE
and xxx NE
pleckstrin xxx NE
homology xxx NE
domains xxx NE
and xxx NE
a x NE
putative xxx NE
guanine xxx NE
nucleotide xxx NE
exchange xxx NE
domain xxx NE
. . NE

The Xxx NE
role xxx NE
of xx NE
p95vav xddxxx protein
in xx NE
TCR XXX NE
-mediated -xxx NE
signaling xxx NE
processes xxx NE
is xx NE
unclear xxx NE
. . NE

Here Xxxx NE
, , NE
we xx NE
show xxx NE
that xxx NE
overexpression xxx NE
of xx NE
p95vav xddxxx protein
alone xxx NE
in xx NE
Jurkat Xxxx NE
T X cell_type_B
cells xxx cell_type_E
leads xxx NE
to xx NE
activation xxx NE
of xx NE
the xxx NE
nuclear xxx protein_B
factors xxx protein_E
, , NE
including xxx NE
NFAT XXXX protein
, , NE
involved xxx NE
in xx NE
interleukin-2 xxx-d NE
expression xxx NE
. . NE

Furthermore Xxxx NE
, , NE
p95vav xddxxx protein
synergizes xxx NE
with xxx NE
TCR XXX NE
stimulation xxx NE
in xx NE
inducing xxx NE
NFAT-dependent XXXX-xxx NE
transcription xxx NE
and xxx NE
interleukin-2-dependent xxx-d-xxx NE
transcription xxx NE

In Xx NE
contrast xxx NE
, , NE
NFAT XXXX NE
activation xxx NE
by xx NE
a x NE
G-protein-coupled X-xxx-xxx protein_B
receptor xxx protein_E
is xx NE
not xxx NE
modulated xxx NE
by xx NE
p95vav xddxxx NE
overexpression xxx NE
, , NE
suggesting xxx NE
that xxx NE
the xxx NE
effect xxx NE
is xx NE
specific xxx NE
to xx NE
the xxx NE
TCR XXX NE
signaling xxx NE
pathways xxx NE
. . NE

Although Xxxx NE
removal xxx NE
of xx NE
the xxx NE
first xxx protein_B
67 dd protein_M
amino xxx protein_M
acids xxx protein_E
of xx NE
p95vav xddxxx protein
activates xxx NE
its xxx NE
transforming xxx NE
potential xxx NE
in xx NE
NIH XXX cell_line_B
3T3 dXd cell_line_M
cells xxx cell_line_E
, , NE
this xxx NE
region xxx NE
appears xxx NE
to xx NE
be xx NE
required xxx NE
for xxx NE
its xxx NE
function xxx NE
in xx NE
T X cell_type_B
cells xxx cell_type_E
. . NE

We Xx NE
further xxx NE
demonstrate xxx NE
that xxx NE
the xxx NE
p95vav xddxxx NE
-induced -xxx NE
NFAT XXXX NE
activation xxx NE
is xx NE
not xxx NE
mimicked xxx NE
by xx NE
Ras Xxx NE
activation xxx NE
, , NE
though xxx NE
its xxx NE
function xxx NE
is xx NE
dependent xxx NE
upon xxx NE
Ras Xxx NE
and xxx NE
Raf Xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
activating xxx NE
function xxx NE
of xx NE
p95vav xddxxx protein
is xx NE
blocked xxx NE
by xx NE
FK506 XXddd NE
, , NE
suggesting xxx NE
that xxx NE
its xxx NE
activity xxx NE
also xxx NE
depends xxx NE
on xx NE
calcineurin xxx protein
. . NE

To Xx NE
further xxx NE
dissect xxx NE
p95vav xddxxx NE
involvement xxx NE
in xx NE
TCR XXX NE
signaling xxx NE
, , NE
we xx NE
analyzed xxx NE
various xxx NE
Jurkat Xxxx cell_line_B
mutants xxx cell_line_E
deficient xxx NE
in xx NE
TCR XXX NE
signaling xxx NE
function xxx NE
or xx NE
TCR XXX NE
expression xxx NE
and xxx NE
showed xxx NE
that xxx NE
an xx NE
intact xxx NE
TCR XXX NE
signaling xxx NE
pathway xxx NE
is xx NE
required xxx NE
for xxx NE
p95vav xddxxx protein
to xx NE
function xxx NE
. . NE

However Xxxx NE
, , NE
overexpression xxx NE
of xx NE
p95vav xddxxx protein
does xxx NE
not xxx NE
appear xxx NE
to xx NE
influence xxx NE
TCR XXX NE
-induced -xxx NE
protein xxx NE
tyrosine xxx NE
phosphorylation xxx NE
or xx NE
increases xxx NE
in xx NE
cytoplasmic xxx NE
free xxx NE
calcium xxx NE
. . NE

Taken Xxxx NE
together xxx NE
, , NE
our xxx NE
data xxx NE
suggest xxx NE
that xxx NE
p95vav xddxxx protein
plays xxx NE
an xx NE
important xxx NE
role xxx NE
at xx NE
an xx NE
yet xxx NE
unidentified xxx NE
proximal xxx NE
position xxx NE
in xx NE
the xxx NE
TCR XXX NE
signaling xxx NE
cascade xxx NE
. . NE

positive xxx NE
regulation xxx NE
and xxx NE
negative xxx NE
regulation xxx NE
of xx NE
granulocyte-macrophage xxx-xxx NE
colony-stimulating xxx-xxx NE
factor xxx NE
promoter xxx NE
activity xxx NE
by xx NE
AML1-related XXXd-xxx protein_B
transcription xxx protein_M
factor xxx protein_E
, , NE
PEBP2 XXXXd protein
. . NE

The Xxx NE
granulocyte-macrophage xxx-xxx DNA_B
colony-stimulating xxx-xxx DNA_M
factor xxx DNA_M
( ( DNA_E
GM-CSF XX-XXX NE
) ) NE
gene xxx NE
promoter xxx NE
contains xxx NE
a x NE
consensus xxx NE
sequence xxx NE
for xxx NE
the xxx NE
polyomavirus xxx protein_B
enhancer xxx protein_M
binding-protein xxx-xxx protein_M
2 d protein_M
( ( protein_E
PEBP2 XXXXd NE
) ) NE
transcription xxx NE
factor xxx NE
, , NE
which xxx NE
consists xxx NE
of xx NE
alpha xxx protein_B
subunit xxx protein_M
and xxx protein_M
beta xxx protein_M
subunit xxx protein_E

There Xxxx NE
are xxx NE
at xx NE
least xxx NE
two xxx NE
genes xxx NE
, , NE
alpha xxx DNA_B
A X DNA_E
and xxx NE
alpha xxx DNA_B
B X DNA_E
, , NE
encoding xxx NE
the xxx NE
alpha xxx protein_B
subunit xxx protein_E
. . NE

alpha xxx DNA_B
B X DNA_E
is xx NE
the xxx NE
mouse xxx DNA_B
homologue xxx DNA_E
of xx NE
human xxx DNA_B
AML1 XXXd DNA_M
gene xxx DNA_E
detected xxx NE
at xx NE
the xxx NE
breakpoints xxx NE
of xx NE
t(8;21) x(d;dd) NE
myeloid xxx NE
leukemia xxx NE
and xxx NE
t(3;21) x(d;dd) NE
myeloid xxx NE
leukemia xxx NE

We Xx NE
examined xxx NE
alpha xxx protein_B
A1 Xd protein_E
(an (xx NE
alpha xxx NE
A X NE
-gene -xxx NE
product xxx NE
) ) NE
and xxx NE
alpha xxx NE
B1 Xd NE
and xxx NE
alpha xxx NE
B2 Xd NE
(two (xxx NE
alpha xxx NE
B X NE
-encoded -xxx NE
isomers xxx NE
) ) NE
for xxx NE
their xxx NE
effects xxx NE
on xx NE
the xxx NE
GM-CSF XX-XXX NE
promoter xxx NE
. . NE

PEBP2 XXXXd protein_B
alpha xxx protein_M
A1 Xd protein_E
, , NE
alpha xxx protein_B
B1 Xd protein_E
, , NE
and xxx NE
alpha xxx protein_B
B2 Xd protein_M
proteins xxx protein_E
bound xxx NE
the xxx NE
PEBP2 XXXXd DNA_B
site xxx DNA_E
within xxx NE
the xxx NE
mouse xxx DNA_B
GM-CSF XX-XXX DNA_M
promoter xxx DNA_E
. . NE

PEBP2 XXXXd protein_B
alpha xxx protein_M
A1 Xd protein_E
and xxx NE
alpha xxx protein_B
B1 Xd protein_E
enhanced xxx NE
the xxx NE
expression xxx NE
of xx NE
the xxx NE
GM-CSF XX-XXX DNA_B
promoter-driven xxx-xxx DNA_M
reporter xxx DNA_M
plasmid xxx DNA_E
in xx NE
unstimulated xxx cell_line_B
human xxx cell_line_M
Jurkat Xxxx cell_line_M
T X cell_line_M
cell xxx cell_line_M
and xxx cell_line_M
12-O-tetradecanoylphorbol dd-X-xxx cell_line_M
13-acetate/phytohemagglutinin-stimulated dd-xxx/xxx-xxx cell_line_M
human xxx cell_line_M
Jurkat Xxxx cell_line_M
T X cell_line_M
cell xxx cell_line_E

In Xx NE
contrast xxx NE
, , NE
the xxx NE
promoter xxx NE
activity xxx NE
was xxx NE
suppressed xxx NE
by xx NE
alpha xxx protein_B
B2 Xd protein_E
. . NE

Coexpression Xxxx NE
of xx NE
alpha xxx protein_B
B1 Xd protein_E
and xxx NE
alpha xxx protein_B
B2 Xd protein_E
showed xxx NE
that xxx NE
the xxx NE
promoter xxx NE
activity xxx NE
could xxx NE
be xx NE
determined xxx NE
by xx NE
the xxx NE
alpha xxx NE
B1 Xd NE
/alpha /xxx NE
B2 Xd NE
ratio xxx NE
. . NE

Jurkat Xxxx NE
cell xxx NE
extract xxx NE
contained xxx NE
PEBP2 XXXXd protein_B
site-binding xxx-xxx protein_M
protein xxx protein_E
(s) (x) NE
that xxx NE
cross-reacted xxx-xxx NE
with xxx NE
antimouse xxx NE
alpha xxx NE
A1 Xd NE
antibodies xxx NE
. . NE

Northern Xxxx NE
blot xxx NE
analysis xxx NE
indicated xxx NE
the xxx NE
expression xxx NE
of xx NE
human xxx NE
PEBP2 XXXXd protein_B
alpha xxx protein_M
A X protein_E
, , NE
alpha xxx DNA_B
B X DNA_E
( ( NE
AML1 XXXd DNA
) ) NE
, , NE
and xxx NE
beta xxx DNA_B
genes xxx DNA_E
in xx NE
Jurkat Xxxx cell_line_B
cells xxx cell_line_E
. . NE

Although Xxxx NE
further xxx NE
studies xxx NE
are xxx NE
required xxx NE
to xx NE
determine xxx NE
the xxx NE
precise xxx NE
role xxx NE
of xx NE
PEBP2 XXXXd protein
in xx NE
the xxx NE
GM-CSF XX-XXX NE
promoter xxx NE
activity xxx NE
, , NE
the xxx NE
present xxx NE
findings xxx NE
suggested xxx NE
the xxx NE
importance xxx NE
of xx NE
the xxx NE
relative xxx NE
ratio xxx NE
of xx NE
different xxx NE
PEBP2 XXXXd protein_B
isoforms xxx protein_E
in xx NE
regulating xxx NE
the xxx NE
levels xxx NE
of xx NE
the xxx NE
promoter xxx NE
activity xxx NE
. . NE

IFN-gamma XXX-xxx protein
priming xxx NE
of xx NE
monocytes xxx cell_type
enhances xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
production xxx NE
by xx NE
augmenting xxx NE
both xxx NE
transcription xxx NE
and xxx NE
MRNA XXXX NE
stability xxx NE
. . NE

The Xxx NE
induction xxx NE
of xx NE
cytokine xxx NE
expression xxx NE
in xx NE
monocytes xxx cell_type
/ / NE
macrophages xxx cell_type
by xx NE
bacterial xxx protein_B
endotoxin xxx protein_E
or xx NE
lipopolysaccharide xxx NE
is xx NE
a x NE
critical xxx NE
, , NE
highly xxx NE
regulated xxx NE
host xxx NE
defence xxx NE
response xxx NE
. . NE

The Xxx NE
augmentation xxx NE
of xx NE
LPS XXX NE
responses xxx NE
by xx NE
interferon xxx protein_B
gamma xxx protein_E
( ( NE
IFN-gamma XXX-xxx protein
) ) NE
, , NE
referred xxx NE
to xx NE
as xx NE
priming xxx NE
, , NE
is xx NE
well xxx NE
established xxx NE
. . NE

However Xxxx NE
, , NE
the xxx NE
mechanism(s) xxx(x) NE
by xx NE
which xxx NE
priming xxx NE
occurs xxx NE
is xx NE
poorly xxx NE
defined xxx NE
. . NE

Using Xxxx NE
tumour xxx NE
necrosis xxx NE
factor xxx NE
( ( NE
TNF XXX NE
) ) NE
induction xxx NE
as xx NE
a x NE
model xxx NE
, , NE
experiments xxx NE
were xxx NE
designed xxx NE
to xx NE
analyse xxx NE
in xx NE
detail xxx NE
the xxx NE
priming xxx NE
effect xxx NE
on xx NE
the xxx NE
LPS XXX NE
response xxx NE
in xx NE
human xxx NE
monocytes xxx NE
. . NE

Priming Xxxx NE
by xx NE
IFN-gamma XXX-xxx protein
was xxx NE
primarily xxx NE
manifested xxx NE
at xx NE
the xxx NE
level xxx NE
of xx NE
TNF XXX NE
mRNA xXXX NE
accumulation xxx NE
. . NE

IFN-gamma XXX-xxx NE
pre-treatment xxx-xxx NE
affected xxx NE
the xxx NE
magnitude xxx NE
rather xxx NE
than xxx NE
the xxx NE
sensitivity xxx NE
of xx NE
the xxx NE
LPS XXX NE
response xxx NE
. . NE

Priming Xxxx NE
occurred xxx NE
after xxx NE
several xxx NE
hours xxx NE
of xx NE
treatment xxx NE
, , NE
and xxx NE
the xxx NE
primed xxx NE
state xxx NE
was xxx NE
induced xxx NE
by xx NE
either xxx NE
IFN-gamma XXX-xxx protein
or xx NE
GM-CSF XX-XXX protein
, , NE
but xxx NE
not xxx NE
M-CSF X-XXX protein
. . NE

Primed Xxxx NE
monocytes xxx cell_type
transcribed xxx NE
TNF XXX RNA_B
mRNA xXXX RNA_E
at xx NE
a x NE
higher xxx NE
rate xxx NE
than xxx NE
freshly xxx NE
isolated xxx NE
monocytes xxx cell_type
upon xxx NE
activation xxx NE
with xxx NE
LPS XXX NE
. . NE

The Xxx NE
increased xxx NE
transcriptional xxx NE
rate xxx NE
correlated xxx NE
with xxx NE
a x NE
marked xxx NE
increase xxx NE
in xx NE
nuclear xxx NE
factor-kappa xxx-xxx NE
B X NE
activity xxx NE
in xx NE
these xxx NE
cells xxx NE
as xx NE
determined xxx NE
by xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
using xxx NE
a x NE
consensus xxx DNA_B
NF-kappa XX-xxx DNA_M
B X DNA_M
oligonucleotide xxx DNA_E
. . NE

An Xx NE
additional xxx NE
significant xxx NE
finding xxx NE
was xxx NE
than xxx NE
TNF XXX RNA_B
mRNA xXXX RNA_E
induced xxx NE
in xx NE
primed xxx cell_line_B
cells xxx cell_line_E
was xxx NE
much xxx NE
more xxx NE
stable xxx NE
than xxx NE
in xx NE
unprimed xxx cell_line_B
cells xxx cell_line_E
(T1/2 (Xd/d NE
increased xxx NE
6-8-fold) d-d-xxx) NE
. . NE

Consistent Xxxx NE
with xxx NE
the xxx NE
increased xxx NE
mRNA xXXX NE
stability xxx NE
, , NE
the xxx NE
duration xxx NE
of xx NE
mRNA xXXX NE
accumulation xxx NE
was xxx NE
longer xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
in xx NE
primed xxx NE
monocytes xxx cell_type
, , NE
in xx NE
addition xxx NE
to xx NE
being xxx NE
of xx NE
greater xxx NE
magnitude xxx NE
. . NE

Finally Xxxx NE
, , NE
primed xxx NE
and xxx NE
unprimed xxx NE
cells xxx NE
possessed xxx NE
a x NE
differential xxx NE
sensitivity xxx NE
to xx NE
the xxx NE
kinase xxx NE
inhibitor xxx NE
H-89 X-dd NE
. . NE

H-89 X-dd NE
substantially xxx NE
suppressed xxx NE
LPS XXX NE
-induced -xxx NE
TNF XXX NE
mRNA xXXX NE
accumulation xxx NE
in xx NE
unprimed xxx NE
cells xxx NE
, , NE
but xxx NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
primed xxx NE
monocytes xxx NE
following xxx NE
LPS XXX NE
stimulation xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

A X NE
Myc-associated Xxx-xxx DNA_B
zinc xxx DNA_M
finger xxx DNA_M
protein xxx DNA_M
binding xxx DNA_M
site xxx DNA_E
is xx NE
one xxx NE
of xx NE
four xxx NE
important xxx NE
functional xxx DNA_B
regions xxx DNA_E
in xx NE
the xxx NE
CD4 XXd DNA_B
promoter xxx DNA_E
. . NE

The Xxx NE
CD4 XXd DNA_B
promoter xxx DNA_E
plays xxx NE
an xx NE
important xxx NE
role xxx NE
in xx NE
the xxx NE
developmental xxx NE
control xxx NE
of xx NE
CD4 XXd NE
transcription xxx NE
. . NE

In Xx NE
this xxx NE
report xxx NE
, , NE
we xx NE
show xxx NE
that xxx NE
the xxx NE
minimal xxx NE
CD4 XXd DNA_B
promoter xxx DNA_E
has xxx NE
four xxx NE
factor xxx DNA_B
binding xxx DNA_M
sites xxx DNA_E
, , NE
each xxx NE
of xx NE
which xxx NE
is xx NE
required xxx NE
for xxx NE
full xxx NE
function xxx NE
. . NE

Using Xxxx NE
biochemical xxx NE
analysis xxx NE
and xxx NE
mutagenesis xxx NE
analysis xxx NE
analyses xxx NE
, , NE
we xx NE
determined xxx NE
that xxx NE
multiple xxx NE
nuclear xxx protein_B
factors xxx protein_E
bind xxx NE
to xx NE
these xxx NE
independent xxx NE
sites xxx NE
. . NE

We Xx NE
determined xxx NE
that xxx NE
an xx NE
initiator-like xxx-xxx DNA_B
sequence xxx DNA_E
present xxx NE
at xx NE
the xxx NE
cap xxx DNA_B
site xxx DNA_E
and xxx NE
an xx NE
Ets Xxx DNA_B
consensus xxx DNA_M
sequence xxx DNA_E
are xxx NE
required xxx NE
for xxx NE
full xxx NE
promoter xxx NE
function xxx NE
. . NE

We Xx NE
also xxx NE
demonstrate xxx NE
that xxx NE
the xxx NE
Myc-associated Xxx-xxx protein_B
zinc xxx protein_M
finger xxx protein_M
protein xxx protein_E
( ( NE
MAZ XXX protein
) ) NE
appears xxx NE
to xx NE
be xx NE
the xxx NE
predominant xxx protein_B
factor xxx protein_E
binding xxx NE
to xx NE
one xxx NE
of xx NE
these xxx NE
sites xxx NE
. . NE

This Xxxx NE
last xxx NE
site xxx NE
closely xxx NE
resembles xxx NE
the xxx NE
ME1a1 XXdxd DNA_B
G3AG4AG3 XdXXdXXd DNA_M
motif xxx DNA_E
previously xxx NE
shown xxx NE
to xx NE
be xx NE
a x NE
critical xxx NE
element xxx NE
in xx NE
the xxx NE
P2 Xd DNA_B
promoter xxx DNA_E
of xx NE
the xxx NE
c-myc x-xxx DNA_B
gene xxx DNA_E
. . NE

We Xx NE
therefore xxx NE
believe xxx NE
that xxx NE
the xxx NE
MAZ XXX protein_B
transcription xxx protein_M
factor xxx protein_E
is xx NE
also xxx NE
likely xxx NE
to xx NE
play xxx NE
an xx NE
important xxx NE
role xxx NE
in xx NE
the xxx NE
control xxx NE
of xx NE
developmental xxx NE
expression xxx NE
of xx NE
the xxx NE
CD4 XXd DNA_B
gene xxx DNA_E
. . NE

Erythropoietin Xxxx protein
stimulates xxx NE
transcription xxx NE
of xx NE
the xxx NE
TAL1/SCL XXXd/XXX DNA_B
gene xxx DNA_E
and xxx NE
phosphorylation xxx NE
of xx NE
its xxx NE
protein xxx protein_B
products xxx protein_E
. . NE

Activation Xxxx NE
of xx NE
the xxx NE
TAL1 XXXd DNA_B
(or (xx DNA_M
SCL) XXX) DNA_M
gene xxx DNA_E
, , NE
originally xxx NE
identified xxx NE
through xxx NE
its xxx NE
involvement xxx NE
by xx NE
a x NE
recurrent xxx NE
chromosomal xxx NE
translocation xxx NE
, , NE
is xx NE
the xxx NE
most xxx NE
frequent xxx NE
molecular xxx DNA_B
lesion xxx DNA_E
recognized xxx NE
in xx NE
T-cell X-xxx NE
acute xxx NE
lymphoblastic xxx NE
leukemia xxx NE
. . NE

The Xxx NE
protein xxx protein_B
products xxx protein_E
of xx NE
this xxx NE
gene xxx NE
contain xxx NE
the xxx NE
basic-helix-loop-helix xxx-xxx-xxx-xxx protein_B
motif xxx protein_E
characteristic xxx NE
of xx NE
a x NE
large xxx NE
family xxx NE
of xx NE
transcription xxx protein_B
factors xxx protein_E
that xxx NE
bind xxx NE
to xx NE
the xxx NE
canonical xxx DNA_B
DNA XXX DNA_M
sequence xxx DNA_M
CANNTG XXXXXX DNA_E
as xx NE
protein xxx protein_B
heterodimers xxx protein_E
. . NE

TAL1 XXXd NE
expression xxx NE
by xx NE
erythroid xxx cell_type_B
cells xxx cell_type_E
in xx NE
vivo xxx NE
and xxx NE
in xx NE
chemical-induced xxx-xxx cell_line_B
erythroleukemia xxx cell_line_M
cell xxx cell_line_M
lines xxx cell_line_E
in xx NE
vivo xxx NE
suggested xxx NE
the xxx NE
gene xxx NE
might xxx NE
regulate xxx NE
aspects xxx NE
of xx NE
erythroid xxx NE
differentiation xxx NE
. . NE

Since Xxxx NE
the xxx NE
terminal xxx NE
events xxx NE
of xx NE
erythropoiesis xxx NE
are xxx NE
controlled xxx NE
by xx NE
the xxx NE
glycoprotein xxx protein_B
hormone xxx protein_M
erythropoietin xxx protein_E
( ( NE
Epo Xxx protein
) ) NE
, , NE
we xx NE
investigated xxx NE
whether xxx NE
the xxx NE
expression xxx NE
or xx NE
activity xxx NE
of xx NE
the xxx NE
TAL1 XXXd DNA_B
gene xxx DNA_E
and xxx NE
its xxx NE
protein xxx protein_B
products xxx protein_E
were xxx NE
affected xxx NE
by xx NE
Epo Xxx protein
in xx NE
splenic xxx cell_type_B
erythroblasts xxx cell_type_E
from xxx NE
mice xxx NE
infected xxx NE
with xxx NE
an xx NE
anemia-inducing xxx-xxx NE
strain xxx NE
of xx NE
Friend Xxxx NE
virus xxx NE
(FVA (XXX NE
cells) xxx) NE
. . NE

Epo Xxx protein
elicited xxx NE
a x NE
rapid xxx NE
, , NE
dose-related xxx-xxx NE
increase xxx NE
in xx NE
TAL1 XXXd RNA_B
mRNA xXXX RNA_E
by xx NE
increasing xxx NE
transcription xxx NE
of xx NE
the xxx NE
gene xxx NE
and xxx NE
stabilizing xxx NE
one xxx NE
of xx NE
its xxx NE
mRNAs xXXXx RNA
. . NE

An Xx NE
Epo Xxx NE
-inducible -xxx NE
TAL1 XXXd NE
DNA XXX NE
binding xxx NE
activity xxx NE
was xxx NE
identified xxx NE
in xx NE
FVA XXX NE
cell xxx NE
nuclear xxx NE
extracts xxx NE
that xxx NE
subsequently xxx NE
decayed xxx NE
despite xxx NE
accumulating xxx NE
mRNA xXXX NE
and xxx NE
protein xxx NE
. . NE

Induction Xxxx NE
of xx NE
DNA XXX NE
binding xxx NE
activity xxx NE
was xxx NE
associated xxx NE
temporally xxx NE
with xxx NE
Epo Xxx NE
-induced -xxx NE
phosphorylation xxx NE
of xx NE
nuclear xxx NE
TAL1 XXXd NE
protein xxx NE
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
Epo Xxx protein
acts xxx NE
at xx NE
both xxx NE
transcriptional xxx NE
level xxx NE
and xxx NE
posttranscriptional xxx NE
level xxx NE
on xx NE
the xxx NE
TAL1 XXXd protein
locus xxx NE
in xx NE
Friend Xxxx cell_line_B
virus xxx cell_line_E
-induced -xxx NE
erythroblasts xxx NE
and xxx NE
establish xxx NE
a x NE
link xxx NE
between xxx NE
Epo Xxx NE
signaling xxx NE
mechanisms xxx NE
and xxx NE
a x NE
member xxx NE
of xx NE
a x NE
family xxx NE
of xx NE
transcription xxx protein_B
factors xxx protein_E
involved xxx NE
in xx NE
the xxx NE
differentiation xxx NE
of xx NE
diverse xxx cell_type_B
cell xxx cell_type_M
lineages xxx cell_type_E
. . NE

Nonradioactive Xxxx NE
quantification xxx NE
of xx NE
glucocorticoid xxx NE
receptor xxx NE
expression xxx NE
during xxx NE
differentiation xxx NE
of xx NE
human xxx NE
monocytic xxx cell_type_B
cells xxx cell_type_E
( ( NE
U937 Xddd cell_line
) ) NE
. . NE

We Xx NE
describe xxx NE
a x NE
method xxx NE
for xxx NE
relative xxx NE
quantification xxx NE
of xx NE
specific xxx NE
mRNA xXXX RNA
using xxx NE
a x NE
nonradioactive xxx NE
assay xxx NE
based xxx NE
on xx NE
DNA XXX NE
strand xxx NE
competition xxx NE
between xxx NE
identical xxx NE
sequences xxx NE
of xx NE
biotin- xxx- NE
and xxx NE
fluorescein-labeled xxx-xxx NE
amplicon xxx NE
(probe) (xxx) NE
and xxx NE
unlabeled xxx NE
amplicon xxx NE
(target) (xxx) NE
during xxx NE
hybridization xxx NE
. . NE

As Xx NE
the xxx NE
target xxx NE
quantity xxx NE
increased xxx NE
, , NE
that xxx NE
of xx NE
the xxx NE
double-labeled xxx-xxx NE
probe xxx NE
decreased xxx NE
in xx NE
accordance xxx NE
with xxx NE
the xxx NE
mass xxx NE
action xxx NE
law xxx NE
. . NE

This Xxxx NE
technique xxx NE
was xxx NE
successfully xxx NE
applied xxx NE
to xx NE
evaluate xxx NE
differences xxx NE
in xx NE
glucocorticoid xxx NE
receptor xxx NE
expression xxx NE
in xx NE
U937 Xddd cell_line_B
cells xxx cell_line_E
before xxx NE
and xxx NE
after xxx NE
the xxx NE
addition xxx NE
of xx NE
potent xxx NE
differentiation xxx NE
inducers xxx NE
: : NE
12-O-tetradecanoylphorbol dd-X-xxx NE
13-acetate dd-xxx NE
( ( NE
TPA XXX NE
) ) NE
and xxx NE
a x NE
combination xxx NE
of xx NE
all-trans xxx-xxx NE
retinoic xxx NE
acid xxx NE
( ( NE
RA XX NE
) ) NE
and xxx NE
1,25-dihydroxyvitamin d,dd-xxx NE
D2 Xd NE
( ( NE
VD XX NE
) ) NE
. . NE

We Xx NE
observed xxx NE
that xxx NE
TPA XXX NE
treatment xxx NE
was xxx NE
associated xxx NE
with xxx NE
an xx NE
increase xxx NE
in xx NE
specific xxx NE
binding xxx NE
of xx NE
[3H]dexamethasone [dX]xxx NE
and xxx NE
up-regulation xx-xxx NE
of xx NE
GR XX RNA_B
mRNA xXXX RNA_E
while xxx NE
no xx NE
enhanced xxx NE
GR XX NE
expression xxx NE
was xxx NE
perceived xxx NE
with xxx NE
RA/VD XX/XX NE
treatment xxx NE
. . NE

Induction Xxxx NE
of xx NE
Sp1 Xxd NE
phosphorylation xxx NE
and xxx NE
NF-kappa XX-xxx NE
B X NE
-independent -xxx NE
HIV XXX NE
promoter xxx NE
domain xxx NE
activity xxx NE
in xx NE
T X NE
lymphocytes xxx NE
stimulated xxx NE
by xx NE
okadaic xxx NE
acid xxx NE
. . NE

In Xx NE
contrast xxx NE
to xx NE
the xxx NE
purely xxx NE
enhancer-dependent xxx-xxx NE
effect xxx NE
of xx NE
cytokines xxx protein
such xxx NE
as xx NE
TNF XXX protein
on xx NE
the xxx NE
activity xxx NE
of xx NE
the xxx NE
HIV XXX DNA_B
regulatory xxx DNA_M
region xxx DNA_E
( ( NE
LTR XXX DNA
) ) NE
, , NE
we xx NE
observed xxx NE
that xxx NE
okadaic xxx NE
acid xxx NE
( ( NE
OKA XXX NE
) ) NE
activates xxx NE
HIV XXX NE
transcription xxx NE
through xxx NE
both xxx NE
the xxx NE
enhancer xxx NE
, , NE
responding xxx NE
to xx NE
the xxx NE
factor xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
, , NE
and xxx NE
the xxx NE
promoter xxx DNA_B
domain xxx DNA_E
of xx NE
the xxx NE
LTR XXX DNA
. . NE

The Xxx NE
inducibility xxx NE
of xx NE
HIV XXX NE
LTR XXX NE
-driven -xxx NE
luciferase xxx NE
expression xxx NE
constructs xxx NE
in xx NE
lymphoblastoid xxx NE
cells xxx NE
stimulated xxx NE
by xx NE
OKA XXX NE
depended xxx NE
on xx NE
both xxx NE
functional xxx NE
Sp1 Xxd NE
binding xxx NE
elements xxx NE
and xxx NE
the xxx NE
ability xxx NE
of xx NE
the xxx NE
TATA XXXX NE
box xxx NE
to xx NE
bind xxx NE
the xxx NE
protein xxx NE
TBP XXX NE
. . NE

In Xx NE
both xxx NE
transformed xxx cell_type_B
lymphocyte xxx cell_type_M
and xxx cell_type_M
normal xxx cell_type_M
lymphocyte xxx cell_type_E
OKA XXX NE
stimulation xxx NE
induced xxx NE
intense xxx NE
phosphorylation xxx NE
of xx NE
the xxx NE
constitutively xxx NE
expressed xxx NE
Sp1 Xxd protein_B
protein xxx protein_E
in xx NE
the xxx NE
nucleus xxx NE
, , NE
a x NE
property xxx NE
of xx NE
OKA XXX NE
not xxx NE
shared xxx NE
by xx NE
TNF XXX protein
, , NE
phorbol xxx NE
ester xxx NE
, , NE
or xx NE
PHA XXX protein
and xxx NE
interleukin xxx protein_B
2 d protein_E
. . NE

Responsiveness Xxxx NE
of xx NE
LTR XXX DNA_B
constructs xxx DNA_E
deleted xxx NE
of xx NE
kappa xxx DNA_B
B X DNA_M
elements xxx DNA_E
to xx NE
HIV XXX NE
Tat Xxx NE
expression xxx NE
was xxx NE
increased xxx NE
upon xxx NE
OKA XXX NE
stimulation xxx NE
but xxx NE
not xxx NE
TNF XXX NE
stimulation xxx NE
but xxx NE
not xxx NE
TNF XXX NE
stimulation xxx NE
. . NE

Our Xxx NE
results xxx NE
suggest xxx NE
that xxx NE
SP1 XXd protein
phosphorylation xxx NE
induced xxx NE
by xx NE
OKA XXX NE
, , NE
a x NE
selective xxx NE
inhibitor xxx NE
of xx NE
the xxx NE
serine-threonine xxx-xxx protein_B
phosphatase xxx protein_E
PP2A XXdX protein
, , NE
facilitates xxx NE
the xxx NE
formation xxx NE
of xx NE
a x NE
transcription xxx protein_B
complex xxx protein_E
involving xxx NE
general xxx NE
transcription xxx protein_B
factors xxx protein_E
, , NE
HIV XXX protein_B
Tat Xxx protein_E
, , NE
and xxx NE
Sp1 Xxd protein_B
proteins xxx protein_E
. . NE

The Xxx NE
formation xxx NE
of xx NE
this xxx NE
complex xxx NE
would xxx NE
increase xxx NE
, , NE
independently xxx NE
of xx NE
an xx NE
in xx NE
synergy xxx NE
with xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
, , NE
the xxx NE
low xxx NE
basal xxx NE
activity xxx NE
of xx NE
the xxx NE
HIV XXX DNA_B
LTR XXX DNA_E
observed xxx NE
in xx NE
normal xxx cell_type_B
T X cell_type_M
lymphocytes xxx cell_type_E
. . NE

The Xxx NE
role xxx NE
of xx NE
shared xxx protein_B
receptor xxx protein_M
motifs xxx protein_E
and xxx NE
common xxx protein_B
Stat Xxxx protein_M
proteins xxx protein_E
in xx NE
the xxx NE
generation xxx NE
of xx NE
cytokine xxx NE
pleiotropy xxx NE
and xxx NE
redundancy xxx NE
by xx NE
IL-2 XX-d protein
, , NE
IL-4 XX-d protein
, , NE
IL-7 XX-d protein
, , NE
IL-13 XX-dd protein
, , NE
and xxx NE
IL-15 XX-dd protein
. . NE

To Xx NE
understand xxx NE
the xxx NE
molecular xxx NE
bases xxx NE
for xxx NE
cytokine xxx NE
redundancy xxx NE
and xxx NE
cytokine xxx NE
pleiotropy xxx NE
cytokine xxx protein
Stat Xxxx NE
proteins xxx NE
activated xxx NE
in xx NE
peripheral xxx cell_type_B
blood xxx cell_type_M
lymphocytes xxx cell_type_E
( ( NE
PBLs XXXx cell_type
) ) NE
by xx NE
cytokines xxx NE
with xxx NE
shared xxx NE
and xxx NE
distinct xxx NE
actions xxx NE
. . NE

Interleukin-2 Xxxx-d protein
( ( NE
IL-2 XX-d protein
) ) NE
rapidly xxx NE
activated xxx NE
Stat5 Xxxxd protein
in xx NE
fresh xxx NE
PBL XXX cell_type
, , NE
and xxx NE
Stat3 Xxxxd protein
and xxx NE
Stat5 Xxxxd protein
in xx NE
preactivated xxx cell_type_B
PBL XXX cell_type_E
. . NE

IL-7 XX-d protein
and xxx NE
IL-15 XX-dd protein
induced xxx NE
the xxx NE
same xxx NE
complexes xxx NE
as xx NE
IL-2 XX-d protein
, , NE
a x NE
feature xxx NE
explained xxx NE
by xx NE
the xxx NE
existence xxx NE
of xx NE
similar xxx NE
tyrosine xxx NE
-phosphorylated -xxx NE
motifs xxx NE
in xx NE
the xxx NE
cytoplasmic xxx NE
domains xxx NE
of xx NE
IL-2R XX-dX NE
beta xxx NE
and xxx NE
IL-7R XX-dX NE
that xxx NE
can xxx NE
serve xxx NE
as xx NE
docking xxx NE
sites xxx NE
for xxx NE
Stat Xxxx NE
proteins xxx NE
. . NE

IL-13 XX-dd protein
Induced Xxxx NE
the xxx NE
same xxx NE
complexes xxx NE
as xx NE
IL-4 XX-d protein
, , NE
a x NE
finding xxx NE
explained xxx NE
by xx NE
our xxx NE
studies xxx NE
implicating xxx NE
IL-4R XX-dX protein
as xx NE
a x NE
shared xxx NE
component xxx NE
of xx NE
the xxx NE
receptors xxx protein
. . NE

These Xxxx NE
studies xxx NE
demonstrate xxx NE
that xxx NE
a x NE
single xxx NE
cytokine xxx protein
can xxx NE
activate xxx NE
different xxx NE
combinations xxx NE
of xx NE
Stat Xxxx protein_B
proteins xxx protein_E
under xxx NE
different xxx NE
physiological xxx NE
conditions xxx NE
, , NE
and xxx NE
also xxx NE
indicate xxx NE
two xxx NE
mechanisms xxx NE
by xx NE
which xxx NE
distinct xxx NE
cytokines xxx protein
can xxx NE
activate xxx NE
the xxx NE
same xxx NE
Stat Xxxx protein_B
protein xxx protein_E
. . NE

Control Xxxx NE
of xx NE
I X NE
kappa xxx NE
B-alpha X-xxx NE
proteolysis xxx NE
by xx NE
site-specific xxx-xxx NE
, , NE
signal-induced xxx-xxx NE
phosphorylation xxx NE
. . NE

I X protein_B
kappa xxx protein_M
B-alpha X-xxx protein_E
inhibits xxx NE
transcription xxx protein_B
factor xxx protein_E
NF-kappa XX-xxx protein_B
B X protein_E
by xx NE
retaining xxx NE
it xx NE
in xx NE
the xxx NE
cytoplasm xxx NE
. . NE

Various Xxxx NE
stimuli xxx NE
, , NE
typically xxx NE
those xxx NE
associated xxx NE
with xxx NE
stress xxx NE
or xx NE
pathogens xxx NE
, , NE
rapidly xxx NE
inactivate xxx NE
I X protein_B
kappa xxx protein_M
B-alpha X-xxx protein_E
. . NE

This Xxxx NE
liberates xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
to xx NE
translocate xxx NE
to xx NE
the xxx NE
nucleus xxx NE
and xxx NE
initiate xxx NE
transcription xxx NE
of xx NE
genes xxx DNA
important xxx NE
for xxx NE
the xxx NE
defense xxx NE
of xx NE
the xxx NE
organism xxx NE
. . NE

Activation Xxxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
correlates xxx NE
with xxx NE
phosphorylation xxx NE
of xx NE
I X protein_B
kappa xxx protein_M
B-alpha X-xxx protein_E
and xxx NE
requires xxx NE
the xxx NE
proteolysis xxx NE
of xx NE
this xxx NE
inhibitor xxx NE
. . NE

When Xxxx NE
either xxx NE
serine-32 xxx-dd NE
or xx NE
serine-36 xxx-dd NE
of xx NE
I X protein_B
kappa xxx protein_M
B-alpha X-xxx protein_E
was xxx NE
mutated xxx NE
, , NE
the xxx NE
protein xxx NE
did xxx NE
not xxx NE
undergo xxx NE
signal-induced xxx-xxx NE
phosphorylation xxx NE
or xx NE
degradation xxx NE
, , NE
and xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
could xxx NE
not xxx NE
be xx NE
activated xxx NE
. . NE

These Xxxx NE
results xxx NE
suggest xxx NE
that xxx NE
phosphorylation xxx NE
at xx NE
one xxx NE
or xx NE
both xxx NE
of xx NE
these xxx NE
residues xxx NE
is xx NE
critical xxx NE
for xxx NE
activation xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
. . NE

Regulation Xxxx NE
of xx NE
transcription xxx NE
of xx NE
the xxx NE
human xxx DNA_B
erythropoietin xxx DNA_M
receptor xxx DNA_M
gene xxx DNA_E
by xx NE
proteins xxx NE
binding xxx NE
to xx NE
GATA-1 XXXX-d DNA_B
and xxx DNA_M
Sp1 Xxd DNA_M
motifs xxx DNA_E
. . NE

Erythropoietin Xxxx protein
( ( NE
Epo Xxx protein
) ) NE
, , NE
the xxx NE
primary xxx NE
regulator xxx NE
of xx NE
the xxx NE
production xxx NE
of xx NE
erythroid xxx cell_type_B
cells xxx cell_type_E
, , NE
acts xxx NE
by xx NE
binding xxx NE
to xx NE
a x NE
cell xxx protein_B
surface xxx protein_M
receptor xxx protein_E
( ( NE
EpoR XxxX protein
) ) NE
on xx NE
erythroid xxx cell_type_B
progenitors xxx cell_type_E
. . NE

We Xx NE
used xxx NE
deletion xxx NE
analysis xxx NE
and xxx NE
transfection xxx NE
assays xxx NE
with xxx NE
reporter xxx DNA_B
gene xxx DNA_M
constructs xxx DNA_E
to xx NE
examine xxx NE
the xxx NE
transcription xxx DNA_B
control xxx DNA_M
elements xxx DNA_E
in xx NE
the xxx NE
5' d' DNA_B
flanking xxx DNA_M
region xxx DNA_E
of xx NE
the xxx NE
human xxx DNA_B
EpoR XxxX DNA_M
gene xxx DNA_E
. . NE

In Xx NE
erythroid xxx cell_type_B
cells xxx cell_type_E
most xxx NE
of xx NE
the xxx NE
transcription xxx NE
activity xxx NE
was xxx NE
contained xxx NE
in xx NE
a x NE
150 ddd DNA_B
bp xx DNA_M
promoter xxx DNA_E
fragment xxx NE
with xxx NE
binding xxx DNA_B
sites xxx DNA_E
for xxx NE
transcription xxx protein_B
factors xxx protein_E
AP2 XXd protein
, , NE
Sp1 Xxd protein
and xxx NE
the xxx NE
erythroid-specific xxx-xxx protein_B
GATA-1 XXXX-d protein_E
. . NE

The Xxx NE
150 ddd DNA_B
bp xx DNA_M
hEpoR xXxxX DNA_M
promoter xxx DNA_E
exhibited xxx NE
high xxx NE
and xxx NE
low xxx NE
activity xxx NE
in xx NE
erythroid xxx NE
OCIM1 XXXXd cell_line
and xxx NE
K562 Xddd cell_line_B
cells xxx cell_line_E
, , NE
respectively xxx NE
, , NE
reflecting xxx NE
the xxx NE
high xxx NE
and xxx NE
low xxx NE
levels xxx NE
of xx NE
constitutive xxx NE
hEpoR xXxxX NE
expression xxx NE
. . NE

The Xxx NE
GATA-1 XXXX-d DNA_B
binding xxx DNA_M
site xxx DNA_M
and xxx DNA_M
Sp1 Xxd DNA_M
binding xxx DNA_M
site xxx DNA_E
in xx NE
this xxx NE
promoter xxx NE
lacking xxx NE
a x NE
TATA XXXX DNA_B
sequence xxx DNA_E
were xxx NE
necessary xxx NE
for xxx NE
a x NE
high xxx NE
level xxx NE
of xx NE
transcription xxx NE
activation xxx NE
. . NE

Protein-DNA Xxxx-XXX NE
binding xxx NE
studies xxx NE
suggested xxx NE
that xxx NE
Sp1 Xxd protein
and xxx NE
two xxx NE
other xxx NE
CCGCCC XXXXXX protein_B
binding xxx protein_M
proteins xxx protein_E
from xxx NE
erythroid xxx cell_type_B
cell xxx cell_type_M
and xxx cell_type_M
non-erythroid xxx-xxx cell_type_M
cell xxx cell_type_E
could xxx NE
bind xxx NE
to xx NE
the xxx NE
Sp1 Xxd DNA_B
binding xxx DNA_M
motif xxx DNA_E
. . NE

By Xx NE
increasing xxx NE
GATA-1 XXXX-d NE
levels xxx NE
via xxx NE
co-transfection xx-xxx NE
, , NE
we xx NE
were xxx NE
able xxx NE
to xx NE
transactivate xxx NE
the xxx NE
hEpoR xXxxX DNA_B
promoter xxx DNA_E
in xx NE
K562 Xddd cell_line_B
cells xxx cell_line_E
and xxx NE
non-erythroid xxx-xxx cell_type_B
cells xxx cell_type_E
, , NE
but xxx NE
not xxx NE
in xx NE
the xxx NE
highly xxx NE
active xxx NE
OCIM1 XXXXd cell_type_B
cells xxx cell_type_E
, , NE
although xxx NE
GATA-1 XXXX-d NE
mRNA xXXX NE
levels xxx NE
were xxx NE
comparable xxx NE
in xx NE
OCIM1 XXXXd cell_line
and xxx NE
K562 Xddd cell_line
. . NE

Interestingly Xxxx NE
, , NE
when xxx NE
we xx NE
mutated xxx NE
the xxx NE
Sp1 Xxd DNA_B
site xxx DNA_E
, , NE
resulting xxx NE
in xx NE
a x NE
marked xxx NE
decrease xxx NE
in xx NE
hEpoR xXxxX NE
promoter xxx NE
activity xxx NE
, , NE
we xx NE
could xxx NE
restore xxx NE
transactivation xxx NE
by xx NE
increasing xxx NE
GATA-1 XXXX-d NE
levels xxx NE
in xx NE
OCIM1 XXXXd cell_type_B
cells xxx cell_type_E
. . NE

These Xxxx NE
data xxx NE
suggest xxx NE
that xxx NE
while xxx NE
GATA-1 XXXX-d protein
can xxx NE
transactivate xxx NE
the xxx NE
EpoR XxxX DNA_B
promoter xxx DNA_E
, , NE
the xxx NE
level xxx NE
of xx NE
hEpoR xXxxX NE
gene xxx NE
expression xxx NE
does xxx NE
not xxx NE
depend xxx NE
on xx NE
GATA-1 XXXX-d protein
alone xxx NE
. . NE

Rather Xxxx NE
, , NE
hEpoR xXxxX NE
transcription xxx NE
activity xxx NE
depends xxx NE
on xx NE
coordination xxx NE
between xxx NE
Sp1 Xxd protein
and xxx NE
GATA-1 XXXX-d protein
with xxx NE
other xxx NE
cell-specific xxx-xxx protein_B
factors xxx protein_E
, , NE
including xxx NE
possibly xxx NE
other xxx NE
Sp1 Xxd NE
-like -xxx NE
binding xxx NE
proteins xxx NE
, , NE
to xx NE
provide xxx NE
high xxx NE
level xxx NE
, , NE
tissue-specific xxx-xxx NE
expression xxx NE
. . NE

Overexpression Xxxx NE
of xx NE
DR-nm23 XX-xxdd protein
, , NE
a x NE
protein xxx NE
encoded xxx NE
by xx NE
a x NE
member xxx NE
of xx NE
the xxx NE
nm23 xxdd DNA_B
gene xxx DNA_M
family xxx DNA_E
, , NE
inhibits xxx NE
granulocyte xxx NE
differentiation xxx NE
and xxx NE
induces xxx NE
apoptosis xxx NE
in xx NE
32Dc13 ddXxdd cell_line_B
myeloid xxx cell_line_M
cells xxx cell_line_E
. . NE

Chronic Xxxx NE
myelogenous xxx NE
leukemia xxx NE
evolves xxx NE
in xx NE
two xxx NE
clinically xxx NE
distinct xxx NE
stages xxx NE
: : NE
a x NE
chronic xxx NE
and xxx NE
a x NE
blast xxx NE
crisis xxx NE
phase xxx NE
. . NE

The Xxx NE
molecular xxx NE
changes xxx NE
associated xxx NE
with xxx NE
chronic xxx NE
phase xxx NE
to xx NE
blast xxx NE
crisis xxx NE
transition xxx NE
are xxx NE
largely xxx NE
unknown xxx NE
. . NE

We Xx NE
have xxx NE
identified xxx NE
a x NE
cDNA xXXX DNA_B
clone xxx DNA_E
, , NE
DR-nm23 XX-xxdd protein
, , NE
differentially xxx NE
expressed xxx NE
in xx NE
a x NE
blast-crisis xxx-xxx NE
cDNA xXXX NE
library xxx NE
, , NE
which xxx NE
has xxx NE
approximately xxx NE
70% dd% NE
sequence xxx NE
similarity xxx NE
to xx NE
the xxx NE
putative xxx NE
metastatic xxx NE
suppressor xxx NE
genes xxx NE
, , NE
nm23-H1 xxdd-Xd NE
and xxx NE
nm23-H2 xxdd-Xd NE
. . NE

The Xxx NE
deduced xxx NE
amino xxx NE
acid xxx NE
sequence xxx NE
similarity xxx NE
to xx NE
the xxx NE
proteins xxx NE
encoded xxx NE
by xx NE
these xxx NE
two xxx NE
latter xxx NE
genes xxx NE
is xx NE
approximately xxx NE
65% dd% NE
and xxx NE
includes xxx NE
domains xxx NE
and xxx NE
amino xxx NE
acid xxx NE
residues xxx NE
(the (xxx NE
leucine xxx NE
zipper-like xxx-xxx NE
and xxx NE
the xxx NE
RGD XXX NE
domain xxx NE
, , NE
a x NE
serine xxx NE
and xxx NE
a x NE
histidine xxx NE
residue xxx NE
in xx NE
the xxx NE
NH2- XXd- NE
and xxx NE
in xx NE
the xxx NE
COOH-terminal XXXX-xxx NE
portion xxx NE
of xx NE
the xxx NE
protein xxx NE
, , NE
respectively) xxx) NE
postulated xxx NE
to xx NE
be xx NE
important xxx NE
for xxx NE
nm23 xxdd NE
function xxx NE
. . NE

DR-nm23 XX-xxdd RNA_B
mRNA xXXX RNA_E
is xx NE
preferentially xxx NE
expressed xxx NE
at xx NE
early xxx NE
stages xxx NE
of xx NE
myeloid xxx NE
differentiation xxx NE
of xx NE
highly xxx cell_line_B
purified xxx cell_line_M
CD34+ XXdd+ cell_line_M
cells xxx cell_line_E
. . NE

Its Xxx NE
constitutive xxx NE
expression xxx NE
in xx NE
the xxx NE
myeloid xxx cell_line_B
precursor xxx cell_line_M
32Dc13 ddXxdd cell_line_M
cell xxx cell_line_M
line xxx cell_line_E
, , NE
which xxx NE
is xx NE
growth-factor xxx-xxx NE
dependent xxx NE
for xxx NE
both xxx NE
proliferation xxx NE
and xxx NE
differentiation xxx NE
, , NE
results xxx NE
in xx NE
inhibition xxx NE
of xx NE
granulocytic xxx NE
differentiation xxx NE
induced xxx NE
by xx NE
granulocyte xxx protein_B
colony-stimulating xxx-xxx protein_M
factor xxx protein_E
and xxx NE
causes xxx NE
apoptotic xxx NE
cell xxx NE
death xxx NE
. . NE

These Xxxx NE
results xxx NE
are xxx NE
consistent xxx NE
with xxx NE
a x NE
role xxx NE
for xxx NE
DR-nm23 XX-xxdd protein
in xx NE
normal xxx NE
hematopoiesis xxx NE
and xxx NE
raise xxx NE
the xxx NE
possibility xxx NE
that xxx NE
its xxx NE
overexpression xxx NE
contributes xxx NE
to xx NE
differentiation xxx NE
arrest xxx NE
, , NE
a x NE
feature xxx NE
of xx NE
blastic xxx NE
transformation xxx NE
in xx NE
chronic xxx NE
myelogenous xxx NE
leukemia xxx NE
. . NE

An Xx NE
interferon-gamma xxx-xxx DNA_B
activation xxx DNA_M
sequence xxx DNA_E
mediates xxx NE
the xxx NE
transcriptional xxx NE
regulation xxx NE
of xx NE
the xxx NE
IgG XxX DNA_B
Fc Xx DNA_M
receptor xxx DNA_M
type xxx DNA_M
IC XX DNA_M
gene xxx DNA_E
by xx NE
interferon-gamma xxx-xxx protein
. . NE

Expression Xxxx NE
of xx NE
the xxx NE
IgG XxX protein_B
Fc Xx protein_M
receptor xxx protein_M
type xxx protein_M
I X protein_E
( ( NE
Fc Xx protein_B
gamma xxx protein_M
RI XX protein_E
) ) NE
on xx NE
myeloid xxx cell_type_B
cells xxx cell_type_E
is xx NE
dramatically xxx NE
increased xxx NE
by xx NE
treatment xxx NE
with xxx NE
interferon-gamma xxx-xxx protein
( ( NE
IFN-gamma XXX-xxx protein
) ) NE
. . NE

We Xx NE
observed xxx NE
that xxx NE
Fc Xx NE
gamma xxx NE
RI XX NE
transcript xxx NE
levels xxx NE
in xx NE
monoblast-like xxx-xxx cell_line_B
U937 Xddd cell_line_M
cells xxx cell_line_E
were xxx NE
elevated xxx NE
within xxx NE
3 d NE
hr xx NE
and xxx NE
peaked xxx NE
12 dd NE
hr xx NE
after xxx NE
exposure xxx NE
to xx NE
IFN-gamma XXX-xxx protein
. . NE

Treatment Xxxx NE
of xx NE
U937 Xddd cell_line
with xxx NE
IFN-gamma XXX-xxx protein
for xxx NE
9 d NE
hr xx NE
in xx NE
the xxx NE
presence xxx NE
of xx NE
cycloheximide xxx NE
led xxx NE
to xx NE
super-induction xxx-xxx NE
of xx NE
Fc Xx protein_B
gamma xxx protein_M
RI XX protein_E
expression xxx NE
. . NE

Nuclear Xxxx NE
run-on xxx-xx NE
analysis xxx NE
revealed xxx NE
that xxx NE
the xxx NE
rate xxx NE
of xx NE
Fc Xx protein_B
gamma xxx protein_M
RI XX protein_E
transcription xxx NE
was xxx NE
increased xxx NE
by xx NE
IFN-gamma XXX-xxx protein
. . NE

Genomic Xxxx NE
sequence xxx NE
upstream xxx NE
of xx NE
the xxx NE
Fc Xx DNA_B
gamma xxx DNA_M
RIC XXX DNA_M
gene xxx DNA_E
was xxx NE
cloned xxx NE
and xxx NE
subjected xxx NE
to xx NE
primer xxx NE
extension xxx NE
analysis xxx NE
, , NE
which xxx NE
demonstrated xxx NE
a x NE
single xxx NE
transcription xxx DNA_B
initiation xxx DNA_M
site xxx DNA_E
without xxx NE
a x NE
TATA XXXX DNA_B
box xxx DNA_E
. . NE

Transient Xxxx NE
transfections xxx NE
of xx NE
CAT XXX DNA_B
reporter xxx DNA_M
gene xxx DNA_M
constructs xxx DNA_E
containing xxx NE
various xxx NE
Fc Xx DNA_B
gamma xxx DNA_M
RIC XXX DNA_M
promoter xxx DNA_M
sequences xxx DNA_E
into xxx NE
U937 Xddd cell_line_B
cells xxx cell_line_E
revealed xxx NE
that xxx NE
a x NE
20-bp dd-xx DNA_B
region xxx DNA_E
surrounding xxx NE
the xxx NE
transcription xxx DNA_B
start xxx DNA_M
site xxx DNA_E
(-7 (-d NE
to xx NE
+13) +dd) NE
was xxx NE
capable xxx NE
of xx NE
mediating xxx NE
transcription xxx NE
initiation xxx NE
and xxx NE
that xxx NE
an xx NE
IFN-gamma XXX-xxx DNA_B
responsive xxx DNA_M
element xxx DNA_E
( ( NE
GIRE XXXX DNA
) ) NE
was xxx NE
present xxx NE
within xxx NE
74 dd DNA_B
bp xx DNA_M
upstream xxx DNA_E
of xx NE
the xxx NE
transcription xxx DNA_B
initiation xxx DNA_M
site xxx DNA_E
. . NE

A X NE
17-bp dd-xx DNA_B
sequence xxx DNA_E
between xxx NE
positions xxx NE
-51 -dd NE
and xxx NE
-35 -dd NE
conferred xxx NE
IFN-gamma XXX-xxx NE
responsiveness xxx NE
on xx NE
a x NE
heterologous xxx DNA_B
promoter xxx DNA_E
. . NE

Double-stranded Xxxx-xxx DNA_B
GIRE XXXX DNA_M
sequence xxx DNA_E
, , NE
but xxx NE
not xxx NE
a x NE
scrambled xxx DNA_B
sequence xxx DNA_E
, , NE
was xxx NE
specifically xxx NE
bound xxx NE
by xx NE
nuclear xxx protein_B
proteins xxx protein_E
from xxx NE
IFN-gamma XXX-xxx cell_line_B
treated xxx cell_line_M
U937 Xddd cell_line_M
cells xxx cell_line_E
. . NE

Gel Xxx NE
shift xxx NE
experiments xxx NE
further xxx NE
showed xxx NE
that xxx NE
the xxx NE
STAT1 XXXXd protein_B
alpha xxx protein_M
protein xxx protein_E
bound xxx NE
to xx NE
the xxx NE
Fc Xx DNA_B
gamma xxx DNA_M
RIC XXX DNA_M
GIRE XXXX DNA_E
in xx NE
response xxx NE
to xx NE
IFN-gamma XXX-xxx NE
treatment xxx NE
of xx NE
U937 Xddd cell_line_B
cells xxx cell_line_E
. . NE

The Xxx NE
Fc Xx DNA_B
gamma xxx DNA_M
RIC XXX DNA_M
GIRE XXXX DNA_E
is xx NE
homologous xxx NE
to xx NE
the xxx NE
IFN-gamma XXX-xxx DNA_B
activation xxx DNA_M
sequence xxx DNA_E
( ( NE
GAS XXX DNA
) ) NE
of xx NE
the xxx NE
guanylate xxx protein_B
binding xxx protein_M
protein xxx protein_E
and xxx NE
to xx NE
X X DNA_B
box xxx DNA_M
elements xxx DNA_E
of xx NE
class xxx DNA_B
II XX DNA_M
MHC XXX DNA_M
genes xxx DNA_E
. . NE

Our Xxx NE
results xxx NE
demonstrate xxx NE
that xxx NE
transcriptional xxx NE
regulation xxx NE
of xx NE
the xxx NE
Fc Xx DNA_B
gamma xxx DNA_M
RIC XXX DNA_M
gene xxx DNA_E
by xx NE
IFN-gamma XXX-xxx protein
involves xxx NE
the xxx NE
binding xxx NE
of xx NE
STAT1 XXXXd protein_B
alpha xxx protein_E
to xx NE
a x NE
17-bp dd-xx DNA_B
GAS XXX DNA_M
homology xxx DNA_E
in xx NE
the xxx NE
proximal xxx DNA_B
promoter xxx DNA_E
. . NE

Constitutively Xxxx NE
activated xxx NE
Jak Xxx NE
-STAT -XXXX NE
pathway xxx NE
in xx NE
T X NE
cells xxx NE
transformed xxx NE
with xxx NE
HTLV-I XXXX-X NE
. . NE

Human Xxxx NE
T X NE
cell xxx NE
lymphotropic xxx NE
virus xxx NE
I X NE
( ( NE
HTLV-I XXXX-X NE
) ) NE
is xx NE
the xxx NE
etiological xxx NE
agent xxx NE
for xxx NE
adult xxx NE
T X NE
cell xxx NE
leukemia xxx NE
and xxx NE
tropical xxx NE
spastic xxx NE
paraparesis xxx NE
(also (xxx NE
termed xxx NE
HTLV-I XXXX-X NE
-associated -xxx NE
myelopathy xxx NE
) ) NE
. . NE

HTLV-I XXXX-X NE
-infected -xxx NE
peripheral xxx NE
blood xxx NE
T X NE
cells xxx NE
exhibit xxx NE
an xx NE
initial xxx NE
phase xxx NE
of xx NE
interleukin-2 xxx-d NE
( ( NE
IL-2 XX-d NE
)-dependent )-xxx NE
growth xxx NE
; ; NE
over xxx NE
time xxx NE
, , NE
by xx NE
an xx NE
unknown xxx NE
mechanism xxx NE
, , NE
the xxx NE
cells xxx NE
become xxx NE
IL-2 XX-d NE
-independent -xxx NE
. . NE

Whereas Xxxx NE
the xxx NE
Jak Xxx protein_B
kinases xxx protein_E
Jak1 Xxxd protein
and xxx NE
Jak3 Xxxd protein
and xxx NE
the xxx NE
signal xxx NE
transducer xxx NE
and xxx NE
activator xxx NE
of xx NE
transcription xxx protein_B
proteins xxx protein_E
Stat3 Xxxxd protein
and xxx NE
Stat5 Xxxxd protein
are xxx NE
activated xxx NE
in xx NE
normal xxx cell_type_B
T X cell_type_M
cells xxx cell_type_E
in xx NE
response xxx NE
to xx NE
IL-2 XX-d protein
, , NE
this xxx NE
signaling xxx NE
pathway xxx NE
was xxx NE
constitutively xxx NE
activated xxx NE
in xx NE
HTLV-I XXXX-X NE
-transformed -xxx NE
cells xxx NE
. . NE

In Xx NE
HTLV-I XXXX-X NE
-infected -xxx NE
cord xxx NE
blood xxx NE
lymphocytes xxx NE
, , NE
the xxx NE
transition xxx NE
from xxx NE
IL-2 XX-d NE
-dependent -xxx NE
to xx NE
IL-2 XX-d NE
-independent -xxx NE
growth xxx NE
correlated xxx NE
with xxx NE
the xxx NE
acquisition xxx NE
of xx NE
a x NE
constitutively xxx NE
activated xxx NE
Jak Xxx NE
-STAT -XXXX NE
pathway xxx NE
, , NE
which xxx NE
suggests xxx NE
that xxx NE
this xxx NE
pathway xxx NE
participates xxx NE
in xx NE
HTLV-I XXXX-X NE
-mediated -xxx NE
T X NE
cell xxx NE
transformation xxx NE
. . NE

Nitric Xxxx NE
oxide xxx NE
decreases xxx NE
cytokine xxx NE
-induced -xxx NE
endothelial xxx NE
activation xxx NE
. . NE

Nitric Xxxx NE
oxide xxx NE
selectively xxx NE
reduces xxx NE
endothelial xxx NE
expression xxx NE
of xx NE
adhesion xxx protein_B
molecules xxx protein_E
and xxx NE
proinflammatory xxx protein_B
cytokines xxx protein_E
. . NE

To Xx NE
test xxx NE
the xxx NE
hypothesis xxx NE
that xxx NE
nitric xxx NE
oxide xxx NE
( ( NE
NO XX NE
) ) NE
limits xxx NE
endothelial xxx NE
activation xxx NE
, , NE
we xx NE
treated xxx NE
cytokine-stimulated xxx-xxx cell_line_B
human xxx cell_line_M
saphenous xxx cell_line_M
vein xxx cell_line_M
endothelial xxx cell_line_M
cells xxx cell_line_E
with xxx NE
several xxx NE
NO XX NE
donors xxx NE
and xxx NE
assessed xxx NE
their xxx NE
effects xxx NE
on xx NE
the xxx NE
inducible xxx NE
expression xxx NE
of xx NE
vascular xxx protein_B
cell xxx protein_M
adhesion xxx protein_M
molecule-1 xxx-d protein_E
( ( NE
VCAM-1 XXXX-d protein
) ) NE
. . NE

In Xx NE
a x NE
concentration-dependent xxx-xxx NE
manner xxx NE
, , NE
NO XX NE
inhibited xxx NE
interleukin xxx NE
(IL)-1 (XX)-d NE
alpha-stimulated xxx-xxx NE
VCAM-1 XXXX-d NE
expression xxx NE
by xx NE
35-55% dd-dd% NE
as xx NE
determined xxx NE
by xx NE
cell xxx NE
surface xxx NE
enzyme xxx NE
immunoassays xxx NE
and xxx NE
flow xxx NE
cytometry xxx NE
. . NE

This Xxxx NE
inhibition xxx NE
was xxx NE
paralleled xxx NE
by xx NE
reduced xxx NE
monocyte xxx NE
adhesion xxx NE
to xx NE
endothelial xxx NE
monolayers xxx NE
in xx NE
nonstatic xxx NE
assays xxx NE
, , NE
was xxx NE
unaffected xxx NE
by xx NE
cGMP xXXX NE
analogues xxx NE
, , NE
and xxx NE
was xxx NE
quantitatively xxx NE
similar xxx NE
after xxx NE
stimulation xxx NE
by xx NE
either xxx NE
IL-1 XX-d protein_B
alpha xxx protein_E
, , NE
IL-1 XX-d protein_B
beta xxx protein_E
, , NE
IL-4 XX-d protein
, , NE
tumor xxx protein_B
necrosis xxx protein_M
factor xxx protein_E
( ( NE
TNF XXX protein_B
alpha xxx protein_E
) ) NE
, , NE
or xx NE
bacterial xxx NE
lipopolysaccharide xxx NE
. . NE

NO XX NE
also xxx NE
decreased xxx NE
the xxx NE
endothelial xxx NE
expression xxx NE
of xx NE
other xxx NE
leukocyte xxx protein_B
adhesion xxx protein_M
molecules xxx protein_E
( ( NE
E-selectin X-xxx protein
and xxx NE
to xx NE
a x NE
lesser xxx NE
extent xxx NE
, , NE
intercellular xxx protein_B
adhesion xxx protein_M
molecule-1 xxx-d protein_E
) ) NE
and xxx NE
secretable xxx NE
cytokines xxx protein
( ( NE
IL-6 XX-d protein
and xxx NE
IL-8 XX-d protein
) ) NE
. . NE

Inhibition Xxxx NE
of xx NE
endogenous xxx NE
NO XX NE
production xxx NE
by xx NE
L-N-monomethyl-arginine X-X-xxx-xxx NE
also xxx NE
induced xxx NE
the xxx NE
expression xxx NE
of xx NE
VCAM-1 XXXX-d protein
, , NE
but xxx NE
did xxx NE
not xxx NE
augment xxx NE
cytokine-induced xxx-xxx NE
VCAM-1 XXXX-d NE
expression xxx NE
. . NE

Nuclear Xxxx NE
run-on xxx-xx NE
assays xxx NE
, , NE
transfection xxx NE
studies xxx NE
using xxx NE
various xxx NE
VCAM-1 XXXX-d NE
promoter xxx NE
reporter xxx NE
gene xxx NE
constructs xxx NE
, , NE
and xxx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assays xxx NE
indicated xxx NE
that xxx NE
NO XX NE
represses xxx NE
VCAM-1 XXXX-d NE
gene xxx NE
transcription xxx NE
, , NE
in xx NE
part xxx NE
, , NE
by xx NE
inhibiting xxx NE
NF-kappa XX-xxx NE
B X NE
. . NE

We Xx NE
propose xxx NE
that xxx NE
NO XX NE
's 'x NE
ability xxx NE
to xx NE
limit xxx NE
endothelial xxx NE
activation xxx NE
and xxx NE
inhibit xxx NE
monocyte xxx NE
adhesion xxx NE
may xxx NE
contribute xxx NE
to xx NE
some xxx NE
of xx NE
its xxx NE
antiatherogenic xxx NE
property xxx NE
and xxx NE
antiinflammatory xxx NE
property xxx NE
properties xxx NE
within xxx NE
the xxx NE
vessel xxx NE
wall xxx NE
. . NE

MIP1 XXXd protein_B
alpha xxx protein_M
nuclear xxx protein_M
protein xxx protein_E
( ( NE
MNP XXX protein
) ) NE
, , NE
a x NE
novel xxx NE
transcription xxx protein_B
factor xxx protein_E
expressed xxx NE
in xx NE
hematopoietic xxx NE
cells xxx NE
that xxx NE
is xx NE
crucial xxx NE
for xxx NE
transcription xxx NE
of xx NE
the xxx NE
human xxx DNA_B
MIP-1 XXX-d DNA_M
alpha xxx DNA_M
gene xxx DNA_E
. . NE

Murine Xxxx protein_B
macrophage xxx protein_M
inflammatory xxx protein_M
protein xxx protein_M
1 d protein_M
alpha xxx protein_E
( ( NE
MIP-1 XXX-d protein_B
alpha xxx protein_E
) ) NE
and xxx NE
its xxx NE
human xxx protein_B
equivalent xxx protein_E
( ( NE
GOS19 XXXdd protein
, , NE
LD78 XXdd protein
, , NE
or xx NE
AT464 XXddd protein
) ) NE
are xxx NE
members xxx NE
of xx NE
the xxx NE
-C-C -X-X protein_B
family xxx protein_E
of xx NE
low-molecular-weight xxx-xxx-xxx protein_B
chemokines xxx protein_E
. . NE

Secreted Xxxx NE
from xxx NE
activated xxx cell_type_B
T X cell_type_M
cells xxx cell_type_E
and xxx NE
macrophages xxx cell_type
, , NE
bone xxx NE
marrow-derived xxx-xxx NE
MIP-1 XXX-d NE
alpha xxx NE
/GOS19 /XXXdd NE
inhibits xxx NE
primitive xxx NE
hematopoietic xxx NE
stem xxx NE
cells xxx NE
and xxx NE
appears xxx NE
to xx NE
be xx NE
involved xxx NE
in xx NE
the xxx NE
homeostatic xxx NE
control xxx NE
of xx NE
stem xxx NE
cell xxx NE
proliferation xxx NE
. . NE

It Xx NE
also xxx NE
induces xxx NE
chemotaxis xxx NE
and xxx NE
inflammatory xxx NE
responses xxx NE
in xx NE
mature xxx cell_type_B
cell xxx cell_type_M
types xxx cell_type_E
. . NE

Therefore Xxxx NE
, , NE
it xx NE
is xx NE
important xxx NE
to xx NE
understand xxx NE
the xxx NE
mechanisms xxx NE
which xxx NE
control xxx NE
the xxx NE
expression xxx NE
of xx NE
MIP-1 XXX-d protein_B
alpha xxx protein_E
/GOS19 /XXXdd NE
. . NE

Previous Xxxx NE
work xxx NE
has xxx NE
shown xxx NE
that xxx NE
in xx NE
Jurkat Xxxx cell_line_B
T X cell_line_M
cells xxx cell_line_E
, , NE
a x NE
set xxx NE
of xx NE
widely xxx NE
expressed xxx NE
transcription xxx protein_B
factors xxx protein_E
(the (xxx NE
ICK-1 XXX-d protein_B
family xxx protein_E
) ) NE
affect xxx NE
the xxx NE
GOS19 XXXdd DNA_B
promoter xxx DNA_E
. . NE

One Xxx NE
member xxx NE
, , NE
ICK-1A XXX-dX protein
, , NE
behaves xxx NE
as xx NE
a x NE
strong xxx protein_B
negative xxx protein_M
regulator xxx protein_E
. . NE

In Xx NE
this xxx NE
communication xxx NE
, , NE
we xx NE
provide xxx NE
evidence xxx NE
that xxx NE
the xxx NE
pathway xxx NE
of xx NE
induction xxx NE
in xx NE
the xxx NE
macrophage xxx cell_line_B
cell xxx cell_line_M
line xxx cell_line_E
U937 Xddd cell_line
is xx NE
different xxx NE
from xxx NE
that xxx NE
in xx NE
Jurkat Xxxx cell_line_B
cells xxx cell_line_E
. . NE

Furthermore Xxxx NE
, , NE
we xx NE
show xxx NE
that xxx NE
the xxx NE
ICK-1 XXX-d DNA_B
binding xxx DNA_M
site xxx DNA_E
does xxx NE
not xxx NE
confer xxx NE
negative xxx NE
regulation xxx NE
in xx NE
U937 Xddd cell_line_B
cells xxx cell_line_E
. . NE

We Xx NE
provide xxx NE
evidence xxx NE
for xxx NE
an xx NE
additional xxx NE
binding xxx DNA_B
site xxx DNA_E
, , NE
the xxx NE
MIP-1 XXX-d DNA_B
alpha xxx DNA_M
nuclear xxx DNA_M
protein xxx DNA_M
(MNP) (XXX) DNA_M
site xxx DNA_E
, , NE
which xxx NE
overlaps xxx NE
the xxx NE
ICK-1 XXX-d DNA_B
site xxx DNA_E
. . NE

Interaction Xxxx NE
of xx NE
nuclear xxx NE
extracts xxx NE
from xxx NE
various xxx cell_line_B
cell xxx cell_line_M
lines xxx cell_line_E
and xxx NE
tissue xxx NE
with xxx NE
the xxx NE
MNP XXX DNA_B
site xxx DNA_E
leads xxx NE
to xx NE
the xxx NE
formation xxx NE
of xx NE
fast-migrating xxx-xxx NE
protein-DNA xxx-XXX NE
complexes xxx NE
with xxx NE
similar xxx NE
but xxx NE
distinct xxx NE
electrophoretic xxx NE
mobilities xxx NE
. . NE

A X NE
mutation xxx NE
of xx NE
the xxx NE
MNP XXX DNA_B
site xxx DNA_E
which xxx NE
does xxx NE
not xxx NE
abrogate xxx NE
ICK-1 XXX-d NE
binding xxx NE
inactivates xxx NE
the xxx NE
GOS19.1 XXXdd.d DNA_B
promoter xxx DNA_E
in xx NE
U937 Xddd cell_line_B
cells xxx cell_line_E
and xxx NE
reduces xxx NE
its xxx NE
activity xxx NE
by xx NE
fourfold xxx NE
in xx NE
Jurkat Xxxx cell_line_B
cells xxx cell_line_E
. . NE

We Xx NE
propose xxx NE
that xxx NE
the xxx NE
MNP XXX protein_B
protein xxx protein_E
(s) (x) NE
binding xxx NE
at xx NE
the xxx NE
MNP XXX DNA_B
site xxx DNA_E
constitutes xxx NE
a x NE
novel xxx NE
transcription xxx protein_B
factor xxx protein_E
(s) (x) NE
expressed xxx NE
in xx NE
hematopoietic xxx cell_type_B
cells xxx cell_type_E
. . NE

The Xxx NE
effect xxx NE
of xx NE
Toremifene Xxxx NE
on xx NE
the xxx NE
expression xxx NE
of xx NE
some xxx NE
genes xxx NE
in xx NE
human xxx cell_type_B
mononuclear xxx cell_type_M
cells xxx cell_type_E
. . NE

Toremifene Xxxx NE
exerts xxx NE
multiple xxx NE
and xxx NE
varied xxx NE
effects xxx NE
on xx NE
the xxx NE
gene xxx NE
expression xxx NE
of xx NE
human xxx cell_type_B
peripheral xxx cell_type_M
mononuclear xxx cell_type_M
cells xxx cell_type_E
. . NE

After Xxxx NE
short-term xxx-xxx NE
, , NE
in xx NE
vitro xxx NE
exposure xxx NE
to xx NE
therapeutical xxx NE
levels xxx NE
, , NE
distinct xxx NE
changes xxx NE
in xx NE
P-glycoprotein X-xxx NE
expression xxx NE
and xxx NE
steroid xxx NE
receptors xxx NE
expression xxx NE
and xxx NE
p53 xdd NE
expression xxx NE
and xxx NE
Bcl-2 Xxx-d NE
expression xxx NE

In Xx NE
view xxx NE
of xx NE
the xxx NE
increasing xxx NE
use xxx NE
of xx NE
antiestrogens xxx NE
in xx NE
cancer xxx NE
therapy xxx NE
and xxx NE
prevention xxx NE
, , NE
there xxx NE
is xx NE
obvious xxx NE
merit xxx NE
in xx NE
long-term xxx-xxx NE
in xx NE
vivo xxx NE
studies xxx NE
to xx NE
be xx NE
conducted xxx NE
. . NE

The Xxx NE
interleukin-5 xxx-d NE
/receptor /xxx NE
interaction xxx NE
activates xxx NE
Lyn Xxx protein_B
tyrosine xxx protein_M
kinase xxx protein_M
and xxx protein_M
Jak2 Xxxd protein_M
tyrosine xxx protein_M
kinase xxx protein_E
pathways xxx NE
in xx protein
eosinophils xxx NE
. . NE

We Xx NE
have xxx NE
shown xxx NE
that xxx NE
the xxx NE
interaction xxx NE
of xx NE
interleukin xxx protein_B
(IL)-5 (XX)-d protein_E
with xxx NE
the xxx NE
receptor xxx NE
activates xxx NE
Lyn Xxx protein_B
tyrosine xxx protein_M
kinase xxx protein_E
within xxx NE
1 d NE
min xxx NE
and xxx NE
Jak2 Xxxd protein_B
tyrosine xxx protein_M
kinase xxx protein_E
within xxx NE
1-3 d-d NE
min xxx NE
. . NE

IL-5 XX-d protein
also xxx NE
stimulates xxx NE
GTP XXX NE
binding xxx NE
to xx NE
p21ras xddxxx protein
. . NE

The Xxx NE
signal xxx NE
is xx NE
subsequently xxx NE
propagated xxx NE
through xxx NE
the xxx NE
activation xxx NE
of xx NE
Raf-1 Xxx-d protein
, , NE
MEK XXX protein
, , NE
and xxx NE
MAP XXX protein_B
kinases xxx protein_E
as xx NE
shown xxx NE
by xx NE
their xxx NE
increased xxx NE
autophosphorylation xxx NE
in xx NE
vitro xxx NE
and xxx NE
phosphorylation xxx NE
in xx NE
situ xxx NE
. . NE

Jak2 Xxxd protein_B
kinase xxx protein_E
has xxx NE
been xxx NE
shown xxx NE
to xx NE
phosphorylate xxx NE
STAT XXXX protein_B
nuclear xxx protein_M
proteins xxx protein_E
. . NE

The Xxx NE
activation xxx NE
of xx NE
STAT XXXX protein_B
nuclear xxx protein_M
factors xxx protein_E
was xxx NE
studied xxx NE
by xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
using xxx NE
a x NE
gamma xxx NE
activation xxx NE
site xxx NE
( ( NE
GAS XXX NE
) ) NE
probe xxx NE
. . NE

We Xx NE
found xxx NE
that xxx NE
IL-5 XX-d protein
induces xxx NE
two xxx NE
GAS-binding XXX-xxx protein_B
proteins xxx protein_E
in xx NE
eosinophils xxx cell_type
, , NE
one xxx NE
of xx NE
which xxx NE
is xx NE
STAT1 XXXXd protein
. . NE

We Xx NE
conclude xxx NE
that xxx NE
IL-5 XX-d NE
induced xxx NE
signals xxx NE
are xxx NE
propagated xxx NE
through xxx NE
two xxx NE
distinct xxx NE
pathways xxx NE
: : NE
(1) (d) NE
Lyn Xxx protein
--> --> NE
Ras Xxx protein
--> --> NE
Raf-1 Xxx-d protein
--> --> NE
MEK XXX protein
--> --> NE
MAP XXX protein_B
kinase xxx protein_E
and xxx NE
(2) (d) NE
Jak2 Xxxd protein
--> --> NE
STAT1 XXXXd protein
. . NE

The Xxx NE
retinoblastoma xxx protein_B
gene xxx protein_M
product xxx protein_E
negatively xxx NE
regulates xxx NE
transcriptional xxx protein_B
activation xxx protein_E
mediated xxx NE
by xx NE
the xxx NE
human xxx protein_B
cytomegalovirus xxx protein_M
IE2 XXd protein_M
protein xxx protein_E
. . NE

The Xxx NE
IE2 XXd protein_B
gene xxx protein_M
product xxx protein_E
of xx NE
human xxx NE
cytomegalovirus xxx NE
( ( NE
HCMV XXXX NE
) ) NE
is xx NE
one xxx NE
of xx NE
a x NE
few xxx NE
viral xxx protein_B
regulatory xxx protein_M
proteins xxx protein_E
expressed xxx NE
immediately xxx NE
upon xxx NE
infection xxx NE
of xx NE
the xxx NE
host xxx cell_type_B
cell xxx cell_type_E
. . NE

It Xx NE
is xx NE
a x NE
potent xxx NE
transcriptional xxx protein_B
activator xxx protein_E
of xx NE
many xxx NE
viral xxx DNA_B
promoter xxx DNA_M
and xxx DNA_M
cellular xxx DNA_M
promoter xxx DNA_E

We Xx NE
found xxx NE
that xxx NE
the xxx NE
retinoblastoma xxx protein_B
susceptibility xxx protein_M
gene xxx protein_M
product xxx protein_E
( ( NE
Rb Xx protein
) ) NE
dramatically xxx NE
suppressed xxx NE
this xxx NE
IE2 XXd NE
transactivation xxx NE
of xx NE
various xxx DNA_B
promoters xxx DNA_E
. . NE

However Xxxx NE
, , NE
unlike xxx NE
another xxx NE
tumor xxx protein_B
suppressor xxx protein_M
protein xxx protein_E
, , NE
p53 xdd protein
, , NE
Rb Xx protein
did xxx NE
not xxx NE
have xxx NE
any xxx NE
significant xxx NE
effect xxx NE
on xx NE
basal xxx NE
levels xxx NE
of xx NE
transcription xxx NE
, , NE
suggesting xxx NE
that xxx NE
Rb Xx protein
specifically xxx NE
interacts xxx NE
with xxx NE
IE2 XXd protein
rather xxx NE
than xxx NE
other xxx NE
cellular xxx protein_B
factors xxx protein_E
involved xxx NE
in xx NE
the xxx NE
general xxx NE
transcription xxx NE
machinery xxx NE
. . NE

We Xx NE
found xxx NE
by xx NE
protein-affinity xxx-xxx NE
chromatography xxx NE
that xxx NE
Rb Xx protein
in xx NE
nuclear xxx NE
extracts xxx NE
or xx NE
produced xxx NE
by xx NE
in xx NE
vitro xxx NE
translation xxx NE
directly xxx NE
bound xxx NE
to xx NE
IE2 XXd protein
. . NE

Our Xxx NE
results xxx NE
suggest xxx NE
that xxx NE
Rb Xx protein
may xxx NE
regulate xxx NE
the xxx NE
life xxx NE
cycle xxx NE
of xx NE
HCMV XXXX NE
, , NE
which xxx NE
is xx NE
endemic xxx NE
in xx NE
the xxx NE
human xxx NE
population xxx NE
. . NE

Furthermore Xxxx NE
, , NE
these xxx NE
data xxx NE
may xxx NE
provide xxx NE
new xxx NE
insights xxx NE
into xxx NE
the xxx NE
slow xxx NE
rate xxx NE
of xx NE
HCMV XXXX NE
DNA XXX NE
replication xxx NE
in xx NE
cells xxx NE
and xxx NE
the xxx NE
possible xxx NE
involvement xxx NE
of xx NE
HCMV XXXX NE
in xx NE
tumorigenesis xxx NE
. . NE

Expression Xxxx NE
of xx NE
the xxx NE
nucleoside xxx protein_B
diphosphate xxx protein_M
kinase xxx protein_E
in xx NE
human xxx NE
skin xxx NE
cancers xxx NE
: : NE
an xx NE
immunohistochemical xxx NE
study xxx NE
. . NE

Expression Xxxx NE
of xx NE
nucleoside xxx protein_B
diphosphate(NDP) xxx(XXX) protein_M
kinase xxx protein_E
, , NE
which xxx NE
is xx NE
homologous xxx NE
to xx NE
the xxx NE
nm23 xxdd protein_B
gene xxx protein_M
product xxx protein_E
in xx NE
a x NE
variety xxx NE
of xx NE
species xxx NE
, , NE
has xxx NE
been xxx NE
found xxx NE
to xx NE
be xx NE
inversely xxx NE
associated xxx NE
with xxx NE
metastatic xxx NE
potential xxx NE
. . NE

However Xxxx NE
, , NE
the xxx NE
relationship xxx NE
remains xxx NE
controversial xxx NE
according xxx NE
to xx NE
the xxx NE
tumor xxx cell_type_B
cell xxx cell_type_M
types xxx cell_type_E
and xxx NE
experimental xxx NE
system xxx NE
, , NE
with xxx NE
conflicting xxx NE
results xxx NE
from xxx NE
different xxx NE
research xxx NE
groups xxx NE
. . NE

In Xx NE
order xxx NE
to xx NE
determine xxx NE
whether xxx NE
NDP XXX NE
kinase xxx NE
expression xxx NE
serves xxx NE
as xx NE
a x NE
marker xxx NE
for xxx NE
metastatic xxx NE
potential xxx NE
in xx NE
human xxx NE
skin xxx NE
cancer xxx NE
, , NE
we xx NE
assessed xxx NE
the xxx NE
levels xxx NE
of xx NE
NDP XXX NE
kinase xxx NE
expression xxx NE
in xx NE
9 d NE
keratoacanthomas xxx NE
( ( NE
KAs XXx NE
) ) NE
, , NE
26 dd NE
squamous xxx NE
cell xxx NE
carcinomas xxx NE
( ( NE
SCCs XXXx NE
) ) NE
, , NE
and xxx NE
25 dd NE
basal xxx NE
cell xxx NE
carcinomas xxx NE
( ( NE
BCCs XXXx NE
) ) NE
using xxx NE
immunohistochemistry xxx NE
. . NE

The Xxx NE
expression xxx NE
of xx NE
NDP XXX protein_B
kinase xxx protein_E
was xxx NE
intense xxx NE
in xx NE
KA XX NE
and xxx NE
SCC XXX NE
compared xxx NE
with xxx NE
BCC XXX NE
. . NE

However Xxxx NE
, , NE
the xxx NE
difference xxx NE
of xx NE
NDP XXX NE
kinase xxx NE
expression xxx NE
between xxx NE
KA XX NE
and xxx NE
SCC XXX NE
was xxx NE
not xxx NE
statistically xxx NE
significant xxx NE
. . NE

And Xxx NE
there xxx NE
was xxx NE
no xx NE
statistically xxx NE
significant xxx NE
difference xxx NE
in xx NE
NDP XXX NE
kinase xxx NE
expression xxx NE
between xxx NE
SCC XXX NE
with xxx NE
metastasis xxx NE
and xxx NE
SCC XXX NE
without xxx NE
metastasis xxx NE
. . NE

Our Xxx NE
results xxx NE
contradict xxx NE
the xxx NE
hypothesis xxx NE
concerning xxx NE
the xxx NE
possible xxx NE
role xxx NE
of xx NE
nm23 xxdd DNA_B
gene xxx DNA_E
as xx NE
a x NE
metastatic xxx NE
suppressor xxx NE
gene xxx NE
in xx NE
human xxx NE
skin xxx NE
cancer xxx NE
. . NE

The Xxx NE
mechanism xxx NE
of xx NE
overexpression xxx NE
in xx NE
various xxx NE
tumor xxx cell_type_B
cell xxx cell_type_M
types xxx cell_type_E
and xxx NE
its xxx NE
biological xxx NE
significance xxx NE
in xx NE
cutaneous xxx NE
carcinogenesis xxx NE
remain xxx NE
to xx NE
be xx NE
determined xxx NE
. . NE

RB XX protein
and xxx NE
a x NE
novel xxx NE
E2F-1 XdX-d protein_B
binding xxx protein_M
protein xxx protein_E
in xx NE
MHC XXX cell_line_B
class xxx cell_line_M
II XX cell_line_M
deficient xxx cell_line_M
B-cell X-xxx cell_line_M
lines xxx cell_line_E
and xxx NE
normal xxx NE
IFN-gamma XXX-xxx NE
induction xxx NE
of xx NE
the xxx NE
class xxx DNA_B
IL XX DNA_M
transactivator xxx DNA_E
CIITA XXXXX DNA
in xx NE
class xxx NE
II XX NE
non-inducible xxx-xxx NE
RB XX NE
-defective -xxx NE
tumor xxx NE
lines xxx NE
. . NE

The Xxx NE
major xxx DNA_B
histocompatibility xxx DNA_M
(MHC) (XXX) DNA_M
class xxx DNA_M
II XX DNA_M
genes xxx DNA_E
encode xxx NE
cell xxx protein_B
surface xxx protein_M
proteins xxx protein_E
that xxx NE
bind xxx NE
antigenic xxx NE
peptide xxx NE
for xxx NE
presentation xxx NE
to xx NE
T-cells X-xxx cell_type
. . NE

The Xxx NE
class xxx protein_B
II XX protein_M
proteins xxx protein_E
are xxx NE
expressed xxx NE
constitutively xxx NE
on xx NE
B-cells X-xxx cell_type
and xxx NE
EBV-transformed XXX-xxx cell_line_B
B-cells X-xxx cell_line_E
, , NE
and xxx NE
are xxx NE
inducible xxx NE
by xx NE
IFN-gamma XXX-xxx protein
on xx NE
a x NE
wide xxx NE
variety xxx NE
of xx NE
cell xxx cell_type_B
types xxx cell_type_E
. . NE

Retinoblastoma Xxxx protein_B
protein xxx protein_E
( ( NE
RB XX protein
) ) NE
is xx NE
a x NE
tumor xxx NE
suppressor xxx NE
and xxx NE
functions xxx NE
as xx NE
a x NE
transcriptional xxx protein_B
repressor xxx protein_E
by xx NE
binding xxx NE
and xxx NE
inactivating xxx NE
the xxx NE
transactivator xxx DNA_B
E2F-I XdX-X DNA_E
. . NE

RB XX NE
-defective -xxx NE
tumor xxx NE
lines xxx NE
are xxx NE
non-inducible xxx-xxx NE
for xxx NE
MHC XXX NE
class xxx NE
II XX NE
by xx NE
IFN-gamma XXX-xxx NE
, , NE
or xx NE
very xxx NE
weakly xxx NE
inducible xxx NE
, , NE
but xxx NE
transfection xxx NE
of xx NE
2 d NE
different xxx NE
lines xxx NE
with xxx NE
RB XX NE
expression xxx NE
vectors xxx NE
re-establishes xx-xxx NE
or xx NE
substantially xxx NE
enhances xxx NE
class xxx NE
II XX NE
inducibility xxx NE
. . NE

Therefore Xxxx NE
, , NE
we xx NE
examined xxx NE
the xxx NE
RB XX protein
status xxx NE
of xx NE
a x NE
series xxx NE
of xx NE
B-cell X-xxx NE
mutants xxx NE
that xxx NE
are xxx NE
defective xxx NE
in xx NE
class xxx NE
II XX NE
expression xxx NE
, , NE
generated xxx NE
either xxx NE
in xx NE
vitro xxx NE
or xx NE
derived xxx NE
from xxx NE
Bare Xxxx NE
Lymphocyte Xxxx NE
Syndrome Xxxx NE
(BLS) (XXX) NE
patients xxx NE
. . NE

Nuclear Xxxx NE
matrix-bound xxx-xxx NE
RB XX protein
was xxx NE
detectable xxx NE
in xx NE
all xxx NE
cases xxx NE
, , NE
indicating xxx NE
that xxx NE
loss xxx NE
of xx NE
RB XX protein
is xx NE
not xxx NE
responsible xxx NE
for xxx NE
decreased xxx NE
class xxx NE
II XX NE
expression xxx NE
in xx NE
these xxx NE
lines xxx NE
. . NE

A X NE
second xxx NE
E2F-I XdX-X NE
binding xxx NE
protein xxx NE
, , NE
most xxx NE
likely xxx NE
DP-I XX-X NE
, , NE
was xxx NE
also xxx NE
apparently xxx NE
normal xxx NE
in xx NE
both xxx NE
class xxx NE
II-positive XX-xxx NE
and xxx NE
-negative -xxx NE
B-cell X-xxx NE
lines xxx NE
. . NE

We Xx NE
also xxx NE
examined xxx NE
the xxx NE
IFN-gamma XXX-xxx NE
induction xxx NE
of xx NE
CIITA XXXXX DNA
in xx NE
RB XX protein
-defective -xxx NE
lines xxx NE
. . NE

CIITA XXXXX DNA
is xx NE
a x NE
class xxx DNA_B
II XX DNA_M
gene xxx DNA_M
transactivator xxx DNA_E
known xxx NE
to xx NE
be xx NE
defective xxx NE
in xx NE
one xxx NE
form xxx NE
of xx NE
BLS XXX NE
and xxx NE
to xx NE
be xx NE
required xxx NE
for xxx NE
the xxx NE
induction xxx NE
of xx NE
MHC XXX protein_B
class xxx protein_M
II XX protein_E
by xx NE
IFN-gamma XXX-xxx protein
. . NE

CIITA XXXXX RNA_B
mRNA xXXX RNA_E
is xx NE
normally xxx NE
inducible xxx NE
by xx NE
IFN-gamma XXX-xxx protein
in xx NE
class xxx NE
II XX NE
non-inducible xxx-xxx NE
, , NE
RB XX NE
-defective -xxx NE
lines xxx NE
, , NE
and xxx NE
in xx NE
one xxx NE
line xxx NE
, , NE
re-expression xx-xxx NE
of xx NE
RB XX NE
has xxx NE
no xx NE
effect xxx NE
on xx NE
CIITA XXXXX NE
mRNA xXXX NE
induction xxx NE
levels xxx NE
. . NE

Thus Xxxx NE
, , NE
the xxx NE
block xxx NE
in xx NE
MHC XXX NE
class xxx NE
II XX NE
inducibility xxx NE
in xx NE
RB XX NE
-defective -xxx NE
cells xxx NE
is xx NE
not xxx NE
due xxx NE
to xx NE
a x NE
block xxx NE
in xx NE
CIITA XXXXX NE
inducibility xxx NE
. . NE

Interleukin Xxxx protein_B
12 dd protein_E
induces xxx NE
tyrosine xxx NE
phosphorylation xxx NE
and xxx NE
activation xxx NE
of xx NE
STAT4 XXXXd protein
in xx NE
human xxx cell_type_B
lymphocytes xxx cell_type_E
. . NE

Interleukin Xxxx protein_B
12 dd protein_E
( ( NE
IL-12 XX-dd protein
) ) NE
is xx NE
an xx NE
important xxx NE
immunoregulatory xxx protein_B
cytokine xxx protein_E
whose xxx NE
receptor xxx NE
is xx NE
a x NE
member xxx NE
of xx NE
the xxx NE
hematopoietin xxx protein_B
receptor xxx protein_M
superfamily xxx protein_E
. . NE

We Xx NE
have xxx NE
recently xxx NE
demonstrated xxx NE
that xxx NE
stimulation xxx NE
of xx NE
human xxx cell_type_B
T X cell_type_M
cell xxx cell_type_M
and xxx cell_type_M
human xxx cell_type_M
natural xxx cell_type_M
killer xxx cell_type_M
cell xxx cell_type_E
with xxx NE
IL-12 XX-dd protein
induces xxx NE
tyrosine xxx NE
phosphorylation xxx NE
of xx NE
the xxx NE
Janus Xxxx protein_B
family xxx protein_M
tyrosine xxx protein_M
kinase xxx protein_E
JAK2 XXXd NE
and xxx NE
Tyk2 Xxxd protein
, , NE
implicating xxx NE
these xxx NE
kinases xxx protein
in xx NE
the xxx NE
immediate xxx NE
biochemical xxx NE
response xxx NE
to xx NE
IL-12 XX-dd protein
. . NE

Recently Xxxx NE
, , NE
transcription xxx protein_B
factors xxx protein_E
known xxx NE
as xx NE
STATs XXXXx protein
( ( NE
signal xxx protein_B
transducers xxx protein_M
and xxx protein_M
activators xxx protein_M
of xx protein_M
transcription xxx protein_E
) ) NE
have xxx NE
been xxx NE
shown xxx NE
to xx NE
be xx NE
tyrosine xxx NE
phosphorylated xxx NE
and xxx NE
activated xxx NE
in xx NE
response xxx NE
to xx NE
a x NE
number xxx NE
of xx NE
cytokines xxx protein
that xxx NE
bind xxx NE
hematopoietin xxx protein_B
receptors xxx protein_E
and xxx NE
activate xxx NE
JAK XXX protein_B
kinases xxx protein_E
. . NE

In Xx NE
this xxx NE
report xxx NE
we xx NE
demonstrate xxx NE
that xxx NE
IL-12 XX-dd protein
induces xxx NE
tyrosine xxx NE
phosphorylation xxx NE
of xx NE
a x NE
recently xxx NE
identified xxx NE
STAT XXXX protein_B
family xxx protein_M
member xxx protein_E
, , NE
STAT4 XXXXd protein
, , NE
and xxx NE
show xxx NE
that xxx NE
STAT4 XXXXd NE
expression xxx NE
is xx NE
regulated xxx NE
by xx NE
T-cell X-xxx NE
activation xxx NE
. . NE

Furthermore Xxxx NE
, , NE
we xx NE
show xxx NE
that xxx NE
IL-12 XX-dd protein
stimulates xxx NE
formation xxx NE
of xx NE
a x NE
DNA-binding XXX-xxx protein_B
complex xxx protein_E
that xxx NE
recognizes xxx NE
a x NE
DNA XXX NE
sequence xxx NE
previously xxx NE
shown xxx NE
to xx NE
bind xxx NE
STAT XXXX protein_B
proteins xxx protein_E
and xxx NE
that xxx NE
this xxx NE
complex xxx NE
contains xxx NE
STAT4 XXXXd protein
. . NE

These Xxxx NE
data xxx NE
, , NE
and xxx NE
the xxx NE
recent xxx NE
demonstration xxx NE
of xx NE
JAK XXX NE
phosphorylation xxx NE
by xx NE
IL-12 XX-dd protein
, , NE
identify xxx NE
a x NE
rapid xxx NE
signal-transduction xxx-xxx NE
pathway xxx NE
likely xxx NE
to xx NE
mediate xxx NE
IL-12 XX-dd NE
-induced -xxx NE
gene xxx NE
expression xxx NE
. . NE

Temperature-induced Xxxx-xxx NE
down-regulation xxx-xxx NE
of xx NE
the xxx NE
glucocorticoid xxx protein_B
receptor xxx protein_E
in xx NE
peripheral xxx cell_type_B
blood xxx cell_type_M
mononuclear xxx cell_type_M
leucocyte xxx cell_type_E
in xx NE
patients xxx NE
with xxx NE
sepsis xxx NE
or xx NE
septic xxx NE
shock xxx NE
. . NE

OBJECTIVE XXXXXXXXX NE
: : NE
Activation Xxxx NE
of xx NE
the xxx NE
hypothalamic-pituitary-adrenal xxx-xxx-xxx NE
axis xxx NE
is xx NE
of xx NE
vital xxx NE
importance xxx NE
during xxx NE
critical xxx NE
illness xxx NE
. . NE

We Xx NE
have xxx NE
studied xxx NE
the xxx NE
adaptive xxx NE
mechanisms xxx NE
which xxx NE
occur xxx NE
at xx NE
the xxx NE
level xxx NE
of xx NE
the xxx NE
glucocorticoid xxx protein_B
receptor xxx protein_E
in xx NE
glucocorticoid xxx NE
target xxx NE
tissues xxx NE
in xx NE
patients xxx NE
with xxx NE
sepsis xxx NE
or xx NE
septic xxx NE
shock xxx NE
. . NE

DESIGN XXXXXX NE
: : NE
The Xxx NE
effects xxx NE
of xx NE
hypercortisolaemia xxx NE
, , NE
hyperthermia xxx NE
and xxx NE
cellular xxx NE
composition xxx NE
on xx NE
number xxx NE
of xx NE
glucocorticoid xxx protein_B
receptors xxx protein_E
per xxx NE
cell xxx NE
and xxx NE
their xxx NE
affinity xxx NE
were xxx NE
evaluated xxx NE
, , NE
both xxx NE
in xx NE
vitro xxx NE
and xxx NE
in xx NE
vivo xxx NE
, , NE
in xx NE
peripheral xxx cell_type_B
blood xxx cell_type_M
mononuclear xxx cell_type_M
leucocytes xxx cell_type_E
of xx NE
control xxx NE
subjects xxx NE
and xxx NE
in xx NE
patients xxx NE
with xxx NE
sepsis xxx NE
or xx NE
septic xxx NE
shock xxx NE
. . NE

SUBJECTS XXXXXXXX NE
: : NE
Fifteen Xxxx NE
patients xxx NE
(age (xxx NE
25-79) dd-dd) NE
with xxx NE
sepsis xxx NE
or xx NE
septic xxx NE
shock xxx NE
who xxx NE
were xxx NE
admitted xxx NE
to xx NE
an xx NE
intensive xxx NE
care xxx NE
unit xxx NE
were xxx NE
studied xxx NE
. . NE

The Xxx NE
control xxx NE
group xxx NE
consisted xxx NE
of xx NE
24 dd NE
healthy xxx NE
laboratory xxx NE
employees xxx NE
. . NE

MEASUREMENTS XXXXXXXXXXXX NE
: : NE
The Xxx NE
binding xxx NE
capacity xxx NE
and xxx NE
affinity xxx NE
of xx NE
the xxx NE
glucocorticoid xxx protein_B
receptors xxx protein_E
were xxx NE
measured xxx NE
and xxx NE
compared xxx NE
to xx NE
clinical xxx NE
data xxx NE
and xxx NE
the xxx NE
plasma xxx NE
cortisol xxx NE
concentrations xxx NE
. . NE

RESULTS XXXXXXX NE
: : NE
Hypercortisolaemia Xxxx NE
, , NE
in xx NE
vitro xxx NE
, , NE
resulted xxx NE
in xx NE
a x NE
decreased xxx NE
affinity xxx NE
and xxx NE
a x NE
decreased xxx NE
binding xxx NE
capacity xxx NE
of xx NE
the xxx NE
glucocorticoid xxx protein_B
receptor xxx protein_E
. . NE

In Xx NE
vitro xxx NE
, , NE
hyperthermia xxx NE
as xx NE
well xxx NE
as xx NE
variations xxx NE
in xx NE
the xxx NE
cellular xxx NE
composition xxx NE
did xxx NE
not xxx NE
influence xxx NE
the xxx NE
glucocorticoid xxx NE
receptor xxx NE
. . NE

In Xx NE
vivo xxx NE
, , NE
there xxx NE
was xxx NE
no xx NE
change xxx NE
in xx NE
the xxx NE
number xxx NE
of xx NE
receptors xxx NE
per xxx NE
cell xxx NE
in xx NE
patients xxx NE
with xxx NE
sepsis xxx NE
or xx NE
septic xxx NE
shock xxx NE
as xx NE
compared xxx NE
to xx NE
healthy xxx NE
controls xxx NE
. . NE

However Xxxx NE
, , NE
a x NE
decreased xxx NE
affinity xxx NE
of xx NE
the xxx NE
glucocorticoid xxx protein_B
receptor xxx protein_E
was xxx NE
observed xxx NE
. . NE

There Xxxx NE
was xxx NE
a x NE
weak xxx NE
but xxx NE
significant xxx NE
negative xxx NE
correlation xxx NE
between xxx NE
body xxx NE
temperature xxx NE
and xxx NE
the xxx NE
number xxx NE
of xx NE
glucocorticoid xxx protein_B
receptors xxx protein_E
in xx NE
the xxx NE
patient xxx NE
group xxx NE
. . NE

There Xxxx NE
was xxx NE
no xx NE
relation xxx NE
between xxx NE
circulating xxx NE
cortisol xxx NE
concentrations xxx NE
and xxx NE
glucocorticoid xxx NE
receptor xxx NE
affinity xxx NE
and xxx NE
number xxx NE
. . NE

CONCLUSIONS XXXXXXXXXXX NE
: : NE
There Xxxx NE
is xx NE
no xx NE
obvious xxx NE
regulation xxx NE
of xx NE
the xxx NE
number xxx NE
of xx NE
glucocorticoid xxx protein_B
receptors xxx protein_E
by xx NE
plasma xxx NE
cortisol xxx NE
concentrations xxx NE
in xx NE
vivo xxx NE
. . NE

The Xxx NE
decreased xxx NE
affinity xxx NE
of xx NE
the xxx NE
glucocorticoid xxx protein_B
receptor xxx protein_E
together xxx NE
with xxx NE
the xxx NE
negative xxx NE
correlation xxx NE
between xxx NE
hyperthermia xxx NE
and xxx NE
the xxx NE
number xxx NE
of xx NE
glucocorticoid xxx protein_B
receptors xxx protein_E
in xx NE
patients xxx NE
with xxx NE
sepsis xxx NE
or xx NE
septic xxx NE
shock xxx NE
suggest xxx NE
that xxx NE
hypothalamic-pituitary-adrenal xxx-xxx-xxx NE
axis xxx NE
activation xxx NE
during xxx NE
critical xxx NE
illness xxx NE
is xx NE
accompanied xxx NE
by xx NE
peripheral xxx NE
adaptation xxx NE
in xx NE
glucocorticoid xxx NE
receptor xxx NE
number xxx NE
and xxx NE
affinity xxx NE
. . NE

Integrin-mediated Xxxx-xxx NE
tyrosine xxx NE
phosphorylation xxx NE
and xxx NE
cytokine xxx NE
message xxx NE
induction xxx NE
in xx NE
monocytic xxx cell_type_B
cells xxx cell_type_E
. . NE

A X NE
possible xxx NE
signaling xxx NE
role xxx NE
for xxx NE
the xxx NE
Syk Xxx protein_B
tyrosine xxx protein_M
kinase xxx protein_E
. . NE

Activation Xxxx NE
of xx NE
cytoplasmic xxx protein_B
tyrosine xxx protein_M
kinases xxx protein_E
is xx NE
an xx NE
important xxx NE
aspect xxx NE
of xx NE
signal xxx NE
transduction xxx NE
mediated xxx NE
by xx NE
integrins xxx protein
. . NE

In Xx NE
the xxx NE
human xxx cell_line_B
monocytic xxx cell_line_M
cell xxx cell_line_M
line xxx cell_line_M
THP-1 XXX-d cell_line_E
, , NE
either xxx NE
integrin xxx NE
-dependent -xxx NE
cell xxx NE
adhesion xxx NE
to xx NE
fibronectin xxx protein
or xx NE
ligation xxx NE
of xx NE
beta xxx protein_B
1 d protein_M
integrins xxx protein_E
with xxx NE
antibodies xxx protein
causes xxx NE
a x NE
rapid xxx NE
and xxx NE
intense xxx NE
tyrosine xxx NE
phosphorylation xxx NE
of xx NE
two xxx NE
sets xxx NE
of xx NE
proteins xxx protein
of xx NE
about xxx NE
65-75 dd-dd protein_B
kDa xXx protein_M
and xxx protein_M
120-125 ddd-ddd protein_M
kDa xXx protein_E

In Xx NE
addition xxx NE
, , NE
integrin xxx NE
ligation xxx NE
leads xxx NE
to xx NE
nuclear xxx NE
translocation xxx NE
of xx NE
the xxx NE
p50 xdd protein
and xxx NE
p65 xdd protein_B
subunits xxx protein_E
of xx NE
the xxx NE
NF-kappa XX-xxx protein_B
B X protein_M
transcription xxx protein_M
factor xxx protein_E
, , NE
to xx NE
activation xxx NE
of xx NE
a x NE
reporter xxx DNA_B
gene xxx DNA_E
driven xxx NE
by xx NE
a x NE
promoter xxx DNA
containing xxx NE
NF-kappa XX-xxx DNA_B
B X DNA_M
sites xxx DNA_E
, , NE
and xxx NE
to xx NE
increased xxx NE
levels xxx NE
of xx NE
mRNAs xXXXx RNA
for xxx NE
immediate-early xxx-xxx DNA_B
genes xxx DNA_E
, , NE
including xxx NE
the xxx NE
cytokine xxx protein_B
interleukin xxx protein_M
(IL)-1 (XX)-d protein_M
beta xxx protein_E
. . NE

The Xxx NE
tyrosine xxx NE
kinase xxx NE
inhibitors xxx NE
genistein xxx NE
and xxx NE
herbimycin xxx NE
A X NE
block xxx NE
both xxx NE
integrin xxx NE
-mediated -xxx NE
tyrosine xxx NE
phosphorylation xxx NE
and xxx NE
increases xxx NE
in xx NE
IL-1 XX-d NE
beta xxx NE
message xxx NE
levels xxx NE
, , NE
indicating xxx NE
a x NE
causal xxx NE
relationship xxx NE
between xxx NE
the xxx NE
two xxx NE
events xxx NE
. . NE

The Xxx NE
components xxx NE
tyrosine xxx NE
phosphorylated xxx NE
subsequent xxx NE
to xx NE
cell xxx NE
adhesion xxx NE
include xxx NE
paxillin xxx protein
, , NE
pp125FAK xxdddXXX protein
, , NE
and xxx NE
the xxx NE
SH2 XXd protein_B
domain xxx protein_M
containing xxx protein_M
tyrosine xxx protein_M
kinase xxx protein_M
Syk Xxx protein_E
. . NE

In Xx NE
contrast xxx NE
, , NE
integrin xxx NE
ligation xxx NE
with xxx NE
antibodies xxx NE
induces xxx NE
tyrosine xxx NE
phosphorylation xxx NE
of xx NE
Syk Xxx NE
but xxx NE
not xxx NE
of xx NE
FAK XXX NE
or xx NE
paxillin xxx NE
. . NE

In Xx NE
adhering xxx cell_type_B
cells xxx cell_type_E
, , NE
pre-treatment xxx-xxx NE
with xxx NE
cytochalasin xxx NE
D X NE
suppresses xxx NE
tyrosine xxx NE
phosphorylation xxx NE
of xx NE
FAK XXX protein
and xxx NE
paxillin xxx protein
but xxx NE
not xxx NE
of xx NE
Syk Xxx protein
, , NE
while xxx NE
IL-1 XX-d protein_B
beta xxx protein_E
message xxx NE
induction xxx NE
is xx NE
unaffected xxx NE
. . NE

These Xxxx NE
observations xxx NE
indicate xxx NE
that xxx NE
the xxx NE
Syk Xxx protein
tyrosine xxx NE
kinase xxx NE
may xxx NE
be xx NE
an xx NE
important xxx NE
component xxx NE
of xx NE
an xx NE
integrin xxx NE
signaling xxx NE
pathway xxx NE
in xx NE
monocytic xxx cell_type_B
cells xxx cell_type_E
, , NE
leading xxx NE
to xx NE
activation xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
and xxx NE
to xx NE
increased xxx NE
levels xxx NE
of xx NE
cytokine xxx NE
messages xxx NE
. . NE

Inhibition Xxxx NE
of xx NE
dexamethasone xxx NE
binding xxx NE
to xx NE
human xxx protein_B
glucocorticoid xxx protein_M
receptor xxx protein_E
by xx NE
New Xxx NE
World Xxxx NE
primate xxx NE
cell xxx NE
extracts xxx NE
. . NE

To Xx NE
determine xxx NE
if xx NE
New Xxx NE
World Xxxx NE
primates xxx NE
express xxx NE
an xx NE
inhibitor xxx NE
that xxx NE
influences xxx NE
glucocorticoid xxx NE
receptor xxx NE
( ( NE
GR XX NE
) ) NE
binding xxx NE
characteristics xxx NE
, , NE
we xx NE
examined xxx NE
[3H]dexamethasone [dX]xxx NE
binding xxx NE
in xx NE
cytosol xxx NE
prepared xxx NE
from xxx NE
B95-8 Xdd-d NE
lymphoid xxx NE
cells xxx NE
, , NE
derived xxx NE
from xxx NE
the xxx NE
cotton xxx NE
top xxx NE
tamarin xxx NE
( ( NE
Saguinus Xxxx NE
oedipus xxx NE
) ) NE
, , NE
in xx NE
combination xxx NE
with xxx NE
cytosol xxx NE
prepared xxx NE
from xxx NE
human xxx NE
or xx NE
rat xxx NE
tissues xxx NE
. . NE

B95-8 Xdd-d NE
cytosol xxx NE
inhibited xxx NE
specific xxx NE
binding xxx NE
of xx NE
[3H]dexamethasone [dX]xxx NE
(P (X NE
< < NE
0.01) d.dd) NE
when xxx NE
mixed xxx NE
with xxx NE
cytosol xxx NE
prepared xxx NE
from xxx NE
either xxx NE
a x NE
human xxx cell_line_B
lymphoid xxx cell_line_M
cell xxx cell_line_M
line xxx cell_line_E
( ( NE
HL XX cell_line
) ) NE
or xx NE
rat xxx NE
thymus xxx NE
. . NE

The Xxx NE
inhibitory xxx NE
activity xxx NE
was xxx NE
heat xxx NE
labile xxx NE
and xxx NE
trypsin xxx NE
sensitive xxx NE
. . NE

Peak Xxxx NE
inhibitory xxx NE
activity xxx NE
was xxx NE
found xxx NE
in xx NE
the xxx NE
150-200 ddd-ddd NE
kd xx NE
fractions xxx NE
after xxx NE
Sephacryl Xxxx NE
G-200 X-ddd NE
ultrafiltration xxx NE
. . NE

Scatchard Xxxx NE
analysis xxx NE
of xx NE
[3H]dexamethasone [dX]xxx NE
binding xxx NE
using xxx NE
mixed xxx NE
cytosol xxx NE
showed xxx NE
a x NE
diminished xxx NE
GR XX protein
apparent xxx NE
binding xxx NE
affinity xxx NE
when xxx NE
compared xxx NE
to xx NE
HL XX NE
cytosol xxx NE
. . NE

Kinetic Xxxx NE
studies xxx NE
using xxx NE
mixed xxx NE
cytosol xxx NE
indicated xxx NE
that xxx NE
B95-8 Xdd-d NE
cytosol xxx NE
did xxx NE
not xxx NE
affect xxx NE
the xxx NE
apparent xxx NE
dissociation xxx NE
rate xxx NE
of xx NE
[3H]dexamethasone [dX]xxx NE
. . NE

These Xxxx NE
data xxx NE
demonstrate xxx NE
that xxx NE
B95-8 Xdd-d cell_type_B
cells xxx cell_type_E
contain xxx NE
a x NE
competitive xxx NE
inhibitor xxx NE
that xxx NE
prevents xxx NE
binding xxx NE
of xx NE
dexamethasone xxx NE
to xx NE
its xxx NE
cognate xxx protein_B
receptor xxx protein_E
. . NE

Disruption Xxxx NE
of xx NE
a x NE
GATA XXXX DNA_B
motif xxx DNA_E
in xx NE
the xxx NE
Duffy Xxxx DNA_B
gene xxx DNA_M
promoter xxx DNA_E
abolishes xxx NE
erythroid xxx NE
gene xxx NE
expression xxx NE
in xx NE
Duffy-negative Xxxx-xxx NE
individuals xxx NE
. . NE

The Xxx NE
mRNA xXXX RNA
for xxx NE
the xxx NE
Duffy Xxxx protein_B
blood xxx protein_M
group xxx protein_M
antigen xxx protein_E
, , NE
the xxx NE
erythrocyte xxx protein_B
receptor xxx protein_E
for xxx NE
the xxx NE
Plasmodium Xxxx NE
vivax xxx NE
malaria xxx NE
parasite xxx NE
, , NE
has xxx NE
recently xxx NE
been xxx NE
cloned xxx NE
and xxx NE
shown xxx NE
to xx NE
encode xxx NE
a x NE
widely xxx NE
expressed xxx NE
chemokine xxx protein_B
receptor xxx protein_E
. . NE

Here Xxxx NE
, , NE
we xx NE
show xxx NE
that xxx NE
the xxx NE
Duffy Xxxx DNA_B
antigen/chemokine xxx/xxx DNA_M
receptor xxx DNA_M
gene xxx DNA_E
( ( NE
DARC XXXX DNA
) ) NE
is xx NE
composed xxx NE
of xx NE
a x NE
single xxx NE
exon xxx DNA
and xxx NE
that xxx NE
most xxx NE
Duffy-negative Xxxx-xxx NE
blacks xxx NE
carry xxx NE
a x NE
silent xxx DNA_B
FY*B XX*X DNA_M
allele xxx DNA_E
with xxx NE
a x NE
single xxx NE
T X NE
to xx NE
C X NE
substitution xxx NE
at xx NE
nucleotide xxx NE
-46 -dd NE
. . NE

This Xxxx NE
mutation xxx NE
impairs xxx NE
the xxx NE
promoter xxx NE
activity xxx NE
in xx NE
erythroid xxx cell_type_B
cells xxx cell_type_E
by xx NE
disrupting xxx NE
a x NE
binding xxx DNA_B
site xxx DNA_E
for xxx NE
the xxx NE
GATA1 XXXXd protein_B
erythroid xxx protein_M
transcription xxx protein_M
factor xxx protein_E
. . NE

With Xxxx NE
the xxx NE
recent xxx NE
characterization xxx NE
of xx NE
the xxx NE
FY*A XX*X DNA_B
allele xxx DNA_M
and xxx DNA_M
FY*B XX*X DNA_M
allele xxx DNA_E
Duffy Xxxx NE
blood xxx NE
group xxx NE
system xxx NE
and xxx NE
an xx NE
explanation xxx NE
for xxx NE
the xxx NE
erythroid-specific xxx-xxx NE
repression xxx NE
of xx NE
the xxx NE
DARC XXXX DNA_B
gene xxx DNA_E
in xx NE
Duffy-negative Xxxx-xxx NE
individuals xxx NE
. . NE

Activation Xxxx NE
of xx NE
pp90rsk xxddxxx protein
and xxx NE
early xxx NE
growth xxx NE
response-1 xxx-d NE
gene xxx NE
expression xxx NE
by xx NE
pokeweed xxx protein_B
mitogen xxx protein_E
in xx NE
human xxx cell_type_B
B X cell_type_M
cells xxx cell_type_E
. . NE

The Xxx NE
present xxx NE
studies xxx NE
have xxx NE
examined xxx NE
the xxx NE
effects xxx NE
of xx NE
pokeweed xxx protein_B
mitogen xxx protein_E
( ( NE
PWM XXX protein
) ) NE
on xx NE
the xxx NE
induction xxx NE
of xx NE
early xxx DNA_B
growth xxx DNA_M
response-1 xxx-d DNA_M
gene xxx DNA_E
( ( NE
EGR-1 XXX-d DNA
) ) NE
in xx NE
normal xxx cell_type_B
human xxx cell_type_M
B X cell_type_M
cells xxx cell_type_E
. . NE

PWM XXX protein
regulates xxx NE
EGR-1 XXX-d NE
gene xxx NE
expression xxx NE
by xx NE
both xxx NE
transcriptional xxx NE
mechanism xxx NE
and xxx NE
post-transcriptional xxx-xxx NE
mechanism xxx NE

Transient Xxxx NE
transfection xxx NE
assays xxx NE
with xxx NE
EGR-1 XXX-d DNA_B
promoter xxx DNA_M
fragments xxx DNA_E
linked xxx NE
to xx NE
the xxx NE
chloramphenicol xxx NE
acetyltransferase xxx NE
( ( NE
CAT XXX NE
) ) NE
gene xxx NE
demonstrated xxx NE
that xxx NE
PWM XXX NE
induced xxx NE
EGR-1 XXX-d NE
transcription xxx NE
is xx NE
conferred xxx NE
by xx NE
the xxx NE
CArG XXxX NE
motif xxx NE
( ( NE
C X NE
C[AT]6GG X[XX]dXX NE
) ) NE
in xx NE
the xxx NE
EGR-1 XXX-d NE
promoter xxx NE
. . NE

The Xxx NE
results xxx NE
further xxx NE
demonstrated xxx NE
the xxx NE
activation xxx NE
of xx NE
S6 Xd protein_B
kinase xxx protein_E
( ( NE
pp90rsk xxddxxx protein
) ) NE
, , NE
evidenced xxx NE
by xx NE
phosphorylation xxx NE
of xx NE
S6 Xd protein
and xxx NE
serum xxx NE
response xxx NE
factor xxx NE
(SRF) (XXX) NE
peptides xxx NE
, , NE
in xx NE
PWM XXX cell_line_B
treated xxx cell_line_M
B X cell_line_M
cells xxx cell_line_E
. . NE

Taken Xxxx NE
together xxx NE
, , NE
these xxx NE
findings xxx NE
suggest xxx NE
that xxx NE
PWM XXX protein
is xx NE
able xxx NE
to xx NE
initiate xxx NE
an xx NE
intracytoplasmic xxx NE
signalling xxx NE
cascade xxx NE
and xxx NE
EGR-1 XXX-d NE
induction xxx NE
in xx NE
normal xxx cell_type_B
human xxx cell_type_M
B X cell_type_M
cells xxx cell_type_E
. . NE

A X NE
conserved xxx DNA_B
motif xxx DNA_E
in xx NE
the xxx NE
promoters xxx DNA
of xx NE
several xxx NE
cytokines xxx protein
expressed xxx NE
by xx NE
human xxx cell_line_B
Th2-type Xxd-xxx cell_line_M
lymphocytes xxx cell_line_E
. . NE

We Xx NE
have xxx NE
recently xxx NE
found xxx NE
a x NE
novel xxx NE
conserved xxx DNA_B
motif xxx DNA_E
in xx NE
the xxx NE
promoters xxx DNA
of xx NE
several xxx NE
T-cell-expressed X-xxx-xxx protein_B
cytokines xxx protein_E
[ [ NE
human xxx protein_B
interleukin-2 xxx-d protein_M
and xxx protein_M
human xxx protein_M
interleukin-4 xxx-d protein_M
and xxx protein_M
human xxx protein_M
interleukin-5 xxx-d protein_M
and xxx protein_M
human xxx protein_M
interleukin-13 xxx-dd protein_E
mouse xxx NE
human xxx protein_B
granulocyte/macrophage-colony xxx/xxx-xxx protein_M
stimulating xxx protein_M
factor xxx protein_M
and xxx protein_M
mouse xxx protein_M
granulocyte/macrophage-colony xxx/xxx-xxx protein_M
stimulating xxx protein_M
factor xxx protein_E

It Xx NE
contains xxx NE
a x NE
core xxx DNA_B
sequence xxx DNA_E
CTTGG XXXXX NE
.. .. NE
. . NE
CCAAG XXXXX NE
which xxx NE
is xx NE
present xxx NE
as xx NE
part xxx NE
of xx NE
larger xxx NE
palindromic xxx NE
sequences xxx NE
in xx NE
each xxx NE
gene xxx NE
. . NE

This Xxxx NE
suggest xxx NE
that xxx NE
they xxx NE
may xxx NE
interact xxx NE
with xxx NE
a x NE
new xxx NE
family xxx NE
of xx NE
trans-acting xxx-xxx protein_B
factors xxx protein_E
. . NE

In Xx NE
transfection xxx NE
assays xxx NE
, , NE
the xxx NE
human xxx DNA_B
GM-CSF XX-XXX DNA_M
element xxx DNA_E
has xxx NE
a x NE
strong xxx NE
positive xxx NE
effect xxx NE
on xx NE
the xxx NE
expression xxx NE
of xx NE
a x NE
reporter xxx DNA_B
gene xxx DNA_E
by xx NE
the xxx NE
human xxx cell_line_B
T X cell_line_M
cell xxx cell_line_M
line xxx cell_line_E
Jurkat Xxxx cell_line_B
J6 Xd cell_line_E
upon xxx NE
stimulation xxx NE
. . NE

In Xx NE
DNA XXX NE
mobility xxx NE
shift xxx NE
assays xxx NE
, , NE
this xxx NE
sequence xxx NE
can xxx NE
give xxx NE
either xxx NE
six xxx NE
different xxx NE
specific xxx NE
bands xxx NE
which xxx NE
are xxx NE
competed xxx NE
out xxx NE
by xx NE
different xxx NE
parts xxx NE
of xx NE
the xxx NE
sequence xxx NE
or xx NE
one xxx NE
specific xxx NE
band xxx NE
which xxx NE
is xx NE
competed xxx NE
out xxx NE
by xx NE
each xxx NE
of xx NE
the xxx NE
inverted xxx NE
repeats xxx NE
, , NE
depending xxx NE
on xx NE
the xxx NE
reconstitution xxx NE
conditions xxx NE
. . NE

In Xx NE
different xxx NE
genes xxx DNA
, , NE
the xxx NE
core xxx DNA_B
sequences xxx DNA_E
are xxx NE
separated xxx NE
by xx NE
integer xxx NE
numbers xxx NE
of xx NE
helical xxx DNA_B
turns xxx DNA_E
. . NE

Considering Xxxx NE
the xxx NE
strong xxx NE
positive xxx NE
regulatory xxx NE
effect xxx NE
of xx NE
this xxx NE
element xxx DNA
and xxx NE
its xxx NE
presence xxx NE
in xx NE
several xxx NE
T-cell-expressed X-xxx-xxx DNA_B
cytokine xxx DNA_M
genes xxx DNA_E
, , NE
it xx NE
may xxx NE
be xx NE
crucial xxx NE
to xx NE
the xxx NE
coordinated xxx NE
expression xxx NE
of xx NE
these xxx NE
cytokines xxx protein
in xx NE
T X cell_type_B
helper xxx cell_type_M
cells xxx cell_type_E
. . NE

cDNA xXXX NE
cloning xxx NE
of xx NE
a x NE
NGFI-B/nur77-related XXXX-X/xxxdd-xxx protein_B
transcription xxx protein_M
factor xxx protein_E
from xxx NE
an xx NE
apoptotic xxx cell_line_B
human xxx cell_line_M
T X cell_line_M
cell xxx cell_line_M
line xxx cell_line_E
. . NE

A X NE
human xxx cell_line_B
T X cell_line_M
lymphoid xxx cell_line_M
cell xxx cell_line_M
line xxx cell_line_E
, , NE
PEER XXXX cell_line
, , NE
dies xxx NE
by xx NE
apoptosis xxx NE
in xx NE
the xxx NE
presence xxx NE
of xx NE
PMA XXX NE
and xxx NE
calcium xxx NE
ionophore xxx NE
. . NE

A X NE
new xxx NE
gene xxx DNA
, , NE
TINUR XXXXX DNA
, , NE
was xxx NE
cloned xxx NE
from xxx NE
apoptotic xxx cell_line_B
PEER XXXX cell_line_M
cells xxx cell_line_E
. . NE

The Xxx NE
expression xxx NE
of xx NE
the xxx NE
TINUR XXXXX DNA_B
gene xxx DNA_E
is xx NE
induced xxx NE
within xxx NE
1 d NE
h x NE
after xxx NE
the xxx NE
cross-linking xxx-xxx NE
of xx NE
the xxx NE
T X protein_B
cell xxx protein_M
Ag Xx protein_M
receptor xxx protein_M
complex xxx protein_E
. . NE

TINUR XXXXX DNA
belongs xxx NE
to xx NE
the xxx NE
NGFI-B/nur77 XXXX-X/xxxdd protein_B
family xxx protein_E
of xx NE
the xxx NE
steroid xxx protein_B
receptor xxx protein_M
superfamily xxx protein_E
and xxx NE
is xx NE
an xx NE
orphan xxx protein_B
receptor xxx protein_E
. . NE

TINUR XXXXX DNA
binds xxx NE
to xx NE
the xxx NE
same xxx NE
DNA XXX DNA_B
sequence xxx DNA_E
as xx NE
NGFI-B/nur77 XXXX-X/xxxdd protein
. . NE

We Xx NE
also xxx NE
propose xxx NE
that xxx NE
the xxx NE
NGFI-B/nur77 XXXX-X/xxxdd protein_B
family xxx protein_E
can xxx NE
be xx NE
classified xxx NE
into xxx NE
two xxx NE
subtypes xxx NE
. . NE

Aspirin Xxxx NE
inhibits xxx NE
nuclear xxx NE
factor-kappa xxx-xxx NE
B X NE
mobilization xxx NE
and xxx NE
monocyte xxx NE
adhesion xxx NE
in xx NE
stimulated xxx cell_line_B
human xxx cell_line_M
endothelial xxx cell_line_M
cells xxx cell_line_E
. . NE

BACKGROUND XXXXXXXXXX NE
: : NE
The Xxx NE
induction xxx NE
of xx NE
vascular xxx protein_B
cell xxx protein_M
adhesion xxx protein_M
molecule-1 xxx-d protein_E
( ( NE
VCAM-1 XXXX-d protein
) ) NE
and xxx NE
E-selectin X-xxx protein
by xx NE
tumor xxx protein_B
necrosis xxx protein_M
factor-alpha xxx-xxx protein_E
( ( NE
TNF XXX protein
) ) NE
is xx NE
mediated xxx NE
by xx NE
mobilization xxx NE
of xx NE
the xxx NE
transcription xxx protein_B
factor xxx protein_E
nuclear xxx protein_B
factor-kappa xxx-xxx protein_M
B X protein_E
( ( NE
NF-kappa XX-xxx protein_B
B X protein_E
) ) NE
. . NE

Since Xxxx NE
salicylates xxx NE
have xxx NE
been xxx NE
reported xxx NE
to xx NE
inhibit xxx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
by xx NE
preventing xxx NE
the xxx NE
degradation xxx NE
of xx NE
its xxx NE
inhibitor xxx NE
I X protein_B
kappa xxx protein_M
B X protein_E
, , NE
we xx NE
studied xxx NE
a x NE
potential xxx NE
inhibition xxx NE
of xx NE
this xxx NE
pathway xxx NE
by xx NE
acetylsalicylate xxx NE
( ( NE
aspirin xxx NE
) ) NE
in xx NE
human xxx cell_line_B
umbilical xxx cell_line_M
vein xxx cell_line_M
endothelial xxx cell_line_M
cells xxx cell_line_E
( ( NE
HUVECs XXXXXx cell_line
) ) NE
. . NE

METHODS XXXXXXX NE
AND XXX NE
RESULTS XXXXXXX NE
: : NE
Gel-shift Xxx-xxx NE
analyses xxx NE
demonstrated xxx NE
dose-dependent xxx-xxx NE
inhibition xxx NE
of xx NE
TNF XXX NE
-induced -xxx NE
NF-kappa XX-xxx NE
B X NE
mobilization xxx NE
by xx NE
aspirin xxx NE
at xx NE
concentrations xxx NE
ranging xxx NE
from xxx NE
1 d NE
to xx NE
10 dd NE
mmol/L xxx/X NE
. . NE

Induction Xxxx NE
of xx NE
VCAM-1 XXXX-d protein
and xxx NE
E-selectin X-xxx NE
surface xxx NE
expression xxx NE
by xx NE
TNF XXX protein
was xxx NE
dose-dependently xxx-xxx NE
reduced xxx NE
by xx NE
aspirin xxx NE
over xxx NE
the xxx NE
same xxx NE
range xxx NE
, , NE
while xxx NE
induction xxx NE
of xx NE
intercellular xxx protein_B
adhesion xxx protein_M
molecule-1 xxx-d protein_E
( ( NE
ICAM-1 XXXX-d protein
) ) NE
was xxx NE
hardly xxx NE
affected xxx NE
. . NE

Aspirin Xxxx NE
appeared xxx NE
to xx NE
prevent xxx NE
VCAM-1 XXXX-d NE
transcription xxx NE
, , NE
since xxx NE
it xx NE
dose-dependently xxx-xxx NE
inhibited xxx NE
induction xxx NE
of xx NE
VCAM-1 XXXX-d RNA_B
mRNA xXXX RNA_E
by xx NE
TNF XXX protein
. . NE

As Xx NE
a x NE
functional xxx NE
consequence xxx NE
, , NE
adhesion xxx NE
of xx NE
U937 Xddd cell_line_B
monocytes xxx cell_line_E
to xx NE
TNF XXX NE
-stimulated -xxx NE
HUVECs XXXXXx NE
was xxx NE
markedly xxx NE
reduced xxx NE
by xx NE
aspirin xxx NE
due xxx NE
to xx NE
suppression xxx NE
of xx NE
VCAM-1 XXXX-d NE
and xxx NE
E-selectin X-xxx NE
upregulation xxx NE
. . NE

These Xxxx NE
effects xxx NE
of xx NE
aspirin xxx NE
were xxx NE
not xxx NE
related xxx NE
to xx NE
the xxx NE
inhibition xxx NE
of xx NE
cyclooxygenase xxx NE
activity xxx NE
, , NE
since xxx NE
indomethacin xxx NE
was xxx NE
ineffective xxx NE
. . NE

CONCLUSIONS XXXXXXXXXXX NE
: : NE
Our Xxx NE
data xxx NE
suggest xxx NE
that xxx NE
aspirin xxx NE
inhibits xxx NE
NF-kappa XX-xxx NE
B X NE
mobilization xxx NE
, , NE
induction xxx NE
of xx NE
VCAM-1 XXXX-d protein
and xxx NE
E-selectin X-xxx protein
, , NE
and xxx NE
subsequent xxx NE
monocyte xxx NE
adhesion xxx NE
in xx NE
endothelial xxx cell_type_B
cells xxx cell_type_E
stimulated xxx NE
by xx NE
TNF XXX protein
, , NE
thereby xxx NE
providing xxx NE
an xx NE
additional xxx NE
mechanism xxx NE
for xxx NE
therapeutic xxx NE
effects xxx NE
of xx NE
aspirin xxx NE
. . NE

Activation Xxxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
by xx NE
phosphatase xxx NE
inhibitors xxx NE
involves xxx NE
the xxx NE
phosphorylation xxx NE
of xx NE
I X protein_B
kappa xxx protein_M
B X protein_M
alpha xxx protein_E
at xx NE
phosphatase xxx protein_B
2A-sensitive dX-xxx protein_M
sites xxx protein_E
. . NE

Activation Xxxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
by xx NE
various xxx NE
cellular xxx NE
stimuli xxx NE
involves xxx NE
the xxx NE
phosphorylation xxx NE
and xxx NE
subsequent xxx NE
degradation xxx NE
of xx NE
its xxx NE
inhibitor xxx NE
, , NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
, , NE
although xxx NE
the xxx NE
underlying xxx NE
mechanism xxx NE
remains xxx NE
unclear xxx NE
. . NE

In Xx NE
the xxx NE
present xxx NE
study xxx NE
, , NE
the xxx NE
role xxx NE
of xx NE
serine/threonine xxx/xxx protein_B
phosphatases xxx protein_E
in xx NE
the xxx NE
regulation xxx NE
of xx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
phosphorylation xxx NE
was xxx NE
investigated xxx NE
. . NE

Our Xxx NE
studies xxx NE
demonstrate xxx NE
that xxx NE
incubation xxx NE
of xx NE
human xxx cell_type_B
T X cell_type_M
cells xxx cell_type_E
with xxx NE
low xxx NE
concentrations xxx NE
(approximately (xxx NE
1-5 d-d NE
nM) xX) NE
of xx NE
calyculin xxx NE
A X NE
or xx NE
okadaic xxx NE
acid xxx NE
, , NE
potent xxx NE
inhibitors xxx NE
of xx NE
protein xxx protein_B
phosphatase xxx protein_M
type xxx protein_M
1 d protein_M
(PP-1) (XX-d) protein_M
and xxx protein_M
protein xxx protein_M
phosphatase xxx protein_M
type xxx protein_M
2A dX protein_E
phosphorylation xxx NE
of xx NE
I X protein_B
kappa xxx protein_M
B X protein_M
alpha xxx protein_E
even xxx NE
in xx NE
the xxx NE
absence xxx NE
of xx NE
any xxx NE
cellular xxx NE
stimulus xxx NE
. . NE

This Xxxx NE
action xxx NE
of xx NE
the xxx NE
phosphatase xxx NE
inhibitors xxx NE
, , NE
which xxx NE
is xx NE
associated xxx NE
with xxx NE
the xxx NE
activation xxx NE
of xx NE
the xxx NE
RelA.p50 XxxX.xdd protein_B
NF-kappa XX-xxx protein_M
B X protein_M
heterodimer xxx protein_E
, , NE
is xx NE
not xxx NE
affected xxx NE
by xx NE
agents xxx NE
that xxx NE
block xxx NE
the xxx NE
induction xxx NE
of xx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
phosphorylation xxx NE
by xx NE
tumor xxx protein_B
necrosis xxx protein_M
factor xxx protein_M
alpha xxx protein_E
( ( NE
TNF-alpha XXX-xxx protein
) ) NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
phosphorylated xxx protein_B
I X protein_M
kappa xxx protein_M
B X protein_M
alpha xxx protein_E
from xxx NE
calyculin xxx NE
A X NE
-treated -xxx NE
cells xxx NE
, , NE
but xxx NE
not xxx NE
that xxx NE
from xxx NE
TNF-alpha XXX-xxx NE
-stimulated -xxx NE
cells xxx NE
, , NE
is xx NE
sensitive xxx NE
to xx NE
PP-2A XX-dX NE
in xx NE
vitro xxx NE
, , NE
suggesting xxx NE
the xxx NE
existence xxx NE
of xx NE
fundamental xxx NE
differences xxx NE
in xx NE
the xxx NE
phosphorylation xxx NE
of xx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
induced xxx NE
by xx NE
the xxx NE
two xxx NE
different xxx NE
NF-kappa XX-xxx NE
B X NE
inducers xxx NE
. . NE

However Xxxx NE
, , NE
induction xxx NE
of xx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
phosphorylation xxx NE
by xx NE
both xxx NE
TNF-alpha XXX-xxx protein
and xxx NE
the xxx NE
phosphatase xxx NE
inhibitors xxx NE
is xx NE
associated xxx NE
with xxx NE
the xxx NE
subsequent xxx NE
degradation xxx NE
of xx NE
I X protein_B
kappa xxx protein_M
B X protein_M
alpha xxx protein_E
. . NE

We Xx NE
further xxx NE
demonstrate xxx NE
that xxx NE
TNF-alpha-degradation XXX-xxx-xxx NE
and xxx NE
calyculin xxx NE
A-induced X-xxx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
degradation xxx NE
exhibits xxx NE
similar xxx NE
but xxx NE
not xxx NE
identical xxx NE
sensitivities xxx NE
to xx NE
a x NE
proteasome xxx NE
inhibitor xxx NE
. . NE

Together Xxxx NE
, , NE
these xxx NE
results xxx NE
suggest xxx NE
that xxx NE
phosphorylation xxx NE
of xx NE
I X protein_B
kappa xxx protein_M
B X protein_M
alpha xxx protein_E
, , NE
mediated xxx NE
through xxx NE
both xxx NE
the xxx NE
TNF-alpha XXX-xxx protein
-inducible -xxx NE
and xxx NE
the xxx NE
PP-2A XX-dX NE
-opposing -xxx NE
kinases xxx NE
, , NE
may xxx NE
serve xxx NE
to xx NE
target xxx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
for xxx NE
proteasome xxx NE
-mediated -xxx NE
degradation xxx NE
. . NE

Sp1 Xxd NE
functions xxx NE
in xx NE
a x NE
chromatin xxx NE
-dependent -xxx NE
manner xxx NE
to xx NE
augment xxx NE
human xxx NE
alpha-globin xxx-xxx NE
promoter xxx NE
activity xxx NE
. . NE

The Xxx NE
5' d' DNA_B
flanking xxx DNA_M
region xxx DNA_E
of xx NE
the xxx NE
human xxx DNA_B
alpha-globin xxx-xxx DNA_M
gene xxx DNA_E
is xx NE
highly xxx NE
G X DNA_B
+ + DNA_M
C X DNA_M
rich xxx DNA_E
and xxx NE
contains xxx NE
multiple xxx NE
copies xxx NE
of xx NE
the xxx NE
consensus xxx DNA_B
sequence xxx DNA_E
for xxx NE
the xxx NE
Sp1 Xxd DNA_B
binding xxx DNA_M
site xxx DNA_E
. . NE

We Xx NE
investigated xxx NE
the xxx NE
role xxx NE
of xx NE
this xxx NE
G X DNA_B
+ + DNA_M
C-rich X-xxx DNA_M
region xxx DNA_E
in xx NE
augmenting xxx NE
alpha-globin xxx-xxx NE
promoter xxx NE
activity xxx NE
in xx NE
the xxx NE
presence xxx NE
of xx NE
the xxx NE
far-upstream xxx-xxx DNA_B
alpha-globin xxx-xxx DNA_M
enhancer xxx DNA_E
, , NE
HS-40 XX-dd DNA
. . NE

We Xx NE
show xxx NE
that xxx NE
in xx NE
transiently xxx cell_line_B
transfected xxx cell_line_M
erythroid xxx cell_line_M
cells xxx cell_line_E
, , NE
deletion xxx NE
of xx NE
the xxx NE
alpha-globin xxx-xxx DNA_B
G X DNA_M
+ + DNA_M
C-rich X-xxx DNA_M
5' d' DNA_M
flanking xxx DNA_M
region xxx DNA_E
has xxx NE
no xx NE
effect xxx NE
on xx NE
alpha-globin xxx-xxx NE
promoter xxx NE
activity xxx NE
. . NE

However Xxxx NE
, , NE
upon xxx NE
stable xxx NE
integration xxx NE
into xxx NE
chromatin xxx DNA
, , NE
deletion xxx NE
of xx NE
this xxx NE
region xxx NE
causes xxx NE
a x NE
nearly xxx NE
90% dd% NE
decrease xxx NE
in xx NE
promoter xxx NE
activity xxx NE
compared xxx NE
with xxx NE
expression xxx NE
from xxx NE
an xx NE
alpha-globin xxx-xxx DNA_B
promoter xxx DNA_E
retaining xxx NE
this xxx NE
region xxx NE
. . NE

These Xxxx NE
results xxx NE
suggest xxx NE
that xxx NE
the xxx NE
alpha-globin xxx-xxx DNA_B
G X DNA_M
+ + DNA_M
C-rich X-xxx DNA_M
5' d' DNA_M
flanking xxx DNA_M
region xxx DNA_E
augments xxx NE
alpha-globin xxx-xxx NE
promoter xxx NE
activity xxx NE
in xx NE
a x NE
chromatin xxx NE
-dependent -xxx NE
manner xxx NE
. . NE

We Xx NE
further xxx NE
show xxx NE
that xxx NE
this xxx NE
G X DNA_B
+ + DNA_M
C-rich X-xxx DNA_M
region xxx DNA_E
is xx NE
required xxx NE
for xxx NE
the xxx NE
activation xxx NE
of xx NE
alpha-globin xxx-xxx NE
gene xxx NE
expression xxx NE
during xxx NE
erythroid xxx NE
differentiation xxx NE
. . NE

Finally Xxxx NE
, , NE
we xx NE
show xxx NE
by xx NE
both xxx NE
footprint xxx NE
analysis xxx NE
and xxx NE
functional xxx NE
assays xxx NE
that xxx NE
the xxx NE
ability xxx NE
of xx NE
the xxx NE
G X DNA_B
+ + DNA_M
C-rich X-xxx DNA_M
region xxx DNA_E
to xx NE
increase xxx NE
alpha-globin xxx-xxx NE
promoter xxx NE
activity xxx NE
from xxx NE
a x NE
stably xxx NE
integrated xxx NE
alpha-globin xxx-xxx DNA_B
gene xxx DNA_E
is xx NE
mediated xxx NE
by xx NE
its xxx NE
multiple xxx DNA_B
binding xxx DNA_M
sites xxx DNA_E
for xxx NE
the xxx NE
transcription xxx protein_B
factor xxx protein_E
Sp1 Xxd protein
. . NE

Costimulation Xxxx NE
of xx NE
human xxx cell_line_B
CD4+ XXd+ cell_line_M
T X cell_line_M
cells xxx cell_line_E
with xxx NE
LFA-3 XXX-d protein
and xxx NE
B7 Xd protein
induce xxx NE
distinct xxx NE
effects xxx NE
on xx NE
AP-1 XX-d protein
and xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
transcription xxx protein_B
factors xxx protein_E
. . NE

We Xx NE
have xxx NE
earlier xxx NE
shown xxx NE
that xxx NE
stimulation xxx NE
of xx NE
human xxx cell_line_B
CD4+ XXd+ cell_line_M
T X cell_line_M
cells xxx cell_line_E
with xxx NE
SEA XXX NE
presented xxx NE
on xx NE
Chinese Xxxx cell_line_B
hamster xxx cell_line_M
ovary xxx cell_line_M
(CHO)-DR (XXX)-XX cell_line_M
transfectants xxx cell_line_E
coexpressing xxx NE
either xxx NE
B7 Xd protein
or xx NE
LFA-3 XXX-d protein
resulted xxx NE
in xx NE
distinct xxx NE
cytokine xxx NE
profiles xxx NE
. . NE

We Xx NE
now xxx NE
demonstrate xxx NE
that xxx NE
B7 Xd protein
, , NE
but xxx NE
not xxx NE
LFA-3 XXX-d protein
, , NE
strongly xxx NE
costimulated xxx NE
IL-2 XX-d NE
transcription xxx NE
and xxx NE
mRNA xXXX NE
expression xxx NE
in xx NE
CD4+ XXd+ cell_line_B
T X cell_line_M
cells xxx cell_line_E
. . NE

Maximal Xxxx NE
increase xxx NE
in xx NE
IL-2 XX-d NE
transcription xxx NE
was xxx NE
recorded xxx NE
with xxx NE
CHO-DR XXX-XX NE
/ / NE
B7 Xd NE
/ / NE
LFA-3 XXX-d NE
, , NE
suggesting xxx NE
a x NE
cooperative xxx NE
effect xxx NE
of xx NE
B7 Xd NE
and xxx NE
LFA-3 XXX-d NE
at xx NE
the xxx NE
transcriptional xxx NE
level xxx NE
. . NE

Gel-shift Xxx-xxx NE
analysis xxx NE
demonstrated xxx NE
that xxx NE
stimulation xxx NE
of xx NE
CD4+ XXd+ cell_line_B
T X cell_line_M
cells xxx cell_line_E
with xxx NE
CHO-DR XXX-XX protein
and xxx NE
staphylococcal xxx NE
enterotoxin xxx NE
A X NE
was xxx NE
sufficient xxx NE
to xx NE
induce xxx NE
significant xxx NE
amounts xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
binding xxx NE
proteins xxx NE
, , NE
whereas xxx NE
induction xxx NE
of xx NE
AP-1 XX-d protein_B
binding xxx protein_M
proteins xxx protein_E
required xxx NE
costimulation xxx NE
. . NE

LFA-3 XXX-d protein
induced xxx NE
moderate xxx NE
levels xxx NE
of xx NE
AP-1 XX-d protein
, , NE
but xxx NE
did xxx NE
not xxx NE
influence xxx NE
the xxx NE
levels xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
, , NE
while xxx NE
B7 Xd NE
costimulation xxx NE
strongly xxx NE
induced xxx NE
both xxx NE
AP-1 XX-d protein
and xxx NE
substantially xxx NE
enhanced xxx NE
NF-kappa XX-xxx protein_B
B X protein_M
binding xxx protein_M
proteins xxx protein_E
. . NE

The Xxx NE
CHO-DR XXX-XX NE
/ / NE
B7 Xd NE
/ / NE
LFA-3 XXX-d NE
triple xxx NE
transfectant xxx NE
induced xxx NE
a x NE
further xxx NE
increase xxx NE
in xx NE
AP-1 XX-d NE
and xxx NE
NF-kappa XX-xxx NE
B X NE
binding xxx NE
proteins xxx NE
compared xxx NE
with xxx NE
the xxx NE
double xxx NE
transfectants xxx NE
. . NE

The Xxx NE
level xxx NE
of xx NE
Oct-1 Xxx-d protein_B
binding xxx protein_M
proteins xxx protein_E
remained xxx NE
similar xxx NE
in xx NE
all xxx NE
samples xxx NE
. . NE

Super-shift Xxxx-xxx NE
analysis xxx NE
revealed xxx NE
that xxx NE
the xxx NE
NF-kappa XX-xxx protein_B
B X protein_M
complex xxx protein_E
of xx NE
costimulated xxx cell_line_B
CD4+ XXd+ cell_line_M
T X cell_line_M
cells xxx cell_line_E
contained xxx NE
large xxx NE
amounts xxx NE
of xx NE
p50 xdd protein
, , NE
substantial xxx NE
amounts xxx NE
of xx NE
p65 xdd protein
, , NE
and xxx NE
marginal xxx NE
levels xxx NE
of xx NE
c-Rel x-Xxx protein_B
proteins xxx protein_E
. . NE

The Xxx NE
AP-1 XX-d protein_B
binding xxx protein_M
proteins xxx protein_E
contained xxx NE
c-Jun x-Xxx protein
, , NE
Jun-D Xxx-X protein
, , NE
and xxx NE
Fra-1 Xxx-d protein
, , NE
but xxx NE
marginal xxx NE
amounts xxx NE
of xx NE
Jun-B Xxx-X protein
and xxx NE
c-Fos x-Xxx protein
. . NE

Our Xxx NE
results xxx NE
indicate xxx NE
distinct xxx NE
effects xxx NE
of xx NE
B7 Xd NE
and xxx NE
LFA-3 XXX-d NE
costimulation xxx NE
on xx NE
the xxx NE
activity xxx NE
of xx NE
AP-1 XX-d protein
and xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
. . NE

These Xxxx NE
may xxx NE
partly xxx NE
account xxx NE
for xxx NE
the xxx NE
differential xxx NE
effects xxx NE
of xx NE
B7 Xd NE
and xxx NE
LFA-3 XXX-d NE
costimulation xxx NE
on xx NE
IL-2 XX-d NE
expression xxx NE
. . NE

The Xxx NE
Ah Xx protein_B
receptor xxx protein_E
recognizes xxx NE
DNA XXX DNA_B
binding xxx DNA_M
sites xxx DNA_E
for xxx NE
the xxx NE
B X protein_B
cell xxx protein_M
transcription xxx protein_M
factor xxx protein_E
, , NE
BSAP XXXX protein
: : NE
a x NE
possible xxx NE
mechanism xxx NE
for xxx NE
dioxin-mediated xxx-xxx NE
alteration xxx NE
of xx NE
CD19 XXdd NE
gene xxx NE
expression xxx NE
in xx NE
human xxx cell_type_B
B X cell_type_M
lymphocytes xxx cell_type_E
. . NE

2,3,7,8-tetrachlorodibenzo-p-dioxin d,d,d,d-xxx-x-xxx NE
( ( NE
TCDD XXXX NE
) ) NE
inhibits xxx NE
murine xxx NE
B X NE
lymphocyte xxx NE
immunoglobulin xxx NE
production xxx NE
and xxx NE
human xxx NE
B X NE
lymphocyte xxx NE
immunoglobulin xxx NE
production xxx NE

This Xxxx NE
study xxx NE
investigated xxx NE
the xxx NE
effect xxx NE
of xx NE
TCDD XXXX NE
on xx NE
expression xxx NE
of xx NE
the xxx NE
CD19 XXdd DNA_B
gene xxx DNA_E
in xx NE
a x NE
human xxx cell_line_B
B X cell_line_M
lymphocyte xxx cell_line_M
cell xxx cell_line_M
line xxx cell_line_E
. . NE

Northern Xxxx NE
blot xxx NE
analysis xxx NE
showed xxx NE
that xxx NE
TCDD XXXX NE
treatment xxx NE
decreased xxx NE
steady xxx NE
state xxx NE
levels xxx NE
of xx NE
CD19 XXdd RNA_B
mRNA xXXX RNA_E
by xx NE
67% dd% NE
in xx NE
the xxx NE
IM-9 XX-d cell_line_B
cell xxx cell_line_M
line xxx cell_line_E
. . NE

Using Xxxx NE
a x NE
gel xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
, , NE
we xx NE
identified xxx NE
a x NE
DNA-binding XXX-xxx protein_B
complex xxx protein_E
in xx NE
IM-9 XX-d NE
nuclear xxx NE
extracts xxx NE
that xxx NE
by xx NE
several xxx NE
criteria xxx NE
appears xxx NE
to xx NE
be xx NE
the xxx NE
Ah Xx protein_B
receptor xxx protein_E
. . NE

In Xx NE
addition xxx NE
, , NE
the xxx NE
Ah Xx protein_B
receptor xxx protein_M
complex xxx protein_E
recognized xxx NE
a x NE
DNA XXX DNA_B
binding xxx DNA_M
site xxx DNA_E
for xxx NE
B X protein_B
cell xxx protein_M
lineage-specific xxx-xxx protein_M
activator xxx protein_M
protein xxx protein_E
( ( NE
BSAP XXXX protein
) ) NE
in xx NE
the xxx NE
promoter xxx DNA_B
region xxx DNA_E
of xx NE
the xxx NE
human xxx NE
CD19 XXdd DNA_B
gene xxx DNA_E
which xxx NE
is xx NE
similar xxx NE
to xx NE
the xxx NE
consensus xxx DNA_B
Ah Xx DNA_M
receptor xxx DNA_M
DNA XXX DNA_M
binding xxx DNA_M
site xxx DNA_E
. . NE

These Xxxx NE
results xxx NE
suggest xxx NE
that xxx NE
the xxx NE
AhR XxX protein
could xxx NE
interfere xxx NE
with xxx NE
BSAP XXXX NE
-stimulated -xxx NE
CD19 XXdd NE
gene xxx NE
transcription xxx NE
by xx NE
competition xxx NE
for xxx NE
a x NE
common xxx NE
DNA XXX NE
binding xxx NE
site xxx NE
. . NE

Inhibitory Xxxx NE
action xxx NE
of xx NE
nm23 xxdd protein_B
proteins xxx protein_E
on xx NE
induction xxx NE
of xx NE
erythroid xxx NE
differentiation xxx NE
of xx NE
human xxx cell_type_B
leukemia xxx cell_type_M
cells xxx cell_type_E
. . NE

We Xx NE
recently xxx NE
identified xxx NE
a x NE
differentiation xxx protein_B
inhibitory xxx protein_M
factor xxx protein_E
( ( NE
I-factor X-xxx protein
) ) NE
in xx NE
mouse xxx cell_line_B
myeloid xxx cell_line_M
leukemia xxx cell_line_M
M1 Xd cell_line_M
cells xxx cell_line_E
as xx NE
a x NE
murine xxx protein_B
homolog xxx protein_E
of xx NE
the xxx NE
human xxx protein_B
nm23-H2 xxdd-Xd protein_M
gene xxx protein_M
product xxx protein_E
. . NE

nm23 xxdd DNA_B
genes xxx DNA_E
encode xxx NE
proteins xxx NE
that xxx NE
participate xxx NE
in xx NE
tumor xxx NE
metastasis xxx NE
regulation xxx NE
and xxx NE
in xx NE
various xxx NE
fundamental xxx NE
cellular xxx NE
processes xxx NE
, , NE
although xxx NE
their xxx NE
mechanisms xxx NE
of xx NE
action xxx NE
are xxx NE
still xxx NE
unknown xxx NE
. . NE

Although Xxxx NE
all xxx NE
nm23 xxdd protein_B
proteins xxx protein_E
contain xxx NE
nucleoside xxx NE
diphosphate xxx NE
(NDP) (XXX) NE
kinase xxx NE
activity xxx NE
, , NE
it xx NE
has xxx NE
not xxx NE
been xxx NE
established xxx NE
that xxx NE
the xxx NE
enzyme xxx NE
activity xxx NE
mediated xxx NE
the xxx NE
various xxx NE
functions xxx NE
of xx NE
nm23 xxdd protein_B
proteins xxx protein_E
. . NE

In Xx NE
the xxx NE
present xxx NE
experiment xxx NE
, , NE
we xx NE
examined xxx NE
the xxx NE
effect xxx NE
of xx NE
nm23 xxdd protein_B
proteins xxx protein_E
on xx NE
various xxx NE
differentiation xxx NE
induction xxx NE
systems xxx NE
of xx NE
human xxx cell_type_B
leukemic xxx cell_type_M
cells xxx cell_type_E
including xxx NE
HL-60 XX-dd cell_line_B
cell xxx cell_line_M
and xxx cell_line_M
U937 Xddd cell_line_M
cell xxx cell_line_M
and xxx cell_line_M
HEL/S XXX/X cell_line_M
cell xxx cell_line_M
and xxx cell_line_M
KU812F XXdddX cell_line_M
cell xxx cell_line_M
and xxx cell_line_M
K562 Xddd cell_line_M
cell xxx cell_line_M
and xxx cell_line_M
HEL XXX cell_line_M
cell xxx cell_line_E

Native Xxxx protein_B
human xxx protein_M
erythrocyte xxx protein_M
NDP XXX protein_M
kinase xxx protein_M
protein xxx protein_E
inhibited xxx NE
the xxx NE
induction xxx NE
of xx NE
erythroid xxx NE
differentiation xxx NE
of xx NE
HEL XXX cell_line_B
cell xxx cell_line_M
and xxx cell_line_M
KU812 XXddd cell_line_M
cell xxx cell_line_M
and xxx cell_line_M
K562 Xddd cell_line_M
cell xxx cell_line_E
HL-60 XX-dd cell_line_B
cell xxx cell_line_M
and xxx cell_line_M
U937 Xddd cell_line_M
cell xxx cell_line_M
and xxx cell_line_M
HEL/S XXX/X cell_line_M
cell xxx cell_line_E
monocytic xxx NE
or xx NE
monocytic xxx NE
differentiation xxx NE
or xx NE
granulocytic xxx NE
differentiation xxx NE
of xx NE
HL-60 XX-dd NE
, , NE
U937 Xddd NE
and xxx NE
HEL/S XXX/X NE
cells xxx NE
. . NE

The Xxx NE
erythroid xxx NE
differentiation xxx NE
of xx NE
HEL XXX cell_line_B
cells xxx cell_line_E
was xxx NE
inhibited xxx NE
by xx NE
recombinant xxx protein_B
human xxx protein_M
nm23-H1 xxdd-Xd protein_M
protein xxx protein_M
and xxx protein_M
recombinant xxx protein_M
human-H2 xxx-Xd protein_M
protein xxx protein_M
and xxx protein_M
recombinant xxx protein_M
mouse xxx protein_M
nm23-M1 xxdd-Xd protein_M
protein xxx protein_M
and xxx protein_M
recombinant xxx protein_M
mouse xxx protein_M
nm23-M2 xxdd-Xd protein_M
protein xxx protein_E

Moreover Xxxx NE
, , NE
both xxx NE
the xxx NE
mutant xxx protein_B
nm23-H2His xxdd-XdXxx protein_M
protein xxx protein_E
and xxx NE
truncated xxx protein_B
nm23-H2 xxdd-Xd protein_M
protein xxx protein_E
containing xxx NE
N-terminal X-xxx protein_B
(1-60) (d-dd) protein_M
peptide xxx protein_E
, , NE
which xxx NE
do xx NE
not xxx NE
have xxx NE
NDP XXX NE
kinase xxx NE
activity xxx NE
, , NE
also xxx NE
inhibited xxx NE
erythroid xxx NE
differentiation xxx NE
of xx NE
HEL XXX cell_line_B
cells xxx cell_line_E
. . NE

These Xxxx NE
results xxx NE
suggest xxx NE
that xxx NE
(1) (d) NE
the xxx NE
differentiation xxx NE
inhibitory xxx NE
activity xxx NE
of xx NE
I-factor X-xxx NE
/nm23 /xxdd NE
protein xxx NE
is xx NE
not xxx NE
restricted xxx NE
to xx NE
monocytic xxx NE
differentiation xxx NE
of xx NE
M1 Xd NE
cells xxx NE
, , NE
(2) (d) NE
the xxx NE
inhibitory xxx NE
activity xxx NE
is xx NE
exhibited xxx NE
without xxx NE
species xxx NE
specificity xxx NE
, , NE
and xxx NE
(3) (d) NE
the xxx NE
differentiation xxx NE
inhibitory xxx NE
activity xxx NE
of xx NE
the xxx NE
nm23/NDP xxdd/XXX NE
kinase xxx NE
protein xxx NE
is xx NE
independent xxx NE
of xx NE
its xxx NE
enzyme xxx NE
activity xxx NE
and xxx NE
requires xxx NE
the xxx NE
presence xxx NE
of xx NE
N-terminal X-xxx NE
peptides xxx NE
. . NE

Lipopolysaccharide Xxxx NE
-induced -xxx NE
E-selectin X-xxx NE
expression xxx NE
requires xxx NE
continuous xxx NE
presence xxx NE
of xx NE
LPS XXX NE
and xxx NE
is xx NE
inhibited xxx NE
by xx NE
bactericidal/permeability-increasing xxx/xxx-xxx NE
protein xxx NE
. . NE

Endothelial Xxxx cell_type_B
cells xxx cell_type_E
stimulated xxx NE
by xx NE
LPS XXX NE
express xxx NE
E-selectin X-xxx protein
, , NE
which xxx NE
plays xxx NE
an xx NE
important xxx NE
role xxx NE
in xx NE
mediating xxx NE
neutrophil xxx NE
adhesion xxx NE
during xxx NE
inflammation xxx NE
. . NE

E-selectin X-xxx protein
is xx NE
induced xxx NE
within xxx NE
1-2 d-d NE
h x NE
, , NE
peaks xxx NE
at xx NE
4-6 d-d NE
h x NE
, , NE
and xxx NE
gradually xxx NE
returns xxx NE
to xx NE
basal xxx NE
level xxx NE
by xx NE
24 dd NE
h x NE
. . NE

rBPI21 xXXXdd protein
, , NE
a x NE
recombinant xxx protein_B
N-terminal X-xxx protein_M
fragment xxx protein_E
of xx NE
human xxx protein_B
bactericidal/permeability-increasing xxx/xxx-xxx protein_M
protein xxx protein_E
( ( NE
BPI XXX protein
) ) NE
, , NE
inhibited xxx NE
LPS XXX NE
-induced -xxx NE
E-selectin X-xxx NE
expression xxx NE
when xxx NE
added xxx NE
at xx NE
the xxx NE
same xxx NE
time xxx NE
as xx NE
, , NE
and xxx NE
up xx NE
to xx NE
6 d NE
h x NE
after xxx NE
, , NE
LPS XXX NE
. . NE

Delayed Xxxx NE
administration xxx NE
of xx NE
rBPI21 xXXXdd protein
also xxx NE
affected xxx NE
LPS XXX NE
-mediated -xxx NE
activation xxx NE
of xx NE
the xxx NE
nuclear xxx NE
factor xxx NE
, , NE
NF-kappa XX-xxx NE
B X NE
. . NE

Two Xxx NE
to xx NE
4 d NE
h x NE
following xxx NE
LPS XXX NE
addition xxx NE
to xx NE
endothelial xxx cell_type_B
cells xxx cell_type_E
, , NE
when xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
was xxx NE
already xxx NE
activated xxx NE
, , NE
addition xxx NE
of xx NE
rBPI21 xXXXdd protein
resulted xxx NE
in xx NE
marked xxx NE
reduction xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
detectable xxx NE
at xx NE
4 d NE
or xx NE
6 d NE
h x NE
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
endothelial xxx NE
activation xxx NE
requires xxx NE
continuous xxx NE
presence xxx NE
of xx NE
LPS XXX NE
, , NE
and xxx NE
rBPI21 xXXXdd protein
acts xxx NE
to xx NE
reverse xxx NE
LPS XXX NE
-mediated -xxx NE
endothelial xxx NE
activation xxx NE
by xx NE
interrupting xxx NE
the xxx NE
on-going xx-xxx NE
LPS XXX NE
signal xxx NE
. . NE

GM-CSF XX-XXX protein
and xxx NE
IL-2 XX-d protein
share xxx NE
common xxx NE
control xxx NE
mechanisms xxx NE
in xx NE
response xxx NE
to xx NE
costimulatory xxx NE
signals xxx NE
in xx NE
T X cell_type_B
cells xxx cell_type_E
. . NE

Antigen Xxxx NE
complexed xxx NE
with xxx NE
major xxx protein_B
histocompatibility xxx protein_M
complex xxx protein_M
class xxx protein_M
I X protein_M
molecule xxx protein_M
or xx protein_M
major xxx protein_M
histocompatibility xxx protein_M
complex xxx protein_M
class xxx protein_M
II XX protein_M
molecule xxx protein_E
on xx NE
the xxx NE
surface xxx NE
of xx NE
antigen xxx cell_type_B
presenting xxx cell_type_M
cells xxx cell_type_E
interacts xxx NE
with xxx NE
the xxx NE
T X protein_B
cell xxx protein_M
receptor xxx protein_E
( ( NE
TCR XXX protein
) ) NE
on xx NE
the xxx NE
surface xxx NE
of xx NE
T X cell_type_B
cells xxx cell_type_E
and xxx NE
initiates xxx NE
an xx NE
activation xxx NE
cascade xxx NE
. . NE

So Xx NE
called xxx NE
costimulatory xxx NE
signals xxx NE
, , NE
mediated xxx NE
by xx NE
other xxx NE
cell xxx NE
surface xxx NE
interactions xxx NE
or xx NE
soluble xxx protein_B
cytokines xxx protein_E
produced xxx NE
by xx NE
antigen xxx cell_type_B
presenting xxx cell_type_M
cells xxx cell_type_E
, , NE
are xxx NE
also xxx NE
required xxx NE
for xxx NE
complete xxx NE
T X NE
cell xxx NE
activation xxx NE
. . NE

High Xxxx NE
levels xxx NE
of xx NE
cytokine xxx NE
gene xxx NE
expression xxx NE
in xx NE
T X cell_type_B
cells xxx cell_type_E
also xxx NE
required xxx NE
both xxx NE
TCR XXX protein
and xxx NE
costimulatory xxx NE
signals xxx NE
. . NE

The Xxx NE
granulocyte-macrophage xxx-xxx protein_B
colony-stimulating xxx-xxx protein_M
factor xxx protein_E
requires xxx NE
sequences xxx NE
in xx NE
the xxx NE
promoter xxx DNA
as xx NE
well xxx NE
as xx NE
a x NE
powerful xxx NE
enhancer xxx DNA
located xxx NE
3kb dxx NE
upstream xxx NE
to xx NE
respond xxx NE
to xx NE
TCR XXX NE
-like -xxx NE
signals xxx NE
. . NE

These Xxxx NE
promoter xxx DNA_B
and xxx DNA_M
enhancer xxx DNA_M
regions xxx DNA_E
are xxx NE
mainly xxx NE
activated xxx NE
by xx NE
the xxx NE
transcription xxx protein_B
factor xxx protein_M
nuclear xxx protein_M
factor xxx protein_M
of xx protein_M
activated xxx protein_M
T X protein_M
cells xxx protein_E
( ( NE
NFAT XXXX protein
) ) NE
. . NE

The Xxx NE
activation xxx NE
of xx NE
NFAT XXXX protein
by xx NE
TCR XXX protein
signals xxx NE
has xxx NE
been xxx NE
well xxx NE
described xxx NE
for xxx NE
interleukin-2 xxx-d NE
(IL-2) (XX-d) NE
gene xxx NE
transcription xxx NE
and xxx NE
IL-4 XX-d NE
gene xxx NE
transcription xxx NE
T X NE
cells xxx NE
. . NE

Costimulatory Xxxx NE
signals xxx NE
, , NE
such xxx NE
as xx NE
activation xxx NE
of xx NE
the xxx NE
CD28 XXdd protein_B
cell xxx protein_M
surface xxx protein_M
molecule xxx protein_E
on xx NE
T X cell_type_B
cells xxx cell_type_E
, , NE
lead xxx NE
to xx NE
activation xxx NE
through xxx NE
a x NE
distinct xxx NE
region xxx NE
of xx NE
the xxx NE
granulocyte-macrophage xxx-xxx NE
colony-stimulating xxx-xxx NE
factor xxx NE
( ( NE
GM-CSF XX-XXX NE
) ) NE
promoter xxx NE
. . NE

This Xxxx NE
region xxx NE
is xx NE
termed xxx NE
the xxx NE
CK-1 XX-d DNA
or xx NE
CD28RE XXddXX DNA
and xxx NE
appears xxx NE
to xx NE
bind xxx NE
specific xxx NE
members xxx NE
of xx NE
the xxx NE
NF-kappa XX-xxx protein_B
B X protein_M
family xxx protein_E
of xx NE
transcription xxx protein_B
factors xxx protein_E
. . NE

Human Xxxx NE
T X NE
leukemia xxx NE
virus xxx NE
type xxx NE
1 d NE
( ( NE
HTLV-1 XXXX-d NE
) ) NE
infects xxx NE
T X cell_type_B
cells xxx cell_type_E
and xxx NE
can xxx NE
lead xxx NE
to xx NE
increase xxx NE
GM-CSF XX-XXX NE
expression xxx NE
. . NE

We Xx NE
have xxx NE
found xxx NE
that xxx NE
the xxx NE
HTLV-1 XXXX-d protein_B
transactivator xxx protein_M
protein xxx protein_E
, , NE
tax xxx protein
, , NE
acts xxx NE
as xx NE
a x NE
costimulatory xxx NE
signal xxx NE
for xxx NE
GM-CSF XX-XXX NE
gene xxx NE
transcription xxx NE
and xxx NE
IL-2 XX-d NE
gene xxx NE
transcription xxx NE
TCR XXX NE
signals xxx NE
to xx NE
mediate xxx NE
high xxx NE
level xxx NE
gene xxx NE
expression xxx NE
. . NE

Tax Xxx NE
activates xxx NE
the xxx NE
GM-CSF XX-XXX DNA_B
promoter xxx DNA_E
through xxx NE
the xxx NE
CK-1 XX-d DNA
/CD28RE /XXddXX NE
region xxx NE
and xxx NE
also xxx NE
activates xxx NE
nuclear xxx NE
factor-kappa xxx-xxx NE
B X NE
binding xxx NE
to xx NE
this xxx NE
region xxx NE
. . NE

However Xxxx NE
, , NE
other xxx NE
transcription xxx protein_B
factors xxx protein_E
or xx NE
coactivators xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
are xxx NE
required xxx NE
for xxx NE
tax xxx NE
activation xxx NE
but xxx NE
these xxx NE
remain xxx NE
to xx NE
be xx NE
identified xxx NE
. . NE

The Xxx NE
CK-1 XX-d DNA
/CD28RE /XXddXX NE
of xx NE
GM-CSF XX-XXX NE
shows xxx NE
a x NE
high xxx NE
degree xxx NE
of xx NE
similarity xxx NE
to xx NE
the xxx NE
IL-2 XX-d NE
CD28RE XXddXX DNA
and xxx NE
the xxx NE
IL-3 XX-d NE
gene xxx NE
also xxx NE
contains xxx NE
a x NE
related xxx NE
region xxx NE
. . NE

This Xxxx NE
observation xxx NE
, , NE
together xxx NE
with xxx NE
the xxx NE
fact xxx NE
that xxx NE
both xxx NE
GM-CSF XX-XXX protein
and xxx NE
IL-2 XX-d protein
respond xxx NE
to xx NE
TCR XXX protein
signals xxx NE
via xxx NE
NFAT XXXX protein
, , NE
implies xxx NE
a x NE
high xxx NE
degree xxx NE
of xx NE
conservation xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
cytokine xxx NE
gene xxx NE
expression xxx NE
in xx NE
T X cell_type_B
cells xxx cell_type_E
. . NE

Danazol Xxxx NE
decreases xxx NE
transcription xxx NE
of xx NE
estrogen xxx DNA_B
receptor xxx DNA_M
gene xxx DNA_E
in xx NE
human xxx cell_type_B
monocytes xxx cell_type_E
. . NE

1 d NE
. . NE
Administration Xxxx NE
of xx NE
danazol xxx NE
for xxx NE
over xxx NE
one xxx NE
month xxx NE
reduced xxx NE
the xxx NE
levels xxx NE
of xx NE
estrogen xxx protein_B
receptor xxx protein_E
( ( NE
ER XX protein
) ) NE
and xxx NE
its xxx NE
mRNA xXXX RNA
to xx NE
approximately xxx NE
50 dd NE
and xxx NE
20% dd% NE
, , NE
respectively xxx NE
in xx NE
monocytes xxx cell_type
. . NE

2 d NE
. . NE
Danazol Xxxx NE
did xxx NE
not xxx NE
alter xxx NE
the xxx NE
degradation xxx NE
rate xxx NE
of xx NE
ER XX RNA_B
mRNA xXXX RNA_E
in xx NE
monocytes xxx cell_type
. . NE

3 d NE
. . NE
Danazol Xxxx NE
decreased xxx NE
the xxx NE
transcription xxx NE
rate xxx NE
of xx NE
ER XX DNA_B
gene xxx DNA_E
to xx NE
approximately xxx NE
50% dd% NE
in xx NE
monocytes xxx cell_type
in xx NE
a x NE
run-on xxx-xx NE
assay xxx NE
. . NE

4 d NE
. . NE
Danazol Xxxx NE
may xxx NE
release xxx NE
estrogen xxx NE
predominance xxx NE
via xxx NE
the xxx NE
reduction xxx NE
of xx NE
transcription xxx NE
for xxx NE
ER XX DNA_B
gene xxx DNA_E
, , NE
which xxx NE
leads xxx NE
to xx NE
the xxx NE
reduction xxx NE
of xx NE
ER XX RNA_B
mRNA xXXX RNA_E
and xxx NE
ER XX NE
expressions xxx NE
in xx NE
monocytes xxx cell_type
. . NE

Functional Xxxx NE
characterization xxx NE
of xx NE
novel xxx NE
IL-2 XX-d NE
transcriptional xxx NE
inhibitors xxx NE
. . NE

IL-2 XX-d NE
-mediated -xxx NE
T X NE
cell xxx NE
proliferation xxx NE
is xx NE
a x NE
critical xxx NE
early xxx NE
event xxx NE
in xx NE
the xxx NE
inflammatory xxx NE
process xxx NE
. . NE

Formation Xxxx NE
of xx NE
the xxx NE
NFAT XXXX NE
-1 -d NE
transcriptional xxx NE
complex xxx NE
on xx NE
the xxx NE
IL-2 XX-d NE
promoter xxx NE
is xx NE
essential xxx NE
for xxx NE
IL-2 XX-d NE
transcription xxx NE
. . NE

Using Xxxx NE
a x NE
cell xxx NE
line xxx NE
that xxx NE
is xx NE
stably xxx NE
transfected xxx NE
with xxx NE
a x NE
trimer xxx NE
of xx NE
the xxx NE
NFAT XXXX NE
-1 -d NE
regulatory xxx NE
element xxx NE
linked xxx NE
to xx NE
a x NE
lac-Z xxx-X NE
reporter xxx NE
gene xxx NE
, , NE
we xx NE
screened xxx NE
for xxx NE
inhibitors xxx NE
of xx NE
NFAT XXXX NE
-1-mediated -d-xxx NE
beta-galactosidase xxx-xxx NE
activity xxx NE
. . NE

WIN XXX NE
61058 ddddd NE
and xxx NE
WIN XXX NE
53071 ddddd NE
were xxx NE
identified xxx NE
as xx NE
microM xxxX NE
inhibitors xxx NE
. . NE

These Xxxx NE
compounds xxx NE
also xxx NE
inhibited xxx NE
beta-galactosidase xxx-xxx NE
mRNA xXXX NE
levels xxx NE
. . NE

Similar Xxxx NE
inhibition xxx NE
of xx NE
NFAT XXXX NE
-1-mediated -d-xxx NE
gene xxx NE
expression xxx NE
was xxx NE
observed xxx NE
in xx NE
a x NE
second xxx NE
cell xxx NE
line xxx NE
, , NE
which xxx NE
is xx NE
stably xxx NE
transfected xxx NE
with xxx NE
NFAT XXXX NE
-1 -d NE
regulatory xxx NE
elements xxx NE
linked xxx NE
to xx NE
the xxx NE
reporter xxx NE
gene xxx NE
for xxx NE
sCD8 xXXd NE
. . NE

At Xx NE
10 dd NE
microM xxxX NE
, , NE
both xxx NE
compounds xxx NE
inhibited xxx NE
IL-2 XX-d NE
mRNA xXXX NE
level xxx NE
and xxx NE
IL-2 XX-d NE
protein xxx NE
level xxx NE
in xx NE
the xxx NE
NFAT XXXX cell_line
-1-linked -d-xxx NE
lac-Z xxx-X NE
transfectants xxx NE
, , NE
and xxx NE
in xx NE
human xxx cell_type_B
lymphocytes xxx cell_type_E
. . NE

Both Xxxx NE
compounds xxx NE
inhibited xxx NE
the xxx NE
mixed xxx NE
lymphocyte xxx NE
reaction xxx NE
, , NE
and xxx NE
this xxx NE
inhibition xxx NE
was xxx NE
reversed xxx NE
by xx NE
exogenous xxx NE
IL-2 XX-d protein
. . NE

WIN XXX NE
53071 ddddd NE
inhibited xxx NE
IL-2 XX-d NE
production xxx NE
induced xxx NE
in xx NE
the xxx NE
calcium-dependent xxx-xxx NE
PMA XXX NE
and xxx NE
ionomycin xxx NE
pathway xxx NE
. . NE

Conversely Xxxx NE
, , NE
calcium-independent xxx-xxx protein_B
anti-CD28 xxx-XXdd protein_M
Ab Xx protein_E
and xxx NE
PMA-induced XXX-xxx NE
IL-2 XX-d NE
production xxx NE
was xxx NE
resistant xxx NE
. . NE

Both Xxxx NE
compounds xxx NE
altered xxx NE
the xxx NE
NFAT XXXX NE
-1 -d NE
transcriptional xxx NE
complex xxx NE
, , NE
causing xxx NE
its xxx NE
retarded xxx NE
mobility xxx NE
on xx NE
gels xxx NE
. . NE

By Xx NE
these xxx NE
functional xxx NE
criteria xxx NE
, , NE
we xx NE
believe xxx NE
we xx NE
have xxx NE
identified xxx NE
two xxx NE
structurally xxx NE
distinct xxx NE
, , NE
novel xxx NE
inhibitors xxx NE
of xx NE
NFAT XXXX NE
-1-mediated -d-xxx NE
transcription xxx NE
. . NE

Transcriptional Xxxx NE
regulation xxx NE
of xx NE
the xxx NE
vacuolar xxx DNA_B
H(+)-ATPase X(+)-XXXxxx DNA_M
B2 Xd DNA_M
subunit xxx DNA_M
gene xxx DNA_E
in xx NE
differentiating xxx cell_line_B
THP-1 XXX-d cell_line_M
cells xxx cell_line_E
. . NE

Monocyte-macrophage Xxxx-xxx NE
differentiation xxx NE
was xxx NE
used xxx NE
as xx NE
a x NE
model xxx NE
system xxx NE
for xxx NE
studying xxx NE
gene xxx NE
regulation xxx NE
of xx NE
the xxx NE
human xxx protein_B
vacuolar xxx protein_M
H(+)-ATPase X(+)-XXXxxx protein_E
( ( NE
V-ATPase X-XXXxxx protein
) ) NE
. . NE

We Xx NE
examined xxx NE
mRNA xXXX NE
levels xxx NE
of xx NE
various xxx NE
V-ATPase X-XXXxxx protein
subunits xxx NE
during xxx NE
differentiation xxx NE
of xx NE
both xxx NE
native xxx cell_type_B
monocytes xxx cell_type_E
and xxx NE
the xxx NE
cell xxx cell_line_B
line xxx cell_line_E
THP-1 XXX-d NE
, , NE
and xxx NE
found xxx NE
that xxx NE
transcriptional xxx NE
mechanism xxx NE
and xxx NE
post-transcriptional xxx-xxx NE
mechanism xxx NE
could xxx NE
account xxx NE
for xxx NE
increases xxx NE
in xx NE
cell xxx NE
V-ATPase X-XXXxxx NE
content xxx NE
. . NE

From Xxxx NE
nuclear xxx NE
runoff xxx NE
experiments xxx NE
, , NE
we xx NE
found xxx NE
that xxx NE
one xxx NE
subunit xxx NE
in xx NE
particular xxx NE
, , NE
the xxx NE
B2 Xd protein_B
isoform xxx protein_E
(Mr (Xx NE
= = NE
56,000) dd,ddd) NE
, , NE
was xxx NE
amplified xxx NE
primarily xxx NE
by xx NE
transcriptional xxx NE
means xxx NE
. . NE

We Xx NE
have xxx NE
begun xxx NE
to xx NE
examine xxx NE
the xxx NE
structure xxx NE
of xx NE
the xxx NE
B2 Xd DNA_B
subunit xxx DNA_M
promoter xxx DNA_M
region xxx DNA_E
. . NE

Isolation Xxxx NE
and xxx NE
sequencing xxx NE
of xx NE
the xxx NE
first xxx DNA_B
exon xxx DNA_E
and xxx NE
5'-flanking d'-xxx DNA_B
region xxx DNA_E
of xx NE
this xxx NE
gene xxx NE
reveal xxx NE
a x NE
TATA-less XXXX-xxx DNA_B
promoter xxx DNA_E
with xxx NE
a x NE
high xxx NE
G X NE
+ + NE
C X NE
content xxx NE
. . NE

Primer Xxxx NE
extension xxx NE
and xxx NE
ribonuclease xxx NE
protection xxx NE
analyses xxx NE
indicate xxx NE
a x NE
single xxx NE
major xxx NE
transcriptional xxx NE
start xxx NE
site xxx NE
. . NE

We Xx NE
transfected xxx NE
promoter-luciferase xxx-xxx DNA_B
reporter xxx DNA_M
plasmids xxx DNA_E
into xxx NE
THP-1 XXX-d cell_line_B
cells xxx cell_line_E
to xx NE
define xxx NE
sequences xxx NE
that xxx NE
mediate xxx NE
transcriptional xxx NE
control xxx NE
during xxx NE
monocyte xxx NE
differentiation xxx NE
. . NE

We Xx NE
found xxx NE
that xxx NE
sequences xxx NE
downstream xxx NE
from xxx NE
the xxx NE
transcriptional xxx NE
start xxx NE
site xxx NE
were xxx NE
sufficient xxx NE
to xx NE
confer xxx NE
increased xxx NE
expression xxx NE
during xxx NE
THP-1 XXX-d NE
differentiation xxx NE
. . NE

DNase XXxxx NE
I X NE
footprinting xxx NE
and xxx NE
sequence xxx NE
analysis xxx NE
revealed xxx NE
the xxx NE
existence xxx NE
of xx NE
multiple xxx NE
AP2 XXd DNA_B
binding xxx DNA_M
site xxx DNA_M
and xxx DNA_M
Sp1 Xxd DNA_M
binding xxx DNA_M
site xxx DNA_E
in xx NE
the xxx NE
5'-untranslated d'-xxx DNA_B
region xxx DNA_M
and xxx DNA_M
proximal xxx DNA_M
coding xxx DNA_M
region xxx DNA_E

Synergy Xxxx NE
between xxx NE
signal xxx NE
transduction xxx NE
pathways xxx NE
is xx NE
obligatory xxx NE
for xxx NE
expression xxx NE
of xx NE
c-fos x-xxx DNA
in xx NE
B X cell_line_B
cell xxx cell_line_M
line xxx cell_line_M
and xxx cell_line_M
T X cell_line_M
cell xxx cell_line_M
line xxx cell_line_E
B X protein
control xxx NE
via xxx NE
surface xxx NE
immunoglobulin xxx NE
and xxx NE
T X protein_B
cell xxx protein_M
antigen xxx protein_M
receptors xxx protein_E
. . NE

Expression Xxxx NE
of xx NE
the xxx NE
protooncogene xxx DNA_B
c-fos x-xxx DNA_E
is xx NE
controlled xxx NE
by xx NE
three xxx NE
main xxx NE
regulatory xxx NE
pathways xxx NE
involving xxx NE
kinase xxx protein_B
C X protein_E
, , NE
cAMP xXXX NE
, , NE
and xxx NE
calcium xxx NE
. . NE

Kinase Xxxx protein_B
C X protein_E
mediates xxx NE
its xxx NE
effects xxx NE
via xxx NE
phosphorylation xxx NE
of xx NE
serum xxx protein_B
response xxx protein_M
factor xxx protein_E
( ( NE
SRF XXX protein
) ) NE
which xxx NE
interacts xxx NE
with xxx NE
the xxx NE
serum xxx DNA_B
response xxx DNA_M
element xxx DNA_E
( ( NE
SRE XXX DNA
) ) NE
; ; NE
cAMP xXXX NE
and xxx NE
calcium xxx NE
mediate xxx NE
their xxx NE
effects xxx NE
via xxx NE
phosphorylation xxx NE
of xx NE
CREB XXXX protein
( ( NE
cAMP xXXX protein_B
regulatory xxx protein_M
element xxx protein_M
binding xxx protein_M
protein xxx protein_E
) ) NE
presumably xxx NE
by xx NE
activation xxx NE
of xx NE
a x NE
protein xxx protein_B
kinase xxx protein_M
A X protein_E
or xx NE
calmodulin-regulated xxx-xxx protein_B
kinase xxx protein_E
. . NE

We Xx NE
have xxx NE
examined xxx NE
the xxx NE
function xxx NE
of xx NE
these xxx NE
elements xxx NE
in xx NE
Burkitt's Xxxx'x cell_line_B
lymphoma xxx cell_line_M
cells xxx cell_line_E
( ( NE
Ramos Xxxx cell_line
and xxx NE
Daudi Xxxx cell_line
) ) NE
as xx NE
well xxx NE
as xx NE
a x NE
T X cell_line_B
lymphocytic xxx cell_line_M
cell xxx cell_line_M
line xxx cell_line_E
( ( NE
Jurkat Xxxx cell_line
) ) NE
. . NE

We Xx NE
have xxx NE
found xxx NE
that xxx NE
stimulation xxx NE
of xx NE
any xxx NE
one xxx NE
of xx NE
these xxx NE
pathways xxx NE
alone xxx NE
has xxx NE
little xxx NE
or xx NE
no xx NE
effect xxx NE
on xx NE
c-fos x-xxx NE
induction xxx NE
. . NE

However Xxxx NE
, , NE
kinase xxx NE
C X NE
activation xxx NE
( ( NE
PMA XXX NE
stimulation xxx NE
) ) NE
combined xxx NE
with xxx NE
either xxx NE
cAMP xXXX NE
( ( NE
forskolin xxx NE
plus xxx NE
MIX XXX NE
) ) NE
or xx NE
calcium xxx NE
stimulation xxx NE
( ( NE
ionophore xxx NE
) ) NE
leads xxx NE
to xx NE
greatly xxx NE
enhanced xxx NE
c-fos x-xxx NE
induction xxx NE
. . NE

By Xx NE
contrast xxx NE
, , NE
cAMP xXXX NE
in xx NE
the xxx NE
presence xxx NE
of xx NE
calcium xxx NE
shows xxx NE
no xx NE
synergy xxx NE
in xx NE
c-fos x-xxx NE
induction xxx NE
. . NE

Okadaic Xxxx NE
acid xxx NE
augments xxx NE
PMA-mediated XXX-xxx NE
activation xxx NE
as xx NE
well xxx NE
as xx NE
calcium-mediated xxx-xxx NE
activation xxx NE
as xx NE
well xxx NE
as xx NE
calcium- xxx- NE
mediated xxx NE
activation xxx NE
of xx NE
c-fos x-xxx DNA
, , NE
and xxx NE
has xxx NE
little xxx NE
or xx NE
no xx NE
effect xxx NE
when xxx NE
combined xxx NE
with xxx NE
cAMP xXXX NE
. . NE

The Xxx NE
main xxx NE
difference xxx NE
between xxx NE
Ramos Xxxx cell_line
( ( NE
B X cell_type_B
cells xxx cell_type_E
) ) NE
and xxx NE
Jurkat Xxxx cell_line
( ( NE
T X cell_type_B
cells xxx cell_type_E
) ) NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
c-fos x-xxx DNA
is xx NE
that xxx NE
cAMP xXXX NE
plus xxx NE
calcium xxx NE
is xx NE
strongly xxx NE
synergistic xxx NE
in xx NE
Jurkat Xxxx cell_line
and xxx NE
is xx NE
without xxx NE
effect xxx NE
in xx NE
Ramos Xxxx cell_line
. . NE

Analysis Xxxx NE
of xx NE
AP-1 XX-d NE
activity xxx NE
using xxx NE
gel xxx NE
mobility xxx NE
shift xxx NE
assays xxx NE
confirms xxx NE
that xxx NE
the xxx NE
requirements xxx NE
for xxx NE
synergy xxx NE
in xx NE
c-fos x-xxx NE
mRNA xXXX NE
induction xxx NE
are xxx NE
paralleled xxx NE
by xx NE
requirements xxx NE
for xxx NE
synergy xxx NE
in xx NE
induction xxx NE
of xx NE
AP-1 XX-d NE
activity xxx NE
. . NE

Signaling Xxxx NE
in xx NE
B X cell_type_B
cells xxx cell_type_E
due xxx NE
to xx NE
anti-Ig xxx-Xx NE
stimulation xxx NE
involves xxx NE
both xxx NE
kinase xxx protein_B
C X protein_E
activation xxx NE
and xxx NE
release xxx NE
of xx NE
intracellular xxx NE
calcium xxx NE
, , NE
and xxx NE
results xxx NE
in xx NE
c-fos x-xxx NE
mRNA xXXX NE
induction xxx NE
. . NE

Our Xxx NE
results xxx NE
indicate xxx NE
that xxx NE
synergy xxx NE
between xxx NE
the xxx NE
kinase xxx NE
C X NE
activation xxx NE
and xxx NE
calcium xxx NE
is xx NE
needed xxx NE
for xxx NE
efficient xxx NE
c-fos x-xxx NE
induction xxx NE
since xxx NE
neither xxx NE
of xx NE
these xxx NE
two xxx NE
alone xxx NE
induces xxx NE
c-fos x-xxx DNA
well xxx NE
. . NE

That Xxxx NE
synergy xxx NE
of xx NE
signaling xxx NE
pathways xxx NE
is xx NE
relevant xxx NE
for xxx NE
the xxx NE
anti-Ig xxx-Xx NE
induction xxx NE
of xx NE
c-fos x-xxx DNA
is xx NE
supported xxx NE
by xx NE
the xxx NE
fact xxx NE
that xxx NE
cAMP xXXX NE
-inducing -xxx NE
agents xxx NE
and xxx NE
okadaic xxx NE
acid xxx NE
further xxx NE
enhance xxx NE
anti-Ig xxx-Xx NE
induction xxx NE
of xx NE
c-fos x-xxx NE
. . NE

These Xxxx NE
results xxx NE
suggest xxx NE
that xxx NE
cell-specific xxx-xxx NE
patterns xxx NE
of xx NE
synergy xxx NE
are xxx NE
an xx NE
essential xxx NE
feature xxx NE
for xxx NE
c-fos x-xxx NE
induction xxx NE
and xxx NE
may xxx NE
be xx NE
relevant xxx NE
for xxx NE
c-fos x-xxx NE
control xxx NE
through xxx NE
B X protein_B
cell xxx protein_M
antigen xxx protein_M
receptor xxx protein_M
and xxx protein_M
T X protein_M
cell xxx protein_M
antigen xxx protein_M
receptor xxx protein_E

Multiple Xxxx NE
signals xxx NE
are xxx NE
required xxx NE
for xxx NE
function xxx NE
of xx NE
the xxx NE
human xxx DNA_B
granulocyte-macrophage xxx-xxx DNA_M
colony-stimulating xxx-xxx DNA_M
factor xxx DNA_M
gene xxx DNA_M
promoter xxx DNA_E
in xx NE
T X cell_type_B
cells xxx cell_type_E
. . NE

The Xxx NE
human xxx NE
granulocyte-macrophage xxx-xxx NE
CSF XXX NE
( ( NE
GM-CSF XX-XXX NE
) ) NE
gene xxx NE
is xx NE
expressed xxx NE
in xx NE
T X NE
cells xxx NE
in xx NE
response xxx NE
to xx NE
TCR XXX NE
activation xxx NE
that xxx NE
can xxx NE
be xx NE
mimicked xxx NE
by xx NE
treatment xxx NE
of xx NE
the xxx NE
cells xxx NE
with xxx NE
PMA XXX NE
and xxx NE
Ca2+ Xxd+ NE
ionophore xxx NE
. . NE

The Xxx NE
gene xxx NE
contains xxx NE
a x NE
proximal xxx DNA_B
functional xxx DNA_M
promoter xxx DNA_M
region xxx DNA_E
( ( NE
-620 -ddd DNA_B
to xx DNA_M
+34 +dd DNA_E
) ) NE
, , NE
as xx NE
well xxx NE
as xx NE
a x NE
powerful xxx NE
enhancer xxx DNA
located xxx NE
3 d NE
kb xx NE
upstream xxx NE
, , NE
both xxx NE
of xx NE
which xxx NE
are xxx NE
involved xxx NE
in xx NE
the xxx NE
response xxx NE
of xx NE
the xxx NE
gene xxx NE
to xx NE
TCR XXX NE
activation xxx NE
. . NE

The Xxx NE
proximal xxx DNA_B
promoter xxx DNA_E
contains xxx NE
a x NE
region xxx NE
termed xxx NE
CLEO XXXX DNA
( ( NE
-54 -dd DNA_B
to xx DNA_M
-31 -dd DNA_E
) ) NE
that xxx NE
consists xxx NE
of xx NE
a x NE
purine xxx NE
-rich -xxx NE
element xxx NE
abutting xxx NE
an xx NE
activator xxx NE
protein-1 xxx-d NE
( ( NE
AP-1 XX-d NE
)-like )-xxx NE
site xxx NE
, , NE
as xx NE
well xxx NE
as xx NE
an xx NE
upstream xxx NE
nuclear xxx NE
factor-kappa xxx-xxx NE
B X NE
( ( NE
NF-kappa XX-xxx NE
B X NE
) ) NE
site xxx NE
( ( NE
-85 -dd NE
to xx NE
-76 -dd NE
) ) NE
and xxx NE
a x NE
CK-1 XX-d NE
element xxx NE
( ( NE
-101 -ddd NE
to xx NE
-92 -dd NE
) ) NE
. . NE

We Xx NE
show xxx NE
in xx NE
this xxx NE
work xxx NE
that xxx NE
mutations xxx NE
in xx NE
either xxx NE
the xxx NE
purine xxx NE
-rich -xxx NE
region xxx NE
of xx NE
the xxx NE
CLEO XXXX NE
element xxx NE
or xx NE
the xxx NE
NF-kappa XX-xxx NE
B X NE
site xxx NE
result xxx NE
in xx NE
reduced xxx NE
PMA XXX NE
/ / NE
Ca2+ Xxd+ NE
activation xxx NE
of xx NE
a x NE
620-bp ddd-xx NE
human xxx NE
GM-CSF XX-XXX NE
promoter- xxx- NE
luciferase xxx NE
reporter xxx NE
construct xxx NE
in xx NE
Jurkat Xxxx NE
T X NE
cells xxx NE
by xx NE
65% dd% NE
and xxx NE
50% dd% NE
, , NE
respectively xxx NE
. . NE

The Xxx NE
major xxx NE
inducible xxx protein_B
protein xxx protein_M
complex xxx protein_E
that xxx NE
binds xxx NE
to xx NE
the xxx NE
human xxx NE
CLEO XXXX NE
( ( NE
hCLEO xXXXX NE
) ) NE
element xxx NE
is xx NE
an xx NE
AP-1 XX-d NE
-like -xxx NE
complex xxx NE
that xxx NE
is xx NE
inducible xxx NE
by xx NE
PMA XXX NE
alone xxx NE
, , NE
but xxx NE
shows xxx NE
increased xxx NE
binding xxx NE
in xx NE
response xxx NE
to xx NE
PMA XXX NE
together xxx NE
with xxx NE
Ca2+ Xxd+ NE
ionophore xxx NE
. . NE

Although Xxxx NE
the xxx NE
binding xxx NE
of xx NE
this xxx NE
complex xxx NE
is xx NE
not xxx NE
cyclosporin xxx NE
-sensitive -xxx NE
, , NE
promoter xxx NE
induction xxx NE
is xx NE
inhibited xxx NE
by xx NE
cyclosporin xxx NE
treatment xxx NE
. . NE

A X NE
second xxx NE
weak xxx NE
inducible xxx NE
complex xxx NE
resembling xxx NE
nuclear xxx protein_B
factor xxx protein_M
of xx protein_M
activated xxx protein_M
T X protein_M
cells xxx protein_E
( ( NE
NF-AT XX-XX protein
) ) NE
was xxx NE
also xxx NE
observed xxx NE
binding xxx NE
to xx NE
the xxx NE
hCLEO xXXXX DNA_B
region xxx DNA_E
. . NE

By Xx NE
using xxx NE
recombinant xxx protein_B
proteins xxx protein_E
, , NE
we xx NE
confirmed xxx NE
that xxx NE
AP-1 XX-d protein
, , NE
NF-ATp XX-XXx protein
, , NE
and xxx NE
a x NE
higher xxx NE
order xxx NE
NF-ATp XX-XXx NE
/ / NE
AP-1 XX-d NE
complex xxx NE
could xxx NE
all xxx NE
form xxx NE
with xxx NE
the xxx NE
hCLEO xXXXX NE
element xxx NE
, , NE
and xxx NE
we xx NE
have xxx NE
also xxx NE
defined xxx NE
the xxx NE
sequence xxx NE
requirements xxx NE
for xxx NE
binding xxx NE
of xx NE
each xxx NE
of xx NE
these xxx NE
complexes xxx NE
. . NE

We Xx NE
found xxx NE
that xxx NE
expression xxx NE
of xx NE
a x NE
constitutively xxx NE
active xxx NE
form xxx NE
of xx NE
calcineurin xxx protein
could xxx NE
substitute xxx NE
for xxx NE
Ca2+ Xxd+ NE
ionophore xxx NE
and xxx NE
synergize xxx NE
with xxx NE
PMA XXX NE
to xx NE
activate xxx NE
the xxx NE
GM-CSF XX-XXX DNA_B
promoter xxx DNA_E
, , NE
and xxx NE
conversely xxx NE
that xxx NE
mutant-activated xxx-xxx protein_B
Ras Xxx protein_E
could xxx NE
substitute xxx NE
for xxx NE
PMA XXX NE
and xxx NE
cooperate xxx NE
with xxx NE
Ca2+ Xxd+ NE
ionophore xxx NE
. . NE

Co-expression Xx-xxx NE
of xx NE
Ras Xxx protein
and xxx NE
calcineurin xxx protein
, , NE
however xxx NE
, , NE
did xxx NE
not xxx NE
activate xxx NE
the xxx NE
GM-CSF XX-XXX DNA_B
promoter xxx DNA_E
, , NE
but xxx NE
required xxx NE
the xxx NE
additional xxx NE
expression xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_M
p65 xdd protein_E
. . NE

These Xxxx NE
results xxx NE
imply xxx NE
that xxx NE
at xx NE
least xxx NE
three xxx NE
signals xxx NE
are xxx NE
required xxx NE
to xx NE
activate xxx NE
the xxx NE
GM-CSF XX-XXX DNA_B
proximal xxx DNA_M
promoter xxx DNA_E
, , NE
and xxx NE
that xxx NE
the xxx NE
signals xxx NE
impinge xxx NE
on xx NE
distinct xxx NE
transcription xxx protein_B
factors xxx protein_E
that xxx NE
bind xxx NE
to xx NE
the xxx NE
hCLEO xXXXX DNA_B
and xxx DNA_M
NF-kappa XX-xxx DNA_M
B X DNA_M
regions xxx DNA_E
of xx NE
the xxx NE
promoter xxx DNA
. . NE

IL-10 XX-dd NE
induces xxx NE
the xxx NE
tyrosine xxx NE
phosphorylation xxx NE
of xx NE
tyk2 xxxd protein
and xxx NE
Jak1 Xxxd protein
and xxx NE
the xxx NE
differential xxx NE
assembly xxx NE
of xx NE
STAT1 XXXXd protein_B
alpha xxx protein_E
and xxx NE
STAT3 XXXXd NE
complexes xxx NE
in xx NE
human xxx NE
T X NE
cells xxx NE
and xxx NE
monocytes xxx NE
. . NE

IL-10 XX-dd protein
affects xxx NE
monocytes xxx cell_type
and xxx NE
T X cell_type_B
cells xxx cell_type_E
by xx NE
driving xxx NE
the xxx NE
progression xxx NE
of xx NE
immune xxx NE
responsiveness xxx NE
such xxx NE
that xxx NE
Th2 Xxd NE
lymphocyte-mediated xxx-xxx NE
effects xxx NE
predominate xxx NE
. . NE

In Xx NE
this xxx NE
report xxx NE
, , NE
we xx NE
show xxx NE
that xxx NE
in xx NE
monocytes xxx cell_type
and xxx NE
T X cell_type_B
cells xxx cell_type_E
IL-10 XX-dd NE
stimulates xxx NE
tyrosine xxx NE
phosphorylation xxx NE
of xx NE
the xxx NE
signal xxx protein_B
transducers xxx protein_E
and xxx NE
activators xxx NE
of xx NE
transcription xxx NE
, , NE
STAT1 XXXXd protein_B
alpha xxx protein_E
and xxx NE
STAT3 XXXXd protein
, , NE
in xx NE
a x NE
differential xxx NE
manner xxx NE
such xxx NE
that xxx NE
the xxx NE
relative xxx NE
formation xxx NE
of xx NE
homo- xxx- NE
and xxx NE
homodimer xxx protein_B
and xxx protein_M
heterodimer xxx protein_E

Moreover Xxxx NE
, , NE
monocytes xxx cell_type
express xxx NE
a x NE
novel xxx NE
IL-10 XX-dd NE
-stimulated -xxx NE
STAT XXXX NE
protein xxx NE
with xxx NE
an xx NE
M(r) X(x) NE
of xx NE
70 dd NE
kDa xXx NE
that xxx NE
is xx NE
recognized xxx NE
by xx NE
the xxx NE
anti- xxx- NE
STAT3 XXXXd NE
Ab Xx NE
but xxx NE
is xx NE
not xxx NE
observed xxx NE
in xx NE
T X NE
cells xxx NE
. . NE

IL-10 XX-dd protein
treatment xxx NE
of xx NE
both xxx NE
T X cell_type_B
cells xxx cell_type_E
and xxx NE
monocytes xxx cell_type
results xxx NE
in xx NE
the xxx NE
ligand-induced xxx-xxx NE
tyrosine xxx NE
phosphorylation xxx NE
of xx NE
tyk2 xxxd protein
and xxx NE
Jak1 Xxxd protein
, , NE
but xxx NE
not xxx NE
Jak2 Xxxd protein
or xx NE
Jak3 Xxxd protein
. . NE

Selective Xxxx NE
modulation xxx NE
of xx NE
immune xxx NE
responsiveness xxx NE
by xx NE
IL-10 XX-dd protein
in xx NE
cells xxx NE
such xxx NE
as xx NE
monocytes xxx cell_type
and xxx NE
T X cell_type_B
cells xxx cell_type_E
may xxx NE
result xxx NE
in xx NE
part xxx NE
from xxx NE
the xxx NE
differential xxx NE
activation xxx NE
of xx NE
STAT XXXX protein_B
protein xxx protein_M
pairs xxx protein_E
. . NE

Use Xxx NE
of xx NE
new xxx NE
biologic xxx NE
markers xxx NE
in xx NE
the xxx NE
ovulation xxx NE
induction xxx NE
. . NE

Biological Xxxx NE
markers xxx NE
of xx NE
ovulation xxx NE
, , NE
after xxx NE
a x NE
great xxx NE
in xx NE
the xxx NE
past xxx NE
, , NE
have xxx NE
been xxx NE
fallen xxx NE
into xxx NE
disuse xxx NE
for xxx NE
the xxx NE
large xxx NE
diffusion xxx NE
of xx NE
biochemical xxx NE
and xxx NE
biophysical xxx NE
ones xxx NE
. . NE

However Xxxx NE
, , NE
the xxx NE
real xxx NE
effect xxx NE
of xx NE
hormones xxx NE
involved xxx NE
in xx NE
ovulation xxx NE
is xx NE
expressed xxx NE
by xx NE
biological xxx NE
modifications xxx NE
on xx NE
target xxx cell_type_B
tissues xxx cell_type_E
. . NE

To Xx NE
explore xxx NE
the xxx NE
modifications xxx NE
of xx NE
not xxx NE
reproductive xxx NE
target xxx NE
tissues xxx NE
as xx NE
ovulation xxx NE
markers xxx NE
we xx NE
studied xxx NE
the xxx NE
behaviour xxx NE
of xx NE
Albuminemia Xxxx NE
, , NE
Platelet Xxxx protein_B
Factor Xxxx protein_M
IV XX protein_E
(as (xx NE
indicator xxx NE
of xx NE
Platelet Xxxx NE
Aggregation Xxxx NE
) ) NE
, , NE
Type Xxxx protein_B
II XX protein_M
estrogenic xxx protein_M
receptors xxx protein_E
in xx NE
42 dd NE
ovulation xxx NE
induced xxx NE
women xxx NE
, , NE
undergoing xxx NE
our xxx NE
observation xxx NE
. . NE

33 dd NE
of xx NE
them xxx NE
had xxx NE
ovulation xxx NE
and xxx NE
9 d NE
developed xxx NE
a x NE
LUF XXX NE
syndrome xxx NE
, , NE
constituting xxx NE
two xxx NE
biological xxx NE
models xxx NE
of xx NE
an xx NE
opposite xxx NE
situation xxx NE
for xxx NE
the xxx NE
three xxx NE
markers xxx NE
observed xxx NE
. . NE

All Xxx NE
the xxx NE
markers xxx NE
considered xxx NE
were xxx NE
sufficiently xxx NE
sensitive xxx NE
, , NE
but xxx NE
among xxx NE
them xxx NE
, , NE
Platelet Xxxx protein_B
Factor Xxxx protein_M
IV XX protein_E
was xxx NE
the xxx NE
most xxx NE
reliable xxx NE
to xx NE
the xxx NE
hormonal xxx NE
ovulatory xxx NE
situation xxx NE
. . NE

Abnormal Xxxx NE
regulation xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_B
promoter xxx DNA_E
in xx NE
lpr xxx NE
CD4-CD8- XXd-XXd- cell_line_B
T X cell_line_M
lymphocytes xxx cell_line_E
results xxx NE
in xx NE
constitutive xxx NE
expression xxx NE
of xx NE
a x NE
novel xxx NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
-binding -xxx NE
factor xxx NE
. . NE

The Xxx NE
inert xxx NE
quality xxx NE
of xx NE
MRL-Ipr/Ipr XXX-Xxx/Xxx cell_line_B
(Ipr) (Xxx) cell_line_M
peripheral xxx cell_line_M
CD4-CD8- XXd-XXd- cell_line_M
(CD4-8-) (XXd-d-) cell_line_M
T X cell_line_M
cells xxx cell_line_E
manifests xxx NE
primarily xxx NE
as xx NE
an xx NE
inability xxx NE
to xx NE
proliferate xxx NE
or xx NE
produce xxx NE
IL-2 XX-d protein
in xx NE
response xxx NE
to xx NE
TCR XXX protein
or xx NE
mitogenic xxx NE
stimulation xxx NE
. . NE

Yet Xxx NE
these xxx NE
same xxx NE
cells xxx NE
do xx NE
initiate xxx NE
early xxx NE
TCR XXX NE
-mediated -xxx NE
signaling xxx NE
events xxx NE
, , NE
such xxx NE
as xx NE
generation xxx NE
of xx NE
inositol xxx NE
phosphates xxx NE
and xxx NE
increased xxx NE
intracellular xxx NE
calcium xxx NE
. . NE

They Xxxx NE
also xxx NE
display xxx NE
constitutively xxx NE
high xxx NE
levels xxx NE
of xx NE
p59fyn xddxxx protein
and xxx NE
CD3 XXd protein_B
zeta xxx protein_E
tyrosine xxx NE
phosphorylation xxx NE
. . NE

The Xxx NE
generation xxx NE
of xx NE
second xxx NE
messengers xxx NE
in xx NE
T X cell_type_B
cells xxx cell_type_E
normally xxx NE
leads xxx NE
to xx NE
downstream xxx NE
signaling xxx NE
that xxx NE
results xxx NE
in xx NE
transcriptional xxx NE
activation xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_B
gene xxx DNA_E
. . NE

We Xx NE
, , NE
therefore xxx NE
, , NE
compared xxx NE
the xxx NE
activation xxx NE
state xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_B
gene xxx DNA_M
promoter xxx DNA_M
region xxx DNA_E
in xx NE
freshly xxx NE
isolated xxx NE
and xxx NE
stimulated xxx NE
Ipr Xxx cell_line_B
CD4-8- XXd-d- cell_line_M
T X cell_line_M
cells xxx cell_line_E
with xxx NE
that xxx NE
of xx NE
normal xxx cell_type_B
T X cell_type_M
lymphocytes xxx cell_type_E
. . NE

Levels Xxxx NE
of xx NE
the xxx NE
octamer xxx NE
, , NE
NF-kappa XX-xxx protein_B
B X protein_E
( ( NE
p50-p65 xdd-xdd protein_B
heterodimer xxx protein_E
) ) NE
, , NE
and xxx NE
AP-1 XX-d protein_B
transcriptional xxx protein_M
factors xxx protein_E
are xxx NE
constitutively xxx NE
elevated xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
Ipr Xxx cell_line_B
CD4-8- XXd-d- cell_line_M
T X cell_line_M
cells xxx cell_line_E
, , NE
consistent xxx NE
with xxx NE
the xxx NE
activated xxx NE
phenotype xxx NE
of xx NE
these xxx NE
cells xxx NE
. . NE

Upon Xxxx NE
stimulation xxx NE
with xxx NE
mitogens xxx NE
, , NE
formation xxx NE
of xx NE
the xxx NE
transactivating xxx NE
complex xxx NE
, , NE
nuclear xxx protein_B
factor xxx protein_M
of xx protein_M
activated xxx protein_M
T X protein_M
cells xxx protein_E
( ( NE
NF-AT XX-XX protein
) ) NE
, , NE
occurs xxx NE
with xxx NE
normal xxx NE
kinetics xxx NE
in xx NE
Ipr Xxx cell_line_B
CD4-8- XXd-d- cell_line_M
T X cell_line_M
cells xxx cell_line_E
. . NE

Yet Xxx NE
, , NE
the xxx NE
levels xxx NE
of xx NE
the xxx NE
activating xxx NE
NF-AT XX-XX protein_B
complex xxx protein_E
never xxx NE
reach xxx NE
those xxx NE
observed xxx NE
in xx NE
similarly xxx NE
stimulated xxx NE
normal xxx NE
T X cell_type_B
cells xxx cell_type_E
. . NE

Furthermore Xxxx NE
, , NE
nuclear xxx NE
extracts xxx NE
from xxx NE
Ipr Xxx cell_line_B
CD4-8- XXd-d- cell_line_M
T X cell_line_M
cells xxx cell_line_E
display xxx NE
high xxx NE
levels xxx NE
of xx NE
a x NE
novel xxx NE
specific xxx NE
binding xxx NE
activity xxx NE
at xx NE
the xxx NE
NF-AT XX-XX DNA_B
site xxx DNA_E
, , NE
which xxx NE
is xx NE
present xxx NE
at xx NE
much xxx NE
lower xxx NE
levels xxx NE
in xx NE
freshly xxx NE
isolated xxx NE
normal xxx cell_type_B
T X cell_type_M
lymphocytes xxx cell_type_E
. . NE

Upon Xxxx NE
mitogenic xxx NE
stimulation xxx NE
, , NE
the xxx NE
binding xxx NE
activity xxx NE
of xx NE
the xxx NE
novel xxx NE
NF-AT XX-XX NE
-binding -xxx NE
factor xxx NE
is xx NE
rapidly xxx NE
down-regulated xxx-xxx NE
in xx NE
normal xxx NE
T X NE
cells xxx NE
, , NE
but xxx NE
persists xxx NE
at xx NE
high xxx NE
levels xxx NE
in xx NE
Ipr Xxx NE
CD4-8- XXd-d- NE
T X NE
cells xxx NE
. . NE

These Xxxx NE
two xxx NE
abnormalities xxx NE
at xx NE
the xxx NE
NF-AT XX-XX DNA_B
site xxx DNA_E
provide xxx NE
a x NE
potential xxx NE
mechanism xxx NE
to xx NE
account xxx NE
for xxx NE
the xxx NE
defect xxx NE
in xx NE
IL-2 XX-d NE
production xxx NE
from xxx NE
Ipr Xxx cell_line_B
CD4-8- XXd-d- cell_line_M
T X cell_line_M
cells xxx cell_line_E
. . NE

Cross-linking Xxxx-xxx NE
of xx NE
CD30 XXdd protein
induces xxx NE
HIV XXX NE
expression xxx NE
in xx NE
chronically xxx NE
infected xxx NE
T X cell_type_B
cells xxx cell_type_E
. . NE

CD30 XXdd protein
, , NE
a x NE
member xxx NE
of xx NE
the xxx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
(TNF) (XXX) NE
receptor xxx NE
family xxx NE
, , NE
is xx NE
expressed xxx NE
constitutively xxx NE
on xx NE
the xxx NE
surface xxx NE
of xx NE
the xxx NE
human xxx NE
T X NE
cell xxx NE
line xxx NE
ACH-2 XXX-d NE
, , NE
which xxx NE
is xx NE
chronically xxx NE
infected xxx NE
with xxx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type-1 xxx-d NE
( ( NE
HIV XXX NE
)-1 )-d NE
. . NE

We Xx NE
demonstrate xxx NE
that xxx NE
cross-linking xxx-xxx NE
CD30 XXdd protein
with xxx NE
an xx NE
anti- xxx- NE
CD30 XXdd protein
-specific -xxx NE
monoclonal xxx NE
antibody xxx NE
, , NE
which xxx NE
mimics xxx NE
the xxx NE
described xxx NE
biological xxx NE
activities xxx NE
of xx NE
the xxx NE
CD30 XXdd NE
ligand xxx NE
( ( NE
CD30L XXddX NE
) ) NE
, , NE
results xxx NE
in xx NE
HIV XXX NE
expression xxx NE
. . NE

CD30 XXdd protein
cross-linking xxx-xxx NE
does xxx NE
not xxx NE
alter xxx NE
proliferation xxx NE
of xx NE
ACH-2 XXX-d cell_line_B
cells xxx cell_line_E
and xxx NE
the xxx NE
induction xxx NE
of xx NE
HIV XXX NE
expression xxx NE
is xx NE
not xxx NE
mediated xxx NE
by xx NE
endogenous xxx NE
TNF XXX protein_B
alpha/beta xxx/xxx protein_E
. . NE

Furthermore Xxxx NE
, , NE
cross-linking xxx-xxx NE
of xx NE
CD30 XXdd protein
leads xxx NE
to xx NE
NF-kappa XX-xxx protein_B
B X protein_E
activation xxx NE
and xxx NE
enhanced xxx NE
HIV XXX NE
transcription xxx NE
. . NE

Thus Xxxx NE
, , NE
CD30 XXdd NE
-CD30L -XXddX NE
interactions xxx NE
mediate xxx NE
the xxx NE
induction xxx NE
of xx NE
HIV XXX NE
expression xxx NE
by xx NE
a x NE
kappa xxx NE
B-dependent X-xxx NE
pathway xxx NE
that xxx NE
is xx NE
independent xxx NE
of xx NE
TNF XXX NE
. . NE

This Xxxx NE
mechanism xxx NE
may xxx NE
be xx NE
important xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
HIV XXX NE
expression xxx NE
from xxx NE
latently xxx NE
infected xxx NE
CD4+ XXd+ cell_line_B
T X cell_line_M
cells xxx cell_line_E
, , NE
especially xxx NE
in xx NE
lymphoid xxx NE
organs xxx NE
where xxx NE
cell xxx NE
to xx NE
cell xxx NE
contact xxx NE
is xx NE
conducive xxx NE
to xx NE
receptor-ligand xxx-xxx NE
interactions xxx NE
. . NE

Human Xxxx NE
MHC XXX NE
class xxx NE
II XX NE
gene xxx NE
transcription xxx NE
directed xxx NE
by xx NE
the xxx NE
carboxyl xxx protein_B
terminus xxx protein_E
of xx NE
CIITA XXXXX DNA
, , NE
one xxx NE
of xx NE
the xxx NE
defective xxx DNA_B
genes xxx DNA_E
in xx NE
type xxx NE
II XX NE
MHC XXX NE
combined xxx NE
immune xxx NE
deficiency xxx NE
. . NE

Type Xxxx NE
II XX NE
major xxx NE
histocompatibility xxx NE
complex xxx NE
combined xxx NE
immune xxx NE
deficiency xxx NE
( ( NE
type xxx NE
II XX NE
MHC XXX NE
CID XXX NE
or xx NE
bare xxx NE
lymphocyte xxx NE
syndrome xxx NE
) ) NE
is xx NE
a x NE
congenital xxx NE
immunodeficiency xxx NE
disease xxx NE
characterized xxx NE
by xx NE
absent xxx NE
MHC XXX NE
class xxx NE
II XX NE
expression xxx NE
. . NE

Four Xxxx NE
distinct xxx NE
complementation xxx NE
groups xxx NE
have xxx NE
been xxx NE
identified xxx NE
. . NE

Recently Xxxx NE
, , NE
the xxx NE
defective xxx DNA_B
gene xxx DNA_E
in xx NE
group xxx NE
II XX NE
type xxx NE
II XX NE
MHC XXX NE
CID XXX NE
has xxx NE
been xxx NE
isolated xxx NE
and xxx NE
termed xxx NE
CIITA XXXXX DNA
. . NE

Here Xxxx NE
, , NE
we xx NE
demonstrate xxx NE
that xxx NE
CIITA XXXXX DNA
is xx NE
an xx NE
MHC XXX DNA_B
class xxx DNA_M
II XX DNA_M
gene-specific xxx-xxx DNA_M
transcription xxx DNA_M
activator xxx DNA_E
. . NE

The Xxx NE
transcription xxx NE
activation xxx NE
function xxx NE
is xx NE
provided xxx NE
by xx NE
the xxx NE
N-terminal X-xxx protein_B
acidic xxx protein_M
domain xxx protein_E
( ( NE
amino xxx protein_B
acids xxx protein_M
26-137 dd-ddd protein_E
) ) NE
, , NE
which xxx NE
is xx NE
experimentally xxx NE
exchangeable xxx NE
with xxx NE
a x NE
heterologous xxx protein_B
viral xxx protein_M
transcription-activating xxx-xxx protein_M
domain xxx protein_E
. . NE

The Xxx NE
specificity xxx NE
of xx NE
CIITA XXXXX protein
for xxx NE
three xxx NE
major xxx NE
MHC XXX DNA_B
class xxx DNA_M
II XX DNA_M
genes xxx DNA_E
, , NE
DR XX DNA
, , NE
DQ XX DNA
and xxx NE
DP XX DNA
, , NE
is xx NE
mediated xxx NE
by xx NE
its xxx NE
remaining xxx NE
C-terminal X-xxx protein_B
residues xxx protein_E
( ( NE
amino xxx protein_B
acids xxx protein_M
317-1130 ddd-dddd protein_E
) ) NE
. . NE

The Xxx NE
transactivation xxx NE
of xx NE
multiple xxx DNA_B
cis xxx DNA_M
elements xxx DNA_E
, , NE
especially xxx NE
S X DNA
and xxx NE
X2 Xd DNA
, , NE
of xx NE
the xxx NE
DR XX DNA_B
alpha xxx DNA_M
proximal xxx DNA_M
promoter xxx DNA_E
in xx NE
group xxx cell_line_B
II XX cell_line_M
CID XXX cell_line_M
cells xxx cell_line_E
is xx NE
CIITA XXXXX protein
dependent xxx NE
. . NE

Since Xxxx NE
CIITA XXXXX NE
overexpression xxx NE
in xx NE
normal xxx cell_type_B
cells xxx cell_type_E
did xxx NE
not xxx NE
increase xxx NE
class xxx NE
II XX NE
expression xxx NE
, , NE
we xx NE
propose xxx NE
that xxx NE
initiation xxx NE
of xx NE
CIITA XXXXX NE
expression xxx NE
serves xxx NE
as xx NE
the xxx NE
on-off xx-xxx NE
switch xxx NE
, , NE
while xxx NE
availability xxx NE
of xx NE
downstream xxx NE
interactor xxx NE
(s) (x) NE
limits xxx NE
transcription xxx NE
. . NE

Monocyte Xxxx NE
tethering xxx NE
by xx NE
P-selectin X-xxx protein
regulates xxx NE
monocyte xxx protein_B
chemotactic xxx protein_M
protein-1 xxx-d protein_E
and xxx NE
tumor xxx NE
necrosis xxx NE
factor-alpha xxx-xxx NE
secretion xxx NE
. . NE

Signal Xxxx NE
integration xxx NE
and xxx NE
NF-kappa XX-xxx NE
B X NE
translocation xxx NE
[see [xxx NE
comments] xxx] NE

Adhesion Xxxx protein_B
molecules xxx protein_E
that xxx NE
tether xxx NE
circulating xxx cell_type_B
leukocytes xxx cell_type_E
to xx NE
endothelial xxx cell_type_B
cells xxx cell_type_E
may xxx NE
also xxx NE
transduce xxx NE
or xx NE
modulate xxx NE
outside-in xxx-xx NE
signals xxx NE
for xxx NE
cellular xxx NE
activation xxx NE
, , NE
providing xxx NE
an xx NE
initial xxx NE
regulatory xxx NE
point xxx NE
in xx NE
the xxx NE
inflammatory xxx NE
response xxx NE
. . NE

Adhesion Xxxx NE
of xx NE
human xxx cell_type_B
monocytes xxx cell_type_E
to xx NE
P-selectin X-xxx protein
, , NE
the xxx NE
most xxx NE
rapidly xxx NE
expressed xxx NE
endothelial xxx protein_B
tethering xxx protein_M
factor xxx protein_E
, , NE
increased xxx NE
the xxx NE
secretion xxx NE
of xx NE
monocyte xxx protein_B
chemotactic xxx protein_M
protein-1 xxx-d protein_E
( ( NE
MCP-1 XXX-d protein
) ) NE
and xxx NE
tumor xxx protein_B
necrosis xxx protein_M
factor-alpha xxx-xxx protein_E
( ( NE
TNF-alpha XXX-xxx protein
) ) NE
by xx NE
the xxx NE
leukocytes xxx cell_type
when xxx NE
they xxx NE
were xxx NE
stimulated xxx NE
with xxx NE
platelet-activating xxx-xxx protein_B
factor xxx protein_E
. . NE

Increased Xxxx NE
cytokine xxx NE
secretion xxx NE
was xxx NE
specifically xxx NE
inhibited xxx NE
by xx NE
G1 Xd protein
, , NE
an xx NE
anti- xxx- NE
P-selectin X-xxx NE
mAb xXx NE
that xxx NE
prevents xxx NE
P-selectin X-xxx NE
from xxx NE
binding xxx NE
to xx NE
its xxx NE
ligand xxx NE
( ( NE
P-selectin X-xxx NE
glycoprotein xxx NE
ligand-1 xxx-d NE
) ) NE
on xx NE
myeloid xxx NE
cells xxx NE
. . NE

Moreover Xxxx NE
, , NE
tethering xxx NE
by xx NE
P-selectin X-xxx protein
specifically xxx NE
enhanced xxx NE
nuclear xxx NE
translocation xxx NE
of xx NE
nuclear xxx protein_B
factor-kappa xxx-xxx protein_M
B X protein_E
( ( NE
NF-kappa XX-xxx protein_B
B X protein_E
) ) NE
, , NE
a x NE
transcription xxx protein_B
factor xxx protein_E
required xxx NE
for xxx NE
expression xxx NE
of xx NE
MCP-1 XXX-d protein
, , NE
TNF-alpha XXX-xxx protein
, , NE
and xxx NE
other xxx NE
immediate-early xxx-xxx DNA_B
genes xxx DNA_E
. . NE

These Xxxx NE
results xxx NE
demonstrate xxx NE
that xxx NE
P-selectin X-xxx protein
, , NE
through xxx NE
its xxx NE
ligands xxx NE
on xx NE
monocytes xxx cell_type
, , NE
may xxx NE
locally xxx NE
regulate xxx NE
cytokine xxx NE
secretion xxx NE
in xx NE
inflamed xxx NE
tissues xxx NE
. . NE

Functional Xxxx NE
roles xxx NE
of xx NE
in xx DNA_B
vivo xxx DNA_M
footprinted xxx DNA_M
DNA XXX DNA_M
motifs xxx DNA_E
within xxx NE
an xx NE
alpha-globin xxx-xxx DNA_B
enhancer xxx DNA_E
. . NE

Erythroid Xxxx NE
lineage xxx NE
and xxx NE
developmental xxx NE
stage xxx NE
specificities xxx NE
. . NE

Transcriptional Xxxx NE
regulation xxx NE
of xx NE
the xxx NE
human xxx DNA_B
alpha-like xxx-xxx DNA_M
globin xxx DNA_M
genes xxx DNA_E
, , NE
embryonic xxx DNA_B
zeta xxx DNA_M
2 d DNA_E
and xxx NE
adult xxx DNA_B
alpha xxx DNA_E
, , NE
during xxx NE
erythroid xxx NE
development xxx NE
is xx NE
mediated xxx NE
by xx NE
a x NE
distal xxx DNA_B
enhancer xxx DNA_E
, , NE
HS-40 XX-dd DNA
. . NE

Previous Xxxx NE
protein-DNA xxx-XXX NE
binding xxx NE
studies xxx NE
have xxx NE
shown xxx NE
that xxx NE
HS-40 XX-dd DNA
consists xxx NE
of xx NE
multiple xxx NE
nuclear xxx DNA_B
factor xxx DNA_M
binding xxx DNA_M
motifs xxx DNA_E
that xxx NE
are xxx NE
occupied xxx NE
in xx NE
vivo xxx NE
in xx NE
an xx NE
erythroid xxx NE
lineage-specific xxx-xxx NE
manner xxx NE
and xxx NE
developmental xxx NE
stage-specific xxx-xxx NE
manner xxx NE

We Xx NE
have xxx NE
systematically xxx NE
analyzed xxx NE
the xxx NE
functional xxx NE
roles xxx NE
of xx NE
these xxx NE
factor xxx DNA_B
binding xxx DNA_M
motifs xxx DNA_E
of xx NE
HS-40 XX-dd DNA
by xx NE
site-directed xxx-xxx NE
mutagenesis xxx NE
and xxx NE
transient xxx NE
expression xxx NE
assay xxx NE
in xx NE
erythroid xxx cell_line_B
cell xxx cell_line_M
cultures xxx cell_line_E
. . NE

Three Xxxx NE
of xx NE
these xxx NE
HS-40 XX-dd DNA_B
enhancer xxx DNA_M
motifs xxx DNA_E
, , NE
5'NF-E2/AP1 d'XX-Xd/XXd DNA
, , NE
GT XX DNA_B
II XX DNA_E
, , NE
and xxx NE
GATA-1(c) XXXX-d(x) DNA
, , NE
positively xxx NE
regulate xxx NE
the xxx NE
zeta xxx NE
2-globin d-xxx NE
promoter xxx NE
activity xxx NE
in xx NE
embryonic/fetal xxx/xxx cell_line_B
erythroid xxx cell_line_M
K562 Xddd cell_line_M
cells xxx cell_line_E
and xxx NE
the xxx NE
adult xxx NE
alpha xxx NE
-globin -xxx NE
promoter xxx NE
activity xxx NE
in xx NE
adult xxx NE
erythroid xxx NE
MEL XXX NE
cells xxx NE
. . NE

On Xx NE
the xxx NE
other xxx NE
hand xxx NE
, , NE
the xxx NE
3'NF-E2/AP1 d'XX-Xd/XXd DNA_B
motif xxx DNA_E
is xx NE
able xxx NE
to xx NE
exert xxx NE
both xxx NE
positive xxx NE
and xxx NE
negative xxx NE
regulatory xxx NE
effects xxx NE
on xx NE
the xxx NE
zeta xxx NE
2-globin d-xxx NE
promoter xxx NE
activity xxx NE
in xx NE
K562 Xddd cell_line_B
cells xxx cell_line_E
, , NE
and xxx NE
this xxx NE
dual xxx NE
function xxx NE
appears xxx NE
to xx NE
be xx NE
modulated xxx NE
through xxx NE
differential xxx NE
binding xxx NE
of xx NE
the xxx NE
ubiquitous xxx protein_B
AP1 XXd protein_M
factors xxx protein_E
and xxx NE
the xxx NE
erythroid-enriched xxx-xxx protein_B
NF-E2 XX-Xd protein_M
factor xxx protein_E
. . NE

Mutation Xxxx NE
in xx NE
the xxx NE
GATA-1(d) XXXX-d(x) DNA_B
motif xxx DNA_E
, , NE
which xxx NE
exhibits xxx NE
an xx NE
adult xxx DNA_B
erythroid-specific xxx-xxx DNA_M
genomic xxx DNA_M
footprint xxx DNA_E
, , NE
decreases xxx NE
the xxx NE
HS-40 XX-dd DNA_B
enhancer xxx DNA_E
function xxx NE
in xx NE
dimethyl xxx cell_line_B
sulfoxide-induced xxx-xxx cell_line_M
MEL XXX cell_line_M
cells xxx cell_line_E
but xxx NE
not xxx NE
in xx NE
K562 Xddd cell_line_B
cells xxx cell_line_E
. . NE

These Xxxx NE
studies xxx NE
have xxx NE
defined xxx NE
the xxx NE
regulatory xxx NE
roles xxx NE
of xx NE
the xxx NE
different xxx NE
HS-40 XX-dd DNA_B
motifs xxx DNA_E
. . NE

The Xxx NE
remarkable xxx NE
correlation xxx NE
between xxx NE
genomic xxx NE
footprinting xxx NE
data xxx NE
and xxx NE
the xxx NE
mutagenesis xxx NE
results xxx NE
also xxx NE
suggests xxx NE
that xxx NE
the xxx NE
erythroid xxx NE
lineage-specific xxx-xxx NE
regulation xxx NE
and xxx NE
developmental xxx NE
stage-specific xxx-xxx NE
regulation xxx NE
of xx NE
human xxx DNA_B
alpha-like xxx-xxx DNA_M
globin xxx DNA_M
promoters xxx DNA_E
is xx NE
indeed xxx NE
modulated xxx NE
by xx NE
stable xxx NE
binding xxx NE
of xx NE
specific xxx protein_B
nuclear xxx protein_M
factors xxx protein_E
in xx NE
vivo xxx NE
. . NE

Nitric Xxxx NE
oxide xxx NE
-stimulated -xxx NE
guanine xxx NE
nucleotide xxx NE
exchange xxx NE
on xx NE
p21ras xddxxx NE
. . NE

The Xxx NE
protooncogene xxx DNA_B
p21ras xddxxx DNA_E
, , NE
a x NE
monomeric xxx protein_B
G X protein_M
protein xxx protein_M
family xxx protein_M
member xxx protein_E
, , NE
plays xxx NE
a x NE
critical xxx NE
role xxx NE
in xx NE
converting xxx NE
extracellular xxx NE
signals xxx NE
into xxx NE
intracellular xxx NE
biochemical xxx NE
events xxx NE
. . NE

Here Xxxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
nitric xxx NE
oxide xxx NE
( ( NE
NO XX NE
) ) NE
activates xxx NE
p21ras xddxxx DNA
in xx NE
human xxx cell_type_B
T X cell_type_M
cells xxx cell_type_E
as xx NE
evidenced xxx NE
by xx NE
an xx NE
increase xxx NE
in xx NE
GTP XXX NE
-bound -xxx NE
p21ras xddxxx NE
. . NE

In Xx NE
vitro xxx NE
studies xxx NE
using xxx NE
pure xxx protein_B
recombinant xxx protein_M
p21ras xddxxx protein_E
demonstrate xxx NE
that xxx NE
the xxx NE
activation xxx NE
is xx NE
direct xxx NE
and xxx NE
reversible xxx NE
. . NE

Circular Xxxx NE
dichroism xxx NE
analysis xxx NE
reveals xxx NE
that xxx NE
NO XX NE
induces xxx NE
a x NE
profound xxx NE
conformational xxx NE
change xxx NE
in xx NE
p21ras xddxxx DNA
in xx NE
association xxx NE
with xxx NE
GDP XXX NE
/GTP /XXX NE
exchange xxx NE
. . NE

The Xxx NE
mechanism xxx NE
of xx NE
activation xxx NE
is xx NE
due xxx NE
to xx NE
S-nitrosylation X-xxx NE
of xx NE
a x NE
critical xxx NE
cysteine xxx NE
residue xxx NE
which xxx NE
stimulates xxx NE
guanine xxx NE
nucleotide xxx NE
exchange xxx NE
. . NE

Furthermore Xxxx NE
, , NE
we xx NE
demonstrate xxx NE
that xxx NE
p21ras xddxxx protein
is xx NE
essential xxx NE
for xxx NE
NO XX NE
-induced -xxx NE
downstream xxx NE
signaling xxx NE
, , NE
such xxx NE
as xx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
, , NE
and xxx NE
that xxx NE
endogenous xxx NE
NO XX NE
can xxx NE
activate xxx NE
p21ras xddxxx NE
in xx NE
the xxx NE
same xxx NE
cell xxx NE
. . NE

These Xxxx NE
studies xxx NE
identify xxx NE
p21ras xddxxx DNA
as xx NE
a x NE
target xxx NE
of xx NE
the xxx NE
same xxx NE
cell xxx NE
. . NE

These Xxxx NE
studies xxx NE
identify xxx NE
p21ras xddxxx DNA
as xx NE
a x NE
target xxx NE
of xx NE
NO XX NE
in xx NE
T X cell_type_B
cells xxx cell_type_E
and xxx NE
suggest xxx NE
that xxx NE
NO XX NE
activates xxx NE
p21ras xddxxx DNA
by xx NE
an xx NE
action xxx NE
which xxx NE
mimics xxx NE
that xxx NE
of xx NE
guanine xxx protein_B
nucleotide xxx protein_M
exchange xxx protein_M
factors xxx protein_E
. . NE

Interleukin-2 Xxxx-d NE
promoter xxx NE
activity xxx NE
in xx NE
Epstein-Barr Xxxx-Xxxx NE
virus xxx NE
-transformed -xxx NE
B X NE
lymphocytes xxx NE
is xx NE
controlled xxx NE
by xx NE
nuclear xxx NE
factor-chi xxx-xxx NE
B X NE
. . NE

The Xxx NE
regulation xxx NE
of xx NE
interleukin xxx NE
(IL)-2 (XX)-d NE
gene xxx NE
expression xxx NE
has xxx NE
been xxx NE
investigated xxx NE
mainly xxx NE
in xx NE
T X cell_type_B
lymphocytes xxx cell_type_E
, , NE
the xxx NE
predominant xxx NE
producers xxx NE
of xx NE
IL-2 XX-d protein
. . NE

However Xxxx NE
, , NE
B X cell_type_B
cells xxx cell_type_E
can xxx NE
also xxx NE
synthesize xxx NE
IL-2 XX-d protein
. . NE

In Xx NE
the xxx NE
present xxx NE
study xxx NE
we xx NE
analyzed xxx NE
the xxx NE
control xxx NE
of xx NE
IL-2 XX-d NE
promoter xxx NE
activity xxx NE
in xx NE
Epstein-Barr Xxxx-Xxxx NE
virus xxx NE
( ( NE
EBV XXX NE
)-transformed )-xxx NE
B X NE
cell xxx NE
clones xxx NE
which xxx NE
are xxx NE
capable xxx NE
of xx NE
secreting xxx NE
IL-2 XX-d NE
at xx NE
a x NE
low xxx NE
level xxx NE
after xxx NE
stimulation xxx NE
with xxx NE
phorbol xxx NE
12-myristate dd-xxx NE
13-acetate dd-xxx NE
and xxx NE
the xxx NE
Ca2+ Xxd+ NE
ionophore xxx NE
ionomycin xxx NE
. . NE

Transient Xxxx NE
transfections xxx NE
using xxx NE
reporter xxx DNA_B
constructs xxx DNA_E
with xxx NE
multiples xxx NE
of xx NE
transcription xxx DNA_B
factor xxx DNA_M
binding xxx DNA_M
sites xxx DNA_E
from xxx NE
the xxx NE
IL-2 XX-d DNA_B
promoter xxx DNA_E
[ [ NE
distal xxx protein_B
nuclear xxx protein_M
factor xxx protein_M
(NF)-AT (XX)-XX protein_E
, , NE
proximal xxx protein_B
NF-AT XX-XX protein_E
, , NE
AP-1/Octamer XX-d/Xxxx protein
( ( NE
UPS XXX protein
) ) NE
or xx NE
NF-chi XX-xxx protein_B
B X protein_E
( ( NE
TCEd XXXx protein
) ) NE
sites] xxx] NE
were xxx NE
performed xxx NE
. . NE

In Xx NE
EBV-transformed XXX-xxx cell_line_B
B X cell_line_M
clones xxx cell_line_E
, , NE
the xxx NE
chi xxx DNA_B
B X DNA_M
site xxx DNA_E
exerted xxx NE
the xxx NE
strongest xxx NE
inducible xxx NE
activity xxx NE
; ; NE
the xxx NE
NF-AT XX-XX DNA_B
binding xxx DNA_M
sites xxx DNA_E
showed xxx NE
either xxx NE
no xx NE
or xx NE
only xxx NE
weak xxx NE
activity xxx NE
compared xxx NE
to xx NE
Jurkat Xxxx cell_line_B
T X cell_line_M
cells xxx cell_line_E
. . NE

An Xx NE
IL-2 XX-d DNA_B
promoter xxx DNA_E
bearing xxx NE
a x NE
defective xxx NE
NF- XX- NE
chi xxx NE
B X NE
site xxx NE
was xxx NE
completely xxx NE
inactive xxx NE
in xx NE
EBV-transformed XXX-xxx NE
B X NE
cells xxx NE
, , NE
while xxx NE
it xx NE
still xxx NE
had xxx NE
activity xxx NE
in xx NE
Jurkat Xxxx NE
T X NE
cells xxx NE
. . NE

In Xx NE
seven xxx NE
EBV-B XXX-X cell_line_B
cell xxx cell_line_M
clones xxx cell_line_E
or xx NE
lines xxx NE
differing xxx NE
in xx NE
their xxx NE
capacity xxx NE
to xx NE
secrete xxx NE
IL-2 XX-d protein
, , NE
the xxx NE
activity xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_B
promoter xxx DNA_E
correlated xxx NE
well xxx NE
with xxx NE
the xxx NE
status xxx NE
of xx NE
IL-2 XX-d NE
secretion xxx NE
. . NE

Similarly Xxxx NE
, , NE
a x NE
human xxx DNA_B
immunodeficiency xxx DNA_M
virus xxx DNA_M
promoter xxx DNA_E
, , NE
whose xxx NE
activity xxx NE
is xx NE
controlled xxx NE
through xxx NE
chi xxx protein_B
B X protein_M
factors xxx protein_E
, , NE
was xxx NE
found xxx NE
to xx NE
be xx NE
active xxx NE
in xx NE
the xxx NE
IL-2 XX-d NE
producing xxx NE
EBV- XXX- NE
B X NE
cells xxx NE
, , NE
but xxx NE
inactive xxx NE
in xx NE
the xxx NE
non- xxx- NE
IL-2 XX-d NE
-producing -xxx NE
cells xxx NE
. . NE

Electrophoretic Xxxx NE
mobility xxx NE
shift xxx NE
assays xxx NE
using xxx NE
protein xxx protein_B
extracts xxx protein_E
from xxx NE
EBV- XXX- NE
B X NE
cells xxx NE
and xxx NE
the xxx NE
IL-2 XX-d NE
NF-chi XX-xxx NE
B X NE
probe xxx NE
revealed xxx NE
the xxx NE
constitutive xxx NE
generation xxx NE
of xx NE
chi xxx NE
B X NE
complexes xxx NE
in xx NE
IL-2 XX-d NE
-secreting -xxx NE
cells xxx NE
consisting xxx NE
mainly xxx NE
of xx NE
heterodimeric xxx NE
p50/p65 xdd/xdd NE
complexes xxx NE
. . NE

A X NE
weaker xxx NE
chi xxx NE
B X NE
complex xxx NE
formation xxx NE
and xxx NE
faster-migrating xxx-xxx NE
complexes xxx NE
were xxx NE
detected xxx NE
in xx NE
non- xxx- NE
IL-2 XX-d NE
-secreting -xxx NE
cells xxx NE
. . NE

These Xxxx NE
results xxx NE
demonstrate xxx NE
that xxx NE
the xxx NE
IL-2 XX-d DNA_B
NF-chi XX-xxx DNA_M
B X DNA_M
site xxx DNA_E
is xx NE
indispensable xxx NE
for xxx NE
the xxx NE
activity xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_B
promoter xxx DNA_E
in xx NE
EBV-transformed XXX-xxx cell_line_B
B X cell_line_M
cells xxx cell_line_E
, , NE
whereas xxx NE
other xxx NE
transcription xxx protein_B
factors xxx protein_E
appear xxx NE
to xx NE
be xx NE
less xxx NE
important xxx NE
for xxx NE
IL-2 XX-d NE
expression xxx NE
in xx NE
these xxx NE
cells xxx NE
. . NE

Latent Xxxx protein_B
membrane xxx protein_M
protein-1 xxx-d protein_E
induces xxx NE
cyclin xxx NE
D2 Xd NE
expression xxx NE
, , NE
pRb xXx NE
hyperphosphorylation xxx NE
, , NE
and xxx NE
loss xxx NE
of xx NE
TGF-beta XXX-xxx NE
1 d NE
-mediated -xxx NE
growth xxx NE
inhibition xxx NE
in xx NE
EBV-positive XXX-xxx NE
B X NE
cells xxx NE
. . NE

The Xxx NE
normal xxx NE
cell xxx NE
cycle xxx NE
is xx NE
regulated xxx NE
by xx NE
several xxx NE
molecules xxx NE
, , NE
such xxx NE
as xx NE
the xxx NE
tumor-suppressor xxx-xxx protein_B
protein xxx protein_M
pRb xXx protein_E
, , NE
the xxx NE
G1 Xd protein_B
cyclins xxx protein_E
, , NE
the xxx NE
cyclin-dependent xxx-xxx protein_B
kinases xxx protein_E
, , NE
and xxx NE
their xxx NE
inhibitors xxx NE
. . NE

These Xxxx NE
regulators xxx NE
are xxx NE
targeted xxx NE
by xx NE
negative xxx NE
growth xxx NE
regulatory xxx NE
signals xxx NE
, , NE
such xxx NE
as xx NE
that xxx NE
provided xxx NE
by xx NE
TGF-beta XXX-xxx protein
. . NE

Here Xxxx NE
, , NE
we xx NE
show xxx NE
that xxx NE
the xxx NE
presence xxx NE
of xx NE
either xxx NE
wild-type xxx-xxx NE
EBV XXX NE
or xx NE
its xxx NE
transforming xxx protein_B
latent xxx protein_M
membrane xxx protein_M
protein-1 xxx-d protein_E
( ( NE
LMP-1 XXX-d protein
) ) NE
results xxx NE
in xx NE
the xxx NE
loss xxx NE
of xx NE
TGF-beta XXX-xxx NE
1 d NE
-mediated -xxx NE
growth xxx NE
inhibition xxx NE
in xx NE
human xxx NE
B X NE
cells xxx NE
. . NE

Chemical Xxxx NE
cross-linking xxx-xxx NE
with xxx NE
125I-labeled dddX-xxx protein_B
TGF-beta XXX-xxx protein_M
1 d protein_E
showed xxx NE
an xx NE
essentially xxx NE
normal xxx NE
TGF-beta XXX-xxx NE
receptor xxx NE
profile xxx NE
in xx NE
EBV-positive XXX-xxx cell_line_B
Burkitt's Xxxx'x cell_line_M
lymphoma xxx cell_line_M
cell xxx cell_line_M
line xxx cell_line_M
and xxx cell_line_M
EBV-negative XXX-xxx cell_line_M
Burkitt's Xxxx'x cell_line_M
lymphoma xxx cell_line_M
cell xxx cell_line_M
line xxx cell_line_E
transducing xxx NE
signals xxx NE
, , NE
as xx NE
evidenced xxx NE
by xx NE
the xxx NE
TGF-beta XXX-xxx NE
1 d NE
-mediated -xxx NE
modulation xxx NE
of xx NE
junB xxxX NE
gene xxx NE
expression xxx NE
. . NE

However Xxxx NE
, , NE
TGF-beta XXX-xxx protein_B
1 d protein_E
did xxx NE
not xxx NE
induce xxx NE
dephosphorylation xxx NE
of xx NE
pRb xXx protein
in xx NE
EBV XXX NE
(or (xx NE
LMP-1 XXX-d NE
)-positive )-xxx NE
cells xxx NE
as xx NE
opposed xxx NE
to xx NE
EBV XXX NE
-negative -xxx NE
cells xxx NE
, , NE
suggesting xxx NE
a x NE
dichotomy xxx NE
in xx NE
the xxx NE
TGF-beta XXX-xxx NE
1 d NE
signaling xxx NE
pathway xxx NE
leading xxx NE
to xx NE
separable xxx NE
gene xxx NE
regulatory xxx NE
and xxx NE
growth xxx NE
inhibitory xxx NE
responses xxx NE
. . NE

Furthermore Xxxx NE
, , NE
LMP-1 XXX-d protein
was xxx NE
found xxx NE
to xx NE
induce xxx NE
the xxx NE
expression xxx NE
of xx NE
cyclin xxx protein_B
D2 Xd protein_E
; ; NE
normal xxx NE
B X cell_type_B
cells xxx cell_type_E
or xx NE
EBV XXX NE
-negative -xxx NE
Burkitt's Xxxx'x NE
lymphoma xxx NE
cells xxx NE
do xx NE
not xxx NE
express xxx NE
D-type X-xxx NE
cyclins xxx NE
. . NE

Taken Xxxx NE
together xxx NE
, , NE
these xxx NE
data xxx NE
point xxx NE
to xx NE
a x NE
potential xxx NE
mechanism xxx NE
underlying xxx NE
EBV XXX NE
-mediated -xxx NE
B X NE
cell xxx NE
transformation xxx NE
whereby xxx NE
constitutive xxx NE
induction xxx NE
of xx NE
key xxx NE
cell xxx NE
cycle xxx NE
regulators xxx NE
by xx NE
LMP-1 XXX-d NE
can xxx NE
lead xxx NE
to xx NE
pRb xXx NE
hyperphosphorylation xxx NE
and xxx NE
uncontrolled xxx NE
cell xxx NE
proliferation xxx NE
. . NE

Does Xxxx NE
thyroidectomy xxx NE
, , NE
radioactive xxx NE
iodine xxx NE
therapy xxx NE
, , NE
or xx NE
antithyroid xxx NE
drug xxx NE
treatment xxx NE
alter xxx NE
reactivity xxx NE
of xx NE
patients' xxx' NE
T X cell_type_B
cells xxx cell_type_E
to xx NE
epitopes xxx NE
of xx NE
thyrotropin xxx protein_B
receptor xxx protein_E
in xx NE
autoimmune xxx NE
thyroid xxx NE
diseases xxx NE
? ? NE

The Xxx NE
effect xxx NE
of xx NE
treatment xxx NE
on xx NE
thyroid xxx NE
antibody xxx NE
production xxx NE
and xxx NE
T X NE
cell xxx NE
reactivity xxx NE
to xx NE
thyroid xxx NE
antigens xxx NE
was xxx NE
studied xxx NE
in xx NE
15 dd NE
patients xxx NE
with xxx NE
Graves' Xxxx' NE
disease xxx NE
( ( NE
GD XX NE
) ) NE
before xxx NE
and xxx NE
after xxx NE
thyroidectomy xxx NE
, , NE
19 dd NE
patients xxx NE
with xxx NE
GD XX NE
before xxx NE
and xxx NE
after xxx NE
radioactive xxx NE
iodine xxx NE
(RAI) (XXX) NE
therapy xxx NE
, , NE
and xxx NE
9 d NE
patients xxx NE
maintained xxx NE
euthyroid xxx NE
on xx NE
antithyroid xxx NE
drugs xxx NE
( ( NE
ATD XXX NE
) ) NE
. . NE

Twenty Xxxx NE
subjects xxx NE
matched xxx NE
for xxx NE
age xxx NE
and xxx NE
sex xxx NE
without xxx NE
known xxx NE
thyroid xxx NE
disease xxx NE
served xxx NE
as xx NE
controls xxx NE
. . NE

In Xx NE
GD XX NE
patients xxx NE
, , NE
the xxx NE
responses xxx NE
of xx NE
peripheral xxx cell_type_B
blood xxx cell_type_M
mononuclear xxx cell_type_M
cells xxx cell_type_E
( ( NE
PBMC XXXX cell_type
) ) NE
and xxx NE
TSH XXX NE
receptor xxx NE
( ( NE
TSHR XXXX NE
)-specific )-xxx NE
T X NE
cell xxx NE
lines xxx NE
to xx NE
recombinant xxx NE
human xxx NE
TSHR XXXX NE
extracellular xxx NE
domain xxx NE
, , NE
thyroglobulin xxx NE
, , NE
and xxx NE
TSHR XXXX NE
peptides xxx NE
were xxx NE
examined xxx NE
on xx NE
the xxx NE
day xxx NE
of xx NE
surgery xxx NE
or xx NE
RAI XXX NE
therapy xxx NE
(day (xxx NE
0) d) NE
and xxx NE
also xxx NE
6-8 d-d NE
weeks xxx NE
and xxx NE
3-6 d-d NE
months xxx NE
thereafter xxx NE
. . NE

Reactivity Xxxx NE
to xx NE
TSHR XXXX NE
peptides xxx NE
before xxx NE
surgery xxx NE
was xxx NE
heterogeneous xxx NE
and xxx NE
spanned xxx NE
the xxx NE
entire xxx NE
extracellular xxx protein_B
domain xxx protein_E
. . NE

Six Xxx NE
to xx NE
8 d NE
weeks xxx NE
after xxx NE
subtotal xxx NE
thyroidectomy xxx NE
, , NE
the xxx NE
number xxx NE
of xx NE
patients xxx NE
' ' NE
PBMC XXXX cell_type
responding xxx NE
to xx NE
any xxx NE
peptide xxx NE
and xxx NE
the xxx NE
average xxx NE
number xxx NE
of xx NE
recognized xxx NE
peptides xxx NE
decreased xxx NE
. . NE

A X NE
further xxx NE
decrease xxx NE
in xx NE
the xxx NE
T X NE
cell xxx NE
reactivity xxx NE
to xx NE
TSHR XXXX protein
peptides xxx NE
was xxx NE
observed xxx NE
3-6 d-d NE
months xxx NE
after xxx NE
surgery xxx NE
. . NE

The Xxx NE
responses xxx NE
of xx NE
PBMC XXXX cell_type
from xxx NE
Graves' Xxxx' NE
patients xxx NE
before xxx NE
RAI XXX NE
therapy xxx NE
were xxx NE
less xxx NE
than xxx NE
those xxx NE
in xx NE
the xxx NE
presurgical xxx NE
group xxx NE
. . NE

Six Xxx NE
to xx NE
8 d NE
weeks xxx NE
after xxx NE
RAI XXX NE
therapy xxx NE
, , NE
the xxx NE
number xxx NE
of xx NE
patients xxx NE
responding xxx NE
to xx NE
any xxx NE
peptide xxx NE
and xxx NE
the xxx NE
average xxx NE
number xxx NE
of xx NE
recognized xxx NE
peptides xxx NE
increased xxx NE
. . NE

Three Xxxx NE
to xx NE
6 d NE
months xxx NE
after xxx NE
RAI XXX NE
, , NE
T X NE
cell xxx NE
responses xxx NE
to xx NE
TSHR XXXX NE
peptides xxx NE
were xxx NE
less xxx NE
than xxx NE
those xxx NE
6-8 d-d NE
weeks xxx NE
after xxx NE
RAI XXX NE
therapy xxx NE
, , NE
but xxx NE
still xxx NE
higher xxx NE
than xxx NE
the xxx NE
values xxx NE
on xx NE
day xxx NE
0 d NE
. . NE

Responses Xxxx NE
of xx NE
PBMC XXXX cell_type
from xxx NE
patients xxx NE
with xxx NE
GD XX NE
, , NE
maintained xxx NE
euthyroid xxx NE
on xx NE
ATD XXX NE
, , NE
were xxx NE
lower xxx NE
than xxx NE
those xxx NE
before xxx NE
surgery xxx NE
or xx NE
RAI XXX NE
therapy xxx NE
. . NE

The Xxx NE
reactivity xxx NE
of xx NE
T X cell_line_B
cell xxx cell_line_M
lines xxx cell_line_E
in xx NE
different xxx NE
groups xxx NE
reflected xxx NE
a x NE
pattern xxx NE
similar xxx NE
to xx NE
PBMC XXXX cell_type
after xxx NE
treatment xxx NE
. . NE

TSHR XXXX protein_B
antibody xxx protein_E
and xxx NE
microsomal xxx protein_B
antibody xxx protein_E
levels xxx NE
decreased xxx NE
after xxx NE
surgery xxx NE
, , NE
but xxx NE
increased xxx NE
after xxx NE
RAI XXX NE
therapy xxx NE
. . NE

The Xxx NE
difference xxx NE
in xx NE
the xxx NE
number xxx NE
of xx NE
recognized xxx NE
peptides xxx NE
by xx NE
patients xxx NE
' ' NE
PBMC XXXX cell_type
before xxx NE
RAI XXX NE
and xxx NE
surgery xxx NE
may xxx NE
reflect xxx NE
the xxx NE
effect xxx NE
of xx NE
long xxx NE
term xxx NE
therapy xxx NE
with xxx NE
ATD XXX NE
in xx NE
the xxx NE
patients xxx NE
before xxx NE
RAI XXX NE
vs xx NE
. . NE
the xxx NE
shorter xxx NE
period xxx NE
in xx NE
patients xxx NE
before xxx NE
surgery xxx NE
. . NE

The Xxx NE
decreased xxx NE
T X NE
cell xxx NE
reactivity xxx NE
to xx NE
thyroid xxx protein_B
antigens xxx protein_E
after xxx NE
thyroidectomy xxx NE
could xxx NE
be xx NE
the xxx NE
result xxx NE
of xx NE
removal xxx NE
of xx NE
a x NE
major xxx NE
part xxx NE
of xx NE
the xxx NE
thyroid xxx NE
gland xxx NE
or xx NE
redistribution xxx NE
of xx NE
suppressor-inducer xxx-xxx NE
T X cell_type_B
cells xxx cell_type_E
. . NE

The Xxx NE
increased xxx NE
T X NE
cell xxx NE
response xxx NE
after xxx NE
RAI XXX NE
therapy xxx NE
is xx NE
probably xxx NE
epitope xxx NE
specific xxx NE
, , NE
rather xxx NE
than xxx NE
a x NE
response xxx NE
to xx NE
the xxx NE
whole xxx NE
TSHR XXXX protein
molecule xxx NE
. . NE

Synchronous Xxxx NE
recognition xxx NE
of xx NE
peptides xxx NE
158-176 ddd-ddd NE
and xxx NE
248-263 ddd-ddd NE
is xx NE
important xxx NE
for xxx NE
the xxx NE
development xxx NE
of xx NE
GD XX NE
, , NE
and xxx NE
the xxx NE
loss xxx NE
of xx NE
recognition xxx NE
of xx NE
one xxx NE
of xx NE
these xxx NE
epitopes xxx NE
may xxx NE
be xx NE
an xx NE
early xxx NE
sign xxx NE
of xx NE
immune xxx NE
remission xxx NE
and xxx NE
a x NE
predictor xxx NE
of xx NE
euthyroidism xxx NE
. . NE

Circumvention Xxxx NE
of xx NE
tolerance xxx NE
for xxx NE
the xxx NE
nuclear xxx protein_B
T X protein_M
cell xxx protein_M
protein xxx protein_E
TCF-1 XXX-d protein
by xx NE
immunization xxx NE
of xx NE
TCF-1 XXX-d NE
knock-out xxx-xxx NE
mice xxx NE
. . NE

Molecular Xxxx NE
events xxx NE
that xxx NE
underlie xxx NE
the xxx NE
well-defined xxx-xxx NE
phenotypic xxx NE
changes xxx NE
of xx NE
the xxx NE
differentiating xxx cell_type_B
thymocyte xxx cell_type_E
are xxx NE
poorly xxx NE
understood xxx NE
. . NE

A X NE
candidate xxx NE
gene xxx NE
to xx NE
control xxx NE
thymocyte xxx NE
differentiation xxx NE
, , NE
T X protein_B
cell xxx protein_M
factor-1 xxx-d protein_E
( ( NE
TCF-1 XXX-d protein
) ) NE
* * NE
encodes xxx NE
a x NE
DNA-binding XXX-xxx protein_B
protein xxx protein_E
. . NE

Its Xxx NE
mRNA xXXX NE
expression xxx NE
pattern xxx NE
is xx NE
complex xxx NE
during xxx NE
embryogenesis xxx NE
, , NE
yet xxx NE
restricted xxx NE
to xx NE
lymphocytes xxx cell_type
postnatally xxx NE
. . NE

Expression Xxxx NE
studies xxx NE
on xx NE
TCF-1 XXX-d protein_B
protein xxx protein_E
have xxx NE
been xxx NE
hampered xxx NE
by xx NE
the xxx NE
difficulty xxx NE
to xx NE
raise xxx NE
antibodies xxx NE
due xxx NE
to xx NE
extreme xxx NE
evolutionary xxx NE
conservation xxx NE
. . NE

TCF-1 XXX-d NE
knock-out xxx-xxx NE
mice xxx NE
, , NE
generated xxx NE
recently xxx NE
in xx NE
our xxx NE
laboratory xxx NE
, , NE
have xxx NE
strongly xxx NE
decreased xxx NE
numbers xxx NE
of xx NE
thymocytes xxx cell_type
, , NE
but xxx NE
are xxx NE
otherwise xxx NE
normal xxx NE
. . NE

We Xx NE
have xxx NE
used xxx NE
these xxx NE
mice xxx NE
to xx NE
generate xxx NE
anti- xxx- NE
TCF-1 XXX-d NE
antibodies xxx NE
. . NE

By Xx NE
immunization xxx NE
with xxx NE
a x NE
recombinant xxx protein_B
fusion xxx protein_M
protein xxx protein_E
, , NE
we xx NE
show xxx NE
that xxx NE
TCF-1 XXX-d NE
knock-out xxx-xxx NE
mice xxx NE
readily xxx NE
yield xxx NE
antiserum xxx NE
titers xxx NE
against xxx NE
human xxx protein_B
TCF-1 XXX-d protein_M
protein xxx protein_M
and xxx protein_M
mouse xxx protein_M
TCF-1 XXX-d protein_M
protein xxx protein_E

Wild-type Xxxx-xxx NE
littermates xxx NE
remain xxx NE
unresponsive xxx NE
to xx NE
TCF-1 XXX-d protein
while xxx NE
they xxx NE
mount xxx NE
a x NE
high-titer xxx-xxx NE
antibody xxx NE
response xxx NE
to xx NE
the xxx NE
fusion xxx protein_B
protein xxx protein_E
, , NE
Maltose Xxxx protein_B
Binding Xxxx protein_M
Protein Xxxx protein_E
( ( NE
MBP XXX protein
) ) NE
. . NE

Subsequently Xxxx NE
, , NE
TCF-1 XXX-d NE
-specific -xxx NE
hybridomas xxx NE
could xxx NE
be xx NE
prepared xxx NE
from xxx NE
the xxx NE
spleens xxx NE
of xx NE
immunized xxx NE
knock-out xxx-xxx NE
mice xxx NE
. . NE

This Xxxx NE
study xxx NE
illustrates xxx NE
the xxx NE
almost xxx NE
complete xxx NE
tolerance xxx NE
of xx NE
mice xxx NE
for xxx NE
human xxx protein_B
TCF-1 XXX-d protein_E
and xxx NE
demonstrates xxx NE
that xxx NE
this xxx NE
tolerance xxx NE
is xx NE
readily xxx NE
broken xxx NE
by xx NE
gene xxx NE
knock-out xxx-xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
usefulness xxx NE
of xx NE
knock-out xxx-xxx NE
mice xxx NE
for xxx NE
the xxx NE
generation xxx NE
of xx NE
monoclonal xxx NE
antibodies xxx NE
against xxx NE
the xxx NE
gene xxx NE
product xxx NE
of xx NE
interest xxx NE
is xx NE
underscored xxx NE
. . NE

The Xxx NE
transcription xxx protein_B
factor xxx protein_E
, , NE
Nm23H2 XxddXd protein
, , NE
binds xxx NE
to xx NE
and xxx NE
activates xxx NE
the xxx NE
translocated xxx NE
c-myc x-xxx DNA_B
allele xxx DNA_E
in xx NE
Burkitt's Xxxx'x NE
lymphoma xxx NE
. . NE

We Xx NE
have xxx NE
identified xxx NE
an xx NE
in xx NE
vivo xxx NE
footprint xxx NE
over xxx NE
the xxx NE
PuF XxX DNA_B
site xxx DNA_E
on xx NE
the xxx NE
translocated xxx NE
c-myc x-xxx DNA_B
allele xxx DNA_E
in xx NE
Burkitt's Xxxx'x NE
lymphoma xxx NE
cells xxx NE
. . NE

The Xxx NE
PuF XxX DNA_B
site xxx DNA_E
on xx NE
the xxx NE
silent xxx DNA_B
normal xxx DNA_M
c-myc x-xxx DNA_M
allele xxx DNA_E
was xxx NE
unoccupied xxx NE
. . NE

We Xx NE
demonstrated xxx NE
by xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
, , NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
with xxx NE
antibody xxx NE
, , NE
UV XX NE
cross-linking xxx-xxx NE
followed xxx NE
by xx NE
SDS-gel XXX-xxx NE
electrophoresis xxx NE
, , NE
and xxx NE
Western Xxxx NE
analysis xxx NE
that xxx NE
Nm23H2 XxddXd protein
in xx NE
B X NE
cell xxx NE
nuclear xxx NE
extracts xxx NE
bound xxx NE
to xx NE
the xxx NE
c-myc x-xxx NE
PuF XxX DNA_B
site xxx DNA_E
. . NE

Transfection Xxxx NE
experiments xxx NE
with xxx NE
c-myc x-xxx DNA_B
promoter xxx DNA_M
constructs xxx DNA_E
in xx NE
both xxx NE
DHL-9 XXX-d cell_line
and xxx NE
Raji Xxxx cell_line_B
cells xxx cell_line_E
revealed xxx NE
that xxx NE
the xxx NE
PuF XxX DNA_B
site xxx DNA_E
functioned xxx NE
as xx NE
a x NE
positive xxx DNA_B
regulatory xxx DNA_M
element xxx DNA_E
in xx NE
B X cell_type_B
cells xxx cell_type_E
with xxx NE
a x NE
drop xxx NE
in xx NE
activity xxx NE
with xxx NE
mutation xxx NE
of xx NE
this xxx NE
site xxx NE
. . NE

Access Xxxx NE
to xx NE
this xxx NE
site xxx NE
is xx NE
blocked xxx NE
in xx NE
the xxx NE
normal xxx DNA_B
silent xxx DNA_M
c-myc x-xxx DNA_M
allele xxx DNA_E
; ; NE
these xxx NE
data xxx NE
suggest xxx NE
that xxx NE
the xxx NE
Nm23H2 XxddXd protein
protein xxx NE
is xx NE
involved xxx NE
in xx NE
deregulation xxx NE
of xx NE
the xxx NE
translocated xxx NE
c-myc x-xxx DNA_B
allele xxx DNA_E
in xx NE
Burkitt's Xxxx'x cell_line_B
lymphoma xxx cell_line_M
cells xxx cell_line_E
. . NE

Identification Xxxx NE
of xx NE
two xxx NE
novel xxx NE
regulatory xxx DNA_B
elements xxx DNA_E
within xxx NE
the xxx NE
5'-untranslated d'-xxx DNA_B
region xxx DNA_E
of xx NE
the xxx NE
human xxx DNA_B
A X DNA_M
gamma-globin xxx-xxx DNA_M
gene xxx DNA_E
. . NE

Interaction Xxxx NE
between xxx NE
the xxx NE
stage xxx DNA_B
selector xxx DNA_M
element xxx DNA_E
( ( NE
SSE XXX DNA
) ) NE
in xx NE
the xxx NE
proximal xxx DNA_B
gamma-globin xxx-xxx DNA_M
promoter xxx DNA_E
and xxx NE
hypersensitivity xxx DNA_B
site xxx DNA_M
2 d DNA_E
in xx NE
the xxx NE
locus xxx DNA_B
control xxx DNA_M
region xxx DNA_E
partly xxx NE
mediates xxx NE
the xxx NE
competitive xxx NE
silencing xxx NE
of xx NE
the xxx NE
beta-globin xxx-xxx DNA_B
promoter xxx DNA_E
in xx NE
the xxx NE
fetal xxx NE
developmental xxx NE
stage xxx NE
. . NE

We Xx NE
have xxx NE
now xxx NE
demonstrated xxx NE
that xxx NE
a x NE
second xxx NE
SSE-like XXX-xxx DNA_B
element xxx DNA_E
in xx NE
the xxx NE
5'-untranslated d'-xxx DNA_B
region xxx DNA_E
of xx NE
the xxx NE
gamma-gene xxx-xxx DNA
also xxx NE
contributes xxx NE
to xx NE
this xxx NE
competitive xxx NE
silencing xxx NE
of xx NE
the xxx NE
beta-gene xxx-xxx DNA
. . NE

Utilizing Xxxx NE
transient xxx NE
transfection xxx NE
assays xxx NE
in xx NE
the xxx NE
fetal xxx cell_line_B
erythroid xxx cell_line_M
cell xxx cell_line_M
line xxx cell_line_E
, , NE
K562 Xddd cell_line
, , NE
we xx NE
have xxx NE
shown xxx NE
that xxx NE
the xxx NE
core xxx DNA_B
enhancer xxx DNA_E
of xx NE
hypersensitivity xxx DNA_B
site xxx DNA_M
2 d DNA_E
can xxx NE
preferentially xxx NE
interact xxx NE
with xxx NE
the xxx NE
proximal xxx DNA_B
gamma-promoter xxx-xxx DNA_E
in xx NE
the xxx NE
absence xxx NE
of xx NE
the xxx NE
SSE XXX DNA
, , NE
completely xxx NE
silencing xxx NE
a x NE
linked xxx DNA_B
beta-promoter xxx-xxx DNA_E
. . NE

Mutation Xxxx NE
of xx NE
a x NE
20-base dd-xxx NE
pair xxx NE
sequence xxx NE
of xx NE
the xxx NE
gamma-gene xxx-xxx DNA_B
5'-untranslated d'-xxx DNA_M
region xxx DNA_E
( ( NE
UTR XXX DNA
) ) NE
led xxx NE
to xx NE
derepression xxx NE
of xx NE
beta-promoter xxx-xxx NE
activity xxx NE
. . NE

A X NE
marked xxx NE
activation xxx NE
of xx NE
gamma-promoter xxx-xxx NE
activity xxx NE
was xxx NE
also xxx NE
observed xxx NE
with xxx NE
this xxx NE
mutation xxx NE
, , NE
suggesting xxx NE
the xxx NE
presence xxx NE
of xx NE
a x NE
repressor xxx NE
. . NE

Fine Xxxx NE
mutagenesis xxx NE
dissected xxx NE
these xxx NE
activities xxx NE
to xx NE
different xxx NE
regions xxx NE
of xx NE
the xxx NE
5'-UTR d'-XXX DNA
. . NE

The Xxx NE
stage xxx NE
selector xxx NE
activity xxx NE
was xxx NE
localized xxx NE
to xx NE
a x NE
region xxx NE
centered xxx NE
on xx NE
nucleotides xxx DNA_B
+13 +dd DNA_M
to xx DNA_M
+15 +dd DNA_E
. . NE

Electromobility Xxxx NE
shift xxx NE
assays xxx NE
utilizing xxx NE
this xxx NE
sequence xxx NE
demonstrated xxx NE
binding xxx NE
of xx NE
a x NE
fetal-specific xxx-xxx protein_B
protein xxx protein_M
and xxx protein_M
erythroid-specific xxx-xxx protein_M
protein xxx protein_E

The Xxx NE
repressor xxx NE
activity xxx NE
of xx NE
the xxx NE
5'-UTR d'-XXX DNA
was xxx NE
localized xxx NE
to xx NE
tandem xxx NE
GATA-like XXXX-xxx DNA_B
sites xxx DNA_E
, , NE
which xxx NE
appear xxx NE
to xx NE
bind xxx NE
a x NE
complex xxx NE
of xx NE
two xxx NE
proteins xxx NE
, , NE
one xxx NE
of xx NE
which xxx NE
is xx NE
the xxx NE
erythroid xxx protein_B
transcription xxx protein_M
factor xxx protein_E
GATA-1 XXXX-d protein
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
the xxx NE
5'-UTR d'-XXX DNA
of xx NE
the xxx NE
gamma-gene xxx-xxx DNA
contains xxx NE
sequences xxx NE
that xxx NE
may xxx NE
be xx NE
important xxx NE
for xxx NE
its xxx NE
transcriptional xxx NE
and xxx NE
developmental xxx NE
regulation xxx NE
. . NE

Coupling Xxxx NE
of xx NE
a x NE
signal xxx protein_B
response xxx protein_M
domain xxx protein_E
in xx NE
I X protein_B
kappa xxx protein_M
B X protein_M
alpha xxx protein_E
to xx NE
multiple xxx NE
pathways xxx NE
for xxx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
. . NE

The Xxx NE
eukaryotic xxx protein_B
transcription xxx protein_M
factor xxx protein_E
NF-kappa XX-xxx protein_B
B X protein_E
plays xxx NE
a x NE
central xxx NE
role xxx NE
in xx NE
the xxx NE
induced xxx NE
expression xxx NE
of xx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
and xxx NE
in xx NE
many xxx NE
aspects xxx NE
of xx NE
the xxx NE
genetic xxx NE
program xxx NE
mediating xxx NE
normal xxx NE
T-cell X-xxx NE
activation xxx NE
and xxx NE
growth xxx NE
. . NE

The Xxx NE
nuclear xxx NE
activity xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
is xx NE
tightly xxx NE
regulated xxx NE
from xxx NE
the xxx NE
cytoplasmic xxx NE
compartment xxx NE
by xx NE
an xx NE
inhibitory xxx protein_B
subunit xxx protein_E
called xxx NE
I X protein_B
kappa xxx protein_M
B X protein_M
alpha xxx protein_E
. . NE

This Xxxx NE
cytoplasmic xxx NE
inhibitor xxx NE
is xx NE
rapidly xxx NE
phosphorylated xxx NE
and xxx NE
degraded xxx NE
in xx NE
response xxx NE
to xx NE
a x NE
diverse xxx NE
set xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
-inducing -xxx NE
agents xxx NE
, , NE
including xxx NE
T-cell X-xxx NE
mitogens xxx NE
, , NE
proinflammatory xxx NE
cytokines xxx NE
, , NE
and xxx NE
viral xxx NE
transactivators xxx NE
such xxx NE
as xx NE
the xxx NE
Tax Xxx NE
protein xxx NE
of xx NE
human xxx NE
T-cell X-xxx NE
leukemia xxx NE
virus xxx NE
type xxx NE
1 d NE
. . NE

To Xx NE
explore xxx NE
these xxx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
-dependent -xxx NE
mechanisms xxx NE
for xxx NE
NF-kappa XX-xxx NE
B X NE
induction xxx NE
, , NE
we xx NE
identified xxx NE
novel xxx NE
mutants xxx NE
of xx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
that xxx NE
uncouple xxx NE
its xxx NE
inhibitory xxx NE
and xxx NE
signal-transducing xxx-xxx NE
functions xxx NE
in xx NE
human xxx NE
T X NE
lymphocytes xxx NE
. . NE

Specifically Xxxx NE
, , NE
removal xxx NE
of xx NE
the xxx NE
N-terminal X-xxx protein_B
36 dd protein_M
amino xxx protein_M
acids xxx protein_E
of xx NE
I X protein_B
kappa xxx protein_M
B X protein_M
alpha xxx protein_E
failed xxx NE
to xx NE
disrupt xxx NE
its xxx NE
ability xxx NE
to xx NE
form xxx NE
latent xxx NE
complexes xxx NE
with xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
in xx NE
the xxx NE
cytoplasm xxx NE
. . NE

However Xxxx NE
, , NE
this xxx NE
deletion xxx NE
mutation xxx NE
prevented xxx NE
the xxx NE
induced xxx NE
phosphorylation xxx NE
, , NE
degradative xxx NE
loss xxx NE
, , NE
and xxx NE
functional xxx NE
release xxx NE
of xx NE
I X protein_B
kappa xxx protein_M
B X protein_M
alpha xxx protein_E
from xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
in xx NE
Tax Xxx NE
-expressing -xxx NE
cells xxx NE
. . NE

Alanine Xxxx NE
substitutions xxx NE
introduced xxx NE
at xx NE
two xxx NE
serine xxx NE
residues xxx NE
positioned xxx NE
within xxx NE
this xxx NE
N-terminal X-xxx protein_B
regulatory xxx protein_M
region xxx protein_E
of xx NE
I X protein_B
kappa xxx protein_M
B X protein_M
alpha xxx protein_E
also xxx NE
yielded xxx NE
constitutive xxx NE
repressors xxx NE
that xxx NE
escaped xxx NE
from xxx NE
Tax Xxx NE
-induced -xxx NE
turnover xxx NE
and xxx NE
that xxx NE
potently xxx NE
inhibited xxx NE
immune xxx NE
activation xxx NE
pathways xxx NE
for xxx NE
NF-kappa XX-xxx NE
B X NE
induction xxx NE
, , NE
including xxx NE
those xxx NE
initiated xxx NE
from xxx NE
antigen xxx protein_B
receptor xxx protein_M
and xxx protein_M
cytokine xxx protein_M
receptor xxx protein_E

In Xx NE
contrast xxx NE
, , NE
introduction xxx NE
of xx NE
a x NE
phosphoserine xxx NE
mimetic xxx NE
at xx NE
these xxx NE
sites xxx NE
rectified xxx NE
this xxx NE
functional xxx NE
defect xxx NE
, , NE
a x NE
finding xxx NE
consistent xxx NE
with xxx NE
a x NE
causal xxx NE
linkage xxx NE
between xxx NE
the xxx NE
phosphorylation xxx NE
status xxx NE
and xxx NE
proteolytic xxx NE
stability xxx NE
of xx NE
this xxx NE
cytoplasmic xxx protein_B
inhibitor xxx protein_E
. . NE

Together Xxxx NE
, , NE
these xxx NE
in xx NE
vivo xxx NE
studies xxx NE
define xxx NE
a x NE
critical xxx NE
signal xxx NE
response xxx NE
domain xxx NE
in xx NE
I X protein_B
kappa xxx protein_M
B X protein_M
alpha xxx protein_E
that xxx NE
coordinately xxx NE
controls xxx NE
the xxx NE
biologic xxx NE
activities xxx NE
of xx NE
I X protein_B
kappa xxx protein_M
B X protein_M
alpha xxx protein_E
and xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
in xx NE
response xxx NE
to xx NE
viral xxx NE
stimulus xxx NE
and xxx NE
immune xxx NE
stimulus xxx NE
stimuli xxx NE
. . NE

Growth Xxxx NE
regulation xxx NE
and xxx NE
cellular xxx NE
changes xxx NE
during xxx NE
differentiation xxx NE
of xx NE
human xxx cell_line_B
prostatic xxx cell_line_M
cancer xxx cell_line_M
LNCaP XXXxX cell_line_M
cells xxx cell_line_E
as xx NE
induced xxx NE
by xx NE
T X NE
lymphocyte-conditioned xxx-xxx NE
medium xxx NE
. . NE

Human Xxxx cell_line_B
prostatic xxx cell_line_M
epithelial xxx cell_line_M
cells xxx cell_line_E
from xxx NE
an xx NE
androgen-dependent xxx-xxx cell_line_B
LNCaP XXXxX cell_line_M
cell xxx cell_line_M
line xxx cell_line_E
were xxx NE
examined xxx NE
in xx NE
response xxx NE
to xx NE
conditioned xxx NE
medium xxx NE
( ( NE
CM XX NE
) ) NE
derived xxx NE
from xxx NE
phytohemagglutinin xxx NE
( ( NE
PHA XXX NE
)-stimulated )-xxx NE
lymphocytes xxx NE
. . NE

Addition Xxxx NE
of xx NE
CM XX NE
caused xxx NE
a x NE
greater xxx NE
than xxx NE
70% dd% NE
reduction xxx NE
of xx NE
cell xxx NE
proliferation xxx NE
by xx NE
cell xxx NE
counting xxx NE
and xxx NE
cell xxx NE
cycle xxx NE
. . NE

These Xxxx NE
cells xxx NE
showed xxx NE
G1 Xd NE
phase xxx NE
arrest xxx NE
and xxx NE
the xxx NE
clonogenicity xxx NE
was xxx NE
reduced xxx NE
. . NE

The Xxx NE
growth-modulating xxx-xxx NE
effect xxx NE
was xxx NE
dose-dependent xxx-xxx NE
and xxx NE
not xxx NE
due xxx NE
to xx NE
cell xxx NE
lysis xxx NE
or xx NE
apoptosis xxx NE
. . NE

The Xxx NE
binding xxx NE
of xx NE
androgen xxx NE
to xx NE
androgen xxx protein_B
receptor xxx protein_E
on xx NE
these xxx NE
cells xxx NE
showed xxx NE
approximately xxx NE
50% dd% NE
reduction xxx NE
, , NE
underlining xxx NE
a x NE
proliferation xxx NE
reduction xxx NE
mechanism xxx NE
. . NE

The Xxx NE
prostate-specific xxx-xxx protein_B
antigen xxx protein_E
( ( NE
PSA XXX protein
) ) NE
was xxx NE
downregulated xxx NE
to xx NE
approximately xxx NE
75% dd% NE
during xxx NE
the xxx NE
process xxx NE
. . NE

Cell Xxxx NE
morphology xxx NE
showed xxx NE
dendritic xxx NE
processes xxx NE
extending xxx NE
from xxx NE
cytoplasm xxx NE
and xxx NE
other xxx NE
neuroendocrine xxx NE
cell xxx NE
characteristics xxx NE
. . NE

The Xxx NE
expression xxx NE
of xx NE
several xxx NE
cytoskeleton xxx protein_B
protein xxx protein_M
and xxx protein_M
intracellular xxx protein_M
protein xxx protein_E
increased xxx NE
as xx NE
determined xxx NE
by xx NE
immunostaining xxx NE
on xx NE
slides xxx NE
and xxx NE
by xx NE
ELISA XXXXX NE
procedures xxx NE
. . NE

These Xxxx NE
included xxx NE
vimentin xxx protein
, , NE
correlating xxx NE
to xx NE
cell xxx NE
shape xxx NE
changes xxx NE
, , NE
cytokeratins xxx NE
cytokeratin xxx protein_B
8 d protein_M
and xxx protein_M
cytokeratin xxx protein_M
18 dd protein_E
differentiated xxx NE
cell xxx NE
types xxx NE
of xx NE
prostate xxx NE
epithelia xxx NE
, , NE
and xxx NE
neuron-specific xxx-xxx protein_B
enolase xxx protein_E
and xxx NE
serotonin xxx NE
, , NE
associated xxx NE
with xxx NE
neuroendocrine xxx cell_type_B
cells xxx cell_type_E
. . NE

From Xxxx NE
these xxx NE
cellular xxx NE
changes xxx NE
, , NE
we xx NE
can xxx NE
infer xxx NE
that xxx NE
the xxx NE
cell xxx NE
growth xxx NE
was xxx NE
modulated xxx NE
along xxx NE
with xxx NE
induction xxx NE
of xx NE
terminal xxx NE
differentiation xxx NE
. . NE

Activated Xxxx NE
T X cell_type_B
cells xxx cell_type_E
were xxx NE
demonstrated xxx NE
to xx NE
be xx NE
important xxx NE
in xx NE
providing xxx NE
the xxx NE
modulating xxx NE
activity xxx NE
. . NE

This Xxxx NE
growth xxx protein_B
modulator xxx protein_E
was xxx NE
semipurified xxx NE
and xxx NE
had xxx NE
an xx NE
estimated xxx NE
molecular xxx NE
weight xxx NE
13,000 dd,ddd NE
to xx NE
24,000 dd,ddd NE
Da Xx NE
. . NE

The Xxx NE
activity xxx NE
was xxx NE
determined xxx NE
to xx NE
be xx NE
distinct xxx NE
from xxx NE
TGF XXX protein
, , NE
TNF XXX protein
, , NE
and xxx NE
some xxx NE
commonly xxx NE
known xxx NE
lymphokines xxx protein
. . NE

The Xxx NE
interaction xxx NE
between xxx NE
lymphoid xxx cell_type_B
cell xxx cell_type_M
and xxx cell_type_M
prostatic xxx cell_type_M
cell xxx cell_type_E

Platelet-activating Xxxx-xxx protein_B
factor xxx protein_E
stimulates xxx NE
transcription xxx NE
of xx NE
the xxx NE
heparin-binding xxx-xxx protein_B
epidermal xxx protein_M
growth xxx protein_M
factor-like xxx-xxx protein_M
growth xxx protein_M
factor xxx protein_E
in xx NE
monocytes xxx cell_type
. . NE

Correlation Xxxx NE
with xxx NE
an xx NE
increased xxx NE
kappa xxx NE
B X NE
binding xxx NE
activity xxx NE
. . NE

Human Xxxx NE
peripheral xxx NE
blood xxx NE
monocytes xxx cell_type
responded xxx NE
to xx NE
stimulation xxx NE
of xx NE
platelet-activating xxx-xxx protein_B
factor xxx protein_E
( ( NE
PAF XXX protein
) ) NE
with xxx NE
up-regulation xx-xxx NE
of xx NE
the xxx NE
transcript xxx NE
for xxx NE
heparin-binding xxx-xxx protein_B
epidermal xxx protein_M
growth xxx protein_M
factor-like xxx-xxx protein_M
growth xxx protein_M
factor xxx protein_E
( ( NE
HB-EGF XX-XXX protein
) ) NE
, , NE
a x NE
potent xxx protein_B
mitogen xxx protein_E
for xxx NE
vascular xxx cell_type_B
smooth xxx cell_type_M
muscle xxx cell_type_M
cells xxx cell_type_E
. . NE

This Xxxx NE
function xxx NE
of xx NE
PAF XXX protein
was xxx NE
observed xxx NE
at xx NE
nanomolar xxx NE
concentrations xxx NE
of xx NE
the xxx NE
ligand xxx NE
, , NE
starting xxx NE
at xx NE
30 dd NE
min xxx NE
after xxx NE
stimulation xxx NE
. . NE

The Xxx NE
PAF XXX protein
-induced -xxx NE
up-regulation xx-xxx NE
of xx NE
HB-EGF XX-XXX RNA_B
mRNA xXXX RNA_E
was xxx NE
accompanied xxx NE
by xx NE
an xx NE
increase xxx NE
in xx NE
kappa xxx NE
B X NE
binding xxx NE
activity xxx NE
. . NE

These Xxxx NE
functions xxx NE
of xx NE
PAF XXX protein
appeared xxx NE
to xx NE
be xx NE
mediated xxx NE
through xxx NE
the xxx NE
cell xxx protein_B
surface xxx protein_M
PAF XXX protein_M
receptors xxx protein_E
, , NE
as xx NE
two xxx NE
PAF XXX NE
receptor xxx NE
antagonists xxx NE
, , NE
WEB XXX NE
2086 dddd NE
and xxx NE
L-659,989 X-ddd,ddd NE
, , NE
blocked xxx NE
both xxx NE
the xxx NE
up-regulation xx-xxx NE
of xx NE
HB-EGF XX-XXX RNA_B
mRNA xXXX RNA_E
and xxx NE
kappa xxx NE
B X NE
binding xxx NE
activity xxx NE
induced xxx NE
by xx NE
PAF XXX protein
. . NE

The Xxx NE
antagonists xxx NE
, , NE
however xxx NE
, , NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
phorbol xxx NE
ester xxx NE
-induced -xxx NE
up-regulation xx-xxx NE
of xx NE
HB-EGF XX-XXX NE
mRNA xXXX NE
and xxx NE
kappa xxx NE
B X NE
binding xxx NE
activity xxx NE
. . NE

Pretreatment Xxxx NE
of xx NE
monocytes xxx cell_type
with xxx NE
pertussis xxx NE
toxin xxx NE
inhibited xxx NE
these xxx NE
functions xxx NE
of xx NE
PAF XXX protein
, , NE
whereas xxx NE
cholera xxx NE
toxin xxx NE
had xxx NE
no xx NE
inhibitory xxx NE
effect xxx NE
. . NE

Pyrrolidine Xxxx NE
dithiocarbamate xxx NE
, , NE
an xx NE
inhibitor xxx NE
for xxx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
, , NE
markedly xxx NE
reduced xxx NE
PAF XXX NE
-stimulated -xxx NE
kappa xxx NE
B X NE
binding xxx NE
activity xxx NE
as xx NE
well xxx NE
as xx NE
up-regulation xx-xxx NE
of xx NE
HB-EGF XX-XXX NE
mRNA xXXX NE
. . NE

These Xxxx NE
results xxx NE
suggest xxx NE
a x NE
potential xxx NE
role xxx NE
of xx NE
PAF XXX protein
in xx NE
HB-EGF XX-XXX NE
expression xxx NE
and xxx NE
provide xxx NE
evidence xxx NE
that xxx NE
this xxx NE
stimulation xxx NE
may xxx NE
occur xxx NE
through xxx NE
increased xxx NE
kappa xxx NE
B X NE
binding xxx NE
activity xxx NE
. . NE

Mapping Xxxx NE
of xx NE
the xxx NE
interaction xxx protein_B
site xxx protein_E
of xx NE
the xxx NE
defective xxx protein_B
transcription xxx protein_M
factor xxx protein_E
in xx NE
the xxx NE
class xxx cell_line_B
II XX cell_line_M
major xxx cell_line_M
histocompatibility xxx cell_line_M
complex xxx cell_line_M
mutant xxx cell_line_M
cell xxx cell_line_M
line xxx cell_line_M
clone-13 xxx-dd cell_line_E
to xx NE
the xxx NE
divergent xxx DNA_B
X2-box Xd-xxx DNA_E
. . NE

We Xx NE
have xxx NE
previously xxx NE
described xxx NE
a x NE
mutant xxx cell_line_B
B X cell_line_M
lymphoblastoid xxx cell_line_M
cell xxx cell_line_M
line xxx cell_line_E
, , NE
Clone-13 Xxxx-dd NE
, , NE
that xxx NE
expresses xxx NE
HLA-DQ XXX-XX protein
in xx NE
the xxx NE
absence xxx NE
of xx NE
HLA-DR XXX-XX protein_B
and xxx protein_M
HLA-DP XXX-XX protein_E

Several Xxxx NE
criteria xxx NE
indicated xxx NE
that xxx NE
the xxx NE
defect xxx NE
in xx NE
this xxx NE
cell xxx NE
line xxx NE
influences xxx NE
the xxx NE
activity xxx NE
of xx NE
an xx NE
isotype-specific xxx-xxx protein_B
transcription xxx protein_M
factor xxx protein_E
. . NE

Indeed Xxxx NE
, , NE
transient xxx NE
transfection xxx NE
of xx NE
HLA-DRA XXX-XXX DNA_B
reporter xxx DNA_M
construct xxx DNA_M
and xxx DNA_M
DQB XXX DNA_M
reporter xxx DNA_M
construct xxx DNA_E
indicated xxx NE
that xxx NE
the xxx NE
affected xxx NE
factor xxx NE
operates xxx NE
via xxx NE
cis-elements xxx-xxx DNA
located xxx NE
between xxx NE
-141 -ddd DNA_B
base xxx DNA_M
pairs xxx DNA_E
and xxx NE
the xxx NE
transcription xxx DNA_B
initiation xxx DNA_M
site xxx DNA_E
. . NE

A X NE
series xxx NE
of xx NE
hybrid xxx DNA_B
DRA/DQB XXX/XXX DNA_M
reporter xxx DNA_M
constructs xxx DNA_E
was xxx NE
generated xxx NE
to xx NE
further xxx NE
map xxx NE
the xxx NE
relevant xxx NE
cis-elements xxx-xxx DNA
in xx NE
this xxx NE
system xxx NE
. . NE

Insertion Xxxx NE
of xx NE
oligonucleotides xxx NE
spanning xxx NE
the xxx NE
DQB XXX DNA_B
X-box X-xxx DNA_E
(but (xxx NE
not xxx NE
the xxx NE
DQB-W XXX-X DNA_B
region xxx DNA_E
or xx NE
the xxx NE
DQB XXX DNA_B
Y-box X-xxx DNA_E
) ) NE
upstream xxx DNA_B
of xx DNA_M
-141 -ddd DNA_E
in xx NE
a x NE
DRA XXX DNA_B
reporter xxx DNA_M
plasmid xxx DNA_E
rescued xxx NE
expression xxx NE
to xx NE
nearly xxx NE
wild-type xxx-xxx NE
levels xxx NE
. . NE

Substitution Xxxx NE
promoters xxx NE
were xxx NE
then xxx NE
generated xxx NE
where xxx NE
the xxx NE
entire xxx NE
X-box X-xxx DNA
, , NE
or xx NE
only xxx NE
the xxx NE
X1-box Xd-xxx DNA_B
or xx DNA_M
X2-box Xd-xxx DNA_E
boxes xxx NE
of xx NE
HLA-DRA XXX-XXX DNA
were xxx NE
replaced xxx NE
with xxx NE
the xxx NE
analogous xxx NE
regions xxx NE
of xx NE
HLA-DQB XXX-XXX DNA
. . NE

The Xxx NE
DQB XXX DNA_B
X2-box Xd-xxx DNA_E
was xxx NE
able xxx NE
to xx NE
restore xxx NE
expression xxx NE
to xx NE
the xxx NE
silent xxx DNA_B
DRA XXX DNA_M
reporter xxx DNA_M
construct xxx DNA_E
. . NE

Moreover Xxxx NE
, , NE
replacement xxx NE
of xx NE
the xxx NE
DQB XXX DNA_B
X2-box Xd-xxx DNA_E
with xxx NE
the xxx NE
DRA XXX DNA_B
X2-box Xd-xxx DNA_E
markedly xxx NE
diminished xxx NE
the xxx NE
activity xxx NE
of xx NE
the xxx NE
DQB XXX DNA_B
promoter xxx DNA_E
in xx NE
the xxx NE
mutant xxx cell_line_B
cell xxx cell_line_E
. . NE

None Xxxx NE
of xx NE
the xxx NE
hybrid xxx DNA_B
reporter xxx DNA_M
constructs xxx DNA_E
were xxx NE
defective xxx NE
when xxx NE
transfected xxx NE
into xxx NE
the xxx NE
wild-type xxx-xxx protein
, , NE
HLA-DR/-DQ XXX-XX/-XX cell_line_B
positive xxx cell_line_M
parental xxx cell_line_M
cell xxx cell_line_M
line xxx cell_line_E
, , NE
Jijoye Xxxx cell_line
. . NE

These Xxxx NE
studies xxx NE
suggest xxx NE
that xxx NE
the xxx NE
divergent xxx DNA_B
X2-box Xd-xxx DNA_E
of xx NE
the xxx NE
class xxx DNA_B
II XX DNA_M
major xxx DNA_M
histocompatibility xxx DNA_M
complex xxx DNA_M
promoters xxx DNA_E
plays xxx NE
an xx NE
important xxx NE
role xxx NE
in xx NE
influencing xxx NE
differential xxx NE
expression xxx NE
of xx NE
the xxx NE
human xxx DNA_B
class xxx DNA_M
II XX DNA_M
isotypes xxx DNA_E
. . NE

Restoration Xxxx NE
of xx NE
the xxx NE
Epstein-Barr Xxxx-Xxxx protein_B
virus xxx protein_M
ZEBRA XXXXX protein_M
protein xxx protein_E
's 'x NE
capacity xxx NE
to xx NE
disrupt xxx NE
latency xxx NE
by xx NE
the xxx NE
addition xxx NE
of xx NE
heterologous xxx protein_B
activation xxx protein_M
regions xxx protein_E
. . NE

The Xxx NE
ZEBRA XXXXX protein_B
protein xxx protein_E
has xxx NE
a x NE
unique xxx NE
biological xxx NE
function xxx NE
among xxx NE
herpesviral xxx protein_B
proteins xxx protein_E
. . NE

It Xx NE
is xx NE
responsible xxx NE
for xxx NE
the xxx NE
disruption xxx NE
of xx NE
Epstein-Barr Xxxx-Xxxx NE
virus xxx NE
( ( NE
EBV XXX NE
) ) NE
latency xxx NE
and xxx NE
the xxx NE
induction xxx NE
of xx NE
the xxx NE
lytic xxx NE
cycle xxx NE
. . NE

ZEBRA XXXXX protein
is xx NE
a x NE
bZIP xXXX protein_B
transcriptional xxx protein_M
activator xxx protein_E
which xxx NE
binds xxx NE
as xx NE
a x NE
dimer xxx NE
to xx NE
7-bp d-xx DNA_B
response xxx DNA_M
elements xxx DNA_E
within xxx NE
EBV XXX DNA_B
promoters xxx DNA_E
and xxx NE
is xx NE
directly xxx NE
involved xxx NE
in xx NE
the xxx NE
stimulation xxx NE
of xx NE
virus xxx NE
replication xxx NE
at xx NE
the xxx NE
EBV XXX DNA_B
lytic xxx DNA_M
origin xxx DNA_E
. . NE

We Xx NE
have xxx NE
employed xxx NE
the xxx NE
ZEBRA XXXXX NE
/EBV /XXX NE
biological xxx NE
system xxx NE
to xx NE
test xxx NE
whether xxx NE
a x NE
heterologous xxx NE
activation xxx NE
domain xxx NE
can xxx NE
substitute xxx NE
for xxx NE
another xxx NE
activation xxx NE
domain xxx NE
(the (xxx NE
ZEBRA XXXXX NE
domain xxx NE
) ) NE
. . NE

The Xxx NE
ZEBRA XXXXX protein_B
activation xxx protein_M
region xxx protein_E
was xxx NE
replaced xxx NE
with xxx NE
the xxx NE
potent xxx NE
acid xxx protein_B
activation xxx protein_M
region xxx protein_E
from xxx NE
the xxx NE
herpes xxx protein_B
simplex xxx protein_M
virus xxx protein_M
VP16 XXdd protein_M
protein xxx protein_E
or xx NE
with xxx NE
the xxx NE
activation xxx protein_B
region xxx protein_E
of xx NE
the xxx NE
EBV XXX protein_B
R X protein_M
protein xxx protein_E
. . NE

Both Xxxx NE
chimeras xxx NE
were xxx NE
found xxx NE
to xx NE
transactivate xxx NE
model xxx NE
and xxx NE
native xxx NE
promoters xxx NE
at xx NE
equivalent xxx NE
or xx NE
better xxx NE
levels xxx NE
than xxx NE
ZEBRA XXXXX protein
itself xxx NE
. . NE

Activation Xxxx NE
was xxx NE
not xxx NE
target- xxx- NE
or xx NE
cell-type xxx-xxx NE
dependent xxx NE
, , NE
nor xxx NE
was xxx NE
it xx NE
dependent xxx NE
on xx NE
the xxx NE
presence xxx NE
of xx NE
virus xxx NE
. . NE

These Xxxx NE
activation xxx NE
domains xxx NE
restored xxx NE
ZEBRA XXXXX protein
's 'x NE
ability xxx NE
to xx NE
induce xxx NE
early xxx protein_B
antigen xxx protein_E
and xxx NE
to xx NE
stimulate xxx NE
origin xxx NE
replication xxx NE
to xx NE
levels xxx NE
that xxx NE
were xxx NE
equal xxx NE
to xx NE
or xx NE
greater xxx NE
than xxx NE
those xxx NE
of xx NE
wild xxx NE
type xxx NE
. . NE

These Xxxx NE
studies xxx NE
suggest xxx NE
that xxx NE
the xxx NE
specificities xxx NE
of xx NE
some xxx NE
of xx NE
the xxx NE
known xxx NE
biological xxx NE
functions xxx NE
of xx NE
ZEBRA XXXXX protein
are xxx NE
not xxx NE
dependent xxx NE
upon xxx NE
the xxx NE
nature xxx NE
of xx NE
the xxx NE
activation xxx protein_B
domain xxx protein_M
present xxx protein_E
within xxx NE
ZEBRA XXXXX protein
. . NE

Interleukin Xxxx protein_B
4 d protein_E
activates xxx NE
a x NE
signal xxx NE
transducer xxx NE
and xxx NE
activator xxx NE
of xx NE
transcription xxx protein_B
(Stat) (Xxxx) protein_M
protein xxx protein_E
which xxx NE
interacts xxx NE
with xxx NE
an xx NE
interferon-gamma xxx-xxx DNA_B
activation xxx DNA_M
site-like xxx-xxx DNA_M
sequence xxx DNA_E
upstream xxx NE
of xx NE
the xxx NE
I X DNA_B
epsilon xxx DNA_M
exon xxx DNA_E
in xx NE
a x NE
human xxx cell_line_B
B X cell_line_M
cell xxx cell_line_M
line xxx cell_line_E
. . NE

Evidence Xxxx NE
for xxx NE
the xxx NE
involvement xxx NE
of xx NE
Janus Xxxx protein_B
kinase xxx protein_M
3 d protein_E
and xxx NE
interleukin-4 xxx-d protein_B
Stat Xxxx protein_E
. . NE

Germ Xxxx RNA_B
line xxx RNA_M
C X RNA_M
transcripts xxx RNA_E
can xxx NE
be xx NE
induced xxx NE
by xx NE
IL-4 XX-d protein
in xx NE
the xxx NE
human xxx cell_line_B
B X cell_line_M
cell xxx cell_line_M
line xxx cell_line_E
, , NE
BL-2 XX-d cell_line
. . NE

Utilizing Xxxx NE
a x NE
IFN-gamma XXX-xxx DNA_B
activation xxx DNA_M
site-like xxx-xxx DNA_M
DNA XXX DNA_M
sequence xxx DNA_M
element xxx DNA_E
located xxx NE
upstream xxx NE
of xx NE
the xxx NE
I X DNA_B
epsilon xxx DNA_M
exon xxx DNA_E
, , NE
we xx NE
demonstrated xxx NE
by xx NE
gel xxx NE
mobility xxx NE
shift xxx NE
assays xxx NE
that xxx NE
IL-4 XX-d protein
induced xxx NE
a x NE
binding xxx NE
activity xxx NE
in xx NE
the xxx NE
cytosol xxx NE
and xxx NE
nucleus xxx NE
of xx NE
BL-2 XX-d cell_line_B
cells xxx cell_line_E
. . NE

This Xxxx NE
factor xxx NE
was xxx NE
designated xxx NE
IL-4 XX-d protein_B
NAF XXX protein_E
( ( NE
IL-4 XX-d NE
-induced -xxx NE
nuclear-activating xxx-xxx NE
factors xxx NE
) ) NE
and xxx NE
was xxx NE
identified xxx NE
as xx NE
a x NE
tyrosine xxx NE
phosphoprotein xxx NE
, , NE
which xxx NE
translocates xxx NE
from xxx NE
the xxx NE
cytosol xxx NE
to xx NE
the xxx NE
nucleus xxx NE
upon xxx NE
IL-4 XX-d NE
treatment xxx NE
. . NE

Because Xxxx NE
these xxx NE
are xxx NE
the xxx NE
characteristics xxx NE
of xx NE
a x NE
signal xxx protein_B
transducer xxx protein_M
and xxx protein_M
activator xxx protein_M
of xx protein_M
transcription xxx protein_M
(Stat) (Xxxx) protein_M
protein xxx protein_E
, , NE
we xx NE
determined xxx NE
whether xxx NE
antibodies xxx protein_B
to xx protein_M
Stat Xxxx protein_M
proteins xxx protein_E
will xxx NE
interfere xxx NE
with xxx NE
gel xxx NE
mobility xxx NE
shift xxx NE
and xxx NE
found xxx NE
that xxx NE
antibodies xxx protein_B
to xx protein_M
IL-4 XX-d protein_M
Stat Xxxx protein_E
, , NE
also xxx NE
known xxx NE
as xx NE
Stat6 Xxxxd protein
, , NE
but xxx NE
not xxx NE
antibodies xxx NE
to xx NE
other xxx NE
Stat Xxxx NE
proteins xxx NE
, , NE
interfere xxx NE
with xxx NE
the xxx NE
formation xxx NE
of xx NE
the xxx NE
IL-4 XX-d NE
NAF XXX NE
complex xxx NE
. . NE

Congruous Xxxx NE
with xxx NE
the xxx NE
involvement xxx NE
of xx NE
a x NE
Stat Xxxx protein_B
protein xxx protein_E
, , NE
IL-4 XX-d protein
induced xxx NE
robust xxx NE
Janus Xxxx NE
kinase xxx NE
3 d NE
( ( NE
JAK3 XXXd NE
) ) NE
activity xxx NE
in xx NE
BL-2 XX-d NE
cells xxx NE
. . NE

Cotransfection Xxxx NE
of xx NE
JAK3 XXXd protein
with xxx NE
IL-4 XX-d protein_B
Stat Xxxx protein_E
into xxx NE
COS-7 XXX-d cell_line_B
cells xxx cell_line_E
produced xxx NE
an xx NE
intracellular xxx NE
activity xxx NE
which xxx NE
bound xxx NE
the xxx NE
same xxx NE
IFN-gamma XXX-xxx DNA_B
activation xxx DNA_M
site-like xxx-xxx DNA_M
sequence xxx DNA_E
and xxx NE
comigrated xxx NE
with xxx NE
IL-4 XX-d protein_B
NAF XXX protein_E
in xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
. . NE

These Xxxx NE
results xxx NE
show xxx NE
that xxx NE
IL-4 XX-d protein_B
NAF XXX protein_E
is xx NE
IL-4 XX-d protein_B
Stat Xxxx protein_E
, , NE
which xxx NE
is xx NE
activated xxx NE
by xx NE
JAK3 XXXd protein
in xx NE
response xxx NE
to xx NE
IL-4 XX-d NE
receptor xxx NE
engagement xxx NE
. . NE

Does Xxxx NE
activation xxx NE
of xx NE
the xxx NE
TAL1 XXXd DNA_B
gene xxx DNA_E
occur xxx NE
in xx NE
a x NE
majority xxx NE
of xx NE
patients xxx NE
with xxx NE
T-cell X-xxx NE
acute xxx NE
lymphoblastic xxx NE
leukemia xxx NE
? ? NE
A X NE
pediatric xxx NE
oncology xxx NE
group xxx NE
study xxx NE
. . NE

Almost Xxxx NE
25% dd% NE
of xx NE
patients xxx NE
with xxx NE
T-cell X-xxx NE
acute xxx NE
lymphoblastic xxx NE
leukemia xxx NE
( ( NE
T-ALL X-XXX NE
) ) NE
have xxx NE
tumor-specific xxx-xxx NE
rearrangements xxx NE
of xx NE
the xxx NE
TAL1 XXXd DNA_B
gene xxx DNA_E
. . NE

Although Xxxx NE
TAL1 XXXd NE
expression xxx NE
has xxx NE
not xxx NE
been xxx NE
observed xxx NE
in xx NE
normal xxx cell_type_B
lymphocytes xxx cell_type_E
, , NE
TAL1 XXXd protein_B
gene xxx protein_M
products xxx protein_E
are xxx NE
readily xxx NE
detected xxx NE
in xx NE
leukemic xxx cell_type_B
cells xxx cell_type_E
that xxx NE
harbor xxx NE
a x NE
rearranged xxx DNA_B
TAL1 XXXd DNA_M
allele xxx DNA_E
. . NE

Hence Xxxx NE
, , NE
it xx NE
has xxx NE
been xxx NE
proposed xxx NE
that xxx NE
ectopic xxx NE
expression xxx NE
of xx NE
TAL1 XXXd protein
promotes xxx NE
the xxx NE
development xxx NE
of xx NE
T-ALL X-XXX NE
. . NE

In Xx NE
this xxx NE
report xxx NE
, , NE
we xx NE
show xxx NE
that xxx NE
TAL1 XXXd protein
is xx NE
expressed xxx NE
in xx NE
the xxx NE
leukemic xxx cell_type_B
cells xxx cell_type_E
of xx NE
most xxx NE
patients xxx NE
with xxx NE
T-ALL X-XXX NE
, , NE
including xxx NE
many xxx NE
that xxx NE
do xx NE
not xxx NE
display xxx NE
an xx NE
apparent xxx NE
TAL1 XXXd DNA_B
gene xxx DNA_E
alteration xxx NE
. . NE

A X NE
polymorphic xxx NE
dinucleotide xxx NE
repeat xxx NE
in xx NE
the xxx NE
transcribed xxx NE
sequences xxx NE
of xx NE
TAL1 XXXd protein
was xxx NE
used xxx NE
to xx NE
determine xxx NE
the xxx NE
allele xxx NE
specificity xxx NE
of xx NE
TAL1 XXXd protein
transcription xxx NE
in xx NE
primary xxx cell_type_B
T-ALL X-XXX cell_type_M
cells xxx cell_type_E
. . NE

Monoallelic Xxxx NE
expression xxx NE
of xx NE
TAL1 XXXd protein
was xxx NE
observed xxx NE
in xx NE
the xxx NE
leukemic xxx cell_type_B
cells xxx cell_type_E
of xx NE
all xxx NE
patients xxx NE
(8 (d NE
of xx NE
8) d) NE
bearing xxx NE
a x NE
TAL1 XXXd NE
gene xxx NE
rearrangement xxx NE
. . NE

In Xx NE
the xxx NE
leukemic xxx cell_type_B
cells xxx cell_type_E
of xx NE
patients xxx NE
without xxx NE
detectable xxx NE
TAL1 XXXd NE
rearrangements xxx NE
, , NE
TAL1 XXXd NE
transcription xxx NE
occurred xxx NE
in xx NE
either xxx NE
a x NE
monoallelic xxx NE
(3 (d NE
of xx NE
7 d NE
patients xxx NE
) ) NE
or xx NE
a x NE
biallelic xxx NE
(4 (d NE
of xx NE
7 d NE
patients xxx NE
) ) NE
fashion xxx NE
. . NE

Thus Xxxx NE
, , NE
TAL1 XXXd protein
activation xxx NE
in xx NE
these xxx NE
patients xxx NE
may xxx NE
result xxx NE
from xxx NE
subtle xxx NE
alterations xxx NE
in xx NE
cis-acting xxx-xxx DNA_B
regulatory xxx DNA_M
sequences xxx DNA_E
(affecting (xxx NE
expression xxx NE
of xx NE
a x NE
single xxx DNA_B
TAL1 XXXd DNA_M
allele xxx DNA_E
) ) NE
or xx NE
changes xxx NE
in xx NE
trans-acting xxx-xxx NE
factors xxx NE
that xxx NE
control xxx NE
TAL1 XXXd NE
transcription xxx NE
(affecting (xxx NE
expression xxx NE
of xx NE
both xxx NE
TAL1 XXXd DNA_B
alleles xxx DNA_E
) ) NE
. . NE

Expression Xxxx NE
of xx NE
erythroid-specific xxx-xxx DNA_B
genes xxx DNA_E
in xx NE
acute xxx NE
megakaryoblastic xxx NE
leukaemia xxx NE
and xxx NE
transient xxx NE
myeloproliferative xxx NE
disorder xxx NE
in xx NE
Down's Xxxx'x NE
syndrome xxx NE
. . NE

Acute Xxxx NE
megakaryoblastic xxx NE
leukaemia xxx NE
( ( NE
M7 Xd NE
) ) NE
and xxx NE
transient xxx NE
myeloproliferative xxx NE
disorder xxx NE
in xx NE
Down's Xxxx'x NE
syndrome xxx NE
( ( NE
TMD XXX NE
) ) NE
are xxx NE
characterized xxx NE
by xx NE
rapid xxx NE
growth xxx NE
of xx NE
abnormal xxx cell_type_B
blast xxx cell_type_M
cells xxx cell_type_E
which xxx NE
express xxx NE
megakaryocytic xxx protein_B
markers xxx protein_E
. . NE

To Xx NE
clarify xxx NE
properties xxx NE
of xx NE
the xxx NE
blast xxx cell_type_B
cells xxx cell_type_E
in xx NE
M7 Xd NE
and xxx NE
TMD XXX NE
cases xxx NE
, , NE
we xx NE
examined xxx NE
erythroid xxx NE
markers xxx NE
expression xxx NE
in xx NE
blasts xxx cell_type
from xxx NE
six xxx NE
cases xxx NE
with xxx NE
M7 Xd NE
and xxx NE
seven xxx NE
cases xxx NE
with xxx NE
TMD XXX NE
in xx NE
this xxx NE
study xxx NE
. . NE

Erythroid-specific Xxxx-xxx RNA_B
mRNAs xXXXx RNA_E
encoding xxx NE
gamma-globin xxx-xxx protein
and xxx NE
erythroid xxx protein_B
delta-aminolevulinate xxx-xxx protein_M
synthase xxx protein_E
were xxx NE
found xxx NE
to xx NE
be xx NE
expressed xxx NE
in xx NE
blasts xxx cell_type
from xxx NE
most xxx NE
of xx NE
these xxx NE
cases xxx NE
, , NE
indicating xxx NE
that xxx NE
majorities xxx NE
of xx NE
the xxx NE
blasts xxx cell_type
in xx NE
M7 Xd NE
and xxx NE
TMD XXX NE
cases xxx NE
have xxx NE
erythroid xxx NE
phenotype xxx NE
and xxx NE
megakaryocytic xxx NE
phenotype xxx NE

We Xx NE
also xxx NE
found xxx NE
that xxx NE
mRNAs xXXXx RNA
encoding xxx NE
GATA-1 XXXX-d protein
and xxx NE
GATA-2 XXXX-d protein
are xxx NE
expressed xxx NE
in xx NE
all xxx NE
these xxx NE
cases xxx NE
. . NE

These Xxxx NE
results xxx NE
suggest xxx NE
that xxx NE
M7 Xd cell_type_B
blasts xxx cell_type_E
and xxx NE
TMD XXX cell_type_B
blasts xxx cell_type_E
correspond xxx NE
to xx NE
the xxx NE
erythroid/megakaryocytic xxx/xxx cell_type_B
bipotential xxx cell_type_M
progenitor xxx cell_type_M
cells xxx cell_type_E
. . NE

Expression Xxxx NE
of xx NE
Ah Xx protein_B
receptor xxx protein_E
( ( NE
TCDD XXXX protein_B
receptor xxx protein_E
) ) NE
during xxx NE
human xxx NE
monocytic xxx NE
differentiation xxx NE
. . NE

We Xx NE
have xxx NE
previously xxx NE
found xxx NE
a x NE
high xxx NE
expression xxx NE
of xx NE
human xxx NE
Ah Xx NE
receptor xxx NE
( ( NE
TCDD XXXX NE
receptor xxx NE
) ) NE
mRNA xXXX NE
in xx NE
peripheral xxx NE
blood xxx NE
cells xxx NE
of xx NE
individuals xxx NE
. . NE

In Xx NE
this xxx NE
paper xxx NE
, , NE
the xxx NE
expression xxx NE
of xx NE
this xxx NE
gene xxx NE
in xx NE
blood xxx cell_type_B
cells xxx cell_type_E
was xxx NE
first xxx NE
investigated xxx NE
in xx NE
fractions xxx NE
of xx NE
nucleated xxx cell_type_B
cells xxx cell_type_E
, , NE
revealing xxx NE
predominant xxx NE
expression xxx NE
of xx NE
the xxx NE
Ah Xx DNA_B
receptor xxx DNA_M
gene xxx DNA_E
in xx NE
the xxx NE
monocyte xxx cell_type_B
fraction xxx cell_type_E
. . NE

Then Xxxx NE
the xxx NE
expression xxx NE
levels xxx NE
of xx NE
AhR XxX RNA_B
mRNA xXXX RNA_E
in xx NE
various xxx NE
hematopoietic xxx cell_line_B
cell xxx cell_line_M
lines xxx cell_line_E
were xxx NE
examined xxx NE
together xxx NE
with xxx NE
those xxx NE
of xx NE
Arnt Xxxx protein
and xxx NE
P450IA1 XdddXXd protein
. . NE

AhR XxX protein
was xxx NE
expressed xxx NE
at xx NE
high xxx NE
levels xxx NE
in xx NE
monocytoid xxx cell_line_B
U937 Xddd cell_line_E
, , NE
THP1 XXXd cell_line
, , NE
and xxx NE
HEL/S XXX/X cell_line_B
cells xxx cell_line_E
, , NE
and xxx NE
at xx NE
moderate xxx NE
levels xxx NE
in xx NE
promyelocytic xxx cell_line_B
HL60 XXdd cell_line_M
cells xxx cell_line_E
and xxx NE
erythroblastic xxx cell_line_B
HEL XXX cell_line_M
cells xxx cell_line_E
. . NE

However Xxxx NE
, , NE
it xx NE
was xxx NE
not xxx NE
detected xxx NE
in xx NE
lymphoid xxx cell_type_B
cells xxx cell_type_E
MOLT4 XXXXd cell_line
( ( NE
T X cell_type_B
cell xxx cell_type_E
) ) NE
and xxx NE
BALL1 XXXXd cell_line
( ( NE
B X cell_type_B
cell xxx cell_type_E
) ) NE
, , NE
nor xxx NE
in xx NE
K562 Xddd cell_line_B
erythroblasts xxx cell_line_E
. . NE

Furthermore Xxxx NE
, , NE
a x NE
specific xxx NE
induction xxx NE
of xx NE
AhR XxX protein
during xxx NE
monocytic xxx NE
differentiation xxx NE
was xxx NE
investigated xxx NE
in xx NE
HL60 XXdd cell_line
and xxx NE
HEL XXX cell_line_B
cells xxx cell_line_E
. . NE

HL60 XXdd cell_line_B
cells xxx cell_line_E
were xxx NE
induced xxx NE
to xx NE
differentiate xxx NE
toward xxx NE
monocytes-macrophages xxx-xxx cell_type
by xx NE
incubation xxx NE
with xxx NE
phorbol xxx NE
ester xxx NE
, , NE
showing xxx NE
a x NE
5- d- NE
to xx NE
2-fold d-xxx NE
increase xxx NE
of xx NE
AhR XxX RNA_B
mRNA xXXX RNA_E
. . NE

The Xxx NE
incubation xxx NE
with xxx NE
transforming xxx protein_B
growth xxx protein_M
factor xxx protein_M
beta xxx protein_M
1 d protein_E
and xxx NE
1 d NE
alpha,25-dihydroxyvitamin xxx,dd-xxx NE
D3 Xd NE
resulted xxx NE
in xx NE
a x NE
5- d- NE
to xx NE
7-fold d-xxx NE
increase xxx NE
of xx NE
AhR XxX RNA_B
mRNA xXXX RNA_E
. . NE

The Xxx NE
HEL XXX cell_line_B
cells xxx cell_line_E
also xxx NE
exhibited xxx NE
a x NE
similar xxx NE
elevation xxx NE
of xx NE
AhR XxX NE
mRNA xXXX NE
level xxx NE
, , NE
when xxx NE
they xxx NE
had xxx NE
differentiated xxx NE
toward xxx NE
monocyte-macrophage xxx-xxx cell_type_B
cells xxx cell_type_E
by xx NE
these xxx NE
combined xxx NE
inducers xxx NE
, , NE
but xxx NE
little xxx NE
change xxx NE
in xx NE
the xxx NE
mRNA xXXX NE
level xxx NE
was xxx NE
observed xxx NE
when xxx NE
the xxx NE
cells xxx NE
were xxx NE
induced xxx NE
to xx NE
differentiate xxx NE
into xxx NE
other xxx NE
cell xxx NE
types xxx NE
. . NE

Treatment Xxxx NE
of xx NE
the xxx NE
differentiated xxx cell_line_B
HL60 XXdd cell_line_M
cells xxx cell_line_E
with xxx NE
3-methylcholanthrene d-xxx NE
, , NE
a x NE
ligand xxx NE
of xx NE
AhR XxX protein
, , NE
induced xxx NE
the xxx NE
expression xxx NE
of xx NE
the xxx NE
P450IA1 XdddXXd protein
gene xxx NE
. . NE

These Xxxx NE
results xxx NE
indicated xxx NE
that xxx NE
expression xxx NE
of xx NE
AhR XxX RNA_B
mRNA xXXX RNA_E
was xxx NE
significantly xxx NE
induced xxx NE
during xxx NE
monocytic xxx NE
differentiation xxx NE
and xxx NE
that xxx NE
the xxx NE
differentiated xxx cell_type_B
cells xxx cell_type_E
were xxx NE
responsive xxx NE
to xx NE
xenobiotics xxx NE
. . NE

Our Xxx NE
results xxx NE
suggest xxx NE
that xxx NE
AhR XxX protein
may xxx NE
play xxx NE
an xx NE
important xxx NE
role xxx NE
in xx NE
the xxx NE
function xxx NE
of xx NE
monocytes xxx cell_type
and xxx NE
also xxx NE
in xx NE
the xxx NE
eventual xxx NE
activation xxx NE
of xx NE
environmental xxx NE
carcinogens xxx NE
. . NE

Neutrophils Xxxx cell_type
and xxx NE
monocytes xxx cell_type
express xxx NE
high xxx NE
levels xxx NE
of xx NE
PU.1 XX.d protein
( ( NE
Spi-1 Xxx-d protein
) ) NE
but xxx NE
not xxx NE
Spi-B Xxx-X protein
. . NE

PU.1 XX.d protein
(the (xxx NE
Spi-1 Xxx-d DNA_B
oncogene xxx DNA_E
) ) NE
and xxx NE
Spi-B Xxx-X protein
are xxx NE
closely xxx NE
related xxx NE
members xxx NE
of xx NE
the xxx NE
ets xxx protein_B
transcription xxx protein_M
factor xxx protein_M
family xxx protein_E
, , NE
sharing xxx NE
similar xxx NE
DNA XXX NE
binding xxx NE
specificities xxx NE
mediated xxx NE
by xx NE
similar xxx NE
DNA XXX NE
binding xxx NE
domains xxx NE
. . NE

PU.1 XX.d protein
and xxx NE
Spi-B Xxx-X protein
have xxx NE
been xxx NE
previously xxx NE
described xxx NE
as xx NE
being xxx NE
predominantly xxx NE
expressed xxx NE
coordinately xxx NE
in xx NE
macrophages xxx cell_type
and xxx NE
B X cell_type_B
cells xxx cell_type_E
, , NE
but xxx NE
their xxx NE
expression xxx NE
in xx NE
early xxx NE
hematopoietic xxx NE
stages xxx NE
and xxx NE
during xxx NE
the xxx NE
course xxx NE
of xx NE
myeloid xxx NE
differentiation xxx NE
to xx NE
monocytes xxx cell_type
and xxx NE
macrophages xxx cell_type
or xx NE
to xx NE
neutrophils xxx cell_type
has xxx NE
not xxx NE
been xxx NE
extensively xxx NE
investigated xxx NE
. . NE

Here Xxxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
PU.1 XX.d RNA_B
mRNA xXXX RNA_E
is xx NE
upregulated xxx NE
during xxx NE
myeloid xxx NE
differentiation xxx NE
of xx NE
human xxx cell_line_B
purified xxx cell_line_M
CD34+ XXdd+ cell_line_M
cells xxx cell_line_E
and xxx NE
murine xxx cell_line_B
multipotential xxx cell_line_M
FDCP-mix XXXX-xxx cell_line_M
A4 Xd cell_line_M
cells xxx cell_line_E
, , NE
suggesting xxx NE
that xxx NE
PU.1 XX.d protein
is xx NE
upregulated xxx NE
as xx NE
an xx NE
early xxx NE
event xxx NE
during xxx NE
differentiation xxx NE
of xx NE
multipotential xxx cell_type_B
progenitor xxx cell_type_M
cells xxx cell_type_E
. . NE

PU.1 XX.d protein
expression xxx NE
is xx NE
maintained xxx NE
at xx NE
stable xxx NE
levels xxx NE
during xxx NE
differentiation xxx NE
of xx NE
myeloid xxx cell_line_B
cell xxx cell_line_M
lines xxx cell_line_E
U937 Xddd NE
and xxx NE
HL-60 XX-dd cell_line
to xx NE
monocytic xxx cell_type_B
cell xxx cell_type_M
and xxx cell_type_M
neutrophilic xxx cell_type_M
cell xxx cell_type_E

PU.1 XX.d protein
is xx NE
expressed xxx NE
at xx NE
highest xxx NE
levels xxx NE
in xx NE
mature xxx cell_type_B
human xxx cell_type_M
monocytes xxx cell_type_E
and xxx NE
human xxx cell_type_B
peripheral xxx cell_type_M
blood xxx cell_type_M
neutrophils xxx cell_type_E
. . NE

In Xx NE
contrast xxx NE
to xx NE
PU.1 XX.d protein
, , NE
significant xxx NE
levels xxx NE
of xx NE
Spi-B Xxx-X RNA_B
mRNA xXXX RNA_E
and xxx NE
protein xxx NE
are xxx NE
found xxx NE
only xxx NE
in xx NE
some xxx NE
B-cell X-xxx cell_line_B
lines xxx cell_line_E
and xxx NE
spleen xxx NE
but xxx NE
are xxx NE
not xxx NE
found xxx NE
in xx NE
myeloid xxx cell_line_B
cell xxx cell_line_M
lines xxx cell_line_E
, , NE
neutrophils xxx cell_type
, , NE
or xx NE
macrophages xxx cell_type
. . NE

In Xx NE
vitro xxx NE
translated xxx NE
Spi-B Xxx-X protein_B
protein xxx protein_E
can xxx NE
bind xxx NE
to xx NE
PU.1 XX.d DNA_B
binding xxx DNA_M
sites xxx DNA_E
in xx NE
myeloid xxx DNA_B
promoters xxx DNA_E
and xxx NE
transactivate xxx NE
these xxx NE
promoters xxx DNA
in xx NE
nonmyeloid xxx cell_type_B
cells xxx cell_type_E
. . NE

Therefore Xxxx NE
, , NE
although xxx NE
PU.1 XX.d protein
and xxx NE
Spi-B Xxx-X protein
may xxx NE
bind xxx NE
to xx NE
similar xxx NE
DNA XXX NE
control xxx NE
elements xxx NE
and xxx NE
have xxx NE
redundancy xxx NE
of xx NE
transactivation xxx NE
function xxx NE
in xx NE
vitro xxx NE
, , NE
the xxx NE
lack xxx NE
of xx NE
significant xxx NE
levels xxx NE
of xx NE
Spi-B Xxx-X protein
in xx NE
myeloid xxx cell_type_B
cells xxx cell_type_E
makes xxx NE
it xx NE
unlikely xxx NE
that xxx NE
Spi-B Xxx-X protein
plays xxx NE
a x NE
significant xxx NE
role xxx NE
in xx NE
myeloid xxx NE
lineage xxx NE
development xxx NE
and xxx NE
gene xxx NE
expression xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
PU.1 XX.d protein
is xx NE
expressed xxx NE
at xx NE
high xxx NE
levels xxx NE
not xxx NE
only xxx NE
in xx NE
monocytes xxx cell_type
and xxx NE
macrophages xxx cell_type
but xxx NE
also xxx NE
in xx NE
neutrophils xxx cell_type
, , NE
indicating xxx NE
that xxx NE
PU.1 XX.d protein
can xxx NE
activate xxx NE
gene xxx NE
expression xxx NE
in xx NE
both xxx NE
major xxx cell_type_B
myeloid xxx cell_type_M
lineages xxx cell_type_E
. . NE

Identification Xxxx NE
of xx NE
a x NE
major xxx NE
positive xxx DNA_B
regulatory xxx DNA_M
element xxx DNA_E
located xxx NE
5' d' NE
to xx NE
the xxx NE
human xxx DNA_B
zeta-globin xxx-xxx DNA_M
gene xxx DNA_E
. . NE

The Xxx NE
function xxx NE
of xx NE
the xxx NE
zeta-globin xxx-xxx DNA_B
promoter xxx DNA_E
was xxx NE
studied xxx NE
using xxx NE
a x NE
series xxx NE
of xx NE
zeta-globin xxx-xxx DNA_B
promoter xxx DNA_M
deletion xxx DNA_M
constructs xxx DNA_E
to xx NE
drive xxx NE
luciferase xxx NE
expression xxx NE
in xx NE
transiently xxx cell_line_B
transfected xxx cell_line_M
human xxx cell_line_M
erythroleukemia xxx cell_line_M
cells xxx cell_line_E
. . NE

The Xxx NE
promoters xxx DNA
were xxx NE
used xxx NE
without xxx NE
enhancers xxx DNA
, , NE
or xx NE
with xxx NE
enhancers xxx DNA
derived xxx NE
from xxx NE
the xxx NE
beta-globin xxx-xxx DNA_B
locus xxx DNA_M
control xxx DNA_M
region xxx DNA_E
and xxx NE
the xxx NE
alpha-globin xxx-xxx DNA_B
HS-40 XX-dd DNA_M
enhancer xxx DNA_E
. . NE

When Xxxx NE
transfected xxx NE
into xxx NE
K562 Xddd cell_line_B
cells xxx cell_line_E
, , NE
which xxx NE
express xxx NE
zeta-globin xxx-xxx protein
, , NE
comparable xxx NE
amounts xxx NE
of xx NE
activity xxx NE
were xxx NE
obtained xxx NE
from xxx NE
the xxx NE
-557 -ddd DNA_B
and xxx DNA_M
-417 -ddd DNA_M
zeta- xxx- DNA_M
luciferase xxx DNA_M
constructs xxx DNA_E
and xxx NE
the xxx NE
alpha- xxx- NE
luciferase xxx NE
constructs xxx NE
when xxx NE
no xx NE
enhancers xxx NE
or xx NE
the xxx NE
alpha-globin xxx-xxx NE
locus xxx NE
enhancers xxx NE
were xxx NE
used xxx NE
. . NE

When Xxxx NE
the xxx NE
constructs xxx NE
were xxx NE
transfected xxx NE
into xxx NE
OCIM1 XXXXd cell_line_B
cells xxx cell_line_E
, , NE
which xxx NE
do xx NE
not xxx NE
express xxx NE
zeta-globin xxx-xxx protein
, , NE
the xxx NE
zeta-globin xxx-xxx DNA_B
promoters xxx DNA_E
were xxx NE
at xx NE
best xxx NE
20% dd% NE
as xx NE
active xxx NE
as xx NE
the xxx NE
alpha-globin xxx-xxx DNA_B
promoters xxx DNA_E
. . NE

When Xxxx NE
sequences xxx DNA_B
from xxx DNA_M
-417 -ddd DNA_M
to xx DNA_M
-207 -ddd DNA_M
5' d' DNA_E
to xx NE
the xxx NE
zeta-globin xxx-xxx RNA_B
mRNA xXXX RNA_M
cap xxx RNA_M
site xxx RNA_E
were xxx NE
deleted xxx NE
, , NE
up xx NE
to xx NE
95% dd% NE
of xx NE
the xxx NE
zeta-globin xxx-xxx DNA_B
promoter xxx DNA_E
activity xxx NE
was xxx NE
lost xxx NE
in xx NE
K562 Xddd cell_line_B
cells xxx cell_line_E
. . NE

Reinsertion Xxxx NE
of xx NE
these xxx NE
sequences xxx NE
into xxx NE
zeta- xxx- NE
luciferase xxx NE
constructs xxx NE
missing xxx NE
the xxx NE
-417 -ddd NE
to xx NE
-207 -ddd NE
region xxx NE
showed xxx NE
that xxx NE
the xxx NE
sequences xxx NE
lack xxx NE
classical xxx NE
enhancer xxx NE
activity xxx NE
. . NE

Point Xxxx NE
mutation xxx NE
of xx NE
a x NE
GATA-1 XXXX-d DNA_B
site xxx DNA_E
at xx NE
-230 -ddd NE
reduced xxx NE
promoter xxx NE
activity xxx NE
by xx NE
37% dd% NE
. . NE

Point Xxxx NE
mutation xxx NE
of xx NE
a x NE
CCACC XXXXX DNA_B
site xxx DNA_E
at xx NE
-240 -ddd NE
had xxx NE
no xx NE
effect xxx NE
. . NE

Electrophoretic Xxxx NE
mobility xxx NE
shift xxx NE
assays xxx NE
indicated xxx NE
that xxx NE
the xxx NE
-230 -ddd DNA_B
GATA-1 XXXX-d DNA_M
site xxx DNA_E
has xxx NE
a x NE
relatively xxx NE
low xxx NE
affinity xxx NE
for xxx NE
GATA-1 XXXX-d protein
. . NE

These Xxxx NE
experiments xxx NE
show xxx NE
the xxx NE
presence xxx NE
of xx NE
a x NE
strong xxx NE
positive-acting xxx-xxx DNA_B
element xxx DNA_E
, , NE
located xxx NE
between xxx NE
-417 -ddd DNA_B
and xxx DNA_M
-207 -ddd DNA_M
bp xx DNA_M
5' d' DNA_E
to xx NE
the xxx NE
zeta-globin xxx-xxx DNA_B
mRNA xXXX DNA_M
cap xxx DNA_M
site xxx DNA_E
, , NE
is xx NE
necessary xxx NE
for xxx NE
high-level xxx-xxx NE
promoter xxx NE
activity xxx NE
in xx NE
K562 Xddd cell_line_B
cells xxx cell_line_E
. . NE

This Xxxx NE
element xxx NE
requires xxx NE
GATA-1 XXXX-d protein
and xxx NE
additional xxx protein_B
unknown xxx protein_M
factors xxx protein_E
for xxx NE
maximal xxx NE
activity xxx NE
. . NE

Analysis Xxxx NE
of xx NE
the xxx NE
role xxx NE
of xx NE
protein xxx protein_B
kinase xxx protein_M
C-alpha X-xxx protein_M
and xxx protein_M
protein xxx protein_M
kinase xxx protein_M
C-epsilon X-xxx protein_M
and xxx protein_M
protein xxx protein_M
kinase xxx protein_M
C-zeta X-xxx protein_E
T X NE
cell xxx NE
activation xxx NE
. . NE

T X cell_type_B
cells xxx cell_type_E
express xxx NE
multiple xxx NE
isotypes xxx NE
of xx NE
protein xxx protein_B
kinase xxx protein_M
C X protein_E
( ( NE
PKC XXX protein
) ) NE
and xxx NE
although xxx NE
it xx NE
is xx NE
well xxx NE
accepted xxx NE
that xxx NE
PKCs XXXx protein
have xxx NE
an xx NE
important xxx NE
role xxx NE
in xx NE
T X NE
cell xxx NE
activation xxx NE
, , NE
little xxx NE
is xx NE
known xxx NE
about xxx NE
the xxx NE
function xxx NE
of xx NE
individual xxx NE
PKC XXX protein_B
isotypes xxx protein_E
. . NE

To Xx NE
address xxx NE
this xxx NE
issue xxx NE
, , NE
mutationally xxx NE
active xxx NE
PKC-alpha XXX-xxx protein_B
or xx protein_M
PKC-epsilon XXX-xxx protein_M
or xx protein_M
PKC-zeta XXX-xxx protein_E
have xxx NE
been xxx NE
transfected xxx NE
into xxx NE
T X cell_type_B
cells xxx cell_type_E
and xxx NE
the xxx NE
consequences xxx NE
for xxx NE
T X NE
cell xxx NE
activation xxx NE
determined xxx NE
. . NE

p21ras xddxxx protein
plays xxx NE
an xx NE
essential xxx NE
role xxx NE
in xx NE
T X NE
cell xxx NE
activation xxx NE
. . NE

Accordingly Xxxx NE
, , NE
the xxx NE
effects xxx NE
of xx NE
the xxx NE
constitutively xxx protein_B
active xxx protein_M
PKCs XXXx protein_E
were xxx NE
compared xxx NE
to xx NE
the xxx NE
effects xxx NE
of xx NE
mutationally xxx NE
activated xxx NE
p21ras xddxxx protein
. . NE

The Xxx NE
data xxx NE
indicate xxx NE
that xxx NE
PKC-epsilon XXX-xxx protein
and xxx NE
, , NE
to xx NE
a x NE
lesser xxx NE
extent xxx NE
PKC-alpha XXX-xxx protein
but xxx NE
not xxx NE
-zeta -xxx NE
, , NE
can xxx NE
regulate xxx NE
the xxx NE
transcription xxx NE
factors xxx NE
AP-1 XX-d NE
and xxx NE
nuclear xxx NE
factor xxx NE
of xx NE
activated xxx NE
T X NE
cells xxx NE
( ( NE
NF-AT-1 XX-XX-d NE
) ) NE
. . NE

The Xxx NE
ability xxx NE
of xx NE
PKC-epsilon XXX-xxx protein
to xx NE
induce xxx NE
transactivation xxx NE
of xx NE
NF-AT-1 XX-XX-d protein
and xxx NE
AP-1 XX-d protein
was xxx NE
similar xxx NE
to xx NE
the xxx NE
stimulatory xxx NE
effect xxx NE
of xx NE
a x NE
constitutively xxx protein_B
activated xxx protein_M
p21ras xddxxx protein_E
. . NE

PKC-epsilon XXX-xxx protein
, , NE
but xxx NE
not xxx NE
PKC-alpha XXX-xxx protein
nor xxx NE
activated xxx NE
p21ras xddxxx protein
, , NE
was xxx NE
able xxx NE
to xx NE
induce xxx NE
NF-KB XX-XX NE
activity xxx NE
. . NE

Phorbol Xxxx NE
esters xxx NE
induce xxx NE
expression xxx NE
of xx NE
CD69 XXdd protein
whereas xxx NE
none xxx NE
of xx NE
the xxx NE
activated xxx protein_B
PKC XXX protein_M
isotypes xxx protein_E
tested xxx NE
were xxx NE
able xxx NE
to xx NE
have xxx NE
this xxx NE
effect xxx NE
. . NE

Activated Xxxx NE
Src Xxx protein
and xxx NE
p21ras xddxxx protein
were xxx NE
able xxx NE
to xx NE
induce xxx NE
CD69 XXdd NE
expression xxx NE
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
selective xxx NE
functions xxx NE
for xxx NE
different xxx NE
PKC XXX protein_B
isotypes xxx protein_E
in xx NE
T X cell_type_B
cells xxx cell_type_E
. . NE

Moreover Xxxx NE
, , NE
the xxx NE
data xxx NE
comparing xxx NE
the xxx NE
effects xxx NE
of xx NE
activated xxx protein_B
Ras Xxx protein_E
and xxx NE
PKC XXX protein_B
mutants xxx protein_E
suggest xxx NE
that xxx NE
PKC-alpha XXX-xxx protein
, , NE
p21ras xddxxx protein
, , NE
and xxx NE
PKC-epsilon XXX-xxx protein
are xxx NE
not xxx NE
positioned xxx NE
linearly xxx NE
on xx NE
a x NE
single xxx NE
signal xxx NE
transduction xxx NE
pathway xxx NE
. . NE

Differences Xxxx NE
in xx NE
binding xxx NE
of xx NE
glucocorticoid xxx protein_B
receptor xxx protein_E
to xx NE
DNA XXX NE
in xx NE
steroid-resistant xxx-xxx NE
asthma xxx NE
. . NE

Although Xxxx NE
glucocorticosteroids xxx NE
are xxx NE
a x NE
very xxx NE
effective xxx NE
treatment xxx NE
for xxx NE
asthma xxx NE
and xxx NE
other xxx NE
chronic xxx NE
inflammatory xxx NE
diseases xxx NE
, , NE
a x NE
small xxx NE
proportion xxx NE
of xx NE
patients xxx NE
are xxx NE
resistant xxx NE
to xx NE
their xxx NE
therapeutic xxx NE
effects xxx NE
. . NE

The Xxx NE
molecular xxx NE
mechanism xxx NE
for xxx NE
this xxx NE
steroid xxx NE
resistance xxx NE
is xx NE
unclear xxx NE
. . NE

Steroid Xxxx NE
resistance xxx NE
cannot xxx NE
be xx NE
explained xxx NE
by xx NE
pharmacokinetic xxx NE
mechanisms xxx NE
, , NE
by xx NE
a x NE
defect xxx NE
in xx NE
the xxx NE
binding xxx NE
of xx NE
steroids xxx NE
to xx NE
glucocorticoid xxx protein_B
receptors xxx protein_E
, , NE
nor xxx NE
by xx NE
defective xxx NE
nuclear xxx NE
translocation xxx NE
of xx NE
this xxx NE
receptor xxx NE
, , NE
thereby xxx NE
suggesting xxx NE
that xxx NE
the xxx NE
molecular xxx NE
abnormality xxx NE
lies xxx NE
distal xxx NE
to xx NE
nuclear xxx NE
translocation xxx NE
. . NE

We Xx NE
examined xxx NE
the xxx NE
ability xxx NE
of xx NE
nuclear xxx NE
translocated xxx NE
glucocorticoid xxx protein_B
receptors xxx protein_E
to xx NE
bind xxx NE
to xx NE
their xxx NE
DNA XXX DNA_B
binding xxx DNA_M
sites xxx DNA_E
( ( NE
GRE XXX DNA
) ) NE
using xxx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assays xxx NE
in xx NE
PBMC XXXX cell_type
from xxx NE
patients xxx NE
with xxx NE
steroid-sensitive xxx-xxx NE
and xxx NE
steroid-resistant xxx-xxx NE
asthma xxx NE
. . NE

The Xxx NE
binding xxx NE
of xx NE
the xxx NE
glucocorticoid xxx protein_B
receptor xxx protein_E
to xx NE
DNA XXX NE
in xx NE
these xxx NE
patients xxx NE
was xxx NE
also xxx NE
studied xxx NE
using xxx NE
Scatchard Xxxx NE
analysis xxx NE
. . NE

Dexamethasone Xxxx NE
induced xxx NE
a x NE
significant xxx NE
rapid xxx NE
and xxx NE
sustained xxx NE
twofold xxx NE
increase xxx NE
in xx NE
GRE XXX NE
binding xxx NE
in xx NE
PBMCs XXXXx cell_type
from xxx NE
steroid-sensitive xxx-xxx NE
asthmatic xxx NE
patients xxx NE
and xxx NE
nonasthmatic xxx NE
individuals xxx NE
, , NE
but xxx NE
this xxx NE
was xxx NE
markedly xxx NE
reduced xxx NE
in xx NE
steroid-resistant xxx-xxx NE
asthmatic xxx NE
patients xxx NE
. . NE

Scatchard Xxxx NE
analysis xxx NE
of xx NE
glucocorticoid xxx protein_B
receptor xxx protein_E
- - NE
GRE XXX NE
binding xxx NE
showed xxx NE
no xx NE
change xxx NE
in xx NE
binding xxx NE
affinity xxx NE
but xxx NE
did xxx NE
show xxx NE
a x NE
reduced xxx NE
number xxx NE
of xx NE
receptors xxx protein
available xxx NE
for xxx NE
DNA XXX NE
binding xxx NE
in xx NE
the xxx NE
steroid-resistant xxx-xxx NE
patients xxx NE
. . NE

These Xxxx NE
results xxx NE
suggest xxx NE
that xxx NE
the xxx NE
ability xxx NE
of xx NE
the xxx NE
glucocorticoid xxx protein_B
receptor xxx protein_E
to xx NE
bind xxx NE
to xx NE
GRE XXX DNA
is xx NE
impaired xxx NE
in xx NE
steroid-resistant xxx-xxx NE
patients xxx NE
because xxx NE
of xx NE
a x NE
reduced xxx NE
number xxx NE
of xx NE
receptors xxx protein
available xxx NE
for xxx NE
binding xxx NE
to xx NE
DNA XXX NE
. . NE

Interleukin-5 Xxxx-d NE
signaling xxx NE
in xx NE
human xxx cell_type_B
eosinophils xxx cell_type_E
involves xxx NE
JAK2 XXXd protein_B
tyrosine xxx protein_M
kinase xxx protein_E
and xxx NE
Stat1 Xxxxd protein_B
alpha xxx protein_E
. . NE

Signaling Xxxx NE
by xx NE
a x NE
wide xxx NE
variety xxx NE
of xx NE
cytokines xxx protein
, , NE
including xxx NE
interferons xxx protein
, , NE
interleukins xxx protein
, , NE
and xxx NE
growth xxx protein_B
factors xxx protein_E
, , NE
involves xxx NE
activation xxx NE
of xx NE
JAK XXX protein_B
kinases xxx protein_E
and xxx NE
Stat Xxxx NE
( ( NE
Signal Xxxx NE
transducers xxx NE
and xxx NE
activators xxx NE
of xx NE
transcription xxx NE
) ) NE
proteins xxx NE
. . NE

At Xx NE
present xxx NE
, , NE
not xxx NE
much xxx NE
is xx NE
known xxx NE
about xxx NE
the xxx NE
molecular xxx NE
mechanisms xxx NE
by xx NE
which xxx NE
interleukin-5 xxx-d protein
( ( NE
IL-5 XX-d protein
) ) NE
exerts xxx NE
its xxx NE
diverse xxx NE
biologic xxx NE
effects xxx NE
. . NE

Human Xxxx cell_type_B
eosinophils xxx cell_type_E
are xxx NE
one xxx NE
of xx NE
the xxx NE
most xxx NE
important xxx NE
target xxx cell_type_B
cells xxx cell_type_E
for xxx NE
IL-5 XX-d protein
and xxx NE
were xxx NE
used xxx NE
here xxx NE
to xx NE
study xxx NE
IL-5 XX-d NE
signaling xxx NE
in xx NE
a x NE
primary xxx cell_type_B
human xxx cell_type_M
cell xxx cell_type_E
. . NE

IL-5 XX-d protein
induced xxx NE
rapid xxx NE
and xxx NE
transient xxx NE
tyrosine xxx NE
phosphorylation xxx NE
of xx NE
JAK2 XXXd protein
. . NE

Moreover Xxxx NE
, , NE
IL-5 XX-d protein
induced xxx NE
at xx NE
least xxx NE
two xxx NE
DNA-binding XXX-xxx NE
complexes xxx NE
, , NE
using xxx NE
nuclear xxx NE
extracts xxx NE
from xxx NE
normal xxx NE
human xxx NE
eosinophils xxx NE
and xxx NE
the xxx NE
IL-6/interferon-gamma XX-d/xxx-xxx NE
response xxx NE
element xxx NE
of xx NE
the xxx NE
ICAM-1 XXXX-d NE
promoter xxx NE
( ( NE
ICAM-1 XXXX-d NE
pIRE xXXX NE
) ) NE
in xx NE
an xx NE
electromobility xxx NE
shift xxx NE
assay xxx NE
. . NE

From Xxxx NE
supershift xxx NE
experiments xxx NE
it xx NE
was xxx NE
concluded xxx NE
that xxx NE
one xxx NE
DNA-binding XXX-xxx protein_B
complex xxx protein_E
contained xxx NE
Stat1 Xxxxd protein_B
alpha xxx protein_E
, , NE
probably xxx NE
as xx NE
a x NE
homodimer xxx NE
. . NE

Both Xxxx NE
DNA-binding XXX-xxx NE
complexes xxx NE
were xxx NE
inhibited xxx NE
by xx NE
a x NE
phosphotyrosine xxx NE
antibody xxx NE
( ( NE
4G10 dXdd NE
) ) NE
, , NE
suggesting xxx NE
that xxx NE
tyrosine xxx NE
phosphorylation xxx NE
is xx NE
required xxx NE
for xxx NE
complex xxx NE
formation xxx NE
. . NE

IL-3 XX-d protein
and xxx NE
granulocyte-macrophage xxx-xxx protein_B
colony-stimulating xxx-xxx protein_M
factor xxx protein_E
induced xxx NE
, , NE
similar xxx NE
to xx NE
IL-5 XX-d protein
, , NE
two xxx NE
DNA-binding XXX-xxx NE
complexes xxx NE
in xx NE
human xxx NE
eosinophils xxx NE
, , NE
including xxx NE
Stat1 Xxxxd NE
alpha xxx NE
. . NE

These Xxxx NE
data xxx NE
show xxx NE
for xxx NE
the xxx NE
first xxx NE
time xxx NE
that xxx NE
molecular xxx NE
mechanisms xxx NE
of xx NE
IL-5 XX-d NE
signaling xxx NE
in xx NE
human xxx cell_type_B
eosinophils xxx cell_type_E
involve xxx NE
members xxx NE
of xx NE
the xxx NE
JAK XXX protein_B
kinase xxx protein_M
family xxx protein_E
as xx NE
well xxx NE
as xx NE
members xxx NE
of xx NE
the xxx NE
Stat Xxxx protein_B
family xxx protein_E
. . NE

Infection Xxxx NE
and xxx NE
replication xxx NE
of xx NE
Tat- Xxx- NE
human xxx NE
immunodeficiency xxx NE
viruses xxx NE
: : NE
genetic xxx NE
analyses xxx NE
of xx NE
LTR XXX DNA
and xxx NE
tat xxx protein_B
mutations xxx protein_E
in xx NE
primary xxx cell_type_B
human xxx cell_type_M
lymphoid xxx cell_type_M
cell xxx cell_type_M
and xxx cell_type_M
long-term xxx-xxx cell_type_M
human xxx cell_type_M
lymphoid xxx cell_type_M
cell xxx cell_type_E

Tat Xxx protein
is xx NE
an xx NE
essential xxx NE
regulatory xxx protein_B
protein xxx protein_E
for xxx NE
the xxx NE
replication xxx NE
of xx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
( ( NE
HIV XXX NE
) ) NE
. . NE

Mutations Xxxx NE
in xx NE
the xxx NE
tat xxx DNA_B
gene xxx DNA_E
have xxx NE
been xxx NE
shown xxx NE
to xx NE
block xxx NE
HIV XXX NE
replication xxx NE
in xx NE
human xxx cell_type_B
T X cell_type_M
cells xxx cell_type_E
. . NE

Several Xxxx NE
studies xxx NE
have xxx NE
established xxx NE
that xxx NE
Tat Xxx protein
releases xxx NE
an xx NE
elongation xxx protein_B
block xxx protein_E
to xx NE
the xxx NE
transcription xxx NE
of xx NE
HIV XXX DNA_B
long xxx DNA_M
terminal xxx DNA_M
repeat xxx DNA_E
( ( NE
LTR XXX DNA
) ) NE
; ; NE
however xxx NE
, , NE
it xx NE
is xx NE
not xxx NE
known xxx NE
whether xxx NE
this xxx NE
mechanism xxx NE
alone xxx NE
is xx NE
sufficient xxx NE
to xx NE
explain xxx NE
the xxx NE
block xxx NE
to xx NE
HIV XXX NE
replication xxx NE
in xx NE
human xxx cell_type_B
T X cell_type_M
cells xxx cell_type_E
when xxx NE
Tat Xxx protein
is xx NE
absent xxx NE
. . NE

It Xx NE
is xx NE
possible xxx NE
that xxx NE
Tat Xxx protein
is xx NE
also xxx NE
needed xxx NE
for xxx NE
other xxx NE
functions xxx NE
during xxx NE
HIV XXX NE
replication xxx NE
. . NE

To Xx NE
test xxx NE
these xxx NE
hypotheses xxx NE
, , NE
we xx NE
studied xxx NE
several xxx NE
tat xxx protein_B
mutants xxx protein_E
, , NE
including xxx NE
two xxx NE
stop xxx protein_B
codon xxx protein_M
mutants xxx protein_E
and xxx NE
one xxx NE
deletion xxx protein_B
mutant xxx protein_E
using xxx NE
replication-competent xxx-xxx DNA_B
HIV-1 XXX-d DNA_M
constructs xxx DNA_E
carrying xxx NE
wild-type xxx-xxx DNA_B
LTR XXX DNA_M
or xx DNA_M
mutant xxx DNA_M
LTR XXX DNA_E
with xxx NE
modifications xxx NE
in xx NE
the xxx NE
NF-kappa XX-xxx DNA_B
B X DNA_M
binding xxx DNA_M
site xxx DNA_M
and/or xxx/xx DNA_M
Sp1 Xxd DNA_M
binding xxx DNA_M
site xxx DNA_E

In Xx NE
this xxx NE
study xxx NE
, , NE
we xx NE
show xxx NE
that xxx NE
Tat- Xxx- NE
HIV-1 XXX-d NE
with xxx NE
wild-type xxx-xxx DNA_B
LTRs XXXx DNA_E
can xxx NE
replicate xxx NE
in xx NE
HeLa XxXx cell_line_B
cells xxx cell_line_E
, , NE
and xxx NE
the xxx NE
virus xxx NE
produced xxx NE
from xxx NE
HeLa XxXx cell_line_B
cells xxx cell_line_E
can xxx NE
infect xxx NE
primary xxx NE
peripheral xxx cell_type_B
blood xxx cell_type_M
lymphocytes xxx cell_type_E
and xxx NE
macrophages xxx cell_type
. . NE

It Xx NE
was xxx NE
found xxx NE
that xxx NE
the xxx NE
propagation xxx NE
of xx NE
the xxx NE
Tat Xxx protein_B
mutants xxx protein_E
containing xxx NE
wild-type xxx-xxx DNA_B
LTRs XXXx DNA_E
was xxx NE
less xxx NE
efficient xxx NE
than xxx NE
that xxx NE
of xx NE
the xxx NE
LTR-modified XXX-xxx protein_B
Tat Xxx protein_M
mutants xxx protein_E
. . NE

Large Xxxx NE
amounts xxx NE
of xx NE
viral xxx RNA_B
RNA XXX RNA_E
and xxx NE
particles xxx NE
were xxx NE
synthesized xxx NE
in xx NE
infections xxx NE
established xxx NE
using xxx NE
the xxx NE
tat xxx protein_B
mutants xxx protein_E
that xxx NE
contain xxx NE
modified xxx DNA_B
LTRs XXXx DNA_E
. . NE

However Xxxx NE
, , NE
this xxx NE
efficient xxx NE
propagation xxx NE
of xx NE
the xxx NE
LTR-modified XXX-xxx protein_B
tat xxx protein_M
mutants xxx protein_E
was xxx NE
restricted xxx NE
to xx NE
some xxx NE
lymphoid xxx cell_line_B
cell xxx cell_line_M
lines xxx cell_line_E
that xxx NE
have xxx NE
been xxx NE
transformed xxx NE
with xxx NE
other xxx NE
viruses xxx NE
. . NE

Thus Xxxx NE
, , NE
despite xxx NE
its xxx NE
essential xxx NE
role xxx NE
for xxx NE
releasing xxx NE
an xx NE
elongation xxx protein_B
block xxx protein_E
, , NE
Tat Xxx protein
is xx NE
not xxx NE
otherwise xxx NE
absolutely xxx NE
required xxx NE
for xxx NE
synthesis xxx NE
of xx NE
full-length xxx-xxx RNA_B
HIV XXX RNA_M
transcripts xxx RNA_E
and xxx NE
assembly xxx NE
of xx NE
virus xxx NE
particles xxx NE
. . NE

Direct Xxxx NE
sequencing xxx NE
of xx NE
the xxx NE
viral xxx DNA_B
genomes xxx DNA_E
and xxx NE
reinfection xxx NE
kinetics xxx NE
showed xxx NE
no xx NE
evidence xxx NE
of xx NE
wild-type xxx-xxx NE
reversion xxx NE
even xxx NE
after xxx NE
prolonged xxx NE
infection xxx NE
with xxx NE
the xxx NE
Tat Xxx NE
-virus -xxx NE
. . NE

The Xxx NE
implications xxx NE
for xxx NE
in xx NE
vivo xxx NE
HIV-1 XXX-d NE
replication xxx NE
and xxx NE
potential xxx NE
application xxx NE
of xx NE
this xxx NE
system xxx NE
to xx NE
the xxx NE
study xxx NE
of xx NE
alternative xxx NE
Tat Xxx NE
function xxx NE
are xxx NE
discussed xxx NE
. . NE

Functional Xxxx NE
roles xxx NE
of xx NE
the xxx NE
transcription xxx protein_B
factor xxx protein_M
Oct-2A Xxx-dX protein_E
and xxx NE
the xxx NE
high xxx protein_B
mobility xxx protein_M
group xxx protein_M
protein xxx protein_E
I/Y X/X protein
in xx NE
HLA-DRA XXX-XXX NE
gene xxx NE
expression xxx NE
. . NE

The Xxx NE
class xxx DNA_B
II XX DNA_M
major xxx DNA_M
histocompatibility xxx DNA_M
complex xxx DNA_M
gene xxx DNA_E
HLA-DRA XXX-XXX DNA
is xx NE
expressed xxx NE
in xx NE
B X cell_type_B
cells xxx cell_type_E
, , NE
activated xxx NE
T X cell_type_B
lymphocytes xxx cell_type_E
, , NE
and xxx NE
in xx NE
antigen-presenting xxx-xxx cell_type_B
cells xxx cell_type_E
. . NE

In Xx NE
addition xxx NE
, , NE
HLA-DRA XXX-XXX NE
gene xxx NE
expression xxx NE
is xx NE
inducible xxx NE
in xx NE
a x NE
variety xxx NE
of xx NE
cell xxx NE
types xxx NE
by xx NE
interferon-gamma xxx-xxx protein
( ( NE
IFN-gamma XXX-xxx protein
) ) NE
. . NE

Here Xxxx NE
we xx NE
show xxx NE
that xxx NE
the xxx NE
lymphoid-specific xxx-xxx protein_B
transcription xxx protein_M
factor xxx protein_M
Oct-2A Xxx-dX protein_E
plays xxx NE
a x NE
critical xxx NE
role xxx NE
in xx NE
HLA-DRA XXX-XXX NE
gene xxx NE
expression xxx NE
in xx NE
class xxx cell_line_B
II-positive XX-xxx cell_line_M
B X cell_line_M
cell xxx cell_line_M
lines xxx cell_line_E
, , NE
and xxx NE
that xxx NE
the xxx NE
high xxx protein_B
mobility xxx protein_M
group xxx protein_M
protein xxx protein_E
( ( NE
HMG XXX protein
) ) NE
I/Y X/X protein
binds xxx NE
to xx NE
multiple xxx NE
sites xxx NE
within xxx NE
the xxx NE
DRA XXX DNA_B
promoter xxx DNA_E
, , NE
including xxx NE
the xxx NE
Oct-2A Xxx-dX DNA_B
binding xxx DNA_M
site xxx DNA_E
. . NE

Coexpression Xxxx NE
of xx NE
HMG XXX protein_B
I/Y X/X protein_E
and xxx NE
Oct-2 Xxx-d protein
in xx NE
cell xxx cell_line_B
lines xxx cell_line_E
lacking xxx NE
Oct-2 Xxx-d protein
results xxx NE
in xx NE
high xxx NE
levels xxx NE
of xx NE
HLA-DRA XXX-XXX NE
gene xxx NE
expression xxx NE
, , NE
and xxx NE
in xx NE
vitro xxx NE
DNA-binding XXX-xxx NE
studies xxx NE
reveal xxx NE
that xxx NE
HMG XXX NE
I/Y X/X protein
stimulates xxx NE
Oct-2A Xxx-dX NE
binding xxx NE
to xx NE
the xxx NE
HLA-DRA XXX-XXX DNA_B
promoter xxx DNA_E
. . NE

Thus Xxxx NE
, , NE
Oct-2A Xxx-dX protein
and xxx NE
HMG XXX protein_B
I/Y X/X protein_E
may xxx NE
synergize xxx NE
to xx NE
activate xxx NE
HLA-DRA XXX-XXX NE
expression xxx NE
in xx NE
B X cell_type_B
cells xxx cell_type_E
. . NE

By Xx NE
contrast xxx NE
, , NE
Oct-2A Xxx-dX protein
is xx NE
not xxx NE
involved xxx NE
in xx NE
the xxx NE
IFN-gamma XXX-xxx NE
induction xxx NE
of xx NE
the xxx NE
HLA-DRA XXX-XXX DNA_B
gene xxx DNA_E
in xx NE
HeLa XxXx cell_line_B
cells xxx cell_line_E
, , NE
but xxx NE
antisense xxx DNA_B
HMG XXX DNA_M
I/Y X/X DNA_E
dramatically xxx NE
decreases xxx NE
the xxx NE
level xxx NE
of xx NE
induction xxx NE
. . NE

We Xx NE
conclude xxx NE
that xxx NE
distinct xxx NE
sets xxx NE
of xx NE
transcription xxx protein_B
factors xxx protein_E
are xxx NE
involved xxx NE
in xx NE
the xxx NE
two xxx NE
modes xxx NE
of xx NE
HLA-DRA XXX-XXX NE
expression xxx NE
, , NE
and xxx NE
that xxx NE
HMG XXX protein_B
I/Y X/X protein_E
may xxx NE
be xx NE
important xxx NE
for xxx NE
B X NE
cell-specific xxx-xxx NE
expression xxx NE
, , NE
and xxx NE
is xx NE
essential xxx NE
for xxx NE
IFN-gamma XXX-xxx NE
induction xxx NE
. . NE

Heterogeneous Xxxx NE
expression xxx NE
of xx NE
Epstein-Barr Xxxx-Xxxx protein_B
virus xxx protein_M
latent xxx protein_M
proteins xxx protein_E
in xx NE
endemic xxx NE
Burkitt's Xxxx'x NE
lymphoma xxx NE
. . NE

Epstein-Barr Xxxx-Xxxx cell_type_B
virus xxx cell_type_M
(EBV)-infected (XXX)-xxx cell_type_M
cells xxx cell_type_E
may xxx NE
sustain xxx NE
three xxx NE
distinct xxx NE
forms xxx NE
of xx NE
virus xxx NE
latency xxx NE
. . NE

In Xx cell_line
lymphoblastoid xxx NE
cell xxx NE
lines xxx NE
, , NE
six xxx NE
EBV-encoded XXX-xxx protein_B
nuclear xxx protein_M
antigens xxx protein_E
( ( NE
EBNA1 XXXXd protein_B
and xxx protein_M
EBNA2 XXXXd protein_M
and xxx protein_M
EBNA3A XXXXdX protein_M
and xxx protein_M
EBNA3B XXXXdX protein_M
and xxx protein_M
EBNA3C XXXXdX protein_M
and xxx protein_M
EBNA-LP XXXX-XX protein_E
latent xxx NE
membrane xxx NE
proteins xxx NE
( ( NE
LMP1 XXXd protein
, , NE
2A dX protein
, , NE
2B dX protein
) ) NE
, , NE
and xxx NE
two xxx NE
nuclear xxx RNA_B
RNAs XXXx RNA_E
( ( NE
EBERs XXXXx RNA
) ) NE
are xxx NE
expressed xxx NE
. . NE

This Xxxx NE
form xxx NE
of xx NE
latency xxx NE
, , NE
termed xxx NE
latency xxx NE
III XXX NE
, , NE
is xx NE
also xxx NE
encountered xxx NE
in xx NE
some xxx NE
posttransplant xxx NE
lymphoproliferative xxx NE
disorders xxx NE
. . NE

In Xx NE
EBV-positive XXX-xxx NE
cases xxx NE
of xx NE
Hodgkin's Xxxx'x NE
disease xxx NE
, , NE
the xxx NE
EBERs XXXXx RNA
, , NE
EBNA1 XXXXd protein
, , NE
and xxx NE
the xxx NE
LMPs XXXx protein
are xxx NE
expressed xxx NE
( ( NE
latency xxx NE
II XX NE
) ) NE
, , NE
whereas xxx NE
in xx NE
Burkitt's Xxxx'x NE
lymphoma xxx NE
(BL) (XX) NE
only xxx NE
the xxx NE
EBERs XXXXx RNA
and xxx NE
EBNA1 XXXXd protein
have xxx NE
been xxx NE
detected xxx NE
( ( NE
latency xxx NE
I X NE
) ) NE
. . NE

We Xx NE
have xxx NE
studied xxx NE
the xxx NE
expression xxx NE
of xx NE
EBV XXX protein_B
proteins xxx protein_E
in xx NE
17 dd NE
cases xxx NE
of xx NE
EBV-positive XXX-xxx NE
endemic xxx NE
BL XX NE
by xx NE
immunohistology xxx NE
. . NE

Expression Xxxx NE
of xx NE
LMP1 XXXd protein
was xxx NE
seen xxx NE
in xx NE
variable xxx NE
proportions xxx NE
of xx NE
tumor xxx cell_type_B
cells xxx cell_type_E
in xx NE
two xxx NE
cases xxx NE
and xxx NE
EBNA2 XXXXd protein
was xxx NE
detected xxx NE
in xx NE
some xxx NE
tumor xxx cell_type_B
cells xxx cell_type_E
in xx NE
three xxx NE
other xxx NE
cases xxx NE
. . NE

Also Xxxx NE
, , NE
the xxx NE
BZLF1 XXXXd protein_B
trans-activator xxx-xxx protein_M
protein xxx protein_E
was xxx NE
expressed xxx NE
in xx NE
a x NE
few xxx NE
tumor xxx cell_type_B
cells xxx cell_type_E
in xx NE
6 d NE
cases xxx NE
, , NE
indicating xxx NE
entry xxx NE
into xxx NE
the xxx NE
lytic xxx NE
cycle xxx NE
. . NE

A X NE
phenotypic xxx NE
drift xxx NE
from xxx NE
latency xxx NE
I X NE
to xx NE
latency xxx NE
III XXX NE
has xxx NE
been xxx NE
observed xxx NE
previously xxx NE
in xx NE
some xxx NE
BL XX cell_line_B
cell xxx cell_line_M
lines xxx cell_line_E
. . NE

Our Xxx NE
results xxx NE
suggest xxx NE
that xxx NE
a x NE
similar xxx NE
phenomenon xxx NE
may xxx NE
occur xxx NE
in xx NE
BL XX NE
in xx NE
vivo xxx NE
and xxx NE
indicate xxx NE
that xxx NE
the xxx NE
operational xxx NE
definition xxx NE
of xx NE
EBV XXX NE
latencies xxx NE
is xx NE
not xxx NE
easily xxx NE
applied xxx NE
to xx NE
human xxx NE
tumors xxx NE
. . NE

The Xxx NE
activation xxx NE
of xx NE
the xxx NE
Jak Xxx NE
-STAT -XXXX NE
1 d NE
signaling xxx NE
pathway xxx NE
by xx NE
IL-5 XX-d NE
in xx NE
eosinophils xxx NE
. . NE

The Xxx NE
intracellular xxx NE
signal xxx NE
transduction xxx NE
of xx NE
IL-5 XX-d protein
in xx NE
eosinophils xxx cell_type
is xx NE
unknown xxx NE
. . NE

The Xxx NE
objective xxx NE
of xx NE
this xxx NE
study xxx NE
was xxx NE
to xx NE
investigate xxx NE
the xxx NE
involvement xxx NE
of xx NE
the xxx NE
newly xxx NE
discovered xxx NE
Jak Xxx NE
-STAT -XXXX NE
pathway xxx NE
in xx NE
the xxx NE
IL-5 XX-d NE
signal xxx NE
transduction xxx NE
mechanism xxx NE
. . NE

Eosinophils Xxxx cell_type
were xxx NE
purified xxx NE
from xxx NE
peripheral xxx NE
blood xxx NE
by xx NE
discontinuous xxx NE
Percoll Xxxx NE
gradients xxx NE
and xxx NE
stimulated xxx NE
with xxx NE
IL-5 XX-d protein
. . NE

The Xxx NE
involvement xxx NE
of xx NE
Jak Xxx NE
2 d NE
was xxx NE
investigated xxx NE
by xx NE
immunoprecipitation xxx NE
followed xxx NE
by xx NE
immunoblotting xxx NE
for xxx NE
tyrosine xxx NE
phosphorylation xxx NE
. . NE

The Xxx NE
activation xxx NE
of xx NE
Jak Xxx NE
2 d NE
was xxx NE
studied xxx NE
by xx NE
autophosphorylation xxx NE
of xx NE
the xxx NE
immunoprecipitated xxx NE
kinase xxx NE
. . NE

Jak Xxx NE
2 d NE
was xxx NE
tyrosine xxx NE
phosphorylated xxx NE
within xxx NE
1 d NE
to xx NE
3 d NE
min xxx NE
after xxx NE
stimulation xxx NE
of xx NE
eosinophils xxx NE
with xxx NE
IL-5 XX-d NE
. . NE

Further Xxxx NE
, , NE
the xxx NE
immunoprecipitated xxx protein_B
Jak Xxx protein_M
2 d protein_E
obtained xxx NE
from xxx NE
IL-5 XX-d NE
-stimulated -xxx NE
cells xxx NE
underwent xxx NE
autophosphorylation xxx NE
. . NE

Jak Xxx NE
2 d NE
coprecipitated xxx NE
with xxx NE
the xxx NE
beta-subunit xxx-xxx NE
of xx NE
the xxx NE
IL-5 XX-d NE
receptor xxx NE
, , NE
suggesting xxx NE
a x NE
physical xxx NE
association xxx NE
of xx NE
the xxx NE
kinase xxx NE
with xxx NE
the xxx NE
receptor xxx NE
. . NE

The Xxx NE
nuclear xxx protein_B
factor xxx protein_M
STAT-1 XXXX-d protein_E
( ( NE
p91 xdd protein
) ) NE
was xxx NE
investigated xxx NE
by xx NE
immunoprecipitation xxx NE
followed xxx NE
by xx NE
immunoblotting xxx NE
for xxx NE
tyrosine xxx NE
phosphorylation xxx NE
. . NE

STAT-1 XXXX-d protein
was xxx NE
tyrosine xxx NE
phosphorylated xxx NE
within xxx NE
15 dd NE
min xxx NE
of xx NE
IL-5 XX-d NE
stimulation xxx NE
. . NE

The Xxx NE
presence xxx NE
of xx NE
STAT-1 XXXX-d protein
in xx NE
the xxx NE
nuclear xxx NE
extract xxx NE
was xxx NE
studied xxx NE
by xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
. . NE

IL-5 XX-d protein
induced xxx NE
two xxx NE
proteins xxx NE
that xxx NE
bound xxx NE
to xx NE
the xxx NE
gamma-activating xxx-xxx DNA_B
sequence xxx DNA_E
. . NE

In Xx NE
the xxx NE
presence xxx NE
of xx NE
an xx NE
anti- xxx- NE
STAT-1 XXXX-d NE
Ab Xx NE
, , NE
the xxx NE
band xxx NE
was xxx NE
supershifted xxx NE
. . NE

Thus Xxxx NE
, , NE
we xx NE
demonstrated xxx NE
that xxx NE
IL-5 XX-d protein
activated xxx NE
the xxx NE
Jak Xxx NE
2 d NE
-STAT -XXXX NE
1 d NE
signaling xxx NE
pathway xxx NE
in xx NE
eosinophils xxx NE
. . NE

We Xx NE
speculate xxx NE
that xxx NE
the xxx NE
Jak Xxx NE
2 d NE
-STAT -XXXX NE
1 d NE
pathway xxx NE
may xxx NE
be xx NE
involved xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
IL-5 XX-d NE
-inducible -xxx NE
genes xxx NE
in xx NE
eosinophils xxx NE
. . NE

Reduced Xxxx NE
mitogenic xxx NE
stimulation xxx NE
of xx NE
peripheral xxx cell_type_B
blood xxx cell_type_M
mononuclear xxx cell_type_M
cells xxx cell_type_E
as xx NE
a x NE
prognostic xxx NE
parameter xxx NE
for xxx NE
the xxx NE
course xxx NE
of xx NE
breast xxx NE
cancer xxx NE
: : NE
a x NE
prospective xxx NE
longitudinal xxx NE
study xxx NE
. . NE

Immunosuppression Xxxx NE
has xxx NE
been xxx NE
often xxx NE
associated xxx NE
with xxx NE
the xxx NE
course xxx NE
of xx NE
malignant xxx NE
diseases xxx NE
. . NE

In Xx NE
the xxx NE
present xxx NE
study xxx NE
, , NE
the xxx NE
proliferation xxx NE
of xx NE
peripheral xxx cell_type_B
blood xxx cell_type_M
mononuclear xxx cell_type_M
cells xxx cell_type_E
( ( NE
PBMCs XXXXx cell_type
) ) NE
in xx NE
response xxx NE
to xx NE
mitogenic xxx NE
stimulation xxx NE
with xxx NE
phytohaemagglutinin xxx protein
( ( NE
PHA XXX protein
) ) NE
was xxx NE
assessed xxx NE
prospectively xxx NE
in xx NE
90 dd NE
patients xxx NE
with xxx NE
stage xxx NE
I-III X-XXX NE
breast xxx NE
cancer xxx NE
. . NE

Whereas Xxxx NE
PHA XXX NE
-induced -xxx NE
proliferation xxx NE
of xx NE
PBMCs XXXXx NE
derived xxx NE
from xxx NE
patients xxx NE
with xxx NE
breast xxx NE
cancer xxx NE
preoperatively xxx NE
was xxx NE
significantly xxx NE
decreased xxx NE
when xxx NE
compared xxx NE
with xxx NE
data xxx NE
obtained xxx NE
in xx NE
healthy xxx NE
control xxx NE
individuals xxx NE
(P (X NE
< < NE
0.001) d.ddd) NE
, , NE
the xxx NE
degree xxx NE
of xx NE
the xxx NE
defect xxx NE
in xx NE
PHA XXX NE
-induced -xxx NE
proliferation xxx NE
of xx NE
PBMCs XXXXx NE
depended xxx NE
upon xxx NE
the xxx NE
tumour xxx NE
burden xxx NE
as xx NE
manifested xxx NE
by xx NE
tumour xxx NE
size xxx NE
and xxx NE
axillary xxx NE
lymph xxx NE
node xxx NE
involvement xxx NE
(P (X NE
< < NE
0.003 d.ddd NE
in xx NE
each xxx NE
case) xxx) NE
. . NE

PHA XXX NE
-induced -xxx NE
proliferation xxx NE
of xx NE
PBMCs XXXXx NE
dropped xxx NE
significantly xxx NE
in xx NE
patients xxx NE
who xxx NE
received xxx NE
adjuvant xxx NE
chemotherapy xxx NE
consisting xxx NE
of xx NE
cyclophosphamide xxx NE
, , NE
methotrexate xxx NE
and xxx NE
fluorouracil xxx NE
( ( NE
CMF XXX NE
) ) NE
after xxx NE
an xx NE
observation xxx NE
period xxx NE
of xx NE
6 d NE
months xxx NE
(P (X NE
< < NE
0.01) d.dd) NE
, , NE
but xxx NE
not xxx NE
in xx NE
patients xxx NE
under xxx NE
adjuvant xxx NE
treatment xxx NE
with xxx NE
tamoxifen xxx NE
only xxx NE
. . NE

After Xxxx NE
an xx NE
additional xxx NE
6 d NE
months xxx NE
(i.e (x.x NE
. . NE
12 dd NE
months xxx NE
after xxx NE
surgery) xxx) NE
, , NE
PHA XXX NE
-induced -xxx NE
proliferation xxx NE
of xx NE
PBMCs XXXXx NE
was xxx NE
similar xxx NE
in xx NE
patients xxx NE
after xxx NE
adjuvant xxx NE
chemotherapy xxx NE
with xxx NE
CMF XXX NE
and xxx NE
in xx NE
those xxx NE
receiving xxx NE
continued xxx NE
adjuvant xxx NE
tamoxifen xxx NE
treatment xxx NE
(P (X NE
> > NE
0.1) d.d) NE
, , NE
but xxx NE
in xx NE
all xxx NE
patients xxx NE
still xxx NE
significantly xxx NE
decreased xxx NE
as xx NE
compared xxx NE
with xxx NE
healthy xxx NE
controls xxx NE
(P (X NE
< < NE
0.001) d.ddd) NE
. . NE

When Xxxx NE
data xxx NE
obtained xxx NE
preoperatively xxx NE
and xxx NE
after xxx NE
12 dd NE
months xxx NE
were xxx NE
compared xxx NE
, , NE
it xx NE
was xxx NE
found xxx NE
that xxx NE
out xxx NE
of xx NE
23 dd NE
patients xxx NE
whose xxx NE
PBMCs XXXXx cell_type
had xxx NE
experienced xxx NE
a x NE
drop xxx NE
in xx NE
their xxx NE
PHA XXX NE
-induced -xxx NE
proliferation xxx NE
, , NE
14 dd NE
(61%) (dd%) NE
had xxx NE
developed xxx NE
metastatic xxx NE
disease xxx NE
within xxx NE
the xxx NE
subsequent xxx NE
24 dd NE
months xxx NE
(i.e (x.x NE
. . NE
36 dd NE
months xxx NE
after xxx NE
surgery) xxx) NE
. . NE

In Xx NE
contrast xxx NE
, , NE
out xxx NE
of xx NE
59 dd NE
patients xxx NE
whose xxx NE
PBMCs XXXXx cell_type
showed xxx NE
an xx NE
increase xxx NE
in xx NE
their xxx NE
PHA XXX NE
-induced -xxx NE
proliferation xxx NE
within xxx NE
the xxx NE
first xxx NE
12 dd NE
months xxx NE
after xxx NE
surgery xxx NE
, , NE
only xxx NE
one xxx NE
(2%) (d%) NE
presented xxx NE
with xxx NE
disease xxx NE
progression xxx NE
. . NE

We Xx NE
thus xxx NE
conclude xxx NE
that xxx NE
PHA XXX NE
-induced -xxx NE
proliferation xxx NE
of xx NE
PBMCs XXXXx NE
derived xxx NE
from xxx NE
patients xxx NE
with xxx NE
breast xxx NE
cancer xxx NE
depends xxx NE
upon xxx NE
the xxx NE
tumour xxx NE
load xxx NE
and xxx NE
is xx NE
a x NE
good xxx NE
clinical xxx NE
predictor xxx NE
for xxx NE
the xxx NE
further xxx NE
course xxx NE
of xx NE
the xxx NE
disease xxx NE
. . NE

Activation Xxxx NE
of xx NE
transcription xxx NE
by xx NE
binding xxx NE
of xx NE
NF-E1 XX-Xd protein
( ( NE
YY1 XXd protein
) ) NE
to xx NE
a x NE
newly xxx NE
identified xxx NE
element xxx NE
in xx NE
the xxx NE
first xxx NE
exon xxx NE
of xx NE
the xxx NE
human xxx DNA_B
DR XX DNA_M
alpha xxx DNA_M
gene xxx DNA_E
. . NE

A X NE
previously xxx NE
unrecognized xxx NE
element xxx NE
, , NE
located xxx NE
downstream xxx NE
of xx NE
the xxx NE
start xxx DNA_B
site xxx DNA_M
of xx DNA_M
transcription xxx DNA_E
in xx NE
the xxx NE
first xxx NE
exon xxx DNA
of xx NE
the xxx NE
DR XX DNA_B
alpha xxx DNA_M
gene xxx DNA_E
, , NE
has xxx NE
been xxx NE
defined xxx NE
that xxx NE
enhances xxx NE
promoter xxx NE
activity xxx NE
up xx NE
to xx NE
eightfold xxx NE
in xx NE
a x NE
position-dependent xxx-xxx NE
manner xxx NE
. . NE

Mutations Xxxx NE
in xx NE
this xxx NE
DNA-binding XXX-xxx DNA_B
site xxx DNA_E
abolished xxx NE
binding xxx NE
of xx NE
a x NE
nuclear xxx protein_B
factor xxx protein_E
in xx NE
human xxx NE
B X NE
cell xxx NE
nuclear xxx NE
extract xxx NE
and xxx NE
decreased xxx NE
the xxx NE
activity xxx NE
of xx NE
the xxx NE
DR XX DNA_B
alpha xxx DNA_M
promoter xxx DNA_E
to xx NE
a x NE
basal xxx NE
level xxx NE
. . NE

Significant Xxxx NE
sequence xxx NE
homology xxx NE
of xx NE
this xxx NE
element xxx DNA
was xxx NE
found xxx NE
in xx NE
the xxx NE
DNA XXX NE
of xx NE
the xxx NE
DR XX DNA_B
beta xxx DNA_M
gene xxx DNA_M
and xxx DNA_M
DP XX DNA_M
alpha xxx DNA_M
gene xxx DNA_M
and xxx DNA_M
DP-beta XX-xxx DNA_M
gene xxx DNA_M
and xxx DNA_M
DQ XX DNA_M
alpha xxx DNA_M
gene xxx DNA_E
transcriptional xxx NE
start xxx NE
site xxx NE
. . NE

The Xxx NE
nuclear xxx NE
factor xxx NE
binds xxx NE
to xx NE
the xxx NE
DR XX DNA_B
alpha xxx DNA_M
element xxx DNA_M
and xxx DNA_M
DP XX DNA_M
alpha xxx DNA_M
element xxx DNA_E
but xxx NE
not xxx NE
to xx NE
the xxx NE
element xxx NE
in xx NE
the xxx NE
DQ XX DNA_B
alpha xxx DNA_M
gene xxx DNA_E
. . NE

It Xx NE
was xxx NE
identified xxx NE
as xx NE
NF-E1 XX-Xd protein
( ( NE
YY1 XXd protein
) ) NE
. . NE

This Xxxx NE
protein xxx NE
, , NE
previously xxx NE
identified xxx NE
by xx NE
its xxx NE
binding xxx NE
to xx NE
the xxx NE
Ig Xx DNA_B
kappa xxx DNA_M
3' d' DNA_M
enhancer xxx DNA_E
and xxx NE
the xxx NE
Ig Xx DNA_B
heavy xxx DNA_M
chain xxx DNA_M
mu xx DNA_M
E1 Xd DNA_M
site xxx DNA_E
, , NE
thus xxx NE
also xxx NE
appears xxx NE
to xx NE
be xx NE
quite xxx NE
important xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
MHC XXX NE
class xxx NE
II XX NE
gene xxx NE
expression xxx NE
. . NE

Transcriptional Xxxx NE
activity xxx NE
of xx NE
core xxx protein_B
binding xxx protein_M
factor-alpha xxx-xxx protein_M
(AML1) (XXXd) protein_M
and xxx protein_M
core xxx protein_M
binding xxx protein_M
factor-beta xxx-xxx protein_E
subunits xxx NE
on xx NE
murine xxx DNA_B
leukemia xxx DNA_M
virus xxx DNA_M
enhancer xxx DNA_M
cores xxx DNA_E
. . NE

Core Xxxx protein_B
binding xxx protein_M
factor xxx protein_E
( ( NE
CBF XXX protein
) ) NE
, , NE
also xxx NE
known xxx NE
as xx NE
polyomavirus xxx protein_B
enhancer-binding xxx-xxx protein_M
protein xxx protein_M
2 d protein_E
and xxx NE
SL3 XXd protein_B
enhancer xxx protein_M
factor xxx protein_M
1 d protein_E
, , NE
is xx NE
a x NE
mammalian xxx protein_B
transcription xxx protein_M
factor xxx protein_E
that xxx NE
binds xxx NE
to xx NE
an xx NE
element xxx NE
termed xxx NE
the xxx NE
core xxx NE
within xxx NE
the xxx NE
enhancers xxx DNA
of xx NE
the xxx NE
murine xxx NE
leukemia xxx NE
virus xxx NE
family xxx NE
of xx NE
retroviruses xxx NE
. . NE

The Xxx NE
core xxx DNA_B
elements xxx DNA_E
of xx NE
the xxx NE
SL3 XXd NE
virus xxx NE
are xxx NE
important xxx NE
genetic xxx NE
determinants xxx NE
of xx NE
the xxx NE
ability xxx NE
of xx NE
this xxx NE
virus xxx NE
to xx NE
induce xxx NE
T-cell X-xxx NE
lymphomas xxx NE
and xxx NE
the xxx NE
transcriptional xxx NE
activity xxx NE
of xx NE
the xxx NE
viral xxx DNA_B
long xxx DNA_M
terminal xxx DNA_M
repeat xxx DNA_E
in xx NE
T X cell_type_B
lymphocytes xxx cell_type_E
. . NE

CBF XXX protein
consists xxx NE
of xx NE
two xxx NE
subunits xxx NE
, , NE
a x NE
DNA XXX protein_B
binding xxx protein_M
subunit xxx protein_E
, , NE
CBF XXX protein_B
alpha xxx protein_E
, , NE
and xxx NE
a x NE
second xxx NE
subunit xxx NE
, , NE
CBF XXX protein_B
beta xxx protein_E
, , NE
that xxx NE
stimulates xxx NE
the xxx NE
DNA XXX NE
binding xxx NE
activity xxx NE
of xx NE
CBF XXX protein_B
alpha xxx protein_E
. . NE

One Xxx NE
of xx NE
the xxx NE
genes xxx NE
that xxx NE
encodes xxx NE
a x NE
CBF XXX protein_B
alpha xxx protein_M
subunit xxx protein_E
is xx NE
AML1 XXXd protein
, , NE
also xxx NE
called xxx NE
Cbf Xxx protein_B
alpha xxx protein_M
2 d protein_E
. . NE

This Xxxx NE
locus xxx NE
is xx NE
rearranged xxx NE
by xx NE
chromosomal xxx NE
translocations xxx NE
in xx NE
human xxx NE
myeloproliferative xxx NE
disorders xxx NE
and xxx NE
leukemias xxx NE
. . NE

An Xx NE
exogenously xxx NE
expressed xxx NE
Cbf Xxx NE
alpha xxx NE
2 d NE
-encoded -xxx NE
subunit xxx NE
( ( NE
CBF XXX NE
alpha xxx NE
2-451 d-ddd NE
) ) NE
stimulated xxx NE
transcription xxx NE
from xxx NE
the xxx NE
SL3 XXd NE
enhancer xxx NE
in xx NE
P19 Xdd NE
and xxx NE
HeLa XxXx NE
cells xxx NE
. . NE

Activity Xxxx NE
was xxx NE
mediated xxx NE
through xxx NE
the xxx NE
core xxx DNA_B
elements xxx DNA_E
. . NE

Three Xxxx NE
different xxx NE
isoforms xxx NE
of xx NE
CBF XXX protein_B
beta xxx protein_E
were xxx NE
also xxx NE
tested xxx NE
for xxx NE
transcriptional xxx NE
activity xxx NE
on xx NE
the xxx NE
SL3 XXd DNA_B
enhancer xxx DNA_E
. . NE

The Xxx NE
longest xxx NE
form xxx NE
, , NE
CBF XXX NE
beta xxx NE
-187 -ddd NE
, , NE
increased xxx NE
the xxx NE
transcriptional xxx NE
stimulation xxx NE
by xx NE
CBF XXX NE
alpha xxx NE
2-451 d-ddd NE
twofold xxx NE
in xx NE
HeLa XxXx NE
cells xxx NE
, , NE
although xxx NE
it xx NE
had xxx NE
no xx NE
effect xxx NE
in xx NE
P19 Xdd NE
cells xxx NE
. . NE

Transcriptional Xxxx NE
activation xxx NE
by xx NE
CBF XXX protein_B
beta xxx protein_E
required xxx NE
binding xxx NE
to xx NE
the xxx NE
CBF XXX protein_B
alpha xxx protein_M
subunit xxx protein_E
, , NE
as xx NE
a x NE
form xxx NE
of xx NE
CBF XXX protein_B
beta xxx protein_E
that xxx NE
lacked xxx NE
binding xxx NE
ability, xxx, NE
CBF XXX NE
beta xxx NE
-148 -ddd NE
, , NE
failed xxx NE
to xx NE
increase xxx NE
activity xxx NE
. . NE

These Xxxx NE
results xxx NE
indicated xxx NE
that xxx NE
at xx NE
least xxx NE
in xx NE
certain xxx NE
cell xxx NE
types xxx NE
, , NE
the xxx NE
maximum xxx NE
activity xxx NE
of xx NE
CBF XXX protein
required xxx NE
both xxx NE
subunits xxx NE
. . NE

They Xxxx NE
also xxx NE
provided xxx NE
support xxx NE
for xxx NE
the xxx NE
hypothesis xxx NE
that xxx NE
CBF XXX protein
is xx NE
a x NE
factor xxx NE
in xx NE
T X cell_type_B
lymphocytes xxx cell_type_E
that xxx NE
is xx NE
responsible xxx NE
for xxx NE
recognition xxx NE
of xx NE
the xxx NE
SL3 XXd DNA_B
cores xxx DNA_E
. . NE

We Xx NE
also xxx NE
examined xxx NE
whether xxx NE
CBF XXX protein
could xxx NE
distinguish xxx NE
a x NE
1-bp d-xx NE
difference xxx NE
between xxx NE
the xxx NE
enhancer xxx DNA_B
core xxx DNA_M
of xx DNA_M
SL3 XXd DNA_E
and xxx NE
the xxx NE
core xxx NE
of xx NE
the xxx NE
nonleukemogenic xxx NE
virus xxx NE
, , NE
Akv Xxx NE
. . NE

This Xxxx NE
difference xxx NE
strongly xxx NE
affects xxx NE
transcription xxx NE
in xx NE
T X NE
cells xxx NE
and xxx NE
leukemogenicity xxx NE
of xx NE
SL3 XXd DNA
. . NE

However Xxxx NE
, , NE
no xx NE
combination xxx NE
of xx NE
CBF XXX protein_B
alpha xxx protein_E
and xxx NE
CBF XXX protein_B
beta xxx protein_E
subunits xxx NE
that xxx NE
we xx NE
tested xxx NE
was xxx NE
able xxx NE
to xx NE
distinguish xxx NE
the xxx NE
1-bp d-xx NE
difference xxx NE
in xx NE
transcription xxx NE
assays xxx NE
. . NE

Thus Xxxx NE
, , NE
a x NE
complete xxx NE
understanding xxx NE
of xx NE
how xxx NE
T X cell_type_B
cells xxx cell_type_E
recognize xxx NE
the xxx NE
SL3 XXd DNA_B
core xxx DNA_E
remains xxx NE
to xx NE
be xx NE
elucidated xxx NE
. . NE

Interleukin Xxxx protein_B
(IL)-10 (XX)-dd protein_E
inhibits xxx NE
nuclear xxx NE
factor xxx NE
kappa xxx NE
B X NE
( ( NE
NF XX NE
kappa xxx NE
B X NE
) ) NE
activation xxx NE
in xx NE
human xxx NE
monocytes xxx NE
. . NE

IL-10 XX-dd protein
and xxx NE
IL-4 XX-d protein
suppress xxx NE
cytokine xxx NE
synthesis xxx NE
by xx NE
different xxx NE
mechanisms xxx NE
. . NE

Our Xxx NE
previous xxx NE
studies xxx NE
in xx NE
human xxx cell_type_B
monocytes xxx cell_type_E
have xxx NE
demonstrated xxx NE
that xxx NE
interleukin xxx protein_B
(IL)-10 (XX)-dd protein_E
inhibits xxx NE
lipopolysaccharide xxx NE
(LPS)-stimulated (XXX)-xxx NE
production xxx NE
of xx NE
inflammatory xxx protein_B
cytokines xxx protein_E
, , NE
IL-1 XX-d protein_B
beta xxx protein_E
, , NE
IL-6 XX-d protein
, , NE
IL-8 XX-d protein
, , NE
and xxx NE
tumor xxx protein_B
necrosis xxx protein_M
factor xxx protein_M
(TNF)-alpha (XXX)-xxx protein_E
by xx NE
blocking xxx NE
gene xxx NE
transcription xxx NE
. . NE

Using Xxxx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assays xxx NE
( ( NE
EMSA XXXX NE
) ) NE
, , NE
we xx NE
now xxx NE
show xxx NE
that xxx NE
, , NE
in xx NE
monocytes xxx NE
stimulated xxx NE
with xxx NE
LPS XXX NE
or xx NE
TNF XXX protein_B
alpha xxx protein_E
, , NE
IL-10 XX-dd protein
inhibits xxx NE
nuclear xxx NE
stimulation xxx NE
of xx NE
nuclear xxx protein_B
factor xxx protein_M
kappa xxx protein_M
B X protein_E
( ( NE
NF XX protein_B
kappa xxx protein_M
B X protein_E
) ) NE
, , NE
a x NE
transcription xxx protein_B
factor xxx protein_E
involved xxx NE
in xx NE
the xxx NE
expression xxx NE
of xx NE
inflammatory xxx DNA_B
cytokine xxx DNA_M
genes xxx DNA_E
. . NE
Several Xxxx NE
other xxx NE
transcription xxx protein_B
factors xxx protein_E
including xxx NE
NF- XX- NE
IL-6 XX-d protein
, , NE
AP-1 XX-d protein
, , NE
AP-2 XX-d protein
, , NE
GR XX protein
, , NE
CREB XXXX protein
, , NE
Oct-1 Xxx-d protein
, , NE
and xxx NE
Sp-1 Xx-d protein
are xxx NE
not xxx NE
affected xxx NE
by xx NE
IL-10 XX-dd protein
. . NE

This Xxxx NE
selective xxx NE
inhibition xxx NE
by xx NE
IL-10 XX-dd protein
of xx NE
NF XX NE
kappa xxx NE
B X NE
activation xxx NE
occurs xxx NE
rapidly xxx NE
and xxx NE
in xx NE
a x NE
dose-dependent xxx-xxx NE
manner xxx NE
and xxx NE
correlates xxx NE
well xxx NE
with xxx NE
IL-10 XX-dd NE
's 'x NE
cytokine xxx NE
synthesis xxx NE
inhibitory xxx NE
activity xxx NE
in xx NE
terms xxx NE
of xx NE
both xxx NE
kinetics xxx NE
and xxx NE
dose xxx NE
responsiveness xxx NE
. . NE

Furthermore Xxxx NE
, , NE
compounds xxx NE
such xxx NE
as xx NE
tosylphenylalanyl xxx NE
chloromethyl xxx NE
ketone xxx NE
and xxx NE
pyrrolidinedithiocarbamate xxx NE
that xxx NE
are xxx NE
known xxx NE
to xx NE
selectively xxx NE
inhibit xxx NE
NF XX NE
kappa xxx NE
B X NE
activation xxx NE
block xxx NE
cytokine xxx NE
gene xxx NE
transcription xxx NE
in xx NE
LPS XXX NE
-stimulated -xxx NE
monocytes xxx NE
. . NE

Taken Xxxx NE
together xxx NE
, , NE
these xxx NE
results xxx NE
suggest xxx NE
that xxx NE
inhibition xxx NE
of xx NE
NF XX protein_B
kappa xxx protein_M
B X protein_E
activation xxx NE
may xxx NE
be xx NE
an xx NE
important xxx NE
mechanism xxx NE
for xxx NE
IL-10 XX-dd protein
suppression xxx NE
of xx NE
cytokine xxx NE
gene xxx NE
transcription xxx NE
in xx NE
human xxx cell_type_B
monocytes xxx cell_type_E
. . NE

IL-4 XX-d protein
, , NE
another xxx NE
cytokine xxx protein
that xxx NE
inhibits xxx NE
cytokine xxx NE
mRNA xXXX NE
accumulation xxx NE
in xx NE
monocytes xxx cell_type
, , NE
shows xxx NE
little xxx NE
inhibitory xxx NE
effect xxx NE
on xx NE
LPS XXX NE
-induced -xxx NE
NF XX NE
kappa xxx NE
B X NE
activation xxx NE
. . NE

Further Xxxx NE
examination xxx NE
reveals xxx NE
that xxx NE
, , NE
unlike xxx NE
IL-10 XX-dd protein
, , NE
IL-4 XX-d protein
enhances xxx NE
mRNA xXXX NE
degradation xxx NE
and xxx NE
does xxx NE
not xxx NE
suppress xxx NE
cytokine xxx NE
gene xxx NE
transcription xxx NE
. . NE

These Xxxx NE
data xxx NE
indicate xxx NE
that xxx NE
IL-10 XX-dd protein
and xxx NE
IL-4 XX-d protein
inhibit xxx NE
cytokine xxx NE
production xxx NE
by xx NE
different xxx NE
mechanisms xxx NE
. . NE

LMP-1 XXX-d protein
activates xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
by xx NE
targeting xxx NE
the xxx NE
inhibitory xxx protein_B
molecule xxx protein_M
I X protein_M
kappa xxx protein_M
B X protein_M
alpha xxx protein_E
. . NE

LMP-1 XXX-d protein
, , NE
an xx NE
Epstein-Barr Xxxx-Xxxx protein_B
virus xxx protein_M
membrane xxx protein_M
protein xxx protein_E
expressed xxx NE
during xxx NE
latent xxx NE
infection xxx NE
, , NE
has xxx NE
oncogenic xxx NE
properties xxx NE
, , NE
as xx NE
judged xxx NE
from xxx NE
its xxx NE
ability xxx NE
to xx NE
transform xxx NE
B X NE
lymphocytes xxx NE
and xxx NE
rodent xxx NE
fibroblasts xxx NE
. . NE

LMP-1 XXX-d protein
induces xxx NE
the xxx NE
expression xxx NE
of xx NE
bcl2 xxxd DNA
, , NE
an xx NE
oncogene xxx DNA
which xxx NE
protects xxx NE
cells xxx NE
from xxx NE
apoptosis xxx NE
, , NE
as xx NE
well xxx NE
as xx NE
of xx NE
genes xxx NE
encoding xxx NE
other xxx NE
proteins xxx NE
involved xxx NE
in xx NE
cell xxx NE
regulation xxx NE
and xxx NE
growth xxx NE
control xxx NE
. . NE

The Xxx NE
mechanisms xxx NE
by xx NE
which xxx NE
LMP-1 XXX-d protein
upregulates xxx NE
these xxx NE
proteins xxx NE
is xx NE
unknown xxx NE
, , NE
but xxx NE
it xx NE
is xx NE
plausible xxx NE
that xxx NE
LMP-1 XXX-d protein
modifies xxx NE
signal xxx NE
transduction xxx NE
pathways xxx NE
that xxx NE
result xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
one xxx NE
or xx NE
more xxx NE
transcription xxx protein_B
factors xxx protein_E
that xxx NE
ultimately xxx NE
regulate xxx NE
transcription xxx NE
of xx NE
oncogenic xxx DNA_B
genes xxx DNA_E
. . NE

NF-kappa XX-xxx protein_B
B X protein_E
, , NE
a x NE
transcription xxx protein_B
factor xxx protein_E
controlling xxx NE
the xxx NE
expression xxx NE
of xx NE
genes xxx DNA
involved xxx NE
in xx NE
cell xxx NE
activation xxx NE
and xxx NE
growth xxx NE
control xxx NE
, , NE
has xxx NE
been xxx NE
shown xxx NE
to xx NE
be xx NE
activated xxx NE
by xx NE
LMP-1 XXX-d protein
. . NE

The Xxx NE
mechanism(s) xxx(x) NE
regulating xxx NE
this xxx NE
activation xxx NE
remains xxx NE
unknown xxx NE
. . NE

Our Xxx NE
data xxx NE
indicate xxx NE
that xxx NE
increased xxx NE
NF-kappa XX-xxx NE
B X NE
DNA XXX NE
binding xxx NE
and xxx NE
functional xxx NE
activity xxx NE
are xxx NE
present xxx NE
in xx NE
B-lymphoid X-xxx cell_type_B
cells xxx cell_type_E
stably xxx NE
or xx NE
transiently xxx NE
expressing xxx NE
LMP-1 XXX-d protein
. . NE

I X protein_B
kappa xxx protein_M
B X protein_M
alpha xxx protein_E
is xx NE
selectively xxx NE
modified xxx NE
in xx NE
LMP-1 XXX-d NE
-expressing -xxx NE
B X NE
cells xxx NE
. . NE

A X NE
phosphorylated xxx NE
form xxx NE
of xx NE
I X protein_B
kappa xxx protein_M
B X protein_M
alpha xxx protein_E
and xxx NE
increased xxx NE
protein xxx NE
turnover-degradation xxx-xxx NE
correlate xxx NE
with xxx NE
increased xxx NE
NF-kappa XX-xxx NE
B X NE
nuclear xxx NE
translocation xxx NE
. . NE

This Xxxx NE
results xxx NE
in xx NE
increased xxx NE
transcription xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
-dependent-genes -xxx-xxx NE
, , NE
including xxx NE
those xxx NE
encoding xxx NE
p105 xddd NE
and xxx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
( ( NE
MAD3 XXXd NE
) ) NE
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
LMP-1 XXX-d protein
activates xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
in xx NE
B-cell X-xxx cell_line_B
lines xxx cell_line_E
by xx NE
targeting xxx NE
I X protein_B
kappa xxx protein_M
B X protein_M
alpha xxx protein_E
. . NE

Identification Xxxx NE
of xx NE
the xxx NE
pathways xxx NE
activated xxx NE
by xx NE
LMP-1 XXX-d protein
to xx NE
result xxx NE
in xx NE
posttranslational xxx NE
modifications xxx NE
of xx NE
I X protein_B
kappa xxx protein_M
B X protein_M
alpha xxx protein_E
will xxx NE
aid xxx NE
in xx NE
determining xxx NE
the xxx NE
role xxx NE
of xx NE
this xxx NE
virus-host xxx-xxx NE
cell xxx NE
protein xxx NE
interaction xxx NE
in xx NE
Epstein-Barr Xxxx-Xxxx NE
virus xxx NE
-mediated -xxx NE
oncogenesis xxx NE
. . NE

Identification Xxxx NE
of xx NE
human xxx DNA_B
TR2 XXd DNA_M
orphan xxx DNA_M
receptor xxx DNA_M
response xxx DNA_M
element xxx DNA_E
in xx NE
the xxx NE
transcriptional xxx DNA_B
initiation xxx DNA_M
site xxx DNA_E
of xx NE
the xxx NE
simian xxx DNA_B
virus xxx DNA_M
40 dd DNA_M
major xxx DNA_M
late xxx DNA_M
promoter xxx DNA_E
[published [xxx NE
erratum xxx NE
appears xxx NE
in xx NE
J X NE
Biol Xxxx NE
Chem Xxxx NE
1995 dddd NE
Nov Xxx NE
3;270(44):26721] d;ddd(dd):ddddd] NE

A X NE
DNA XXX DNA_B
response xxx DNA_M
element xxx DNA_E
( ( NE
TR2RE-SV40 XXdXX-XXdd DNA
) ) NE
for xxx NE
the xxx NE
TR2 XXd protein_B
orphan xxx protein_M
receptor xxx protein_E
, , NE
a x NE
member xxx NE
of xx NE
the xxx NE
steroid-thyroid xxx-xxx protein_B
hormone xxx protein_M
receptor xxx protein_M
superfamily xxx protein_E
, , NE
has xxx NE
been xxx NE
identified xxx NE
in xx NE
the xxx NE
simian xxx NE
virus xxx NE
40 dd NE
( ( NE
SV40 XXdd NE
) ) NE
+55 +dd NE
region xxx NE
( ( NE
nucleotide xxx NE
numbers xxx NE
368-389 ddd-ddd NE
, , NE
5'-GTTAAGGTTCGTAGGTCATGGA-3' d'-XXXXXXXXXXXXXXXXXXXXXX-d' NE
) ) NE
. . NE

Electrophoretic Xxxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
, , NE
using xxx NE
in xx NE
vitro xxx NE
translated xxx NE
TR2 XXd protein_B
orphan xxx protein_M
receptor xxx protein_E
with xxx NE
a x NE
molecular xxx NE
mass xxx NE
of xx NE
67 dd protein_B
kilodaltons xxx protein_E
, , NE
showed xxx NE
a x NE
specific xxx NE
binding xxx NE
with xxx NE
high xxx NE
affinity xxx NE
(dissociation (xxx NE
constant xxx NE
= = NE
9 d NE
nM) xX) NE
for xxx NE
this xxx NE
DNA XXX DNA_B
sequence xxx DNA_E
. . NE

DNA-swap XXX-xxx NE
experiments xxx NE
using xxx NE
chloramphenicol xxx NE
acetyl-transferase xxx-xxx NE
assay xxx NE
demonstrated xxx NE
that xxx NE
androgen xxx NE
can xxx NE
suppress xxx NE
the xxx NE
transcriptional xxx NE
activities xxx NE
of xx NE
SV40 XXdd DNA_B
early xxx DNA_M
promoter xxx DNA_E
via xxx NE
the xxx NE
interaction xxx NE
between xxx NE
this xxx NE
TR2RE- XXdXX- DNA
SV40 XXdd NE
and xxx NE
the xxx NE
chimeric xxx protein_B
receptor xxx protein_M
AR/TR2/AR XX/XXd/XX protein_E
with xxx NE
the xxx NE
DNA-binding XXX-xxx protein_B
domain xxx protein_E
of xx NE
the xxx NE
TR2 XXd protein_B
orphan xxx protein_M
receptor xxx protein_E
flanked xxx NE
by xx NE
the xxx NE
N-terminal X-xxx protein_B
domain xxx protein_M
and xxx protein_M
androgen-binding xxx-xxx protein_M
domain xxx protein_E
of xx NE
the xxx NE
androgen xxx protein_B
receptor xxx protein_E
. . NE

In Xx NE
addition xxx NE
, , NE
this xxx NE
TR2RE- XXdXX- DNA
SV40 XXdd NE
can xxx NE
function xxx NE
as xx NE
a x NE
repressor xxx NE
to xx NE
suppress xxx NE
the xxx NE
transcriptional xxx NE
activities xxx NE
of xx NE
both xxx NE
SV40 XXdd DNA_B
early xxx DNA_M
promoter xxx DNA_M
and xxx DNA_M
SV40 XXdd DNA_M
late xxx DNA_M
promoter xxx DNA_E

Together Xxxx NE
, , NE
these xxx NE
data xxx NE
suggest xxx NE
the xxx NE
TR2RE- XXdXX- NE
SV40 XXdd NE
may xxx NE
represent xxx NE
the xxx NE
first xxx NE
identified xxx NE
natural xxx NE
DNA XXX NE
response xxx NE
element xxx NE
for xxx NE
the xxx NE
TR2 XXd NE
orphan xxx NE
receptor xxx NE
that xxx NE
may xxx NE
function xxx NE
as xx NE
a x NE
repressor xxx NE
for xxx NE
the xxx NE
SV40 XXdd NE
gene xxx NE
expression xxx NE
. . NE

Detection Xxxx NE
of xx NE
the xxx NE
chromosome xxx RNA_B
16 dd RNA_M
CBF XXX RNA_M
beta-MYH11 xxx-XXXdd RNA_M
fusion xxx RNA_M
transcript xxx RNA_E
in xx NE
myelomonocytic xxx NE
leukemias xxx NE
. . NE

Karyotypic Xxxx NE
detection xxx NE
of xx NE
chromosomal xxx NE
16 dd NE
abnormalities xxx NE
classically xxx NE
associated xxx NE
with xxx NE
AML XXX NE
M4Eo XdXx NE
can xxx NE
be xx NE
difficult xxx NE
. . NE

Characterization Xxxx NE
of xx NE
the xxx NE
two xxx NE
genes xxx NE
involved xxx NE
in xx NE
the xxx NE
inv(16)(p13q22) xxx(dd)(xddxdd) NE
, , NE
CBF XXX DNA_B
beta xxx DNA_E
and xxx NE
MYH11 XXXdd DNA
, , NE
has xxx NE
allowed xxx NE
the xxx NE
detection xxx NE
of xx NE
fusion xxx RNA_B
transcripts xxx RNA_E
by xx NE
reverse-transcriptase xxx-xxx NE
polymerase xxx NE
chain xxx NE
reaction xxx NE
( ( NE
RT-PCR XX-XXX NE
) ) NE
. . NE

We Xx NE
have xxx NE
analyzed xxx NE
CBF XXX NE
beta xxx NE
-MYH11 -XXXdd NE
fusion xxx NE
transcripts xxx NE
by xx NE
RT-PCR XX-XXX NE
in xx NE
myelomonocytic xxx NE
leukemias xxx NE
, , NE
with xxx NE
or xx NE
without xxx NE
eosinophilia xxx NE
, , NE
to xx NE
determine xxx NE
whether xxx NE
their xxx NE
presence xxx NE
correlates xxx NE
with xxx NE
morphology xxx NE
. . NE

Fifty-three Xxxx-xxx NE
cases xxx NE
(11 (dd NE
AML XXX NE
M4Eo XdXx NE
; ; NE
1 d NE
AML XXX NE
M4 Xd NE
with xxx NE
atypical xxx cell_type_B
abnormal xxx cell_type_M
eosinophils xxx cell_type_E
(AML (XXX NE
M4 Xd NE
"Eo") "Xx") NE
; ; NE
29 dd NE
AML XXX NE
M4 Xd NE
; ; NE
8 d NE
AML XXX NE
M5 Xd NE
; ; NE
3 d NE
CMML XXXX NE
; ; NE
and xxx NE
1 d NE
AML XXX NE
M2 Xd NE
with xxx NE
eosinophilia xxx NE
) ) NE
were xxx NE
analyzed xxx NE
. . NE

All Xxx NE
11 dd NE
typical xxx NE
AML XXX NE
M4Eo XdXx NE
were xxx NE
CBF XXX DNA_B
beta xxx DNA_E
-MYH11 -XXXdd NE
positive xxx NE
. . NE

The Xxx NE
single xxx NE
case xxx NE
of xx NE
AML XXX NE
M4 Xd NE
with xxx NE
distinctive xxx NE
eosinophil xxx NE
abnormalities xxx NE
was xxx NE
negative xxx NE
by xx NE
karyotype xxx NE
, , NE
RT-PCR XX-XXX NE
and xxx NE
fluorescent xxx NE
in xx NE
situ xxx NE
hybridization xxx NE
( ( NE
FISH XXXX NE
) ) NE
. . NE

Three Xxxx NE
of xx NE
29 dd NE
(10%) (dd%) NE
AML XXX NE
M4 Xd NE
without xxx NE
abnormal xxx cell_type_B
eosinophils xxx cell_type_E
were xxx NE
CBF XXX DNA_B
beta xxx DNA_E
-MYH11 -XXXdd NE
positive xxx NE
, , NE
1 d NE
of xx NE
which xxx NE
did xxx NE
not xxx NE
show xxx NE
any xxx NE
apparent xxx NE
chromosome xxx NE
16 dd NE
abnormalities xxx NE
by xx NE
classical xxx NE
metaphase xxx NE
analysis xxx NE
(2 (d NE
not xxx NE
tested) xxx) NE
. . NE

Both Xxxx NE
cases xxx NE
tested xxx NE
also xxx NE
showed xxx NE
MYH11 XXXdd NE
genomic xxx NE
rearrangement xxx NE
. . NE

None Xxxx NE
of xx NE
the xxx NE
other xxx NE
leukemias xxx NE
were xxx NE
RT-PCR XX-XXX NE
positive xxx NE
. . NE

Follow-up Xxxx-xx NE
of xx NE
three xxx NE
patient xxx NE
showed xxx NE
residual xxx NE
positivity xxx NE
in xx NE
apparent xxx NE
complete xxx NE
remission xxx NE
. . NE

These Xxxx NE
data xxx NE
show xxx NE
that xxx NE
CBF XXX NE
beta xxx NE
-MYH11 -XXXdd NE
fusion xxx NE
transcripts xxx NE
occur xxx NE
not xxx NE
only xxx NE
in xx NE
the xxx NE
vast xxx NE
majority xxx NE
of xx NE
typical xxx NE
AML XXX NE
M4Eo XdXx NE
, , NE
but xxx NE
also xxx NE
in xx NE
approximately xxx NE
10% dd% NE
of xx NE
AML XXX NE
M4 Xd NE
without xxx NE
eosinophilic xxx NE
abnormalities xxx NE
, , NE
a x NE
much xxx NE
higher xxx NE
incidence xxx NE
than xxx NE
the xxx NE
sporadic xxx NE
reports xxx NE
of xx NE
chromosome xxx NE
16 dd NE
abnormalities xxx NE
in xx NE
AML XXX NE
M4 Xd NE
would xxx NE
suggest xxx NE
. . NE

Taken Xxxx NE
together xxx NE
with xxx NE
the xxx NE
detection xxx NE
of xx NE
CBF XXX DNA_B
beta xxx DNA_E
- - NE
MYH11 XXXdd RNA_B
transcripts xxx RNA_E
in xx NE
the xxx NE
absence xxx NE
of xx NE
apparent xxx NE
chromosome xxx NE
16 dd NE
abnormalities xxx NE
by xx NE
classical xxx NE
banding xxx NE
techniques xxx NE
, , NE
these xxx NE
data xxx NE
show xxx NE
that xxx NE
additional xxx NE
screening xxx NE
by xx NE
either xxx NE
RT-PCR XX-XXX NE
or xx NE
FISH XXXX NE
should xxx NE
be xx NE
performed xxx NE
in xx NE
all xxx NE
AML XXX NE
M4 Xd NE
, , NE
regardless xxx NE
of xx NE
morphologic xxx NE
features xxx NE
, , NE
to xx NE
allow xxx NE
accurate xxx NE
evaluation xxx NE
of xx NE
the xxx NE
prognostic xxx NE
importance xxx NE
of xx NE
this xxx NE
fusion xxx NE
transcript xxx NE
. . NE

HIV-1 XXX-d protein_B
Tat Xxx protein_E
potentiates xxx NE
TNF XXX NE
-induced -xxx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
and xxx NE
cytotoxicity xxx NE
by xx NE
altering xxx NE
the xxx NE
cellular xxx NE
redox xxx NE
state xxx NE
. . NE

This Xxxx NE
study xxx NE
demonstrates xxx NE
that xxx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
( ( NE
HIV-1 XXX-d NE
) ) NE
Tat Xxx NE
protein xxx NE
amplifies xxx NE
the xxx NE
activity xxx NE
of xx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
( ( NE
TNF XXX NE
) ) NE
, , NE
a x NE
cytokine xxx NE
that xxx NE
stimulates xxx NE
HIV-1 XXX-d NE
replication xxx NE
through xxx NE
activation xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
. . NE

In Xx NE
HeLa XxXx cell_line_B
cells xxx cell_line_E
stably xxx NE
transfected xxx NE
with xxx NE
the xxx NE
HIV-1 XXX-d DNA_B
tat xxx DNA_M
gene xxx DNA_E
( ( NE
HeLa-tat XxXx-xxx cell_line_B
cells xxx cell_line_E
) ) NE
, , NE
expression xxx NE
of xx NE
the xxx NE
Tat Xxx protein_B
protein xxx protein_E
enhanced xxx NE
both xxx NE
TNF XXX NE
-induced -xxx NE
activation xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
and xxx NE
TNF XXX NE
-mediated -xxx NE
cytotoxicity xxx NE
. . NE

A X NE
similar xxx NE
potentiation xxx NE
of xx NE
TNF XXX protein
effects xxx NE
was xxx NE
observed xxx NE
in xx NE
Jurkat Xxxx NE
T X NE
cells xxx NE
and xxx NE
HeLa XxXx cell_line_B
cells xxx cell_line_E
treated xxx NE
with xxx NE
soluble xxx NE
Tat Xxx protein_B
protein xxx protein_E
. . NE

TNF XXX protein
-mediated -xxx NE
activation xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
and xxx NE
cytotoxicity xxx NE
involves xxx NE
the xxx NE
intracellular xxx NE
formation xxx NE
of xx NE
reactive xxx NE
oxygen xxx NE
intermediates xxx NE
. . NE

Therefore Xxxx NE
, , NE
Tat Xxx NE
-mediated -xxx NE
effects xxx NE
on xx NE
the xxx NE
cellular xxx NE
redox xxx NE
state xxx NE
were xxx NE
analyzed xxx NE
. . NE

In Xx NE
both xxx NE
T X cell_type_B
cells xxx cell_type_E
and xxx NE
HeLa XxXx cell_line_B
cells xxx cell_line_E
HIV-1 XXX-d protein_B
Tat Xxx protein_E
suppressed xxx NE
the xxx NE
expression xxx NE
of xx NE
Mn-dependent Xx-xxx protein_B
superoxide xxx protein_M
dismutase xxx protein_E
( ( NE
Mn-SOD Xx-XXX protein
) ) NE
, , NE
a x NE
mitochondrial xxx protein_B
enzyme xxx protein_E
that xxx NE
is xx NE
part xxx NE
of xx NE
the xxx NE
cellular xxx NE
defense xxx NE
system xxx NE
against xxx NE
oxidative xxx NE
stress xxx NE
. . NE

Thus Xxxx NE
, , NE
Mn-SOD Xx-XXX NE
RNA XXX NE
protein xxx NE
levels xxx NE
and xxx NE
activity xxx NE
were xxx NE
markedly xxx NE
reduced xxx NE
in xx NE
the xxx NE
presence xxx NE
of xx NE
Tat Xxx protein
. . NE

Decreased Xxxx NE
Mn-SOD Xx-XXX NE
expression xxx NE
was xxx NE
associated xxx NE
with xxx NE
decreased xxx NE
levels xxx NE
of xx NE
glutathione xxx NE
and xxx NE
a x NE
lower xxx NE
ratio xxx NE
of xx NE
reduced:oxidized xxx:xxx NE
glutathione xxx NE
. . NE

A X NE
truncated xxx NE
Tat Xxx protein_B
protein xxx protein_E
( ( NE
Tat1-72 Xxxd-dd protein
) ) NE
, , NE
known xxx NE
to xx NE
transactivate xxx NE
the xxx NE
HIV-1 XXX-d DNA_B
long xxx DNA_M
terminal xxx DNA_M
repeat xxx DNA_E
( ( NE
LTR XXX DNA
) ) NE
, , NE
no xx NE
longer xxx NE
affected xxx NE
Mn-SOD Xx-XXX NE
expression xxx NE
, , NE
the xxx NE
cellular xxx NE
redox xxx NE
state xxx NE
or xx NE
TNF XXX NE
-mediated -xxx NE
cytotoxicity xxx NE
. . NE

Thus Xxxx NE
, , NE
our xxx NE
experiments xxx NE
demonstrate xxx NE
that xxx NE
the xxx NE
C-terminal X-xxx protein_B
region xxx protein_E
of xx NE
HIV-1 XXX-d protein_B
Tat Xxx protein_E
is xx NE
required xxx NE
to xx NE
suppress xxx NE
Mn-SOD Xx-XXX NE
expression xxx NE
and xxx NE
to xx NE
induce xxx NE
pro-oxidative xxx-xxx NE
conditions xxx NE
reflected xxx NE
by xx NE
a x NE
drop xxx NE
in xx NE
reduced xxx NE
glutathione xxx NE
( ( NE
GSH XXX protein
) ) NE
and xxx NE
the xxx NE
GSH:oxidized XXX:xxx NE
GSH XXX NE
( ( NE
GSSG XXXX NE
) ) NE
ratio xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

The Xxx NE
use xxx NE
of xx NE
glucocorticoids xxx NE
in xx NE
acute xxx NE
lymphoblastic xxx NE
leukemia xxx NE
of xx NE
childhood xxx NE
. . NE

Molecular Xxxx NE
, , NE
cellular xxx NE
, , NE
and xxx NE
clinical xxx NE
considerations xxx NE
. . NE

Glucocorticoids Xxxx NE
have xxx NE
been xxx NE
included xxx NE
in xx NE
almost xxx NE
all xxx NE
treatment xxx NE
regimens xxx NE
for xxx NE
childhood xxx NE
acute xxx NE
lymphoblastic xxx NE
leukemia xxx NE
for xxx NE
decades xxx NE
. . NE

However Xxxx NE
, , NE
optimal xxx NE
agents xxx NE
, , NE
doses xxx NE
, , NE
and/or xxx/xx NE
schedules xxx NE
have xxx NE
yet xxx NE
to xx NE
be xx NE
defined xxx NE
despite xxx NE
extensive xxx NE
clinical xxx NE
application xxx NE
. . NE

New Xxx NE
data xxx NE
on xx NE
the xxx NE
pharmacokinetics xxx NE
, , NE
pharmacodynamics xxx NE
, , NE
and xxx NE
molecular xxx NE
mechanisms xxx NE
of xx NE
action xxx NE
of xx NE
glucocorticoids xxx NE
have xxx NE
suggested xxx NE
alternative xxx NE
approaches xxx NE
in xx NE
ALL XXX NE
. . NE

These Xxxx NE
suggest xxx NE
that xxx NE
prolonged xxx NE
, , NE
i.e x.x NE
. . NE
28 dd NE
day xxx NE
, , NE
glucocorticoid xxx NE
therapy xxx NE
may xxx NE
be xx NE
unnecessary xxx NE
as xx NE
exposure xxx NE
to xx NE
glucocorticoid xxx NE
induces xxx NE
down-regulation xxx-xxx NE
of xx NE
glucocorticoid xxx protein_B
receptors xxx protein_E
. . NE

Dexamethasone Xxxx NE
may xxx NE
be xx NE
superior xxx NE
to xx NE
prednisone xxx NE
in xx NE
conventional xxx NE
equi-effective xxx-xxx NE
doses xxx NE
. . NE

Blast Xxxx NE
sensitivity xxx NE
to xx NE
glucocorticoids xxx NE
correlates xxx NE
closely xxx NE
with xxx NE
sensitivity xxx NE
to xx NE
other xxx NE
, , NE
putatively xxx NE
non-cross-resisting xxx-xxx-xxx NE
agents xxx NE
and xxx NE
with xxx NE
outcome xxx NE
after xxx NE
multi-agent xxx-xxx NE
therapy xxx NE
, , NE
suggesting xxx NE
overlapping xxx NE
mechanisms xxx NE
of xx NE
action xxx NE
, , NE
and xxx NE
focusing xxx NE
attention xxx NE
on xx NE
the xxx NE
determinants xxx NE
of xx NE
the xxx NE
threshold xxx NE
for xxx NE
apoptosis xxx NE
. . NE

Increasing Xxxx NE
success xxx NE
in xx NE
the xxx NE
treatment xxx NE
of xx NE
childhood xxx NE
acute xxx NE
lymphoblastic xxx NE
leukemia xxx NE
has xxx NE
led xxx NE
to xx NE
increasing xxx NE
awareness xxx NE
of xx NE
avascular xxx NE
necrosis xxx NE
of xx NE
bone xxx NE
as xx NE
a x NE
potentially xxx NE
disabling xxx NE
sequela xxx NE
of xx NE
glucocorticoid xxx NE
therapy xxx NE
, , NE
especially xxx NE
in xx NE
adolescent xxx NE
patient xxx NE
and xxx NE
young xxx NE
adult xxx NE
patient xxx NE

Epstein-Barr Xxxx-Xxxx NE
virus xxx NE
nuclear xxx NE
protein xxx NE
2 d NE
transactivation xxx NE
of xx NE
the xxx NE
latent xxx DNA_B
membrane xxx DNA_M
protein xxx DNA_M
1 d DNA_M
promoter xxx DNA_E
is xx NE
mediated xxx NE
by xx NE
J X protein_B
kappa xxx protein_E
and xxx NE
PU.1 XX.d protein
. . NE

Expression Xxxx NE
of xx NE
the xxx NE
Epstein-Barr Xxxx-Xxxx NE
virus xxx NE
( ( NE
EBV XXX NE
) ) NE
latent xxx NE
membrane xxx NE
protein xxx NE
1 d NE
( ( NE
LMP-1 XXX-d NE
) ) NE
oncogene xxx NE
is xx NE
regulated xxx NE
by xx NE
the xxx NE
EBV XXX NE
nuclear xxx NE
protein xxx NE
2 d NE
( ( NE
EBNA-2 XXXX-d NE
) ) NE
transactivator xxx NE
. . NE

EBNA-2 XXXX-d protein
is xx NE
known xxx NE
to xx NE
interact xxx NE
with xxx NE
the xxx NE
cellular xxx protein_B
DNA-binding XXX-xxx protein_M
protein xxx protein_E
J X protein_B
kappa xxx protein_E
and xxx NE
is xx NE
recruited xxx NE
to xx NE
promoters xxx DNA
containing xxx NE
the xxx NE
GTGGGAA XXXXXXX NE
J X DNA_B
kappa xxx DNA_M
recognition xxx DNA_M
sequence xxx DNA_E
. . NE

The Xxx NE
minimal xxx NE
EBNA-2 XXXX-d NE
-responsive -xxx NE
LMP-1 XXX-d NE
promoter xxx NE
includes xxx NE
one xxx NE
J X NE
kappa xxx NE
-binding -xxx NE
site xxx NE
, , NE
and xxx NE
we xx NE
now xxx NE
show xxx NE
that xxx NE
mutation xxx NE
of xx NE
that xxx NE
site xxx NE
, , NE
such xxx NE
that xxx NE
J X NE
kappa xxx NE
cannot xxx NE
bind xxx NE
, , NE
reduces xxx NE
EBNA-2 XXXX-d NE
responsiveness xxx NE
by xx NE
60% dd% NE
. . NE

To Xx NE
identify xxx NE
other xxx NE
factors xxx NE
which xxx NE
interact xxx NE
with xxx NE
the xxx NE
LMP-1 XXX-d DNA_B
EBNA-2 XXXX-d DNA_M
response xxx DNA_M
element xxx DNA_E
( ( NE
E2RE XdXX DNA
) ) NE
, , NE
a x NE
-236/-145 -ddd/-ddd DNA_B
minimal xxx DNA_M
E2RE XdXX DNA_E
was xxx NE
used xxx NE
as xx NE
a x NE
probe xxx NE
in xx NE
an xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
. . NE

The Xxx NE
previously xxx NE
characterized xxx NE
factors xxx NE
J X protein_B
kappa xxx protein_E
, , NE
PU.1 XX.d protein
, , NE
and xxx NE
AML1 XXXd protein
bind xxx NE
to xx NE
the xxx NE
LMP-1 XXX-d DNA_B
E2RE XdXX DNA_E
, , NE
along xxx NE
with xxx NE
six xxx NE
other xxx NE
unidentified xxx NE
factors xxx NE
( ( NE
LBF2 XXXd protein
to xx NE
LBF7 XXXd protein
) ) NE
. . NE

Binding Xxxx NE
sites xxx NE
were xxx NE
mapped xxx NE
for xxx NE
each xxx NE
factor xxx NE
. . NE

LBF4 XXXd protein
is xx NE
B- X- NE
and xxx NE
T-cell X-xxx NE
specific xxx NE
and xxx NE
recognizes xxx NE
the xxx NE
PU.1 XX.d DNA_B
GGAA XXXX DNA_M
core xxx DNA_M
sequence xxx DNA_E
as xx NE
shown xxx NE
by xx NE
methylation xxx NE
interference xxx NE
. . NE

LBF4 XXXd protein
has xxx NE
a x NE
molecular xxx NE
mass xxx NE
of xx NE
105 ddd NE
kDa xXx NE
and xxx NE
is xx NE
probably xxx NE
unrelated xxx NE
to xx NE
PU.1 XX.d protein
. . NE

LBF2 XXXd protein
was xxx NE
found xxx NE
only xxx NE
in xx NE
epithelial xxx cell_line_B
cell xxx cell_line_M
lines xxx cell_line_E
, , NE
whereas xxx NE
LBF3 XXXd protein
, , NE
LBF5 XXXd protein
, , NE
LBF6 XXXd protein
, , NE
and xxx NE
LBF7 XXXd protein
were xxx NE
not xxx NE
cell xxx NE
type xxx NE
specific xxx NE
. . NE

Mutations Xxxx NE
of xx NE
the xxx NE
AML1-binding XXXd-xxx DNA_B
site xxx DNA_M
or xx DNA_M
LBF4-binding XXXd-xxx DNA_M
site xxx DNA_E
had xxx NE
no xx NE
effect xxx NE
on xx NE
EBNA-2 XXXX-d NE
transactivation xxx NE
, , NE
whereas xxx NE
mutation xxx NE
of xx NE
the xxx NE
PU.1 XX.d DNA
-binding -xxx NE
site xxx NE
completely xxx NE
eliminated xxx NE
EBNA-2 XXXX-d NE
responses xxx NE
. . NE

A X NE
gst- xxx- NE
EBNA-2 XXXX-d NE
fusion xxx NE
protein xxx NE
specifically xxx NE
depleted xxx NE
PU.1 XX.d NE
from xxx NE
nuclear xxx NE
extracts xxx NE
and xxx NE
bound xxx NE
in xx NE
vitro xxx NE
translated xxx NE
PU.1 XX.d NE
, , NE
providing xxx NE
biochemical xxx NE
evidence xxx NE
for xxx NE
a x NE
direct xxx NE
EBNA-2 XXXX-d NE
-PU.1 -XX.d NE
interaction xxx NE
. . NE

Thus Xxxx NE
, , NE
EBNA-2 XXXX-d protein
transactivation xxx NE
of xx NE
the xxx NE
LMP-1 XXX-d DNA_B
promoter xxx DNA_E
is xx NE
dependent xxx NE
on xx NE
interaction xxx NE
with xxx NE
at xx NE
least xxx NE
two xxx NE
distinct xxx NE
sequence-specific xxx-xxx NE
DNA-binding XXX-xxx protein_B
proteins xxx protein_E
, , NE
J X protein_B
kappa xxx protein_E
and xxx NE
PU.1 XX.d protein
. . NE

LBF3 XXXd protein
, , NE
LBF5 XXXd protein
, , NE
LBF6 XXXd protein
, , NE
or xx NE
LBF7 XXXd protein
may xxx NE
also xxx NE
be xx NE
involved xxx NE
, , NE
since xxx NE
their xxx NE
binding xxx NE
sites xxx NE
also xxx NE
contribute xxx NE
to xx NE
EBNA-2 XXXX-d NE
responsiveness xxx NE
. . NE

Lymphocyte Xxxx protein_B
glucocorticoid xxx protein_M
receptor xxx protein_E
: : NE
predictor xxx NE
of xx NE
sertraline xxx NE
response xxx NE
in xx NE
adolescent xxx NE
major xxx NE
depressive xxx NE
disorder xxx NE
( ( NE
MDD XXX NE
) ) NE
. . NE

Major Xxxx NE
depressive xxx NE
disorder xxx NE
( ( NE
MDD XXX NE
) ) NE
in xx NE
adolescents xxx NE
demonstrates xxx NE
resistance xxx NE
to xx NE
tricyclic xxx NE
antidepressants xxx NE
and xxx NE
absence xxx NE
of xx NE
hypercortisolemia xxx NE
. . NE

The Xxx NE
efficacy xxx NE
of xx NE
serotonin xxx NE
reuptake xxx NE
inhibitors xxx NE
( ( NE
SRIs XXXx NE
) ) NE
is xx NE
uncertain xxx NE
, , NE
and xxx NE
response xxx NE
predictors xxx NE
are xxx NE
unavailable xxx NE
. . NE

Abnormal Xxxx NE
fast xxx NE
feedback xxx NE
and xxx NE
negative xxx NE
feedback xxx NE
of xx NE
the xxx NE
hypothalamic-pituitary-adrenal xxx-xxx-xxx NE
axis xxx NE
implicates xxx NE
a x NE
dampened xxx NE
limbic-hippocampal xxx-xxx protein_B
glucocorticoid xxx protein_M
type xxx protein_M
II XX protein_M
receptor xxx protein_E
( ( NE
GCII XXXX protein
) ) NE
. . NE

We Xx NE
hypothesized xxx NE
that xxx NE
lymphocyte xxx protein_B
GCII XXXX protein_E
is xx NE
altered xxx NE
in xx NE
adolescent xxx NE
MDD XXX NE
and xxx NE
could xxx NE
serve xxx NE
as xx NE
a x NE
marker xxx NE
for xxx NE
response xxx NE
to xx NE
SRIs XXXx NE
. . NE

In Xx NE
an xx NE
open-label xxx-xxx NE
study xxx NE
, , NE
adolescents xxx NE
(n (x NE
= = NE
20) dd) NE
meeting xxx NE
DSM-III-R XXX-XXX-X NE
criteria xxx NE
for xxx NE
MDD XXX NE
showed xxx NE
baseline xxx NE
lymphocyte xxx protein_B
GCII XXXX protein_M
sites xxx protein_E
per xxx NE
cell xxx NE
(sites/cell) (xxx/xxx) NE
values xxx NE
of xx NE
793 ddd NE
+/- +/- NE
106 ddd NE
versus xxx NE
2,563 d,ddd NE
+/- +/- NE
499 ddd NE
(+/- (+/- NE
SEM) XXX) NE
for xxx NE
matched xxx NE
controls xxx NE
(n (x NE
= = NE
18) dd) NE
(t (x NE
= = NE
3.5 d.d NE
; ; NE
df xx NE
= = NE
36 dd NE
; ; NE
p x NE
< < NE
.001) .ddd) NE
. . NE

GCII XXXX protein
was xxx NE
bimodally xxx NE
distributed xxx NE
, , NE
with xxx NE
SRI XXX NE
responders xxx NE
differing xxx NE
from xxx NE
nonresponders xxx NE
(t (x NE
= = NE
3.9 d.d NE
; ; NE
df xx NE
= = NE
14 dd NE
; ; NE
p x NE
< < NE
.001) .ddd) NE
. . NE

GCII XXXX protein
accurately xxx NE
classified xxx NE
90 dd NE
percent xxx NE
of xx NE
sertraline xxx NE
responders xxx NE
and xxx NE
80 dd NE
percent xxx NE
of xx NE
nonresponders xxx NE
. . NE

Only Xxxx NE
SRI XXX NE
responders xxx NE
showed xxx NE
GCII XXXX protein
sites/cell xxx/xxx NE
upregulated xxx NE
after xxx NE
6 d NE
weeks xxx NE
of xx NE
treatment xxx NE
(t (x NE
= = NE
2.1 d.d NE
, , NE
df xx NE
= = NE
10 dd NE
; ; NE
p x NE
< < NE
.05) .dd) NE
. . NE

The Xxx NE
role xxx NE
of xx NE
NFATp XXXXx protein
in xx NE
cyclosporin xxx NE
A-sensitive X-xxx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
-alpha -xxx NE
gene xxx NE
transcription xxx NE
. . NE

The Xxx NE
tumor xxx NE
necrosis xxx NE
factor-alpha xxx-xxx NE
( ( NE
TNF XXX NE
alpha) xxx) NE
gene xxx NE
is xx NE
an xx NE
immediate xxx NE
early xxx NE
gene xxx NE
in xx NE
activated xxx NE
T X NE
cells xxx NE
, , NE
in xx NE
that xxx NE
it xx NE
is xx NE
rapidly xxx NE
induced xxx NE
without xxx NE
a x NE
requirement xxx NE
for xxx NE
protein xxx NE
synthesis xxx NE
. . NE

Maximal Xxxx NE
induction xxx NE
of xx NE
TNF XXX RNA_B
alpha xxx RNA_M
mRNA xXXX RNA_E
can xxx NE
be xx NE
induced xxx NE
by xx NE
treatment xxx NE
of xx NE
T X cell_type_B
cells xxx cell_type_E
with xxx NE
calcium xxx NE
ionophores xxx NE
alone xxx NE
, , NE
via xxx NE
a x NE
calcineurin xxx NE
-dependent -xxx NE
process xxx NE
that xxx NE
is xx NE
blocked xxx NE
by xx NE
cyclosporin xxx NE
A X NE
. . NE

We Xx NE
have xxx NE
previously xxx NE
identified xxx NE
a x NE
promoter xxx DNA_B
element xxx DNA_E
, , NE
kappa xxx DNA_B
3 d DNA_E
, , NE
that xxx NE
is xx NE
required xxx NE
for xxx NE
calcium-stimulated xxx-xxx NE
, , NE
cyclosporin xxx NE
A X NE
-sensitive -xxx NE
induction xxx NE
of xx NE
the xxx NE
TNF XXX NE
alpha xxx NE
gene xxx NE
in xx NE
activated xxx NE
T X NE
cells xxx NE
. . NE

Here Xxxx NE
, , NE
we xx NE
demonstrate xxx NE
that xxx NE
the xxx NE
kappa xxx protein_B
3 d protein_M
binding xxx protein_M
factor xxx protein_E
contains xxx NE
NFATp XXXXx protein
, , NE
a x NE
cyclosporin-sensitive xxx-xxx protein_B
DNA-binding XXX-xxx protein_M
protein xxx protein_E
required xxx NE
for xxx NE
interleukin-2 xxx-d NE
gene xxx NE
transcription xxx NE
. . NE

NFATp XXXXx protein
binds xxx NE
to xx NE
two xxx NE
sites xxx NE
within xxx NE
the xxx NE
kappa xxx DNA_B
3 d DNA_M
element xxx DNA_E
, , NE
and xxx NE
occupancy xxx NE
of xx NE
both xxx NE
sites xxx NE
is xx NE
required xxx NE
for xxx NE
TNF XXX NE
alpha xxx NE
gene xxx NE
induction xxx NE
. . NE

Thus Xxxx NE
, , NE
although xxx NE
the xxx NE
kappa xxx DNA_B
3 d DNA_M
element xxx DNA_E
has xxx NE
little xxx NE
sequence xxx NE
similarity xxx NE
to xx NE
other xxx NE
NFATp XXXXx NE
-binding -xxx NE
sites xxx NE
, , NE
it xx NE
appears xxx NE
to xx NE
function xxx NE
as xx NE
a x NE
cyclosporin-sensitive xxx-xxx NE
promoter xxx NE
element xxx NE
in xx NE
T X NE
cells xxx NE
by xx NE
virtue xxx NE
of xx NE
its xxx NE
ability xxx NE
to xx NE
bind xxx NE
NFATp XXXXx NE
. . NE

The Xxx NE
involvement xxx NE
of xx NE
NFATp XXXXx protein
in xx NE
transcriptional xxx NE
activation xxx NE
of xx NE
both xxx NE
the xxx NE
interleukin-2 xxx-d protein
and xxx NE
TNF XXX DNA_B
alpha xxx DNA_M
genes xxx DNA_E
suggests xxx NE
that xxx NE
this xxx NE
factor xxx NE
plays xxx NE
an xx NE
important xxx NE
role xxx NE
in xx NE
the xxx NE
coordinate xxx NE
induction xxx NE
of xx NE
multiple xxx NE
cytokine xxx DNA_B
genes xxx DNA_E
, , NE
starting xxx NE
at xx NE
the xxx NE
earliest xxx NE
stages xxx NE
of xx NE
T X NE
cell xxx NE
activation xxx NE
. . NE

Regulation Xxxx NE
and xxx NE
specificity xxx NE
of xx NE
MNDA XXXX NE
expression xxx NE
in xx NE
monocytes xxx cell_type
, , NE
macrophages xxx cell_type
, , NE
and xxx NE
leukemia/B xxx/X cell_line_B
lymphoma xxx cell_line_M
cell xxx cell_line_M
lines xxx cell_line_E
. . NE

The Xxx NE
expression xxx NE
of xx NE
the xxx NE
human xxx protein_B
myeloid xxx protein_M
cell xxx protein_M
nuclear xxx protein_M
differentiation xxx protein_M
antigen xxx protein_E
( ( NE
MNDA XXXX protein
) ) NE
was xxx NE
observed xxx NE
specifically xxx NE
in xx NE
cells xxx NE
of xx NE
the xxx NE
granulocyte-macrophage xxx-xxx NE
lineage xxx NE
in xx NE
our xxx NE
earlier xxx NE
reports xxx NE
. . NE

The Xxx NE
specificity xxx NE
of xx NE
MNDA XXXX NE
expression xxx NE
for xxx NE
cells xxx NE
in xx NE
the xxx NE
granulocyte-macrophage xxx-xxx NE
lineage xxx NE
was xxx NE
reexamined xxx NE
in xx NE
cell xxx cell_line_B
lines xxx cell_line_E
established xxx NE
from xxx NE
patients xxx NE
with xxx NE
Philadelphia Xxxx NE
chromosome-positive xxx-xxx NE
chronic xxx NE
myeloid xxx NE
leukemia xxx NE
. . NE

Cell Xxxx NE
lines xxx NE
that xxx NE
expressed xxx NE
MNDA XXXX protein
exhibited xxx NE
myeloid xxx NE
cell xxx NE
features xxx NE
and xxx NE
granulocyte xxx NE
differentiation xxx NE
or xx NE
monocyte xxx NE
differentiation xxx NE
multipotential xxx NE
cells xxx NE
did xxx NE
not xxx NE
express xxx NE
MNDA XXXX protein
. . NE

Cells Xxxx NE
originating xxx NE
from xxx NE
cases xxx NE
of xx NE
Burkitt's Xxxx'x NE
lymphoma xxx NE
were xxx NE
negative xxx NE
. . NE

By Xx NE
contrast xxx NE
, , NE
three xxx NE
lymphoblastoid xxx cell_line_B
cell xxx cell_line_M
lines xxx cell_line_E
(immortalized (xxx NE
in xx NE
vitro xxx NE
with xxx NE
Epstein-Barr Xxxx-Xxxx NE
virus xxx NE
) ) NE
were xxx NE
weakly xxx NE
positive xxx NE
and xxx NE
MNDA XXXX protein
was xxx NE
up-regulated xx-xxx NE
by xx NE
interferon-alpha xxx-xxx NE
( ( NE
IFN-alpha XXX-xxx NE
) ) NE
treatment xxx NE
. . NE

As Xx NE
we xx NE
reported xxx NE
previously xxx NE
, , NE
MNDA XXXX NE
mRNA xXXX NE
level xxx NE
in xx NE
adherent xxx NE
monocytes xxx cell_type
is xx NE
elevated xxx NE
by xx NE
IFN-alpha XXX-xxx protein
; ; NE
in xx NE
this xxx NE
study xxx NE
, , NE
we xx NE
further xxx NE
assessed xxx NE
MNDA XXXX NE
expression xxx NE
in xx NE
in xx NE
vitro xxx NE
monocyte-derived xxx-xxx NE
macrophages xxx cell_type
. . NE

Three Xxxx NE
additional xxx NE
agents xxx NE
( ( NE
endotoxin xxx NE
, , NE
phytohemagglutinin xxx protein
, , NE
and xxx NE
phorbol xxx NE
ester xxx NE
) ) NE
and xxx NE
other xxx NE
conditions xxx NE
that xxx NE
affect xxx NE
function xxx NE
, , NE
cytokine xxx NE
production xxx NE
, , NE
differentiation xxx NE
, , NE
and/or xxx/xx NE
growth xxx NE
of xx NE
monocytes xxx cell_type
were xxx NE
examined xxx NE
for xxx NE
their xxx NE
ability xxx NE
to xx NE
alter xxx NE
MNDA XXXX NE
expression xxx NE
. . NE

The Xxx NE
results xxx NE
varied xxx NE
with xxx NE
the xxx NE
agent xxx NE
, , NE
cell xxx NE
type xxx NE
, , NE
and xxx NE
stage xxx NE
of xx NE
differentiation xxx NE
. . NE

Changes Xxxx NE
in xx NE
MNDA XXXX NE
expression xxx NE
occurred xxx NE
slowly xxx NE
(hours (xxx NE
to xx NE
days) xxx) NE
, , NE
suggesting xxx NE
that xxx NE
MNDA XXXX protein
could xxx NE
mediate xxx NE
changes xxx NE
realized xxx NE
over xxx NE
a x NE
long xxx NE
period xxx NE
. . NE

The Xxx NE
results xxx NE
also xxx NE
reveal xxx NE
a x NE
discordance xxx NE
in xx NE
certain xxx NE
MNDA XXXX cell_line_B
positive xxx cell_line_M
cells xxx cell_line_E
between xxx NE
steady-state xxx-xxx NE
levels xxx NE
or xx NE
changes xxx NE
in xx NE
levels xxx NE
of xx NE
protein xxx NE
and xxx NE
mRNA xXXX RNA
indicating xxx NE
that xxx NE
the xxx NE
regulation xxx NE
of xx NE
MNDA XXXX NE
expression xxx NE
occurs xxx NE
at xx NE
more xxx NE
than xxx NE
one xxx NE
point xxx NE
. . NE

Changes Xxxx NE
in xx NE
MNDA XXXX NE
expression xxx NE
are xxx NE
consistent xxx NE
with xxx NE
a x NE
role xxx NE
in xx NE
opposing xxx NE
macrophage xxx NE
differentiation xxx NE
and xxx NE
activation xxx NE
of xx NE
monocytes xxx cell_type
/macrophages /xxx NE
. . NE

DNA-binding XXX-xxx NE
studies xxx NE
of xx NE
the xxx NE
Epstein-Barr Xxxx-Xxxx protein_B
virus xxx protein_M
nuclear xxx protein_M
antigen xxx protein_M
2 d protein_E
( ( NE
EBNA-2 XXXX-d protein
) ) NE
: : NE
evidence xxx NE
for xxx NE
complex xxx NE
formation xxx NE
by xx NE
latent xxx protein_B
membrane xxx protein_M
protein xxx protein_M
gene xxx protein_M
promoter-binding xxx-xxx protein_M
proteins xxx protein_E
in xx NE
EBNA-2 XXXX-d NE
-positive -xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
Epstein-Barr Xxxx-Xxxx NE
virus xxx NE
( ( NE
EBV XXX NE
) ) NE
nuclear xxx NE
antigen xxx NE
2 d NE
( ( NE
EBNA-2 XXXX-d NE
) ) NE
protein xxx NE
is xx NE
essential xxx NE
for xxx NE
the xxx NE
immortalization xxx NE
of xx NE
human xxx NE
primary xxx NE
B X NE
cells xxx NE
by xx NE
EBV XXX NE
. . NE

EBNA-2 XXXX-d protein
trans-activates xxx-xxx NE
cellular xxx DNA_B
gene xxx DNA_M
and xxx DNA_M
viral xxx DNA_M
gene xxx DNA_E
like xxx NE
CD23 XXdd DNA
, , NE
c-fgr x-xxx DNA
, , NE
latent xxx protein_B
membrane xxx protein_M
protein xxx protein_M
1 d protein_E
( ( NE
LMP1 XXXd protein
) ) NE
and xxx NE
terminal xxx protein_B
protein xxx protein_M
1 d protein_E
( ( NE
TP1 XXd protein
) ) NE
. . NE

Trans-activation Xxxx-xxx NE
of xx NE
the xxx NE
TP1 XXd DNA_B
promoter xxx DNA_E
and xxx NE
of xx NE
the xxx NE
BamHI XxxXX DNA_B
C X DNA_M
promoter xxx DNA_E
has xxx NE
already xxx NE
been xxx NE
investigated xxx NE
in xx NE
detail xxx NE
and xxx NE
appears xxx NE
to xx NE
be xx NE
mediated xxx NE
via xxx NE
protein-protein xxx-xxx NE
interactions xxx NE
and xxx NE
not xxx NE
by xx NE
direct xxx NE
binding xxx NE
of xx NE
EBNA-2 XXXX-d protein_B
type xxx protein_M
A X protein_E
(of (xx NE
EBV XXX NE
type xxx NE
1 d NE
) ) NE
to xx NE
the xxx NE
DNA XXX NE
. . NE

EBNA-2 XXXX-d protein
is xx NE
able xxx NE
to xx NE
trans-activate xxx-xxx NE
the xxx NE
expression xxx NE
of xx NE
the xxx NE
LMP XXX DNA_B
gene xxx DNA_E
in xx NE
several xxx NE
cell xxx NE
lines xxx NE
. . NE

Various Xxxx NE
reports xxx NE
have xxx NE
delineated xxx NE
the xxx NE
cis-acting xxx-xxx DNA_B
elements xxx DNA_E
of xx NE
the xxx NE
LMP XXX DNA_B
promoter xxx DNA_E
through xxx NE
which xxx NE
EBNA-2 XXXX-d protein
mediates xxx NE
trans-activation xxx-xxx NE
. . NE

To Xx NE
determine xxx NE
whether xxx NE
EBNA-2 XXXX-d protein
also xxx NE
trans-activates xxx-xxx NE
the xxx NE
LMP XXX DNA_B
promoter xxx DNA_E
by xx NE
protein-protein xxx-xxx NE
interactions xxx NE
, , NE
we xx NE
performed xxx NE
a x NE
series xxx NE
of xx NE
gel xxx NE
retardation xxx NE
assays xxx NE
and xxx NE
competition xxx NE
experiments xxx NE
with xxx NE
LMP XXX DNA_B
promoter xxx DNA_M
fragments xxx DNA_E
of xx NE
different xxx NE
sizes xxx NE
. . NE

We Xx NE
determined xxx NE
that xxx NE
the xxx NE
protein-binding xxx-xxx DNA_B
region xxx DNA_E
on xx NE
the xxx NE
LMP XXX DNA_B
promoter xxx DNA_E
was xxx NE
within xxx NE
a x NE
42 dd DNA_B
bp xx DNA_M
fragment xxx DNA_E
encompassing xxx NE
nucleotides xxx DNA_B
-135 -ddd DNA_M
to xx DNA_M
-176 -ddd DNA_E
relative xxx NE
to xx NE
the xxx NE
LMP XXX DNA_B
transcriptional xxx DNA_M
start xxx DNA_M
site xxx DNA_E
. . NE

None Xxxx NE
of xx NE
the xxx NE
DNA XXX NE
fragments xxx NE
investigated xxx NE
indicated xxx NE
interaction xxx NE
of xx NE
EBNA-2 XXXX-d protein
with xxx NE
the xxx NE
DNA XXX NE
via xxx NE
protein-protein xxx-xxx NE
interactions xxx NE
. . NE

No Xx NE
significant xxx NE
differences xxx NE
between xxx NE
EBNA-2 XXXX-d protein
-positive -xxx NE
and xxx NE
EBNA-2 XXXX-d protein
-negative -xxx NE
nuclear xxx NE
extracts xxx NE
could xxx NE
be xx NE
seen xxx NE
in xx NE
the xxx NE
gel xxx NE
retardation xxx NE
assay xxx NE
under xxx NE
conditions xxx NE
that xxx NE
clearly xxx NE
showed xxx NE
binding xxx NE
of xx NE
EBNA-2A XXXX-dX protein
to xx NE
the xxx NE
TP1 XXd DNA_B
promoter xxx DNA_E
. . NE

However Xxxx NE
, , NE
analysis xxx NE
of xx NE
sucrose xxx NE
gradient xxx NE
fractions xxx NE
in xx NE
the xxx NE
gel xxx NE
retardation xxx NE
assay xxx NE
provided xxx NE
evidence xxx NE
that xxx NE
the xxx NE
LMP XXX NE
promoter xxx NE
-binding -xxx NE
proteins xxx NE
form xxx NE
a x NE
complex xxx NE
of xx NE
higher xxx NE
M(r) X(x) NE
in xx NE
EBNA-2 XXXX-d NE
-positive -xxx NE
cell xxx NE
extracts xxx NE
. . NE

These Xxxx NE
complexes xxx NE
were xxx NE
destroyed xxx NE
by xx NE
detergent xxx NE
. . NE

We Xx NE
deduce xxx NE
from xxx NE
these xxx NE
results xxx NE
that xxx NE
EBNA-2 XXXX-d NE
-positive -xxx NE
cells xxx NE
might xxx NE
indeed xxx NE
contain xxx NE
specific xxx NE
complexes xxx NE
bound xxx NE
to xx NE
the xxx NE
LMP XXX NE
promoter xxx NE
which xxx NE
are xxx NE
, , NE
however xxx NE
, , NE
too xxx NE
labile xxx NE
to xx NE
be xx NE
detected xxx NE
in xx NE
a x NE
standard xxx NE
gel xxx NE
retardation xxx NE
assay xxx NE
. . NE

Simultaneous Xxxx NE
activation xxx NE
of xx NE
Ig Xx protein
and xxx NE
Oct-2 Xxx-d NE
synthesis xxx NE
and xxx NE
reduction xxx NE
of xx NE
surface xxx NE
MHC XXX NE
class xxx NE
II XX NE
expression xxx NE
by xx NE
IL-6 XX-d protein
. . NE

Terminal Xxxx NE
differentiation xxx NE
of xx NE
B X cell_type_B
cells xxx cell_type_E
to xx NE
plasma xxx cell_type_B
cells xxx cell_type_E
in xx NE
vivo xxx NE
is xx NE
characterized xxx NE
by xx NE
secretion xxx NE
of xx NE
Ig Xx protein
and xxx NE
extinction xxx NE
of xx NE
MHC XXX NE
class xxx NE
II XX NE
expression xxx NE
on xx NE
the xxx NE
cell xxx NE
surface xxx NE
. . NE

We Xx NE
show xxx NE
that xxx NE
IL-6 XX-d protein
signaling xxx NE
leads xxx NE
to xx NE
marked xxx NE
increases xxx NE
in xx NE
the xxx NE
synthesis xxx NE
and xxx NE
secretion xxx NE
of xx NE
Ig Xx protein
in xx NE
clonal xxx cell_line_B
human xxx cell_line_M
B X cell_line_M
cell xxx cell_line_M
lines xxx cell_line_E
and xxx NE
newly xxx NE
isolated xxx cell_type_B
polyclonal xxx cell_type_M
B X cell_type_M
lymphocytes xxx cell_type_E
in xx NE
vitro xxx NE
. . NE

The Xxx NE
IL-6-induced XX-d-xxx cell_line_B
cells xxx cell_line_E
resemble xxx NE
plasma xxx cell_type_B
cells xxx cell_type_E
in xx NE
ultrastructure xxx NE
and xxx NE
in xx NE
reduced xxx NE
expression xxx NE
of xx NE
surface xxx protein_B
MHC XXX protein_M
class xxx protein_M
II XX protein_E
. . NE

Enhanced Xxxx NE
Ig Xx protein
synthesis xxx NE
is xx NE
a x NE
result xxx NE
of xx NE
coordinated xxx NE
transcriptional xxx NE
activation xxx NE
of xx NE
Ig Xx DNA_B
genes xxx DNA_E
without xxx NE
promoter xxx NE
or xx NE
isotype xxx NE
specificity xxx NE
, , NE
and xxx NE
differential xxx NE
accumulation xxx NE
of xx NE
the xxx NE
mRNA xXXX RNA
encoding xxx NE
the xxx NE
secreted xxx NE
form xxx NE
of xx NE
Ig Xx protein_B
heavy xxx protein_M
chain xxx protein_E
. . NE

It Xx NE
is xx NE
saturable xxx NE
and xxx NE
subject xxx NE
to xx NE
negative xxx NE
control xxx NE
when xxx NE
IL-6 XX-d NE
stimulation xxx NE
is xx NE
prolonged xxx NE
. . NE

Coordinate Xxxx NE
with xxx NE
temporal xxx NE
changes xxx NE
in xx NE
Ig Xx NE
synthesis xxx NE
, , NE
the xxx NE
DNA-binding XXX-xxx NE
activity xxx NE
and xxx NE
the xxx NE
synthesis xxx NE
of xx NE
the xxx NE
B X protein_B
cell-enriched xxx-xxx protein_M
transcription xxx protein_M
factor xxx protein_E
Oct-2 Xxx-d protein
are xxx NE
regulated xxx NE
. . NE

Thus Xxxx NE
, , NE
differentiation xxx NE
of xx NE
B X cell_type_B
cells xxx cell_type_E
with xxx NE
IL-6 XX-d protein
in xx NE
vitro xxx NE
recapitulates xxx NE
the xxx NE
hallmarks xxx NE
of xx NE
terminal xxx NE
B X NE
differentiation xxx NE
in xx NE
vivo xxx NE
; ; NE
Oct-2 Xxx-d protein
may xxx NE
have xxx NE
a x NE
role xxx NE
in xx NE
this xxx NE
process xxx NE
. . NE

T-cell X-xxx DNA_B
functional xxx DNA_M
regions xxx DNA_E
of xx NE
the xxx NE
human xxx DNA_B
IL-3 XX-d DNA_M
proximal xxx DNA_M
promoter xxx DNA_E
. . NE

The Xxx NE
human xxx NE
interleukin-3 xxx-d NE
( ( NE
IL-3 XX-d NE
) ) NE
gene xxx NE
is xx NE
expressed xxx NE
almost xxx NE
exclusively xxx NE
in xx NE
activated xxx NE
T X NE
cells xxx NE
. . NE

Its Xxx NE
expression xxx NE
is xx NE
regulated xxx NE
at xx NE
both xxx NE
the xxx NE
transcriptional xxx NE
and xxx NE
post-transcriptional xxx-xxx NE
level xxx NE
. . NE

We Xx NE
have xxx NE
previously xxx NE
shown xxx NE
that xxx NE
treatment xxx NE
of xx NE
Jurkat Xxxx cell_line_B
T X cell_line_M
cells xxx cell_line_E
with xxx NE
phytohemaglutinin xxx protein
( ( NE
PHA XXX protein
) ) NE
and xxx NE
the xxx NE
phorbol xxx NE
ester xxx NE
, , NE
PMA XXX NE
, , NE
activated xxx NE
transcription xxx NE
initiation xxx NE
from xxx NE
the xxx NE
IL-3 XX-d DNA_B
gene xxx DNA_E
. . NE

To Xx NE
define xxx NE
the xxx NE
regions xxx NE
of xx NE
the xxx NE
gene xxx NE
required xxx NE
for xxx NE
transcription xxx NE
activation xxx NE
, , NE
we xx NE
generated xxx NE
a x NE
series xxx NE
of xx NE
reporter xxx NE
constructs xxx NE
containing xxx NE
different xxx NE
regions xxx NE
of xx NE
the xxx NE
IL-3 XX-d DNA_B
gene xxx DNA_M
5' d' DNA_M
and xxx DNA_M
3' d' DNA_M
flanking xxx DNA_M
sequences xxx DNA_E
. . NE

Both Xxxx NE
positive xxx DNA_B
regulatory xxx DNA_M
element xxx DNA_M
and xxx DNA_M
negative xxx DNA_M
regulatory xxx DNA_M
element xxx DNA_E
were xxx NE
identified xxx NE
in xx NE
the xxx NE
proximal xxx DNA_B
5' d' DNA_M
flanking xxx DNA_M
region xxx DNA_E
of xx NE
the xxx NE
IL-3 XX-d DNA_B
gene xxx DNA_E
. . NE

The Xxx NE
promoter xxx DNA_B
region xxx DNA_E
between xxx NE
-173 -ddd DNA_B
and xxx DNA_M
-60 -dd DNA_E
contained xxx NE
the xxx NE
strongest xxx NE
activating xxx DNA_B
elements xxx DNA_E
. . NE

The Xxx NE
transcription xxx protein_B
factor xxx protein_E
AP-1 XX-d protein
could xxx NE
bind xxx NE
to xx NE
this xxx NE
positive xxx NE
activator xxx NE
region xxx NE
of xx NE
the xxx NE
promoter xxx NE
. . NE

We Xx NE
also xxx NE
examined xxx NE
the xxx NE
function xxx NE
of xx NE
the xxx NE
IL-3 XX-d DNA_B
CK-1/CK-2 XX-d/XX-d DNA_M
elements xxx DNA_E
that xxx NE
are xxx NE
present xxx NE
in xx NE
many xxx NE
cytokine xxx DNA_B
genes xxx DNA_E
and xxx NE
found xxx NE
that xxx NE
they xxx NE
acted xxx NE
as xx NE
a x NE
repressor xxx NE
of xx NE
basal xxx NE
level xxx NE
expression xxx NE
when xxx NE
cloned xxx NE
upstream xxx NE
of xx NE
a x NE
heterologous xxx DNA_B
promoter xxx DNA_E
but xxx NE
were xxx NE
also xxx NE
inducible xxx NE
by xx NE
PMA XXX NE
/PHA /XXX NE
. . NE

Expression Xxxx NE
of xx NE
the xxx NE
Runt Xxxx NE
domain xxx NE
-encoding -xxx NE
PEBP2 XXXXd NE
alpha xxx NE
genes xxx NE
in xx NE
T X NE
cells xxx NE
during xxx NE
thymic xxx NE
development xxx NE
. . NE

The Xxx NE
PEBP2 XXXXd DNA_B
alpha xxx DNA_M
A X DNA_M
gene xxx DNA_M
and xxx DNA_M
PEBP2 XXXXd DNA_M
alpha xxx DNA_M
B X DNA_M
gene xxx DNA_E
encode xxx NE
the xxx NE
DNA-binding XXX-xxx protein_B
subunit xxx protein_E
of xx NE
a x NE
murine xxx protein_B
transcription xxx protein_M
factor xxx protein_E
, , NE
PEBP2 XXXXd protein
, , NE
which xxx NE
is xx NE
implicated xxx NE
as xx NE
a x NE
T-cell-specific X-xxx-xxx protein_B
transcriptional xxx protein_M
regulator xxx protein_E
. . NE

These Xxxx NE
two xxx NE
related xxx NE
genes xxx NE
share xxx NE
the xxx NE
evolutionarily xxx NE
conserved xxx NE
region xxx NE
encoding xxx NE
the xxx NE
Runt Xxxx protein_B
domain xxx protein_E
. . NE

PEBP2 XXXXd protein_B
alpha xxx protein_M
B X protein_E
is xx NE
the xxx NE
murine xxx protein_B
counterpart xxx protein_E
of xx NE
human xxx protein_B
AML1 XXXd protein_E
, , NE
which xxx NE
is xx NE
located xxx NE
at xx NE
the xxx NE
breakpoints xxx NE
of xx NE
the xxx NE
8;21 d;dd DNA_B
chromosome xxx DNA_M
translocation xxx DNA_M
and xxx DNA_M
3;21 d;dd DNA_M
chromosome xxx DNA_M
translocation xxx DNA_E
associated xxx NE
with xxx NE
acute xxx NE
myeloid xxx NE
leukemia xxx NE
. . NE

Northern Xxxx NE
(RNA) (XXX) NE
blots xxx NE
of xx NE
various xxx NE
adult xxx NE
mouse xxx NE
tissues xxx NE
revealed xxx NE
that xxx NE
the xxx NE
levels xxx NE
of xx NE
expression xxx NE
of xx NE
both xxx NE
genes xxx NE
were xxx NE
most xxx NE
prominent xxx NE
in xx NE
the xxx NE
thymus xxx NE
. . NE

Furthermore Xxxx NE
, , NE
transcripts xxx NE
of xx NE
PEBP2 XXXXd protein_B
alpha xxx protein_M
A X protein_E
and xxx NE
mouse xxx NE
AML1 XXXd NE
/ / NE
PEBP2 XXXXd NE
alpha xxx NE
B X NE
were xxx NE
detected xxx NE
in xx NE
T X NE
lymphocytes xxx NE
in xx NE
the xxx NE
thymuses xxx NE
from xxx NE
day xxx NE
16 dd NE
embryos xxx NE
and xxx NE
newborns xxx NE
, , NE
as xx NE
well xxx NE
as xx NE
4-week-old d-xxx-xxx NE
adult xxx NE
mice xxx NE
, , NE
by xx NE
in xx NE
situ xxx NE
hybridization xxx NE
. . NE

The Xxx NE
expression xxx NE
of xx NE
the xxx NE
genes xxx NE
persisted xxx NE
in xx NE
peripheral xxx NE
lymph xxx NE
nodes xxx NE
of xx NE
adult xxx NE
mice xxx NE
. . NE

The Xxx NE
transcripts xxx NE
were xxx NE
detected xxx NE
in xx NE
all xxx NE
the xxx NE
CD4- XXd- cell_type_B
CD8- XXd- cell_type_M
cell xxx cell_type_M
population xxx cell_type_M
and xxx cell_type_M
CD4+ XXd+ cell_type_M
CD8+ XXd+ cell_type_M
cell xxx cell_type_M
population xxx cell_type_M
and xxx cell_type_M
CD4+ XXd+ cell_type_M
CD8- XXd- cell_type_M
cell xxx cell_type_M
population xxx cell_type_M
and xxx cell_type_M
CD4- XXd- cell_type_M
CD8+ XXd+ cell_type_M
cell xxx cell_type_M
population xxx cell_type_E

The Xxx NE
results xxx NE
indicated xxx NE
that xxx NE
both xxx NE
genes xxx NE
are xxx NE
expressed xxx NE
in xx NE
T X cell_type_B
cells xxx cell_type_E
throughout xxx NE
their xxx NE
development xxx NE
, , NE
supporting xxx NE
the xxx NE
notion xxx NE
that xxx NE
PEBP2 XXXXd protein
is xx NE
a x NE
T-cell-specific X-xxx-xxx protein_B
transcription xxx protein_M
factor xxx protein_E
. . NE

Transcripts Xxxx NE
of xx NE
mouse xxx NE
AML1 XXXd NE
/ / NE
PEBP2 XXXXd NE
alpha xxx NE
B X NE
were xxx NE
also xxx NE
detected xxx NE
in xx NE
day xxx NE
12 dd NE
fetal xxx NE
hematopoietic xxx NE
liver xxx NE
and xxx NE
in xx NE
the xxx NE
bone xxx NE
marrow xxx NE
cells xxx NE
of xx NE
newborn xxx NE
mice xxx NE
. . NE

The Xxx NE
implication xxx NE
of xx NE
mouse xxx NE
AML1 XXXd NE
/ / NE
PEBP2 XXXXd NE
alpha xxx NE
B X NE
expression xxx NE
in xx NE
hematopoietic xxx NE
cells xxx NE
other xxx NE
than xxx NE
those xxx NE
of xx NE
T-cell X-xxx NE
lineage xxx NE
is xx NE
discussed xxx NE
in xx NE
relation xxx NE
to xx NE
myeloid xxx NE
leukemogenesis xxx NE
. . NE

Effects Xxxx NE
of xx NE
glucocorticoids xxx NE
on xx NE
transcription xxx NE
factor xxx NE
activation xxx NE
in xx NE
human xxx cell_type_B
peripheral xxx cell_type_M
blood xxx cell_type_M
mononuclear xxx cell_type_M
cells xxx cell_type_E
. . NE

Glucocorticoids Xxxx NE
have xxx NE
an xx NE
inhibitory xxx NE
effect xxx NE
on xx NE
inflammatory xxx NE
response xxx NE
and xxx NE
immune xxx NE
response xxx NE
transcription xxx NE
factor xxx NE
binding xxx NE
to xx NE
DNA XXX NE
. . NE

The Xxx NE
interaction xxx NE
of xx NE
the xxx NE
transcription xxx protein_B
factors xxx protein_E
, , NE
activator xxx protein_B
protein-1 xxx-d protein_E
( ( NE
AP-1 XX-d protein
) ) NE
, , NE
nuclear xxx protein_B
factor xxx protein_M
kappa xxx protein_M
B X protein_E
( ( NE
NF XX protein_B
kappa xxx protein_M
B X protein_E
) ) NE
, , NE
and xxx NE
cAMP-responsive xXXX-xxx protein_B
element xxx protein_M
binding xxx protein_M
protein xxx protein_E
( ( NE
CREB XXXX protein
) ) NE
with xxx NE
DNA XXX NE
and xxx NE
glucocorticoid xxx protein_B
receptors xxx protein_E
( ( NE
GR XX protein
) ) NE
was xxx NE
analyzed xxx NE
in xx NE
human xxx cell_type_B
peripheral xxx cell_type_M
blood xxx cell_type_M
mononuclear xxx cell_type_M
cells xxx cell_type_E
by xx NE
gel xxx NE
mobility xxx NE
shift xxx NE
assays xxx NE
. . NE

TNF-alpha, XXX-xxx, NE
IL-1 XX-d NE
beta xxx NE
treatment xxx NE
and xxx NE
phorbol xxx NE
myristate xxx NE
acetate xxx NE
(PMA) (XXX) NE
treatment xxx NE
increased xxx NE
AP-1 XX-d protein
and xxx NE
NF XX NE
kappa xxx NE
B X NE
DNA XXX NE
binding xxx NE
by xx NE
up xx NE
to xx NE
200% ddd% NE
but xxx NE
decreased xxx NE
CREB XXXX NE
binding xxx NE
(38%) (dd%) NE
over xxx NE
a x NE
60-min dd-xxx NE
time xxx NE
course xxx NE
. . NE

Dexamethasone Xxxx NE
produced xxx NE
a x NE
rapid xxx NE
and xxx NE
sustained xxx NE
increase xxx NE
in xx NE
glucocorticoid xxx NE
response xxx NE
element xxx NE
binding xxx NE
and xxx NE
a x NE
concomitant xxx NE
40-50% dd-dd% NE
decrease xxx NE
in xx NE
AP-1 XX-d NE
DNA XXX NE
binding xxx NE
and xxx NE
NF XX NE
kappa xxx NE
B X NE
DNA XXX NE
binding xxx NE
and xxx NE
CREB XXXX NE
DNA XXX NE
binding xxx NE
that xxx NE
was xxx NE
blocked xxx NE
by xx NE
combined xxx NE
dexamethasone xxx NE
and xxx NE
cytokine xxx NE
or xx NE
PMA XXX NE
treatment xxx NE
. . NE

These Xxxx NE
latter xxx NE
effects xxx NE
were xxx NE
due xxx NE
to xx NE
increases xxx NE
in xx NE
the xxx NE
nuclear xxx NE
localization xxx NE
of xx NE
GR XX protein
, , NE
not xxx NE
to xx NE
reduced xxx NE
amounts xxx NE
of xx NE
the xxx NE
other xxx NE
transcription xxx protein_B
factors xxx protein_E
. . NE

This Xxxx NE
suggests xxx NE
that xxx NE
in xx NE
these xxx NE
cells xxx NE
GR XX protein
within xxx NE
the xxx NE
nucleus xxx protein
interacts xxx NE
with xxx NE
cytokine xxx NE
-stimulated -xxx NE
transcription xxx NE
factors xxx NE
by xx NE
the xxx NE
process xxx NE
of xx NE
cross xxx NE
coupling xxx NE
. . NE

This Xxxx NE
may xxx NE
be xx NE
an xx NE
important xxx NE
molecular xxx NE
site xxx NE
of xx NE
steroid xxx NE
action xxx NE
. . NE

Differential Xxxx NE
induction xxx NE
of xx NE
the xxx NE
NF-AT XX-XX protein_B
complex xxx protein_E
during xxx NE
restimulation xxx NE
and xxx NE
the xxx NE
induction xxx NE
of xx NE
T-cell X-xxx NE
anergy xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
human xxx cell_line_B
CD4+ XXd+ cell_line_M
T-cell X-xxx cell_line_M
clones xxx cell_line_E
through xxx NE
the xxx NE
T-cell X-xxx protein_B
receptor xxx protein_E
( ( NE
TcR XxX protein
) ) NE
by xx NE
high xxx NE
doses xxx NE
of xx NE
specific xxx NE
peptide xxx NE
results xxx NE
in xx NE
the xxx NE
induction xxx NE
of xx NE
a x NE
long-lived xxx-xxx NE
state xxx NE
of xx NE
nonresponsiveness xxx NE
that xxx NE
has xxx NE
been xxx NE
called xxx NE
anergy xxx NE
. . NE

During Xxxx NE
the xxx NE
induction xxx NE
of xx NE
anergy xxx NE
, , NE
T X cell_type_B
cells xxx cell_type_E
are xxx NE
phenotypically xxx NE
similar xxx NE
to xx NE
cells xxx NE
responding xxx NE
to xx NE
an xx NE
immunogenic xxx NE
stimulus xxx NE
. . NE

The Xxx NE
amount xxx NE
of xx NE
TcR XxX protein
at xx NE
the xxx NE
cell xxx NE
surface xxx NE
is xx NE
downmodulated xxx NE
, , NE
whereas xxx NE
the xxx NE
CD2 XXd protein_B
receptor xxx protein_M
and xxx protein_M
CD25 XXdd protein_M
receptor xxx protein_E

When Xxxx NE
restimulated xxx NE
, , NE
however xxx NE
, , NE
anergic xxx cell_type_B
T X cell_type_M
cells xxx cell_type_E
fail xxx NE
to xx NE
up-regulate xx-xxx NE
transcription xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_B
gene xxx DNA_E
and xxx NE
in xx NE
consequence xxx NE
do xx NE
not xxx NE
produce xxx NE
IL-2 XX-d protein
. . NE

In Xx NE
this xxx NE
study xxx NE
, , NE
we xx NE
have xxx NE
compared xxx NE
the xxx NE
ability xxx NE
of xx NE
various xxx NE
transcription xxx protein_B
factors xxx protein_E
to xx NE
bind xxx NE
to xx NE
their xxx NE
appropriate xxx NE
site xxx NE
on xx NE
DNA XXX NE
. . NE

Factors Xxxx NE
were xxx NE
isolated xxx NE
from xxx NE
the xxx NE
nuclei xxx NE
of xx NE
T X cell_type_B
cells xxx cell_type_E
that xxx NE
were xxx NE
in xx NE
the xxx NE
induction xxx NE
phase xxx NE
of xx NE
anergy xxx NE
or xx NE
were xxx NE
undergoing xxx NE
activation xxx NE
. . NE

The Xxx NE
pattern xxx NE
of xx NE
binding xxx NE
activity xxx NE
in xx NE
restimulated xxx NE
T X cell_type_B
cells xxx cell_type_E
is xx NE
consistent xxx NE
with xxx NE
the xxx NE
pattern xxx NE
that xxx NE
has xxx NE
previously xxx NE
been xxx NE
shown xxx NE
to xx NE
regulate xxx NE
T-cell-specific X-xxx-xxx NE
expression xxx NE
of xx NE
the xxx NE
IL-2 XX-d protein
and xxx NE
the xxx NE
beta xxx NE
chain xxx NE
of xx NE
the xxx NE
TcR XxX DNA_B
genes xxx DNA_E
. . NE

The Xxx NE
measured xxx NE
binding xxx NE
to xx NE
a x NE
TCF-1 XXX-d DNA_B
site xxx DNA_E
is xx NE
the xxx NE
same xxx NE
in xx NE
the xxx NE
nuclei xxx NE
of xx NE
resting xxx cell_type_B
cell xxx cell_type_M
and xxx cell_type_M
activated xxx cell_type_M
cell xxx cell_type_M
and xxx cell_type_M
anergized xxx cell_type_M
cell xxx cell_type_E

The Xxx NE
inducible xxx protein_B
factors xxx protein_E
NK-kappa XX-xxx protein_B
B X protein_E
, , NE
beta xxx protein_B
E2 Xd protein_E
, , NE
CD28RC XXddXX protein
, , NE
and xxx NE
AP-1 XX-d protein
are xxx NE
not xxx NE
expressed xxx NE
in xx NE
resting xxx cell_type_B
cells xxx cell_type_E
and xxx NE
are xxx NE
twofold xxx NE
lower xxx NE
in xx NE
anergized xxx NE
as xx NE
compared xxx NE
with xxx NE
activated xxx NE
cells xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
anergic xxx cell_type_B
T X cell_type_M
cells xxx cell_type_E
express xxx NE
approximately xxx NE
eightfold xxx NE
lower xxx NE
amounts xxx NE
of xx NE
NF-AT XX-XX protein
, , NE
a x NE
member xxx NE
of xx NE
the xxx NE
class xxx NE
of xx NE
inducible xxx protein_B
factors xxx protein_E
that xxx NE
regulates xxx NE
IL-2 XX-d DNA_B
gene xxx DNA_E
transcription xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

The Xxx NE
number xxx NE
of xx NE
glucocorticoid xxx protein_B
receptors xxx protein_E
in xx NE
peripheral xxx cell_type_B
human xxx cell_type_M
lymphocytes xxx cell_type_E
is xx NE
elevated xxx NE
by xx NE
a x NE
zinc xxx NE
containing xxx NE
trace xxx NE
element xxx NE
preparation xxx NE
. . NE

A X NE
trace xxx NE
element xxx NE
preparation xxx NE
( ( NE
Beres Xxxx NE
Drops Xxxx NE
Plus Xxxx NE
, , NE
BDP XXX NE
) ) NE
elevates xxx NE
the xxx NE
number xxx NE
of xx NE
glucocorticoid xxx protein_B
receptors xxx protein_E
( ( NE
gcR xxX protein
) ) NE
in xx NE
peripheral xxx cell_type_B
lymphocytes xxx cell_type_E
isolated xxx NE
both xxx NE
from xxx NE
healthy xxx NE
blood xxx NE
donors xxx NE
and xxx NE
rheumatoid xxx NE
arthritis xxx NE
patients xxx NE
. . NE

This Xxxx NE
enhancement xxx NE
by xx NE
BDP XXX NE
was xxx NE
found xxx NE
either xxx NE
for xxx NE
constitutive xxx NE
expression xxx NE
of xx NE
gcRs xxXx protein
or xx NE
in xx NE
experiments xxx NE
when xxx NE
the xxx NE
lymphocytes xxx cell_type
were xxx NE
stimulated xxx NE
by xx NE
interleukin xxx protein_B
(IL)-6 (XX)-d protein_E
. . NE

There Xxxx NE
was xxx NE
no xx NE
significant xxx NE
effect xxx NE
of xx NE
BDP XXX NE
on xx NE
IL-1-induced XX-d-xxx NE
change xxx NE
and xxx NE
tumour xxx NE
necrosis xxx NE
factor xxx NE
alpha xxx NE
(TNF (XXX NE
alpha)-induced xxx)-xxx NE
change xxx NE
of xx NE
gcRs xxXx protein
. . NE

The Xxx NE
effect xxx NE
of xx NE
BDP XXX NE
was xxx NE
greatly xxx NE
dependent xxx NE
on xx NE
the xxx NE
presence xxx NE
of xx NE
Zn++ Xx++ NE
ions xxx NE
in xx NE
the xxx NE
preparation xxx NE
, , NE
since xxx NE
the xxx NE
augmenting xxx NE
effect xxx NE
was xxx NE
abolished xxx NE
if xx NE
BDP XXX NE
did xxx NE
not xxx NE
contain xxx NE
zinc xxx NE
. . NE

The Xxx NE
DNA XXX NE
and xxx NE
steroid xxx protein_B
binding xxx protein_M
domains xxx protein_E
of xx NE
the xxx NE
glucocorticoid xxx protein_B
receptor xxx protein_E
are xxx NE
not xxx NE
altered xxx NE
in xx NE
mononuclear xxx cell_type_B
cells xxx cell_type_E
of xx NE
treated xxx NE
CLL XXX NE
patients xxx NE
. . NE

The Xxx NE
aim xxx NE
of xx NE
this xxx NE
study xxx NE
was xxx NE
to xx NE
investigate xxx NE
whether xxx NE
mutations xxx NE
in xx NE
the xxx NE
glucocorticoid xxx protein_B
receptor xxx protein_E
could xxx NE
account xxx NE
for xxx NE
the xxx NE
increasing xxx NE
unresponsiveness xxx NE
of xx NE
patients xxx NE
with xxx NE
chronic xxx NE
lymphatic xxx NE
leukemia xxx NE
( ( NE
CLL XXX NE
) ) NE
to xx NE
combination xxx NE
chemotherapy xxx NE
. . NE

The Xxx NE
receptor xxx NE
was xxx NE
tested xxx NE
immunocytochemically xxx NE
, , NE
in xx NE
steroid xxx NE
binding xxx NE
assays xxx NE
, , NE
and xxx NE
by xx NE
a x NE
mutation xxx NE
screening xxx NE
( ( NE
denaturing xxx NE
gradient xxx NE
gel xxx NE
electrophoresis xxx NE
) ) NE
of xx NE
the xxx NE
receptor-cDNA xxx-xXXX protein
. . NE

The Xxx NE
receptor xxx NE
concentration xxx NE
, , NE
as xx NE
measured xxx NE
by xx NE
staining xxx NE
and xxx NE
steroid xxx NE
binding xxx NE
test xxx NE
, , NE
varied xxx NE
considerably xxx NE
but xxx NE
showed xxx NE
no xx NE
clear xxx NE
correlation xxx NE
to xx NE
clinical xxx NE
response xxx NE
. . NE

Using Xxxx NE
a x NE
highly xxx NE
sensitive xxx NE
mutation xxx NE
screening xxx NE
assay xxx NE
of xx NE
the xxx NE
DNA-binding XXX-xxx protein_B
region xxx protein_M
and xxx protein_M
the xxx protein_M
steroid-binding xxx-xxx protein_M
region xxx protein_E
patients xxx NE
revealed xxx NE
any xxx NE
mutation xxx NE
, , NE
suggesting xxx NE
that xxx NE
the xxx NE
glucocorticoid xxx protein_B
receptor xxx protein_E
in xx NE
the xxx NE
CLL XXX NE
patients xxx NE
tested xxx NE
is xx NE
not xxx NE
altered xxx NE
in xx NE
these xxx NE
domains xxx NE
. . NE

In Xx NE
one xxx NE
individual xxx NE
who xxx NE
had xxx NE
not xxx NE
been xxx NE
treated xxx NE
before xxx NE
analysis xxx NE
a x NE
silent xxx NE
mutation xxx NE
was xxx NE
found xxx NE
in xx NE
one xxx NE
receptor xxx NE
allele xxx NE
. . NE

The Xxx NE
results xxx NE
suggest xxx NE
that xxx NE
mechanisms xxx NE
other xxx NE
than xxx NE
altered xxx NE
ligand xxx NE
or xx NE
DNA XXX NE
binding xxx NE
of xx NE
the xxx NE
receptor xxx NE
may xxx NE
be xx NE
responsible xxx NE
for xxx NE
the xxx NE
lack xxx NE
of xx NE
response xxx NE
to xx NE
chemotherapy xxx NE
. . NE

This Xxxx NE
conclusion xxx NE
is xx NE
discussed xxx NE
in xx NE
relation xxx NE
to xx NE
the xxx NE
mechanism xxx NE
of xx NE
corticoid xxx NE
resistance xxx NE
in xx NE
mouse xxx cell_line_B
lymphoma xxx cell_line_M
cell xxx cell_line_M
and xxx cell_line_M
human xxx cell_line_M
lymphoma xxx cell_line_M
cell xxx cell_line_E

An Xx NE
AP1 XXd DNA_B
binding xxx DNA_M
site xxx DNA_E
upstream xxx NE
of xx NE
the xxx NE
kappa xxx DNA_B
immunoglobulin xxx DNA_M
intron xxx DNA_M
enhancer xxx DNA_E
binds xxx NE
inducible xxx protein_B
factors xxx protein_E
and xxx NE
contributes xxx NE
to xx NE
expression xxx NE
. . NE

Expression Xxxx NE
of xx NE
the xxx NE
kappa xxx DNA_B
immunoglobulin xxx DNA_M
light xxx DNA_M
chain xxx DNA_M
gene xxx DNA_E
requires xxx NE
developmental- xxx- NE
and xxx NE
tissue-specific xxx-xxx NE
regulation xxx NE
by xx NE
trans-acting xxx-xxx protein_B
factors xxx protein_E
which xxx NE
interact xxx NE
with xxx NE
two xxx NE
distinct xxx NE
enhancer xxx DNA_B
elements xxx DNA_E
. . NE

A X NE
new xxx NE
protein-DNA xxx-XXX NE
interaction xxx NE
has xxx NE
been xxx NE
identified xxx NE
upstream xxx NE
of xx NE
the xxx NE
intron xxx DNA_B
enhancer xxx DNA_E
, , NE
within xxx NE
the xxx NE
matrix-associated xxx-xxx DNA_B
region xxx DNA_E
of xx NE
the xxx NE
J-C X-X DNA_B
intron xxx DNA_E
. . NE

The Xxx NE
binding xxx NE
activity xxx NE
is xx NE
greatly xxx NE
inducible xxx NE
in xx NE
pre-B xxx-X cell_type_B
cells xxx cell_type_E
by xx NE
bacterial xxx NE
lipopolysaccharide xxx NE
and xxx NE
interleukin-1 xxx-d protein
but xxx NE
specific xxx NE
complexes xxx NE
are xxx NE
found xxx NE
at xx NE
all xxx NE
stages xxx NE
of xx NE
B X NE
cell xxx NE
development xxx NE
tested xxx NE
. . NE

The Xxx NE
footprinted xxx DNA_B
binding xxx DNA_M
site xxx DNA_E
is xx NE
homologous xxx NE
to xx NE
the xxx NE
consensus xxx DNA_B
AP1 XXd DNA_M
motif xxx DNA_E
. . NE

The Xxx NE
protein xxx NE
components xxx NE
of xx NE
this xxx NE
complex xxx NE
are xxx NE
specifically xxx NE
competed xxx NE
by xx NE
an xx NE
AP1 XXd DNA_B
consensus xxx DNA_M
motif xxx DNA_E
and xxx NE
were xxx NE
shown xxx NE
by xx NE
supershift xxx NE
to xx NE
include xxx NE
c-Jun x-Xxx protein
and xxx NE
c-Fos x-Xxx protein
, , NE
suggesting xxx NE
that xxx NE
this xxx NE
binding xxx DNA_B
site xxx DNA_E
is xx NE
an xx NE
AP1 XXd DNA_B
motif xxx DNA_E
and xxx NE
that xxx NE
the xxx NE
Jun Xxx protein_B
family xxx protein_M
and xxx protein_M
Fos Xxx protein_M
family xxx protein_E
families xxx NE
of xx NE
transcription xxx protein_B
factors xxx protein_E
play xxx NE
a x NE
role xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
the xxx NE
kappa xxx DNA_B
light xxx DNA_M
chain xxx DNA_M
gene xxx DNA_E
. . NE

Mutation Xxxx NE
of xx NE
the xxx NE
AP1 XXd DNA_B
motif xxx DNA_E
in xx NE
the xxx NE
context xxx NE
of xx NE
the xxx NE
intron xxx DNA_B
enhancer xxx DNA_E
was xxx NE
shown xxx NE
to xx NE
decrease xxx NE
enhancer-mediated xxx-xxx NE
activation xxx NE
of xx NE
the xxx NE
promoter xxx NE
in xx NE
both xxx NE
pre-B xxx-X cell_type_B
cells xxx cell_type_E
induced xxx NE
with xxx NE
LPS XXX NE
and xxx NE
constitutive xxx NE
expression xxx NE
in xx NE
mature xxx cell_type_B
B X cell_type_M
cells xxx cell_type_E
. . NE

Distinct Xxxx NE
DNase-I XXxxx-X DNA_B
hypersensitive xxx DNA_M
sites xxx DNA_E
are xxx NE
associated xxx NE
with xxx NE
TAL-1 XXX-d NE
transcription xxx NE
in xx NE
erythroid xxx cell_line_B
cell xxx cell_line_M
line xxx cell_line_M
and xxx cell_line_M
T-cell X-xxx cell_line_M
line xxx cell_line_E

The Xxx NE
tal-1 xxx-d DNA_B
gene xxx DNA_E
, , NE
frequently xxx NE
activated xxx NE
in xx NE
human xxx NE
T-cell X-xxx NE
acute xxx NE
lymphoblastic xxx NE
leukemia xxx NE
( ( NE
T-ALL X-XXX NE
) ) NE
, , NE
is xx NE
expressed xxx NE
in xx NE
the xxx NE
erythroid xxx cell_type_B
cell xxx cell_type_M
lineage xxx cell_type_M
and xxx cell_type_M
megakaryocytic xxx cell_type_M
cell xxx cell_type_M
lineage xxx cell_type_M
and xxx cell_type_M
mast xxx cell_type_M
cell xxx cell_type_M
lineage xxx cell_type_E
during xxx NE
normal xxx NE
hematopoiesis xxx NE
. . NE

To Xx NE
gain xxx NE
further xxx NE
insight xxx NE
into xxx NE
the xxx NE
molecular xxx NE
mechanisms xxx NE
that xxx NE
control xxx NE
tal-1 xxx-d NE
expression xxx NE
, , NE
we xx NE
investigated xxx NE
tal-1 xxx-d DNA_B
chromatin xxx DNA_M
structure xxx DNA_E
in xx NE
erythroid/megakaryocytic xxx/xxx cell_line_B
cell xxx cell_line_M
lines xxx cell_line_E
and xxx NE
in xx NE
T-cell X-xxx cell_line_B
lines xxx cell_line_E
either xxx NE
with xxx NE
or xx NE
without xxx NE
tal-1 xxx-d DNA_B
rearrangements xxx DNA_E
. . NE

Tal-1 Xxx-d NE
transcription xxx NE
was xxx NE
shown xxx NE
to xx NE
be xx NE
monoallelic xxx NE
in xx NE
Jurkat Xxxx cell_line
, , NE
a x NE
T-cell X-xxx NE
line xxx NE
that xxx NE
expresses xxx NE
tal-1 xxx-d DNA
in xx NE
the xxx NE
absence xxx NE
of xx NE
apparent xxx NE
genomic xxx NE
alteration xxx NE
of xx NE
the xxx NE
locus xxx NE
. . NE

Methylation Xxxx NE
studies xxx NE
indicated xxx NE
that xxx NE
the xxx NE
tal-15' xxx-dd' NE
GC-rich XX-xxx NE
region xxx NE
behaves xxx NE
like xxx NE
a x NE
CpG XxX NE
island xxx NE
, , NE
hypomethylated xxx NE
in xx NE
normal xxx NE
cells xxx NE
, , NE
and xxx NE
methylated xxx NE
de xx NE
novo xxx NE
on xx NE
transcriptionally xxx NE
inactive xxx NE
alleles xxx NE
in xx NE
established xxx NE
cell xxx NE
lines xxx NE
. . NE

Five Xxxx NE
major xxx NE
DNase-I XXxxx-X DNA_B
hypersensitive xxx DNA_M
sites xxx DNA_E
( ( NE
HS XX DNA
) ) NE
were xxx NE
mapped xxx NE
in xx NE
the xxx NE
tal-1 xxx-d DNA
locus xxx NE
. . NE

HS XX DNA_B
I X DNA_M
and xxx DNA_M
HS XX DNA_M
IV XX DNA_M
and xxx DNA_M
HS XX DNA_M
V X DNA_E
were xxx NE
exclusively xxx NE
observed xxx NE
in xx NE
the xxx NE
erythroid/megakaryocytic xxx/xxx cell_line_B
cell xxx cell_line_M
lines xxx cell_line_E
that xxx NE
express xxx NE
tal-1 xxx-d DNA
from xxx NE
the xxx NE
promoters xxx NE
promoter xxx DNA_B
1a dx DNA_M
and xxx DNA_M
promoter xxx DNA_M
1b dx DNA_E

HS XX DNA_B
II XX DNA_E
was xxx NE
weak xxx NE
in xx NE
hematopoietic xxx cell_line_B
cell xxx cell_line_M
lines xxx cell_line_E
, , NE
absent xxx NE
in xx NE
Hela Xxxx cell_line
, , NE
and xxx NE
greatly xxx NE
enhanced xxx NE
in xx NE
Jurkat Xxxx cell_line
, , NE
suggesting xxx NE
that xxx NE
this xxx NE
region xxx NE
might xxx NE
be xx NE
implicated xxx NE
in xx NE
the xxx NE
cis-activation xxx-xxx NE
of xx NE
tal-1 xxx-d DNA_B
promoter xxx DNA_M
1b dx DNA_E
in xx NE
this xxx NE
cell xxx NE
line xxx NE
. . NE

HS XX DNA_B
III XXX DNA_E
was xxx NE
weak xxx NE
in xx NE
HEL XXX cell_line
and xxx NE
Jurkat Xxxx cell_line
, , NE
and xxx NE
greatly xxx NE
enhanced xxx NE
in xx NE
DU528 XXddd cell_line
, , NE
a x NE
T-cell X-xxx cell_line_B
line xxx cell_line_E
that xxx NE
bears xxx NE
a x DNA_B
t x DNA_M
(1;14) (d;dd) DNA_E
and xxx NE
initiates xxx NE
tal-1 xxx-d NE
transcription xxx NE
within xxx NE
exon xxx DNA_B
4 d DNA_E
. . NE

These Xxxx NE
results xxx NE
suggest xxx NE
that xxx NE
distinct xxx NE
regulatory xxx DNA_B
elements xxx DNA_E
are xxx NE
associated xxx NE
with xxx NE
the xxx NE
use xxx NE
of xx NE
the xxx NE
different xxx NE
tal-1 xxx-d DNA_B
promoters xxx DNA_E
. . NE

Erythropoietin Xxxx NE
-dependent -xxx NE
induction xxx NE
of xx NE
hemoglobin xxx NE
synthesis xxx NE
in xx NE
a x NE
cytokine xxx NE
-dependent -xxx NE
cell xxx NE
line xxx NE
M-TAT X-XXX NE
. . NE

M-TAT X-XXX cell_line
is xx NE
a x NE
cytokine xxx cell_line
-dependent -xxx NE
cell xxx NE
line xxx NE
with xxx NE
the xxx NE
potential xxx NE
to xx NE
differentiate xxx NE
along xxx NE
the xxx NE
erythroid xxx cell_type_B
lineage xxx cell_type_M
and xxx cell_type_M
megakaryocytic xxx cell_type_M
lineage xxx cell_type_E

We Xx NE
cultured xxx NE
M-TAT X-XXX cell_line_B
cells xxx cell_line_E
long xxx NE
term xxx NE
(> (> NE
1 d NE
year) xxx) NE
in xx NE
the xxx NE
continuous xxx NE
presence xxx NE
of xx NE
erythropoietin xxx protein
( ( NE
EPO XXX protein
) ) NE
, , NE
granulocyte-macrophage xxx-xxx protein_B
colony-stimulating xxx-xxx protein_M
factor xxx protein_E
( ( NE
GM-CSF XX-XXX protein
) ) NE
, , NE
or xx NE
stem xxx protein_B
cell xxx protein_M
factor xxx protein_E
( ( NE
SCF XXX protein
) ) NE
. . NE

These Xxxx NE
long xxx NE
term xxx NE
cultures xxx NE
are xxx NE
referred xxx NE
to xx NE
as xx NE
M-TAT/EPO X-XXX/XXX cell_line_B
cell xxx cell_line_M
and xxx cell_line_M
M-TAT/GM-CSF X-XXX/XX-XXX cell_line_M
cell xxx cell_line_M
and xxx cell_line_M
M-TAT/SCF X-XXX/XXX cell_line_M
cell xxx cell_line_E

Hemoglobin Xxxx NE
concentration xxx NE
and xxx NE
gamma-globin xxx-xxx protein
and xxx NE
erythroid xxx NE
delta-aminolevulinate xxx-xxx NE
synthase xxx NE
mRNA xXXX NE
levels xxx NE
were xxx NE
significantly xxx NE
higher xxx NE
in xx NE
M-TAT/EPO X-XXX/XXX cell_line_B
cells xxx cell_line_E
than xxx NE
in xx NE
M-TAT/GM-CSF X-XXX/XX-XXX cell_line_B
cells xxx cell_line_E
. . NE

When Xxxx NE
the xxx NE
supplemented xxx NE
cytokine xxx protein
was xxx NE
switched xxx NE
from xxx NE
GM-CSF XX-XXX protein
to xx NE
EPO XXX protein
, , NE
hemoglobin xxx NE
synthesis xxx NE
in xx NE
M-TAT/GM-CSF X-XXX/XX-XXX cell_line_B
cells xxx cell_line_E
increased xxx NE
rapidly xxx NE
(within (xxx NE
5 d NE
h) x) NE
, , NE
and xxx NE
the xxx NE
level xxx NE
of xx NE
GATA-1 XXXX-d RNA_B
mRNA xXXX RNA_E
increased xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
the xxx NE
addition xxx NE
of xx NE
GM-CSF XX-XXX protein
to xx NE
the xxx NE
M-TAT/EPO X-XXX/XXX cell_line_B
cell xxx cell_line_M
culture xxx cell_line_E
decreased xxx NE
the xxx NE
amount xxx NE
of xx NE
hemoglobin xxx NE
, , NE
even xxx NE
in xx NE
the xxx NE
presence xxx NE
of xx NE
EPO XXX protein
, , NE
indicating xxx NE
that xxx NE
the xxx NE
EPO XXX protein
signal xxx NE
for xxx NE
erythroid xxx NE
differentiation xxx NE
is xx NE
suppressed xxx NE
by xx NE
GM-CSF XX-XXX protein
. . NE

Thus Xxxx NE
, , NE
erythroid xxx NE
development xxx NE
of xx NE
M-TAT X-XXX cell_line_B
cells xxx cell_line_E
is xx NE
promoted xxx NE
by xx NE
EPO XXX protein
and xxx NE
suppressed xxx NE
by xx NE
GM-CSF XX-XXX protein
. . NE

These Xxxx NE
results xxx NE
support xxx NE
the xxx NE
hypothesis xxx NE
that xxx NE
EPO XXX protein
actively xxx NE
influences xxx NE
the xxx NE
programming xxx NE
of xx NE
gene xxx NE
expression xxx NE
required xxx NE
for xxx NE
erythroid xxx NE
progenitor xxx NE
cell xxx NE
differentiation xxx NE
. . NE

The Xxx NE
role xxx NE
of xx NE
cellular xxx protein_B
transcription xxx protein_M
factor xxx protein_M
E2F XdX protein_E
in xx NE
the xxx NE
regulation xxx NE
of xx NE
cdc2 xxxd NE
mRNA xXXX NE
expression xxx NE
and xxx NE
cell xxx NE
cycle xxx NE
control xxx NE
of xx NE
human xxx NE
hematopoietic xxx cell_type_B
cells xxx cell_type_E
. . NE

cdc2 xxxd RNA_B
mRNA xXXX RNA_M
transcripts xxx RNA_E
were xxx NE
detected xxx NE
in xx NE
immature xxx cell_type_B
bone xxx cell_type_M
marrow xxx cell_type_M
cells xxx cell_type_E
and xxx NE
became xxx NE
undetectable xxx NE
along xxx NE
with xxx NE
differentiation xxx NE
. . NE

Peripheral Xxxx cell_type_B
blood xxx cell_type_M
resting xxx cell_type_M
cells xxx cell_type_E
did xxx NE
not xxx NE
express xxx NE
cdc2 xxxd RNA_B
mRNA xXXX RNA_E
, , NE
but xxx NE
it xx NE
was xxx NE
induced xxx NE
in xx NE
T-lymphocytes X-xxx cell_type
when xxx NE
the xxx NE
cells xxx NE
reentered xxx NE
the xxx NE
cell xxx NE
cycle xxx NE
in xx NE
response xxx NE
to xx NE
specific xxx NE
mitogens xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
cdc2 xxxd RNA_B
mRNA xXXX RNA_E
could xxx NE
not xxx NE
be xx NE
induced xxx NE
in xx NE
granulocytes xxx cell_type
and xxx NE
monocytes xxx cell_type
even xxx NE
after xxx NE
the xxx NE
culture xxx NE
with xxx NE
the xxx NE
appropriate xxx NE
stimulants xxx NE
. . NE

In Xx NE
order xxx NE
to xx NE
investigate xxx NE
the xxx NE
mechanism xxx NE
of xx NE
the xxx NE
regulation xxx NE
of xx NE
cdc2 xxxd NE
mRNA xXXX NE
expression xxx NE
in xx NE
hematopoietic xxx cell_type_B
cells xxx cell_type_E
, , NE
we xx NE
isolated xxx NE
the xxx NE
5'-flanking d'-xxx DNA_B
sequence xxx DNA_E
of xx NE
the xxx NE
cdc2 xxxd DNA_B
gene xxx DNA_E
and xxx NE
found xxx NE
the xxx NE
putative xxx NE
E2F XdX NE
binding xxx DNA_B
site xxx DNA_E
at xx NE
the xxx NE
position xxx NE
of xx NE
nucleotides xxx DNA_B
-124 -ddd DNA_M
to xx DNA_M
-117 -ddd DNA_E
. . NE

The Xxx NE
binding xxx NE
of xx NE
E2F XdX protein
at xx NE
this xxx NE
region xxx NE
was xxx NE
detected xxx NE
by xx NE
a x NE
gel-retardation xxx-xxx NE
assay xxx NE
and xxx NE
DNaseI XXxxxX NE
footprinting xxx NE
in xx NE
phytohemagglutinin xxx NE
-stimulated -xxx NE
T-lymphocytes X-xxx NE
, , NE
which xxx NE
was xxx NE
coincident xxx NE
with xxx NE
the xxx NE
expression xxx NE
of xx NE
cdc2 xxxd NE
mRNA xXXX NE
. . NE

E2F XdX NE
binding xxx NE
was xxx NE
not xxx NE
observed xxx NE
in xx NE
both xxx NE
granulocytes xxx cell_type
and xxx NE
monocytes xxx cell_type
. . NE

Transient Xxxx NE
chloramphenicol xxx NE
acetyltransferase xxx NE
assay xxx NE
revealed xxx NE
that xxx NE
the xxx NE
region xxx NE
containing xxx NE
E2F XdX DNA_B
binding xxx DNA_M
site xxx DNA_E
had xxx NE
a x NE
strong xxx NE
promoter xxx NE
activity xxx NE
, , NE
and xxx NE
introduction xxx NE
of xx NE
the xxx NE
mutation xxx NE
at xx NE
the xxx NE
E2F XdX DNA_B
binding xxx DNA_M
site xxx DNA_E
resulted xxx NE
in xx NE
a x NE
significant xxx NE
loss xxx NE
of xx NE
the xxx NE
activity xxx NE
. . NE

E2F-1 XdX-d RNA_B
mRNA xXXX RNA_M
and xxx RNA_M
DP-1 XX-d RNA_M
mRNA xXXX RNA_E
were xxx NE
not xxx NE
detectable xxx NE
in xx NE
granulocytes xxx cell_type
, , NE
monocytes xxx cell_type
and xxx NE
resting xxx cell_type_B
T-lymphocytes X-xxx cell_type_E
but xxx NE
were xxx NE
induced xxx NE
after xxx NE
the xxx NE
mitogenic xxx NE
stimulation xxx NE
of xx NE
T-lymphocytes X-xxx cell_type
. . NE

The Xxx NE
induction xxx NE
of xx NE
E2F XdX protein
activity xxx NE
preceded xxx NE
the xxx NE
appearance xxx NE
of xx NE
cdc2 xxxd RNA_B
mRNA xXXX RNA_E
, , NE
which xxx NE
is xx NE
consistent xxx NE
with xxx NE
the xxx NE
role xxx NE
of xx NE
E2F XdX protein
in xx NE
the xxx NE
regulation xxx NE
of xx NE
cdc2 xxxd cell_type_B
mRNA xXXX cell_type_M
expression xxx cell_type_E
. . NE

These Xxxx NE
results xxx NE
suggest xxx NE
that xxx NE
cdc2 xxxd NE
mRNA xXXX NE
expression xxx NE
is xx NE
related xxx NE
to xx NE
the xxx NE
cell xxx NE
cycling xxx NE
of xx NE
normal xxx cell_type_B
human xxx cell_type_M
hematopoietic xxx cell_type_M
cells xxx cell_type_E
and xxx NE
that xxx NE
E2F XdX protein
plays xxx NE
some xxx NE
roles xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
its xxx NE
expression xxx NE
. . NE

Association Xxxx NE
of xx NE
alterations xxx NE
in xx NE
NF-kappa XX-xxx NE
B X NE
moieties xxx NE
with xxx NE
HIV XXX NE
type xxx NE
1 d NE
proviral xxx NE
latency xxx NE
in xx NE
certain xxx NE
monocytic xxx NE
cells xxx NE
. . NE

Human Xxxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
( ( NE
HIV-1 XXX-d NE
) ) NE
replication xxx NE
is xx NE
controlled xxx NE
by xx NE
a x NE
complex xxx NE
array xxx NE
of xx NE
virally xxx protein_B
encoded xxx protein_M
protein xxx protein_M
and xxx protein_M
cellular xxx protein_M
protein xxx protein_E

A X NE
wide xxx NE
spectrum xxx NE
of xx NE
levels xxx NE
of xx NE
HIV-1 XXX-d NE
expression xxx NE
have xxx NE
been xxx NE
demonstrated xxx NE
in xx NE
various xxx NE
cells xxx NE
, , NE
both xxx NE
in xx NE
cell xxx NE
culture xxx NE
and xxx NE
in xx NE
vivo xxx NE
. . NE

Molecular Xxxx NE
mechanisms xxx NE
leading xxx NE
to xx NE
restricted xxx NE
HIV-1 XXX-d NE
replication xxx NE
may xxx NE
differ xxx NE
between xxx NE
certain xxx NE
cell xxx NE
types xxx NE
. . NE

It Xx NE
is xx NE
now xxx NE
demonstrated xxx NE
that xxx NE
HIV-1 XXX-d NE
proviral xxx NE
latency xxx NE
in xx NE
the xxx NE
monocytic xxx cell_line_B
cell xxx cell_line_M
line xxx cell_line_M
U1 Xd cell_line_E
, , NE
in xx NE
which xxx NE
only xxx NE
extremely xxx NE
low xxx NE
levels xxx NE
of xx NE
HIV-1 XXX-d NE
expression xxx NE
are xxx NE
detected xxx NE
in xx NE
the xxx NE
baseline xxx NE
unstimulated xxx NE
state xxx NE
, , NE
is xx NE
associated xxx NE
with xxx NE
alterations xxx NE
in xx NE
nuclear xxx NE
factor-kappa xxx-xxx NE
B X NE
( ( NE
NF-kappa XX-xxx NE
B X NE
) ) NE
moieties xxx NE
demonstrated xxx NE
in xx NE
these xxx NE
cells xxx NE
by xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assays xxx NE
( ( NE
EMSAs XXXXx NE
) ) NE
and xxx NE
in xx NE
situ xxx NE
UV XX NE
cross-linking xxx-xxx NE
studies xxx NE
. . NE

A X NE
predominance xxx NE
of xx NE
p50 xdd protein
NF-kappa XX-xxx NE
B X NE
moieties xxx NE
and xxx NE
possibly xxx NE
p50 xdd protein_B
homodimers xxx protein_E
or xx NE
closely xxx NE
related xxx NE
species xxx NE
, , NE
rather xxx NE
than xxx NE
the xxx NE
p50-p56 xdd-xdd protein_B
heterodimer xxx protein_E
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
that xxx NE
is xx NE
the xxx NE
predominant xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
species xxx NE
in xx NE
most xxx NE
T X cell_type_B
lymphocytic xxx cell_type_M
cell xxx cell_type_M
and xxx cell_type_M
monocytic xxx cell_type_M
cell xxx cell_type_E
nuclei xxx NE
of xx NE
U1 Xd cell_line_B
cells xxx cell_line_E
. . NE

This Xxxx NE
pattern xxx NE
of xx NE
NF-kappa XX-xxx NE
B-related X-xxx NE
moieties xxx NE
differs xxx NE
from xxx NE
the xxx NE
latently xxx NE
infected xxx NE
T X NE
lymphocytic xxx NE
cell xxx NE
line xxx NE
ACH-2 XXX-d NE
, , NE
and xxx NE
from xxx NE
the xxx NE
U937 Xddd NE
monocytic xxx NE
line xxx NE
, , NE
the xxx NE
parental xxx NE
cell xxx NE
line xxx NE
of xx NE
the xxx NE
U1 Xd NE
cellular xxx NE
clone xxx NE
. . NE

As Xx NE
such xxx NE
, , NE
these xxx NE
data xxx NE
suggest xxx NE
that xxx NE
different xxx NE
proximal xxx NE
mechanisms xxx NE
may xxx NE
lead xxx NE
to xx NE
restricted xxx NE
HIV-1 XXX-d NE
replication xxx NE
in xx NE
various xxx NE
cell xxx NE
types xxx NE
. . NE

[Regulation [Xxxx NE
of xx NE
transcription xxx NE
of xx NE
the xxx NE
interleukin-2 xxx-d DNA_B
gene xxx DNA_E
in xx NE
B-lymphocytes X-xxx cell_type
] ] NE

Since Xxxx NE
most xxx NE
B X cell_line_B
cell xxx cell_line_M
clones xxx cell_line_E
immortalized xxx NE
with xxx NE
EBV XXX NE
virus xxx NE
can xxx NE
be xx NE
induced xxx NE
to xx NE
produce xxx NE
interleukin-2 xxx-d protein
, , NE
a x NE
typical xxx NE
T X protein_B
cell xxx protein_M
cytokine xxx protein_E
, , NE
we xx NE
studied xxx NE
the xxx NE
role xxx NE
of xx NE
different xxx NE
elements xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_B
promoter xxx DNA_E
in xx NE
such xxx NE
clones xxx NE
by xx NE
transfection xxx NE
. . NE

It Xx NE
was xxx NE
found xxx NE
, , NE
in xx NE
particular xxx NE
, , NE
that xxx NE
the xxx NE
element xxx NE
TCEd XXXx DNA
, , NE
which xxx NE
binds xxx NE
the xxx NE
transcription xxx protein_B
factor xxx protein_E
NF-kB XX-xX protein
, , NE
is xx NE
very xxx NE
active xxx NE
in xx NE
all xxx NE
three xxx NE
B X cell_line_B
clones xxx cell_line_E
tested xxx NE
. . NE

This Xxxx NE
element xxx NE
has xxx NE
no xx NE
activity xxx NE
in xx NE
T X cell_type_B
cells xxx cell_type_E
of xx NE
the xxx NE
Jurkat Xxxx cell_line_B
line xxx cell_line_E
. . NE

The Xxx NE
NFATd XXXXx DNA_B
element xxx DNA_E
, , NE
which xxx NE
binds xxx NE
the xxx NE
transcription xxx protein_B
factor xxx protein_E
NFAT-1 XXXX-d protein
and xxx NE
is xx NE
very xxx NE
active xxx NE
in xx NE
T X cell_type_B
cells xxx cell_type_E
, , NE
is xx NE
only xxx NE
weakly xxx NE
active xxx NE
in xx NE
one xxx NE
B X cell_line_B
clone xxx cell_line_E
and xxx NE
not xxx NE
at xx NE
all xxx NE
in xx NE
another xxx NE
. . NE

Different Xxxx NE
elements xxx NE
thus xxx NE
contribute xxx NE
to xx NE
IL-2 XX-d DNA_B
promoter xxx DNA_E
activity xxx NE
in xx NE
different xxx NE
cells xxx NE
. . NE

Regulation Xxxx NE
of xx NE
I X protein_B
kappa xxx protein_M
B X protein_M
alpha xxx protein_E
and xxx NE
p105 xddd protein
in xx NE
monocytes xxx cell_type
and xxx NE
macrophages xxx cell_type
persistently xxx NE
infected xxx NE
with xxx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
. . NE

The Xxx NE
mechanisms xxx NE
regulating xxx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
( ( NE
HIV XXX NE
) ) NE
persistence xxx NE
in xx NE
human xxx NE
monocytes xxx cell_type
/macrophages /xxx NE
are xxx NE
partially xxx NE
understood xxx NE
. . NE

Persistent Xxxx NE
HIV XXX NE
infection xxx NE
of xx NE
U937 Xddd cell_line_B
monocytic xxx cell_line_M
cells xxx cell_line_E
results xxx NE
in xx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
. . NE

Whether Xxxx NE
virus-induced xxx-xxx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
is xx NE
a x NE
mechanism xxx NE
that xxx NE
favors xxx NE
continuous xxx NE
viral xxx NE
replication xxx NE
in xx NE
macrophages xxx cell_type
remains xxx NE
unknown xxx NE
. . NE

To Xx NE
further xxx NE
delineate xxx NE
the xxx NE
molecular xxx NE
mechanisms xxx NE
involved xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
in xx NE
HIV XXX NE
-infected -xxx NE
monocytes xxx cell_type
and xxx NE
macrophages xxx cell_type
, , NE
we xx NE
have xxx NE
focused xxx NE
on xx NE
the xxx NE
regulation xxx NE
of xx NE
the xxx NE
I X NE
kappa xxx NE
B X NE
molecules xxx NE
. . NE

First Xxxx NE
, , NE
we xx NE
show xxx NE
that xxx NE
persistent xxx NE
HIV XXX NE
infection xxx NE
results xxx NE
in xx NE
the xxx NE
activation xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
not xxx NE
only xxx NE
in xx NE
monocytic xxx NE
cells xxx NE
but xxx NE
also xxx NE
in xx NE
macrophages xxx cell_type
. . NE

In Xx NE
HIV XXX NE
-infected -xxx NE
cells xxx NE
, , NE
I X protein_B
kappa xxx protein_M
B X protein_M
alpha xxx protein_E
protein xxx NE
levels xxx NE
are xxx NE
decreased xxx NE
secondary xxx NE
to xx NE
enhanced xxx NE
protein xxx NE
degradation xxx NE
. . NE

This Xxxx NE
parallels xxx NE
the xxx NE
increased xxx NE
I X protein_B
kappa xxx protein_M
B X protein_M
alpha xxx protein_E
synthesis xxx NE
secondary xxx NE
to xx NE
increased xxx NE
I X protein_B
kappa xxx protein_M
B X protein_M
alpha xxx protein_E
gene xxx NE
transcription xxx NE
, , NE
i.e. x.x. NE
, , NE
increased xxx NE
RNA XXX NE
and xxx NE
transcriptional xxx NE
activity xxx NE
of xx NE
its xxx NE
promoter-enhancer xxx-xxx NE
. . NE

Another Xxxx NE
protein xxx NE
with xxx NE
I X NE
kappa xxx NE
B X NE
function xxx NE
, , NE
p105 xddd protein
, , NE
is xx NE
also xxx NE
modified xxx NE
in xx NE
HIV XXX NE
-infected -xxx NE
cells xxx NE
: : NE
p105 xddd protein
and xxx NE
p50 xdd protein
steady-state xxx-xxx NE
protein xxx NE
levels xxx NE
are xxx NE
increased xxx NE
as xx NE
a x NE
result xxx NE
of xx NE
increased xxx NE
synthesis xxx NE
and xxx NE
proteolytic xxx NE
processing xxx NE
of xx NE
p105 xddd protein
. . NE

Transcriptional Xxxx NE
activity xxx NE
of xx NE
p105 xddd protein
is xx NE
also xxx NE
increased xxx NE
in xx NE
infected xxx cell_type_B
cells xxx cell_type_E
and xxx NE
is xx NE
also xxx NE
mediated xxx NE
by xx NE
NF-kappa XX-xxx protein_B
B X protein_E
through xxx NE
a x NE
specific xxx NE
kappa xxx DNA_B
B X DNA_M
motif xxx DNA_E
. . NE

These Xxxx NE
results xxx NE
demonstrate xxx NE
the xxx NE
existence xxx NE
of xx NE
a x NE
triple xxx NE
autoregulatory xxx DNA_B
loop xxx DNA_E
in xx NE
monocytes xxx cell_type
and xxx NE
macrophages xxx cell_type
involving xxx NE
HIV XXX NE
, , NE
p105 xddd protein
and xxx NE
p50 xdd protein
, , NE
and xxx NE
MAD3 XXXd protein
, , NE
with xxx NE
the xxx NE
end xxx NE
result xxx NE
of xx NE
persistent xxx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
and xxx NE
viral xxx NE
persistence xxx NE
. . NE

Furthermore Xxxx NE
, , NE
persistent xxx NE
HIV XXX NE
infection xxx NE
of xx NE
monocytes xxx cell_type
and xxx NE
macrophages xxx cell_type
provides xxx NE
a x NE
useful xxx NE
model xxx NE
with xxx NE
which xxx NE
to xx NE
study xxx NE
concomitant xxx NE
modifications xxx NE
of xx NE
different xxx NE
I X protein_B
kappa xxx protein_M
B X protein_M
molecules xxx protein_E
. . NE

Glucocorticoid Xxxx NE
-induced -xxx NE
apoptosis xxx NE
of xx NE
human xxx NE
leukemic xxx NE
cells xxx NE
is xx NE
caused xxx NE
by xx NE
the xxx NE
repressive xxx NE
function xxx NE
of xx NE
the xxx NE
glucocorticoid xxx NE
receptor xxx NE
. . NE

Induction Xxxx NE
of xx NE
apoptosis xxx NE
in xx NE
lymphocytes xxx cell_type
, , NE
which xxx NE
may xxx NE
account xxx NE
for xxx NE
the xxx NE
therapeutic xxx NE
effects xxx NE
of xx NE
glucocorticoids xxx NE
in xx NE
various xxx NE
diseases xxx NE
including xxx NE
leukemia xxx NE
, , NE
depends xxx NE
on xx NE
the xxx NE
glucocorticoid xxx protein_B
receptor xxx protein_E
. . NE

However Xxxx NE
, , NE
the xxx NE
events xxx NE
leading xxx NE
from xxx NE
the xxx NE
activated xxx NE
receptor xxx NE
to xx NE
cell xxx NE
lysis xxx NE
are xxx NE
not xxx NE
understood xxx NE
. . NE

A X NE
prevailing xxx NE
hypothesis xxx NE
postulates xxx NE
induction xxx NE
of xx NE
so-called xx-xxx NE
' ' NE
lysis xxx DNA_B
genes xxx DNA_E
' ' NE
by xx NE
the xxx NE
activated xxx protein_B
receptor xxx protein_E
. . NE

In Xx NE
this xxx NE
study xxx NE
, , NE
we xx NE
show xxx NE
that xxx NE
an xx NE
activation-deficient xxx-xxx protein_B
glucocorticoid xxx protein_M
receptor xxx protein_M
mutant xxx protein_E
is xx NE
as xx NE
effective xxx NE
as xx NE
the xxx NE
wild-type xxx-xxx protein_B
receptor xxx protein_E
in xx NE
repression xxx NE
of xx NE
AP-1 XX-d NE
activity xxx NE
, , NE
inhibition xxx NE
of xx NE
interleukin-2 xxx-d NE
production xxx NE
, , NE
inhibition xxx NE
of xx NE
c-myc x-xxx NE
expression xxx NE
and xxx NE
induction xxx NE
of xx NE
apoptosis xxx NE
. . NE

Furthermore Xxxx NE
, , NE
we xx NE
show xxx NE
that xxx NE
retinoic xxx NE
acid xxx NE
can xxx NE
also xxx NE
induce xxx NE
apoptosis xxx NE
in xx NE
these xxx NE
cells xxx NE
through xxx NE
the xxx NE
retinoic xxx protein_B
acid xxx protein_M
receptor xxx protein_E
, , NE
whose xxx NE
repressive xxx NE
functions xxx NE
but xxx NE
not xxx NE
target xxx NE
site xxx NE
specificity xxx NE
, , NE
are xxx NE
similar xxx NE
to xx NE
those xxx NE
of xx NE
the xxx NE
glucocorticoid xxx protein_B
receptor xxx protein_E
. . NE

Therefore Xxxx NE
, , NE
the xxx NE
primary xxx NE
effect xxx NE
of xx NE
the xxx NE
receptor xxx NE
in xx NE
glucocorticoid xxx NE
-mediated -xxx NE
apoptosis xxx NE
correlates xxx NE
with xxx NE
transcriptional xxx NE
repression xxx NE
rather xxx NE
than xxx NE
activation xxx NE
and xxx NE
could xxx NE
be xx NE
mediated xxx NE
by xx NE
interference xxx NE
with xxx NE
other xxx NE
transcription xxx NE
factors xxx NE
required xxx NE
for xxx NE
cell xxx NE
survival xxx NE
. . NE

HIV XXX NE
type xxx NE
1 d NE
protease xxx NE
activation xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
within xxx NE
T X cell_type_B
lymphoid xxx cell_type_M
cells xxx cell_type_E
. . NE

NF-kappa XX-xxx protein_B
B X protein_E
is xx NE
a x NE
nuclear xxx protein_B
protein xxx protein_E
of xx NE
the xxx NE
rel xxx protein_B
oncogene xxx protein_M
family xxx protein_E
capable xxx NE
of xx NE
enhancing xxx NE
transcription xxx NE
of xx NE
several xxx DNA_B
cellular xxx DNA_M
genes xxx DNA_E
, , NE
including xxx NE
IL-2 XX-d protein
and xxx NE
the xxx NE
IL-2 XX-d protein_B
receptor xxx protein_E
, , NE
and xxx NE
viral xxx DNA_B
genes xxx DNA_E
transcribed xxx NE
from xxx NE
the xxx NE
HIV-1 XXX-d DNA_B
LTR XXX DNA_E
. . NE

It Xx NE
has xxx NE
been xxx NE
reported xxx NE
that xxx NE
HIV-1 XXX-d protein_B
protease xxx protein_E
may xxx NE
cleave xxx NE
the xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
precursor xxx NE
to xx NE
its xxx NE
active xxx NE
form xxx NE
in xx NE
vitro xxx NE
. . NE

In Xx NE
this xxx NE
study xxx NE
the xxx NE
effects xxx NE
of xx NE
HIV XXX NE
protease xxx NE
on xx NE
NF-kappa XX-xxx NE
B X NE
precursor xxx NE
activation xxx NE
were xxx NE
examined xxx NE
in xx NE
Jurkat Xxxx NE
T X cell_type_B
cells xxx cell_type_E
by xx NE
introducing xxx NE
a x NE
protease xxx DNA_B
expression xxx DNA_M
vector xxx DNA_E
into xxx NE
the xxx NE
cells xxx NE
. . NE

Increased Xxxx NE
NF-kappa XX-xxx NE
B X NE
activity xxx NE
was xxx NE
observed xxx NE
and xxx NE
this xxx NE
increased xxx NE
activity xxx NE
was xxx NE
blocked xxx NE
by xx NE
a x NE
specific xxx NE
inhibitor xxx NE
of xx NE
the xxx NE
viral xxx protein_B
protease xxx protein_E
. . NE

Viral Xxxx NE
transcription xxx NE
, , NE
as xx NE
measured xxx NE
using xxx NE
LTR XXX NE
-CAT -XXX NE
assays xxx NE
, , NE
was xxx NE
only xxx NE
slightly xxx NE
enhanced xxx NE
in xx NE
the xxx NE
HIV-protease XXX-xxx NE
expressing xxx NE
cells xxx NE
, , NE
while xxx NE
secretion xxx NE
of xx NE
IL-2 XX-d NE
and xxx NE
expression xxx NE
of xx NE
the xxx NE
IL-2 XX-d NE
receptor xxx NE
were xxx NE
not xxx NE
affected xxx NE
. . NE

The Xxx NE
limited xxx NE
activation xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
by xx NE
HIV XXX protein_B
protease xxx protein_E
appears xxx NE
unlikely xxx NE
to xx NE
have xxx NE
a x NE
significant xxx NE
effect xxx NE
on xx NE
virus xxx NE
expression xxx NE
or xx NE
T X NE
cell xxx NE
function xxx NE
. . NE

Inhibition Xxxx NE
of xx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
replication xxx NE
by xx NE
a x NE
Tat-activated, Xxx-xxx, DNA_B
transduced xxx DNA_M
interferon xxx DNA_M
gene xxx DNA_E
: : NE
targeted xxx NE
expression xxx NE
to xx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
-infected -xxx NE
cells xxx NE
. . NE

We Xx NE
have xxx NE
examined xxx NE
the xxx NE
feasibility xxx NE
of xx NE
using xxx NE
interferon xxx NE
( ( NE
IFN XXX NE
) ) NE
gene xxx NE
transfer xxx NE
as xx NE
a x NE
novel xxx NE
approach xxx NE
to xx NE
anti- xxx- NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
(HIV-1) (XXX-d) NE
therapy xxx NE
in xx NE
this xxx NE
study xxx NE
. . NE

To Xx NE
limit xxx NE
expression xxx NE
of xx NE
a x NE
transduced xxx NE
HIV-1 XXX-d DNA_B
long xxx DNA_M
terminal xxx DNA_M
repeat xxx DNA_M
(LTR)-IFNA2 (XXX)-XXXXd DNA_E
(the (xxx NE
new xxx NE
approved xxx NE
nomenclature xxx NE
for xxx NE
IFN XXX DNA_B
genes xxx DNA_E
is xx NE
used xxx NE
throughout xxx NE
this xxx NE
article) xxx) NE
hybrid xxx DNA_B
gene xxx DNA_E
to xx NE
the xxx NE
HIV-1-infected XXX-d-xxx cell_line_B
cells xxx cell_line_E
, , NE
HIV-1 XXX-d DNA_B
LTR XXX DNA_E
was xxx NE
modified xxx NE
. . NE

Deletion Xxxx NE
of xx NE
the xxx NE
NF-kappa XX-xxx DNA_B
B X DNA_M
elements xxx DNA_E
of xx NE
the xxx NE
HIV-1 XXX-d DNA_B
LTR XXX DNA_E
significantly xxx NE
inhibited xxx NE
Tat Xxx NE
-mediated -xxx NE
transactivation xxx NE
in xx NE
T-cell X-xxx NE
lines xxx NE
, , NE
as xx NE
well xxx NE
as xx NE
in xx NE
a x NE
monocyte xxx NE
line xxx NE
, , NE
U937 Xddd NE
. . NE

Replacement Xxxx NE
of xx NE
the xxx NE
NF-kappa XX-xxx DNA_B
B X DNA_M
elements xxx DNA_E
in xx NE
the xxx NE
HIV-1 XXX-d DNA_B
LTR XXX DNA_E
by xx NE
a x NE
DNA XXX DNA_B
fragment xxx DNA_E
derived xxx NE
from xxx NE
the xxx NE
5'-flanking d'-xxx DNA_B
region xxx DNA_E
of xx NE
IFN-stimulated XXX-xxx DNA_B
gene xxx DNA_M
15 dd DNA_E
( ( NE
ISG15 XXXdd DNA
) ) NE
, , NE
containing xxx NE
the xxx NE
IFN-stimulated XXX-xxx DNA_B
response xxx DNA_M
element xxx DNA_E
, , NE
partially xxx NE
restored xxx NE
Tat Xxx NE
-mediated -xxx NE
activation xxx NE
of xx NE
LTR XXX NE
in xx NE
T X NE
cells xxx NE
as xx NE
well xxx NE
as xx NE
in xx NE
monocytes xxx NE
. . NE

Insertion Xxxx NE
of xx NE
this xxx NE
chimeric xxx DNA_B
promoter xxx DNA_E
( ( NE
ISG15 XXXdd DNA_B
LTR XXX DNA_E
) ) NE
upstream xxx NE
of xx NE
the xxx NE
human xxx DNA_B
IFNA2 XXXXd DNA_M
gene xxx DNA_E
directed xxx NE
high xxx NE
levels xxx NE
of xx NE
IFN XXX NE
synthesis xxx NE
in xx NE
Tat-expressing Xxx-xxx cell_line_B
cells xxx cell_line_E
, , NE
while xxx NE
this xxx NE
promoter xxx NE
was xxx NE
not xxx NE
responsive xxx NE
to xx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
alpha xxx NE
-mediated -xxx NE
activation xxx NE
. . NE

ISG15-LTR-IFN XXXdd-XXX-XXX DNA_B
hybrid xxx DNA_M
gene xxx DNA_E
inserted xxx NE
into xxx NE
the xxx NE
retrovirus xxx DNA_B
vector xxx DNA_E
was xxx NE
transduced xxx NE
into xxx NE
Jurkat Xxxx cell_line
and xxx NE
U937 Xddd cell_line_B
cells xxx cell_line_E
. . NE

Selected Xxxx NE
transfected xxx cell_line_B
clones xxx cell_line_E
produced xxx NE
low xxx NE
levels xxx NE
of xx NE
IFN XXX protein_B
A X protein_E
( ( NE
IFNA XXXX protein
) ) NE
constitutively xxx NE
, , NE
and xxx NE
their xxx NE
abilities xxx NE
to xx NE
express xxx NE
interleukin-2 xxx-d protein
and xxx NE
interleukin-2 xxx-d protein_B
receptor xxx protein_E
upon xxx NE
stimulation xxx NE
with xxx NE
phytohemagglutinin xxx protein
and xxx NE
phorbol xxx NE
myristate xxx NE
acetate xxx NE
were xxx NE
retained xxx NE
. . NE

Enhancement Xxxx NE
of xx NE
IFNA XXXX NE
synthesis xxx NE
observed xxx NE
upon xxx NE
HIV-1 XXX-d NE
infection xxx NE
resulted xxx NE
in xx NE
significant xxx NE
inhibition xxx NE
of xx NE
HIV-1 XXX-d NE
replication xxx NE
for xxx NE
a x NE
period xxx NE
of xx NE
at xx NE
least xxx NE
30 dd NE
days xxx NE
. . NE

Virus Xxxx NE
isolated xxx NE
from xxx NE
IFNA XXXX NE
-producing -xxx NE
cells xxx NE
was xxx NE
able xxx NE
to xx NE
replicate xxx NE
in xx NE
the xxx NE
U937 Xddd NE
cells xxx NE
but xxx NE
did xxx NE
not xxx NE
replicate xxx NE
efficiently xxx NE
in xx NE
U937 Xddd NE
cells xxx NE
transduced xxx NE
with xxx NE
the xxx NE
IFNA XXXX NE
gene xxx NE
. . NE

These Xxxx NE
results xxx NE
suggest xxx NE
that xxx NE
targeting xxx NE
IFN XXX NE
synthesis xxx NE
to xx NE
HIV-1 XXX-d NE
-infected -xxx NE
cells xxx NE
is xx NE
an xx NE
attainable xxx NE
goal xxx NE
and xxx NE
that xxx NE
autocrine xxx NE
IFN XXX NE
synthesis xxx NE
results xxx NE
in xx NE
a x NE
long-lasting xxx-xxx NE
and xxx NE
permanent xxx NE
suppression xxx NE
of xx NE
HIV-1 XXX-d NE
replication xxx NE
. . NE

Chromosomal Xxxx NE
localization xxx NE
of xx NE
two xxx NE
KOX XXX DNA_B
zinc xxx DNA_M
finger xxx DNA_M
genes xxx DNA_E
on xx NE
chromosome xxx DNA_B
bands xxx DNA_E
7q21-q22 dxdd-xdd DNA
. . NE

Human Xxxx DNA_B
cDNAs xXXXx DNA_E
encoding xxx NE
Kruppel-type Xxxx-xxx protein_B
zinc xxx protein_M
finger xxx protein_M
domains xxx protein_E
, , NE
designated xxx NE
KOX XXX DNA_B
1-32 d-dd DNA_E
, , NE
have xxx NE
been xxx NE
cloned xxx NE
from xxx NE
human xxx NE
T X NE
lymphocyte xxx NE
cell xxx NE
line xxx NE
libraries xxx NE
. . NE

We Xx NE
report xxx NE
here xxx NE
the xxx NE
regional xxx NE
localizations xxx NE
by xx NE
in xx NE
situ xxx NE
hybridization xxx NE
of xx NE
KOX XXX DNA_B
18 dd DNA_E
and xxx NE
KOX XXX DNA_B
25 dd DNA_E
on xx NE
chromosome xxx DNA_B
bands xxx DNA_M
7q21q22 dxddxdd DNA_E
. . NE

Pulse-field Xxxx-xxx NE
gel xxx NE
electrophoresis xxx NE
(PFGE) (XXXX) NE
analysis xxx NE
showed xxx NE
that xxx NE
these xxx NE
genes xxx NE
are xxx NE
physically xxx NE
located xxx NE
within xxx NE
a x NE
DNA XXX DNA_B
fragment xxx DNA_E
of xx NE
250 ddd DNA_B
kb xx DNA_E
. . NE

The Xxx NE
genes xxx NE
KOX XXX DNA_B
4 d DNA_E
and xxx NE
KOX XXX DNA_B
9 d DNA_E
, , NE
mapped xxx NE
on xx NE
chromosome xxx DNA_B
8q24 dxdd DNA_E
, , NE
were xxx NE
found xxx NE
to xx NE
be xx NE
located xxx NE
within xxx NE
a x NE
DNA XXX DNA_B
fragment xxx DNA_E
of xx NE
450 ddd NE
kb xx NE
. . NE

From Xxxx NE
the xxx NE
present xxx NE
and xxx NE
previous xxx NE
data xxx NE
, , NE
eighteen xxx NE
different xxx NE
KOX XXX DNA_B
genes xxx DNA_E
have xxx NE
been xxx NE
located xxx NE
at xx NE
least xxx NE
two xxx NE
by xx NE
two xxx NE
within xxx NE
nine xxx NE
DNA XXX DNA_B
fragments xxx DNA_E
of xx NE
200 ddd NE
to xx NE
580 ddd NE
kb xx NE
. . NE

Influence Xxxx NE
of xx NE
age xxx NE
on xx NE
the xxx NE
production xxx NE
of xx NE
Fos Xxx protein
and xxx NE
Jun Xxx protein
by xx NE
influenza xxx cell_type_B
virus-exposed xxx-xxx cell_type_M
T X cell_type_M
cells xxx cell_type_E
. . NE

This Xxxx NE
study xxx NE
investigated xxx NE
age-related xxx-xxx NE
T X NE
cell xxx NE
responses xxx NE
after xxx NE
in xx NE
vitro xxx NE
exposure xxx NE
to xx NE
influenza xxx NE
A X NE
virus xxx NE
. . NE

Mononuclear Xxxx cell_type_B
leukocytes xxx cell_type_E
from xxx NE
young xxx NE
or xx NE
elderly xxx NE
persons xxx NE
were xxx NE
sham-exposed xxx-xxx NE
or xx NE
exposed xxx NE
to xx NE
influenza xxx NE
virus xxx NE
for xxx NE
1 d NE
, , NE
24 dd NE
, , NE
and xxx NE
72 dd NE
h x NE
. . NE

Immunofluorescent Xxxx NE
staining xxx NE
and xxx NE
flow xxx NE
cytometric xxx NE
analysis xxx NE
were xxx NE
then xxx NE
used xxx NE
to xx NE
detect xxx NE
T X cell_type_B
cells xxx cell_type_E
producing xxx NE
the xxx NE
transcriptional xxx protein_B
regulating xxx protein_M
proteins xxx protein_E
Fos Xxx protein
and xxx NE
Jun Xxx protein
. . NE

Fewer Xxxx NE
virus-exposed xxx-xxx NE
cells xxx NE
from xxx NE
elderly xxx NE
donors xxx NE
stained xxx NE
for xxx NE
Fos Xxx protein
and xxx NE
Jun Xxx protein
at xx NE
each xxx NE
data xxx NE
point xxx NE
compared xxx NE
with xxx NE
cells xxx NE
from xxx NE
young xxx NE
donors xxx NE
. . NE

Flow Xxxx NE
cytometric xxx NE
analysis xxx NE
also xxx NE
showed xxx NE
that xxx NE
at xx NE
72 dd NE
h x NE
of xx NE
virus xxx NE
exposure xxx NE
fewer xxx NE
T X cell_type_B
cells xxx cell_type_E
from xxx NE
the xxx NE
elderly xxx NE
produced xxx NE
interferon-gamma xxx-xxx protein
( ( NE
IFN-gamma XXX-xxx protein
) ) NE
, , NE
suggesting xxx NE
a x NE
link xxx NE
between xxx NE
the xxx NE
magnitude xxx NE
of xx NE
the xxx NE
Fos Xxx protein
and xxx NE
Jun Xxx protein
and xxx NE
IFN-gamma XXX-xxx protein
responses xxx NE
. . NE

Thus Xxxx NE
, , NE
failure xxx NE
of xx NE
virus-exposed xxx-xxx cell_type_B
T X cell_type_M
cells xxx cell_type_E
to xx NE
produce xxx NE
Fos Xxx protein
and xxx NE
Jun Xxx protein
could xxx NE
contribute xxx NE
to xx NE
the xxx NE
increase xxx NE
in xx NE
illness xxx NE
due xxx NE
to xx NE
influenza xxx NE
virus xxx NE
in xx NE
the xxx NE
elderly xxx NE
. . NE

The Xxx NE
regulation xxx NE
of xx NE
HIV XXX NE
by xx NE
retinoic xxx NE
acid xxx NE
correlates xxx NE
with xxx NE
cellular xxx NE
expression xxx NE
of xx NE
the xxx NE
retinoic xxx protein_B
acid xxx protein_M
receptors xxx protein_E
. . NE

OBJECTIVES XXXXXXXXXX NE
: : NE
To Xx NE
analyze xxx NE
the xxx NE
effect xxx NE
of xx NE
retinoic xxx NE
acids xxx NE
( ( NE
RA XX NE
) ) NE
on xx NE
HIV-1 XXX-d NE
expression xxx NE
and xxx NE
correlate xxx NE
this xxx NE
effect xxx NE
with xxx NE
expression xxx NE
levels xxx NE
of xx NE
RA XX protein_B
receptors xxx protein_E
( ( NE
RARs XXXx protein
) ) NE
in xx NE
T-lymphoid X-xxx cell_line_B
cell xxx cell_line_M
line xxx cell_line_M
and xxx cell_line_M
monocytoid xxx cell_line_M
cell xxx cell_line_M
line xxx cell_line_E

DESIGN XXXXXX NE
AND XXX NE
METHODS XXXXXXX NE
: : NE
The Xxx NE
effect xxx NE
of xx NE
all-trans xxx-xxx NE
RA XX NE
and xxx NE
9-cis d-xxx NE
RA XX NE
on xx NE
HIV-1 XXX-d NE
production xxx NE
in xx NE
T-lymphoid X-xxx cell_line
( ( NE
H9, Xd, cell_line_B
CEM XXX cell_line_E
) ) NE
and xxx NE
monocytoid xxx cell_line_B
(U937,THP-1) (Xddd,XXX-d) cell_line_M
cell xxx cell_line_M
lines xxx cell_line_E
was xxx NE
measured xxx NE
during xxx NE
acute xxx NE
infection xxx NE
and xxx NE
chronic xxx NE
infection xxx NE

The Xxx NE
expression xxx NE
levels xxx NE
of xx NE
human xxx protein_B
RAR XXX protein_M
alpha xxx protein_E
( ( NE
hRAR xXXX protein_B
alpha, xxx, protein_M
receptor xxx protein_E
for xxx NE
all-trans xxx-xxx NE
RA XX NE
) ) NE
and xxx NE
the xxx NE
human xxx protein_B
retinoid-X xxx-X protein_M
receptor xxx protein_M
alpha xxx protein_E
( ( NE
hRXR xXXX protein_B
alpha xxx protein_M
receptor xxx protein_E
for xxx NE
9-cis d-xxx NE
RA XX NE
) ) NE
were xxx NE
determined xxx NE
by xx NE
Northern Xxxx NE
blot xxx NE
analysis xxx NE
. . NE

RESULTS XXXXXXX NE
: : NE
Both Xxxx NE
all-trans xxx-xxx NE
RA XX NE
and xxx NE
9-cis d-xxx NE
RA XX NE
inhibited xxx NE
virus xxx NE
replication xxx NE
in xx NE
HIV-1 XXX-d cell_line_B
IIIB-infected XXXX-xxx cell_line_M
monocytoid xxx cell_line_M
cells xxx cell_line_E
, , NE
in xx NE
the xxx NE
presence xxx NE
and xxx NE
absence xxx NE
of xx NE
the xxx NE
co-stimulatory xx-xxx NE
agent xxx NE
phorbol xxx NE
myristate xxx NE
acetate xxx NE
( ( NE
PMA XXX NE
) ) NE
. . NE

The Xxx NE
retinoids xxx NE
had xxx NE
weak xxx NE
or xx NE
no xx NE
stimulatory xxx NE
effects xxx NE
on xx NE
HIV XXX NE
production xxx NE
by xx NE
T-cell X-xxx cell_line_B
lines xxx cell_line_E
. . NE

HIV XXX NE
production xxx NE
by xx NE
PMA XXX NE
-stimulated -xxx NE
T-cell X-xxx NE
lines xxx NE
was xxx NE
inhibited xxx NE
by xx NE
these xxx NE
retinoids xxx NE
. . NE

The Xxx NE
9-cis d-xxx NE
RA XX NE
was xxx NE
generally xxx NE
more xxx NE
effective xxx NE
than xxx NE
all-trans xxx-xxx NE
RA XX NE
in xx NE
inhibiting xxx NE
HIV XXX NE
production xxx NE
and xxx NE
in xx NE
combination xxx NE
generally xxx NE
more xxx NE
effective xxx NE
than xxx NE
the xxx NE
single xxx NE
agents xxx NE
alone xxx NE
. . NE

Human Xxxx protein_B
RAR XXX protein_M
alpha xxx protein_E
was xxx NE
expressed xxx NE
in xx NE
H9 Xd cell_line
, , NE
U937 Xddd cell_line
and xxx NE
THP-1 XXX-d cell_line_B
cells xxx cell_line_E
, , NE
but xxx NE
almost xxx NE
undetectable xxx NE
in xx NE
CEM XXX cell_line_B
cells xxx cell_line_E
. . NE

Human Xxxx protein_B
RXR XXX protein_M
alpha xxx protein_E
was xxx NE
significantly xxx NE
expressed xxx NE
in xx NE
U937 Xddd cell_line_B
cell xxx cell_line_M
and xxx cell_line_M
THP-1 XXX-d cell_line_M
cell xxx cell_line_E
H9 Xd NE
cells xxx NE
and xxx NE
not xxx NE
detectable xxx NE
in xx NE
CEM XXX cell_line_B
cells xxx cell_line_E
. . NE

After Xxxx NE
stimulation xxx NE
by xx NE
PMA XXX NE
, , NE
RXR XXX NE
alpha xxx NE
expression xxx NE
increased xxx NE
in xx NE
H9 Xd cell_line
and xxx NE
U937 Xddd cell_line_B
cells xxx cell_line_E
but xxx NE
not xxx NE
in xx NE
CEM XXX cell_line_B
cells xxx cell_line_E
. . NE

Human Xxxx NE
RAR XXX NE
alpha xxx NE
expression xxx NE
was xxx NE
unchanged xxx NE
in xx NE
H9 Xd cell_line
and xxx NE
CEM XXX cell_line_B
cells xxx cell_line_E
, , NE
and xxx NE
elevated xxx NE
in xx NE
U937 Xddd cell_line_B
cells xxx cell_line_E
, , NE
after xxx NE
PMA XXX NE
stimulation xxx NE
. . NE

CONCLUSION XXXXXXXXXX NE
: : NE
The Xxx NE
effect xxx NE
of xx NE
RA XX NE
on xx NE
HIV-1 XXX-d NE
expression xxx NE
was xxx NE
cell-type-dependent xxx-xxx-xxx NE
and xxx NE
partially xxx NE
correlated xxx NE
with xxx NE
cellular xxx NE
expression xxx NE
of xx NE
RARs XXXx protein
. . NE

Endogenous Xxxx NE
or xx NE
exogenously xxx NE
administered xxx NE
RA XX NE
may xxx NE
have xxx NE
a x NE
significant xxx NE
role xxx NE
in xx NE
HIV XXX NE
regulation xxx NE
. . NE

Functions Xxxx NE
of xx NE
glutathione xxx NE
and xxx NE
glutathione xxx NE
disulfide xxx NE
in xx NE
immunology xxx NE
and xxx NE
immunopathology xxx NE
. . NE

Even Xxxx NE
a x NE
moderate xxx NE
increase xxx NE
in xx NE
the xxx NE
cellular xxx NE
cysteine xxx NE
supply xxx NE
elevates xxx NE
the xxx NE
intracellular xxx NE
glutathione xxx NE
( ( NE
GSH XXX NE
) ) NE
and xxx NE
glutathione xxx NE
disulfide xxx NE
( ( NE
GSSG XXXX NE
) ) NE
levels xxx NE
and xxx NE
potentiates xxx NE
immunological xxx NE
functions xxx NE
of xx NE
lymphocytes xxx cell_type
in xx NE
vitro xxx NE
. . NE

At Xx NE
low xxx NE
GSSG XXXX NE
levels xxx NE
, , NE
T X cell_type_B
cells xxx cell_type_E
cannot xxx NE
optimally xxx NE
activate xxx NE
the xxx NE
immunologically xxx NE
important xxx NE
transcription xxx protein_B
factor xxx protein_E
NF XX protein_B
kappa xxx protein_M
B X protein_E
, , NE
whereas xxx NE
high xxx NE
GSSG XXXX NE
levels xxx NE
inhibit xxx NE
the xxx NE
DNA XXX NE
binding xxx NE
activity xxx NE
of xx NE
NF XX protein_B
kappa xxx protein_M
B X protein_E
. . NE

The Xxx NE
effects xxx NE
of xx NE
GSSG XXXX NE
are xxx NE
antagonized xxx NE
by xx NE
reduced xxx NE
thioredoxin xxx protein
( ( NE
TRX XXX protein
) ) NE
. . NE

As Xx NE
the xxx NE
protein xxx NE
tyrosine xxx NE
kinase xxx NE
activities xxx NE
p56lck xddxxx NE
and xxx NE
p59fyn xddxxx NE
are xxx NE
activated xxx NE
in xx NE
intact xxx NE
cells xxx NE
by xx NE
hydrogen xxx NE
peroxide xxx NE
, , NE
they xxx NE
are xxx NE
likely xxx NE
targets xxx NE
for xxx NE
GSSG XXXX NE
action xxx NE
. . NE

These Xxxx NE
redox-regulated xxx-xxx protein_B
enzymes xxx protein_E
trigger xxx NE
signal xxx NE
cascades xxx NE
for xxx NE
NF XX NE
kappa xxx NE
B X NE
activation xxx NE
and xxx NE
transduce xxx NE
signals xxx NE
from xxx NE
the xxx NE
T X protein_B
cell xxx protein_M
antigen xxx protein_M
receptor xxx protein_E
, , NE
from xxx NE
CD4 XXd protein
and xxx NE
CD8 XXd protein_B
molecules xxx protein_E
, , NE
and xxx NE
from xxx NE
the xxx NE
IL-2 XX-d protein_B
receptor xxx protein_M
beta-chain xxx-xxx protein_E
. . NE

The Xxx NE
effector xxx NE
phase xxx NE
of xx NE
cytotoxic xxx NE
T X NE
cell xxx NE
responses xxx NE
and xxx NE
IL-2 XX-d NE
-dependent -xxx NE
functions xxx NE
are xxx NE
inhibited xxx NE
even xxx NE
by xx NE
a x NE
partial xxx NE
depletion xxx NE
of xx NE
the xxx NE
intracellular xxx NE
GSH XXX NE
pool xxx NE
. . NE

As Xx NE
signal xxx NE
transduction xxx NE
is xx NE
facilitated xxx NE
by xx NE
prooxidant xxx NE
conditions xxx NE
, , NE
we xx NE
propose xxx NE
that xxx NE
the xxx NE
well-known xxx-xxx NE
immunological xxx NE
consequences xxx NE
of xx NE
GSH XXX NE
depletion xxx NE
ultimately xxx NE
may xxx NE
be xx NE
results xxx NE
of xx NE
the xxx NE
accompanying xxx NE
GSSG XXXX NE
deficiency xxx NE
. . NE

decreased xxx NE
plasma xxx NE
cyst(e)ine xxx(x)xxx NE
level xxx NE
and xxx NE
intracellular xxx NE
GSH XXX NE
level xxx NE
HIV XXX NE
-infected -xxx NE
patients xxx NE
and xxx NE
SIV-infected XXX-xxx NE
rhesus xxx NE
macaques xxx NE
have xxx NE
, , NE
on xx NE
the xxx NE
average xxx NE
, , NE
significantly xxx NE
decreased xxx NE
plasma xxx NE
cyst(e)ine xxx(x)xxx NE
and xxx NE
intracellular xxx NE
GSH XXX NE
levels xxx NE
, , NE
we xx NE
also xxx NE
hypothesize xxx NE
that xxx NE
AIDS XXXX NE
may xxx NE
be xx NE
the xxx NE
consequence xxx NE
of xx NE
a x NE
GSSG XXXX NE
deficiency xxx NE
as xx NE
well xxx NE
. . NE

T X cell_type_B
cells xxx cell_type_E
from xxx NE
renal xxx NE
cell xxx NE
carcinoma xxx NE
patients xxx NE
exhibit xxx NE
an xx NE
abnormal xxx NE
pattern xxx NE
of xx NE
kappa xxx NE
B-specific X-xxx NE
DNA-binding XXX-xxx NE
activity xxx NE
: : NE
a x NE
preliminary xxx NE
report xxx NE
. . NE

Recent Xxxx NE
data xxx NE
suggest xxx NE
that xxx NE
the xxx NE
poor xxx NE
induction xxx NE
of xx NE
a x NE
T-cell X-xxx NE
response xxx NE
to xx NE
human xxx NE
renal xxx NE
cell xxx NE
carcinoma xxx NE
( ( NE
RCC XXX NE
) ) NE
may xxx NE
be xx NE
related xxx NE
to xx NE
alterations xxx NE
in xx NE
signal xxx NE
transduction xxx NE
pathways xxx NE
. . NE

We Xx NE
report xxx NE
that xxx NE
T X cell_type_B
cells xxx cell_type_E
from xxx NE
RCC XXX NE
patients xxx NE
have xxx NE
two xxx NE
alterations xxx NE
in xx NE
kappa xxx NE
B X NE
motif xxx NE
-specific -xxx NE
DNA-binding XXX-xxx NE
activity xxx NE
. . NE

The Xxx NE
first xxx NE
alteration xxx NE
involves xxx NE
the xxx NE
constitutive xxx NE
expression xxx NE
of xx NE
substantial xxx NE
kappa xxx NE
B-binding X-xxx NE
activity xxx NE
in xx NE
nuclear xxx NE
extracts xxx NE
, , NE
which xxx NE
was xxx NE
observed xxx NE
in xx NE
the xxx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assay xxx NE
. . NE

The Xxx NE
magnitude xxx NE
of xx NE
kappa xxx NE
B X NE
activity xxx NE
in xx NE
unstimulated xxx cell_type_B
patient xxx cell_type_M
T X cell_type_M
cells xxx cell_type_E
was xxx NE
similar xxx NE
to xx NE
that xxx NE
observed xxx NE
in xx NE
T X cell_type_B
cells xxx cell_type_E
from xxx NE
normal xxx NE
individuals xxx NE
that xxx NE
had xxx NE
been xxx NE
activated xxx NE
in xx NE
vitro xxx NE
. . NE

On Xx NE
the xxx NE
basis xxx NE
of xx NE
Western Xxxx NE
blotting xxx NE
experiments xxx NE
using xxx NE
antibodies xxx NE
to xx NE
kappa xxx NE
B/Rel X/Xxx NE
family xxx NE
proteins xxx NE
, , NE
the xxx NE
kappa xxx NE
B-binding X-xxx NE
activity xxx NE
constitutively xxx NE
expressed xxx NE
in xx NE
T X NE
cells xxx NE
from xxx NE
RCC XXX NE
patients xxx NE
is xx NE
composed xxx NE
mostly xxx NE
of xx NE
the xxx NE
NF-kappa XX-xxx NE
B1 Xd NE
( ( NE
p50 xdd NE
) ) NE
subunit xxx NE
. . NE

The Xxx NE
second xxx NE
abnormality xxx NE
in xx NE
kappa xxx NE
B-binding X-xxx NE
activity xxx NE
in xx NE
T X cell_type_B
cells xxx cell_type_E
from xxx NE
these xxx NE
patients xxx NE
is xx NE
that xxx NE
RelA XxxX protein
, , NE
a x NE
member xxx NE
of xx NE
the xxx NE
Rel Xxx protein_B
homology xxx protein_M
family xxx protein_E
which xxx NE
is xx NE
part xxx NE
of xx NE
the xxx NE
normal xxx NE
NF-kappa XX-xxx protein_B
B X protein_M
complex xxx protein_E
, , NE
was xxx NE
not xxx NE
induced xxx NE
in xx NE
the xxx NE
nucleus xxx NE
following xxx NE
activation xxx NE
. . NE

Western Xxxx NE
blotting xxx NE
analysis xxx NE
did xxx NE
not xxx NE
detect xxx NE
any xxx NE
RelA XxxX protein
in xx NE
nuclear xxx NE
extracts xxx NE
either xxx NE
before xxx NE
or xx NE
after xxx NE
stimulation xxx NE
of xx NE
T X cell_type_B
cells xxx cell_type_E
. . NE

The Xxx NE
altered xxx NE
kappa xxx NE
B-binding X-xxx NE
activity xxx NE
in xx NE
T X cell_type_B
cells xxx cell_type_E
from xxx NE
RCC XXX NE
patients xxx NE
may xxx NE
impair xxx NE
their xxx NE
capacity xxx NE
to xx NE
respond xxx NE
normally xxx NE
to xx NE
various xxx NE
stimuli xxx NE
. . NE

Hemoglobin Xxxx NE
switching xxx NE
in xx NE
humans xxx NE
is xx NE
accompanied xxx NE
by xx NE
changes xxx NE
in xx NE
the xxx NE
ratio xxx NE
of xx NE
the xxx NE
transcription xxx protein_B
factors xxx protein_E
, , NE
GATA-1 XXXX-d protein
and xxx NE
SP1 XXd protein
. . NE

BACKGROUND XXXXXXXXXX NE
: : NE
Understanding Xxxx NE
the xxx NE
mechanism xxx NE
of xx NE
developmental xxx NE
regulation xxx NE
of xx NE
hemoglobin xxx NE
switching xxx NE
has xxx NE
scientific xxx NE
as xx NE
well xxx NE
as xx NE
clinical xxx NE
relevance xxx NE
because xxx NE
of xx NE
the xxx NE
influence xxx NE
of xx NE
fetal xxx NE
hemoglobin xxx NE
( ( NE
HbF XxX NE
) ) NE
production xxx NE
in xx NE
adulthood xxx NE
on xx NE
the xxx NE
clinical xxx NE
manifestation xxx NE
of xx NE
thalassemia xxx NE
and xxx NE
sickle xxx NE
cell xxx NE
anemia xxx NE
. . NE

We Xx NE
have xxx NE
previously xxx NE
found xxx NE
that xxx NE
the xxx NE
normal xxx NE
developmental xxx NE
patterns xxx NE
of xx NE
globin xxx NE
gene xxx NE
expression xxx NE
are xxx NE
recapitulated xxx NE
in xx NE
an xx NE
experimental xxx NE
system xxx NE
of xx NE
primary xxx cell_line_B
cultures xxx cell_line_E
that xxx NE
support xxx NE
differentiation xxx NE
of xx NE
erythroid xxx cell_type_B
progenitors xxx cell_type_E
. . NE

We Xx NE
further xxx NE
found xxx NE
that xxx NE
high xxx NE
activities xxx NE
of xx NE
the xxx NE
transcriptional xxx protein_B
activators xxx protein_E
, , NE
GATA-1 XXXX-d protein
and xxx NE
SP1 XXd protein
, , NE
are xxx NE
associated xxx NE
with xxx NE
normal xxx NE
adult xxx NE
erythroid xxx NE
differentiation xxx NE
. . NE

MATERIALS XXXXXXXXX NE
AND XXX NE
METHODS XXXXXXX NE
: : NE
In Xx NE
the xxx NE
present xxx NE
work xxx NE
, , NE
we xx NE
have xxx NE
studied xxx NE
, , NE
the xxx NE
activities xxx NE
of xx NE
GATA-1 XXXX-d protein
and xxx NE
SP1 XXd protein
during xxx NE
differentiation xxx NE
of xx NE
cultured xxx NE
erythroid xxx cell_type_B
progenitors xxx cell_type_E
derived xxx NE
from xxx NE
cord xxx NE
blood xxx NE
and xxx NE
from xxx NE
fetal xxx NE
livers xxx NE
, , NE
as xx NE
well xxx NE
as xx NE
from xxx NE
beta xxx NE
zero- xxx- NE
thalassemia xxx NE
patients xxx NE
. . NE

RESULTS XXXXXXX NE
: : NE
The Xxx NE
results xxx NE
showed xxx NE
high xxx NE
GATA-1 XXXX-d NE
binding xxx NE
activity xxx NE
and xxx NE
very xxx NE
low xxx NE
SP1 XXd NE
activity xxx NE
in xx NE
the xxx NE
fetal xxx cell_line_B
liver xxx cell_line_M
cultures xxx cell_line_E
. . NE

This Xxxx NE
pattern xxx NE
was xxx NE
in xx NE
contrast xxx NE
to xx NE
cultures xxx NE
derived xxx NE
from xxx NE
normal xxx NE
adult xxx NE
peripheral xxx NE
blood xxx NE
, , NE
in xx NE
which xxx NE
both xxx NE
GATA-1 XXXX-d protein
and xxx NE
SP1 XXd protein
activities xxx NE
were xxx NE
high xxx NE
. . NE

Cord Xxxx NE
blood xxx NE
cultures xxx NE
showed xxx NE
an xx NE
additive xxx NE
combination xxx NE
of xx NE
"adult" "xxx" NE
and xxx NE
"fetal" "xxx" NE
patterns xxx NE
. . NE

The Xxx NE
progenitors xxx NE
derived xxx NE
from xxx NE
a x NE
beta xxx NE
zero- xxx- NE
thalassemia xxx NE
patient xxx NE
with xxx NE
high xxx NE
HbF XxX NE
production xxx NE
showed xxx NE
"fetal" "xxx" NE
pattern xxx NE
. . NE

On Xx NE
the xxx NE
other xxx NE
hand xxx NE
, , NE
in xx NE
cultures xxx NE
of xx NE
2 d NE
beta xxx NE
zero- xxx- NE
thalassemia xxx NE
patients xxx NE
without xxx NE
high xxx NE
HbF XxX NE
, , NE
"adult" "xxx" NE
pattern xxx NE
was xxx NE
observed xxx NE
. . NE

CONCLUSIONS XXXXXXXXXXX NE
: : NE
In Xx NE
the xxx NE
present xxx NE
work xxx NE
, , NE
we xx NE
show xxx NE
that xxx NE
human xxx cell_type_B
fetal xxx cell_type_M
erythroid xxx cell_type_M
progenitor xxx cell_type_M
and xxx cell_type_M
human xxx cell_type_M
adult xxx cell_type_M
erythroid xxx cell_type_M
progenitor xxx cell_type_E
are xxx NE
distinct xxx NE
in xx NE
their xxx NE
transcription xxx protein_B
factors xxx protein_E
, , NE
and xxx NE
that xxx NE
the xxx NE
commitment xxx NE
to xx NE
fetal xxx NE
or xx NE
adult xxx NE
program xxx NE
occurs xxx NE
at xx NE
a x NE
very xxx NE
early xxx NE
differentiation xxx NE
stage xxx NE
. . NE

Our Xxx NE
studies xxx NE
also xxx NE
demonstrate xxx NE
that xxx NE
under xxx NE
anemic xxx NE
stress xxx NE
, , NE
recruitment xxx NE
of xx NE
fetal xxx cell_type_B
progenitors xxx cell_type_E
may xxx NE
occur xxx NE
in xx NE
adulthood xxx NE
. . NE

Transcription-independent Xxxx-xxx NE
turnover xxx NE
of xx NE
I X protein_B
kappa xxx protein_M
B X protein_M
alpha xxx protein_E
during xxx NE
monocyte xxx NE
adherence xxx NE
: : NE
implications xxx NE
for xxx NE
a x NE
translational xxx NE
component xxx NE
regulating xxx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
/MAD-3 /XXX-d NE
mRNA xXXX NE
levels xxx NE
. . NE

We Xx NE
identified xxx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
/MAD-3 /XXX-d NE
as xx NE
an xx NE
immediate-early xxx-xxx NE
gene xxx NE
in xx NE
human xxx NE
monocytes xxx NE
that xxx NE
is xx NE
expressed xxx NE
in xx NE
response xxx NE
to xx NE
a x NE
variety xxx NE
of xx NE
signals xxx NE
, , NE
including xxx NE
adhesion xxx NE
, , NE
lipopolysaccharide xxx NE
, , NE
and xxx NE
phorbol xxx NE
myristate xxx NE
acetate xxx NE
. . NE

Within Xxxx NE
5 d NE
min xxx NE
of xx NE
monocyte xxx NE
adhesion xxx NE
, , NE
the xxx NE
level xxx NE
of xx NE
the xxx NE
I X protein_B
kappa xxx protein_M
B X protein_M
alpha xxx protein_M
protein xxx protein_E
is xx NE
markedly xxx NE
diminished xxx NE
but xxx NE
is xx NE
rapidly xxx NE
replaced xxx NE
in xx NE
a x NE
cycloheximide-sensitive xxx-xxx NE
manner xxx NE
within xxx NE
20 dd NE
min xxx NE
. . NE

Accompanying Xxxx NE
the xxx NE
rapid xxx NE
turnover xxx NE
of xx NE
the xxx NE
I X protein_B
kappa xxx protein_M
B X protein_M
alpha xxx protein_M
protein xxx protein_E
is xx NE
simultaneous xxx NE
translocation xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B-related X-xxx protein_M
transcription xxx protein_M
factors xxx protein_E
to xx NE
nuclei xxx NE
of xx NE
adhered xxx NE
monocytes xxx NE
. . NE

The Xxx NE
demonstration xxx NE
that xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
can xxx NE
regulate xxx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
/MAD-3 /XXX-d NE
gene xxx NE
transcription xxx NE
in xx NE
other xxx NE
cell xxx NE
types xxx NE
suggested xxx NE
that xxx NE
the xxx NE
rapid xxx NE
increase xxx NE
in xx NE
steady-state xxx-xxx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
/MAD-3 /XXX-d NE
mRNA xXXX NE
levels xxx NE
we xx NE
observed xxx NE
within xxx NE
30 dd NE
min xxx NE
of xx NE
monocyte xxx NE
adherence xxx NE
would xxx NE
result xxx NE
from xxx NE
NF-kappa XX-xxx NE
B X NE
-dependent -xxx NE
transcriptional xxx NE
stimulation xxx NE
of xx NE
the xxx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
/MAD-3 /XXX-d NE
gene xxx NE
. . NE

Nuclear Xxxx NE
run-on xxx-xx NE
analyses xxx NE
indicated xxx NE
that xxx NE
, , NE
instead xxx NE
, , NE
while xxx NE
several xxx NE
immediate-early xxx-xxx DNA_B
cytokine xxx DNA_M
genes xxx DNA_E
, , NE
such xxx NE
as xx NE
the xxx NE
interleukin xxx NE
1 d NE
beta xxx NE
( ( NE
IL-1 XX-d NE
beta xxx NE
) ) NE
gene xxx NE
, , NE
were xxx NE
transcriptionally xxx NE
activated xxx NE
during xxx NE
monocyte xxx NE
adhesion xxx NE
, , NE
the xxx NE
rate xxx NE
of xx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
/MAD-3 /XXX-d NE
gene xxx NE
transcription xxx NE
remained xxx NE
constant xxx NE
. . NE

The Xxx NE
adherence-dependent xxx-xxx NE
increase xxx NE
in xx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
/MAD-3 /XXX-d NE
mRNA xXXX NE
levels xxx NE
was xxx NE
also xxx NE
not xxx NE
a x NE
consequence xxx NE
of xx NE
mRNA xXXX NE
stabilization xxx NE
events xxx NE
. . NE

Interestingly Xxxx NE
, , NE
while xxx NE
increases xxx NE
in xx NE
both xxx NE
IL-1 XX-d NE
beta xxx NE
mRNA xXXX NE
level xxx NE
and xxx NE
I X NE
kappa xxx NE
B X NE
alpha/MAD-3 xxx/XXX-d NE
mRNA xXXX NE
level xxx NE
IL-1 XX-d RNA_B
beta xxx RNA_E
were xxx NE
detected xxx NE
in xx NE
nuclei xxx NE
of xx NE
adherent xxx cell_type_B
monocytes xxx cell_type_E
, , NE
cytoplasmic xxx NE
levels xxx NE
of xx NE
IL-1 XX-d NE
beta xxx NE
mRNA xXXX RNA
increased xxx NE
during xxx NE
adherence xxx NE
whereas xxx NE
those xxx NE
of xx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
/MAD-3 /XXX-d NE
mRNA xXXX NE
did xxx NE
not xxx NE
. . NE

Taken Xxxx NE
together xxx NE
, , NE
our xxx NE
data xxx NE
suggest xxx NE
that xxx NE
two xxx NE
interactive xxx NE
mechanisms xxx NE
regulate xxx NE
monocytic xxx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
/MAD-3 /XXX-d NE
mRNA xXXX NE
levels xxx NE
. . NE

We Xx NE
propose xxx NE
that xxx NE
adherent xxx cell_type_B
monocytes xxx cell_type_E
regulate xxx NE
nuclear xxx NE
processing xxx NE
(or (xx NE
decay) xxx) NE
of xx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
/MAD-3 /XXX-d NE
mRNA xXXX NE
, , NE
thereby xxx NE
increasing xxx NE
mRNA xXXX NE
levels xxx NE
without xxx NE
stimulating xxx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
/MAD-3 /XXX-d NE
gene xxx NE
transcription xxx NE
. . NE

Moreover Xxxx NE
, , NE
since xxx NE
inhibition xxx NE
of xx NE
protein xxx NE
synthesis xxx NE
leads xxx NE
to xx NE
accumulation xxx NE
of xx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
/MAD-3 /XXX-d NE
mRNA xXXX NE
without xxx NE
stimulating xxx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
/MAD-3 /XXX-d NE
gene xxx NE
transcription xxx NE
, , NE
we xx NE
suggest xxx NE
that xxx NE
low xxx NE
cytoplasmic xxx NE
levels xxx NE
of xx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
/MAD-3 /XXX-d NE
mRNA xXXX NE
are xxx NE
maintained xxx NE
by xx NE
a x NE
translation-dependent xxx-xxx NE
degradation xxx NE
mechanism xxx NE
. . NE

Distinct Xxxx NE
roles xxx NE
of xx NE
the xxx NE
molecular xxx NE
chaperone xxx protein_B
hsp90 xxxdd protein_E
in xx NE
modulating xxx NE
dioxin xxx NE
receptor xxx NE
function xxx NE
via xxx NE
the xxx NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx protein
and xxx NE
PAS XXX protein_B
domains xxx protein_E
. . NE

The Xxx NE
intracellular xxx protein_B
dioxin xxx protein_M
receptor xxx protein_E
mediates xxx NE
signal xxx NE
transduction xxx NE
by xx NE
dioxin xxx NE
and xxx NE
functions xxx NE
as xx NE
a x NE
ligand-activated xxx-xxx protein_B
transcription xxx protein_M
factor xxx protein_E
. . NE

It Xx NE
contains xxx NE
a x NE
basic xxx NE
helix-loop-helix xxx-xxx-xxx NE
( ( NE
bHLH xXXX NE
) ) NE
motif xxx NE
contiguous xxx NE
with xxx NE
a x NE
Per-Arnt-Sim Xxx-Xxxx-Xxx NE
(PAS) (XXX) NE
homology xxx NE
region xxx NE
. . NE

In Xx NE
extracts xxx NE
from xxx NE
nonstimulated xxx NE
cells xxx NE
the xxx NE
receptor xxx NE
is xx NE
recovered xxx NE
in xx NE
an xx NE
inducible xxx NE
cytoplasmic xxx NE
form xxx NE
associated xxx NE
with xxx NE
the xxx NE
90-kDa dd-xXx protein_B
heat xxx protein_M
shock xxx protein_M
protein xxx protein_E
( ( NE
hsp90 xxxdd protein
) ) NE
, , NE
a x NE
molecular xxx protein_B
chaperone xxx protein_E
. . NE

We Xx NE
have xxx NE
reconstituted xxx NE
ligand-dependent xxx-xxx NE
activation xxx NE
of xx NE
the xxx NE
receptor xxx NE
to xx NE
a x NE
DNA-binding XXX-xxx protein_B
form xxx protein_E
by xx NE
using xxx NE
the xxx NE
dioxin xxx protein_B
receptor xxx protein_E
and xxx NE
its xxx NE
bHLH-PAS xXXX-XXX protein_B
partner xxx protein_M
factor xxx protein_E
Arnt Xxxx protein
expressed xxx NE
by xx NE
in xx NE
vitro xxx NE
translation xxx NE
in xx NE
reticulocyte xxx NE
lysate xxx NE
. . NE

Deletion Xxxx NE
of xx NE
the xxx NE
PAS XXX protein_B
domain xxx protein_E
of xx NE
the xxx NE
receptor xxx NE
resulted xxx NE
in xx NE
constitutive xxx NE
dimerization xxx NE
with xxx NE
Arnt Xxxx protein
. . NE

In Xx NE
contrast xxx NE
, , NE
this xxx NE
receptor xxx NE
mutant xxx NE
showed xxx NE
low xxx NE
levels xxx NE
of xx NE
xenobiotic xxx NE
response xxx NE
element-binding xxx-xxx NE
activity xxx NE
, , NE
indicating xxx NE
that xxx NE
the xxx NE
PAS XXX protein_B
domain xxx protein_E
may xxx NE
be xx NE
important xxx NE
for xxx NE
DNA-binding XXX-xxx NE
affinity xxx NE
and/or xxx/xx NE
specificity xxx NE
of xx NE
the xxx NE
receptor xxx NE
. . NE

It Xx NE
was xxx NE
not xxx NE
possible xxx NE
to xx NE
reconstitute xxx NE
dioxin xxx protein_B
receptor xxx protein_E
function xxx NE
with xxx NE
proteins xxx NE
expressed xxx NE
in xx NE
wheat xxx NE
germ xxx NE
lysate xxx NE
. . NE

In Xx NE
line xxx NE
with xxx NE
these xxx NE
observations xxx NE
, , NE
reticulocyte xxx NE
lysate xxx NE
but xxx NE
not xxx NE
wheat xxx NE
germ xxx NE
lysate xxx NE
promoted xxx NE
the xxx NE
association xxx NE
of xx NE
de xx NE
novo xxx NE
synthesized xxx NE
dioxin xxx protein_B
receptor xxx protein_E
with xxx NE
hsp90 xxxdd protein
. . NE

At Xx NE
least xxx NE
two xxx NE
distinct xxx NE
domains xxx NE
of xx NE
the xxx NE
receptor xxx NE
mediated xxx NE
interaction xxx NE
with xxx NE
hsp90 xxxdd protein
: : NE
the xxx NE
ligand-binding xxx-xxx protein_B
domain xxx protein_E
located xxx NE
within xxx NE
the xxx NE
PAS XXX protein_B
region xxx protein_E
and xxx NE
, , NE
surprisingly xxx NE
, , NE
the xxx NE
bHLH xXXX protein_B
domain xxx protein_E
. . NE

Whereas Xxxx NE
ligand-binding xxx-xxx NE
activity xxx NE
correlated xxx NE
with xxx NE
association xxx NE
with xxx NE
hsp90 xxxdd protein
, , NE
bHLH- xXXX- NE
hsp90 xxxdd NE
interaction xxx NE
appeared xxx NE
to xx NE
be xx NE
important xxx NE
for xxx NE
DNA-binding XXX-xxx NE
activity xxx NE
but xxx NE
not xxx NE
for xxx NE
dimerization xxx NE
of xx NE
the xxx NE
receptor xxx NE
. . NE

Several Xxxx NE
distinct xxx NE
roles xxx NE
for xxx NE
hsp90 xxxdd protein
in xx NE
modulating xxx NE
dioxin xxx protein_B
receptor xxx protein_E
function xxx NE
are xxx NE
therefore xxx NE
likely xxx NE
: : NE
correct xxx NE
folding xxx NE
of xx NE
the xxx NE
ligand-binding xxx-xxx NE
domain xxx NE
, , NE
interference xxx NE
with xxx NE
Arnt Xxxx protein
heterodimerization xxx NE
, , NE
and xxx NE
folding xxx NE
of xx NE
a x NE
DNA-binding XXX-xxx NE
conformation xxx NE
of xx NE
the xxx NE
bHLH xXXX protein_B
domain xxx protein_E
. . NE

Thus Xxxx NE
, , NE
the xxx NE
dioxin xxx protein_B
receptor xxx protein_E
system xxx NE
provides xxx NE
a x NE
complex xxx NE
and xxx NE
interesting xxx NE
model xxx NE
of xx NE
the xxx NE
regulation xxx NE
of xx NE
transcription xxx protein_B
factors xxx protein_E
by xx NE
hsp90 xxxdd protein
. . NE

Induction Xxxx NE
of xx NE
transcription xxx protein_B
factors xxx protein_E
in xx NE
human xxx cell_type_B
T X cell_type_M
lymphocytes xxx cell_type_E
by xx NE
aspirin xxx NE
-like -xxx NE
drugs xxx NE
. . NE

Aspirin-like Xxxx-xxx NE
drugs xxx NE
( ( NE
ALD XXX NE
) ) NE
induce xxx NE
calcium xxx NE
mobilization xxx NE
, , NE
an xx NE
essential xxx NE
component xxx NE
of xx NE
T X NE
cell xxx NE
activation xxx NE
, , NE
but xxx NE
do xx NE
not xxx NE
induce xxx NE
the xxx NE
biosynthesis xxx NE
of xx NE
IL-2 XX-d protein
. . NE

To Xx NE
understand xxx NE
the xxx NE
extent xxx NE
to xx NE
which xxx NE
ALD XXX NE
may xxx NE
mimic xxx NE
mitogenic xxx NE
stimulation xxx NE
, , NE
we xx NE
studied xxx NE
cytoplasmic xxx NE
signaling xxx NE
step xxx NE
and xxx NE
nuclear xxx NE
signaling xxx NE
step xxx NE
ALD XXX NE
-treated -xxx cell_line_B
T X cell_line_M
cells xxx cell_line_E
. . NE

We Xx NE
found xxx NE
that xxx NE
ALD XXX NE
induce xxx NE
a x NE
transient xxx NE
activation xxx NE
of xx NE
protein xxx protein_B
kinase xxx protein_E
( ( NE
PKC XXX protein
) ) NE
but xxx NE
have xxx NE
no xx NE
effect xxx NE
(in (xx NE
comparison xxx NE
to xx NE
anti-CD3 xxx-XXd NE
antibodies xxx NE
) ) NE
on xx NE
protein xxx NE
tyrosine xxx NE
phosphorylation xxx NE
nor xxx NE
on xx NE
PCL XXX NE
gamma xxx NE
1 d NE
tyrosine xxx NE
phosphorylation xxx NE
. . NE

ALD XXX NE
-induced -xxx NE
calcium xxx NE
mobilization xxx NE
and xxx NE
PKC XXX NE
activation xxx NE
are xxx NE
independent xxx NE
of xx NE
tyrosine xxx NE
protein xxx NE
kinase xxx NE
activity xxx NE
as xx NE
shown xxx NE
by xx NE
the xxx NE
lack xxx NE
of xx NE
effect xxx NE
of xx NE
herbimycin xxx NE
, , NE
a x NE
tyrosine xxx NE
-protein -xxx NE
kinase xxx NE
-specific -xxx NE
inhibitor xxx NE
. . NE

Although Xxxx NE
we xx NE
detected xxx NE
no xx NE
IL-2 XX-d RNA_B
mRNA xXXX RNA_E
in xx NE
ALD XXX NE
-treated -xxx NE
cells xxx NE
, , NE
the xxx NE
nuclei xxx NE
of xx NE
these xxx NE
cells xxx NE
contain xxx NE
proteins xxx NE
capable xxx NE
of xx NE
binding xxx NE
to xx NE
three xxx NE
regulatory xxx NE
sequences xxx NE
in xx NE
the xxx NE
IL-2 XX-d NE
promoter xxx NE
region xxx NE
: : NE
NFAT XXXX NE
, , NE
NF XX NE
kappa xxx NE
B X NE
, , NE
and xxx NE
AP-1 XX-d NE
. . NE

These Xxxx NE
binding xxx NE
activities xxx NE
are xxx NE
expressed xxx NE
only xxx NE
in xx NE
activated xxx cell_type_B
T X cell_type_M
cells xxx cell_type_E
. . NE

The Xxx NE
expression xxx NE
of xx NE
AP-1 XX-d protein
depended xxx NE
on xx NE
calcium xxx NE
mobilization xxx NE
and xxx NE
PKC XXX NE
activation xxx NE
. . NE

These Xxxx NE
data xxx NE
suggest xxx NE
that xxx NE
ALD XXX NE
cause xxx NE
transient xxx NE
but xxx NE
significant xxx NE
changes xxx NE
in xx NE
T X NE
cell xxx NE
transmembrane xxx NE
signaling xxx NE
, , NE
although xxx NE
some xxx NE
events xxx NE
induced xxx NE
by xx NE
stimulation xxx NE
with xxx NE
anti-CD3 xxx-XXd NE
antibodies xxx NE
are xxx NE
not xxx NE
induced xxx NE
by xx NE
ALD XXX NE
. . NE

The Xxx NE
signal xxx NE
is xx NE
transmitted xxx NE
to xx NE
the xxx NE
nucleus xxx NE
and xxx NE
induces xxx NE
DNA-binding XXX-xxx NE
activity xxx NE
by xx NE
several xxx NE
transcription xxx protein_B
factors xxx protein_E
. . NE

However Xxxx NE
, , NE
the xxx NE
ALD XXX NE
stimulus xxx NE
is xx NE
not xxx NE
capable xxx NE
of xx NE
causing xxx NE
complete xxx NE
T X NE
cell xxx NE
activation xxx NE
. . NE

Protein Xxxx protein_B
kinase xxx protein_M
C X protein_E
is xx NE
not xxx NE
a x NE
downstream xxx NE
effector xxx NE
of xx NE
p21ras xddxxx DNA
in xx NE
activated xxx cell_type_B
T X cell_type_M
cells xxx cell_type_E
. . NE

The Xxx NE
aim xxx NE
of xx NE
this xxx NE
present xxx NE
study xxx NE
was xxx NE
to xx NE
investigate xxx NE
the xxx NE
role xxx NE
of xx NE
protein xxx protein_B
kinase xxx protein_M
C X protein_E
( ( NE
PKC XXX protein
) ) NE
, , NE
downstream xxx NE
of xx NE
p21ras xddxxx DNA
, , NE
in xx NE
activating xxx NE
interleukin-2 xxx-d NE
(IL-2) (XX-d) NE
gene xxx NE
expression xxx NE
. . NE

It Xx NE
has xxx NE
been xxx NE
reported xxx NE
that xxx NE
PKC XXX protein
is xx NE
an xx NE
effector xxx protein
of xx NE
p21ras xddxxx DNA
in xx NE
T X cell_type_B
cells xxx cell_type_E
. . NE

Data Xxxx NE
is xx NE
presented xxx NE
, , NE
using xxx NE
the xxx NE
potent xxx NE
and xxx NE
selective xxx NE
PKC XXX NE
inhibitor xxx NE
Ro Xx NE
31-8425 dd-dddd NE
and xxx NE
transient xxx NE
expression xxx NE
of xx NE
a x NE
constitutively xxx NE
active xxx NE
ras xxx NE
mutant xxx NE
, , NE
which xxx NE
clearly xxx NE
shows xxx NE
that xxx NE
PKC XXX protein
is xx NE
not xxx NE
downstream xxx NE
of xx NE
p21ras xddxxx DNA
in xx NE
the xxx NE
induction xxx NE
of xx NE
NF-AT XX-XX protein
and xxx NE
AP-1 XX-d NE
transcriptional xxx NE
activity xxx NE
and xxx NE
in xx NE
the xxx NE
expression xxx NE
of xx NE
IL-2 XX-d protein
in xx NE
human xxx cell_line_B
Jurkat Xxxx cell_line_M
T X cell_line_M
cells xxx cell_line_E
. . NE

Reporter Xxxx NE
gene xxx NE
experiments xxx NE
demonstrated xxx NE
that xxx NE
NF-kappa XX-xxx NE
B X NE
transcriptional xxx NE
activity xxx NE
is xx NE
not xxx NE
affected xxx NE
by xx NE
expression xxx NE
of xx NE
activated xxx NE
p21ras xddxxx DNA
. . NE

The Xxx NE
signaling xxx NE
pathways xxx NE
involving xxx NE
PKC XXX NE
activation xxx NE
, , NE
calcium xxx NE
mobilization xxx NE
and xxx NE
ras xxx NE
activation xxx NE
combine xxx NE
to xx NE
provide xxx NE
the xxx NE
necessary xxx NE
components xxx NE
for xxx NE
production xxx NE
of xx NE
IL-2 XX-d protein
during xxx NE
T X NE
cell xxx NE
activation xxx NE
. . NE

The Xxx NE
C-terminus X-xxx protein
of xx NE
the xxx NE
B X protein_B
cell xxx protein_M
activator xxx protein_E
Oct-2 Xxx-d protein
functions xxx NE
as xx NE
an xx NE
activation xxx protein_B
domain xxx protein_E
in xx NE
yeast xxx NE
. . NE

Oct-1 Xxx-d protein
and xxx NE
Oct-2 Xxx-d protein
are xxx NE
human xxx NE
transcriptional xxx protein_B
activators xxx protein_E
that xxx NE
bind xxx NE
to xx NE
the xxx NE
same xxx NE
DNA XXX NE
element xxx NE
but xxx NE
activate xxx NE
distinct xxx NE
sets xxx NE
of xx NE
genes xxx NE
. . NE

We Xx NE
expressed xxx NE
these xxx NE
factors xxx NE
in xx NE
S. X. NE
cerevisiae xxx NE
and xxx NE
observed xxx NE
greater xxx NE
than xxx NE
5-fold d-xxx NE
stimulation xxx NE
of xx NE
a x NE
lacZ xxxX DNA_B
reporter xxx DNA_M
gene xxx DNA_E
only xxx NE
with xxx NE
Oct-2 Xxx-d protein
. . NE

Transfer Xxxx NE
of xx NE
the xxx NE
Oct-2 Xxx-d protein_B
C-terminal X-xxx protein_M
domain xxx protein_E
onto xxx NE
either xxx NE
Oct-1 Xxx-d protein
( ( NE
Oct1.2 Xxxd.d protein
) ) NE
or xx NE
a x NE
nonactivating xxx protein_B
DNA-binding XXX-xxx protein_M
domain xxx protein_E
from xxx NE
GAL4 XXXd protein
created xxx NE
activators xxx NE
capable xxx NE
of xx NE
greater xxx NE
than xxx NE
15 dd NE
and xxx NE
10-fold dd-xxx NE
stimulation xxx NE
of xx NE
activity xxx NE
, , NE
respectively xxx NE
. . NE

Thus Xxxx NE
, , NE
the xxx NE
C-terminus X-xxx protein
of xx NE
Oct-2 Xxx-d protein
is xx NE
sufficient xxx NE
to xx NE
confer xxx NE
activation xxx NE
potential xxx NE
to xx NE
nonactive xxx NE
DNA-binding XXX-xxx DNA_B
fragments xxx DNA_E
in xx NE
yeast xxx NE
. . NE

Glucocorticoid-induced Xxxx-xxx NE
apoptosis xxx NE
of xx NE
lymphoid xxx cell_type_B
cells xxx cell_type_E
. . NE

The Xxx NE
induction xxx NE
of xx NE
cell xxx NE
death xxx NE
in xx NE
lymphoid xxx cell_type_B
cells xxx cell_type_E
by xx NE
glucocorticoids xxx NE
is xx NE
one xxx NE
of xx NE
the xxx NE
earliest xxx NE
and xxx NE
most xxx NE
thoroughly xxx NE
studied xxx NE
models xxx NE
of xx NE
apoptosis xxx NE
. . NE

Although Xxxx NE
the xxx NE
exact xxx NE
mechanism xxx NE
by xx NE
which xxx NE
apoptosis xxx NE
occurs xxx NE
in xx NE
lymphocytes xxx cell_type
is xx NE
unknown xxx NE
many xxx NE
biochemical xxx NE
and xxx NE
molecular xxx NE
changes xxx NE
have xxx NE
been xxx NE
shown xxx NE
to xx NE
occur xxx NE
in xx NE
these xxx NE
cells xxx NE
in xx NE
response xxx NE
to xx NE
glucocorticoids xxx NE
. . NE

The Xxx NE
role xxx NE
of xx NE
chromatin xxx NE
degradation xxx NE
and xxx NE
endonucleases xxx protein
in xx NE
the xxx NE
apoptotic xxx NE
process xxx NE
has xxx NE
been xxx NE
closely xxx NE
studied xxx NE
, , NE
as xx NE
well xxx NE
as xx NE
the xxx NE
involvement xxx NE
of xx NE
several xxx NE
oncogenes xxx DNA
in xx NE
glucocorticoid xxx NE
-induced -xxx NE
cell xxx NE
lysis xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
the xxx NE
clinical xxx NE
importance xxx NE
of xx NE
glucocorticoid xxx NE
-induced -xxx NE
apoptosis xxx NE
in xx NE
the xxx NE
treatment xxx NE
of xx NE
lymphoid xxx NE
neoplasms xxx NE
has xxx NE
recently xxx NE
received xxx NE
increased xxx NE
attention xxx NE
. . NE

Interleukin-2 Xxxx-d protein
induces xxx NE
tyrosine xxx NE
phosphorylation xxx NE
and xxx NE
nuclear xxx NE
translocation xxx NE
of xx NE
stat3 xxxd protein
in xx NE
human xxx cell_type_B
T X cell_type_M
lymphocytes xxx cell_type_E
. . NE

An Xx NE
early xxx NE
biochemical xxx NE
event xxx NE
associated xxx NE
with xxx NE
T X NE
cell xxx NE
activation xxx NE
through xxx NE
the xxx NE
interleukin-2 xxx-d protein_B
receptor xxx protein_E
( ( NE
IL-2R XX-dX protein
) ) NE
is xx NE
tyrosine xxx NE
phosphorylation xxx NE
of xx NE
several xxx NE
intracellular xxx NE
substrates xxx NE
. . NE

The Xxx NE
exact xxx NE
mechanism xxx NE
by xx NE
which xxx NE
IL-2 XX-d protein
regulates xxx NE
transcription xxx NE
of xx NE
different xxx NE
genes xxx NE
is xx NE
presently xxx NE
unknown xxx NE
. . NE

Here Xxxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
stimulation xxx NE
through xxx NE
the xxx NE
IL-2R XX-dX protein
induced xxx NE
tyrosine xxx NE
phosphorylation xxx NE
and xxx NE
subsequent xxx NE
nuclear xxx NE
translocation xxx NE
of xx NE
stat3 xxxd protein
, , NE
a x NE
newly xxx NE
identified xxx NE
member xxx NE
of xx NE
the xxx NE
signal xxx protein_B
transducers xxx protein_M
and xxx protein_M
activators xxx protein_M
of xx protein_M
transcription xxx protein_M
(STAT) (XXXX) protein_M
family xxx protein_E
of xx NE
proteins xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
stat1 xxxd NE
proteins xxx NE
were xxx NE
not xxx NE
tyrosine xxx NE
phosphorylated xxx NE
after xxx NE
IL-2 XX-d NE
ligation xxx NE
, , NE
whereas xxx NE
tyrosine xxx protein
-phosphorylated -xxx NE
stat1 xxxd NE
proteins xxx NE
( ( NE
91 dd protein_B
kDa xXx protein_M
protein xxx protein_M
and xxx protein_M
84 dd protein_M
kDa xXx protein_M
protein xxx protein_E
nucleus xxx NE
following xxx NE
interferon-gamma xxx-xxx NE
treatment xxx NE
of xx NE
HeLa XxXx cell_line_B
cells xxx cell_line_E
. . NE

Apart Xxxx NE
from xxx NE
stat3 xxxd protein
, , NE
another xxx NE
cytoplasmic xxx protein_B
protein xxx protein_E
was xxx NE
tyrosine xxx NE
phosphorylated xxx NE
and xxx NE
subsequently xxx NE
translocated xxx NE
to xx NE
the xxx NE
nucleus xxx NE
in xx NE
response xxx NE
to xx NE
IL-2 XX-d protein
. . NE

This Xxxx NE
protein xxx NE
had xxx NE
an xx NE
apparent xxx NE
molecular xxx NE
mass xxx NE
of xx NE
84 dd protein_B
kDa xXx protein_E
and xxx NE
was xxx NE
not xxx NE
recognized xxx NE
by xx NE
stat3 xxxd protein
or xx NE
stat1 xxxd protein_B
mAb xXx protein_E
or xx NE
antisera xxx NE
. . NE

Since Xxxx NE
IL-2 XX-d protein
induced xxx NE
nuclear xxx NE
translocation xxx NE
of xx NE
the xxx NE
84 dd protein_B
kDa xXx protein_M
protein xxx protein_E
and xxx NE
stat3 xxxd protein
followed xxx NE
identical xxx NE
kinetics xxx NE
, , NE
p84 xdd protein
is xx NE
a x NE
candidate xxx NE
for xxx NE
a x NE
new xxx NE
, , NE
yet xxx NE
undefined xxx NE
, , NE
member xxx NE
of xx NE
the xxx NE
STAT XXXX NE
family xxx NE
. . NE

Taken Xxxx NE
together xxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
IL-2 XX-d protein
induces xxx NE
tyrosine xxx NE
phosphorylation xxx NE
and xxx NE
subsequent xxx NE
nuclear xxx NE
translocation xxx NE
of xx NE
stat3 xxxd protein
and xxx NE
an xx NE
as xx NE
yet xxx NE
undefined xxx NE
84-kDa dd-xXx protein_B
protein xxx protein_E
in xx NE
antigen-specific xxx-xxx cell_line_B
human xxx cell_line_M
T X cell_line_M
cell xxx cell_line_M
lines xxx cell_line_E
. . NE

Human Xxxx NE
T-cell X-xxx NE
leukemia xxx NE
virus xxx NE
type xxx NE
I X NE
Tax Xxx NE
activation xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
/Rel /Xxx NE
involves xxx NE
phosphorylation xxx NE
and xxx NE
degradation xxx NE
of xx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
and xxx NE
RelA XxxX NE
( ( NE
p65 xdd NE
)-mediated )-xxx NE
induction xxx NE
of xx NE
the xxx NE
c-rel x-xxx NE
gene xxx NE
. . NE

The Xxx NE
tax xxx NE
gene xxx NE
product xxx NE
of xx NE
human xxx NE
T-cell X-xxx NE
leukemia xxx NE
virus xxx NE
type xxx NE
I X NE
( ( NE
HTLV-I XXXX-X NE
) ) NE
is xx NE
a x NE
potent xxx NE
transcriptional xxx protein_B
activator xxx protein_E
that xxx NE
both xxx NE
stimulates xxx NE
viral xxx NE
gene xxx NE
expression xxx NE
and xxx NE
activates xxx NE
an xx NE
array xxx NE
of xx NE
cellular xxx DNA_B
genes xxx DNA_E
involved xxx NE
in xx NE
T-cell X-xxx NE
growth xxx NE
. . NE

Tax Xxx NE
acts xxx NE
indirectly xxx NE
by xx NE
inducing xxx NE
or xx NE
modifying xxx NE
the xxx NE
action xxx NE
of xx NE
various xxx NE
host xxx NE
transcription xxx protein_B
factors xxx protein_E
, , NE
including xxx NE
members xxx NE
of xx NE
the xxx NE
NF-kappa XX-xxx NE
B X NE
/Rel /Xxx NE
family xxx NE
of xx NE
enhancer-binding xxx-xxx NE
proteins xxx NE
. . NE

In Xx NE
resting xxx cell_type_B
T X cell_type_M
cells xxx cell_type_E
, , NE
many xxx NE
of xx NE
these xxx NE
NF-kappa XX-xxx NE
B X NE
/Rel /Xxx NE
factors xxx NE
are xxx NE
sequestered xxx NE
in xx NE
the xxx NE
cytoplasm xxx NE
by xx NE
various xxx NE
ankyrin-rich xxx-xxx NE
inhibitory xxx NE
proteins xxx NE
, , NE
including xxx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
. . NE

HTLV-I XXXX-X NE
Tax Xxx NE
expression xxx NE
leads xxx NE
to xx NE
the xxx NE
constitutive xxx NE
nuclear xxx NE
expression xxx NE
of xx NE
biologically xxx NE
active xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
and xxx NE
c-Rel x-Xxx NE
complexes xxx NE
; ; NE
however xxx NE
, , NE
the xxx NE
biochemical xxx NE
mechanism xxx NE
(s) (x) NE
underlying xxx NE
this xxx NE
response xxx NE
remains xxx NE
poorly xxx NE
understood xxx NE
. . NE

In Xx NE
this xxx NE
study xxx NE
, , NE
we xx NE
demonstrate xxx NE
that xxx NE
Tax Xxx NE
-stimulated -xxx NE
nuclear xxx NE
expression xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
in xx NE
both xxx NE
HTLV-I XXXX-X NE
-infected -xxx NE
and xxx NE
Tax Xxx NE
-transfected -xxx NE
human xxx NE
T X NE
cells xxx NE
is xx NE
associated xxx NE
with xxx NE
the xxx NE
phosphorylation xxx NE
and xxx NE
rapid xxx NE
proteolytic xxx NE
degradation xxx NE
of xx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
. . NE

In Xx NE
contrast xxx NE
to xx NE
prior xxx NE
in xx NE
vitro xxx NE
studies xxx NE
, , NE
at xx NE
least xxx NE
a x NE
fraction xxx NE
of xx NE
the xxx NE
phosphorylated xxx NE
form xxx NE
of xx NE
I X protein_B
kappa xxx protein_M
B X protein_M
alpha xxx protein_E
remains xxx NE
physically xxx NE
associated xxx NE
with xxx NE
the xxx NE
NF-kappa XX-xxx protein_B
B X protein_M
complex xxx protein_E
in xx NE
vivo xxx NE
but xxx NE
is xx NE
subject xxx NE
to xx NE
rapid xxx NE
degradation xxx NE
, , NE
thereby xxx NE
promoting xxx NE
the xxx NE
nuclear xxx NE
translocation xxx NE
of xx NE
the xxx NE
active xxx NE
NF-kappa XX-xxx protein_B
B X protein_M
complex xxx protein_E
. . NE

We Xx NE
further xxx NE
demonstrate xxx NE
that xxx NE
Tax Xxx NE
induction xxx NE
of xx NE
nuclear xxx NE
c-Rel x-Xxx NE
expression xxx NE
is xx NE
activated xxx NE
by xx NE
the xxx NE
RelA XxxX protein
( ( NE
p65 xdd protein
) ) NE
subunit xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
, , NE
which xxx NE
activates xxx NE
transcription xxx NE
of xx NE
the xxx NE
c-rel x-xxx DNA_B
gene xxx DNA_E
through xxx NE
an xx NE
intrinsic xxx NE
kappa xxx DNA_B
B X DNA_M
enhancer xxx DNA_M
element xxx DNA_E
. . NE

In Xx NE
normal xxx NE
cells xxx NE
, , NE
the xxx NE
subsequent xxx NE
accumulation xxx NE
of xx NE
nuclear xxx protein_B
c-Rel x-Xxx protein_E
acts xxx NE
to xx NE
inhibit xxx NE
its xxx NE
own xxx NE
continued xxx NE
production xxx NE
, , NE
indicating xxx NE
the xxx NE
presence xxx NE
of xx NE
an xx NE
autoregulatory xxx NE
loop xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Activation Xxxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
in xx NE
vivo xxx NE
is xx NE
regulated xxx NE
by xx NE
multiple xxx NE
phosphorylations xxx NE
. . NE

The Xxx NE
activation xxx NE
of xx NE
nuclear xxx protein_B
factor xxx protein_M
kappa xxx protein_M
B X protein_E
( ( NE
NF-kappa XX-xxx protein_B
B X protein_E
) ) NE
in xx NE
intact xxx NE
cells xxx NE
is xx NE
mechanistically xxx NE
not xxx NE
well xxx NE
understood xxx NE
. . NE

Therefore Xxxx NE
we xx NE
investigated xxx NE
the xxx NE
modifications xxx NE
imposed xxx NE
on xx NE
NF-kappa XX-xxx NE
B X NE
/I /X NE
kappa xxx NE
B X NE
components xxx NE
following xxx NE
stimulation xxx NE
and xxx NE
show xxx NE
that xxx NE
the xxx NE
final xxx NE
step xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
induction xxx NE
in xx NE
vivo xxx NE
involves xxx NE
phosphorylation xxx NE
of xx NE
several xxx NE
members xxx NE
of xx NE
the xxx NE
NF-kappa XX-xxx NE
B X NE
/I /X NE
kappa xxx NE
B X NE
protein xxx NE
families xxx NE
. . NE

In Xx NE
HeLa XxXx cell_line_B
cells xxx cell_line_E
as xx NE
well xxx NE
as xx NE
in xx NE
B X cell_type_B
cells xxx cell_type_E
, , NE
TNF-alpha XXX-xxx NE
rapidly xxx NE
induced xxx NE
nuclear xxx NE
translocation xxx NE
primarily xxx NE
of xx NE
p50-p65 xdd-xdd protein
, , NE
but xxx NE
not xxx NE
of xx NE
c-rel x-xxx protein
. . NE

Both Xxxx NE
NF-kappa XX-xxx protein_B
B X protein_E
precursors xxx NE
and xxx NE
I X protein_B
kappa xxx protein_M
B X protein_M
alpha xxx protein_E
became xxx NE
strongly xxx NE
phosphorylated xxx NE
with xxx NE
the xxx NE
same xxx NE
kinetics xxx NE
. . NE

In Xx NE
addition xxx NE
to xx NE
the xxx NE
inducible xxx NE
phosphorylation xxx NE
after xxx NE
stimulation xxx NE
, , NE
B X cell_type_B
lymphocytes xxx cell_type_E
containing xxx NE
constitutive xxx NE
nuclear xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
revealed xxx NE
constitutively xxx NE
phosphorylated xxx NE
p65 xdd protein
and xxx NE
I X protein_B
kappa xxx protein_M
B X protein_M
alpha xxx protein_E
. . NE

Phosphorylation Xxxx NE
was xxx NE
accompanied xxx NE
by xx NE
induced xxx NE
processing xxx NE
of xx NE
the xxx NE
precursors xxx NE
p100 xddd protein
and xxx NE
p105 xddd protein
and xxx NE
by xx NE
degradation xxx NE
of xx NE
I X protein_B
kappa xxx protein_M
B X protein_M
alpha xxx protein_E
. . NE

As Xx NE
an xx NE
in xx NE
vitro xxx NE
model xxx NE
we xx NE
show xxx NE
that xxx NE
phosphorylation xxx NE
of xx NE
p105 xddd protein
impedes xxx NE
its xxx NE
ability xxx NE
to xx NE
interact xxx NE
with xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
, , NE
as xx NE
has xxx NE
been xxx NE
shown xxx NE
before xxx NE
for xxx NE
I X protein_B
kappa xxx protein_M
B X protein_M
alpha xxx protein_E
. . NE

Surprisingly Xxxx NE
, , NE
even xxx NE
p65 xdd protein
, , NE
but xxx NE
not xxx NE
c-rel x-xxx protein
, , NE
was xxx NE
phosphorylated xxx NE
after xxx NE
induction xxx NE
in xx NE
vivo xxx NE
, , NE
suggesting xxx NE
that xxx NE
TNF-alpha XXX-xxx protein
selectively xxx NE
activates xxx NE
only xxx NE
specific xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
heteromers xxx NE
and xxx NE
that xxx NE
modifications xxx NE
regulate xxx NE
not xxx NE
only xxx NE
I X protein_B
kappa xxx protein_M
B X protein_M
molecules xxx protein_E
but xxx NE
also xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
molecules xxx NE
. . NE

In Xx NE
fact xxx NE
, , NE
cellular xxx NE
NF-kappa XX-xxx NE
B X NE
activity xxx NE
was xxx NE
phosphorylation-dependent xxx-xxx NE
and xxx NE
the xxx NE
DNA XXX NE
binding xxx NE
activity xxx NE
of xx NE
p65 xdd NE
-containing -xxx NE
NF-kappa XX-xxx NE
B X NE
was xxx NE
enhanced xxx NE
by xx NE
phosphorylation xxx NE
in xx NE
vitro xxx NE
. . NE

Furthermore Xxxx NE
, , NE
we xx NE
found xxx NE
that xxx NE
the xxx NE
induction xxx NE
by xx NE
hydrogen xxx NE
peroxide xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
translocation xxx NE
to xx NE
the xxx NE
nucleus xxx NE
, , NE
which xxx NE
is xx NE
assumed xxx NE
to xx NE
be xx NE
triggered xxx NE
by xx NE
reactive xxx NE
oxygen xxx NE
intermediates xxx NE
, , NE
also xxx NE
coincided xxx NE
with xxx NE
incorporation xxx NE
of xx NE
phosphate xxx NE
into xxx NE
the xxx NE
same xxx NE
subunits xxx NE
that xxx NE
were xxx NE
modified xxx NE
after xxx NE
stimulation xxx NE
by xx NE
TNF-alpha XXX-xxx protein
. . NE

Thus Xxxx NE
, , NE
phosphorylation xxx NE
appears xxx NE
to xx NE
be xx NE
a x NE
general xxx NE
mechanism xxx NE
for xxx NE
activation xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
in xx NE
vivo xxx NE
. . NE

Treatment Xxxx NE
of xx NE
HL60 XXdd cell_line_B
cells xxx cell_line_E
with xxx NE
various xxx NE
combinations xxx NE
of xx NE
retinoids xxx NE
and xxx NE
1 d NE
alpha,25 xxx,dd NE
dihydroxyvitamin xxx NE
D3 Xd NE
results xxx NE
in xx NE
differentiation xxx NE
towards xxx NE
neutrophils xxx cell_type
or xx NE
monocytes xxx cell_type
or xx NE
a x NE
failure xxx NE
to xx NE
differentiate xxx NE
and xxx NE
apoptosis xxx NE
. . NE

It Xx NE
is xx NE
well xxx NE
documented xxx NE
that xxx NE
treatment xxx NE
of xx NE
serum-grown xxx-xxx cell_line_B
HL60 XXdd cell_line_M
cells xxx cell_line_E
with xxx NE
10(-7) dd(-d) NE
M X NE
all-trans xxx-xxx NE
retinoic xxx NE
acid xxx NE
( ( NE
all-trans xxx-xxx NE
RA XX NE
) ) NE
induces xxx NE
neutrophil xxx NE
differentiation xxx NE
, , NE
whereas xxx NE
treatment xxx NE
with xxx NE
10(-7) dd(-d) NE
M X NE
1 d NE
alpha,25 xxx,dd NE
dihydroxyvitamin xxx NE
D3 Xd NE
( ( NE
D3 Xd NE
) ) NE
induces xxx NE
differentiation xxx NE
towards xxx NE
monocytes xxx cell_type
. . NE

In Xx NE
recent xxx NE
investigations xxx NE
, , NE
using xxx NE
serum-free xxx-xxx cell_line_B
grown xxx cell_line_M
HL60 XXdd cell_line_M
cells xxx cell_line_E
, , NE
we xx NE
observed xxx NE
that xxx NE
all-trans xxx-xxx NE
RA XX NE
, , NE
at xx NE
10(-7) dd(-d) NE
M X NE
, , NE
did xxx NE
not xxx NE
induce xxx NE
neutrophil xxx NE
differentiation xxx NE
and xxx NE
that xxx NE
all-trans xxx-xxx NE
RA XX NE
, , NE
at xx NE
10(-8) dd(-d) NE
M X NE
, , NE
reduced xxx NE
the xxx NE
D3 Xd NE
concentration xxx NE
required xxx NE
for xxx NE
monocyte xxx NE
differentiation xxx NE
to xx NE
5 d NE
x x NE
10(-9) dd(-d) NE
M X NE
. . NE

In Xx NE
this xxx NE
study xxx NE
, , NE
co-operative xx-xxx NE
interactions xxx NE
between xxx NE
all-trans xxx-xxx NE
RA XX NE
and xxx NE
9-cis d-xxx NE
RA XX NE
D3 Xd NE
which xxx NE
promote xxx NE
neutrophil xxx NE
and xxx NE
monocyte xxx NE
differentiation xxx NE
of xx NE
HL60 XXdd cell_line_B
cells xxx cell_line_E
have xxx NE
been xxx NE
analysed xxx NE
in xx NE
detail xxx NE
. . NE

Treatment Xxxx NE
of xx NE
serum-free xxx-xxx cell_line_B
grown xxx cell_line_M
HL60 XXdd cell_line_M
cells xxx cell_line_E
with xxx NE
5 d NE
x x NE
10(-7) dd(-d) NE
M X NE
all-trans xxx-xxx NE
RA XX NE
or xx NE
9-cis d-xxx NE
RA XX NE
resulted xxx NE
in xx NE
sub-optimal xxx-xxx NE
neutrophil xxx NE
differentiation xxx NE
(up (xx NE
to xx NE
25% dd% NE
mature xxx NE
cells) xxx) NE
. . NE

As Xx NE
shown xxx NE
for xxx NE
all-trans xxx-xxx NE
RA XX NE
, , NE
9-cis d-xxx NE
RA XX NE
cooperated xxx NE
with xxx NE
D3 Xd NE
to xx NE
promote xxx NE
monocyte xxx NE
differentiation xxx NE
. . NE

Culture Xxxx NE
of xx NE
HL60 XXdd cell_line_B
cells xxx cell_line_E
in xx NE
5 d NE
x x NE
10(-7) dd(-d) NE
M X NE
9-cis d-xxx NE
RA XX NE
together xxx NE
with xxx NE
a x NE
wide xxx NE
range xxx NE
of xx NE
concentrations xxx NE
of xx NE
D3 Xd NE
resulted xxx NE
in xx NE
promotion xxx NE
of xx NE
neutrophil xxx NE
differentiation xxx NE
at xx NE
10(-15)-10(-12) dd(-dd)-dd(-dd) NE
D3 Xd NE
, , NE
a x NE
failure xxx NE
to xx NE
differentiate xxx NE
and xxx NE
apoptosis xxx NE
at xx NE
10(-11)-10(-10) dd(-dd)-dd(-dd) NE
M X NE
D3 Xd NE
, , NE
followed xxx NE
by xx NE
co-operativity xx-xxx NE
between xxx NE
9-cis d-xxx NE
RA XX NE
and xxx NE
5 d NE
x x NE
10(-9) dd(-d) NE
M X NE
D3 Xd NE
in xx NE
inducing xxx NE
monocyte xxx NE
differentiation xxx NE
in xx NE
the xxx NE
absence xxx NE
of xx NE
neutrophil xxx NE
differentiation xxx NE
. . NE

Similar Xxxx NE
results xxx NE
were xxx NE
obtained xxx NE
when xxx NE
HL60 XXdd cell_line_B
cells xxx cell_line_E
were xxx NE
treated xxx NE
with xxx NE
5 d NE
x x NE
10(-7) dd(-d) NE
all-trans xxx-xxx NE
RA XX NE
together xxx NE
with xxx NE
a x NE
wide xxx NE
range xxx NE
of xx NE
concentrations xxx NE
of xx NE
D3 Xd NE
. . NE

Cross Xxxx NE
titration xxx NE
analyses xxx NE
of xx NE
the xxx NE
effects xxx NE
of xx NE
9-cis d-xxx NE
RA XX NE
and xxx NE
D3 Xd NE
on xx NE
HL60 XXdd NE
cell xxx NE
differentiation xxx NE
were xxx NE
undertaken xxx NE
to xx NE
determine xxx NE
the xxx NE
boundaries xxx NE
of xx NE
the xxx NE
concentrations xxx NE
of xx NE
each xxx NE
agent xxx NE
, , NE
alone xxx NE
and xxx NE
in xx NE
combination xxx NE
, , NE
that xxx NE
give xxx NE
rise xxx NE
to xx NE
optimal xxx NE
neutrophil xxx NE
differentiation xxx NE
and xxx NE
monocyte xxx NE
differentiation xxx NE
of xx NE
HL60 XXdd cell_line_B
cells xxx cell_line_E
. . NE

The Xxx NE
observed xxx NE
cooperativities xxx NE
between xxx NE
either xxx NE
9-cis d-xxx NE
RA XX NE
or xx NE
all-trans xxx-xxx NE
RA XX NE
and xxx NE
D3 Xd NE
have xxx NE
important xxx NE
implications xxx NE
for xxx NE
the xxx NE
use xxx NE
of xx NE
combinations xxx NE
of xx NE
these xxx NE
agents xxx NE
in xx NE
differentiation xxx NE
therapy xxx NE
. . NE

Isolation Xxxx NE
of xx NE
differentially xxx NE
expressed xxx NE
sequence xxx NE
tags xxx NE
from xxx NE
steroid-responsive xxx-xxx cell_type_B
cells xxx cell_type_E
using xxx NE
mRNA xXXX NE
differential xxx NE
display xxx NE
. . NE

Transcriptional Xxxx NE
control xxx NE
of xx NE
steroid-regulated xxx-xxx DNA_B
gene xxx DNA_M
networks xxx DNA_E
by xx NE
nuclear xxx protein_B
receptor xxx protein_M
proteins xxx protein_E
results xxx NE
in xx NE
the xxx NE
coordinate xxx NE
expression xxx NE
of xx NE
a x NE
limited xxx NE
number xxx NE
of xx NE
target xxx DNA_B
genes xxx DNA_E
. . NE

Although Xxxx NE
much xxx NE
is xx NE
known xxx NE
about xxx NE
the xxx NE
structure xxx NE
and xxx NE
function xxx NE
of xx NE
steroid xxx NE
receptors xxx NE
, , NE
relatively xxx NE
few xxx NE
cell-specific xxx-xxx NE
steroid-regulated xxx-xxx NE
genes xxx NE
have xxx NE
been xxx NE
isolated xxx NE
and xxx NE
characterized xxx NE
. . NE

In Xx NE
this xxx NE
paper xxx NE
we xx NE
describe xxx NE
results xxx NE
using xxx NE
mRNA xXXX NE
differential xxx NE
display xxx NE
reverse xxx NE
transcriptase xxx NE
PCR XXX NE
( ( NE
DDPCR XXXXX NE
) ) NE
to xx NE
identify xxx NE
and xxx NE
isolate xxx NE
short xxx NE
cDNA xXXX NE
sequence xxx NE
tags xxx NE
from xxx NE
thymocyte xxx cell_type
and xxx NE
prostate xxx cell_type_B
cells xxx cell_type_E
under xxx NE
various xxx NE
hormone xxx NE
conditions xxx NE
. . NE

Using Xxxx NE
this xxx NE
technique xxx NE
we xx NE
have xxx NE
isolated xxx NE
several xxx NE
differentially xxx DNA_B
expressed xxx DNA_M
sequence xxx DNA_M
tags xxx DNA_E
( ( NE
DESTs XXXXx DNA
) ) NE
from xxx NE
the xxx NE
mouse xxx cell_line_B
thymocyte xxx cell_line_M
cell xxx cell_line_M
line xxx cell_line_E
WEHI XXXX cell_line_B
7.2 d.d cell_line_E
. . NE

Two Xxx NE
of xx NE
these xxx NE
DESTs XXXXx DNA
, , NE
GIG10 XXXdd DNA
and xxx NE
GIG18 XXXdd DNA
, , NE
are xxx NE
rapidly xxx NE
induced xxx NE
by xx NE
dexamethasone xxx NE
within xxx NE
2 d NE
h x NE
of xx NE
treatment xxx NE
. . NE

GIG10 XXXdd DNA
is xx NE
a x NE
novel xxx NE
sequence xxx NE
and xxx NE
GIG18 XXXdd DNA
is xx NE
the xxx NE
mouse xxx NE
homologue xxx NE
of xx NE
a x NE
human xxx DNA_B
expressed xxx DNA_M
sequence xxx DNA_M
tag xxx DNA_E
isolated xxx NE
from xxx NE
activated xxx cell_type_B
B X cell_type_M
lymphocytes xxx cell_type_E
. . NE

We Xx NE
also xxx NE
used xxx NE
DDPCR XXXXX NE
to xx NE
isolate xxx NE
DESTs XXXXx DNA
from xxx NE
androgen-modulated xxx-xxx NE
rat xxx NE
ventral xxx NE
prostate xxx NE
tissue xxx NE
, , NE
one xxx NE
of xx NE
which xxx NE
we xx NE
characterized xxx NE
and xxx NE
found xxx NE
to xx NE
correspond xxx NE
to xx NE
the xxx NE
3' d' RNA_B
end xxx RNA_E
of xx NE
prostatic xxx RNA_B
spermine xxx RNA_M
binding xxx RNA_M
protein xxx RNA_M
mRNA xXXX RNA_E
, , NE
a x NE
known xxx NE
androgen-regulated xxx-xxx DNA_B
gene xxx DNA_E
. . NE

Modifications Xxxx NE
of xx NE
the xxx NE
original xxx NE
DDPCR XXXXX NE
protocol xxx NE
, , NE
which xxx NE
we xx NE
found xxx NE
can xxx NE
potentially xxx NE
decrease xxx NE
the xxx NE
frequency xxx NE
of xx NE
isolating xxx NE
false-positive xxx-xxx NE
DESTs XXXXx DNA
, , NE
are xxx NE
described xxx NE
and xxx NE
the xxx NE
merits xxx NE
of xx NE
DDPCR XXXXX NE
, , NE
relative xxx NE
to xx NE
other xxx NE
differential xxx NE
cDNA xXXX NE
cloning xxx NE
strategies xxx NE
, , NE
are xxx NE
discussed xxx NE
. . NE

Activation Xxxx NE
of xx NE
human xxx cell_type_B
thymocytes xxx cell_type_E
after xxx NE
infection xxx NE
by xx NE
EBV XXX NE
. . NE

The Xxx NE
discovery xxx NE
of xx NE
EBV XXX NE
in xx NE
certain xxx NE
T X NE
cell xxx NE
malignancies xxx NE
and xxx NE
the xxx NE
expression xxx NE
of xx NE
the xxx NE
EBV XXX NE
receptor xxx NE
, , NE
CR2/CD21 XXd/XXdd NE
, , NE
on xx NE
a x NE
population xxx NE
of xx NE
immature xxx NE
thymocytes xxx NE
, , NE
T X NE
lymphoblastoid xxx NE
cell xxx NE
lines xxx NE
, , NE
and xxx NE
childhood xxx NE
acute xxx NE
T X NE
lymphoblastic xxx NE
leukemia xxx NE
cells xxx NE
suggested xxx NE
that xxx NE
EBV XXX NE
-receptor -xxx NE
interactions xxx NE
on xx NE
T X NE
cells xxx NE
may xxx NE
be xx NE
of xx NE
importance xxx NE
. . NE

We Xx NE
have xxx NE
shown xxx NE
that xxx NE
, , NE
within xxx NE
the xxx NE
thymus xxx NE
, , NE
a x NE
population xxx NE
of xx NE
large, xxx, cell_type_B
immature xxx cell_type_M
cells xxx cell_type_E
expresses xxx NE
CD21 XXdd protein
. . NE

EBV XXX NE
altered xxx NE
the xxx NE
activation xxx NE
responses xxx NE
of xx NE
immature xxx cell_type_B
thymocytes xxx cell_type_E
in xx NE
vitro xxx NE
. . NE

Triggering Xxxx NE
through xxx NE
CD2 XXd protein
is xx NE
mitogenic xxx NE
for xxx NE
mature xxx NE
, , NE
but xxx NE
not xxx NE
immature xxx NE
, , NE
T X cell_type_B
cells xxx cell_type_E
. . NE

However Xxxx NE
, , NE
during xxx NE
infection xxx NE
by xx NE
EBV XXX NE
, , NE
ligation xxx NE
of xx NE
CD2 XXd protein
caused xxx NE
thymocytes xxx cell_type
to xx NE
proliferate xxx NE
in xx NE
the xxx NE
absence xxx NE
of xx NE
exogenous xxx protein_B
cytokines xxx protein_E
. . NE

This Xxxx NE
function xxx NE
was xxx NE
a x NE
result xxx NE
of xx NE
the xxx NE
interaction xxx NE
of xx NE
EBV XXX NE
with xxx NE
its xxx NE
receptor xxx NE
, , NE
CD21 XXdd protein
, , NE
but xxx NE
was xxx NE
caused xxx NE
by xx NE
infection xxx NE
rather xxx NE
than xxx NE
surface xxx NE
signaling xxx NE
, , NE
because xxx NE
neither xxx NE
specific xxx protein_B
mAb xXx protein_E
nor xxx NE
the xxx NE
P3HR-1 XdXX-d NE
strain xxx NE
of xx NE
virus xxx NE
mimicked xxx NE
the xxx NE
effect xxx NE
of xx NE
B95-8 Xdd-d NE
. . NE

Immature Xxxx NE
thymocytes xxx cell_type
were xxx NE
infected xxx NE
by xx NE
EBV XXX NE
, , NE
as xx NE
determined xxx NE
by xx NE
the xxx NE
internalization xxx NE
of xx NE
the xxx NE
viral xxx DNA_B
genome xxx DNA_E
and xxx NE
its xxx NE
transcriptional xxx NE
activity xxx NE
. . NE

Consistent Xxxx NE
with xxx NE
the xxx NE
activity xxx NE
of xx NE
B95-8 Xdd-d protein
, , NE
EBNA-2 XXXX-d RNA_B
transcripts xxx RNA_E
were xxx NE
identified xxx NE
within xxx NE
infected xxx cell_line_B
thymocyte xxx cell_line_M
populations xxx cell_line_E
. . NE

In Xx NE
addition xxx NE
, , NE
components xxx NE
of xx NE
the xxx NE
viral xxx NE
replicative xxx NE
pathway xxx NE
were xxx NE
expressed xxx NE
during xxx NE
infection xxx NE
of xx NE
thymocytes xxx cell_type
. . NE

These Xxxx NE
components xxx NE
included xxx NE
transcription xxx NE
of xx NE
BZLF-1 XXXX-d DNA
, , NE
an xx NE
early xxx DNA_B
gene xxx DNA_E
that xxx NE
characterizes xxx NE
EBV XXX NE
-infected -xxx NE
B X NE
cells xxx NE
after xxx NE
disruption xxx NE
of xx NE
latency xxx NE
. . NE

A X NE
second xxx NE
transcript xxx NE
was xxx NE
identified xxx NE
as xx NE
encoding xxx NE
the xxx NE
recently xxx NE
characterized xxx NE
RAZ XXX protein
, , NE
which xxx NE
also xxx NE
is xx NE
associated xxx NE
with xxx NE
replicative xxx NE
infection xxx NE
. . NE

The Xxx NE
consequences xxx NE
of xx NE
EBV XXX NE
infection xxx NE
of xx NE
T X cell_type_B
cells xxx cell_type_E
at xx NE
an xx NE
early xxx NE
stage xxx NE
of xx NE
differentiation xxx NE
may xxx NE
lead xxx NE
to xx NE
failure xxx NE
of xx NE
normal xxx NE
T X NE
cell xxx NE
repertoire xxx NE
development xxx NE
, , NE
autoimmunity xxx NE
, , NE
or xx NE
malignancy xxx NE
. . NE

Effects Xxxx NE
of xx NE
intranasal xxx NE
glucocorticoids xxx NE
on xx NE
endogenous xxx NE
glucocorticoid xxx NE
peripheral xxx NE
function xxx NE
and xxx NE
endogenous xxx NE
glucocorticoid xxx NE
central xxx NE
function xxx NE

Glucocorticoids Xxxx NE
are xxx NE
among xxx NE
the xxx NE
most xxx NE
potent xxx NE
antiinflammatory xxx NE
agents xxx NE
that xxx NE
can xxx NE
be xx NE
used xxx NE
in xx NE
the xxx NE
treatment xxx NE
of xx NE
rhinitis xxx NE
. . NE

Their Xxxx NE
mechanisms xxx NE
of xx NE
action xxx NE
are xxx NE
multiple xxx NE
and xxx NE
complex xxx NE
and xxx NE
a x NE
number xxx NE
of xx NE
reports xxx NE
describe xxx NE
significant xxx NE
systemic xxx NE
effects xxx NE
of xx NE
locally xxx NE
administered xxx NE
glucocorticoids xxx NE
. . NE

In Xx NE
order xxx NE
to xx NE
evaluate xxx NE
the xxx NE
short-term xxx-xxx NE
systemic xxx NE
effects xxx NE
of xx NE
intranasally xxx NE
administered xxx NE
glucocorticoids xxx NE
, , NE
14 dd NE
normal xxx NE
healthy xxx NE
subjects xxx NE
were xxx NE
treated xxx NE
with xxx NE
two xxx NE
doses xxx NE
of xx NE
either xxx NE
budesonide xxx NE
( ( NE
BUD XXX NE
) ) NE
or xx NE
fluticasone xxx NE
propionate xxx NE
( ( NE
FP XX NE
) ) NE
for xxx NE
2 d NE
weeks xxx NE
. . NE

Before Xxxx NE
treatment xxx NE
, , NE
at xx NE
regular xxx NE
intervals xxx NE
during xxx NE
the xxx NE
treatment xxx NE
, , NE
1 d NE
week xxx NE
and xxx NE
finally xxx NE
6 d NE
weeks xxx NE
after xxx NE
termination xxx NE
of xx NE
treatment xxx NE
, , NE
the xxx NE
effects xxx NE
on xx NE
glucocorticoid xxx NE
receptor xxx NE
(GR) (XX) NE
mRNA xXXX NE
expression xxx NE
level xxx NE
and xxx NE
methallothionein xxx NE
(MTIIa) (XXXXx) NE
mRNA xXXX NE
expression xxx NE
level xxx NE
were xxx NE
examined xxx NE
in xx NE
peripheral xxx cell_type_B
lymphocytes xxx cell_type_E
using xxx NE
a x NE
solution xxx NE
hybridization xxx NE
assay xxx NE
. . NE

serum xxx NE
cortisol xxx NE
level xxx NE
and xxx NE
serum xxx NE
osteocalcin xxx NE
level xxx NE
and xxx NE
urinary xxx NE
cortisol xxx NE
level xxx NE

An Xx NE
insulin xxx NE
tolerance xxx NE
test xxx NE
( ( NE
ITT XXX NE
) ) NE
was xxx NE
performed xxx NE
at xx NE
the xxx NE
end xxx NE
of xx NE
the xxx NE
second xxx NE
week xxx NE
of xx NE
treatment xxx NE
and xxx NE
at xx NE
the xxx NE
end xxx NE
of xx NE
the xxx NE
6-week d-xxx NE
washout xxx NE
period xxx NE
with xxx NE
no xx NE
statistically xxx NE
significant xxx NE
change xxx NE
in xx NE
cortisol xxx NE
response xxx NE
. . NE

In Xx NE
peripheral xxx cell_type_B
lymphocytes xxx cell_type_E
, , NE
GR XX NE
mRNA xXXX NE
levels xxx NE
were xxx NE
significantly xxx NE
down-regulated xxx-xxx NE
. . NE

MTIIa XXXXx NE
mRNA xXXX NE
levels xxx NE
increased xxx NE
significantly xxx NE
. . NE

Serum Xxxx NE
osteocalcin xxx protein
decreased xxx NE
significantly xxx NE
during xxx NE
treatment xxx NE
with xxx NE
both xxx NE
BUD XXX NE
and xxx NE
FP XX NE
. . NE

Serum Xxxx NE
cortisol xxx NE
decreased xxx NE
after xxx NE
1 d NE
week xxx NE
of xx NE
treatment xxx NE
whereas xxx NE
urinary xxx NE
cortisol xxx NE
was xxx NE
not xxx NE
affected xxx NE
until xxx NE
the xxx NE
second xxx NE
week xxx NE
of xx NE
treatment xxx NE
. . NE

In Xx NE
conclusion xxx NE
, , NE
intranasal xxx NE
glucocorticoids xxx NE
at xx NE
clinically xxx NE
recommended xxx NE
doses xxx NE
have xxx NE
not xxx NE
only xxx NE
significant xxx NE
systemic xxx NE
effects xxx NE
on xx NE
adrenal xxx NE
function xxx NE
, , NE
but xxx NE
also xxx NE
have xxx NE
an xx NE
effect xxx NE
on xx NE
specific xxx NE
gene xxx NE
expression xxx NE
in xx NE
peripheral xxx cell_type_B
lymphocytes xxx cell_type_E
. . NE

These Xxxx NE
effects xxx NE
are xxx NE
receptor-dependent xxx-xxx NE
, , NE
reversible xxx NE
, , NE
and xxx NE
according xxx NE
to xx NE
serum xxx NE
and xxx NE
urinary xxx NE
cortisol xxx NE
levels xxx NE
and xxx NE
ITT XXX NE
, , NE
leave xxx NE
the xxx NE
hypothalamic-pituitary-adrenal xxx-xxx-xxx NE
function xxx NE
intact xxx NE
. . NE

Finally Xxxx NE
, , NE
these xxx NE
short-term xxx-xxx NE
systemic xxx NE
effects xxx NE
were xxx NE
not xxx NE
associated xxx NE
with xxx NE
any xxx NE
of xx NE
the xxx NE
noticeable xxx NE
side-effects xxx-xxx NE
usually xxx NE
observed xxx NE
during xxx NE
long-term xxx-xxx NE
treatment xxx NE
with xxx NE
glucocorticoids xxx NE
. . NE

Biphasic Xxxx NE
control xxx NE
of xx NE
nuclear xxx NE
factor-kappa xxx-xxx NE
B X NE
activation xxx NE
by xx NE
the xxx NE
T X protein_B
cell xxx protein_M
receptor xxx protein_M
complex xxx protein_E
: : NE
role xxx NE
of xx NE
tumor xxx protein_B
necrosis xxx protein_M
factor xxx protein_M
alpha xxx protein_E
. . NE

The Xxx NE
regulation xxx NE
of xx NE
nuclear xxx NE
factor xxx NE
(NF)-kappa (XX)-xxx NE
B X NE
activation xxx NE
by xx NE
the xxx NE
T X protein_B
cell xxx protein_M
receptor xxx protein_M
(TcR)/CD3 (XxX)/XXd protein_M
complex xxx protein_E
in xx NE
primary xxx NE
human xxx NE
T X cell_type_B
cells xxx cell_type_E
has xxx NE
been xxx NE
studied xxx NE
at xx NE
various xxx NE
times xxx NE
after xxx NE
activation xxx NE
. . NE

Only Xxxx NE
p50 xdd protein_B
NF-kappa XX-xxx protein_M
B X protein_M
protein xxx protein_E
bound xxx NE
the xxx NE
kappa xxx DNA_B
B X DNA_M
element xxx DNA_E
of xx NE
interleukin-2 xxx-d NE
receptor xxx NE
( ( NE
IL-2R XX-dX NE
) ) NE
alpha xxx NE
chain xxx NE
promoter xxx NE
on xx NE
resting xxx NE
T X NE
cells xxx NE
. . NE

However Xxxx NE
, , NE
immediately xxx NE
after xxx NE
TcR/CD3 XxX/XXd protein
cross-linking xxx-xxx NE
(after (xxx NE
approximately xxx NE
1 d NE
h x NE
; ; NE
immediate) xxx) NE
binding xxx NE
of xx NE
p50.p65 xdd.xdd protein_B
heterodimers xxx protein_E
was xxx NE
observed xxx NE
. . NE

p50.c-rel xdd.x-xxx protein_B
heterodimers xxx protein_E
were xxx NE
also xxx NE
detected xxx NE
bound xxx NE
to xx NE
this xxx NE
sequence xxx NE
at xx NE
early xxx NE
time xxx NE
points xxx NE
(7-16 (d-dd NE
h x NE
; ; NE
early) xxx) NE
, , NE
and xxx NE
both xxx NE
remained xxx NE
active xxx NE
at xx NE
later xxx NE
time xxx NE
points xxx NE
(40 (dd NE
h x NE
; ; NE
late) xxx) NE
after xxx NE
activation xxx NE
. . NE

This Xxxx NE
regulation xxx NE
takes xxx NE
place xxx NE
mainly xxx NE
at xx NE
the xxx NE
level xxx NE
of xx NE
nuclear xxx NE
translocation xxx NE
of xx NE
p65 xdd protein
and xxx NE
c-rel x-xxx protein
, , NE
at xx NE
immediate xxx NE
and xxx NE
early xxx NE
time xxx NE
points xxx NE
. . NE

Activation Xxxx NE
also xxx NE
induced xxx NE
c-rel x-xxx NE
mRNA xXXX NE
synthesis xxx NE
and xxx NE
p105/p50 xddd/xdd NE
mRNA xXXX NE
synthesis xxx NE
p65 xdd NE
mRNA xXXX RNA
whose xxx NE
expression xxx NE
was xxx NE
constitutive xxx NE
. . NE

Interestingly Xxxx NE
, , NE
all xxx NE
those xxx NE
early xxx NE
and xxx NE
late xxx NE
events xxx NE
, , NE
but xxx NE
not xxx NE
the xxx NE
immediate xxx NE
ones xxx NE
, , NE
were xxx NE
inhibited xxx NE
by xx NE
a x NE
neutralizing xxx NE
anti- xxx- NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
alpha xxx NE
(TNF-alpha) (XXX-xxx) NE
monoclonal xxx NE
antibody xxx NE
. . NE

Similarly Xxxx NE
, , NE
cycloheximide xxx NE
prevented xxx NE
the xxx NE
p65 xdd protein
and xxx NE
c-rel x-xxx protein
translocation xxx NE
and xxx NE
consequent xxx NE
formation xxx NE
of xx NE
active xxx NE
binding xxx NE
heterodimers xxx NE
, , NE
at xx NE
early xxx NE
and xxx NE
late xxx NE
times xxx NE
. . NE

Cyclosporin Xxxx NE
A X NE
impaired xxx NE
not xxx NE
only xxx NE
early xxx NE
and xxx NE
late xxx NE
, , NE
but xxx NE
also xxx NE
immediate xxx NE
events xxx NE
; ; NE
however xxx NE
, , NE
addition xxx NE
of xx NE
TNF-alpha XXX-xxx protein
prevented xxx NE
all xxx NE
inhibition xxx NE
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
the xxx NE
regulation xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
during xxx NE
T X NE
cell xxx NE
activation xxx NE
by xx NE
TcR/CD3 XxX/XXd protein
signals xxx NE
is xx NE
biphasic xxx NE
: : NE
TcR/CD3 XxX/XXd protein
triggers xxx NE
its xxx NE
immediate xxx NE
translocation xxx NE
, , NE
which xxx NE
is xx NE
transient xxx NE
if xx NE
no xx NE
TNF-alpha XXX-xxx protein
is xx NE
present xxx NE
. . NE

TNF-alpha XXX-xxx protein
, , NE
therefore xxx NE
, , NE
emerges xxx NE
as xx NE
the xxx NE
main xxx NE
factor xxx NE
responsible xxx NE
for xxx NE
a x NE
second xxx NE
phase xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
regulation xxx NE
, , NE
controlling xxx NE
both xxx NE
translocation xxx NE
of xx NE
p65 xdd protein
and xxx NE
c-rel x-xxx protein
, , NE
and xxx NE
new xxx NE
mRNA xXXX RNA
synthesis xxx NE
for xxx NE
c-rel x-xxx protein
and xxx NE
p105/p50 xddd/xdd protein
. . NE

The Xxx NE
transcription xxx protein_B
factor xxx protein_M
Sp1 Xxd protein_E
is xx NE
required xxx NE
for xxx NE
induction xxx NE
of xx NE
the xxx NE
murine xxx DNA_B
GM-CSF XX-XXX DNA_M
promoter xxx DNA_E
in xx NE
T X cell_type_B
cells xxx cell_type_E
. . NE

The Xxx NE
cis-acting xxx-xxx DNA_B
region xxx DNA_E
, , NE
GM-kappa XX-xxx DNA_B
B/GC-box X/XX-xxx DNA_E
( ( NE
positions xxx NE
-95 -dd NE
and xxx NE
-73 -dd NE
) ) NE
, , NE
within xxx NE
the xxx NE
murine xxx NE
GM-CSF XX-XXX NE
gene xxx NE
promoter xxx NE
is xx NE
required xxx NE
for xxx NE
maximal xxx NE
induction xxx NE
by xx NE
stimulation xxx NE
with xxx NE
phorbol-12-myristate xxx-dd-xxx NE
acetate xxx NE
( ( NE
PMA XXX NE
) ) NE
and xxx NE
calcium xxx NE
ionophore xxx NE
( ( NE
A23187 Xddddd NE
) ) NE
in xx NE
T X NE
cells xxx NE
. . NE

GM-kappa XX-xxx protein_B
B X protein_E
defines xxx NE
a x NE
binding xxx NE
site xxx NE
for xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
, , NE
and xxx NE
GC-box XX-xxx DNA
defines xxx NE
a x NE
binding xxx NE
site xxx NE
for xxx NE
three xxx NE
( ( NE
A1 Xd protein
, , NE
A2 Xd protein
, , NE
B X protein
) ) NE
constitutive xxx protein_B
proteins xxx protein_E
. . NE

We Xx NE
report xxx NE
here xxx NE
that xxx NE
three xxx NE
copies xxx NE
of xx NE
the xxx NE
GC-box XX-xxx DNA
can xxx NE
functionally xxx NE
compensate xxx NE
for xxx NE
the xxx NE
GM-kappa XX-xxx NE
B X NE
/ / NE
GC-box XX-xxx NE
region xxx NE
, , NE
suggesting xxx NE
that xxx NE
the xxx NE
GC-motif XX-xxx NE
can xxx NE
function xxx NE
independently xxx NE
of xx NE
the xxx NE
GM-kappa XX-xxx NE
B X NE
motif xxx NE
. . NE

The Xxx NE
major xxx NE
GC-box XX-xxx NE
binding xxx NE
activity xxx NE
A1 Xd protein
was xxx NE
purified xxx NE
and xxx NE
identified xxx NE
as xx NE
the xxx NE
transcription xxx protein_B
factor xxx protein_M
Sp1 Xxd protein_E
. . NE

We Xx NE
show xxx NE
that xxx NE
depletion xxx NE
of xx NE
Sp1 Xxd protein
( ( NE
A1 Xd protein
) ) NE
from xxx NE
nuclear xxx NE
extracts xxx NE
specifically xxx NE
decreases xxx NE
in xx NE
vitro xxx NE
transcription xxx NE
activity xxx NE
on xx NE
GM-CSF XX-XXX NE
templates xxx NE
. . NE

Since Xxxx NE
the xxx NE
human xxx DNA_B
GM-CSF XX-XXX DNA_M
promoter xxx DNA_E
has xxx NE
a x NE
base xxx NE
difference xxx NE
within xxx NE
the xxx NE
GC-box XX-xxx DNA
, , NE
we xx NE
speculate xxx NE
that xxx NE
this xxx NE
may xxx NE
explain xxx NE
why xxx NE
the xxx NE
human xxx NE
promoter xxx NE
is xx NE
weak xxx NE
and xxx NE
that xxx NE
an xx NE
upstream xxx DNA_B
enhancer xxx DNA_E
is xx NE
required xxx NE
for xxx NE
the xxx NE
induction xxx NE
of xx NE
the xxx NE
human xxx DNA_B
GM-CSF XX-XXX DNA_M
gene xxx DNA_E
. . NE

A X NE
factor xxx NE
that xxx NE
regulates xxx NE
the xxx NE
class xxx DNA_B
II XX DNA_M
major xxx DNA_M
histocompatibility xxx DNA_M
complex xxx DNA_M
gene xxx DNA_E
DPA XXX DNA
is xx NE
a x NE
member xxx NE
of xx NE
a x NE
subfamily xxx NE
of xx NE
zinc xxx protein_B
finger xxx protein_M
proteins xxx protein_E
that xxx NE
includes xxx NE
a x NE
Drosophila Xxxx protein_B
developmental xxx protein_M
control xxx protein_M
protein xxx protein_E
. . NE

A X NE
novel xxx NE
DNA XXX DNA_B
sequence xxx DNA_M
element xxx DNA_E
termed xxx NE
the xxx NE
J X DNA_B
element xxx DNA_E
involved xxx NE
in xx NE
the xxx NE
regulated xxx NE
expression xxx NE
of xx NE
class xxx DNA_B
II XX DNA_M
major xxx DNA_M
histocompatibility xxx DNA_M
complex xxx DNA_M
genes xxx DNA_E
was xxx NE
recently xxx NE
described xxx NE
. . NE

To Xx NE
study xxx NE
this xxx NE
element xxx NE
and xxx NE
its xxx NE
role xxx NE
in xx NE
class xxx NE
II XX NE
gene xxx NE
regulation xxx NE
further xxx NE
, , NE
a x NE
cDNA xXXX DNA_B
library xxx DNA_E
was xxx NE
screened xxx NE
with xxx NE
oligonucleotide xxx NE
probes xxx NE
containing xxx NE
both xxx NE
the xxx NE
S X DNA_B
element xxx DNA_E
and xxx NE
the xxx NE
nearby xxx NE
J X DNA_B
element xxx DNA_E
of xx NE
the xxx NE
human xxx DNA_B
DPA XXX DNA_M
gene xxx DNA_E
. . NE

Several Xxxx NE
DNA XXX DNA_B
clones xxx DNA_E
were xxx NE
obtained xxx NE
by xx NE
this xxx NE
procedure xxx NE
, , NE
one xxx NE
of xx NE
which xxx NE
, , NE
clone xxx DNA_B
18 dd DNA_E
, , NE
is xx NE
reported xxx NE
and xxx NE
characterized xxx NE
here xxx NE
. . NE

It Xx NE
encodes xxx NE
a x NE
protein xxx NE
predicted xxx NE
to xx NE
contain xxx NE
688 ddd NE
amino xxx NE
acid xxx NE
residues xxx NE
, , NE
including xxx NE
11 dd NE
zinc xxx protein_B
finger xxx protein_M
motifs xxx protein_E
of xx NE
the xxx NE
C2H2 XdXd protein_B
type xxx protein_E
in xx NE
the xxx NE
C-terminal X-xxx protein_B
region xxx protein_E
, , NE
that xxx NE
are xxx NE
Kruppel-like Xxxx-xxx NE
in xx NE
the xxx NE
conservation xxx NE
of xx NE
the xxx NE
H/C X/X protein_B
link xxx protein_M
sequence xxx protein_E
connecting xxx NE
them xxx NE
. . NE

The Xxx NE
160 ddd protein_B
N-terminal X-xxx protein_M
amino xxx protein_M
acids xxx protein_E
in xx NE
the xxx NE
nonfinger xxx protein_B
region xxx protein_E
of xx NE
clone xxx protein_B
18 dd protein_E
are xxx NE
highly xxx NE
homologous xxx NE
with xxx NE
similar xxx NE
regions xxx NE
of xx NE
several xxx NE
other xxx NE
human xxx DNA_B
sequence xxx DNA_M
and xxx DNA_M
mouse xxx DNA_M
sequence xxx DNA_M
and xxx DNA_M
Drosophila Xxxx DNA_M
sequence xxx DNA_E
zinc xxx NE
finger xxx NE
proteins xxx NE
termed xxx NE
TAB XXX protein
( ( NE
tramtrack xxx protein_B
[ttk]-associated [xxx]-xxx protein_M
box xxx protein_E
) ) NE
here xxx NE
. . NE

One Xxx NE
of xx NE
the xxx NE
Drosophila Xxxx DNA_B
sequences xxx DNA_E
, , NE
ttk xxx DNA
, , NE
is xx NE
a x NE
developmental xxx DNA_B
control xxx DNA_M
gene xxx DNA_E
, , NE
while xxx NE
a x NE
second xxx NE
does xxx NE
not xxx NE
contain xxx NE
a x NE
zinc xxx protein_B
finger xxx protein_M
region xxx protein_E
but xxx NE
encodes xxx NE
a x NE
structure xxx NE
important xxx NE
in xx NE
oocyte xxx NE
development xxx NE
. . NE

An Xx NE
acidic xxx protein_B
activation xxx protein_M
domain xxx protein_E
is xx NE
located xxx NE
between xxx NE
the xxx NE
N-terminal X-xxx protein_B
conserved xxx protein_M
region xxx protein_E
of xx NE
clone xxx protein_B
18 dd protein_E
and xxx NE
its xxx NE
zinc xxx protein_B
fingers xxx protein_E
. . NE

This Xxxx NE
protein xxx NE
appears xxx NE
to xx NE
require xxx NE
both xxx NE
the xxx NE
S X DNA_B
element xxx DNA_M
and xxx DNA_M
J X DNA_M
element xxx DNA_E
10 dd NE
bp xx NE
for xxx NE
optimal xxx NE
binding xxx NE
. . NE

Antisense Xxxx NE
cDNA xXXX NE
to xx NE
clone xxx protein_B
18 dd protein_E
inhibited xxx NE
the xxx NE
expression xxx NE
of xx NE
a x NE
reporter xxx NE
construct xxx NE
containing xxx NE
the xxx NE
DPA XXX DNA_B
promoter xxx DNA_E
, , NE
indicating xxx NE
its xxx NE
functional xxx NE
importance xxx NE
in xx NE
the xxx NE
expression xxx NE
of xx NE
this xxx NE
class xxx DNA_B
II XX DNA_M
gene xxx DNA_E
. . NE

Separation Xxxx NE
of xx NE
oxidant-initiated xxx-xxx NE
and xxx NE
redox-regulated xxx-xxx NE
steps xxx NE
in xx NE
the xxx NE
NF-kappa XX-xxx NE
B X NE
signal xxx NE
transduction xxx NE
pathway xxx NE
. . NE

Studies Xxxx NE
presented xxx NE
here xxx NE
show xxx NE
that xxx NE
overall xxx NE
NF-kappa XX-xxx NE
B X NE
signal xxx NE
transduction xxx NE
begins xxx NE
with xxx NE
a x NE
parallel xxx NE
series xxx NE
of xx NE
stimuli-specific xxx-xxx NE
pathways xxx NE
through xxx NE
which xxx NE
cytokines xxx protein
( ( NE
tumor xxx protein_B
necrosis xxx protein_M
factor xxx protein_M
alpha xxx protein_E
) ) NE
, , NE
oxidants xxx NE
( ( NE
hydrogen xxx NE
peroxide xxx NE
and xxx NE
mitomycin xxx NE
C X NE
) ) NE
, , NE
and xxx NE
phorbol xxx NE
ester xxx NE
( ( NE
phorbol xxx NE
12-myristate dd-xxx NE
13-acetate dd-xxx NE
) ) NE
individually xxx NE
initiate xxx NE
signaling xxx NE
. . NE

These Xxxx NE
initial xxx NE
pathways xxx NE
culminate xxx NE
in xx NE
a x NE
common xxx NE
pathway xxx NE
through xxx NE
which xxx NE
all xxx NE
of xx NE
the xxx NE
stimulating xxx NE
agents xxx NE
ultimately xxx NE
signal xxx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
. . NE

We Xx NE
distinguish xxx NE
the xxx NE
stimuli-specific xxx-xxx NE
pathways xxx NE
by xx NE
showing xxx NE
that xxx NE
the xxx NE
oxidative xxx NE
stimuli xxx NE
trigger xxx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
in xx NE
only xxx NE
one xxx NE
of xx NE
two xxx NE
human xxx cell_line_B
T-cell X-xxx cell_line_M
lines xxx cell_line_E
( ( NE
Wurzburg Xxxx cell_line
but xxx NE
not xxx NE
Jurkat Xxxx cell_line
) ) NE
, , NE
whereas xxx NE
tumor xxx protein_B
necrosis xxx protein_M
factor xxx protein_M
alpha xxx protein_E
and xxx NE
phorbol xxx NE
12-myristate dd-xxx NE
13-acetate dd-xxx NE
readily xxx NE
stimulate xxx NE
in xx NE
both xxx NE
lines xxx NE
. . NE

We Xx NE
propose xxx NE
the xxx NE
common xxx NE
pathway xxx NE
as xx NE
the xxx NE
simplest xxx NE
way xxx NE
of xx NE
accounting xxx NE
for xxx NE
the xxx NE
common xxx NE
requirements xxx NE
and xxx NE
properties xxx NE
of xx NE
the xxx NE
signaling xxx NE
pathway xxx NE
. . NE

We Xx NE
include xxx NE
a x NE
redox-regulatory xxx-xxx NE
mechanism xxx NE
(s) (x) NE
in xx NE
this xxx NE
common xxx NE
pathway xxx NE
to xx NE
account xxx NE
for xxx NE
the xxx NE
previously xxx NE
demonstrated xxx NE
redox xxx NE
regulation xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
in xx NE
Jurkat Xxxx cell_line_B
cells xxx cell_line_E
(in (xx NE
which xxx NE
oxidants xxx NE
don't xxx'x NE
activate xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
) ) NE
; ; NE
we xx NE
put xxx NE
tyrosine xxx NE
phosphorylation xxx NE
in xx NE
the xxx NE
common xxx NE
pathway xxx NE
by xx NE
showing xxx NE
that xxx NE
kinase xxx NE
activity xxx NE
(inhibitable (xxx NE
by xx NE
herbimycin xxx NE
A X NE
and xxx NE
tyrphostin xxx NE
47 dd NE
) ) NE
is xx NE
required xxx NE
for xxx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
by xx NE
all xxx NE
stimuli xxx NE
tested xxx NE
in xx NE
both xxx NE
cell xxx NE
lines xxx NE
. . NE

Since Xxxx NE
internal xxx NE
sites xxx NE
of xx NE
oxidant xxx NE
production xxx NE
have xxx NE
been xxx NE
shown xxx NE
to xx NE
play xxx NE
a x NE
key xxx NE
role xxx NE
in xx NE
the xxx NE
cytokine xxx NE
-stimulated -xxx NE
activation xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
, , NE
and xxx NE
since xxx NE
tyrosine xxx NE
kinase xxx NE
and xxx NE
phosphatase xxx NE
activities xxx NE
are xxx NE
known xxx NE
to xx NE
be xx NE
altered xxx NE
by xx NE
oxidants xxx NE
, , NE
these xxx NE
findings xxx NE
suggest xxx NE
that xxx NE
intracellular xxx NE
redox xxx NE
status xxx NE
controls xxx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
by xx NE
regulating xxx NE
tyrosine xxx NE
phosphorylation xxx NE
event(s) xxx(x) NE
within xxx NE
the xxx NE
common xxx NE
step xxx NE
of xx NE
the xxx NE
NF-kappa XX-xxx NE
B X NE
signal xxx NE
transduction xxx NE
pathway xxx NE
. . NE

Deleted Xxxx NE
chromosome xxx DNA_B
20 dd DNA_E
from xxx NE
a x NE
patient xxx NE
with xxx NE
Alagille Xxxx NE
syndrome xxx NE
isolated xxx NE
in xx NE
a x NE
cell xxx NE
hybrid xxx NE
through xxx NE
leucine xxx NE
transport xxx NE
selection xxx NE
: : NE
study xxx NE
of xx NE
three xxx NE
candidate xxx NE
genes xxx NE
. . NE

Alagille Xxxx NE
syndrome xxx NE
( ( NE
AGS XXX NE
) ) NE
is xx NE
a x NE
well-defined xxx-xxx NE
genetic xxx NE
entity xxx NE
assigned xxx NE
to xx NE
the xxx NE
short xxx DNA_B
arm xxx DNA_E
of xx NE
Chromosome Xxxx DNA_B
(Chr) (Xxx) DNA_M
20 dd DNA_E
by xx NE
a x NE
series xxx NE
of xx NE
observations xxx NE
of xx NE
AGS XXX NE
patients xxx NE
associated xxx NE
with xxx NE
microdeletions xxx NE
in xx NE
this xxx NE
region xxx NE
. . NE

By Xx NE
fusing xxx NE
lymphoblastoid xxx cell_type_B
cells xxx cell_type_E
of xx NE
an xx NE
AGS XXX NE
patient xxx NE
that xxx NE
exhibited xxx NE
a x NE
microdeletion xxx NE
in xx NE
the xxx NE
short xxx DNA_B
arm xxx DNA_M
of xx DNA_M
Chr Xxx DNA_M
20 dd DNA_E
encompassing xxx NE
bands xxx NE
p11.23 xdd.dd DNA_B
to xx DNA_M
p12.3 xdd.d DNA_E
with xxx NE
rodent xxx cell_line_B
thermosensitive xxx cell_line_M
mutant xxx cell_line_M
cells xxx cell_line_E
( ( NE
CHOtsH1-1 XXXxxXd-d cell_line
) ) NE
deficient xxx NE
in-leucyl-tRNA xx-xxx-xXXX protein_B
synthetase xxx protein_E
, , NE
we xx NE
isolated xxx NE
a x NE
somatic xxx cell_line_B
cell xxx cell_line_M
hybrid xxx cell_line_E
segregating xxx NE
the xxx NE
deleted xxx NE
human xxx NE
Chr Xxx DNA_B
20 dd DNA_E
. . NE

This Xxxx NE
hybrid xxx NE
clone xxx NE
, , NE
designated xxx NE
NR2 XXd cell_line
, , NE
was xxx NE
characterized xxx NE
by xx NE
several xxx NE
methods xxx NE
, , NE
including xxx NE
PCR XXX NE
, , NE
with xxx NE
eight xxx NE
pairs xxx NE
of xx NE
oligonucleotides xxx NE
mapped xxx NE
to xx NE
Chr Xxx DNA_B
20 dd DNA_E
: : NE
D20S5 XddXd DNA
, , NE
D20S41 XddXdd DNA
, , NE
D20S42 XddXdd DNA
, , NE
D20S56 XddXdd DNA
, , NE
D20S57 XddXdd DNA
, , NE
D20S58 XddXdd DNA
, , NE
adenosine xxx DNA_B
deaminase xxx DNA_E
( ( NE
ADA XXX protein
) ) NE
, , NE
and xxx NE
Prion Xxxx DNA_B
protein xxx DNA_E
( ( NE
PRIP XXXX protein
) ) NE
; ; NE
Restriction Xxxx NE
Fragment Xxxx NE
Length Xxxx NE
Polymorphism Xxxx NE
( ( NE
RFLP XXXX NE
) ) NE
analyses xxx NE
with xxx NE
four xxx NE
genomic xxx NE
anonymous xxx NE
probes xxx NE
( ( NE
D20S5 XddXd NE
, , NE
cD3H12 xXdXdd NE
, , NE
D20S17 XddXdd NE
, , NE
D20S18 XddXdd NE
) ) NE
; ; NE
and xxx NE
fluorescent xxx NE
in xx NE
situ xxx NE
hybridization xxx NE
( ( NE
FISH XXXX NE
) ) NE
with xxx NE
total xxx NE
human xxx NE
DNA XXX NE
and xxx NE
D20Z1 XddXd NE
, , NE
a x NE
sequence xxx NE
specific xxx NE
to xx NE
the xxx NE
human xxx NE
Chr Xxx NE
20 dd NE
centromere xxx NE
, , NE
as xx NE
probes xxx NE
. . NE

The Xxx NE
NR2 XXd cell_line_B
hybrid xxx cell_line_E
allowed xxx NE
us xx NE
to xx NE
exclude xxx NE
three xxx NE
candidate xxx DNA_B
genes xxx DNA_E
for xxx NE
AGS XXX NE
: : NE
hepatic xxx DNA_B
nuclear xxx DNA_M
factor xxx DNA_M
3 d DNA_M
beta xxx DNA_E
( ( NE
HNF3 XXXd DNA_B
beta xxx DNA_E
) ) NE
, , NE
paired xxx DNA_B
box xxx DNA_M
1 d DNA_E
( ( NE
PAX1 XXXd DNA
) ) NE
, , NE
and xxx NE
cystatin xxx DNA_B
C X DNA_E
( ( NE
CST3 XXXd DNA
) ) NE
as xx NE
shown xxx NE
by xx NE
their xxx NE
localization xxx NE
outside xxx NE
of xx NE
the xxx NE
deletion xxx NE
. . NE

The Xxx NE
NR2 XXd cell_line_B
hybrid xxx cell_line_E
is xx NE
a x NE
powerful xxx NE
tool xxx NE
for xxx NE
the xxx NE
mapping xxx NE
of xx NE
new xxx NE
probes xxx NE
of xx NE
this xxx NE
region xxx NE
, , NE
as xx NE
well xxx NE
as xx NE
for xxx NE
obtaining xxx NE
new xxx NE
informative xxx NE
probes xxx NE
specific xxx NE
for xxx NE
the xxx NE
deletion xxx NE
by xx NE
subtractive xxx NE
cloning xxx NE
of xx NE
the xxx NE
region xxx NE
. . NE

Such Xxxx NE
markers xxx NE
will xxx NE
be xx NE
useful xxx NE
for xxx NE
linkage xxx NE
analysis xxx NE
and xxx NE
screening xxx NE
of xx NE
cDNA xXXX NE
libraries xxx NE
. . NE

positive xxx NE
regulation xxx NE
and xxx NE
negative xxx NE
regulation xxx NE
of xx NE
the xxx NE
composite xxx DNA_B
octamer xxx DNA_M
motif xxx DNA_E
of xx NE
the xxx NE
interleukin xxx DNA_B
2 d DNA_M
enhancer xxx DNA_E
by xx NE
AP-1 XX-d protein
, , NE
Oct-2 Xxx-d protein
, , NE
and xxx NE
retinoic xxx protein_B
acid xxx protein_M
receptor xxx protein_E
. . NE

The Xxx NE
differentiating xxx NE
agent xxx NE
retinoic xxx NE
acid xxx NE
( ( NE
RA XX NE
) ) NE
has xxx NE
been xxx NE
previously xxx NE
reported xxx NE
to xx NE
interfere xxx NE
with xxx NE
12-O-tetradecanoyl-phorbol-13-acetate dd-X-xxx-xxx-dd-xxx NE
( ( NE
TPA XXX NE
) ) NE
/ / NE
Ca(2+) Xx(d+) NE
-induced -xxx NE
signals xxx NE
for xxx NE
the xxx NE
regulation xxx NE
of xx NE
the xxx NE
-96 -dd NE
to xx NE
-66-bp -dd-xx NE
octamer xxx NE
motif xxx NE
found xxx NE
in xx NE
the xxx NE
enhancer xxx NE
for xxx NE
the xxx NE
interleukin xxx NE
(IL)-2 (XX)-d NE
gene xxx NE
, , NE
which xxx NE
encodes xxx NE
a x NE
major xxx NE
T X NE
lymphocyte xxx NE
growth xxx NE
factor xxx NE
. . NE

The Xxx NE
IL-2 XX-d DNA_B
octamer xxx DNA_M
motif xxx DNA_E
is xx NE
a x NE
composite xxx NE
cis-element xxx-xxx DNA
which xxx NE
binds xxx NE
Oct-1 Xxx-d protein
and xxx NE
Oct-2 Xxx-d protein
as xx NE
well xxx NE
as xx NE
a x NE
TPA XXX NE
/ / NE
Ca(2+) Xx(d+) NE
-inducible -xxx NE
nuclear xxx NE
factor xxx NE
, , NE
previously xxx NE
termed xxx NE
octamer-associated xxx-xxx NE
protein xxx NE
( ( NE
OAP40 XXXdd NE
) ) NE
. . NE

We Xx NE
show xxx NE
here xxx NE
that xxx NE
Oct-2 Xxx-d protein
, , NE
despite xxx NE
the xxx NE
presence xxx NE
of xx NE
an xx NE
active xxx NE
transcriptional xxx NE
activation xxx NE
domain xxx NE
, , NE
requires xxx NE
TPA/Ca(2+)-induced XXX/Xx(d+)-xxx NE
signals xxx NE
to xx NE
strongly xxx NE
transactivate xxx NE
the xxx NE
IL-2 XX-d DNA_B
octamer xxx DNA_M
motif xxx DNA_E
in xx NE
Jurkat Xxxx NE
T X NE
cells xxx NE
. . NE

This Xxxx NE
Oct-2 Xxx-d NE
-dependent -xxx NE
transactivation xxx NE
is xx NE
inhibited xxx NE
by xx NE
RA XX NE
. . NE

The Xxx NE
presence xxx NE
of xx NE
an xx NE
intact xxx protein_B
COOH-terminal XXXX-xxx protein_M
domain xxx protein_E
of xx NE
Oct-2 Xxx-d protein
contributes xxx NE
to xx NE
both xxx NE
TPA XXX NE
/ / NE
Ca(2+) Xx(d+) NE
-induced -xxx NE
transactivation xxx NE
and xxx NE
the xxx NE
RA XX NE
-mediated -xxx NE
repression xxx NE
. . NE

We Xx NE
also xxx NE
show xxx NE
that xxx NE
both xxx NE
Fos Xxx protein
and xxx NE
Jun Xxx protein
components xxx NE
of xx NE
the xxx NE
AP-1 XX-d protein
factors xxx NE
participate xxx NE
in xx NE
the xxx NE
OAP40 XXXdd protein_B
complex xxx protein_E
. . NE

Furthermore Xxxx NE
, , NE
transfected xxx NE
c-jun x-xxx DNA_B
expression xxx DNA_M
vector xxx DNA_M
or xx DNA_M
jun-B xxx-X DNA_M
expression xxx DNA_M
vector xxx DNA_M
or xx DNA_M
jun-D xxx-X DNA_M
expression xxx DNA_M
vector xxx DNA_M
or xx DNA_M
c-fos x-xxx DNA_M
expression xxx DNA_M
vector xxx DNA_M
or xx DNA_M
Fos-B Xxx-X DNA_M
expression xxx DNA_M
vector xxx DNA_E
TPA XXX NE
and xxx NE
Ca2+ Xxd+ NE
and xxx NE
cooperate xxx NE
with xxx NE
Oct-2 Xxx-d protein
for xxx NE
the xxx NE
transactivation xxx NE
of xx NE
the xxx NE
combined xxx NE
OAP/octamer XXX/xxx DNA_B
cis-element xxx-xxx DNA_E
. . NE

Mutations Xxxx NE
of xx NE
the xxx NE
genuine xxx DNA_B
octamer-binding xxx-xxx DNA_M
site xxx DNA_E
abrogate xxx NE
both xxx NE
the xxx NE
binding xxx NE
of xx NE
Oct-1 Xxx-d protein
and xxx NE
Oct-2 Xxx-d protein
and xxx NE
the xxx NE
TPA XXX NE
/ / NE
Ca(2+) Xx(d+) NE
-induced -xxx NE
transactivation xxx NE
of xx NE
the xxx NE
OAP XXX NE
/octamer /xxx NE
motif xxx NE
. . NE

OAP XXX protein
confers xxx NE
to xx NE
Oct-2 Xxx-d protein
responsivity xxx NE
to xx NE
both xxx NE
TPA XXX NE
/Ca2+ /Xxd+ NE
and xxx NE
RA XX NE
, , NE
since xxx NE
specific xxx NE
mutations xxx NE
of xx NE
the xxx NE
AP-1 XX-d NE
/ / NE
OAP XXX NE
-binding -xxx NE
site xxx NE
significantly xxx NE
reduce xxx NE
the xxx NE
transactivation xxx NE
by xx NE
Oct-2 Xxx-d NE
in xx NE
response xxx NE
to xx NE
TPA XXX NE
and xxx NE
Ca2+ Xxd+ NE
and xxx NE
abolish xxx NE
the xxx NE
inhibition xxx NE
by xx NE
RA XX NE
. . NE

Furthermore Xxxx NE
, , NE
retinoic xxx protein_B
acid xxx protein_M
receptor xxx protein_E
( ( NE
RAR XXX protein
) ) NE
alpha xxx NE
is xx NE
able xxx NE
to xx NE
inhibit xxx NE
in xx NE
vitro xxx NE
the xxx NE
formation xxx NE
of xx NE
the xxx NE
complex xxx NE
between xxx NE
the xxx NE
nuclear xxx NE
AP-1 XX-d protein
/OAP /XXX NE
and xxx NE
its xxx NE
specific xxx NE
binding xxx NE
site xxx NE
, , NE
resulting xxx NE
in xx NE
the xxx NE
interference xxx NE
with xxx NE
Oct-2 Xxx-d NE
-dependent -xxx NE
cis-regulatory xxx-xxx NE
function xxx NE
of xx NE
this xxx NE
AP-1 XX-d NE
element xxx NE
. . NE

Therefore Xxxx NE
, , NE
we xx NE
propose xxx NE
that xxx NE
the xxx NE
TPA XXX NE
/ / NE
calcium xxx NE
-activated -xxx NE
AP-1 XX-d protein
/OAP /XXX NE
element xxx NE
is xx NE
the xxx NE
main xxx NE
target xxx NE
of xx NE
positive xxx NE
or xx NE
negative xxx NE
regulatory xxx NE
signals xxx NE
influencing xxx NE
the xxx NE
IL-2 XX-d NE
octamer xxx NE
motif xxx NE
, , NE
through xxx NE
synergism xxx NE
with xxx NE
Oct-2 Xxx-d NE
and xxx NE
antagonism xxx NE
by xx NE
RAR XXX NE
. . NE

Missense Xxxx NE
mutation xxx NE
in xx NE
exon xxx DNA_B
7 d DNA_E
of xx NE
the xxx NE
common xxx DNA_B
gamma xxx DNA_M
chain xxx DNA_M
gene xxx DNA_E
causes xxx NE
a x NE
moderate xxx NE
form xxx NE
of xx NE
X-linked X-xxx NE
combined xxx NE
immunodeficiency xxx NE
. . NE

Clinical Xxxx NE
and xxx NE
immunologic xxx NE
features xxx NE
of xx NE
a x NE
recently xxx NE
recognized xxx NE
X-linked X-xxx NE
combined xxx NE
immunodeficiency xxx NE
disease xxx NE
( ( NE
XCID XXXX NE
) ) NE
suggested xxx NE
that xxx NE
XCID XXXX NE
and xxx NE
X-linked X-xxx NE
severe xxx NE
combined xxx NE
immunodeficiency xxx NE
( ( NE
XSCID XXXXX NE
) ) NE
might xxx NE
arise xxx NE
from xxx NE
different xxx NE
genetic xxx NE
defects xxx NE
. . NE

The Xxx NE
recent xxx NE
discovery xxx NE
of xx NE
mutations xxx NE
in xx NE
the xxx NE
common xxx DNA_B
gamma xxx DNA_M
chain xxx DNA_M
(gamma (xxx DNA_M
c) x) DNA_M
gene xxx DNA_E
, , NE
a x NE
constituent xxx NE
of xx NE
several xxx NE
cytokine xxx protein_B
receptors xxx protein_E
, , NE
in xx NE
XSCID XXXXX NE
provided xxx NE
an xx NE
opportunity xxx NE
to xx NE
test xxx NE
directly xxx NE
whether xxx NE
a x NE
previously xxx NE
unrecognized xxx NE
mutation xxx NE
in xx NE
this xxx NE
same xxx NE
gene xxx NE
was xxx NE
responsible xxx NE
for xxx NE
XCID XXXX NE
. . NE

The Xxx NE
status xxx NE
of xx NE
X X NE
chromosome xxx NE
inactivation xxx NE
in xx NE
blood xxx NE
leukocytes xxx NE
from xxx NE
obligate xxx NE
carriers xxx NE
of xx NE
XCID XXXX NE
was xxx NE
determined xxx NE
from xxx NE
the xxx NE
polymorphic xxx NE
, , NE
short xxx DNA_B
tandem xxx DNA_M
repeats xxx DNA_E
( ( NE
CAG XXX NE
) ) NE
, , NE
in xx NE
the xxx NE
androgen xxx DNA_B
receptor xxx DNA_M
gene xxx DNA_E
, , NE
which xxx NE
also xxx NE
contains xxx NE
a x NE
methylation-sensitive xxx-xxx DNA_B
HpaII XxxXX DNA_M
site xxx DNA_E
. . NE

As Xx NE
in xx NE
XSCID XXXXX NE
, , NE
X-chromosome X-xxx NE
inactivation xxx NE
in xx NE
obligate xxx NE
carriers xxx NE
of xx NE
XCID XXXX NE
was xxx NE
nonrandom xxx NE
in xx NE
T X cell_type_B
lymphocyte xxx cell_type_M
and xxx cell_type_M
B X cell_type_M
lymphocyte xxx cell_type_E

In Xx NE
addition xxx NE
, , NE
X X DNA_B
chromosome xxx DNA_E
inactivation xxx NE
in xx NE
PMNs XXXx NE
was xxx NE
variable xxx NE
. . NE

Findings Xxxx NE
from xxx NE
this xxx NE
analysis xxx NE
prompted xxx NE
sequencing xxx NE
of xx NE
the xxx NE
gamma xxx DNA_B
c x DNA_M
gene xxx DNA_E
in xx NE
this xxx NE
pedigree xxx NE
. . NE

A X NE
missense xxx NE
mutation xxx NE
in xx NE
the xxx NE
region xxx NE
coding xxx NE
for xxx NE
the xxx NE
cytoplasmic xxx NE
portion xxx NE
of xx NE
the xxx NE
gamma xxx DNA_B
c x DNA_M
gene xxx DNA_E
was xxx NE
found xxx NE
in xx NE
three xxx NE
affected xxx NE
males xxx NE
but xxx NE
not xxx NE
in xx NE
a x NE
normal xxx NE
brother xxx NE
. . NE

Therefore Xxxx NE
, , NE
this xxx NE
point xxx NE
mutation xxx NE
in xx NE
the xxx NE
gamma xxx DNA_B
c x DNA_M
gene xxx DNA_E
leads xxx NE
to xx NE
a x NE
less xxx NE
severe xxx NE
degree xxx NE
of xx NE
deficiency xxx NE
in xx NE
cellular xxx NE
and xxx NE
humoral xxx NE
immunity xxx NE
than xxx NE
that xxx NE
seen xxx NE
in xx NE
XSCID XXXXX NE
. . NE

Posttranscriptional Xxxx NE
regulation xxx NE
of xx NE
macrophage xxx NE
tissue xxx NE
factor xxx NE
expression xxx NE
by xx NE
antioxidants xxx NE
. . NE

Tissue Xxxx NE
factor xxx NE
( ( NE
TF XX NE
) ) NE
expression xxx NE
by xx NE
cells xxx NE
of xx NE
monocyte/macrophage xxx/xxx NE
lineage xxx NE
represents xxx NE
an xx NE
important xxx NE
mechanism xxx NE
underlying xxx NE
the xxx NE
initiation xxx NE
of xx NE
fibrin xxx NE
deposition xxx NE
at xx NE
sites xxx NE
of xx NE
extravascular xxx NE
inflammation xxx NE
. . NE

Recent Xxxx NE
evidence xxx NE
suggests xxx NE
a x NE
role xxx NE
for xxx NE
oxidant xxx NE
stress xxx NE
in xx NE
the xxx NE
signalling xxx NE
pathway xxx NE
of xx NE
various xxx NE
cell xxx NE
types xxx NE
by xx NE
virtue xxx NE
of xx NE
its xxx NE
ability xxx NE
to xx NE
induce xxx NE
DNA XXX NE
binding xxx NE
of xx NE
various xxx NE
transcription xxx protein_B
factors xxx protein_E
, , NE
including xxx NE
nuclear xxx protein_B
factor xxx protein_M
kappa xxx protein_M
B X protein_E
and xxx NE
AP-1 XX-d protein
. . NE

The Xxx NE
effect xxx NE
of xx NE
antioxidant xxx NE
treatment xxx NE
on xx NE
lipopolysaccharide xxx NE
( ( NE
LPS XXX NE
)-induced )-xxx NE
TF XX NE
expression xxx NE
was xxx NE
examined xxx NE
in xx NE
murine xxx NE
peritoneal xxx NE
macrophages xxx NE
and xxx NE
human xxx NE
monocytes xxx NE
. . NE

Both Xxxx NE
pyrrolidine xxx NE
dithiocarbamate xxx NE
, , NE
an xx NE
oxidant xxx NE
scavenger xxx NE
, , NE
and xxx NE
N-acetyl-cysteine X-xxx-xxx NE
, , NE
a x NE
precursor xxx NE
of xx NE
the xxx NE
endogenous xxx NE
antioxidant xxx NE
glutathione xxx NE
, , NE
inhibited xxx NE
stimulation xxx NE
of xx NE
macrophage xxx NE
procoagulant xxx NE
activity xxx NE
by xx NE
LPS XXX NE
. . NE

Northern Xxxx NE
blot xxx NE
analysis xxx NE
showed xxx NE
that xxx NE
neither xxx NE
of xx NE
these xxx NE
agents xxx NE
reduced xxx NE
LPS XXX NE
-stimulated -xxx NE
TF XX NE
mRNA xXXX NE
accumulation xxx NE
, , NE
thereby xxx NE
suggesting xxx NE
a x NE
posttranscriptional xxx NE
mechanism xxx NE
for xxx NE
the xxx NE
effect xxx NE
. . NE

Immunofluorescence Xxxx NE
studies xxx NE
of xx NE
human xxx NE
monocytes xxx NE
using xxx NE
polyclonal xxx NE
anti- xxx- NE
TF XX NE
antibody xxx NE
showed xxx NE
that xxx NE
N-acetyl-cysteine X-xxx-xxx NE
treatment xxx NE
prevented xxx NE
the xxx NE
characteristic xxx NE
plasmalemmal xxx NE
localization xxx NE
of xx NE
TF XX NE
antigen xxx NE
that xxx NE
occurs xxx NE
in xx NE
response xxx NE
to xx NE
LPS XXX NE
. . NE

Western Xxxx NE
blot xxx NE
analysis xxx NE
showed xxx NE
that xxx NE
N-acetyl-cysteine X-xxx-xxx NE
reduced xxx NE
the xxx NE
accumulation xxx NE
of xx NE
the xxx NE
47-kD dd-xX protein_B
mature xxx protein_M
glycoprotein xxx protein_E
in xx NE
LPS XXX NE
-treated -xxx NE
cells xxx NE
, , NE
a x NE
finding xxx NE
consistent xxx NE
with xxx NE
the xxx NE
results xxx NE
of xx NE
the xxx NE
immunofluorescence xxx NE
studies xxx NE
. . NE

Furthermore Xxxx NE
, , NE
these xxx NE
conditions xxx NE
did xxx NE
not xxx NE
result xxx NE
in xx NE
an xx NE
accumulation xxx NE
of xx NE
the xxx NE
less xxx NE
mature xxx NE
forms xxx NE
of xx NE
TF XX protein
. . NE

When Xxxx NE
considered xxx NE
together xxx NE
, , NE
these xxx NE
data xxx NE
suggest xxx NE
that xxx NE
antioxidants xxx NE
exert xxx NE
their xxx NE
effects xxx NE
by xx NE
impairing xxx NE
translation xxx NE
and/or xxx/xx NE
by xx NE
causing xxx NE
degradation xxx NE
of xx NE
newly xxx NE
translated xxx protein_B
protein xxx protein_E
. . NE

The Xxx NE
effect xxx NE
of xx NE
antioxidants xxx NE
on xx NE
tumor xxx protein_B
necrosis xxx protein_M
factor xxx protein_E
appeared xxx NE
to xx NE
be xx NE
species xxx NE
specific xxx NE
, , NE
with xxx NE
no xx NE
effect xxx NE
on xx NE
LPS XXX NE
-induced -xxx NE
tumor xxx NE
necrosis xxx NE
factor xxx NE
in xx NE
murine xxx NE
cells xxx NE
, , NE
but xxx NE
with xxx NE
inhibition xxx NE
in xx NE
human xxx cell_type_B
monocytes xxx cell_type_E
. . NE

The Xxx NE
posttranscriptional xxx NE
effect xxx NE
of xx NE
antioxidants xxx NE
on xx NE
TF XX NE
expression xxx NE
data xxx NE
suggests xxx NE
a x NE
novel xxx NE
mechanism xxx NE
whereby xxx NE
these xxx NE
agents xxx NE
might xxx NE
modulate xxx NE
monocyte xxx NE
/macrophage /xxx NE
activation xxx NE
. . NE

Characterization Xxxx NE
of xx NE
the xxx NE
CD48 XXdd DNA_B
gene xxx DNA_E
demonstrates xxx NE
a x NE
positive xxx NE
element xxx NE
that xxx NE
is xx NE
specific xxx NE
to xx NE
Epstein-Barr Xxxx-Xxxx NE
virus xxx NE
-immortalized -xxx NE
B-cell X-xxx NE
lines xxx NE
and xxx NE
contains xxx NE
an xx NE
essential xxx NE
NF-kappa XX-xxx NE
B X NE
site xxx NE
. . NE

Epstein-Barr Xxxx-Xxxx NE
virus xxx NE
( ( NE
EBV XXX NE
) ) NE
infection xxx NE
of xx NE
mature xxx NE
, , NE
resting xxx cell_type_B
B X cell_type_M
cells xxx cell_type_E
drives xxx NE
them xxx NE
to xx NE
become xxx NE
lymphoblasts xxx NE
expressing xxx NE
high xxx NE
levels xxx NE
of xx NE
cell xxx NE
surface xxx NE
molecules xxx NE
, , NE
such xxx NE
as xx NE
CD48 XXdd protein
, , NE
characteristically xxx NE
expressed xxx NE
on xx NE
normal xxx cell_type_B
activated xxx cell_type_M
B X cell_type_M
cells xxx cell_type_E
. . NE

Here Xxxx NE
, , NE
we xx NE
report xxx NE
on xx NE
the xxx NE
identification xxx NE
of xx NE
an xx NE
enhancer xxx DNA_B
element xxx DNA_E
in xx NE
the xxx NE
CD48 XXdd DNA_B
gene xxx DNA_E
which xxx NE
reproducibly xxx NE
confers xxx NE
strong xxx NE
transcriptional xxx NE
activity xxx NE
only xxx NE
in xx NE
EBV XXX NE
-positive -xxx NE
B-lymphoblastoid X-xxx NE
cell xxx NE
lines xxx NE
. . NE

The Xxx NE
element xxx NE
is xx NE
not xxx NE
activated xxx NE
upon xxx NE
infection xxx NE
of xx NE
established xxx NE
EBV XXX NE
-negative -xxx NE
B-cell X-xxx NE
lines xxx NE
, , NE
indicating xxx NE
that xxx NE
EBV XXX NE
fails xxx NE
to xx NE
drive xxx NE
these xxx NE
cells xxx NE
to xx NE
a x NE
fully xxx NE
lymphoblastoid xxx NE
phenotype xxx NE
. . NE

An Xx NE
NF-kappa XX-xxx DNA_B
B X DNA_M
binding xxx DNA_M
site xxx DNA_E
is xx NE
an xx NE
essential xxx NE
component xxx NE
of xx NE
the xxx NE
element xxx NE
but xxx NE
alone xxx NE
is xx NE
not xxx NE
sufficient xxx NE
to xx NE
account xxx NE
for xxx NE
the xxx NE
activity xxx NE
or xx NE
the xxx NE
specificity xxx NE
of xx NE
the xxx NE
element xxx NE
. . NE

We Xx NE
have xxx NE
detected xxx NE
a x NE
specific xxx NE
nuclear xxx protein_B
protein xxx protein_M
complex xxx protein_E
that xxx NE
binds xxx NE
to xx NE
the xxx NE
element xxx NE
and xxx NE
show xxx NE
that xxx NE
NF-kappa XX-xxx protein_B
B1 Xd protein_E
( ( NE
p50 xdd protein
) ) NE
is xx NE
a x NE
part xxx NE
of xx NE
this xxx NE
complex xxx NE
. . NE

The Xxx NE
EBV XXX NE
-encoded -xxx NE
latent xxx NE
membrane xxx NE
protein xxx NE
1 d NE
is xx NE
capable xxx NE
of xx NE
transactivating xxx NE
the xxx NE
isolated xxx NE
CD48 XXdd NE
NF-kappa XX-xxx NE
B X NE
site xxx NE
but xxx NE
not xxx NE
the xxx NE
intact xxx NE
element xxx NE
, , NE
suggesting xxx NE
that xxx NE
the xxx NE
latent xxx NE
membrane xxx NE
protein xxx NE
1 d NE
-driven -xxx NE
activation xxx NE
of xx NE
NF-kappa XX-xxx NE
B/Rel X/Xxx NE
must xxx NE
interact xxx NE
with xxx NE
other xxx NE
regulatory xxx NE
pathways xxx NE
to xx NE
control xxx NE
expression xxx NE
of xx NE
cellular xxx NE
genes xxx NE
as xx NE
EBV XXX NE
drives xxx NE
resting xxx NE
B X NE
cells xxx NE
into xxx NE
the xxx NE
cell xxx NE
cycle xxx NE
. . NE

Thapsigargin Xxxx NE
induces xxx NE
IL-2 XX-d protein_B
receptor xxx protein_M
alpha-chain xxx-xxx protein_E
in xx NE
human xxx NE
peripheral xxx NE
and xxx NE
Jurkat Xxxx NE
T X NE
cells xxx NE
via xxx NE
a x NE
protein xxx NE
kinase xxx NE
C X NE
-independent -xxx NE
mechanism xxx NE
. . NE

Thapsigargin Xxxx NE
( ( NE
TG XX NE
) ) NE
, , NE
an xx NE
inhibitor xxx NE
of xx NE
Ca(2+)-ATPase Xx(d+)-XXXxxx protein
, , NE
depletes xxx NE
intracellular xxx NE
Ca2+ Xxd+ NE
stores xxx NE
and xxx NE
induces xxx NE
a x NE
sustained xxx NE
Ca2+ Xxd+ NE
influx xxx NE
without xxx NE
altering xxx NE
phosphatidyl xxx NE
inositol xxx NE
levels xxx NE
. . NE

TG XX NE
plus xxx NE
phorbol xxx NE
myristate xxx NE
acetate xxx NE
( ( NE
PMA XXX NE
) ) NE
but xxx NE
not xxx NE
TG XX NE
alone xxx NE
induced xxx NE
IL-2 XX-d protein
in xx NE
Jurkat Xxxx cell_line_B
T X cell_line_M
cells xxx cell_line_E
, , NE
suggesting xxx NE
that xxx NE
TG XX NE
had xxx NE
no xx NE
effect xxx NE
on xx NE
protein xxx protein_B
kinase xxx protein_M
C X protein_E
( ( NE
PKC XXX protein
) ) NE
. . NE

However Xxxx NE
, , NE
TG XX NE
induced xxx NE
increases xxx NE
in xx NE
IL-2R XX-dX protein_B
alpha xxx protein_M
protein xxx protein_E
as xx NE
well xxx NE
as xx NE
IL-2R XX-dX RNA_B
alpha xxx RNA_M
mRNA xXXX RNA_E
in xx NE
Jurkat Xxxx cell_line_B
T X cell_line_M
cells xxx cell_line_E
in xx NE
a x NE
dose-dependent xxx-xxx NE
manner xxx NE
. . NE

A X NE
similar xxx NE
increase xxx NE
in xx NE
IL-2R XX-dX protein_B
alpha xxx protein_E
by xx NE
TG XX NE
was xxx NE
also xxx NE
observed xxx NE
in xx NE
human xxx cell_type_B
peripheral xxx cell_type_M
T X cell_type_M
cells xxx cell_type_E
. . NE

Further Xxxx NE
, , NE
like xxx NE
PMA XXX NE
, , NE
TG XX NE
markedly xxx NE
induced xxx NE
NF XX protein_B
kappa xxx protein_M
B X protein_E
in xx NE
Jurkat Xxxx cell_line_B
T X cell_line_M
cells xxx cell_line_E
. . NE

However Xxxx NE
, , NE
TG XX NE
and xxx NE
PMA XXX NE
exhibited xxx NE
a x NE
synergistic xxx NE
action xxx NE
on xx NE
IL-2R XX-dX protein_B
alpha xxx protein_E
expression xxx NE
, , NE
suggesting xxx NE
that xxx NE
TG XX NE
and xxx NE
PMA XXX NE
induce xxx NE
IL-2R XX-dX protein_B
alpha xxx protein_E
through xxx NE
distinct xxx NE
pathways xxx NE
. . NE

PMA-induced XXX-xxx protein_B
IL-2R XX-dX protein_M
alpha xxx protein_M
but xxx protein_M
not xxx protein_M
TG-induced XX-xxx protein_M
IL-2R XX-dX protein_M
alpha xxx protein_E
TG-induced XX-xxx protein_B
IL-2R XX-dX protein_M
alpha xxx protein_M
but xxx protein_M
not xxx protein_M
PMA-induced XXX-xxx protein_M
IL-2R XX-dX protein_M
alpha xxx protein_E
is xx NE
inhibited xxx NE
by xx NE
the xxx NE
PKC XXX NE
inhibitor xxx NE
H7 Xd NE
, , NE
whereas xxx NE
TG XX NE
-but -xxx NE
not xxx NE
PMA XXX NE
-induced -xxx NE
IL-2R XX-dX NE
alpha xxx NE
was xxx NE
inhibited xxx NE
by xx NE
cholera xxx NE
toxin xxx NE
, , NE
forskolin xxx NE
and xxx NE
1,9-dideoxy d,d-xxx NE
forskolin xxx NE
. . NE

In Xx NE
toto xxx NE
, , NE
these xxx NE
results xxx NE
suggest xxx NE
that xxx NE
TG XX NE
induces xxx NE
IL-2R XX-dX protein_B
alpha xxx protein_E
in xx NE
human xxx cell_type_B
T X cell_type_M
cells xxx cell_type_E
through xxx NE
a x NE
PKC XXX NE
-independent -xxx NE
pathway xxx NE
. . NE

Physiological Xxxx NE
concentration xxx NE
of xx NE
estradiol xxx NE
inhibits xxx NE
polymorphonuclear xxx NE
leukocyte xxx NE
chemotaxis xxx NE
via xxx NE
a x NE
receptor xxx NE
mediated xxx NE
system xxx NE
. . NE

Estrogen Xxxx NE
exhibits xxx NE
a x NE
variety xxx NE
of xx NE
actions xxx NE
, , NE
including xxx NE
immuno-modulatory xxx-xxx NE
effects xxx NE
, , NE
in xx NE
vivo xxx NE
and xxx NE
in xx NE
vitro xxx NE
. . NE

The Xxx NE
mechanism xxx NE
by xx NE
which xxx NE
estrogen xxx NE
exerts xxx NE
its xxx NE
anti-inflammatory xxx-xxx NE
effect xxx NE
is xx NE
not xxx NE
yet xxx NE
understood xxx NE
. . NE

We Xx NE
investigated xxx NE
the xxx NE
possible xxx NE
mechanisms xxx NE
of xx NE
estradiol xxx NE
acting xxx NE
via xxx NE
the xxx NE
polymorphonuclear xxx cell_type_B
leukocytes xxx cell_type_E
( ( NE
PMNs XXXx cell_type
) ) NE
, , NE
which xxx NE
are xxx NE
important xxx NE
in xx NE
the xxx NE
immune xxx NE
response xxx NE
. . NE

The Xxx NE
agent xxx NE
, , NE
17 dd NE
beta- xxx- NE
estradiol xxx NE
, , NE
but xxx NE
not xxx NE
17 dd NE
alpha- xxx- NE
estradiol xxx NE
, , NE
significantly xxx NE
reduced xxx NE
PMNs XXXx NE
chemotaxis xxx NE
to xx NE
FMLP XXXX NE
in xx NE
a x NE
dose-dependent xxx-xxx NE
manner xxx NE
(control (xxx NE
vs xx NE
estrogen xxx NE
10(-10)-(-6) dd(-dd)-(-d) NE
M X NE
, , NE
P X NE
< < NE
0.05) d.dd) NE
. . NE

Physiological Xxxx NE
concentrations xxx NE
of xx NE
estradiol xxx NE
significantly xxx NE
reduced xxx NE
the xxx NE
chemotaxis xxx NE
of xx NE
PMNs XXXx cell_type
(10(-10) (dd(-dd) NE
mol) xxx) NE
. . NE

Pre-incubation Xxx-xxx NE
with xxx NE
clomiphene xxx NE
or xx NE
tamoxifen xxx NE
which xxx NE
are xxx NE
estrogen xxx NE
receptor xxx NE
antagonists xxx NE
, , NE
eliminated xxx NE
the xxx NE
inhibitory xxx NE
effect xxx NE
of xx NE
17 dd NE
beta- xxx- NE
estradiol xxx NE
on xx NE
the xxx NE
chemotaxis xxx NE
of xx NE
PMNs XXXx NE
, , NE
restoring xxx NE
it xx NE
to xx NE
the xxx NE
control xxx NE
level xxx NE
. . NE

These Xxxx NE
observations xxx NE
suggest xxx NE
that xxx NE
17 dd NE
beta- xxx- NE
estradiol xxx NE
suppressed xxx NE
the xxx NE
chemotaxis xxx NE
of xx NE
PMNs XXXx NE
by xx NE
a x NE
receptor-dependent xxx-xxx NE
mechanism xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
the xxx NE
level xxx NE
of xx NE
estradiol xxx NE
in xx NE
human xxx cell_type_B
plasma xxx cell_type_E
, , NE
which xxx NE
PMNs XXXx cell_type
were xxx NE
drawn xxx NE
, , NE
showed xxx NE
a x NE
close xxx NE
, , NE
inverse xxx NE
correlation xxx NE
with xxx NE
the xxx NE
PMNs XXXx cell_type
chemotaxis xxx NE
to xx NE
FMLP XXXX NE
(r (x NE
= = NE
-0.821 -d.ddd NE
p x NE
< < NE
0.001) d.ddd) NE
. . NE

Estrogen Xxxx NE
may xxx NE
modify xxx NE
the xxx NE
activity xxx NE
of xx NE
neutrophils xxx cell_type
during xxx NE
the xxx NE
normal xxx NE
menstrual xxx NE
cycle xxx NE
, , NE
not xxx NE
only xxx NE
during xxx NE
pregnancy xxx NE
, , NE
and xxx NE
influence xxx NE
inflammation xxx NE
. . NE

Identification Xxxx NE
of xx NE
the xxx NE
TCL1 XXXd DNA_B
gene xxx DNA_E
involved xxx NE
in xx NE
T-cell X-xxx NE
malignancies xxx NE
. . NE

The Xxx NE
TCL1 XXXd DNA_B
locus xxx DNA_E
on xx NE
chromosome xxx DNA_B
14q32.1 ddxdd.d DNA_E
is xx NE
frequently xxx NE
involved xxx NE
in xx NE
chromosomal xxx NE
translocations xxx NE
and xxx NE
inversions xxx NE
with xxx NE
one xxx NE
of xx NE
the xxx NE
T-cell X-xxx DNA_B
receptor xxx DNA_M
loci xxx DNA_E
in xx NE
human xxx NE
T-cell X-xxx NE
leukemias xxx NE
and xxx NE
lymphomas xxx NE
. . NE

The Xxx NE
chromosome xxx DNA_B
14 dd DNA_M
region xxx DNA_E
translocated xxx NE
or xx NE
rearranged xxx NE
involves xxx NE
approximately xxx NE
350 ddd NE
kb xx NE
of xx NE
DNA XXX NE
at xx NE
chromosome xxx DNA_B
band xxx DNA_M
14q32.1 ddxdd.d DNA_E
. . NE

Within Xxxx NE
this xxx NE
region xxx NE
we xx NE
have xxx NE
identified xxx NE
a x NE
gene xxx NE
coding xxx NE
for xxx NE
a x NE
1.3-kb d.d-xx RNA_B
transcript xxx RNA_E
, , NE
expressed xxx NE
only xxx NE
in xx NE
restricted xxx NE
subsets xxx NE
of xx NE
cells xxx NE
within xxx NE
the xxx NE
lymphoid xxx cell_type_B
lineage xxx cell_type_E
and xxx NE
expressed xxx NE
at xx NE
high xxx NE
levels xxx NE
in xx NE
leukemic xxx cell_type_B
cells xxx cell_type_E
carrying xxx NE
a x NE
t(14;14)(q11;q32) x(dd;dd)(xdd;xdd) DNA_B
chromosome xxx DNA_M
translocation xxx DNA_E
or xx NE
a x NE
inv(14)(q11;q32) xxx(dd)(xdd;xdd) DNA_B
chromosome xxx DNA_M
inversion xxx DNA_E
. . NE

The Xxx NE
cognate xxx DNA_B
cDNA xXXX DNA_M
sequence xxx DNA_E
reveals xxx NE
an xx NE
open xxx DNA_B
reading xxx DNA_M
frame xxx DNA_E
of xx NE
342 ddd NE
nt xx NE
encoding xxx NE
a x NE
protein xxx protein_B
of xx protein_M
14 dd protein_M
kDa xXx protein_E
. . NE

The Xxx NE
TCL1 XXXd DNA_B
gene xxx DNA_E
sequence xxx NE
, , NE
which xxx NE
, , NE
to xx NE
our xxx NE
knowledge xxx NE
, , NE
shows xxx NE
no xx NE
sequence xxx NE
homology xxx NE
with xxx NE
other xxx NE
human xxx DNA_B
genes xxx DNA_E
, , NE
is xx NE
preferentially xxx NE
expressed xxx NE
early xxx NE
in xx NE
T-lymphocyte X-xxx cell_type_B
and xxx cell_type_M
B-lymphocyte X-xxx cell_type_E

Identification Xxxx NE
of xx NE
a x NE
region xxx NE
which xxx NE
directs xxx NE
the xxx NE
monocytic xxx NE
activity xxx NE
of xx NE
the xxx NE
colony-stimulating xxx-xxx NE
factor xxx NE
1 d NE
( ( NE
macrophage xxx NE
colony-stimulating xxx-xxx NE
factor xxx NE
) ) NE
receptor xxx NE
promoter xxx NE
and xxx NE
binds xxx NE
PEBP2/CBF XXXXd/XXX NE
( ( NE
AML1 XXXd NE
) ) NE
. . NE

The Xxx NE
receptor xxx NE
for xxx NE
the xxx NE
macrophage xxx protein_B
colony-stimulating xxx-xxx protein_M
factor xxx protein_E
(or (xx NE
colony-stimulating xxx-xxx protein_B
factor xxx protein_M
1 d protein_E
[ [ NE
CSF-1 XXX-d protein
]) ]) NE
is xx NE
expressed xxx NE
from xxx NE
different xxx NE
promoters xxx NE
in xx NE
monocytic xxx cell_type_B
cells xxx cell_type_E
and xxx NE
placental xxx cell_type_B
trophoblasts xxx cell_type_E
. . NE

We Xx NE
have xxx NE
demonstrated xxx NE
that xxx NE
the xxx NE
monocyte-specific xxx-xxx NE
expression xxx NE
of xx NE
the xxx NE
CSF-1 XXX-d protein_B
receptor xxx protein_E
is xx NE
regulated xxx NE
at xx NE
the xxx NE
level xxx NE
of xx NE
transcription xxx NE
by xx NE
a x NE
tissue-specific xxx-xxx DNA_B
promoter xxx DNA_E
whose xxx NE
activity xxx NE
is xx NE
stimulated xxx NE
by xx NE
the xxx NE
monocyte/B-cell-specific xxx/X-xxx-xxx protein_B
transcription xxx protein_M
factor xxx protein_E
PU.1 XX.d protein
(D.-E.Zhang (X.-X.Xxxx NE
, , NE
C.J.Hetherington X.X.Xxxx NE
, , NE
H.-M.Chen X.-X.Xxxx NE
, , NE
and xxx NE
D.G.Tenen X.X.Xxxx NE
, , NE
Mol.Cell Xxx.Xxxx NE
. . NE
Biol.14:373-381 Xxxx.dd:ddd-ddd NE
, , NE
1994) dddd) NE
. . NE

Here Xxxx NE
we xx NE
report xxx NE
that xxx NE
the xxx NE
tissue xxx NE
specificity xxx NE
of xx NE
this xxx NE
promoter xxx DNA
is xx NE
also xxx NE
mediated xxx NE
by xx NE
sequences xxx NE
in xx NE
a x NE
region xxx DNA_B
II XX DNA_E
(bp (xx NE
-88 -dd NE
to xx NE
- - NE
59) dd) NE
, , NE
which xxx NE
lies xxx NE
10 dd DNA_B
bp xx DNA_M
upstream xxx DNA_E
from xxx NE
the xxx NE
PU.1 XX.d NE
-binding -xxx NE
site xxx NE
. . NE

When Xxxx NE
analyzed xxx NE
by xx NE
DNase XXxxx NE
footprinting xxx NE
, , NE
region xxx DNA_B
II XX DNA_E
was xxx NE
protected xxx NE
preferentially xxx NE
in xx NE
monocytic xxx cell_type_B
cells xxx cell_type_E
. . NE

Electrophoretic Xxxx NE
mobility xxx NE
shift xxx NE
assays xxx NE
confirmed xxx NE
that xxx NE
region xxx DNA_B
II XX DNA_E
interacts xxx NE
specifically xxx NE
with xxx NE
nuclear xxx protein_B
proteins xxx protein_E
from xxx NE
monocytic xxx cell_type_B
cells xxx cell_type_E
. . NE

Two Xxx NE
gel xxx NE
shift xxx NE
complexes xxx NE
( ( NE
Mono Xxxx NE
A X NE
and xxx NE
Mono Xxxx NE
B X NE
) ) NE
were xxx NE
formed xxx NE
with xxx NE
separate xxx NE
sequence xxx NE
elements xxx NE
within xxx NE
this xxx NE
region xxx NE
. . NE

Competition Xxxx NE
and xxx NE
supershift xxx NE
experiments xxx NE
indicate xxx NE
that xxx NE
Mono Xxxx NE
B X NE
contains xxx NE
a x NE
member xxx NE
of xx NE
the xxx NE
polyomavirus xxx NE
enhancer-binding xxx-xxx NE
protein xxx NE
2/core-binding d/xxx-xxx NE
factor xxx NE
( ( NE
PEBP2/CBF XXXXd/XXX NE
) ) NE
family xxx NE
, , NE
which xxx NE
includes xxx NE
the xxx NE
AML1 XXXd NE
gene xxx NE
product xxx NE
, , NE
while xxx NE
Mono Xxxx NE
A X NE
is xx NE
a x NE
distinct xxx NE
complex xxx NE
preferentially xxx NE
expressed xxx NE
in xx NE
monocytic xxx NE
cells xxx NE
. . NE

Promoter Xxxx DNA_B
constructs xxx DNA_E
with xxx NE
mutations xxx NE
in xx NE
these xxx NE
sequence xxx NE
elements xxx NE
were xxx NE
no xx NE
longer xxx NE
expressed xxx NE
specifically xxx NE
in xx NE
monocytes xxx cell_type
. . NE

Furthermore Xxxx NE
, , NE
multimerized xxx DNA_B
region xxx DNA_M
II XX DNA_M
sequence xxx DNA_M
elements xxx DNA_E
enhanced xxx NE
the xxx NE
activity xxx NE
of xx NE
a x NE
heterologous xxx DNA_B
thymidine xxx DNA_M
kinase xxx DNA_M
promoter xxx DNA_E
in xx NE
monocytic xxx cell_type_B
cells xxx cell_type_E
but xxx NE
not xxx NE
other xxx NE
cell xxx NE
types xxx NE
tested xxx NE
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
the xxx NE
monocyte/B-cell-specific xxx/X-xxx-xxx protein_B
transcription xxx protein_M
factor xxx protein_E
PU.1 XX.d NE
and xxx NE
the xxx NE
Mono Xxxx protein_B
A X protein_M
protein xxx protein_M
complex xxx protein_M
and xxx protein_M
Mono Xxxx protein_M
B X protein_M
protein xxx protein_M
complex xxx protein_E
protein xxx NE
complexes xxx NE
act xxx NE
in xx NE
concert xxx NE
to xx NE
regulate xxx NE
monocyte-specific xxx-xxx NE
transcription xxx NE
of xx NE
the xxx NE
CSF-1 XXX-d protein_B
receptor xxx protein_E
. . NE

Pyrrolidine Xxxx NE
dithiocarbamate xxx NE
, , NE
a x NE
potent xxx NE
inhibitor xxx NE
of xx NE
nuclear xxx protein_B
factor xxx protein_M
kappa xxx protein_M
B X protein_E
( ( NE
NF-kappa XX-xxx protein_B
B X protein_E
) ) NE
activation xxx NE
, , NE
prevents xxx NE
apoptosis xxx NE
in xx NE
human xxx NE
promyelocytic xxx cell_line_B
leukemia xxx cell_line_M
HL-60 XX-dd cell_line_M
cells xxx cell_line_E
and xxx NE
thymocytes xxx cell_type
. . NE

We Xx NE
examined xxx NE
the xxx NE
effect xxx NE
of xx NE
pyrrolidine xxx NE
dithiocarbamate xxx NE
( ( NE
PDTC XXXX NE
) ) NE
, , NE
which xxx NE
potently xxx NE
blocks xxx NE
the xxx NE
activation xxx NE
of xx NE
nuclear xxx protein_B
factor xxx protein_M
kappa xxx protein_M
B X protein_E
( ( NE
NF-kappa XX-xxx protein_B
B X protein_E
) ) NE
, , NE
on xx NE
the xxx NE
induction xxx NE
of xx NE
apoptosis xxx NE
by xx NE
a x NE
variety xxx NE
of xx NE
agents xxx NE
. . NE

Treatment Xxxx NE
of xx NE
a x NE
human xxx cell_line_B
promyelocytic xxx cell_line_M
leukemia xxx cell_line_M
cell xxx cell_line_M
line xxx cell_line_E
, , NE
HL-60 XX-dd cell_line
, , NE
with xxx NE
10 dd NE
micrograms/mL xxx/xX NE
etoposide xxx NE
or xx NE
2 d NE
microM xxxX NE
1-beta-D-arabinofuranosylcytosine d-xxx-X-xxx NE
induced xxx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
within xxx NE
1 d NE
hr xx NE
and xxx NE
subsequently xxx NE
caused xxx NE
apoptosis xxx NE
within xxx NE
3-4 d-d NE
hr xx NE
. . NE

The Xxx NE
simultaneous xxx NE
addition xxx NE
of xx NE
50-500 dd-ddd NE
microM xxxX NE
PDTC XXXX NE
with xxx NE
these xxx NE
agents xxx NE
blocked xxx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
and xxx NE
completely xxx NE
abrogated xxx NE
both xxx NE
morphologically xxx NE
apoptotic xxx NE
changes xxx NE
and xxx NE
internucleosomal xxx NE
DNA XXX NE
fragmentation xxx NE
for xxx NE
up xx NE
to xx NE
6 d NE
hr xx NE
. . NE

However Xxxx NE
, , NE
PDTC XXXX NE
failed xxx NE
to xx NE
inhibit xxx NE
the xxx NE
endonuclease xxx NE
activity xxx NE
contained xxx NE
in xx NE
the xxx NE
whole xxx NE
cell xxx NE
lysates xxx NE
. . NE

The Xxx NE
inhibitory xxx NE
effect xxx NE
of xx NE
PDTC XXXX NE
was xxx NE
also xxx NE
observed xxx NE
in xx NE
etoposide xxx NE
-and -xxx NE
dexamethasone-induced xxx-xxx NE
apoptosis xxx NE
in xx NE
human xxx cell_type_B
thymocytes xxx cell_type_E
at xx NE
a x NE
concentration xxx NE
of xx NE
1-10 d-dd NE
microM xxxX NE
. . NE

Since Xxxx NE
PDTC XXXX NE
has xxx NE
both xxx NE
antioxidant xxx NE
and xxx NE
metal-ion xxx-xxx NE
chelating xxx NE
activities xxx NE
, , NE
we xx NE
tested xxx NE
the xxx NE
effects xxx NE
of xx NE
N-acetyl-L-cysteine X-xxx-X-xxx NE
( ( NE
NAC XXX NE
) ) NE
( ( NE
antioxidant xxx NE
) ) NE
or xx NE
o-phenanthroline x-xxx NE
( ( NE
OP XX NE
) ) NE
( ( NE
metal-ion xxx-xxx NE
chelator xxx NE
) ) NE
on xx NE
the xxx NE
induction xxx NE
of xx NE
apoptosis xxx NE
. . NE

Pretreatment Xxxx NE
of xx NE
HL-60 XX-dd NE
cells xxx NE
or xx NE
thymocytes xxx cell_type
with xxx NE
100-500 ddd-ddd NE
microM xxxX NE
OP XX NE
for xxx NE
2 d NE
hr xx NE
, , NE
but xxx NE
not xxx NE
10-60 dd-dd NE
mM xX NE
NAC XXX NE
, , NE
suppressed xxx NE
subsequent xxx NE
occurrence xxx NE
of xx NE
apoptosis xxx NE
induced xxx NE
by xx NE
etoposide xxx NE
. . NE

These Xxxx NE
results xxx NE
suggest xxx NE
that xxx NE
the xxx NE
activation xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
plays xxx NE
an xx NE
important xxx NE
role xxx NE
in xx NE
the xxx NE
apoptotic xxx NE
process xxx NE
of xx NE
human xxx cell_type_B
hematopoietic xxx cell_type_M
cells xxx cell_type_E
. . NE

Overexpression Xxxx NE
of xx NE
protein xxx NE
kinase xxx NE
C X NE
-zeta -xxx NE
stimulates xxx NE
leukemic xxx NE
cell xxx NE
differentiation xxx NE
. . NE

A X NE
function xxx NE
for xxx NE
protein xxx NE
kinase xxx NE
C X NE
-zeta -xxx NE
( ( NE
PKC XXX NE
-zeta -xxx NE
) ) NE
, , NE
a x NE
member xxx NE
of xx NE
the xxx NE
phorbol xxx NE
ester xxx NE
nonresponsive xxx NE
atypical xxx NE
protein xxx NE
kinase xxx NE
C X NE
subfamily xxx NE
, , NE
in xx NE
modulating xxx NE
differentiation xxx NE
was xxx NE
examined xxx NE
in xx NE
the xxx NE
leukemic xxx NE
U937 Xddd NE
cell xxx NE
. . NE

Transfected Xxxx NE
U937 Xddd cell_line_B
cells xxx cell_line_E
stably xxx NE
overexpressing xxx NE
PKC-zeta XXX-xxx protein
displayed xxx NE
a x NE
longer xxx NE
doubling xxx NE
time xxx NE
, , NE
lower xxx NE
saturation xxx NE
density xxx NE
at xx NE
confluency xxx NE
, , NE
and xxx NE
an xx NE
increase xxx NE
in xx NE
adherence xxx NE
to xx NE
plastic xxx NE
as xx NE
compared xxx NE
to xx NE
control xxx cell_line_B
cells xxx cell_line_E
. . NE

PKC-zeta XXX-xxx cell_line_B
cells xxx cell_line_E
expressed xxx NE
a x NE
more xxx NE
differentiated xxx NE
phenotype xxx NE
as xx NE
assessed xxx NE
by xx NE
changes xxx NE
in xx NE
morphology xxx NE
, , NE
surface xxx NE
antigen xxx NE
expression xxx NE
, , NE
and xxx NE
lysosomal xxx NE
enzyme xxx NE
activities xxx NE
and xxx NE
were xxx NE
distinct xxx NE
from xxx NE
parental xxx NE
U937 Xddd NE
cells xxx NE
stimulated xxx NE
to xx NE
differentiate xxx NE
by xx NE
exposure xxx NE
to xx NE
phorbol xxx NE
esters xxx NE
. . NE

In Xx NE
contrast xxx NE
to xx NE
parental xxx NE
U937 Xddd cell_line_B
cells xxx cell_line_E
, , NE
PKC-zeta XXX-xxx cell_line_B
cells xxx cell_line_E
constitutively xxx NE
expressed xxx NE
mRNA xXXX RNA_B
transcripts xxx RNA_E
for xxx NE
c-jun x-xxx DNA
and xxx NE
a x NE
low xxx NE
mobility xxx NE
AP-1 XX-d NE
binding xxx NE
activity xxx NE
. . NE

Thus Xxxx NE
, , NE
PKC-zeta XXX-xxx protein
overexpression xxx NE
stimulates xxx NE
a x NE
type xxx NE
of xx NE
phenotypic xxx NE
differentiation xxx NE
that xxx NE
differs xxx NE
significantly xxx NE
from xxx NE
maturation xxx NE
occurring xxx NE
upon xxx NE
activation xxx NE
of xx NE
other xxx NE
PKC XXX protein_B
subfamilies xxx protein_E
induced xxx NE
by xx NE
phorbol xxx NE
ester xxx NE
treatment xxx NE
. . NE

Increased Xxxx NE
expression xxx NE
of xx NE
the xxx NE
c-jun x-xxx DNA
protooncogene xxx NE
and xxx NE
an xx NE
increase xxx NE
in xx NE
AP-1 XX-d NE
binding xxx NE
activity xxx NE
in xx NE
PKC-zeta XXX-xxx cell_line_B
cells xxx cell_line_E
provides xxx NE
a x NE
potential xxx NE
mechanism xxx NE
for xxx NE
explaining xxx NE
the xxx NE
altered xxx NE
differentiation xxx NE
status xxx NE
of xx NE
this xxx NE
cell xxx NE
. . NE

A X NE
family xxx NE
of xx NE
serine xxx protein_B
proteases xxx protein_E
expressed xxx NE
exclusively xxx NE
in xx NE
myelo- xxx- NE
monocytic xxx cell_type_B
cells xxx cell_type_E
specifically xxx NE
processes xxx NE
the xxx NE
nuclear xxx protein_B
factor-kappa xxx-xxx protein_M
B X protein_M
subunit xxx protein_M
p65 xdd protein_E
in xx NE
vitro xxx NE
and xxx NE
may xxx NE
impair xxx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
replication xxx NE
in xx NE
these xxx NE
cells xxx NE
. . NE

Two Xxx NE
groups xxx NE
of xx NE
U937 Xddd cell_line_B
promonocytic xxx cell_line_M
cells xxx cell_line_E
were xxx NE
obtained xxx NE
by xx NE
limiting xxx NE
dilution xxx NE
cloning xxx NE
which xxx NE
differed xxx NE
strikingly xxx NE
in xx NE
their xxx NE
ability xxx NE
to xx NE
support xxx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
1 d NE
( ( NE
HIV-1 XXX-d NE
) ) NE
replication xxx NE
. . NE

"Plus" "Xxxx" cell_line_B
clones xxx cell_line_E
replicated xxx NE
the xxx NE
virus xxx NE
efficiently xxx NE
, , NE
whereas xxx NE
"minus" "xxx" cell_line_B
clones xxx cell_line_E
did xxx NE
not xxx NE
. . NE

We Xx NE
examined xxx NE
these xxx NE
clones xxx NE
for xxx NE
differences xxx NE
in xx NE
nuclear xxx NE
factor xxx NE
(NF)-kappa (XX)-xxx NE
B X NE
activity xxx NE
which xxx NE
might xxx NE
account xxx NE
for xxx NE
the xxx NE
observed xxx NE
phenomenon xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
plus xxx cell_line_B
clones xxx cell_line_E
liberated xxx NE
the xxx NE
classical xxx NE
p50-p65 xdd-xdd protein_B
complex xxx protein_E
from xxx NE
cytoplasmic xxx NE
pools xxx NE
, , NE
whereas xxx NE
minus xxx cell_line_B
clones xxx cell_line_E
produced xxx NE
an xx NE
apparently xxx NE
novel xxx NE
, , NE
faster-migrating xxx-xxx protein_B
complex xxx protein_E
, , NE
as xx NE
judged xxx NE
by xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assays xxx NE
. . NE

It Xx NE
is xx NE
surprising xxx NE
that xxx NE
the xxx NE
faster-migrating xxx-xxx protein_B
complex xxx protein_E
was xxx NE
composed xxx NE
also xxx NE
of xx NE
p50 xdd protein
and xxx NE
p65 xdd protein
. . NE

However Xxxx NE
, , NE
the xxx NE
p65 xdd protein_B
subunit xxx protein_E
was xxx NE
COOH-terminally XXXX-xxx NE
truncated xxx NE
, , NE
as xx NE
shown xxx NE
by xx NE
immunoprecipitation xxx NE
. . NE

The Xxx NE
truncation xxx NE
resulted xxx NE
from xxx NE
limited xxx NE
proteolysis xxx NE
of xx NE
p65 xdd protein
during xxx NE
cellular xxx NE
extraction xxx NE
which xxx NE
released xxx NE
particular xxx NE
lysosomal xxx protein_B
serine xxx protein_M
proteases xxx protein_E
, , NE
such xxx NE
as xx NE
elastase xxx protein
, , NE
cathepsin xxx protein_B
G X protein_E
, , NE
and xxx NE
proteinase xxx protein_B
3 d protein_E
. . NE

These Xxxx NE
specific xxx NE
proteases xxx NE
are xxx NE
coordinately xxx NE
expressed xxx NE
and xxx NE
were xxx NE
present xxx NE
exclusively xxx NE
in xx NE
the xxx NE
minus xxx cell_line_B
U937 Xddd cell_line_M
clones xxx cell_line_E
, , NE
but xxx NE
not xxx NE
in xx NE
the xxx NE
plus xxx cell_line_B
clones xxx cell_line_E
, , NE
as xx NE
demonstrated xxx NE
in xx NE
the xxx NE
case xxx NE
of xx NE
cathepsin xxx protein_B
G X protein_E
. . NE

In Xx NE
addition xxx NE
, , NE
these xxx NE
proteases xxx NE
were xxx NE
detected xxx NE
in xx NE
certain xxx NE
subclones xxx NE
of xx NE
THP-1 XXX-d cell_line
and xxx NE
HL-60 XX-dd cell_line_B
cells xxx cell_line_E
and xxx NE
in xx NE
primary xxx NE
monocytes xxx cell_type
, , NE
in xx NE
each xxx NE
case xxx NE
correlating xxx NE
with xxx NE
the xxx NE
truncated xxx NE
from xxx NE
of xx NE
p65 xdd protein
. . NE

We Xx NE
demonstrate xxx NE
in xx NE
vitro xxx NE
cleavage xxx NE
of xx NE
p65 xdd protein
by xx NE
purified xxx NE
elastase xxx protein
and xxx NE
cathepsin xxx protein_B
G X protein_E
. . NE

It Xx NE
is xx NE
possible xxx NE
that xxx NE
particular xxx NE
serine xxx protein_B
proteases xxx protein_E
may xxx NE
have xxx NE
inhibiting xxx NE
effects xxx NE
on xx NE
the xxx NE
replication xxx NE
of xx NE
HIV-1 XXX-d NE
in xx NE
myelo- xxx- NE
monocytic xxx NE
cells xxx NE
. . NE

The Xxx NE
data xxx NE
also xxx NE
demonstrate xxx NE
that xxx NE
special xxx NE
precautions xxx NE
must xxx NE
be xx NE
taken xxx NE
when xxx NE
making xxx NE
extracts xxx NE
from xxx NE
myelo- xxx- NE
monocytic xxx NE
cells xxx NE
. . NE

A X NE
germline xxx DNA_B
TaqI XxxX DNA_M
restriction xxx DNA_M
fragment xxx DNA_M
length xxx DNA_M
polymorphism xxx DNA_E
in xx NE
the xxx NE
progesterone xxx DNA_B
receptor xxx DNA_M
gene xxx DNA_E
in xx NE
ovarian xxx NE
carcinoma xxx NE
[see [xxx NE
comments] xxx] NE

Clinical Xxxx NE
outcome xxx NE
in xx NE
ovarian xxx NE
carcinoma xxx NE
is xx NE
predicted xxx NE
by xx NE
progesterone xxx NE
receptor xxx NE
status xxx NE
, , NE
indicating xxx NE
an xx NE
endocrine xxx NE
aspect xxx NE
to xx NE
this xxx NE
disease xxx NE
. . NE

Peripheral Xxxx DNA_B
leucocyte xxx DNA_M
genomic xxx DNA_M
DNAs XXXx DNA_E
were xxx NE
obtained xxx NE
from xxx NE
41 dd NE
patients xxx NE
with xxx NE
primary xxx NE
ovarian xxx NE
carcinoma xxx NE
and xxx NE
83 dd NE
controls xxx NE
from xxx NE
Ireland Xxxx NE
, , NE
as xx NE
well xxx NE
as xx NE
from xxx NE
26 dd NE
primary xxx NE
ovarian xxx NE
carcinoma xxx NE
patients xxx NE
and xxx NE
101 ddd NE
controls xxx NE
in xx NE
Germany Xxxx NE
. . NE

Southern Xxxx NE
analysis xxx NE
using xxx NE
a x NE
human xxx NE
progesterone xxx NE
receptor xxx NE
( ( NE
hPR xXX NE
) ) NE
cDNA xXXX NE
probe xxx NE
identified xxx NE
a x NE
germline xxx NE
TaqI XxxX NE
restriction xxx NE
fragment xxx NE
length xxx NE
polymorphism xxx NE
( ( NE
RFLP XXXX NE
) ) NE
defined xxx NE
by xx NE
two xxx NE
alleles xxx NE
: : NE
T1 Xd NE
, , NE
represented xxx NE
by xx NE
a x NE
2.7 d.d NE
kb xx NE
fragment xxx NE
; ; NE
and xxx NE
T2 Xd NE
, , NE
represented xxx NE
by xx NE
a x NE
1.9 d.d NE
kb xx NE
fragment xxx NE
and xxx NE
characterised xxx NE
by xx NE
an xx NE
additional xxx NE
TaqI XxxX NE
restriction xxx NE
site xxx NE
with xxx NE
respect xxx NE
to xx NE
T1 Xd NE
. . NE

An Xx NE
over-representation xxx-xxx NE
of xx NE
T2 Xd DNA
in xx NE
ovarian xxx NE
cancer xxx NE
patients xxx NE
compared xxx NE
with xxx NE
controls xxx NE
in xx NE
the xxx NE
pooled xxx NE
Irish/German Xxxx/Xxxx NE
population xxx NE
(P (X NE
< < NE
0.025) d.ddd) NE
was xxx NE
observed xxx NE
. . NE

A X NE
difference xxx NE
(P (X NE
< < NE
0.02) d.dd) NE
in xx NE
the xxx NE
distribution xxx NE
of xx NE
the xxx NE
RFLP XXXX DNA
genotypes xxx NE
between xxx NE
Irish Xxxx NE
and xxx NE
German Xxxx NE
control xxx NE
populations xxx NE
was xxx NE
also xxx NE
observed xxx NE
. . NE

The Xxx NE
allele xxx NE
distributions xxx NE
could xxx NE
not xxx NE
be xx NE
shown xxx NE
to xx NE
differ xxx NE
significantly xxx NE
from xxx NE
Hardy-Weinberg Xxxx-Xxxx NE
distribution xxx NE
in xx NE
any xxx NE
subgroup xxx NE
. . NE

Using Xxxx NE
hPR xXX DNA_B
cDNA xXXX DNA_M
region-specific xxx-xxx DNA_M
probes xxx DNA_E
, , NE
the xxx NE
extra xxx NE
TaqI XxxX NE
restriction xxx NE
site xxx NE
was xxx NE
mapped xxx NE
to xx NE
intron xxx DNA_B
G X DNA_E
of xx NE
the xxx NE
hPR xXX DNA_B
gene xxx DNA_E
. . NE

OBF-1 XXX-d protein
, , NE
a x NE
novel xxx protein_B
B X protein_M
cell-specific xxx-xxx protein_M
coactivator xxx protein_E
that xxx NE
stimulates xxx NE
immunoglobulin xxx NE
promoter xxx NE
activity xxx NE
through xxx NE
association xxx NE
with xxx NE
octamer-binding xxx-xxx protein_B
proteins xxx protein_E
. . NE

Recent Xxxx NE
biochemical xxx NE
and xxx NE
genetic xxx NE
studies xxx NE
indicate xxx NE
that xxx NE
in xx NE
addition xxx NE
to xx NE
the xxx NE
octamer-binding xxx-xxx protein_B
proteins xxx protein_E
Oct-1 Xxx-d protein
and xxx NE
Oct-2 Xxx-d protein
, , NE
other xxx NE
B X protein_B
cell xxx protein_M
components xxx protein_E
are xxx NE
required xxx NE
for xxx NE
lymphoid-restricted, xxx-xxx, NE
octamer xxx NE
site-mediated xxx-xxx NE
immunoglobulin xxx NE
gene xxx NE
promoter xxx NE
activity xxx NE
. . NE

Using Xxxx NE
a x NE
genetic xxx NE
screen xxx NE
in xx NE
yeast xxx NE
, , NE
we xx NE
have xxx NE
isolated xxx NE
B X DNA_B
cell-derived xxx-xxx DNA_M
cDNAs xXXXx DNA_E
encoding xxx NE
Oct-binding Xxx-xxx protein_B
factor xxx protein_M
1 d protein_E
( ( NE
OBF-1 XXX-d protein
) ) NE
, , NE
a x NE
novel xxx NE
protein xxx NE
that xxx NE
specifically xxx NE
associates xxx NE
with xxx NE
Oct-1 Xxx-d protein
and xxx NE
Oct-2 Xxx-d protein
. . NE

Biochemical Xxxx NE
studies xxx NE
demonstrate xxx NE
that xxx NE
OBF-1 XXX-d protein
has xxx NE
no xx NE
intrinsic xxx NE
DNA-binding XXX-xxx NE
activity xxx NE
and xxx NE
recognizes xxx NE
the xxx NE
POU XXX protein_B
domains xxx protein_E
of xx NE
Oct-1 Xxx-d protein
and xxx NE
Oct-2 Xxx-d protein
, , NE
but xxx NE
not xxx NE
those xxx NE
of xx NE
Oct-4 Xxx-d protein
and xxx NE
Oct-6 Xxx-d protein
. . NE

The Xxx NE
OBF-1 XXX-d RNA_B
mRNA xXXX RNA_E
is xx NE
expressed xxx NE
in xx NE
a x NE
highly xxx NE
cell-specific xxx-xxx NE
manner xxx NE
, , NE
being xxx NE
most xxx NE
abundant xxx NE
in xx NE
B X cell_type_B
cells xxx cell_type_E
and xxx NE
essentially xxx NE
absent xxx NE
in xx NE
most xxx NE
of xx NE
the xxx NE
other xxx NE
cells xxx NE
or xx NE
tissues xxx NE
tested xxx NE
. . NE

Furthermore Xxxx NE
, , NE
expression xxx NE
of xx NE
OBF-1 XXX-d protein
in xx NE
HeLa XxXx cell_line_B
cells xxx cell_line_E
selectively xxx NE
stimulates xxx NE
the xxx NE
activity xxx NE
of xx NE
a x NE
natural xxx NE
immunoglobulin xxx DNA_B
promoter xxx DNA_E
in xx NE
an xx NE
octamer xxx NE
site xxx NE
-dependent -xxx NE
manner xxx NE
. . NE

Thus Xxxx NE
, , NE
OBF-1 XXX-d protein
has xxx NE
all xxx NE
the xxx NE
properties xxx NE
expected xxx NE
for xxx NE
a x NE
B X protein_B
cell-specific xxx-xxx protein_M
transcriptional xxx protein_M
coactivator xxx protein_M
protein xxx protein_E
. . NE

Modulation Xxxx NE
of xx NE
transcription xxx NE
factor xxx NE
NF XX NE
kappa xxx NE
B X NE
activity xxx NE
by xx NE
intracellular xxx NE
glutathione xxx NE
levels xxx NE
and xxx NE
by xx NE
variations xxx NE
of xx NE
the xxx NE
extracellular xxx NE
cysteine xxx NE
supply xxx NE
. . NE

HIV XXX NE
-infected -xxx NE
individuals xxx NE
and xxx NE
SIV XXX NE
-infected -xxx NE
rhesus xxx NE
macaques xxx NE
have xxx NE
, , NE
on xx NE
the xxx NE
average xxx NE
, , NE
decreased xxx NE
plasma xxx NE
cysteine xxx NE
and xxx NE
cystine xxx NE
concentrations xxx NE
and xxx NE
decreased xxx NE
intracellular xxx NE
glutathione xxx NE
levels xxx NE
. . NE

We Xx NE
now xxx NE
show xxx NE
that xxx NE
a x NE
depletion xxx NE
of xx NE
intracellular xxx NE
glutathione xxx NE
in xx NE
a x NE
human xxx cell_line_B
T X cell_line_M
cell xxx cell_line_M
line xxx cell_line_E
( ( NE
Molt-4 Xxxx-d cell_line
) ) NE
inhibits xxx NE
the xxx NE
activation xxx NE
and xxx NE
nuclear xxx NE
translocation xxx NE
of xx NE
the xxx NE
transcription xxx protein_B
factor xxx protein_M
NF XX protein_M
kappa xxx protein_M
B X protein_E
, , NE
whereas xxx NE
incubation xxx NE
with xxx NE
increasing xxx NE
extracellular xxx NE
concentrations xxx NE
of xx NE
cysteine xxx NE
inhibits xxx NE
the xxx NE
DNA-binding XXX-xxx NE
and xxx NE
transactivating xxx NE
activity xxx NE
of xx NE
NF XX protein_B
kappa xxx protein_M
B X protein_E
. . NE

Because Xxxx NE
inhibition xxx NE
of xx NE
DNA-binding XXX-xxx NE
activity xxx NE
is xx NE
associated xxx NE
with xxx NE
increasing xxx NE
intracellular xxx NE
glutathione xxx NE
disulfide xxx NE
levels xxx NE
and xxx NE
GSSG XXXX protein
can xxx NE
be xx NE
shown xxx NE
to xx NE
inhibit xxx NE
the xxx NE
DNA-binding XXX-xxx NE
activity xxx NE
directly xxx NE
in xx NE
cell-free xxx-xxx NE
systems xxx NE
, , NE
our xxx NE
studies xxx NE
suggest xxx NE
that xxx NE
GSSG XXXX protein
is xx NE
a x NE
physiologically xxx NE
relevant xxx NE
inhibitor xxx NE
in xx NE
intact xxx cell_type_B
cells xxx cell_type_E
also xxx NE
. . NE

NF XX protein_B
kappa xxx protein_M
B X protein_E
controls xxx NE
many xxx NE
immunologically xxx DNA_B
important xxx DNA_M
genes xxx DNA_E
, , NE
so xx NE
our xxx NE
studies xxx NE
suggest xxx NE
that xxx NE
the xxx NE
immune xxx NE
system xxx NE
may xxx NE
be xx NE
sensitive xxx NE
not xxx NE
only xxx NE
against xxx NE
a x NE
cysteine xxx NE
and xxx NE
glutathione xxx NE
deficiency xxx NE
but xxx NE
also xxx NE
against xxx NE
an xx NE
excess xxx NE
of xx NE
cysteine xxx NE
. . NE

Two Xxx NE
distinct xxx NE
signalling xxx NE
pathways xxx NE
are xxx NE
involved xxx NE
in xx NE
the xxx NE
control xxx NE
of xx NE
the xxx NE
biphasic xxx NE
junB xxxX NE
transcription xxx NE
induced xxx NE
by xx NE
interleukin-6 xxx-d protein
in xx NE
the xxx NE
B X cell_line_B
cell xxx cell_line_M
hybridoma xxx cell_line_M
7TD1 dXXd cell_line_E
. . NE

We Xx NE
have xxx NE
measured xxx NE
the xxx NE
level xxx NE
of xx NE
junB xxxX RNA_B
mRNA xXXX RNA_E
in xx NE
the xxx NE
B X cell_line_B
hybridoma xxx cell_line_M
cell xxx cell_line_M
line xxx cell_line_M
7TD1 dXXd cell_line_E
, , NE
under xxx NE
interleukin-6 xxx-d protein
( ( NE
IL-6 XX-d protein
) ) NE
stimulation xxx NE
. . NE

IL-6 XX-d protein
increases xxx NE
junB xxxX RNA_B
mRNA xXXX RNA_E
in xx NE
a x NE
biphasic xxx NE
fashion xxx NE
. . NE

The Xxx NE
first xxx NE
early-induced xxx-xxx NE
peak xxx NE
was xxx NE
transient xxx NE
and xxx NE
likely xxx NE
corresponds xxx NE
to xx NE
the xxx NE
well xxx NE
documented xxx NE
typical xxx NE
junB xxxX RNA_B
mRNA xXXX RNA_E
, , NE
stimulated xxx NE
in xx NE
response xxx NE
to xx NE
numerous xxx NE
growth xxx protein_B
factors xxx protein_E
, , NE
including xxx NE
IL-6 XX-d protein
. . NE

At Xx NE
variance xxx NE
, , NE
the xxx NE
second xxx NE
peak xxx NE
which xxx NE
has xxx NE
never xxx NE
been xxx NE
reported xxx NE
previously xxx NE
, , NE
lasted xxx NE
several xxx NE
hours xxx NE
. . NE

As Xx NE
a x NE
consequence xxx NE
of xx NE
its xxx NE
effect xxx NE
on xx NE
junB xxxX RNA_B
mRNA xXXX RNA_E
, , NE
IL-6 XX-d protein
stimulated xxx NE
, , NE
in xx NE
a x NE
biphasic xxx NE
fashion xxx NE
, , NE
the xxx NE
nuclear xxx NE
accumulation xxx NE
of xx NE
the xxx NE
JunB XxxX protein_B
protein xxx protein_E
. . NE

In Xx NE
this xxx NE
study xxx NE
, , NE
we xx NE
demonstrated xxx NE
that xxx NE
IL-6 XX-d protein
regulation xxx NE
occurred xxx NE
exclusively xxx NE
at xx NE
the xxx NE
transcriptional xxx NE
level xxx NE
and xxx NE
that xxx NE
the xxx NE
bimodal xxx NE
increase xxx NE
of xx NE
junB xxxX RNA_B
mRNA xXXX RNA_E
and xxx NE
JunB XxxX protein_B
protein xxx protein_E
can xxx NE
be xx NE
accounted xxx NE
for xxx NE
by xx NE
a x NE
biphasic xxx NE
stimulation xxx NE
of xx NE
junB xxxX NE
transcription xxx NE
. . NE

Furthermore Xxxx NE
, , NE
our xxx NE
data xxx NE
point xxx NE
to xx NE
two xxx NE
major xxx NE
differences xxx NE
between xxx NE
the xxx NE
mechanism xxx NE
of xx NE
control xxx NE
of xx NE
the xxx NE
early xxx NE
and xxx NE
the xxx NE
late xxx NE
IL-6 XX-d NE
-induced -xxx NE
junB xxxX NE
transcription xxx NE
waves xxx NE
. . NE

First Xxxx NE
, , NE
cycloheximide xxx NE
strongly xxx NE
potentiated xxx NE
the xxx NE
transcription xxx NE
of xx NE
the xxx NE
second xxx NE
wave xxx NE
, , NE
whereas xxx NE
it xx NE
failed xxx NE
to xx NE
affect xxx NE
the xxx NE
early-induced xxx-xxx NE
burst xxx NE
. . NE

Second Xxxx NE
, , NE
tyrphostin xxx NE
, , NE
a x NE
tyrosine xxx NE
kinase xxx NE
inhibitor xxx NE
, , NE
impaired xxx NE
the xxx NE
expression xxx NE
of xx NE
the xxx NE
first xxx NE
but xxx NE
not xxx NE
the xxx NE
second xxx NE
junB xxxX NE
mRNA xXXX NE
peak xxx NE
. . NE

Conversely Xxxx NE
, , NE
genistein xxx NE
, , NE
another xxx NE
tyrosine xxx NE
kinase xxx NE
inhibitor xxx NE
, , NE
totally xxx NE
abolished xxx NE
the xxx NE
expression xxx NE
of xx NE
the xxx NE
second xxx NE
peak xxx NE
of xx NE
junB xxxX RNA_B
mRNA xXXX RNA_E
whereas xxx NE
it xx NE
did xxx NE
not xxx NE
affect xxx NE
the xxx NE
expression xxx NE
of xx NE
the xxx NE
first xxx NE
peak xxx NE
. . NE

Altogether Xxxx NE
these xxx NE
data xxx NE
indicate xxx NE
that xxx NE
, , NE
in xx NE
7TD1 dXXd cell_line_B
cells xxx cell_line_E
, , NE
IL-6 XX-d protein
controls xxx NE
junB xxxX NE
transcription xxx NE
in xx NE
a x NE
biphasic xxx NE
fashion xxx NE
by xx NE
means xxx NE
of xx NE
two xxx NE
separate xxx NE
transduction xxx NE
pathways xxx NE
. . NE

A X NE
newly xxx NE
established xxx NE
megakaryoblastic/erythroid xxx/xxx cell_line_B
cell xxx cell_line_M
line xxx cell_line_E
that xxx NE
differentiates xxx NE
to xx NE
red xxx cell_type_B
cells xxx cell_type_E
in xx NE
the xxx NE
presence xxx NE
of xx NE
erythropoietin xxx protein
and xxx NE
produces xxx NE
platelet-like xxx-xxx cell_type_B
particles xxx cell_type_E
. . NE

In Xx NE
August Xxxx NE
, , NE
1992 dddd NE
, , NE
we xx NE
established xxx NE
a x NE
leukemic xxx cell_line_B
cell xxx cell_line_M
line xxx cell_line_E
( ( NE
NS-Meg XX-Xxx cell_line
) ) NE
from xxx NE
a x NE
patient xxx NE
in xx NE
megakaryoblastic xxx NE
transformation xxx NE
of xx NE
Philadelphia Xxxx NE
chromosome-positive xxx-xxx NE
chronic xxx NE
myeloid xxx NE
leukemia xxx NE
. . NE

The Xxx NE
NS-Meg XX-Xxx cell_line_B
cells xxx cell_line_E
were xxx NE
positive xxx NE
for xxx NE
alpha-naphthyl xxx-xxx protein_B
acetate xxx protein_M
esterase xxx protein_E
and xxx NE
periodic xxx NE
acid-Schiff xxx-Xxxx NE
(PAS) (XXX) NE
staining xxx NE
and xxx NE
for xxx NE
surface xxx NE
CD4 XXd protein
, , NE
CD7 XXd protein
, , NE
CD13 XXdd protein
, , NE
CD34 XXdd protein
, , NE
CD41a XXddx protein
, , NE
and xxx NE
glycophorin xxx protein_B
A X protein_M
antigens xxx protein_E
. . NE

Ultrastructurally Xxxx NE
, , NE
the xxx NE
cells xxx NE
had xxx NE
alpha-granules xxx-xxx NE
, , NE
demarcation xxx NE
membranes xxx NE
, , NE
and xxx NE
platelet xxx NE
peroxidase xxx NE
activity xxx NE
. . NE

The Xxx NE
NS-Meg XX-Xxx cell_line_B
cells xxx cell_line_E
spontaneously xxx NE
produced xxx NE
platelet-like xxx-xxx cell_type_B
particles xxx cell_type_E
which xxx NE
contained xxx NE
alpha-granules xxx-xxx NE
, , NE
mitochondria xxx NE
and xxx NE
dense xxx NE
bodies xxx NE
, , NE
strongly xxx NE
suggesting xxx NE
platelet xxx NE
production xxx NE
. . NE

Erythropoietin Xxxx protein
( ( NE
Epo Xxx protein
) ) NE
, , NE
granulocyte/macrophage xxx/xxx protein_B
colony xxx protein_M
stimulating xxx protein_M
factor xxx protein_E
( ( NE
GM-CSF XX-XXX protein
) ) NE
, , NE
and xxx NE
interleukin xxx protein_B
3 d protein_E
( ( NE
IL-3 XX-d protein
) ) NE
promoted xxx NE
the xxx NE
growth xxx NE
of xx NE
NS-Meg XX-Xxx cell_line_B
cells xxx cell_line_E
. . NE

Phorbol-12-myristate-13-acetate Xxxx-dd-xxx-dd-xxx NE
increased xxx NE
the xxx NE
expression xxx NE
of xx NE
both xxx NE
CD41a XXddx protein
and xxx NE
CD61 XXdd NE
antigens xxx NE
. . NE

Ten-day Xxx-xxx NE
exposure xxx NE
to xx NE
Epo Xxx protein
induced xxx NE
mature xxx cell_type_B
erythroblasts xxx cell_type_E
and xxx NE
red xxx cell_type_B
cells xxx cell_type_E
. . NE

These Xxxx NE
benzidine-positive xxx-xxx cell_line_B
cells xxx cell_line_E
were xxx NE
positive xxx NE
for xxx NE
hemoglobin xxx NE
F X NE
staining xxx NE
. . NE

Untreated Xxxx NE
NS-Meg XX-Xxx cell_line_B
cells xxx cell_line_E
expressed xxx NE
mRNA xXXX RNA
for xxx NE
the xxx NE
Epo Xxx protein_B
receptor xxx protein_E
( ( NE
EpoR XxxX protein
) ) NE
, , NE
for xxx NE
GATA-1 XXXX-d protein
, , NE
and xxx NE
for xxx NE
alpha xxx DNA_B
1 d DNA_M
globin xxx DNA_M
gene xxx DNA_M
and xxx DNA_M
alpha xxx DNA_M
2 d DNA_M
globin xxx DNA_M
gene xxx DNA_M
and xxx DNA_M
gamma xxx DNA_M
globin xxx DNA_M
gene xxx DNA_E

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
NS-Meg XX-Xxx cell_line_B
cells xxx cell_line_E
undergo xxx NE
terminal xxx NE
differentiation xxx NE
of xx NE
both xxx NE
megakaryocytic xxx cell_type_B
lineage xxx cell_type_M
and xxx cell_type_M
erythroid xxx cell_type_M
lineage xxx cell_type_E

This Xxxx NE
cell xxx cell_line_B
line xxx cell_line_E
should xxx NE
be xx NE
a x NE
very xxx NE
useful xxx NE
tool xxx NE
for xxx NE
the xxx NE
investigation xxx NE
of xx NE
both xxx NE
megakaryocytic xxx NE
maturation xxx NE
and xxx NE
erythroid xxx NE
maturation xxx NE

Differential Xxxx NE
regulation xxx NE
of xx NE
proto-oncogenes xxx-xxx DNA
c-jun x-xxx DNA
and xxx NE
c-fos x-xxx DNA
in xx NE
T X cell_type_B
lymphocytes xxx cell_type_E
activated xxx NE
through xxx NE
CD28 XXdd protein
. . NE

The Xxx NE
T X protein_B
cell xxx protein_M
surface xxx protein_M
molecule xxx protein_E
CD28 XXdd protein
binds xxx NE
to xx NE
ligands xxx NE
on xx NE
accessory xxx cell_type_B
cells xxx cell_type_E
and xxx NE
APCs XXXx cell_type
, , NE
playing xxx NE
an xx NE
important xxx NE
costimulatory xxx NE
role xxx NE
in xx NE
the xxx NE
response xxx NE
of xx NE
T X cell_type_B
cells xxx cell_type_E
to xx NE
Ags Xxx protein
. . NE

Our Xxx NE
knowledge xxx NE
of xx NE
the xxx NE
intracellular xxx NE
signaling xxx NE
pathways xxx NE
coupled xxx NE
to xx NE
this xxx NE
receptor xxx NE
is xx NE
incomplete xxx NE
. . NE

In Xx NE
addition xxx NE
to xx NE
activation xxx NE
of xx NE
phospholipase xxx protein_B
C X protein_M
gamma xxx protein_M
1 d protein_E
, , NE
ligation xxx NE
of xx NE
this xxx NE
receptor xxx NE
also xxx NE
seems xxx NE
to xx NE
activate xxx NE
a x NE
calcium xxx NE
-independent -xxx NE
, , NE
CD28 XXdd NE
-specific -xxx NE
pathway xxx NE
. . NE

In Xx NE
this xxx NE
paper xxx NE
, , NE
we xx NE
report xxx NE
that xxx NE
cross-linking xxx-xxx NE
of xx NE
CD28 XXdd protein
(but (xxx NE
not xxx NE
CD2 XXd protein
, , NE
CD5 XXd protein
, , NE
LFA-1 XXX-d protein
, , NE
or xx NE
CD7 XXd protein
) ) NE
leads xxx NE
to xx NE
an xx NE
elevation xxx NE
of xx NE
c-jun x-xxx RNA_B
mRNA xXXX RNA_E
, , NE
with xxx NE
only xxx NE
minimal xxx NE
activation xxx NE
of xx NE
c-fos x-xxx NE
expression xxx NE
. . NE

CD28 XXdd NE
-dependent -xxx NE
induction xxx NE
of xx NE
c-jun x-xxx NE
expression xxx NE
requires xxx NE
protein xxx NE
tyrosine xxx NE
kinase xxx NE
activity xxx NE
, , NE
but xxx NE
does xxx NE
not xxx NE
depend xxx NE
on xx NE
activation xxx NE
of xx NE
a x NE
phorbol xxx NE
ester xxx NE
-responsive -xxx NE
protein xxx NE
kinase xxx NE
C X NE
or xx NE
elevation xxx NE
of xx NE
cytosolic xxx NE
calcium xxx NE
. . NE

Furthermore Xxxx NE
, , NE
CD28 XXdd NE
-dependent -xxx NE
elevation xxx NE
of xx NE
c-jun x-xxx NE
mRNA xXXX NE
does xxx NE
not xxx NE
appear xxx NE
to xx NE
be xx NE
mediated xxx NE
at xx NE
the xxx NE
level xxx NE
of xx NE
mRNA xXXX NE
stability xxx NE
. . NE

A X NE
mechanism xxx NE
is xx NE
suggested xxx NE
whereby xxx NE
expression xxx NE
of xx NE
c-jun x-xxx DNA
and xxx NE
junB xxxX DNA
, , NE
in xx NE
the xxx NE
absence xxx NE
of xx NE
members xxx NE
of xx NE
the xxx NE
fos xxx DNA_B
family xxx DNA_E
, , NE
can xxx NE
prevent xxx NE
inappropriate xxx NE
activation xxx NE
of xx NE
T X cell_type_B
cells xxx cell_type_E
caused xxx NE
by xx NE
ligation xxx NE
of xx NE
CD28 XXdd protein
in xx NE
the xxx NE
absence xxx NE
of xx NE
a x NE
specific xxx NE
antigenic xxx NE
stimulus xxx NE
. . NE

Enhanced Xxxx NE
responsiveness xxx NE
to xx NE
nuclear xxx protein_B
factor xxx protein_M
kappa xxx protein_M
B X protein_E
contributes xxx NE
to xx NE
the xxx NE
unique xxx NE
phenotype xxx NE
of xx NE
simian xxx NE
immunodeficiency xxx NE
virus xxx NE
variant xxx NE
SIVsmmPBj14 XXXxxxXXxdd NE
. . NE

Infection Xxxx NE
with xxx NE
a x NE
variant xxx NE
of xx NE
simian xxx NE
immunodeficiency xxx NE
virus xxx NE
, , NE
SIVsmmPBj14 XXXxxxXXxdd NE
, , NE
leads xxx NE
to xx NE
severe xxx NE
acute xxx NE
disease xxx NE
in xx NE
macaques xxx NE
. . NE

This Xxxx NE
study xxx NE
was xxx NE
designed xxx NE
to xx NE
investigate xxx NE
the xxx NE
functional xxx NE
significance xxx NE
of xx NE
previously xxx NE
described xxx NE
mutations xxx NE
in xx NE
the xxx NE
viral xxx DNA_B
long xxx DNA_M
terminal xxx DNA_M
repeat xxx DNA_E
( ( NE
LTR XXX DNA
) ) NE
and xxx NE
to xx NE
elucidate xxx NE
their xxx NE
contribution xxx NE
to xx NE
the xxx NE
unique xxx NE
phenotype xxx NE
of xx NE
SIVsmmPBj14 XXXxxxXXxdd NE
. . NE

LTR XXX NE
-directed -xxx NE
transcription xxx NE
was xxx NE
measured xxx NE
by xx NE
using xxx NE
luciferase xxx NE
reporter xxx NE
constructs xxx NE
that xxx NE
were xxx NE
transiently xxx NE
transfected xxx NE
into xxx NE
cultured xxx NE
cells xxx NE
. . NE

In Xx NE
a x NE
wide xxx NE
range xxx NE
of xx NE
cell xxx NE
types xxx NE
, , NE
the xxx NE
basal xxx NE
transcriptional xxx NE
activity xxx NE
of xx NE
the xxx NE
LTR XXX DNA
from xxx NE
SIVsmmPBj14 XXXxxxXXxdd NE
was xxx NE
found xxx NE
to xx NE
be xx NE
2- d- NE
to xx NE
4.5-fold d.d-xxx NE
higher xxx NE
than xxx NE
that xxx NE
of xx NE
an xx NE
LTR XXX DNA
from xxx NE
a x NE
non-acutely xxx-xxx NE
pathogenic xxx NE
strain xxx NE
. . NE

These Xxxx NE
LTRs XXXx DNA
differ xxx NE
by xx NE
five xxx NE
point xxx NE
mutations xxx NE
and xxx NE
a x NE
22-bp dd-xx DNA_B
duplication xxx DNA_E
in xx NE
SIVsmmPBj14 XXXxxxXXxdd NE
, , NE
which xxx NE
includes xxx NE
a x NE
nuclear xxx NE
factor xxx NE
kappa xxx NE
B X NE
( ( NE
NF XX NE
kappa xxx NE
B X NE
) ) NE
site xxx NE
. . NE

Transcriptional Xxxx NE
differences xxx NE
between xxx NE
these xxx NE
LTRs XXXx DNA
were xxx NE
further xxx NE
enhanced xxx NE
by xx NE
two- xxx- NE
to xx NE
threefold xxx NE
upon xxx NE
treatment xxx NE
of xx NE
cells xxx NE
with xxx NE
phorbol xxx NE
ester xxx NE
or xx NE
tumor xxx protein_B
necrosis xxx protein_M
factor xxx protein_M
alpha xxx protein_E
or xx NE
by xx NE
cotransfection xxx NE
with xxx NE
plasmids xxx DNA
expressing xxx NE
NF XX protein_B
kappa xxx protein_M
B X protein_E
subunits xxx NE
. . NE

Mutagenesis Xxxx NE
studies xxx NE
, , NE
and xxx NE
the xxx NE
use xxx NE
of xx NE
a x NE
reporter xxx NE
construct xxx NE
containing xxx NE
an xx NE
enhancerless xxx NE
promoter xxx NE
, , NE
indicate xxx NE
that xxx NE
these xxx NE
transcriptional xxx NE
effects xxx NE
are xxx NE
due xxx NE
principally xxx NE
to xx NE
the xxx NE
22-bp dd-xx DNA_B
sequence xxx DNA_M
duplication xxx DNA_E
and xxx NE
the xxx NE
NF XX DNA_B
kappa xxx DNA_M
B X DNA_M
site xxx DNA_E
contained xxx NE
within xxx NE
it xx NE
. . NE

Finally Xxxx NE
, , NE
infectious xxx NE
virus xxx NE
stocks xxx NE
that xxx NE
were xxx NE
isogenic xxx NE
except xxx NE
for xxx NE
the xxx NE
LTR XXX DNA
were xxx NE
generated xxx NE
. . NE

The Xxx NE
LTR XXX DNA
from xxx NE
SIVsmmPBj14 XXXxxxXXxdd NE
was xxx NE
found xxx NE
to xx NE
confer xxx NE
an xx NE
increase xxx NE
in xx NE
the xxx NE
kinetics xxx NE
of xx NE
virus xxx NE
replication xxx NE
in xx NE
cultured xxx cell_line_B
cells xxx cell_line_E
. . NE

Inclusion Xxxx NE
of xx NE
this xxx NE
LTR XXX DNA
in xx NE
recombinant xxx NE
SIVs XXXx NE
also xxx NE
resulted xxx NE
in xx NE
a x NE
two- xxx- NE
to xx NE
threefold xxx NE
rise xxx NE
in xx NE
the xxx NE
extent xxx NE
of xx NE
cellular xxx NE
proliferation xxx NE
that xxx NE
was xxx NE
induced xxx NE
in xx NE
quiescent xxx cell_line_B
simian xxx cell_line_M
peripheral xxx cell_line_M
blood xxx cell_line_M
mononuclear xxx cell_line_M
cells xxx cell_line_E
. . NE

These Xxxx NE
studies xxx NE
are xxx NE
consistent xxx NE
with xxx NE
the xxx NE
hypothesis xxx NE
that xxx NE
LTR XXX NE
mutations xxx NE
assist xxx NE
SIVsmmPBj14 XXXxxxXXxdd NE
in xx NE
responding xxx NE
efficiently xxx NE
to xx NE
cellular xxx NE
stimulation xxx NE
and xxx NE
allow xxx NE
it xx NE
to xx NE
replicate xxx NE
to xx NE
high xxx NE
titers xxx NE
during xxx NE
the xxx NE
acute xxx NE
phase xxx NE
of xx NE
viral xxx NE
infection xxx NE
. . NE

Constitutive Xxxx NE
nuclear xxx protein_B
NF-kappa XX-xxx protein_M
B X protein_E
in xx NE
cells xxx NE
of xx NE
the xxx NE
monocyte xxx NE
lineage xxx NE
. . NE

In Xx NE
monocytes xxx cell_type
, , NE
the xxx NE
nuclear xxx protein_B
factor xxx protein_M
NF-kappa XX-xxx protein_M
B X protein_E
has xxx NE
been xxx NE
invoked xxx NE
as xx NE
an xx NE
important xxx NE
transcription xxx protein_B
factor xxx protein_E
in xx NE
the xxx NE
expression xxx NE
of xx NE
cytokine xxx DNA_B
genes xxx DNA_E
, , NE
of xx NE
cell-surface xxx-xxx protein_B
receptors xxx protein_E
and xxx NE
in xx NE
the xxx NE
expression xxx NE
of xx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
. . NE

In Xx NE
such xxx NE
cells xxx NE
, , NE
DNA XXX NE
binding xxx NE
activity xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
can xxx NE
be xx NE
detected xxx NE
without xxx NE
intentional xxx NE
stimulation xxx NE
. . NE

In Xx NE
our xxx NE
studies xxx NE
, , NE
cells xxx NE
of xx NE
the xxx NE
human xxx cell_line_B
monocytic xxx cell_line_M
line xxx cell_line_E
Mono Xxxx cell_line_B
Mac Xxx cell_line_M
6 d cell_line_E
, , NE
cultured xxx NE
in xx NE
medium xxx NE
containing xxx NE
fetal-calf xxx-xxx NE
serum xxx NE
and xxx NE
low xxx NE
levels xxx NE
of xx NE
lipopolysaccharide xxx NE
( ( NE
LPS XXX NE
) ) NE
, , NE
also xxx NE
exhibit xxx NE
such xxx NE
'constitutive' 'xxx' NE
NF-kappa XX-xxx protein_B
B X protein_E
, , NE
as xx NE
demonstrated xxx NE
by xx NE
mobility-shift xxx-xxx NE
analysis xxx NE
of xx NE
nuclear xxx NE
extracts xxx NE
. . NE

This Xxxx NE
nuclear xxx protein_B
NF-kappa XX-xxx protein_M
B X protein_E
was xxx NE
still xxx NE
present xxx NE
when xxx NE
contaminant xxx NE
LPS XXX NE
was xxx NE
removed xxx NE
by xx NE
ultrafiltration xxx NE
and xxx NE
when xxx NE
serum xxx NE
was xxx NE
omitted xxx NE
. . NE

Protein-DNA Xxxx-XXX NE
complexes xxx NE
of xx NE
constitutive xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
are xxx NE
similar xxx NE
in xx NE
mobility xxx NE
to xx NE
the xxx NE
LPS XXX NE
-induced -xxx NE
NF-kappa XX-xxx NE
B X NE
and xxx NE
both xxx NE
are xxx NE
recognized xxx NE
by xx NE
an xx NE
antibody xxx NE
specific xxx NE
to xx NE
the xxx NE
p50 xdd NE
subunit xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
. . NE

By Xx NE
contrast xxx NE
, , NE
treatment xxx NE
of xx NE
cells xxx NE
with xxx NE
pyrrolidine xxx NE
dithiocarbamate xxx NE
( ( NE
PDTC XXXX NE
) ) NE
will xxx NE
only xxx NE
block xxx NE
LPS XXX NE
-induced -xxx NE
NF-kappa XX-xxx NE
B X NE
, , NE
but xxx NE
not xxx NE
the xxx NE
constitutive xxx NE
binding xxx NE
protein xxx NE
. . NE

Using Xxxx NE
LPS-free XXX-xxx NE
condition xxx NE
and xxx NE
serum-free xxx-xxx NE
condition xxx NE
can xxx NE
be xx NE
detected xxx NE
in xx NE
different xxx NE
cell xxx cell_line_B
lines xxx cell_line_E
of xx NE
the xxx NE
monocytic xxx cell_type_B
lineage xxx cell_type_E
( ( NE
HL60 XXdd cell_line
, , NE
U937 Xddd cell_line
, , NE
THP-1 XXX-d cell_line
, , NE
Mono Xxxx cell_line_B
Mac Xxx cell_line_M
1 d cell_line_E
and xxx NE
Mono Xxxx cell_line_B
Mac Xxx cell_line_M
6 d cell_line_E
) ) NE
, , NE
but xxx NE
not xxx NE
in xx NE
Molt Xxxx cell_line_B
4 d cell_line_M
T X cell_line_M
cells xxx cell_line_E
or xx NE
K562 Xddd cell_line_B
stem xxx cell_line_M
cells xxx cell_line_E
. . NE

When Xxxx NE
ordered xxx NE
according xxx NE
to xx NE
stage xxx NE
of xx NE
maturation xxx NE
, , NE
the xxx NE
amount xxx NE
of xx NE
constitutive xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
was xxx NE
not xxx NE
increased xxx NE
in xx NE
more xxx NE
mature xxx cell_line_B
cell xxx cell_line_M
lines xxx cell_line_E
. . NE

Furthermore Xxxx NE
, , NE
when xxx NE
inducing xxx NE
differentiation xxx NE
in xx NE
Mono Xxxx cell_line_B
Mac Xxx cell_line_M
6 d cell_line_M
cells xxx cell_line_E
, , NE
with xxx NE
vitamin xxx NE
D3 Xd NE
, , NE
no xx NE
change xxx NE
in xx NE
constitutive xxx NE
or xx NE
inducible xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
can xxx NE
be xx NE
detected xxx NE
. . NE

Analysis Xxxx NE
of xx NE
primary xxx NE
cells xxx NE
revealed xxx NE
substantial xxx NE
constitutive xxx NE
NF-kappa XX-xxx NE
B X NE
-binding -xxx NE
activity xxx NE
in xx NE
blood xxx NE
monocytes xxx NE
, , NE
pleural xxx NE
macrophages xxx NE
and xxx NE
alveolar xxx NE
macrophages xxx NE
. . NE

The Xxx NE
constitutive xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
appears xxx NE
to xx NE
be xx NE
functionally xxx NE
active xxx NE
, , NE
since xxx NE
a x NE
low xxx NE
level xxx NE
of xx NE
tumour xxx RNA_B
necrosis xxx RNA_M
factor xxx RNA_M
(TNF) (XXX) RNA_M
transcript xxx RNA_E
is xx NE
detectable xxx NE
in xx NE
monocytes xxx cell_type
, , NE
and xxx NE
this xxx NE
level xxx NE
can xxx NE
be xx NE
increased xxx NE
by xx NE
blocking xxx NE
transcript xxx NE
degradation xxx NE
using xxx NE
cycloheximide xxx NE
. . NE

The Xxx NE
level xxx NE
of xx NE
constitutive xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
in xx NE
these xxx NE
cells xxx NE
is xx NE
variable xxx NE
and xxx NE
is xx NE
frequently xxx NE
found xxx NE
to xx NE
be xx NE
lower xxx NE
in xx NE
the xxx NE
more xxx NE
mature xxx cell_type_B
macrophages xxx cell_type_E
. . NE

Constitutive Xxxx NE
NF-kappa XX-xxx protein_B
B X protein_E
was xxx NE
not xxx NE
maintained xxx NE
by xx NE
autocrine xxx NE
action xxx NE
of xx NE
cytokines xxx protein
TNF XXX protein
, , NE
interleukin xxx protein_B
6 d protein_E
, , NE
interleukin xxx protein
10 dd NE
, , NE
granulocyte-macrophage xxx-xxx protein_B
colony-stimulating xxx-xxx protein_M
factor xxx protein_E
or xx NE
macrophage xxx protein_B
colony-stimulating xxx-xxx protein_M
factor xxx protein_E
, , NE
since xxx NE
neutralizing xxx NE
antibodies xxx NE
did xxx NE
not xxx NE
reduce xxx NE
constitutive xxx NE
DNA-binding XXX-xxx NE
activity xxx NE
. . NE

Furthermore Xxxx NE
, , NE
blockade xxx NE
of xx NE
prostaglandin xxx NE
or xx NE
leukotriene xxx NE
biosynthesis xxx NE
did xxx NE
not xxx NE
affect xxx NE
constitutive xxx NE
NF-kappa XX-xxx NE
B X NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
400 ddd NE
WORDS) XXXXX) NE

Steel Xxxx protein_B
factor xxx protein_E
affects xxx NE
SCL XXX NE
expression xxx NE
during xxx NE
normal xxx NE
erythroid xxx NE
differentiation xxx NE
. . NE

Steel Xxxx protein_B
factor xxx protein_E
is xx NE
one xxx NE
of xx NE
the xxx NE
growth xxx protein_B
factors xxx protein_E
that xxx NE
controls xxx NE
the xxx NE
proliferation xxx NE
and xxx NE
differentiation xxx NE
of xx NE
hematopoietic xxx cell_type_B
cells xxx cell_type_E
and xxx NE
SCL XXX protein
, , NE
also xxx NE
known xxx NE
as xx NE
Tcl-5 Xxx-d protein
or xx NE
Tal-1 Xxx-d protein
, , NE
is xx NE
a x NE
transcription xxx protein_B
factor xxx protein_E
involved xxx NE
in xx NE
erythropoiesis xxx NE
. . NE

In Xx NE
this xxx NE
report xxx NE
, , NE
we xx NE
studied xxx NE
the xxx NE
role xxx NE
of xx NE
SCL XXX NE
in xx NE
the xxx NE
proliferation xxx NE
of xx NE
human xxx cell_type_B
peripheral xxx cell_type_M
blood xxx cell_type_M
burst-forming xxx-xxx cell_type_M
unit-erythroid xxx-xxx cell_type_E
( ( NE
BFU-E XXX-X cell_type
) ) NE
and xxx NE
the xxx NE
effects xxx NE
of xx NE
Steel Xxxx protein_B
factor xxx protein_E
on xx NE
SCL XXX NE
expression xxx NE
in xx NE
proliferating xxx cell_type_B
erythroid xxx cell_type_M
cells xxx cell_type_E
. . NE

BFU-E XXX-X NE
-derived -xxx NE
colonies xxx NE
increase xxx NE
progressively xxx NE
in xx NE
size xxx NE
, , NE
as xx NE
determined xxx NE
by xx NE
cell xxx NE
number xxx NE
, , NE
from xxx NE
day xxx NE
7 d NE
to xx NE
day xxx NE
14 dd NE
of xx NE
culture xxx NE
, , NE
with xxx NE
the xxx NE
greatest xxx NE
increase xxx NE
in xx NE
colony xxx NE
size xxx NE
(10-fold (dd-xxx NE
expansion) xxx) NE
occurring xxx NE
between xxx NE
day xxx NE
7 d NE
and xxx NE
day xxx NE
10 dd NE
. . NE

SCL XXX NE
protein xxx NE
levels xxx NE
in xx NE
BFU-E XXX-X NE
-derived -xxx NE
cells xxx NE
were xxx NE
highest xxx NE
in xx NE
day xxx NE
7 d NE
cells xxx NE
and xxx NE
decreased xxx NE
progressively xxx NE
from xxx NE
day xxx NE
7 d NE
to xx NE
day xxx NE
14 dd NE
of xx NE
culture xxx NE
, , NE
suggesting xxx NE
an xx NE
association xxx NE
of xx NE
SCL XXX NE
with xxx NE
erythroid xxx NE
proliferation xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
SCL XXX NE
mRNA xXXX NE
levels xxx NE
did xxx NE
not xxx NE
decrease xxx NE
significantly xxx NE
between xxx NE
day xxx NE
7 d NE
and xxx NE
day xxx NE
14 dd NE
cells xxx NE
, , NE
suggesting xxx NE
that xxx NE
posttranscriptional xxx NE
mechanisms xxx NE
are xxx NE
largely xxx NE
responsible xxx NE
for xxx NE
the xxx NE
decrease xxx NE
in xx NE
SCL XXX protein_B
protein xxx protein_E
observed xxx NE
. . NE

The Xxx NE
role xxx NE
of xx NE
SCL XXX protein
in xx NE
Steel Xxxx NE
factor xxx NE
-induced -xxx NE
erythroid xxx NE
proliferation xxx NE
was xxx NE
then xxx NE
examined xxx NE
. . NE

In Xx NE
BFU-E XXX-X NE
-derived -xxx NE
colonies xxx NE
cultured xxx NE
with xxx NE
Steel Xxxx NE
factor xxx NE
, , NE
colony xxx NE
size xxx NE
was xxx NE
significantly xxx NE
increased xxx NE
compared xxx NE
to xx NE
control xxx NE
. . NE

In Xx NE
day xxx NE
7 d NE
and xxx NE
day xxx NE
10 dd NE
erythroid xxx cell_type_B
precursors xxx cell_type_E
cultured xxx NE
with xxx NE
Steel Xxxx protein_B
factor xxx protein_E
, , NE
SCL XXX protein_B
protein xxx protein_E
was xxx NE
increased xxx NE
significantly xxx NE
compared xxx NE
to xx NE
control xxx NE
. . NE

The Xxx NE
increase xxx NE
in xx NE
SCL XXX NE
protein xxx NE
levels xxx NE
in xx NE
early xxx NE
erythroid xxx cell_type_B
precursors xxx cell_type_E
stimulated xxx NE
with xxx NE
Steel Xxxx protein_B
factor xxx protein_E
suggests xxx NE
one xxx NE
mechanism xxx NE
through xxx NE
which xxx NE
Steel Xxxx protein_B
factor xxx protein_E
may xxx NE
enhance xxx NE
normal xxx NE
erythroid xxx NE
proliferation xxx NE
. . NE

SCL XXX NE
mRNA xXXX NE
levels xxx NE
assessed xxx NE
by xx NE
Northern Xxxx NE
blot xxx NE
in xx NE
day xxx NE
7 d NE
cells xxx NE
did xxx NE
not xxx NE
increase xxx NE
significantly xxx NE
in xx NE
response xxx NE
to xx NE
Steel Xxxx protein_B
factor xxx protein_E
stimulation xxx NE
, , NE
suggesting xxx NE
that xxx NE
posttranscriptional xxx NE
mechanisms xxx NE
may xxx NE
also xxx NE
be xx NE
important xxx NE
in xx NE
the xxx NE
increase xxx NE
in xx NE
SCL XXX protein_B
protein xxx protein_E
observed xxx NE
in xx NE
response xxx NE
to xx NE
Steel Xxxx protein
. . NE

C/EBP X/XXX NE
beta xxx NE
regulation xxx NE
of xx NE
the xxx NE
tumor xxx DNA_B
necrosis xxx DNA_M
factor xxx DNA_M
alpha xxx DNA_M
gene xxx DNA_E
. . NE

Activated Xxxx cell_type_B
macrophages xxx cell_type_E
contribute xxx NE
to xx NE
chronic xxx NE
inflammation xxx NE
by xx NE
the xxx NE
secretion xxx NE
of xx NE
cytokines xxx protein
and xxx NE
proteinases xxx protein
. . NE

Tumor Xxxx protein_B
necrosis xxx protein_M
factor xxx protein_M
alpha xxx protein_E
( ( NE
TNF XXX protein_B
alpha xxx protein_E
) ) NE
is xx NE
particularly xxx NE
important xxx NE
in xx NE
this xxx NE
process xxx NE
because xxx NE
of xx NE
its xxx NE
ability xxx NE
to xx NE
regulate xxx NE
other xxx NE
inflammatory xxx NE
mediators xxx NE
in xx NE
an xx NE
autocrine xxx NE
fashion xxx NE
and xxx NE
paracrine xxx NE
fashion xxx NE

The Xxx NE
mechanism(s) xxx(x) NE
responsible xxx NE
for xxx NE
the xxx NE
cell xxx NE
type-specific xxx-xxx NE
regulation xxx NE
of xx NE
TNF XXX protein_B
alpha xxx protein_E
is xx NE
not xxx NE
known xxx NE
. . NE

We Xx NE
present xxx NE
data xxx NE
to xx NE
show xxx NE
that xxx NE
the xxx NE
expression xxx NE
of xx NE
TNF XXX protein_B
alpha xxx protein_E
is xx NE
regulated xxx NE
by xx NE
the xxx NE
transcription xxx protein_B
factor xxx protein_E
C/EBP X/XXX protein_B
beta xxx protein_E
( ( NE
NF-IL6 XX-XXd protein
) ) NE
. . NE

C/EBP X/XXX protein_B
beta xxx protein_E
activated xxx NE
the xxx NE
TNF XXX DNA_B
alpha xxx DNA_M
gene xxx DNA_M
promoter xxx DNA_E
in xx NE
cotransfection xxx NE
assays xxx NE
and xxx NE
bound xxx NE
to xx NE
it xx NE
at xx NE
a x NE
site xxx NE
which xxx NE
failed xxx NE
to xx NE
bind xxx NE
the xxx NE
closely xxx NE
related xxx NE
protein xxx NE
C/EBP X/XXX protein_B
alpha xxx protein_E
. . NE

Finally Xxxx NE
, , NE
a x NE
dominant-negative xxx-xxx NE
version xxx NE
of xx NE
C/EBP X/XXX protein_B
beta xxx protein_E
blocked xxx NE
TNF XXX DNA_B
alpha xxx DNA_M
promoter xxx DNA_E
activation xxx NE
in xx NE
myeloid xxx cell_type_B
cells xxx cell_type_E
. . NE

Our Xxx NE
results xxx NE
implicate xxx NE
C/EBP X/XXX protein_B
beta xxx protein_E
as xx NE
an xx NE
important xxx NE
regulator xxx NE
of xx NE
TNF XXX protein_B
alpha xxx protein_E
by xx NE
myelomonocytic xxx cell_type_B
cells xxx cell_type_E
. . NE

Calcium/calmodulin-dependent Xxxx/xxx-xxx protein_B
protein xxx protein_M
kinase xxx protein_M
II XX protein_E
downregulates xxx NE
both xxx NE
calcineurin-mediated xxx-xxx NE
pathway xxx NE
and xxx NE
protein xxx NE
kinase xxx NE
C-mediated X-xxx NE
pathway xxx NE
for xxx NE
cytokine xxx NE
gene xxx NE
transcription xxx NE
in xx NE
human xxx cell_type_B
T X cell_type_M
cells xxx cell_type_E
. . NE

Engagement Xxxx NE
of xx NE
the xxx NE
T X protein_B
cell xxx protein_M
receptor xxx protein_E
for xxx NE
antigen xxx NE
activates xxx NE
phospholipase xxx protein_B
C X protein_E
resulting xxx NE
in xx NE
an xx NE
increase xxx NE
in xx NE
intracellular xxx NE
free xxx NE
calcium xxx NE
concentration xxx NE
( ( NE
[ [ NE
Ca2+ Xxd+ NE
]i ]x NE
) ) NE
and xxx NE
activation xxx NE
of xx NE
protein xxx NE
kinase xxx NE
C X NE
( ( NE
PKC XXX NE
) ) NE
. . NE

Increased Xxxx NE
[ [ NE
Ca2+ Xxd+ NE
]i ]x NE
activates xxx NE
Ca2+ Xxd+ NE
/calmodulin-dependent /xxx-xxx NE
kinases xxx NE
including xxx NE
the xxx NE
multifunctional xxx NE
Ca2+ Xxd+ NE
/calmodulin-dependent /xxx-xxx NE
protein xxx NE
kinase xxx NE
II XX NE
( ( NE
CaM-K XxX-X NE
II XX NE
) ) NE
, , NE
as xx NE
well xxx NE
as xx NE
calcineurin xxx NE
, , NE
a x NE
type xxx NE
2B dX NE
protein xxx NE
phosphatase xxx NE
. . NE

Recent Xxxx NE
studies xxx NE
have xxx NE
identified xxx NE
calcineurin xxx protein
as xx NE
a x NE
key xxx NE
enzyme xxx NE
for xxx NE
interleukin xxx NE
(IL)-2 (XX)-d NE
promoter xxx NE
activation xxx NE
and xxx NE
IL-4 XX-d NE
promoter xxx NE
activation xxx NE

However Xxxx NE
, , NE
the xxx NE
role xxx NE
of xx NE
CaM-K XxX-X protein_B
II XX protein_E
remains xxx NE
unknown xxx NE
. . NE

We Xx NE
have xxx NE
used xxx NE
mutants xxx NE
of xx NE
these xxx NE
kinases xxx protein
and xxx NE
phosphatases xxx protein
( ( NE
gamma xxx protein_B
B*CaM-K X*XxX-X protein_E
and xxx NE
delta xxx protein_B
CaM-AI XxX-XX protein_E
, , NE
respectively) xxx) NE
to xx NE
explore xxx NE
their xxx NE
relative xxx NE
role xxx NE
in xx NE
cytokine xxx NE
gene xxx NE
transcription xxx NE
and xxx NE
their xxx NE
interactions xxx NE
with xxx NE
PKC XXX NE
-dependent -xxx NE
signaling xxx NE
systems xxx NE
. . NE

gamma xxx protein_B
B*CaM-K X*XxX-X protein_E
and xxx NE
delta xxx protein_B
CaM-AI XxX-XX protein_E
, , NE
known xxx NE
to xx NE
exhibit xxx NE
constitutive xxx NE
Ca(2+)-independent Xx(d+)-xxx NE
activity xxx NE
, , NE
were xxx NE
cotransfected xxx NE
(alone (xxx NE
or xx NE
in xx NE
combination) xxx) NE
in xx NE
Jurkat Xxxx cell_line_B
T X cell_line_M
cells xxx cell_line_E
with xxx NE
a x NE
plasmid xxx NE
containing xxx NE
the xxx NE
intact xxx NE
IL-2 XX-d DNA_B
promoter xxx DNA_E
driving xxx NE
the xxx NE
expression xxx NE
of xx NE
the xxx NE
chloramphenicol xxx DNA_B
acetyltransferase xxx DNA_M
reporter xxx DNA_M
gene xxx DNA_E
. . NE

Cotransfection Xxxx NE
of xx NE
gamma xxx protein_B
B*CaM-K X*XxX-X protein_E
with xxx NE
the xxx NE
IL-2 XX-d DNA_B
promoter xxx DNA_M
construct xxx DNA_E
downregulated xxx NE
its xxx NE
transcription xxx NE
in xx NE
response xxx NE
to xx NE
stimulation xxx NE
with xxx NE
ionomycin xxx NE
and xxx NE
phorbol xxx NE
myristate xxx NE
acetate xxx NE
( ( NE
PMA XXX NE
) ) NE
. . NE

The Xxx NE
inhibitory xxx NE
effect xxx NE
of xx NE
CaM-K XxX-X protein_B
II XX protein_E
on xx NE
IL-2 XX-d DNA_B
promoter xxx DNA_E
was xxx NE
associated xxx NE
with xxx NE
decreased xxx NE
transcription xxx NE
of xx NE
its xxx NE
AP-1 XX-d NE
transactivating xxx NE
pathway xxx NE
and xxx NE
NF-AT XX-XX NE
transactivating xxx NE
pathway xxx NE

Under Xxxx NE
the xxx NE
same xxx NE
conditions xxx NE
, , NE
delta xxx protein_B
CaM-AI XxX-XX protein_E
superinduced xxx NE
IL-2 XX-d NE
promoter xxx NE
activity xxx NE
(approximately (xxx NE
twofold xxx NE
increase) xxx) NE
. . NE

When Xxxx NE
both xxx NE
mutants xxx NE
were xxx NE
used xxx NE
in xx NE
combination xxx NE
, , NE
gamma xxx protein_B
B*CaM-K X*XxX-X protein_E
inhibited xxx NE
the xxx NE
induction xxx NE
of xx NE
the xxx NE
IL-2 XX-d DNA_B
promoter xxx DNA_E
by xx NE
delta xxx protein_B
CaM-AI XxX-XX protein_E
. . NE

Similar Xxxx NE
results xxx NE
were xxx NE
obtained xxx NE
when xxx NE
a x NE
construct xxx NE
containing xxx NE
the xxx NE
IL-4 XX-d DNA_B
promoter xxx DNA_E
also xxx NE
was xxx NE
used xxx NE
. . NE

gamma xxx protein_B
B*CaM-K X*XxX-X protein_E
also xxx NE
downregulated xxx NE
the xxx NE
activation xxx NE
of xx NE
AP-1 XX-d protein
in xx NE
response xxx NE
to xx NE
transfection xxx NE
with xxx NE
a x NE
constitutively xxx NE
active xxx NE
mutant xxx NE
of xx NE
PKC XXX protein
or xx NE
stimulation xxx NE
with xxx NE
PMA XXX NE
. . NE

These Xxxx NE
results xxx NE
suggest xxx NE
that xxx NE
CaM-K XxX-X protein_B
II XX protein_E
may xxx NE
exert xxx NE
negative xxx NE
influences xxx NE
on xx NE
cytokine xxx NE
gene xxx NE
transcription xxx NE
in xx NE
human xxx cell_type_B
T X cell_type_M
cells xxx cell_type_E
, , NE
and xxx NE
provide xxx NE
preliminary xxx NE
evidence xxx NE
for xxx NE
negative xxx NE
cross-talk xxx-xxx NE
with xxx NE
the xxx NE
calcineurin- xxx- NE
dependent xxx NE
signaling xxx NE
system xxx NE
and xxx NE
PKC- XXX- NE
dependent xxx NE
signaling xxx NE
system xxx NE

Induction Xxxx NE
of xx NE
ICAM-1 XXXX-d protein
and xxx NE
LFA-3 XXX-d protein
by xx NE
Tax1 Xxxd protein
of xx NE
human xxx NE
T-cell X-xxx NE
leukemia xxx NE
virus xxx NE
type xxx NE
1 d NE
and xxx NE
mechanism xxx NE
of xx NE
down-regulation xxx-xxx NE
of xx NE
ICAM-1 XXXX-d protein
or xx NE
LFA-1 XXX-d protein
in xx NE
adult-T-cell-leukemia xxx-X-xxx-xxx cell_line_B
cell xxx cell_line_M
lines xxx cell_line_E
. . NE

The Xxx NE
present xxx NE
study xxx NE
was xxx NE
undertaken xxx NE
to xx NE
determine xxx NE
the xxx NE
role xxx NE
of xx NE
HTLV-I XXXX-X protein_B
TaxI XxxX protein_E
in xx NE
the xxx NE
up-regulation xx-xxx NE
of xx NE
ICAM-I XXXX-X protein
and xxx NE
LFA-3 XXX-d protein
in xx NE
human xxx cell_type_B
T X cell_type_M
cells xxx cell_type_E
transformed xxx NE
with xxx NE
HTLV-I XXXX-X NE
and xxx NE
the xxx NE
mechanism xxx NE
of xx NE
down-regulation xxx-xxx NE
of xx NE
ICAM-I XXXX-X protein
and xxx NE
LFA-I XXX-X protein
in xx NE
ATL-derived XXX-xxx cell_line_B
cell xxx cell_line_M
lines xxx cell_line_E
. . NE

Induction Xxxx NE
of xx NE
TaxI XxxX protein
in xx NE
a x NE
human xxx cell_line_B
T-cell X-xxx cell_line_M
line xxx cell_line_M
Jurkat Xxxx cell_line_E
carrying xxx NE
the xxx NE
TaxI XxxX DNA_B
gene xxx DNA_E
under xxx NE
the xxx NE
metallothionein xxx DNA_B
promoter xxx DNA_E
led xxx NE
to xx NE
increases xxx NE
in xx NE
mRNA xXXX RNA
and xxx NE
surface xxx NE
expression xxx NE
of xx NE
ICAM-I XXXX-X protein
. . NE

The Xxx NE
response xxx NE
of xx NE
LFA-3 XXX-d protein
to xx NE
TaxI XxxX NE
induction xxx NE
was xxx NE
, , NE
on xx NE
the xxx NE
other xxx NE
hand xxx NE
, , NE
relatively xxx NE
slow xxx NE
and xxx NE
weak xxx NE
, , NE
and xxx NE
might xxx NE
be xx NE
indirect xxx NE
. . NE

Transactivation Xxxx NE
of xx NE
the xxx NE
ICAM-I XXXX-X DNA_B
promoter xxx DNA_E
by xx NE
TaxI XxxX protein
was xxx NE
further xxx NE
shown xxx NE
by xx NE
co-transfection xx-xxx NE
of xx NE
a x NE
CAT XXX DNA_B
reporter xxx DNA_M
construct xxx DNA_E
with xxx NE
the xxx NE
ICAM-I XXXX-X DNA_B
promoter xxx DNA_E
and xxx NE
a x NE
plasmid xxx DNA
expressing xxx NE
TaxI XxxX protein
. . NE

The Xxx NE
mechanism xxx NE
of xx NE
down-regulation xxx-xxx NE
of xx NE
ICAM-I XXXX-X protein
or xx NE
LFA-I XXX-X protein
in xx NE
4 d cell_line_B
ATL XXX cell_line_M
cell xxx cell_line_M
lines xxx cell_line_E
was xxx NE
next xxx NE
examined xxx NE
. . NE

ICAM-I XXXX-X RNA_B
mRNA xXXX RNA_E
was xxx NE
quite xxx NE
low xxx NE
in xx NE
MT-I XX-X cell_line
, , NE
but xxx NE
no xx NE
genomic xxx NE
changes xxx NE
were xxx NE
found xxx NE
. . NE

The Xxx NE
CAT XXX DNA_B
reporter xxx DNA_E
with xxx NE
the xxx NE
ICAM-I XXXX-X DNA_B
promoter xxx DNA_E
was xxx NE
inactive xxx NE
in xx NE
MT-I XX-X cell_line
. . NE

Finally Xxxx NE
, , NE
combined xxx NE
treatment xxx NE
of xx NE
MT-I XX-X cell_line
with xxx NE
5-azacytidine d-xxx NE
and xxx NE
IFN-gamma XXX-xxx NE
induced xxx NE
re-expression xx-xxx NE
of xx NE
ICAM-I XXXX-X protein
. . NE

Collectively Xxxx NE
, , NE
(a) (x) NE
transcriptional xxx protein_B
factor xxx protein_E
(s) (x) NE
necessary xxx NE
for xxx NE
expression xxx NE
of xx NE
ICAM-I XXXX-X DNA_B
gene xxx DNA_E
may xxx NE
be xx NE
repressed xxx NE
in xx NE
MT-I XX-X cell_line
through xxx NE
DNA XXX NE
methylation xxx NE
. . NE

Three Xxxx NE
other xxx NE
ATL XXX cell_line_B
cell xxx cell_line_M
lines xxx cell_line_E
( ( NE
TL-OmI XX-XxX cell_line
, , NE
H582 Xddd cell_line
, , NE
HuT102 XxXddd cell_line
) ) NE
were xxx NE
found xxx NE
to xx NE
have xxx NE
little xxx NE
mRNA xXXX RNA
for xxx NE
the xxx NE
LFA-I XXX-X protein_B
beta xxx protein_M
chain xxx protein_E
( ( NE
CD18 XXdd protein
) ) NE
. . NE

H582 Xddd cell_line
and xxx NE
HuT102 XxXddd cell_line
were xxx NE
also xxx NE
negative xxx NE
for xxx NE
the xxx NE
LFA-I XXX-X RNA_B
alpha xxx RNA_M
chain xxx RNA_M
(CDIIa) (XXXXx) RNA_M
mRNA xXXX RNA_E
. . NE

No Xx NE
genomic xxx NE
changes xxx NE
were xxx NE
found xxx NE
, , NE
and xxx NE
a x NE
CAT XXX DNA_B
reporter xxx DNA_M
gene xxx DNA_E
with xxx NE
the xxx NE
CD18 XXdd DNA_B
promoter xxx DNA_E
was xxx NE
inactive xxx NE
in xx NE
the xxx NE
3 d NE
of xx NE
them xxx NE
, , NE
again xxx NE
suggesting xxx NE
lack xxx NE
of xx NE
(a) (x) NE
transcriptional xxx protein_B
factor xxx protein_E
(s) (x) NE
necessary xxx NE
for xxx NE
CD18 XXdd NE
expression xxx NE
. . NE

Infection Xxxx NE
with xxx NE
Theileria Xxxx NE
annulata xxx NE
induces xxx NE
expression xxx NE
of xx NE
matrix xxx protein_B
metalloproteinase xxx protein_M
9 d protein_E
and xxx NE
transcription xxx protein_B
factor xxx protein_E
AP-1 XX-d protein
in xx NE
bovine xxx cell_type_B
leucocytes xxx cell_type_E
. . NE

Theileria Xxxx NE
annulata xxx NE
infects xxx NE
bovine xxx cell_type_B
leucocytes xxx cell_type_E
and xxx NE
results xxx NE
in xx NE
their xxx NE
reversible xxx NE
transformation xxx NE
such xxx NE
that xxx NE
they xxx NE
become xxx NE
immortalised xxx NE
and xxx NE
metastatic xxx NE
. . NE

The Xxx NE
present xxx NE
study xxx NE
describes xxx NE
parasite-induced xxx-xxx NE
changes xxx NE
in xx NE
host xxx NE
cell xxx NE
gene xxx NE
expression xxx NE
which xxx NE
have xxx NE
a x NE
direct xxx NE
bearing xxx NE
on xx NE
this xxx NE
transformation xxx NE
process xxx NE
. . NE

T X NE
. . NE
annulata xxx NE
-infected -xxx NE
leucocytes xxx NE
produce xxx NE
a x NE
number xxx NE
of xx NE
novel xxx NE
metalloproteinase xxx NE
activities xxx NE
. . NE

One Xxx NE
of xx NE
these xxx NE
, , NE
previously xxx NE
called xxx NE
B1 Xd protein
, , NE
is xx NE
a x NE
97-kDa dd-xXx protein_B
protein xxx protein_E
which xxx NE
is xx NE
secreted xxx NE
in xx NE
large xxx NE
amounts xxx NE
and xxx NE
has xxx NE
been xxx NE
purified xxx NE
from xxx NE
protein-free, xxx-xxx, NE
conditioned xxx NE
medium xxx NE
. . NE

An Xx NE
antiserum xxx NE
to xx NE
this xxx NE
enzyme xxx NE
was xxx NE
used xxx NE
to xx NE
isolate xxx NE
a x NE
cDNA xXXX DNA_B
clone xxx DNA_E
. . NE

The Xxx NE
predicted xxx NE
protein xxx NE
sequence xxx NE
of xx NE
B1 Xd protein
is xx NE
81% dd% NE
identical xxx NE
to xx NE
human xxx NE
matrix xxx protein_B
metalloproteinase xxx protein_M
9 d protein_E
( ( NE
MMP9 XXXd protein
) ) NE
, , NE
demonstrating xxx NE
that xxx NE
it xx NE
is xx NE
the xxx NE
bovine xxx NE
homologue xxx NE
of xx NE
this xxx NE
enzyme xxx NE
. . NE

RNAase XXXxxx NE
protection xxx NE
assays xxx NE
demonstrated xxx NE
that xxx NE
the xxx NE
MMP9 XXXd protein
activity xxx NE
, , NE
unique xxx NE
to xx NE
infected xxx cell_type_B
cells xxx cell_type_E
, , NE
is xx NE
due xxx NE
to xx NE
increased xxx NE
MMP9 XXXd NE
mRNA xXXX NE
levels xxx NE
. . NE

We Xx NE
also xxx NE
assayed xxx NE
the xxx NE
levels xxx NE
of xx NE
transcription xxx protein_B
factor xxx protein_E
AP-1 XX-d protein
and xxx NE
demonstrated xxx NE
that xxx NE
it xx NE
was xxx NE
constitutively xxx NE
present xxx NE
in xx NE
increased xxx NE
amounts xxx NE
in xx NE
Theileria-infected Xxxx-xxx cell_type_B
cells xxx cell_type_E
. . NE

In Xx NE
addition xxx NE
we xx NE
assayed xxx NE
the xxx NE
level xxx NE
of xx NE
mRNA xXXX RNA
encoding xxx NE
c-Fos x-Xxx protein
, , NE
a x NE
common xxx NE
component xxx NE
of xx NE
AP-1 XX-d protein
and xxx NE
observed xxx NE
that xxx NE
it xx NE
was xxx NE
indeed xxx NE
up-regulated xx-xxx NE
in xx NE
infected xxx cell_type_B
cells xxx cell_type_E
. . NE

Since Xxxx NE
AP-1 XX-d protein
is xx NE
implicated xxx NE
in xx NE
the xxx NE
control xxx NE
of xx NE
the xxx NE
cell xxx NE
cycle xxx NE
, , NE
and xxx NE
MMP9 XXXd protein
can xxx NE
confer xxx NE
metastatic xxx NE
properties xxx NE
, , NE
these xxx NE
results xxx NE
are xxx NE
of xx NE
considerable xxx NE
significance xxx NE
with xxx NE
respect xxx NE
to xx NE
the xxx NE
transformed xxx NE
phenotype xxx NE
induced xxx NE
by xx NE
Theileria Xxxx NE
infection xxx NE
. . NE

B-cell X-xxx NE
proliferation xxx NE
and xxx NE
induction xxx NE
of xx NE
early xxx NE
G1-regulating Xd-xxx protein_B
proteins xxx protein_E
by xx NE
Epstein-Barr Xxxx-Xxxx NE
virus xxx NE
mutants xxx NE
conditional xxx NE
for xxx NE
EBNA2 XXXXd protein
. . NE

Infection Xxxx NE
of xx NE
primary xxx cell_type_B
B-lymphocytes X-xxx cell_type_E
by xx NE
Epstein-Barr Xxxx-Xxxx NE
virus xxx NE
( ( NE
EBV XXX NE
) ) NE
leads xxx NE
to xx NE
growth xxx NE
transformation xxx NE
of xx NE
these xxx NE
B-cells X-xxx cell_type
in xx NE
vitro xxx NE
. . NE

EBV XXX NE
nuclear xxx NE
antigen xxx NE
2 d NE
( ( NE
EBNA2 XXXXd protein
) ) NE
, , NE
one xxx NE
of xx NE
the xxx NE
first xxx NE
genes xxx NE
expressed xxx NE
after xxx NE
EBV XXX NE
infection xxx NE
of xx NE
B-cells X-xxx cell_type
, , NE
is xx NE
a x NE
transcriptional xxx NE
activator xxx NE
of xx NE
viral xxx DNA_B
and xxx DNA_M
cellular xxx DNA_M
genes xxx DNA_E
and xxx NE
is xx NE
essential xxx NE
for xxx NE
the xxx NE
transforming xxx NE
potential xxx NE
of xx NE
the xxx NE
virus xxx NE
. . NE

We Xx NE
generated xxx NE
conditional xxx NE
EBV XXX NE
mutants xxx NE
by xx NE
expressing xxx NE
EBNA2 XXXXd protein
as xx NE
chimeric xxx protein_B
fusion xxx protein_M
protein xxx protein_E
with xxx NE
the xxx NE
hormone xxx NE
binding xxx NE
domain xxx NE
of xx NE
the xxx NE
estrogen xxx protein_B
receptor xxx protein_E
on xx NE
the xxx NE
genetic xxx NE
background xxx NE
of xx NE
the xxx NE
virus xxx NE
. . NE

Growth Xxxx NE
transformation xxx NE
of xx NE
primary xxx cell_type_B
normal xxx cell_type_M
B-cells X-xxx cell_type_E
by xx NE
mutant xxx NE
virus xxx NE
resulted xxx NE
in xx NE
estrogen xxx NE
-dependent -xxx NE
lymphoblastoid xxx NE
cell xxx NE
lines xxx NE
expressing xxx NE
the xxx NE
chimeric xxx NE
EBNA2 XXXXd NE
protein xxx NE
. . NE

In Xx NE
the xxx NE
absence xxx NE
of xx NE
estrogen xxx NE
about xxx NE
half xxx NE
of xx NE
the xxx NE
cells xxx NE
enter xxx NE
a x NE
quiescent xxx NE
non-proliferative xxx-xxx NE
state xxx NE
whereas xxx NE
the xxx NE
others xxx NE
die xxx NE
by xx NE
apoptosis xxx NE
. . NE

EBNA2 XXXXd protein
is xx NE
thus xxx NE
required xxx NE
not xxx NE
only xxx NE
for xxx NE
initiation xxx NE
but xxx NE
also xxx NE
for xxx NE
maintenance xxx NE
of xx NE
transformation xxx NE
. . NE

Growth Xxxx NE
arrest xxx NE
occurred xxx NE
at xx NE
G1 Xd NE
stage xxx NE
and xxx NE
G2 Xd NE
stage xxx NE
of xx NE
the xxx NE
cell xxx NE
cycle xxx NE
, , NE
indicating xxx NE
that xxx NE
functional xxx NE
EBNA2 XXXXd protein
is xx NE
required xxx NE
at xx NE
different xxx NE
restriction xxx NE
points xxx NE
of xx NE
the xxx NE
cell xxx NE
cycle xxx NE
. . NE

Growth Xxxx NE
arrest xxx NE
is xx NE
reversible xxx NE
for xxx NE
G1/G0 Xd/Xd cell_type_B
cells xxx cell_type_E
as xx NE
indicated xxx NE
by xx NE
the xxx NE
sequential xxx NE
accumulation xxx NE
and xxx NE
modification xxx NE
of xx NE
cell xxx protein_B
cycle xxx protein_M
regulating xxx protein_M
proteins xxx protein_E
. . NE

EBV XXX NE
induces xxx NE
the xxx NE
same xxx NE
cell xxx NE
cycle xxx NE
regulating xxx NE
proteins xxx NE
as xx NE
polyclonal xxx NE
stimuli xxx NE
in xx NE
primary xxx NE
B-cells X-xxx cell_type
. . NE

These Xxxx NE
data xxx NE
suggest xxx NE
that xxx NE
EBV XXX NE
is xx NE
using xxx NE
a x NE
common xxx NE
pathway xxx NE
for xxx NE
B-cell X-xxx NE
activation xxx NE
bypassing xxx NE
the xxx NE
requirement xxx NE
for xxx NE
antigen xxx NE
, , NE
T-cell X-xxx NE
signals xxx NE
and xxx NE
growth xxx protein_B
factors xxx protein_E
. . NE

IL-1 XX-d protein_B
receptor xxx protein_E
and xxx NE
TCR XXX NE
signals xxx NE
synergize xxx NE
to xx NE
activate xxx NE
NF-kappa XX-xxx NE
B X NE
-mediated -xxx NE
gene xxx NE
transcription xxx NE
. . NE

Previous Xxxx NE
studies xxx NE
have xxx NE
demonstrated xxx NE
that xxx NE
IL-1 XX-d NE
receptor xxx NE
( ( NE
IL-1R XX-dX NE
)- )- NE
and xxx NE
TCR XXX NE
-initiated -xxx NE
signals xxx NE
can xxx NE
interact xxx NE
synergistically xxx NE
to xx NE
increase xxx NE
the xxx NE
rate xxx NE
of xx NE
transcription xxx NE
of xx NE
several xxx NE
lymphokine xxx DNA_B
gene xxx DNA_M
and xxx DNA_M
lymphokine xxx DNA_M
receptor xxx DNA_M
gene xxx DNA_E
during xxx NE
the xxx NE
competence xxx NE
phase xxx NE
of xx NE
the xxx NE
activation xxx NE
program xxx NE
in xx NE
T X cell_type_B
helper xxx cell_type_M
lymphocytes xxx cell_type_E
. . NE

In Xx NE
this xxx NE
report xxx NE
we xx NE
describe xxx NE
how xxx NE
signals xxx NE
initiated xxx NE
through xxx NE
the xxx NE
type xxx protein_B
I X protein_M
IL-1R XX-dX protein_E
interact xxx NE
with xxx NE
signals xxx NE
from xxx NE
the xxx NE
antigen xxx NE
receptor xxx NE
to xx NE
synergistically xxx NE
augment xxx NE
the xxx NE
transactivating xxx NE
properties xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
. . NE

The Xxx NE
synergistic xxx NE
antigen xxx protein_B
receptor xxx protein_E
initiated xxx NE
signals xxx NE
are xxx NE
mediated xxx NE
through xxx NE
protein xxx protein_B
kinase xxx protein_M
C X protein_E
because xxx NE
they xxx NE
can xxx NE
be xx NE
mimicked xxx NE
by xx NE
the xxx NE
phorbol xxx NE
ester, xxx, NE
12-O-tetradecanoylphorbol-13-acetate dd-X-xxx-dd-xxx NE
, , NE
but xxx NE
not xxx NE
with xxx NE
calcium xxx NE
ionophores xxx NE
; ; NE
and xxx NE
are xxx NE
staurosporine xxx NE
sensitive xxx NE
but xxx NE
cyclosporine xxx NE
resistant xxx NE
. . NE

Gel Xxx NE
shift xxx NE
analyses xxx NE
demonstrate xxx NE
that xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
nuclear xxx NE
translocation xxx NE
is xx NE
stimulated xxx NE
primarily xxx NE
by xx NE
IL-1 XX-d protein
rather xxx NE
than xxx NE
by xx NE
antigen xxx NE
receptor xxx NE
signals xxx NE
. . NE

Western Xxxx NE
blot xxx NE
and xxx NE
phosphorylation xxx NE
analyses xxx NE
demonstrate xxx NE
that xxx NE
the xxx NE
synergistic xxx NE
effect xxx NE
on xx NE
NF-kappa XX-xxx NE
B X NE
functional xxx NE
activity xxx NE
is xx NE
independent xxx NE
of xx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
( ( NE
MAD3 XXXd NE
)- )- NE
NF-kappa XX-xxx NE
B X NE
dissociation xxx NE
in xx NE
the xxx NE
cytosol xxx NE
and xxx NE
is xx NE
not xxx NE
associated xxx NE
with xxx NE
I X NE
kappa xxx NE
B X NE
nuclear xxx NE
translocation xxx NE
. . NE

The Xxx NE
IL-1 XX-d NE
-induced -xxx NE
NF-kappa XX-xxx NE
B X NE
DNA XXX NE
nuclear xxx NE
localization xxx NE
is xx NE
transient xxx NE
and xxx NE
can xxx NE
be xx NE
prolonged xxx NE
either xxx NE
by xx NE
an xx NE
antigen xxx NE
receptor-initiated xxx-xxx NE
signal xxx NE
or xx NE
by xx NE
inhibiting xxx NE
protein xxx NE
synthesis xxx NE
. . NE

These Xxxx NE
results xxx NE
suggest xxx NE
that xxx NE
IL-1 XX-d protein
induces xxx NE
both xxx NE
NF-kappa XX-xxx NE
B X NE
nuclear xxx NE
translocation xxx NE
and xxx NE
the xxx NE
synthesis xxx NE
of xx NE
a x NE
protein(s) xxx(x) NE
responsible xxx NE
for xxx NE
terminating xxx NE
NF-kappa XX-xxx NE
B X NE
-DNA -XXX NE
interaction xxx NE
in xx NE
the xxx NE
nucleus xxx NE
. . NE

Antigen Xxxx NE
receptor xxx NE
signals xxx NE
prolong xxx NE
NF-kappa XX-xxx NE
B X NE
-DNA -XXX NE
interaction xxx NE
, , NE
probably xxx NE
by xx NE
functionally xxx NE
antagonizing xxx NE
the xxx NE
IL-1 XX-d NE
-induced -xxx NE
synthesis xxx NE
of xx NE
a x NE
protein(s) xxx(x) NE
responsible xxx NE
for xxx NE
the xxx NE
transient xxx NE
NF-kappa XX-xxx NE
B X NE
-DNA -XXX NE
interaction xxx NE
and xxx NE
consequently xxx NE
synergistically xxx NE
enhance xxx NE
IL-1 XX-d NE
-induced -xxx NE
NF-kappa XX-xxx NE
B X NE
-dependent -xxx NE
gene xxx NE
transcription xxx NE
. . NE

Identification Xxxx NE
of xx NE
the xxx NE
promoter xxx DNA_B
region xxx DNA_E
of xx NE
chicken xxx NE
anemia xxx NE
virus xxx NE
( ( NE
CAV XXX NE
) ) NE
containing xxx NE
a x NE
novel xxx NE
enhancer-like xxx-xxx DNA_B
element xxx DNA_E
. . NE

The Xxx NE
single xxx NE
promoter xxx DNA_B
region xxx DNA_E
in xx NE
the xxx NE
cloned xxx NE
genome xxx NE
[Noteborn [Xxxx NE
et xx NE
al. xx. NE
, , NE
J X NE
. . NE
Virol Xxxx NE
. . NE
65 dd NE
(1991) (dddd) NE
3131-3139] dddd-dddd] NE
of xx NE
chicken xxx NE
anemia xxx NE
virus xxx NE
( ( NE
CAV XXX NE
) ) NE
in xx NE
chicken xxx cell_type_B
T-cells X-xxx cell_type_E
was xxx NE
analysed xxx NE
via xxx NE
CAT XXX NE
assays xxx NE
. . NE

A X NE
unique xxx NE
region xxx NE
containing xxx NE
four xxx NE
or xx NE
five xxx NE
near-perfect xxx-xxx NE
direct xxx DNA_B
repeats xxx DNA_E
( ( NE
DR XX DNA
) ) NE
of xx NE
21 dd NE
bp xx NE
with xxx NE
one xxx NE
12-bp dd-xx DNA_B
insert xxx DNA_E
was xxx NE
proven xxx NE
to xx NE
be xx NE
the xxx NE
main xxx NE
transcription-activation xxx-xxx DNA_B
element xxx DNA_E
, , NE
with xxx NE
enhancer-like xxx-xxx NE
characteristics xxx NE
. . NE

PCR XXX NE
studies xxx NE
revealed xxx NE
that xxx NE
CAV XXX NE
isolates xxx NE
from xxx NE
across xxx NE
the xxx NE
world xxx NE
all xxx NE
contained xxx NE
this xxx NE
promoter xxx DNA_B
sequence xxx DNA_E
. . NE

Electrophoretic Xxxx NE
mobility-shift xxx-xxx NE
assays xxx NE
( ( NE
EMSA XXXX NE
) ) NE
showed xxx NE
that xxx NE
individual xxx DNA_B
DR XX DNA_M
units xxx DNA_E
, , NE
as xx NE
well xxx NE
as xx NE
the xxx NE
12-bp dd-xx DNA_B
insert xxx DNA_E
, , NE
can xxx NE
bind xxx NE
to xx NE
nuclear xxx protein_B
factors xxx protein_E
of xx NE
chicken xxx cell_type_B
T-cells X-xxx cell_type_E
. . NE

Competition Xxxx NE
assays xxx NE
revealed xxx NE
that xxx NE
the xxx NE
DR XX DNA_B
units xxx DNA_E
bound xxx NE
to xx NE
factors xxx NE
other xxx NE
than xxx NE
the xxx NE
12-bp dd-xx DNA_B
insert xxx DNA_E
. . NE

A X NE
synthetic xxx NE
oligodeoxyribonucleotide xxx NE
containing xxx NE
an xx NE
SP1-box XXd-xxx DNA
( ( NE
5'-GGGCGG d'-XXXXXX NE
) ) NE
could xxx NE
compete xxx NE
with xxx NE
factors xxx NE
binding xxx NE
to xx NE
the xxx NE
12-bp dd-xx DNA_B
insert xxx DNA_E
. . NE

Purified Xxxx NE
human xxx protein_B
SP1 XXd protein_E
was xxx NE
shown xxx NE
to xx NE
have xxx NE
very xxx NE
strong xxx NE
affinity xxx NE
for xxx NE
the xxx NE
12-bp dd-xx DNA_B
insert xxx DNA_E
. . NE

Functional Xxxx NE
Myc-Max Xxx-Xxx protein_B
heterodimer xxx protein_E
is xx NE
required xxx NE
for xxx NE
activation-induced xxx-xxx NE
apoptosis xxx NE
in xx NE
T X cell_line_B
cell xxx cell_line_M
hybridomas xxx cell_line_E
. . NE

T X cell_line_B
cell xxx cell_line_M
hybridomas xxx cell_line_E
respond xxx NE
to xx NE
activation xxx NE
signals xxx NE
by xx NE
undergoing xxx NE
apoptotic xxx NE
cell xxx NE
death xxx NE
, , NE
and xxx NE
this xxx NE
is xx NE
likely xxx NE
to xx NE
represent xxx NE
comparable xxx NE
events xxx NE
related xxx NE
to xx NE
tolerance xxx NE
induction xxx NE
in xx NE
immature xxx cell_type_B
T X cell_type_M
cell xxx cell_type_M
and xxx cell_type_M
mature xxx cell_type_M
T X cell_type_M
cell xxx cell_type_E

Previous Xxxx NE
studies xxx NE
using xxx NE
antisense xxx NE
oligonucleotides xxx NE
implicated xxx NE
the xxx NE
c-Myc x-Xxx protein_B
protein xxx protein_E
in xx NE
the xxx NE
phenomenon xxx NE
of xx NE
activation-induced xxx-xxx NE
apoptosis xxx NE
. . NE

This Xxxx NE
role xxx NE
for xxx NE
c-Myc x-Xxx protein
in xx NE
apoptosis xxx NE
is xx NE
now xxx NE
confirmed xxx NE
in xx NE
studies xxx NE
using xxx NE
a x NE
dominant xxx NE
negative xxx NE
form xxx NE
of xx NE
its xxx NE
heterodimeric xxx NE
binding xxx NE
partner xxx NE
, , NE
Max Xxx protein
, , NE
which xxx NE
we xx NE
show xxx NE
here xxx NE
inhibits xxx NE
activation-induced xxx-xxx NE
apoptosis xxx NE
. . NE

Further Xxxx NE
, , NE
coexpression xxx NE
of xx NE
a x NE
reciprocally xxx protein_B
mutant xxx protein_M
Myc Xxx protein_M
protein xxx protein_E
capable xxx NE
of xx NE
forming xxx NE
functional xxx NE
heterodimers xxx protein
with xxx NE
the xxx NE
mutant xxx NE
Max Xxx protein
can xxx NE
compensate xxx NE
for xxx NE
the xxx NE
dominant xxx NE
negative xxx NE
activity xxx NE
and xxx NE
restore xxx NE
activation-induced xxx-xxx NE
apoptosis xxx NE
. . NE

These Xxxx NE
results xxx NE
imply xxx NE
that xxx NE
Myc Xxx protein
promotes xxx NE
activation-induced xxx-xxx NE
apoptosis xxx NE
by xx NE
obligatory xxx NE
heterodimerization xxx NE
with xxx NE
Max Xxx protein
, , NE
and xxx NE
therefore xxx NE
, , NE
by xx NE
regulating xxx NE
gene xxx NE
transcription xxx NE
. . NE

Epstein-Barr Xxxx-Xxxx protein_B
virus xxx protein_M
SM XX protein_M
protein xxx protein_E
. . NE

The Xxx NE
protein xxx NE
products xxx NE
of xx NE
the xxx NE
Epstein-Barr Xxxx-Xxxx NE
virus xxx NE
( ( NE
EBV XXX NE
) ) NE
BMLF1 XXXXd NE
open xxx NE
reading xxx NE
frame xxx NE
have xxx NE
been xxx NE
characterized xxx NE
in xx NE
the xxx NE
early xxx NE
productive xxx NE
cycle xxx NE
in xx NE
B95-8 Xdd-d NE
and xxx NE
Akata Xxxx NE
cells xxx NE
. . NE

The Xxx NE
SM XX protein_B
protein xxx protein_E
derived xxx NE
from xxx NE
the xxx NE
spliced xxx NE
RNA XXX NE
joining xxx NE
BSLF2 XXXXd protein
to xx NE
BMLF1 XXXXd protein
is xx NE
much xxx NE
the xxx NE
most xxx NE
abundant xxx NE
protein xxx NE
. . NE

SM XX protein
is xx NE
a x NE
phosphoprotein xxx protein
in xx NE
EBV XXX NE
-infected -xxx NE
cells xxx NE
and xxx NE
can xxx NE
be xx NE
phosphorylated xxx NE
in xx NE
vitro xxx NE
with xxx NE
casein xxx NE
kinase xxx NE
II XX NE
( ( NE
CKII XXXX NE
) ) NE
. . NE

Computer Xxxx NE
analysis xxx NE
of xx NE
the xxx NE
SM XX protein_B
protein xxx protein_M
sequence xxx protein_E
showed xxx NE
a x NE
C X protein_B
terminal xxx protein_M
section xxx protein_E
of xx NE
SM XX protein
to xx NE
be xx NE
related xxx NE
to xx NE
genome xxx protein_B
positional xxx protein_M
homologues xxx protein_E
of xx NE
four xxx NE
other xxx NE
herpesviruses xxx NE
and xxx NE
revealed xxx NE
consensus xxx NE
CKII XXXX NE
sites xxx NE
near xxx NE
the xxx NE
N X NE
termini xxx NE
of xx NE
the xxx NE
EBV XXX NE
SM XX NE
protein xxx NE
, , NE
the xxx NE
herpes xxx NE
simplex xxx NE
virus xxx NE
( ( NE
HSV XXX NE
) ) NE
ICP27 XXXdd NE
protein xxx NE
and xxx NE
the xxx NE
herpesvirus xxx NE
saimiri xxx NE
( ( NE
HVS XXX NE
) ) NE
open xxx NE
reading xxx NE
frame xxx NE
57 dd NE
protein xxx NE
. . NE

Site-directed Xxxx-xxx NE
mutagenesis xxx NE
of xx NE
the xxx NE
consensus xxx DNA_B
CKII XXXX DNA_M
site xxx DNA_E
in xx NE
EBV XXX NE
SM XX NE
greatly xxx NE
reduced xxx NE
the xxx NE
in xx NE
vitro xxx NE
phosphorylation xxx NE
of xx NE
SM XX protein
by xx NE
CKII XXXX protein
. . NE

The Xxx NE
mechanism xxx NE
of xx NE
transactivation xxx NE
by xx NE
BMLF1 XXXXd protein_B
proteins xxx protein_E
has xxx NE
been xxx NE
controversial xxx NE
but xxx NE
SM XX protein
was xxx NE
shown xxx NE
to xx NE
transactivate xxx NE
gene xxx NE
expression xxx NE
from xxx NE
a x NE
CAT XXX DNA_B
reporter xxx DNA_M
construct xxx DNA_E
by xx NE
increasing xxx NE
the xxx NE
amount xxx NE
of xx NE
cytoplasmic xxx RNA_B
CAT XXX RNA_M
mRNA xXXX RNA_E
. . NE

Mutagenesis Xxxx NE
of xx NE
the xxx NE
CKII XXXX protein
site xxx NE
in xx NE
SM XX protein
made xxx NE
no xx NE
difference xxx NE
to xx NE
the xxx NE
transactivation xxx NE
in xx NE
this xxx NE
transient xxx NE
transfection xxx NE
assay xxx NE
. . NE

Inducible Xxxx NE
binding xxx NE
to xx NE
the xxx NE
c-fos x-xxx NE
serum xxx NE
response xxx NE
element xxx NE
during xxx NE
T X NE
cell xxx NE
activation xxx NE
is xx NE
regulated xxx NE
by xx NE
a x NE
phosphotyrosine-containing xxx-xxx protein_B
protein xxx protein_E
. . NE

The Xxx NE
proto-oncogene xxx-xxx DNA_B
c-fos x-xxx DNA_E
is xx NE
an xx NE
immediate-early xxx-xxx DNA_B
gene xxx DNA_E
, , NE
and xxx NE
one xxx NE
of xx NE
the xxx NE
first xxx NE
genes xxx NE
transcribed xxx NE
after xxx NE
stimulation xxx NE
of xx NE
most xxx NE
cells xxx NE
with xxx NE
a x NE
variety xxx NE
of xx NE
ligands xxx NE
. . NE

Fos Xxx NE
expression xxx NE
may xxx NE
be xx NE
a x NE
pivotal xxx NE
event xxx NE
in xx NE
converting xxx NE
ligand-receptor xxx-xxx NE
interactions xxx NE
at xx NE
the xxx NE
membrane xxx NE
into xxx NE
functional xxx NE
modulation xxx NE
of xx NE
cell xxx NE
phenotype xxx NE
. . NE

The Xxx NE
serum xxx DNA_B
response xxx DNA_M
element xxx DNA_E
( ( NE
SRE XXX DNA
) ) NE
in xx NE
the xxx NE
c-fos x-xxx DNA_B
regulatory xxx DNA_M
region xxx DNA_E
participates xxx NE
in xx NE
induction xxx NE
of xx NE
transcription xxx NE
by xx NE
various xxx NE
growth xxx protein_B
factors xxx protein_E
and xxx NE
by xx NE
phorbol xxx NE
esters xxx NE
and xxx NE
subsequent xxx NE
squelching xxx NE
of xx NE
transcription xxx NE
. . NE

We Xx NE
show xxx NE
that xxx NE
an xx NE
inducible xxx NE
protein xxx protein_B
complex xxx protein_E
( ( NE
Band Xxxx protein_B
A X protein_E
) ) NE
binds xxx NE
to xx NE
SRE XXX DNA_B
DNA XXX DNA_E
within xxx NE
10 dd NE
min xxx NE
after xxx NE
mitogenic xxx NE
stimulation xxx NE
of xx NE
human xxx cell_line_B
PBL-T XXX-X cell_line_E
, , NE
and xxx NE
becomes xxx NE
nondetectable xxx NE
by xx NE
60 dd NE
min xxx NE
. . NE

Band Xxxx protein_B
A X protein_E
contains xxx NE
the xxx NE
serum xxx protein_B
response xxx protein_M
factor xxx protein_E
plus xxx NE
additional xxx NE
factor(s) xxx(x) NE
. . NE

A X NE
protein xxx NE
that xxx NE
is xx NE
phosphorylated xxx NE
on xx NE
a x NE
tyrosine xxx NE
residue xxx NE
in xx NE
resting xxx cell_line_B
PBL-T XXX-X cell_line_E
suppresses xxx NE
binding xxx NE
of xx NE
a x NE
component xxx NE
of xx NE
Band Xxxx protein_B
A X protein_E
to xx NE
the xxx NE
SRE XXX DNA_B
motif xxx DNA_E
. . NE

Upon Xxxx NE
stimulation xxx NE
of xx NE
the xxx NE
cells xxx NE
, , NE
this xxx NE
protein xxx NE
no xx NE
longer xxx NE
prevents xxx NE
binding xxx NE
of xx NE
DNA XXX NE
by xx NE
Band Xxxx protein_B
A X protein_E
, , NE
and xxx NE
suppression xxx NE
of xx NE
binding xxx NE
is xx NE
restored xxx NE
within xxx NE
30 dd NE
min xxx NE
. . NE

The Xxx NE
phosphorylated xxx NE
tyrosine xxx NE
residue xxx NE
itself xxx NE
is xx NE
important xxx NE
for xxx NE
the xxx NE
protein-protein xxx-xxx NE
interaction xxx NE
. . NE

In Xx NE
vivo xxx NE
modification xxx NE
of xx NE
major xxx NE
histocompatibility xxx NE
complex xxx NE
class xxx NE
II XX NE
DRA XXX NE
promoter xxx NE
occupancy xxx NE
mediated xxx NE
by xx NE
the xxx NE
AIR-1 XXX-d protein_B
trans-activator xxx-xxx protein_E
. . NE

RJ XX cell_line_B
2.2.5 d.d.d cell_line_E
is xx NE
a x NE
human xxx cell_line_B
B X cell_line_M
cell xxx cell_line_M
mutant xxx cell_line_E
derived xxx NE
from xxx NE
the xxx NE
Burkitt Xxxx cell_line_B
lymphoma xxx cell_line_M
Raji Xxxx cell_line_M
cell xxx cell_line_E
which xxx NE
is xx NE
defective xxx NE
in xx NE
the xxx NE
AIR-1 XXX-d NE
locus xxx NE
function xxx NE
. . NE

This Xxxx NE
locus xxx NE
encodes xxx NE
a x NE
transcriptional xxx NE
trans-activator xxx-xxx NE
required xxx NE
for xxx NE
the xxx NE
constitutive xxx NE
expression xxx NE
of xx NE
major xxx DNA_B
histocompatibility xxx DNA_M
complex xxx DNA_M
(MHC) (XXX) DNA_M
class xxx DNA_M
II XX DNA_M
genes xxx DNA_E
. . NE

Here Xxxx NE
we xx NE
show xxx NE
, , NE
by xx NE
in xx NE
vivo xxx NE
DNase XXxxx NE
I X NE
footprinting xxx NE
, , NE
that xxx NE
the xxx NE
AIR-1 XXX-d DNA_B
locus xxx DNA_M
defect xxx DNA_E
correlates xxx NE
with xxx NE
changes xxx NE
in xx NE
the xxx NE
DRA XXX NE
promoter xxx NE
occupancy xxx NE
. . NE

Interestingly Xxxx NE
, , NE
reexpression xxx NE
of xx NE
human xxx DNA_B
MHC XXX DNA_M
class xxx DNA_M
II XX DNA_M
genes xxx DNA_E
in xx NE
RJ XX cell_line_B
2.2.5 d.d.d cell_line_M
x x cell_line_M
mouse xxx cell_line_M
spleen xxx cell_line_M
cell xxx cell_line_M
hybrids xxx cell_line_E
is xx NE
associated xxx NE
with xxx NE
partial xxx NE
reversion xxx NE
of xx NE
DRA XXX NE
promoter xxx NE
occupancy xxx NE
to xx NE
the xxx NE
Raji Xxxx NE
pattern xxx NE
. . NE

DRA XXX NE
promoter xxx NE
occupancy xxx NE
in xx NE
other xxx NE
class xxx cell_line_B
II-negative XX-xxx cell_line_M
B X cell_line_M
cell xxx cell_line_M
lines xxx cell_line_E
, , NE
derived xxx NE
from xxx NE
patients xxx NE
with xxx NE
bare xxx NE
lymphocyte xxx NE
syndrome xxx NE
, , NE
is xx NE
drastically xxx NE
different xxx NE
from xxx NE
the xxx NE
one xxx NE
observed xxx NE
in xx NE
RJ XX cell_line_B
2.2.5 d.d.d cell_line_E
and xxx NE
Raji Xxxx cell_line_B
cells xxx cell_line_E
. . NE

Moreover Xxxx NE
, , NE
the xxx NE
use xxx NE
of xx NE
the xxx NE
DNase XXxxx protein_B
I X protein_E
as xx NE
an xx NE
in xx NE
vivo xxx NE
footprinting xxx NE
agent xxx NE
reveals xxx NE
that xxx NE
the xxx NE
patients xxx NE
' ' NE
cell xxx NE
lines xxx NE
do xx NE
not xxx NE
display xxx NE
a x NE
completely xxx NE
" " NE
bare xxx NE
promoter xxx NE
" " NE
as xx NE
previously xxx NE
reported xxx NE
using xxx NE
dimethyl xxx NE
sulfate xxx NE
as xx NE
the xxx NE
footprinting xxx NE
agent xxx NE
. . NE

Thus Xxxx NE
, , NE
the xxx NE
use xxx NE
of xx NE
DNase XXxxx protein_B
I X protein_E
allowed xxx NE
us xx NE
, , NE
for xxx NE
the xxx NE
first xxx NE
time xxx NE
, , NE
to xx NE
correlate xxx NE
the xxx NE
AIR-1 XXX-d DNA_B
locus xxx DNA_M
defect xxx DNA_E
with xxx NE
class xxx NE
II XX NE
promoter xxx NE
occupancy xxx NE
alterations xxx NE
and xxx NE
distinguish xxx NE
these xxx NE
alterations xxx NE
from xxx NE
the xxx NE
ones xxx NE
observed xxx NE
in xx NE
phenotypically xxx NE
similar xxx NE
but xxx NE
genetically xxx NE
distinct xxx NE
MHC XXX cell_line_B
class xxx cell_line_M
II-negative XX-xxx cell_line_M
cells xxx cell_line_E
. . NE

Regulation Xxxx NE
of xx NE
cell-type-specific xxx-xxx-xxx NE
interleukin-2 xxx-d NE
receptor xxx NE
alpha-chain xxx-xxx NE
gene xxx NE
expression xxx NE
: : NE
potential xxx NE
role xxx NE
of xx NE
physical xxx NE
interactions xxx NE
between xxx NE
Elf-1 Xxx-d protein
, , NE
HMG-I(Y) XXX-X(X) protein
, , NE
and xxx NE
NF-kappa XX-xxx protein_B
B X protein_M
family xxx protein_M
proteins xxx protein_E
. . NE

The Xxx NE
interleukin xxx NE
2 d NE
receptor xxx NE
alpha-chain xxx-xxx NE
( ( NE
IL-2R XX-dX NE
alpha xxx NE
) ) NE
gene xxx NE
is xx NE
rapidly xxx NE
and xxx NE
potently xxx NE
induced xxx NE
in xx NE
T X NE
cells xxx NE
in xx NE
response xxx NE
to xx NE
mitogenic xxx NE
stimuli xxx NE
. . NE

Previously Xxxx NE
, , NE
an xx NE
inducible xxx DNA_B
enhancer xxx DNA_E
between xxx NE
nucleotides xxx DNA_B
-299 -ddd DNA_M
and xxx DNA_M
-228 -ddd DNA_E
that xxx NE
contains xxx NE
NF-kappa XX-xxx DNA_B
B X DNA_M
motif xxx DNA_M
and xxx DNA_M
CArG XXxX DNA_M
motif xxx DNA_E

We Xx NE
now xxx NE
report xxx NE
the xxx NE
characterization xxx NE
of xx NE
a x NE
second xxx NE
essential xxx DNA_B
positive xxx DNA_M
regulatory xxx DNA_M
element xxx DNA_E
located xxx NE
between xxx NE
nucleotides xxx DNA_B
-137 -ddd DNA_M
and xxx DNA_M
-64 -dd DNA_E
that xxx NE
binds xxx NE
Elf-1 Xxx-d protein
and xxx NE
HMG-I(Y) XXX-X(X) protein
. . NE

This Xxxx NE
element xxx NE
had xxx NE
maximal xxx NE
activity xxx NE
in xx NE
lymphoid xxx cell_type_B
cells xxx cell_type_E
, , NE
paralleling xxx NE
the xxx NE
cell xxx NE
type xxx NE
specificity xxx NE
of xx NE
Elf-1 Xxx-d NE
expression xxx NE
. . NE

Transcription Xxxx NE
from xxx NE
the xxx NE
IL-2R XX-dX DNA_B
alpha xxx DNA_M
promoter xxx DNA_E
was xxx NE
inhibited xxx NE
when xxx NE
either xxx NE
the xxx NE
Elf-1 Xxx-d DNA_B
binding xxx DNA_M
site xxx DNA_M
or xx DNA_M
HMG-I(Y) XXX-X(X) DNA_M
binding xxx DNA_M
site xxx DNA_E

Coexpression Xxxx NE
of xx NE
both xxx NE
proteins xxx NE
activated xxx NE
transcription xxx NE
of xx NE
the xxx NE
-137 -ddd DNA_B
to xx DNA_M
-64 -dd DNA_M
element xxx DNA_E
in xx NE
COS-7 XXX-d cell_line_B
cells xxx cell_line_E
. . NE

Elf-1 Xxx-d protein
physically xxx NE
associated xxx NE
with xxx NE
HMG-I XXX-X protein
and xxx NE
with xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
p50 xdd NE
and xxx NE
c-Rel x-Xxx protein
in xx NE
vitro xxx NE
, , NE
suggesting xxx NE
that xxx NE
protein-protein xxx-xxx NE
interactions xxx NE
might xxx NE
functionally xxx NE
coordinate xxx NE
the xxx NE
actions xxx NE
of xx NE
the xxx NE
upstream xxx DNA_B
positive xxx DNA_M
regulatory xxx DNA_M
element xxx DNA_M
and xxx DNA_M
downstream xxx DNA_M
positive xxx DNA_M
regulatory xxx DNA_M
element xxx DNA_E

This Xxxx NE
is xx NE
the xxx NE
first xxx NE
report xxx NE
of xx NE
a x NE
physical xxx NE
interaction xxx NE
between xxx NE
an xx NE
Ets Xxx NE
family xxx NE
member xxx NE
and xxx NE
NF-kappa XX-xxx protein_B
B X protein_M
family xxx protein_M
proteins xxx protein_E
. . NE

These Xxxx NE
findings xxx NE
provide xxx NE
significant xxx NE
new xxx NE
insights xxx NE
into xxx NE
the xxx NE
protein-protein xxx-xxx NE
and xxx NE
protein-DNA xxx-XXX NE
interactions xxx NE
that xxx NE
regulate xxx NE
cell-type-specific xxx-xxx-xxx NE
and xxx NE
inducible xxx NE
IL-2R XX-dX NE
alpha xxx NE
gene xxx NE
expression xxx NE
and xxx NE
also xxx NE
have xxx NE
implications xxx NE
for xxx NE
other xxx NE
genes xxx NE
regulated xxx NE
by xx NE
Elf-1 Xxx-d protein
and xxx NE
NF-kappa XX-xxx protein_B
B X protein_M
family xxx protein_M
proteins xxx protein_E
. . NE

Isolation Xxxx NE
of xx NE
cDNA xXXX DNA_B
clones xxx DNA_E
for xxx NE
42 dd NE
different xxx NE
Kruppel-related Xxxx-xxx protein_B
zinc xxx protein_M
finger xxx protein_M
proteins xxx protein_E
expressed xxx NE
in xx NE
the xxx NE
human xxx cell_line_B
monoblast xxx cell_line_M
cell xxx cell_line_M
line xxx cell_line_M
U-937 X-ddd cell_line_E
. . NE

To Xx NE
study xxx NE
the xxx NE
complexity xxx NE
and xxx NE
structural xxx NE
characteristics xxx NE
of xx NE
zinc xxx protein_B
finger xxx protein_M
proteins xxx protein_E
expressed xxx NE
during xxx NE
human xxx NE
hematopoiesis xxx NE
and xxx NE
to xx NE
isolate xxx NE
novel xxx NE
regulators xxx NE
of xx NE
blood xxx NE
cell xxx NE
development xxx NE
, , NE
a x NE
degenerate xxx NE
oligonucleotide xxx NE
probe xxx NE
specific xxx NE
for xxx NE
a x NE
consensus xxx protein_B
zinc xxx protein_M
finger xxx protein_M
peptide xxx protein_M
domain xxx protein_E
was xxx NE
used xxx NE
to xx NE
isolate xxx NE
63 dd NE
cDNA xXXX DNA_B
clones xxx DNA_E
for xxx NE
Kruppel-related Xxxx-xxx DNA_B
zinc xxx DNA_M
finger xxx DNA_M
genes xxx DNA_E
from xxx NE
the xxx NE
human xxx cell_line_B
monoblast xxx cell_line_M
cell xxx cell_line_M
line xxx cell_line_M
U-937 X-ddd cell_line_E
. . NE

By Xx NE
extensive xxx NE
nucleotide xxx NE
sequence xxx NE
and xxx NE
Northern Xxxx NE
blot xxx NE
analysis xxx NE
, , NE
these xxx NE
cDNA xXXX NE
clones xxx NE
were xxx NE
found xxx NE
to xx NE
originate xxx NE
from xxx NE
approximately xxx NE
42 dd NE
different xxx NE
genes xxx NE
( ( NE
HZF XXX NE
1-42 d-dd NE
) ) NE
of xx NE
which xxx NE
only xxx NE
8 d NE
have xxx NE
previously xxx NE
been xxx NE
described xxx NE
. . NE

Northern Xxxx NE
blot xxx NE
analysis xxx NE
showed xxx NE
that xxx NE
a x NE
majority xxx NE
of xx NE
these xxx NE
genes xxx NE
were xxx NE
expressed xxx NE
at xx NE
comparable xxx NE
levels xxx NE
in xx NE
U-937 X-ddd cell_line
and xxx NE
HeLa XxXx cell_line_B
cells xxx cell_line_E
. . NE

The Xxx NE
large xxx NE
number xxx NE
of xx NE
individual xxx NE
genes xxx NE
represented xxx NE
among xxx NE
the xxx NE
63 dd NE
clones xxx NE
and xxx NE
their xxx NE
apparent xxx NE
non-cell-type-specific xxx-xxx-xxx-xxx NE
expression xxx NE
suggest xxx NE
that xxx NE
the xxx NE
majority xxx NE
of xx NE
the xxx NE
Kruppel-related Xxxx-xxx DNA_B
zinc xxx DNA_M
finger xxx DNA_M
genes xxx DNA_E
are xxx NE
likely xxx NE
to xx NE
be xx NE
expressed xxx NE
in xx NE
most xxx NE
human xxx NE
tissues xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
some xxx NE
of xx NE
the xxx NE
genes xxx NE
displayed xxx NE
a x NE
restricted xxx NE
expression xxx NE
pattern xxx NE
, , NE
indicating xxx NE
that xxx NE
they xxx NE
represent xxx NE
potential xxx NE
regulators xxx NE
of xx NE
monocyte xxx NE
differentiation xxx NE
or xx NE
proliferation xxx NE
. . NE

Detailed Xxxx NE
structural xxx NE
analysis xxx NE
of xx NE
the xxx NE
first xxx NE
12 dd NE
cDNAs xXXXx DNA
( ( NE
HZF XXX DNA_B
1-10 d-dd DNA_E
) ) NE
and xxx NE
a x NE
partial xxx NE
characterization xxx NE
of xx NE
HZF XXX DNA_B
11-42 dd-dd DNA_E
revealed xxx NE
that xxx NE
a x NE
common xxx NE
feature xxx NE
of xx NE
human xxx protein_B
Kruppel-related Xxxx-xxx protein_M
zinc xxx protein_M
finger xxx protein_M
proteins xxx protein_E
is xx NE
the xxx NE
presence xxx NE
of xx NE
tandem xxx NE
arrays xxx NE
of xx NE
zinc xxx protein_B
fingers xxx protein_E
ranging xxx NE
in xx NE
number xxx NE
from xxx NE
3 d NE
to xx NE
over xxx NE
20 dd NE
that xxx NE
are xxx NE
preferentially xxx NE
located xxx NE
in xx NE
the xxx NE
carboxy-terminal xxx-xxx protein_B
regions xxx protein_E
of xx NE
the xxx NE
proteins xxx NE
. . NE

In Xx NE
addition xxx NE
, , NE
several xxx NE
novel xxx NE
KRAB-containing XXXX-xxx DNA_B
zinc xxx DNA_M
finger xxx DNA_M
genes xxx DNA_E
and xxx NE
a x NE
novel xxx NE
conserved xxx DNA_B
sequence xxx DNA_M
element xxx DNA_E
were xxx NE
identified xxx NE
. . NE

CAG XXX DNA_B
repeat xxx DNA_M
length xxx DNA_M
variation xxx DNA_E
in xx NE
sperm xxx cell_type
from xxx NE
a x NE
patient xxx NE
with xxx NE
Kennedy's Xxxx'x NE
disease xxx NE
. . NE

Using Xxxx NE
a x NE
modified xxx NE
sperm xxx NE
typing xxx NE
protocol xxx NE
, , NE
the xxx NE
mutation xxx NE
frequency xxx NE
of xx NE
the xxx NE
CAG XXX DNA_B
repeat xxx DNA_M
region xxx DNA_E
at xx NE
the xxx NE
androgen xxx DNA_B
receptor xxx DNA_M
locus xxx DNA_E
has xxx NE
been xxx NE
measured xxx NE
using xxx NE
a x NE
rare xxx NE
semen xxx NE
sample xxx NE
from xxx NE
an xx NE
individual xxx NE
with xxx NE
spinal xxx NE
and xxx NE
bulbar xxx NE
muscular xxx NE
atrophy xxx NE
( ( NE
SBMA XXXX NE
) ) NE
. . NE

Among Xxxx NE
258 ddd NE
X X cell_type_B
chromosome-containing xxx-xxx cell_type_M
sperm xxx cell_type_E
, , NE
19% dd% NE
had xxx NE
a x NE
repeat xxx NE
number xxx NE
equal xxx NE
to xx NE
the xxx NE
donor's xxx'x DNA_B
somatic xxx DNA_M
DNA XXX DNA_E
(47 (dd NE
repeats) xxx) NE
, , NE
66% dd% NE
were xxx NE
expansions xxx NE
and xxx NE
15% dd% NE
were xxx NE
contractions xxx NE
. . NE

The Xxx NE
average xxx NE
expansion xxx NE
was xxx NE
2.7 d.d NE
repeats xxx NE
. . NE

More Xxxx NE
than xxx NE
half xxx NE
of xx NE
the xxx NE
expansions xxx NE
involved xxx NE
one xxx NE
or xx NE
two xxx NE
repeats xxx NE
; ; NE
the xxx NE
largest xxx NE
was xxx NE
11 dd NE
repeats xxx NE
. . NE

68% dd% NE
of xx NE
the xxx NE
contractions xxx NE
were xxx NE
also xxx NE
one xxx NE
or xx NE
two xxx NE
repeats xxx NE
but xxx NE
six xxx NE
(16%) (dd%) NE
were xxx NE
very xxx NE
large xxx NE
(12-25 (dd-dd NE
repeats) xxx) NE
. . NE

One Xxx NE
contraction xxx NE
generated xxx NE
an xx NE
allele xxx NE
in xx NE
an xx NE
intermediate xxx NE
size xxx NE
range xxx NE
(33-39 (dd-dd NE
repeats) xxx) NE
. . NE

Such Xxxx NE
alleles xxx NE
have xxx NE
not xxx NE
been xxx NE
observed xxx NE
among xxx NE
more xxx NE
than xxx NE
900 ddd NE
normal xxx NE
and xxx NE
SBMA XXXX DNA_B
X-chromosomes X-xxx DNA_E
that xxx NE
have xxx NE
been xxx NE
examined xxx NE
. . NE

Comparison Xxxx NE
of xx NE
the xxx NE
SBMA XXXX NE
sperm xxx cell_type
typing xxx NE
results xxx NE
with xxx NE
mutation xxx NE
frequency xxx NE
data xxx NE
on xx NE
normal xxx NE
alleles xxx NE
supports xxx NE
the xxx NE
hypothesis xxx NE
that xxx NE
trinucleotide xxx DNA_B
repeat xxx DNA_E
expansions xxx NE
may xxx NE
have xxx NE
a x NE
different xxx NE
molecular xxx NE
origin xxx NE
than xxx NE
contractions xxx NE
. . NE

Aspirin-like Xxxx-xxx NE
drugs xxx NE
can xxx NE
protect xxx NE
human xxx cell_type_B
T X cell_type_M
lymphocytes xxx cell_type_E
against xxx NE
benzoquinone xxx NE
cytotoxicity xxx NE
: : NE
evidence xxx NE
for xxx NE
a x NE
NAD(P)H:quinone XXX(X)X:xxx NE
reductase xxx NE
-dependent -xxx NE
mechanism xxx NE
. . NE

Benzene Xxxx NE
toxicity xxx NE
towards xxx NE
lymphocytes xxx cell_type
is xx NE
thought xxx NE
to xx NE
be xx NE
mediated xxx NE
by xx NE
metabolites xxx NE
of xx NE
benzene xxx NE
including xxx NE
benzoquinone xxx NE
( ( NE
BQ XX NE
) ) NE
. . NE

NAD(P)H:quinone XXX(X)X:xxx protein_B
reductase xxx protein_E
( ( NE
QR XX protein
) ) NE
is xx NE
known xxx NE
to xx NE
protect xxx NE
against xxx NE
BQ XX NE
toxicity xxx NE
. . NE

The Xxx NE
expression xxx NE
of xx NE
the xxx NE
QR XX DNA_B
gene xxx DNA_E
is xx NE
regulated xxx NE
by xx NE
the xxx NE
transcription xxx protein_B
factor xxx protein_E
AP-1 XX-d protein
. . NE

We Xx NE
had xxx NE
previously xxx NE
found xxx NE
that xxx NE
aspirin-like xxx-xxx NE
drugs xxx NE
( ( NE
ALD XXX NE
) ) NE
induce xxx NE
AP-1 XX-d protein
in xx NE
human xxx cell_type_B
T X cell_type_M
lymphocytes xxx cell_type_E
. . NE

It Xx NE
was xxx NE
therefore xxx NE
hypothesized xxx NE
that xxx NE
ALD XXX NE
would xxx NE
protect xxx NE
lymphocytes xxx cell_type
against xxx NE
BQ XX NE
toxicity xxx NE
by xx NE
inducing xxx NE
QR XX protein
. . NE

Molt-4 Xxxx-d cell_line_B
cells xxx cell_line_E
( ( NE
M4 Xd cell_line
) ) NE
, , NE
a x NE
human xxx cell_line_B
T X cell_line_M
lymphocyte xxx cell_line_M
cell xxx cell_line_M
line xxx cell_line_E
, , NE
were xxx NE
incubated xxx NE
with xxx NE
different xxx NE
concentrations xxx NE
of xx NE
two xxx NE
ALD XXX NE
, , NE
flurbiprofen xxx NE
and xxx NE
sodium xxx NE
diclofenac xxx NE
, , NE
and xxx NE
then xxx NE
exposed xxx NE
to xx NE
BQ XX NE
. . NE

Toxicity Xxxx NE
was xxx NE
measured xxx NE
by xx NE
viability xxx NE
( ( NE
trypan xxx NE
blue xxx NE
exclusion xxx NE
) ) NE
. . NE

Both Xxxx NE
drugs xxx NE
protected xxx NE
the xxx NE
cells xxx NE
against xxx NE
BQ XX NE
cytotoxicity xxx NE
in xx NE
a x NE
dose-dependent xxx-xxx NE
manner xxx NE
, , NE
e.g. x.x. NE
, , NE
sodium xxx NE
diclofenac xxx NE
at xx NE
15 dd NE
microM xxxX NE
reduced xxx NE
the xxx NE
fraction xxx NE
of xx NE
BQ XX NE
-treated -xxx NE
dead xxx NE
cells xxx NE
by xx NE
70% dd% NE
. . NE

ALDs XXXx NE
induced xxx NE
QR XX NE
activity xxx NE
in xx NE
the xxx NE
M4 Xd NE
cells xxx NE
in xx NE
the xxx NE
same xxx NE
range xxx NE
of xx NE
concentrations xxx NE
that xxx NE
protected xxx NE
the xxx NE
cells xxx NE
against xxx NE
BQ XX NE
toxicity xxx NE
. . NE

The Xxx NE
protective xxx NE
effect xxx NE
of xx NE
ALD XXX NE
was xxx NE
significantly xxx NE
reduced xxx NE
by xx NE
dicoumarol xxx NE
, , NE
a x NE
QR XX NE
-specific -xxx NE
inhibitor xxx NE
. . NE

Since Xxxx NE
human xxx cell_type_B
T X cell_type_M
cells xxx cell_type_E
and xxx NE
T X cell_type_B
cell xxx cell_type_M
lines xxx cell_type_E
do xx NE
not xxx NE
metabolize xxx NE
arachidonic xxx NE
acid xxx NE
, , NE
our xxx NE
data xxx NE
suggest xxx NE
that xxx NE
ALD XXX NE
can xxx NE
protect xxx NE
human xxx cell_type_B
T X cell_type_M
lymphocytes xxx cell_type_E
against xxx NE
a x NE
metabolite xxx NE
of xx NE
benzene xxx NE
by xx NE
induction xxx NE
of xx NE
QR XX NE
activity xxx NE
. . NE

Correlation Xxxx NE
of xx NE
differentiation-inducing xxx-xxx NE
activity xxx NE
of xx NE
retinoids xxx NE
on xx NE
human xxx cell_line_B
leukemia xxx cell_line_M
cell xxx cell_line_M
lines xxx cell_line_E
HL-60 XX-dd cell_line
and xxx NE
NB4 XXd cell_line
. . NE

Retinoids Xxxx NE
, , NE
including xxx NE
all-trans-retinoic xxx-xxx-xxx NE
acid xxx NE
, , NE
its xxx NE
isomers xxx NE
, , NE
and xxx NE
fifty xxx NE
synthetic xxx NE
retinoids xxx NE
(retinobenzoic (xxx NE
acids) xxx) NE
, , NE
were xxx NE
tested xxx NE
for xxx NE
differentiation-inducing xxx-xxx NE
activity xxx NE
on xx NE
human xxx cell_line_B
leukemia xxx cell_line_M
cell xxx cell_line_M
lines xxx cell_line_E
HL-60 XX-dd cell_line
and xxx NE
NB4 XXd cell_line
. . NE

A X NE
good xxx NE
linear xxx NE
correlation xxx NE
, , NE
with xxx NE
an xx NE
r x NE
value xxx NE
of xx NE
0.91 d.dd NE
, , NE
between xxx NE
the xxx NE
ED50 XXdd NE
values xxx NE
for xxx NE
the xxx NE
differentiation-inducing xxx-xxx NE
activity xxx NE
towards xxx NE
HL-60 XX-dd cell_line_B
cells xxx cell_line_E
and xxx NE
that xxx NE
towards xxx NE
NB4 XXd cell_line_B
cells xxx cell_line_E
was xxx NE
found xxx NE
. . NE

Platelet-activating Xxxx-xxx protein_B
factor xxx protein_E
( ( NE
PAF XXX protein
) ) NE
positively xxx NE
auto-regulates xxx-xxx NE
the xxx NE
expression xxx NE
of xx NE
human xxx protein_B
PAF XXX protein_M
receptor xxx protein_M
transcript xxx protein_M
1 d protein_E
( ( NE
leukocyte-type xxx-xxx NE
) ) NE
through xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
. . NE

The Xxx NE
human xxx NE
platelet-activating xxx-xxx NE
factor xxx NE
receptor xxx NE
( ( NE
PAFR XXXX NE
) ) NE
gene xxx NE
is xx NE
transcribed xxx NE
by xx NE
two xxx NE
distinct xxx NE
promoters xxx NE
( ( NE
promoter xxx NE
1 d NE
and xxx NE
promoter xxx NE
2 d NE
) ) NE
to xx NE
generate xxx NE
two xxx NE
transcripts xxx NE
(designated (xxx NE
as xx NE
PAFR XXXX NE
transcript xxx NE
1 d NE
and xxx NE
PAFR XXXX NE
transcript xxx NE
2 d NE
) ) NE
, , NE
though xxx NE
their xxx NE
open xxx NE
reading xxx NE
frames xxx NE
are xxx NE
identical xxx NE
. . NE

By Xx NE
primer xxx NE
extension xxx NE
analysis xxx NE
to xx NE
discriminate xxx NE
two xxx NE
transcripts xxx NE
, , NE
we xx NE
found xxx NE
that xxx NE
the xxx NE
levels xxx NE
of xx NE
PAFR XXXX RNA_B
transcript xxx RNA_M
1 d RNA_E
( ( NE
leukocyte-type xxx-xxx NE
) ) NE
, , NE
but xxx NE
not xxx NE
PAFR XXXX RNA_B
transcript xxx RNA_M
2 d RNA_E
( ( NE
tissue-type xxx-xxx NE
) ) NE
, , NE
are xxx NE
upregulated xxx NE
by xx NE
PAF XXX protein
as xx NE
well xxx NE
as xx NE
by xx NE
12-O-tetradecanoylphorbol-13-acetate dd-X-xxx-dd-xxx NE
( ( NE
TPA XXX NE
) ) NE
in xx NE
the xxx NE
human xxx cell_line_B
stomach xxx cell_line_M
cancer xxx cell_line_M
cell xxx cell_line_M
line xxx cell_line_E
( ( NE
JR-St XX-Xx cell_line_B
cells xxx cell_line_E
) ) NE
which xxx NE
expresses xxx NE
both xxx NE
functional xxx NE
PAFR XXXX RNA_B
transcript xxx RNA_M
1 d RNA_E
and xxx NE
PAFR XXXX RNA_B
transcript xxx RNA_M
2 d RNA_E
endogenously xxx NE
. . NE

Functional Xxxx NE
analysis xxx NE
of xx NE
the xxx NE
promoter xxx DNA_B
1 d DNA_E
with xxx NE
a x NE
transient xxx NE
expression xxx NE
assay xxx NE
using xxx NE
chloramphenicol xxx DNA_B
acetyltransferase xxx DNA_M
(CAT) (XXX) DNA_M
gene xxx DNA_E
as xx NE
a x NE
reporter xxx NE
showed xxx NE
that xxx NE
both xxx NE
PAF XXX protein
and xxx NE
TPA XXX NE
activated xxx NE
the xxx NE
promoter xxx DNA_B
1 d DNA_E
but xxx NE
not xxx NE
the xxx NE
deleted xxx DNA_B
promoter xxx DNA_E
lacking xxx NE
the xxx NE
three xxx NE
consensus xxx DNA_B
binding xxx DNA_M
sites xxx DNA_E
for xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
located xxx NE
from xxx NE
-571 -ddd NE
bp xx NE
to xx NE
-459 -ddd NE
bp xx NE
. . NE

These Xxxx NE
findings xxx NE
suggest xxx NE
a x NE
molecular xxx NE
mechanism xxx NE
of xx NE
positive xxx NE
regulation xxx NE
of xx NE
PAFR XXXX NE
gene xxx NE
expression xxx NE
by xx NE
PAF XXX protein
through xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
, , NE
possibly xxx NE
by xx NE
a x NE
phosphorylation xxx NE
reaction xxx NE
involving xxx NE
protein xxx protein_B
kinase xxx protein_M
C X protein_E
by xx NE
PAF XXX protein
. . NE

One Xxx NE
gene xxx NE
, , NE
two xxx NE
transcripts xxx RNA
: : NE
isolation xxx NE
of xx NE
an xx NE
alternative xxx NE
transcript xxx NE
encoding xxx NE
for xxx NE
the xxx NE
autoantigen xxx protein_B
La/SS-B Xx/XX-X protein_E
from xxx NE
a x NE
cDNA xXXX DNA_B
library xxx DNA_E
of xx NE
a x NE
patient xxx NE
with xxx NE
primary xxx NE
Sjogrens' Xxxx' NE
syndrome xxx NE
. . NE

A X NE
cDNA xXXX DNA_B
library xxx DNA_E
was xxx NE
prepared xxx NE
from xxx NE
peripheral xxx NE
blood xxx NE
lymphocytes xxx cell_type
of xx NE
an xx NE
autoimmune xxx NE
patient xxx NE
with xxx NE
primary xxx NE
Sjogrens' Xxxx' NE
syndrome xxx NE
. . NE

The Xxx NE
cDNA xXXX DNA_B
library xxx DNA_E
was xxx NE
screened xxx NE
with xxx NE
the xxx NE
patients xxx NE
own xxx NE
autoimmune xxx NE
serum xxx NE
being xxx NE
monospecific xxx NE
for xxx NE
the xxx NE
nuclear xxx protein_B
autoantigen xxx protein_M
La/SS-B Xx/XX-X protein_E
. . NE

Thereby Xxxx NE
an xx NE
alternative xxx NE
type xxx NE
of xx NE
La Xx RNA_B
mRNA xXXX RNA_E
was xxx NE
identified xxx NE
that xxx NE
differed xxx NE
from xxx NE
the xxx NE
known xxx NE
La Xx RNA_B
mRNA xXXX RNA_E
due xxx NE
to xx NE
an xx NE
exchange xxx NE
of xx NE
the xxx NE
exon xxx DNA_B
1 d DNA_E
. . NE

Sequencing Xxxx NE
of xx NE
the xxx NE
genomic xxx NE
region xxx NE
between xxx NE
the xxx NE
exons xxx NE
exon xxx DNA_B
1 d DNA_M
and xxx DNA_M
exon xxx DNA_M
2 d DNA_E
showed xxx NE
that xxx NE
the xxx NE
alternative xxx DNA_B
5'-end d'-xxx DNA_E
is xx NE
a x NE
part xxx NE
of xx NE
the xxx NE
intron xxx DNA
. . NE

In Xx NE
addition xxx NE
, , NE
the xxx NE
presence xxx NE
of xx NE
an xx NE
alternative xxx DNA_B
promoter xxx DNA_M
site xxx DNA_E
, , NE
which xxx NE
exists xxx NE
within xxx NE
the xxx NE
intron xxx DNA
downstream xxx NE
of xx NE
the xxx NE
exon xxx DNA_B
1 d DNA_E
, , NE
became xxx NE
evident xxx NE
. . NE

In Xx NE
consequence xxx NE
, , NE
the xxx NE
alternative xxx RNA_B
La Xx RNA_M
mRNA xXXX RNA_E
is xx NE
the xxx NE
result xxx NE
of xx NE
a x NE
promoter xxx NE
switching xxx NE
combined xxx NE
with xxx NE
an xx NE
alternative xxx NE
splicing xxx NE
mechanism xxx NE
. . NE

In Xx NE
the xxx NE
intron xxx NE
, , NE
further xxx NE
transcription xxx protein_B
factor xxx protein_E
binding xxx NE
sites xxx NE
, , NE
including xxx NE
a x NE
NF-kappa XX-xxx DNA_B
B X DNA_M
element xxx DNA_E
, , NE
were xxx NE
identified xxx NE
leading xxx NE
to xx NE
the xxx NE
suggestion xxx NE
that xxx NE
the xxx NE
expression xxx NE
of xx NE
the xxx NE
gene xxx NE
encoding xxx NE
for xxx NE
the xxx NE
nuclear xxx protein_B
autoantigen xxx protein_M
La/SS-B Xx/XX-X protein_E
alters xxx NE
in xx NE
dependence xxx NE
on xx NE
disease xxx NE
conditions xxx NE
. . NE

Cross-linking Xxxx-xxx NE
CD40 XXdd protein
on xx NE
B X cell_type_B
cells xxx cell_type_E
rapidly xxx NE
activates xxx NE
nuclear xxx protein_B
factor-kappa xxx-xxx protein_M
B X protein_E
. . NE

The Xxx NE
B X protein_B
cell-associated xxx-xxx protein_M
surface xxx protein_M
molecule xxx protein_M
CD40 XXdd protein_E
functions xxx NE
to xx NE
regulate xxx NE
B X NE
cell xxx NE
responses xxx NE
. . NE

Cross-linking Xxxx-xxx NE
CD40 XXdd protein
on xx NE
B X cell_type_B
cells xxx cell_type_E
can xxx NE
lead xxx NE
to xx NE
homotypic xxx NE
cell xxx NE
adhesion xxx NE
, , NE
IL-6 XX-d NE
production xxx NE
, , NE
and xxx NE
, , NE
in xx NE
combination xxx NE
with xxx NE
cytokines xxx protein
, , NE
to xx NE
Ig Xx NE
isotype xxx NE
switching xxx NE
. . NE

Tyrosine Xxxx NE
kinase xxx NE
activity xxx NE
is xx NE
increased xxx NE
shortly xxx NE
after xxx NE
engagement xxx NE
of xx NE
this xxx NE
receptor xxx NE
. . NE

Little Xxxx NE
is xx NE
known xxx NE
about xxx NE
how xxx NE
the xxx NE
very xxx NE
early xxx NE
events xxx NE
induced xxx NE
by xx NE
CD40 XXdd NE
cross-linking xxx-xxx NE
link xxx NE
to xx NE
cellular xxx NE
responses xxx NE
. . NE

In Xx NE
this xxx NE
study xxx NE
, , NE
we xx NE
demonstrate xxx NE
that xxx NE
nuclear xxx protein_B
factor xxx protein_M
(NF)-kappa (XX)-xxx protein_M
B X protein_E
and xxx NE
NF-kappa XX-xxx protein_B
B-like X-xxx protein_M
transcription xxx protein_M
factors xxx protein_E
are xxx NE
activated xxx NE
after xxx NE
cross-linking xxx-xxx NE
CD40 XXdd protein
on xx NE
resting xxx NE
human xxx cell_type_B
tonsillar xxx cell_type_M
B X cell_type_M
cells xxx cell_type_E
and xxx NE
on xx NE
B X cell_line_B
cell xxx cell_line_M
lines xxx cell_line_E
. . NE

The Xxx NE
activation xxx NE
is xx NE
rapid xxx NE
and xxx NE
is xx NE
mediated xxx NE
through xxx NE
a x NE
tyrosine xxx NE
kinase-dependent xxx-xxx NE
pathway xxx NE
. . NE

The Xxx NE
complexes xxx NE
detected xxx NE
in xx NE
electrophoretic xxx NE
mobility xxx NE
shift xxx NE
assays xxx NE
contain xxx NE
p50 xdd protein
, , NE
p65 xdd protein
( ( NE
RelA XxxX protein
) ) NE
, , NE
c-Rel x-Xxx protein
, , NE
and xxx NE
most xxx NE
likely xxx NE
other xxx NE
components xxx NE
. . NE

By Xx NE
using xxx NE
transient xxx NE
transfection xxx NE
assays xxx NE
, , NE
we xx NE
found xxx NE
that xxx NE
cross-linking xxx-xxx NE
CD40 XXdd protein
supports xxx NE
NF-kappa XX-xxx NE
B X NE
-dependent -xxx NE
gene xxx NE
expression xxx NE
. . NE

Our Xxx NE
results xxx NE
define xxx NE
the xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
system xxx NE
as xx NE
an xx NE
intermediate xxx NE
event xxx NE
in xx NE
CD40 XXdd protein
signaling xxx NE
and xxx NE
suggest xxx NE
that xxx NE
the xxx NE
CD40 XXdd NE
pathway xxx NE
can xxx NE
influence xxx NE
the xxx NE
expression xxx NE
of xx NE
B X DNA_B
cell-associated xxx-xxx DNA_M
genes xxx DNA_E
with xxx NE
NF-kappa XX-xxx DNA_B
B X DNA_M
consensus xxx DNA_M
sites xxx DNA_E
. . NE

Protease Xxxx NE
inhibitors xxx NE
block xxx NE
lipopolysaccharide xxx NE
induction xxx NE
of xx NE
tissue xxx NE
factor xxx NE
gene xxx NE
expression xxx NE
in xx NE
human xxx cell_type_B
monocytic xxx cell_type_M
cells xxx cell_type_E
by xx NE
preventing xxx NE
activation xxx NE
of xx NE
c-Rel x-Xxx NE
/ / NE
p65 xdd NE
heterodimers xxx NE
. . NE

Tissue Xxxx protein_B
factor xxx protein_E
( ( NE
TF XX protein
) ) NE
is xx NE
expressed xxx NE
rapidly xxx NE
by xx NE
human xxx cell_type_B
monocytes xxx cell_type_E
exposed xxx NE
to xx NE
bacterial xxx protein_B
endotoxin xxx protein_E
( ( NE
lipopolysaccharide xxx NE
, , NE
or xx NE
LPS XXX NE
) ) NE
. . NE

Transcriptional Xxxx NE
regulation xxx NE
is xx NE
mediated xxx NE
by xx NE
binding xxx NE
of xx NE
c-Rel x-Xxx NE
/p65 /xdd NE
heterodimers xxx NE
to xx NE
a x NE
kappa xxx NE
B-like X-xxx NE
site xxx NE
in xx NE
the xxx NE
TF XX NE
promoter xxx NE
. . NE

Nuclear Xxxx NE
translocation xxx NE
of xx NE
cytosolic xxx NE
c-Rel x-Xxx NE
/ / NE
p65 xdd NE
heterodimers xxx NE
and xxx NE
other xxx NE
members xxx NE
of xx NE
the xxx NE
NF-kappa XX-xxx NE
B X NE
/Rel /Xxx NE
family xxx NE
requires xxx NE
dissociation xxx NE
and xxx NE
proteolytic xxx NE
degradation xxx NE
of xx NE
the xxx NE
inhibitor xxx NE
protein xxx NE
, , NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
. . NE

The Xxx NE
protease xxx NE
inhibitors xxx NE
N X NE
alpha-tosylphenylalanyl xxx-xxx NE
chloromethyl xxx NE
ketone xxx NE
( ( NE
TPCK XXXX NE
) ) NE
and xxx NE
N X NE
alpha-tosyl-L-lysine xxx-xxx-X-xxx NE
chloromethyl xxx NE
ketone xxx NE
( ( NE
TLCK XXXX NE
) ) NE
block xxx NE
activation xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
/Rel /Xxx NE
proteins xxx NE
by xx NE
preventing xxx NE
degradation xxx NE
of xx NE
I X NE
kappa xxx NE
B X NE
alpha xxx NE
. . NE

To Xx NE
determine xxx NE
if xx NE
TPCK XXXX NE
and xxx NE
TLCK XXXX NE
inhibited xxx NE
LPS XXX NE
induction xxx NE
of xx NE
TF XX NE
expression xxx NE
, , NE
freshly xxx NE
isolated xxx NE
human xxx cell_type_B
monocytes xxx cell_type_E
and xxx NE
monocytic xxx cell_line_B
THP-1 XXX-d cell_line_M
cells xxx cell_line_E
were xxx NE
pretreated xxx NE
with xxx NE
these xxx NE
inhibitors xxx NE
for xxx NE
30 dd NE
min xxx NE
before xxx NE
LPS XXX NE
stimulation xxx NE
. . NE

Both Xxxx NE
TPCK XXXX NE
and xxx NE
TLCK XXXX NE
inhibited xxx NE
LPS XXX NE
induction xxx NE
of xx NE
TF XX protein_B
protein xxx protein_E
, , NE
TF XX RNA_B
mRNA xXXX RNA_E
and xxx NE
TF XX NE
promoter xxx NE
activity xxx NE
in xx NE
a x NE
dose-dependent xxx-xxx NE
manner xxx NE
. . NE

These Xxxx NE
inhibitors xxx NE
specifically xxx NE
prevented xxx NE
degradation xxx NE
of xx NE
I X protein_B
kappa xxx protein_M
B X protein_M
alpha xxx protein_E
and xxx NE
nuclear xxx NE
translocation xxx NE
of xx NE
c-Rel x-Xxx NE
/p65 /xdd NE
heterodimers xxx NE
. . NE

In Xx NE
contrast xxx NE
, , NE
TPCK XXXX NE
and xxx NE
TLCK XXXX NE
did xxx NE
not xxx NE
block xxx NE
induction xxx NE
of xx NE
an xx NE
immediate-early xxx-xxx DNA_B
gene xxx DNA_E
encoding xxx NE
the xxx NE
transcription xxx protein_B
factor xxx protein_E
, , NE
Egr-1 Xxx-d protein
. . NE

Taken Xxxx NE
together xxx NE
, , NE
these xxx NE
data xxx NE
indicated xxx NE
that xxx NE
inhibiting xxx NE
nuclear xxx NE
translocation xxx NE
of xx NE
c-Rel x-Xxx NE
/p65 /xdd NE
heterodimers xxx NE
prevented xxx NE
LPS XXX NE
induction xxx NE
of xx NE
TF XX NE
gene xxx NE
transcription xxx NE
in xx NE
monocytic xxx NE
cells xxx NE
. . NE

1,25-Dihydroxyvitamin d,dd-Xxxx protein_B
D3 Xd protein_M
receptors xxx protein_E
in xx NE
peripheral xxx cell_type_B
blood xxx cell_type_M
mononuclear xxx cell_type_M
cells xxx cell_type_E
from xxx NE
patients xxx NE
with xxx NE
primary xxx NE
hyperparathyroidism xxx NE
and xxx NE
secondary xxx NE
hyperparathyroidism xxx NE

A X NE
decreased xxx NE
number xxx NE
of xx NE
calcitriol xxx NE
( ( NE
1,25(OH)2D3 d,dd(XX)dXd NE
) ) NE
receptors xxx NE
has xxx NE
been xxx NE
observed xxx NE
in xx NE
parathyroid xxx NE
glands xxx NE
of xx NE
uremic xxx NE
animals xxx NE
. . NE

In Xx NE
humans xxx NE
, , NE
studies xxx NE
carried xxx NE
out xxx NE
in xx NE
surgically xxx NE
removed xxx NE
parathyroid xxx NE
glands xxx NE
have xxx NE
shown xxx NE
that xxx NE
calcitriol xxx NE
binding xxx NE
is xx NE
higher xxx NE
in xx NE
primary xxx NE
than xxx NE
in xx NE
secondary xxx NE
hyperparathyroidism xxx NE
. . NE

Since Xxxx NE
specific xxx NE
receptors xxx NE
for xxx NE
calcitriol xxx NE
have xxx NE
been xxx NE
described xxx NE
in xx NE
peripheral xxx cell_type_B
blood xxx cell_type_M
mononuclear xxx cell_type_M
cells xxx cell_type_E
( ( NE
PBMC XXXX cell_type
) ) NE
, , NE
we xx NE
have xxx NE
investigated xxx NE
the xxx NE
specific xxx NE
uptake xxx NE
of xx NE
3H-labelled dX-xxx NE
1,25(OH)2D3 d,dd(XX)dXd NE
in xx NE
PBMC XXXX cell_type
of xx NE
12 dd NE
women xxx NE
with xxx NE
primary xxx NE
hyperparathyroidism xxx NE
( ( NE
PHP XXX NE
) ) NE
, , NE
8 d NE
women xxx NE
with xxx NE
hyperparathyroidism xxx NE
secondary xxx NE
to xx NE
chronic xxx NE
renal xxx NE
failure xxx NE
( ( NE
SH XX NE
) ) NE
, , NE
9 d NE
women xxx NE
with xxx NE
renal xxx NE
transplant xxx NE
( ( NE
RT XX NE
) ) NE
, , NE
and xxx NE
23 dd NE
healthy xxx NE
women xxx NE
. . NE

The Xxx NE
median xxx NE
dissociation xxx NE
constant xxx NE
( ( NE
Kd Xx NE
) ) NE
was xxx NE
similar xxx NE
in xx NE
all xxx NE
three xxx NE
groups xxx NE
of xx NE
patients xxx NE
and xxx NE
in xx NE
healthy xxx NE
women xxx NE
(mean (xxx NE
+/- +/- NE
S.D X.X NE
. . NE
(range) (xxx) NE
: : NE
PHP XXX NE
, , NE
1.2 d.d NE
+/- +/- NE
1.0 d.d NE
(0.2-4) (d.d-d) NE
x x NE
10(-10) dd(-dd) NE
M X NE
; ; NE
SH XX NE
, , NE
0.6 d.d NE
+/- +/- NE
0.4 d.d NE
(0.2-1.2) (d.d-d.d) NE
x x NE
10(-10) dd(-dd) NE
M X NE
; ; NE
RT XX NE
, , NE
1.1 d.d NE
+/- +/- NE
0.5 d.d NE
(0.4-1.9) (d.d-d.d) NE
x x NE
10(-10) dd(-dd) NE
M X NE
; ; NE
controls xxx NE
, , NE
1.0 d.d NE
+/- +/- NE
0.6 d.d NE
(0.3-2.6) (d.d-d.d) NE
x x NE
10(-10) dd(-dd) NE
M) X) NE
. . NE
However Xxxx NE
, , NE
the xxx NE
maximal xxx NE
binding xxx NE
capacity xxx NE
( ( NE
Nmax Xxxx NE
) ) NE
was xxx NE
significantly xxx NE
enhanced xxx NE
in xx NE
PHP XXX NE
(3.9 (d.d NE
+/- +/- NE
1.9 d.d NE
(1.3-7.6) (d.d-d.d) NE
fmol/10(7) xxx/dd(d) NE
cells xxx NE
vs xx NE
. . NE
2.3 d.d NE
+/- +/- NE
0.9 d.d NE
(1.1-4.4) (d.d-d.d) NE
fmol/10(7) xxx/dd(d) NE
cells xxx NE
in xx NE
controls xxx NE
; ; NE
P X NE
= = NE
0.0006) d.dddd) NE
and xxx NE
decreased xxx NE
in xx NE
SH XX NE
(0.8 (d.d NE
+/- +/- NE
0.5 d.d NE
(0.2-1.6) (d.d-d.d) NE
fmol/10(7) xxx/dd(d) NE
cells xxx NE
vs xx NE
. . NE
2.3 d.d NE
+/- +/- NE
0.9 d.d NE
(1.1-4.4) (d.d-d.d) NE
fmol/10(7) xxx/dd(d) NE
cells xxx NE
in xx NE
controls xxx NE
; ; NE
P X NE
= = NE
0.0001) d.dddd) NE
, , NE
whereas xxx NE
no xx NE
changes xxx NE
were xxx NE
seen xxx NE
in xx NE
RT XX NE
(2.3 (d.d NE
+/- +/- NE
0.7 d.d NE
(1.2-3.3) (d.d-d.d) NE
fmol/10(7) xxx/dd(d) NE
cells xxx NE
vs xx NE
. . NE
2.3 d.d NE
+/- +/- NE
0.9 d.d NE
(1.1-4.4) (d.d-d.d) NE
fmol/10(7) xxx/dd(d) NE
cells xxx NE
in xx NE
controls xxx NE
) ) NE
. . NE

In Xx NE
three xxx NE
patients xxx NE
with xxx NE
PHP XXX NE
who xxx NE
were xxx NE
subjected xxx NE
to xx NE
parathyroidectomy xxx NE
, , NE
the xxx NE
calcitriol xxx NE
number xxx NE
came xxx NE
down xxx NE
to xx NE
normal xxx NE
. . NE

Changes Xxxx NE
of xx NE
calcitriol xxx protein_B
receptors xxx protein_E
in xx NE
primary xxx NE
and xxx NE
secondary xxx NE
hyperparathyroidism xxx NE
could xxx NE
magnify xxx NE
the xxx NE
consequences xxx NE
of xx NE
disturbances xxx NE
in xx NE
serum xxx NE
concentration xxx NE
of xx NE
calcitriol xxx NE
itself xxx NE
and xxx NE
might xxx NE
play xxx NE
an xx NE
important xxx NE
role xxx NE
in xx NE
the xxx NE
development xxx NE
of xx NE
secondary xxx NE
hyperparathyroidism xxx NE
in xx NE
uremia xxx NE
. . NE

The Xxx NE
severe xxx NE
phenotype xxx NE
of xx NE
females xxx NE
with xxx NE
tiny xxx DNA_B
ring xxx DNA_M
X X DNA_M
chromosomes xxx DNA_E
is xx NE
associated xxx NE
with xxx NE
inability xxx NE
of xx NE
these xxx NE
chromosomes xxx DNA
to xx NE
undergo xxx NE
X X NE
inactivation xxx NE
. . NE

Mental Xxxx NE
retardation xxx NE
and xxx NE
a x NE
constellation xxx NE
of xx NE
congenital xxx NE
malformations xxx NE
not xxx NE
usually xxx NE
associated xxx NE
with xxx NE
Turner Xxxx NE
syndrome xxx NE
are xxx NE
seen xxx NE
in xx NE
some xxx NE
females xxx NE
with xxx NE
a x NE
mosaic xxx DNA_B
45,X/46,X,r(X) dd,X/dd,X,x(X) DNA_M
karyotype xxx DNA_E
. . NE

Studies Xxxx NE
of xx NE
these xxx NE
females xxx NE
show xxx NE
that xxx NE
the xxx NE
XIST XXXX DNA_B
locus xxx DNA_E
on xx NE
their xxx NE
tiny xxx DNA_B
ring xxx DNA_M
X X DNA_M
chromosomes xxx DNA_E
is xx NE
either xxx NE
not xxx NE
present xxx NE
or xx NE
not xxx NE
expressed xxx NE
. . NE

As Xx NE
XIST XXXX NE
transcription xxx NE
is xx NE
well xxx NE
correlated xxx NE
with xxx NE
inactivation xxx NE
of xx NE
the xxx NE
X X DNA_B
chromosome xxx DNA_E
in xx NE
female xxx cell_type_B
somatic xxx cell_type_M
cells xxx cell_type_E
and xxx NE
spermatogonia xxx cell_type
, , NE
nonexpression xxx NE
of xx NE
the xxx NE
locus xxx NE
even xxx NE
when xxx NE
it xx NE
is xx NE
present xxx NE
suggests xxx NE
that xxx NE
these xxx NE
chromosomes xxx DNA
are xxx NE
transcriptionally xxx NE
active xxx NE
. . NE

We Xx NE
examined xxx NE
the xxx NE
transcriptional xxx NE
activity xxx NE
of xx NE
ring xxx NE
X X DNA_B
chromosomes xxx DNA_E
lacking xxx NE
XIST XXXX NE
expression xxx NE
(XISTE-) (XXXXX-) NE
, , NE
from xxx NE
three xxx NE
females xxx NE
with xxx NE
severe xxx NE
phenotypes xxx NE
. . NE

The Xxx NE
two xxx NE
tiny xxx NE
ring xxx NE
X X DNA_B
chromosomes xxx DNA_E
studied xxx NE
with xxx NE
an xx NE
antibody xxx protein
specific xxx NE
for xxx NE
the xxx NE
acetylated xxx NE
isoforms xxx NE
of xx NE
histone xxx protein_B
H4 Xd protein_E
marking xxx NE
transcribed xxx DNA_B
chromatin xxx DNA_M
domains xxx DNA_E
were xxx NE
labeled xxx NE
at xx NE
a x NE
level xxx NE
consistent xxx NE
with xxx NE
their xxx NE
being xxx NE
active xxx NE
. . NE

We Xx NE
also xxx NE
examined xxx NE
tow xxx NE
of xx NE
the xxx NE
XISTE- XXXXX- DNA_B
ring xxx DNA_M
chromosomes xxx DNA_E
to xx NE
determine xxx NE
whether xxx NE
genes xxx DNA
that xxx NE
are xxx NE
normally xxx NE
silent xxx NE
on xx NE
an xx NE
inactive xxx DNA_B
X X DNA_E
are xxx NE
expressed xxx NE
from xxx NE
these xxx NE
chromosomes xxx DNA
. . NE

Analyses Xxxx NE
of xx NE
hybrid xxx cell_line_B
cells xxx cell_line_E
show xxx NE
that xxx NE
TIMP XXXX DNA
, , NE
ZXDA XXXX DNA
, , NE
and xxx NE
ZXDB XXXX DNA_B
loci xxx DNA_E
on xx NE
the xxx NE
proximal xxx DNA_B
short xxx DNA_M
arm xxx DNA_E
, , NE
and xxx NE
AR XX DNA
and xxx NE
PHKA1 XXXXd DNA_B
loci xxx DNA_E
on xx NE
the xxx NE
long xxx NE
arm xxx NE
, , NE
are xxx NE
well xxx NE
expressed xxx NE
from xxx NE
the xxx NE
tiny xxx DNA_B
ring xxx DNA_M
X X DNA_M
chromosome xxx DNA_E
lacking xxx NE
XIST XXXX DNA_B
DNA XXX DNA_E
. . NE

Studies Xxxx NE
of xx NE
the xxx NE
ring xxx DNA_B
chromosome xxx DNA_E
that xxx NE
has xxx NE
XIST XXXX DNA_B
DNA XXX DNA_E
but xxx NE
does xxx NE
not xxx NE
transcribe xxx NE
it xx NE
show xxx NE
that xxx NE
its xxx NE
AR XX NE
allele xxx NE
is xx NE
transcribed xxx NE
along xxx NE
with xxx NE
the xxx NE
one xxx NE
on xx NE
the xxx NE
normal xxx NE
X X NE
allele xxx NE
. . NE

(ABSTRACT (XXXXXXXX NE
TRUNCATED XXXXXXXXX NE
AT XX NE
250 ddd NE
WORDS) XXXXX) NE

Inhibition Xxxx NE
of xx NE
activation xxx NE
of xx NE
transcription xxx protein_B
factor xxx protein_M
AP-1 XX-d protein_E
by xx NE
CD28 XXdd protein
signalling xxx NE
in xx NE
human xxx cell_type_B
T-cells X-xxx cell_type_E
. . NE

Co-stimulation Xx-xxx NE
of xx NE
T-lymphocytes X-xxx cell_type
by xx NE
T-cell X-xxx protein_B
receptor xxx protein_E
( ( NE
TcR XxX protein
) ) NE
occupancy xxx NE
and xxx NE
activation xxx NE
of xx NE
the xxx NE
CD28 XXdd protein_B
surface xxx protein_M
molecule xxx protein_E
results xxx NE
in xx NE
enhanced xxx NE
proliferation xxx NE
and xxx NE
interleukin xxx NE
2 d NE
( ( NE
IL-2 XX-d NE
) ) NE
production xxx NE
. . NE

The Xxx NE
increase xxx NE
in xx NE
IL-2 XX-d protein
gene xxx NE
expression xxx NE
triggered xxx NE
by xx NE
CD28 XXdd protein
involves xxx NE
a x NE
kappa xxx DNA_B
B-like X-xxx DNA_M
sequence xxx DNA_E
in xx NE
the xxx NE
5'-regulatory d'-xxx DNA_B
region xxx DNA_E
of xx NE
the xxx NE
IL-2 XX-d DNA_B
promoter xxx DNA_E
, , NE
called xxx NE
CD28 XXdd NE
-responsive -xxx NE
element xxx NE
. . NE

Stimulation Xxxx NE
of xx NE
T-cells X-xxx cell_type
by xx NE
agonistic xxx NE
anti- xxx- NE
CD28 XXdd NE
antibodies xxx NE
in xx NE
conjunction xxx NE
with xxx NE
phorbol xxx NE
12-myristate dd-xxx NE
13-acetate dd-xxx NE
( ( NE
PMA XXX NE
)- )- NE
or xx NE
TcR XxX NE
-derived -xxx NE
signals xxx NE
induces xxx NE
the xxx NE
enhanced xxx NE
activation xxx NE
of xx NE
the xxx NE
transcription xxx NE
factor xxx NE
NF-kappa XX-xxx NE
B X NE
. . NE

Here Xxxx NE
we xx NE
report xxx NE
that xxx NE
CD28 XXdd protein
engagement xxx NE
, , NE
however xxx NE
, , NE
exerts xxx NE
opposite xxx NE
effects xxx NE
on xx NE
the xxx NE
transcription xxx protein_B
factor xxx protein_M
AP-1 XX-d protein_E
. . NE

Whereas Xxxx NE
anti- xxx- NE
CD28 XXdd NE
together xxx NE
with xxx NE
PMA XXX NE
increased xxx NE
the xxx NE
DNA XXX NE
binding xxx NE
and xxx NE
trans-activation xxx-xxx NE
activity xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
, , NE
PMA XXX NE
-induced -xxx NE
activation xxx NE
of xx NE
AP-1 XX-d NE
was xxx NE
significantly xxx NE
suppressed xxx NE
. . NE

The Xxx NE
inhibitory xxx NE
effect xxx NE
exerted xxx NE
by xx NE
anti- xxx- NE
CD28 XXdd NE
was xxx NE
observed xxx NE
at xx NE
the xxx NE
level xxx NE
of xx NE
DNA XXX NE
binding xxx NE
as xx NE
well xxx NE
as xx NE
in xx NE
functional xxx NE
reporter-gene xxx-xxx NE
assays xxx NE
. . NE

These Xxxx NE
results xxx NE
suggest xxx NE
that xxx NE
the xxx NE
two xxx NE
transcription xxx protein_B
factors xxx protein_E
are xxx NE
independently xxx NE
regulated xxx NE
and xxx NE
may xxx NE
perform xxx NE
different xxx NE
functions xxx NE
during xxx NE
T-cell X-xxx NE
activation xxx NE
. . NE

HIV-1 XXX-d protein_B
Nef Xxx protein_E
leads xxx NE
to xx NE
inhibition xxx NE
or xx NE
activation xxx NE
of xx NE
T X cell_type_B
cells xxx cell_type_E
depending xxx NE
on xx NE
its xxx NE
intracellular xxx NE
localization xxx NE
. . NE

Nef Xxx protein
of xx NE
primate xxx NE
lentiviruses xxx NE
is xx NE
required xxx NE
for xxx NE
viremia xxx NE
and xxx NE
progression xxx NE
to xx NE
AIDS XXXX NE
in xx NE
monkeys xxx NE
. . NE

Negative Xxxx NE
, , NE
positive xxx NE
, , NE
and xxx NE
no xx NE
effects xxx NE
of xx NE
Nef Xxx protein
have xxx NE
also xxx NE
been xxx NE
reported xxx NE
on xx NE
viral xxx NE
replication xxx NE
in xx NE
cells xxx NE
. . NE

To Xx NE
reconcile xxx NE
these xxx NE
observations xxx NE
, , NE
we xx NE
expressed xxx NE
a x NE
hybrid xxx NE
CD8- XXd- NE
Nef Xxx NE
protein xxx NE
in xx NE
Jurkat Xxxx NE
cells xxx NE
. . NE

Two Xxx NE
opposite xxx NE
phenotypes xxx NE
were xxx NE
found xxx NE
, , NE
which xxx NE
depended xxx NE
on xx NE
the xxx NE
intracellular xxx NE
localization xxx NE
of xx NE
Nef Xxx protein
. . NE

Expressed Xxxx NE
in xx NE
the xxx NE
cytoplasm xxx NE
or xx NE
on xx NE
the xxx NE
cell xxx NE
surface xxx NE
, , NE
the xxx NE
chimera xxx protein
inhibited xxx NE
or xx NE
activated xxx NE
early xxx NE
signaling xxx NE
events xxx NE
from xxx NE
the xxx NE
T X protein_B
cell xxx protein_M
antigen xxx protein_M
receptor xxx protein_E
. . NE

Activated Xxxx NE
Jurkat Xxxx cell_line_B
cells xxx cell_line_E
died xxx NE
by xx NE
apoptosis xxx NE
, , NE
and xxx NE
only xxx NE
cells xxx NE
with xxx NE
mutated xxx NE
nef xxx DNA_B
genes xxx DNA_E
expressing xxx NE
truncated xxx NE
Nefs Xxxx protein
survived xxx NE
, , NE
which xxx NE
rendered xxx NE
Nef Xxx protein
nonfunctional xxx NE
. . NE

These Xxxx NE
mutations xxx NE
paralleled xxx NE
those xxx NE
in xx NE
other xxx NE
viral xxx NE
strains xxx NE
passaged xxx NE
in xx NE
vitro xxx NE
. . NE

Not Xxx NE
only xxx NE
do xx NE
these xxx NE
positional xxx NE
effects xxx NE
of xx NE
Nef Xxx protein
reconcile xxx NE
diverse xxx NE
phenotypes xxx NE
of xx NE
Nef Xxx protein
and xxx NE
suggest xxx NE
a x NE
role xxx NE
for xxx NE
its xxx NE
N-terminal X-xxx NE
myristylation xxx NE
, , NE
but xxx NE
they xxx NE
also xxx NE
explain xxx NE
effects xxx NE
of xx NE
Nef Xxx protein
in xx NE
HIV XXX NE
infection xxx NE
and xxx NE
progression xxx NE
to xx NE
AIDS XXXX NE
. . NE

An Xx NE
intricate xxx NE
arrangement xxx NE
of xx NE
binding xxx NE
sites xxx NE
for xxx NE
the xxx NE
Ets Xxx protein_B
family xxx protein_E
of xx NE
transcription xxx protein_B
factors xxx protein_E
regulates xxx NE
activity xxx NE
of xx NE
the xxx NE
alpha xxx DNA_B
4 d DNA_M
integrin xxx DNA_M
gene xxx DNA_M
promoter xxx DNA_E
. . NE

alpha xxx protein_B
4 d protein_M
integrins xxx protein_E
mediate xxx NE
cell-cell xxx-xxx NE
interaction xxx NE
and xxx NE
cell-extracellular xxx-xxx NE
matrix xxx NE
interaction xxx NE
differentiation xxx NE
of xx NE
skeletal xxx NE
muscle xxx NE
. . NE

Here Xxxx NE
we xx NE
examine xxx NE
molecular xxx NE
mechanisms xxx NE
controlling xxx NE
the xxx NE
pattern xxx NE
of xx NE
alpha xxx NE
4 d NE
expression xxx NE
. . NE

The Xxx NE
activity xxx NE
of xx NE
constructs xxx NE
containing xxx NE
5' d' DNA_B
deletion xxx DNA_M
mutants xxx DNA_E
of xx NE
the xxx NE
alpha xxx DNA_B
4 d DNA_M
gene xxx DNA_M
promoter xxx DNA_E
was xxx NE
compared xxx NE
in xx NE
transfection xxx NE
assays xxx NE
into xxx NE
cell xxx cell_line_B
lines xxx cell_line_E
that xxx NE
express xxx NE
alpha xxx protein_B
4 d protein_E
and xxx NE
cell xxx cell_line_B
lines xxx cell_line_E
that xxx NE
do xx NE
not xxx NE
. . NE

The Xxx NE
sequence xxx NE
between xxx NE
position xxx NE
-42 -dd DNA_B
and xxx DNA_M
-76 -dd DNA_M
base xxx DNA_M
pairs xxx DNA_E
(bp) (xx) NE
was xxx NE
required xxx NE
for xxx NE
efficient xxx NE
transcription xxx NE
in xx NE
cells xxx NE
that xxx NE
express xxx NE
alpha xxx protein_B
4 d protein_E
, , NE
but xxx NE
it xx NE
showed xxx NE
no xx NE
activity xxx NE
in xx NE
HeLa XxXx cell_line_B
cells xxx cell_line_E
, , NE
which xxx NE
do xx NE
not xxx NE
express xxx NE
alpha xxx protein_B
4 d protein_E
. . NE

Three Xxxx NE
binding xxx DNA_B
sites xxx DNA_E
for xxx NE
the xxx NE
Ets Xxx protein_B
family xxx protein_E
of xx NE
transcription xxx protein_B
factors xxx protein_E
are xxx NE
found xxx NE
in xx NE
this xxx NE
region xxx NE
: : NE
two xxx NE
adjacent xxx NE
sites xxx NE
at xx NE
positions xxx NE
-50 -dd DNA_B
and xxx DNA_M
-54 -dd DNA_M
bp xx DNA_E
and xxx NE
a x NE
more xxx NE
5' d' DNA_B
site xxx DNA_E
at xx NE
position xxx NE
-67 -dd DNA_B
bp xx DNA_E
. . NE

Using Xxxx NE
a x NE
series xxx NE
of xx NE
constructs xxx NE
containing xxx NE
deletions xxx NE
and xxx NE
mutations xxx NE
in xx NE
this xxx NE
region xxx NE
, , NE
we xx NE
found xxx NE
that xxx NE
the xxx NE
3'-most d'-xxx DNA_B
site xxx DNA_E
alone xxx NE
was xxx NE
sufficient xxx NE
for xxx NE
binding xxx NE
GA-binding XX-xxx protein_B
protein xxx protein_M
alpha xxx protein_E
( ( NE
GABP XXXX NE
alpha xxx NE
) ) NE
/ / NE
GABP XXXX NE
beta xxx NE
and xxx NE
for xxx NE
a x NE
low xxx NE
level xxx NE
of xx NE
transcriptional xxx NE
activation xxx NE
. . NE

When Xxxx NE
all xxx NE
three xxx NE
sites xxx NE
were xxx NE
present xxx NE
, , NE
a x NE
second xxx NE
complex xxx NE
"a" "x" NE
was xxx NE
detected xxx NE
, , NE
which xxx NE
contains xxx NE
an xx NE
unknown xxx NE
member xxx NE
of xx NE
the xxx NE
Ets Xxx protein_B
family xxx protein_E
. . NE

Formation Xxxx NE
of xx NE
complex xxx NE
a x NE
was xxx NE
cell-type xxx-xxx NE
specific xxx NE
and xxx NE
correlated xxx NE
with xxx NE
a x NE
high xxx NE
level xxx NE
of xx NE
transcription xxx NE
. . NE

Deletion Xxxx NE
of xx NE
the xxx NE
5'-most d'-xxx DNA_B
Ets Xxx DNA_M
site xxx DNA_E
had xxx NE
no xx NE
effect xxx NE
on xx NE
binding xxx NE
to xx NE
GABP XXXX protein_B
alpha/GABP xxx/XXXX protein_M
beta xxx protein_E
, , NE
but xxx NE
it xx NE
eliminated xxx NE
a x NE
. . NE

Concomitant Xxxx NE
with xxx NE
this xxx NE
loss xxx NE
of xx NE
a x NE
, , NE
a x NE
new xxx protein_B
Ets-1-containing Xxx-d-xxx protein_M
complex xxx protein_E
" " NE
c x protein
" " NE
appeared xxx NE
. . NE

Complex Xxxx NE
c x NE
substituted xxx NE
efficiently xxx NE
for xxx NE
complex xxx NE
a x NE
in xx NE
transcriptional xxx NE
activation xxx NE
. . NE

We Xx NE
conclude xxx NE
that xxx NE
although xxx NE
neither xxx NE
of xx NE
the xxx NE
two xxx NE
5'-most d'-xxx DNA_B
Ets Xxx DNA_M
sites xxx DNA_E
alone xxx NE
binds xxx NE
nuclear xxx protein_B
protein xxx protein_E
, , NE
they xxx NE
appear xxx NE
to xx NE
act xxx NE
as xx NE
modulators xxx NE
which xxx NE
control xxx NE
the xxx NE
pattern xxx NE
of xx NE
Ets Xxx protein_B
proteins xxx protein_E
that xxx NE
bind xxx NE
the xxx NE
alpha xxx DNA_B
4 d DNA_M
gene xxx DNA_M
promoter xxx DNA_E
. . NE

This Xxxx NE
arrangement xxx NE
of xx NE
Ets Xxx DNA_B
sites xxx DNA_E
, , NE
coupled xxx NE
with xxx NE
the xxx NE
tissue- xxx- NE
and xxx NE
developmental-specific xxx-xxx NE
expression xxx NE
of xx NE
Ets Xxx protein_B
members xxx protein_E
, , NE
likely xxx NE
play xxx NE
a x NE
key xxx NE
role xxx NE
in xx NE
defining xxx NE
the xxx NE
pattern xxx NE
of xx NE
alpha xxx protein_B
4 d protein_M
integrin xxx protein_E
. . NE

Mechanism Xxxx NE
of xx NE
antiandrogen xxx NE
action xxx NE
: : NE
conformational xxx NE
changes xxx NE
of xx NE
the xxx NE
receptor xxx NE
. . NE

Androgen Xxxx RNA_B
receptor xxx RNA_M
mRNA xXXX RNA_E
was xxx NE
translated xxx NE
in xx NE
vitro xxx NE
, , NE
and xxx NE
androgen-bound xxx-xxx protein_B
receptor xxx protein_M
complex xxx protein_M
and xxx protein_M
antiandrogen-bound xxx-xxx protein_M
receptor xxx protein_M
complex xxx protein_E
bound xxx NE
receptor xxx NE
complexes xxx NE
were xxx NE
studied xxx NE
using xxx NE
limited xxx NE
proteolytic xxx NE
digestion xxx NE
by xx NE
trypsin xxx protein
. . NE

Partial Xxxx NE
proteolysis xxx NE
of xx NE
androgen xxx NE
-bound -xxx NE
receptor xxx NE
protein xxx NE
resulted xxx NE
in xx NE
a x NE
29-kDa dd-xXx NE
proteolysis-resisting xxx-xxx NE
fragment xxx NE
, , NE
whereas xxx NE
antiandrogen xxx NE
binding xxx NE
stabilised xxx NE
a x NE
35-kDa dd-xXx NE
fragment xxx NE
. . NE

Both Xxxx NE
fragments xxx NE
contain xxx NE
the xxx NE
entire xxx NE
ligand xxx protein_B
binding xxx protein_M
domain xxx protein_E
, , NE
and xxx NE
the xxx NE
35-kDa dd-xXx protein_B
fragment xxx protein_E
extended xxx NE
into xxx NE
the xxx NE
hinge xxx protein_B
region xxx protein_E
of xx NE
the xxx NE
receptor xxx NE
. . NE

Several Xxxx NE
antiandrogens xxx NE
show xxx NE
agonistic xxx NE
properties xxx NE
for xxx NE
a x NE
mutated xxx protein_B
androgen xxx protein_M
receptor xxx protein_E
( ( NE
LNCaP XXXxX cell_line_B
cell xxx cell_line_M
variant xxx cell_line_E
) ) NE
; ; NE
trypsin xxx protein
digestion xxx NE
of xx NE
antiandrogen xxx NE
-bound -xxx NE
mutated xxx NE
receptor xxx NE
also xxx NE
resulted xxx NE
in xx NE
a x NE
29-kDa dd-xXx NE
fragment xxx NE
. . NE

Our Xxx NE
results xxx NE
point xxx NE
to xx NE
an xx NE
important xxx NE
difference xxx NE
between xxx NE
antiandrogens xxx NE
and xxx NE
antagonists xxx NE
of xx NE
other xxx NE
steroid xxx protein_B
hormone xxx protein_M
receptors xxx protein_E
. . NE

Antiandrogens Xxxx NE
result xxx NE
in xx NE
protection xxx NE
of xx NE
both xxx NE
the xxx NE
hinge xxx protein_B
region xxx protein_E
and xxx NE
C-terminus X-xxx protein
of xx NE
the xxx NE
androgen xxx protein_B
receptor xxx protein_E
agonist xxx NE
proteolytic xxx NE
attack xxx NE
, , NE
whereas xxx NE
other xxx NE
studies xxx NE
showed xxx NE
that xxx NE
antiestrogens xxx NE
and xxx NE
antiprogestagens xxx NE
expose xxx NE
the xxx NE
C-terminal X-xxx protein_B
end xxx protein_E
of xx NE
the xxx NE
ligand xxx protein_B
binding xxx protein_M
domain xxx protein_E
of xx NE
their xxx NE
respective xxx NE
receptors xxx NE
to xx NE
protease xxx protein
. . NE

Differences Xxxx NE
in xx NE
conformation xxx NE
of xx NE
the xxx NE
hinge xxx protein_B
region xxx protein_E
distinguish xxx NE
androgen xxx NE
-bound -xxx NE
from xxx NE
antiandrogen xxx NE
-bound -xxx NE
receptor xxx NE
complexes xxx NE
, , NE
which xxx NE
represents xxx NE
an xx NE
important xxx NE
feature xxx NE
of xx NE
antiandrogen xxx NE
action xxx NE
. . NE

Activation Xxxx NE
of xx NE
nuclear xxx protein_B
factor xxx protein_M
kappa xxx protein_M
B X protein_E
in xx NE
human xxx cell_line_B
neuroblastoma xxx cell_line_M
cell xxx cell_line_M
lines xxx cell_line_E
. . NE

The Xxx NE
nuclear xxx protein_B
factor xxx protein_M
kappa xxx protein_M
B X protein_E
( ( NE
NF-kappa XX-xxx protein_B
B X protein_E
) ) NE
is xx NE
a x NE
eukaryotic xxx NE
transcription xxx protein_B
factor xxx protein_E
. . NE

In Xx NE
B X cell_type_B
cells xxx cell_type_E
and xxx NE
macrophages xxx cell_type
it xx NE
is xx NE
constitutively xxx NE
present xxx NE
in xx NE
cell xxx NE
nuclei xxx NE
, , NE
whereas xxx NE
in xx NE
many xxx NE
other xxx NE
cell xxx NE
types xxx NE
, , NE
NF-kappa XX-xxx protein_B
B X protein_E
translocates xxx NE
from xxx NE
cytosol xxx NE
to xx NE
nucleus xxx NE
as xx NE
a x NE
result xxx NE
of xx NE
transduction xxx NE
by xx NE
tumor xxx protein_B
necrosis xxx protein_M
factor xxx protein_M
alpha xxx protein_E
( ( NE
TNF XXX protein_B
alpha xxx protein_E
) ) NE
, , NE
phorbol xxx NE
ester xxx NE
, , NE
and xxx NE
other xxx NE
polyclonal xxx NE
signals xxx NE
. . NE

Using Xxxx NE
neuroblastoma xxx cell_line_B
cell xxx cell_line_M
lines xxx cell_line_E
as xx NE
models xxx NE
, , NE
we xx NE
have xxx NE
shown xxx NE
that xxx NE
in xx NE
neural xxx cell_type_B
cells xxx cell_type_E
NF-kappa XX-xxx protein_B
B X protein_E
was xxx NE
present xxx NE
in xx NE
the xxx NE
cytosol xxx NE
and xxx NE
translocated xxx NE
into xxx NE
nuclei xxx NE
as xx NE
a x NE
result xxx NE
of xx NE
TNF XXX NE
alpha xxx NE
treatment xxx NE
. . NE

The Xxx NE
TNF XXX protein_B
alpha xxx protein_E
-activated -xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
was xxx NE
transcriptionally xxx NE
functional xxx NE
. . NE

NF-kappa XX-xxx protein_B
B X protein_E
activation xxx NE
by xx NE
TNF XXX protein_B
alpha xxx protein_E
was xxx NE
not xxx NE
correlated xxx NE
with xxx NE
cell xxx NE
differentiation xxx NE
or xx NE
proliferation xxx NE
. . NE

However Xxxx NE
, , NE
reagents xxx NE
such xxx NE
as xx NE
nerve xxx protein_B
growth xxx protein_M
factor xxx protein_E
( ( NE
NGF XXX protein
) ) NE
and xxx NE
the xxx NE
phorbol xxx NE
ester xxx NE
phorbol xxx NE
12-myristate dd-xxx NE
13-acetate dd-xxx NE
( ( NE
PMA XXX NE
) ) NE
, , NE
which xxx NE
induce xxx NE
phenotypical xxx NE
differentiation xxx NE
of xx NE
the xxx NE
SH-SY5Y XX-XXdX cell_line_B
neuroblastoma xxx cell_line_M
cell xxx cell_line_M
line xxx cell_line_E
, , NE
activated xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
, , NE
but xxx NE
only xxx NE
in xx NE
that xxx NE
particular xxx NE
cell xxx cell_line_B
line xxx cell_line_E
. . NE

In Xx NE
a x NE
NGF XXX NE
-responsive -xxx NE
rat xxx NE
pheochromocytoma xxx NE
cell xxx NE
line xxx NE
, , NE
PC12 XXdd NE
, , NE
PMA XXX NE
activated xxx NE
NF-kappa XX-xxx NE
B X NE
, , NE
whereas xxx NE
NGF XXX NE
did xxx NE
not xxx NE
. . NE

In Xx NE
other xxx NE
neuroblastoma xxx cell_line_B
cell xxx cell_line_M
lines xxx cell_line_E
, , NE
such xxx NE
as xx NE
SK-N-Be(2) XX-X-Xx(d) cell_line
, , NE
the xxx NE
lack xxx NE
of xx NE
PMA XXX NE
induction xxx NE
of xx NE
differentiation xxx NE
was xxx NE
correlated xxx NE
with xxx NE
the xxx NE
lack xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
. . NE

We Xx NE
found xxx NE
, , NE
moreover xxx NE
, , NE
that xxx NE
in xx NE
SK-N-Be(2) XX-X-Xx(d) cell_line_B
cells xxx cell_line_E
protein xxx NE
kinase xxx NE
C X NE
( ( NE
PKC XXX NE
) ) NE
enzymatic xxx NE
activity xxx NE
was xxx NE
much xxx NE
lower xxx NE
compared xxx NE
with xxx NE
that xxx NE
in xx NE
a x NE
control xxx NE
cell xxx NE
line xxx NE
and xxx NE
that xxx NE
the xxx NE
low xxx NE
PKC XXX NE
enzymatic xxx NE
activity xxx NE
was xxx NE
due xxx NE
to xx NE
low xxx NE
PKC XXX NE
protein xxx NE
expression xxx NE
. . NE

NF-kappa XX-xxx protein_B
B X protein_E
was xxx NE
not xxx NE
activated xxx NE
by xx NE
retinoic xxx NE
acid xxx NE
, , NE
which xxx NE
induced xxx NE
morphological xxx NE
differentiation xxx NE
of xx NE
all xxx NE
the xxx NE
neuroblastoma xxx cell_line_B
cell xxx cell_line_M
lines xxx cell_line_E
used xxx NE
in xx NE
the xxx NE
present xxx NE
study xxx NE
. . NE

Thus Xxxx NE
, , NE
NF-kappa XX-xxx protein_B
B X protein_E
activation xxx NE
was xxx NE
not xxx NE
required xxx NE
for xxx NE
neuroblastoma xxx NE
cell xxx NE
differentiation xxx NE
. . NE

Furthermore Xxxx NE
, , NE
the xxx NE
results xxx NE
obtained xxx NE
with xxx NE
TNF XXX protein_B
alpha xxx protein_E
proved xxx NE
that xxx NE
NF-kappa XX-xxx NE
B X NE
activation xxx NE
was xxx NE
not xxx NE
sufficient xxx NE
for xxx NE
induction xxx NE
of xx NE
neuroblastoma xxx NE
differentiation xxx NE
. . NE

ERP XXX protein
, , NE
a x NE
new xxx NE
member xxx NE
of xx NE
the xxx NE
ets xxx protein_B
transcription xxx protein_M
factor/oncoprotein xxx/xxx protein_M
family xxx protein_E
: : NE
cloning xxx NE
, , NE
characterization xxx NE
, , NE
and xxx NE
differential xxx NE
expression xxx NE
during xxx NE
B-lymphocyte X-xxx NE
development xxx NE
. . NE

The Xxx NE
ets xxx DNA_B
gene xxx DNA_M
family xxx DNA_E
encodes xxx NE
a x NE
group xxx NE
of xx NE
proteins xxx NE
which xxx NE
function xxx NE
as xx NE
transcription xxx protein_B
factors xxx protein_E
under xxx NE
physiological xxx NE
conditions xxx NE
and xxx NE
, , NE
if xx NE
aberrantly xxx NE
expressed xxx NE
, , NE
can xxx NE
cause xxx NE
cellular xxx NE
transformation xxx NE
. . NE

We Xx NE
have xxx NE
recently xxx NE
identified xxx NE
two xxx NE
regulatory xxx NE
elements xxx NE
in xx NE
the xxx NE
murine xxx DNA_B
immunoglobulin xxx DNA_M
heavy-chain xxx-xxx DNA_M
(IgH) (XxX) DNA_M
enhancer xxx DNA_E
, , NE
pi xx DNA
and xxx NE
microB xxxX DNA
, , NE
which xxx NE
exhibit xxx NE
striking xxx NE
similarity xxx NE
to xx NE
binding xxx DNA_B
sites xxx DNA_E
for xxx NE
ets-related xxx-xxx DNA_B
proteins xxx DNA_E
. . NE

To Xx NE
identify xxx NE
ets-related xxx-xxx protein_B
transcriptional xxx protein_M
regulators xxx protein_E
expressed xxx NE
in xx NE
pre-B xxx-X cell_type_B
lymphocytes xxx cell_type_E
that xxx NE
may xxx NE
interact xxx NE
with xxx NE
either xxx NE
the xxx NE
pi xx DNA
or xx NE
the xxx NE
microB xxxX DNA_B
site xxx DNA_E
, , NE
we xx NE
have xxx NE
used xxx NE
a x NE
PCR XXX NE
approach xxx NE
with xxx NE
degenerate xxx NE
oligonucleotides xxx NE
encoding xxx NE
conserved xxx NE
sequences xxx NE
in xx NE
all xxx NE
members xxx NE
of xx NE
the xxx NE
ets xxx DNA_B
family xxx DNA_E
. . NE

We Xx NE
have xxx NE
cloned xxx NE
the xxx NE
gene xxx NE
for xxx NE
a x NE
new xxx NE
ets-related xxx-xxx protein_B
transcription xxx protein_M
factor xxx protein_E
, , NE
ERP XXX protein
( ( NE
ets-related xxx-xxx protein_B
protein xxx protein_E
) ) NE
, , NE
from xxx NE
the xxx NE
murine xxx cell_line_B
pre-B xxx-X cell_line_M
cell xxx cell_line_M
line xxx cell_line_E
BASC XXXX cell_line_B
6C2 dXd cell_line_E
and xxx NE
from xxx NE
mouse xxx NE
lung xxx NE
tissue xxx NE
. . NE

The Xxx NE
ERP XXX protein
protein xxx NE
contains xxx NE
a x NE
region xxx NE
of xx NE
high xxx NE
homology xxx NE
with xxx NE
the xxx NE
ETS XXX NE
DNA-binding XXX-xxx NE
domain xxx NE
common xxx NE
to xx NE
all xxx NE
members xxx NE
of xx NE
the xxx NE
ets xxx protein_B
transcription xxx protein_M
factor/oncoprotein xxx/xxx protein_M
family xxx protein_E
. . NE

Three Xxxx NE
additional xxx NE
smaller xxx NE
regions xxx NE
show xxx NE
homology xxx NE
to xx NE
the xxx NE
ELK-1 XXX-d NE
and xxx NE
SAP-1 XXX-d protein
genes xxx NE
, , NE
a x NE
subgroup xxx NE
of xx NE
the xxx NE
ets xxx DNA_B
gene xxx DNA_M
family xxx DNA_E
that xxx NE
interacts xxx NE
with xxx NE
the xxx NE
serum xxx protein_B
response xxx protein_M
factor xxx protein_E
. . NE

Full-length Xxxx-xxx NE
ERP XXX protein
expresses xxx NE
only xxx NE
negligible xxx NE
DNA-binding XXX-xxx NE
activity xxx NE
by xx NE
itself xxx NE
. . NE

Removal Xxxx NE
of xx NE
the xxx NE
carboxy xxx protein_B
terminus xxx protein_E
enables xxx NE
ERP XXX protein
to xx NE
interact xxx NE
with xxx NE
a x NE
variety xxx NE
of xx NE
ets-binding xxx-xxx DNA_B
sites xxx DNA_E
including xxx NE
the xxx NE
E74 Xdd DNA_B
site xxx DNA_E
, , NE
the xxx NE
IgH XxX DNA_B
enhancer xxx DNA_M
pi xx DNA_M
site xxx DNA_E
, , NE
and xxx NE
the xxx NE
lck xxx DNA_B
promoter xxx DNA_M
ets xxx DNA_M
site xxx DNA_E
, , NE
suggesting xxx NE
a x NE
carboxy-terminal xxx-xxx protein_B
negative xxx protein_M
regulatory xxx protein_M
domain xxx protein_E
. . NE

At Xx NE
least xxx NE
three xxx NE
ERP XXX NE
-related -xxx NE
transcripts xxx NE
are xxx NE
expressed xxx NE
in xx NE
a x NE
variety xxx NE
of xx NE
tissues xxx NE
. . NE

However Xxxx NE
, , NE
within xxx NE
the xxx NE
B-cell X-xxx cell_type_B
lineage xxx cell_type_E
, , NE
ERP XXX protein
is xx NE
highly xxx NE
expressed xxx NE
primarily xxx NE
at xx NE
early xxx NE
stages xxx NE
of xx NE
B-lymphocyte X-xxx NE
development xxx NE
, , NE
and xxx NE
expression xxx NE
declines xxx NE
drastically xxx NE
upon xxx NE
B-cell X-xxx NE
maturation xxx NE
, , NE
correlating xxx NE
with xxx NE
the xxx NE
enhancer xxx NE
activity xxx NE
of xx NE
the xxx NE
IgH XxX DNA_B
pi xx DNA_M
site xxx DNA_E
. . NE

These Xxxx NE
data xxx NE
suggest xxx NE
that xxx NE
ERP XXX protein
might xxx NE
play xxx NE
a x NE
role xxx NE
in xx NE
B-cell X-xxx NE
development xxx NE
and xxx NE
in xx NE
IgH XxX NE
gene xxx NE
regulation xxx NE
. . NE

Gene Xxxx NE
for xxx NE
a x NE
tissue-specific xxx-xxx protein_B
transcriptional xxx protein_M
activator xxx protein_E
( ( NE
EBF XXX protein
or xx NE
Olf-1 Xxx-d protein
) ) NE
, , NE
expressed xxx NE
in xx NE
early xxx cell_type_B
B X cell_type_M
lymphocytes xxx cell_type_E
, , NE
adipocytes xxx cell_type
, , NE
and xxx NE
olfactory xxx cell_type_B
neurons xxx cell_type_E
, , NE
is xx NE
located xxx NE
on xx NE
human xxx DNA_B
chromosome xxx DNA_M
5 d DNA_E
, , NE
band xxx DNA_B
q34 xdd DNA_E
, , NE
and xxx NE
proximal xxx DNA_B
mouse xxx DNA_M
chromosome xxx DNA_M
11 dd DNA_E
. . NE

Murine Xxxx cell_type_B
B X cell_type_M
lymphocytes xxx cell_type_E
, , NE
adipocytes xxx cell_type
, , NE
and xxx NE
olfactory xxx cell_type_B
neurons xxx cell_type_E
contain xxx NE
a x NE
DNA-binding XXX-xxx protein_B
protein xxx protein_E
that xxx NE
participates xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
genes xxx DNA
encoding xxx NE
tissue-specific xxx-xxx NE
components xxx NE
of xx NE
signal xxx NE
transduction xxx NE
. . NE

Purification Xxxx NE
and xxx NE
cloning xxx NE
of xx NE
this xxx NE
protein xxx NE
, , NE
termed xxx NE
early xxx NE
B-cell X-xxx protein_B
factor xxx protein_E
( ( NE
EBF XXX protein
) ) NE
, , NE
from xxx NE
murine xxx cell_type_B
B X cell_type_M
lymphocytes xxx cell_type_E
and xxx NE
independent xxx NE
cloning xxx NE
of xx NE
a x NE
protein xxx NE
, , NE
termed xxx NE
Olf-1 Xxx-d protein
, , NE
from xxx NE
olfactory xxx cell_type_B
neuronal xxx cell_type_M
cells xxx cell_type_E
revealed xxx NE
virtual xxx NE
complete xxx NE
amino xxx protein_B
acid xxx protein_M
sequence xxx protein_E
identity xxx NE
between xxx NE
these xxx NE
proteins xxx NE
. . NE

As Xx NE
a x NE
first xxx NE
step xxx NE
towards xxx NE
identifying xxx NE
a x NE
human xxx NE
genetic xxx NE
disorder xxx NE
or xx NE
mouse xxx NE
mutation xxx NE
for xxx NE
which xxx NE
EBF XXX protein
could xxx NE
be xx NE
a x NE
candidate xxx NE
gene xxx NE
, , NE
we xx NE
have xxx NE
chromosomally xxx NE
mapped xxx NE
the xxx NE
corresponding xxx NE
locus xxx NE
in xx NE
both xxx NE
species xxx NE
. . NE

By Xx NE
Southern Xxxx NE
hybridization xxx NE
analyses xxx NE
of xx NE
somatic xxx NE
cell xxx NE
hybrid xxx NE
panels xxx NE
with xxx NE
murine xxx NE
cDNA xXXX NE
probe xxx NE
, , NE
fluorescence xxx NE
chromosomal xxx NE
in xx NE
situ xxx NE
hybridization xxx NE
( ( NE
FISH XXXX NE
) ) NE
of xx NE
human xxx NE
genomic xxx NE
clones xxx NE
, , NE
and xxx NE
analysis xxx NE
of xx NE
recombinant xxx NE
inbred xxx NE
mouse xxx NE
strains xxx NE
, , NE
we xx NE
have xxx NE
found xxx NE
single xxx NE
sites xxx NE
for xxx NE
EBF XXX NE
homologous xxx NE
sequences xxx NE
on xx NE
human xxx NE
Chromosome Xxxx NE
(Chr) (Xxx) NE
5 d NE
, , NE
band xxx NE
q34 xdd NE
, , NE
and xxx NE
on xx NE
proximal xxx NE
mouse xxx NE
Chr Xxx NE
11 dd NE
, , NE
in xx NE
an xx NE
evolutionarily xxx NE
conserved xxx NE
region xxx NE
. . NE

Calcineurin Xxxx protein
activates xxx NE
transcription xxx NE
from xxx NE
the xxx NE
GM-CSF XX-XXX DNA_B
promoter xxx DNA_E
in xx NE
synergy xxx NE
with xxx NE
either xxx NE
protein xxx protein_B
kinase xxx protein_M
C X protein_E
or xx NE
NF-kappa XX-xxx protein_B
B X protein_E
/AP-1 /XX-d NE
in xx NE
T X NE
cells xxx NE
. . NE

Two Xxx NE
cis-acting xxx-xxx DNA_B
elements xxx DNA_E
GM-kappa XX-xxx DNA_B
B/GC-box X/XX-xxx DNA_E
and xxx NE
CLE0 XXXd DNA
, , NE
of xx NE
the xxx NE
granulocyte-macrophage xxx-xxx NE
colony-stimulating xxx-xxx NE
factor xxx NE
( ( NE
GM-CSF XX-XXX NE
) ) NE
gene xxx NE
are xxx NE
required xxx NE
for xxx NE
maximal xxx NE
induction xxx NE
in xx NE
Jurkat Xxxx NE
T X NE
cells xxx NE
by xx NE
costimulation xxx NE
with xxx NE
phorbol-12-myristate xxx-dd-xxx NE
acetate xxx NE
( ( NE
PMA XXX NE
) ) NE
and xxx NE
Ca2+ Xxd+ NE
ionophore xxx NE
( ( NE
A23187 Xddddd NE
) ) NE
. . NE

The Xxx NE
GM-kappa XX-xxx DNA_B
B X DNA_M
sequence xxx DNA_E
is xx NE
recognized xxx NE
by xx NE
NF-kappa XX-xxx protein_B
B X protein_E
, , NE
which xxx NE
is xx NE
mainly xxx NE
induced xxx NE
by xx NE
PMA XXX NE
. . NE

The Xxx NE
CLE0 XXXd DNA_B
sequence xxx DNA_E
interacts xxx NE
with xxx NE
factors xxx NE
, , NE
related xxx NE
to xx NE
a x NE
PMA XXX NE
-induced -xxx NE
AP-1 XX-d NE
and xxx NE
a x NE
PMA XXX NE
/ / NE
A23187 Xddddd NE
-induced -xxx NE
NF-AT XX-XX NE
. . NE

We Xx NE
examined xxx NE
whether xxx NE
signal xxx NE
transducing xxx NE
components xxx NE
in xx NE
T X cell_type_B
cells xxx cell_type_E
can xxx NE
activate xxx NE
transcription xxx NE
of xx NE
the xxx NE
GM-CSF XX-XXX DNA_B
gene xxx DNA_E
. . NE

Cotransfection Xxxx NE
of xx NE
NF-kappa XX-xxx DNA_B
B X DNA_M
(p50/p65)- (xdd/xdd)- DNA_M
expression xxx DNA_M
vector xxx DNA_M
or xx DNA_M
AP-1 XX-d DNA_M
(c-Jun/c-Fos)- (x-Xxx/x-Xxx)- DNA_M
expression xxx DNA_M
vector xxx DNA_E
into xxx NE
Jurkat Xxxx cell_line_B
cells xxx cell_line_E
with xxx NE
a x NE
luciferase xxx DNA_B
reporter xxx DNA_E
containing xxx NE
the xxx NE
GM-CSF XX-XXX DNA_B
promoter xxx DNA_E
did xxx NE
not xxx NE
stimulate xxx NE
transcription xxx NE
from xxx NE
the xxx NE
GM-CSF XX-XXX DNA_B
promoter xxx DNA_E
. . NE

In Xx NE
contrast xxx NE
, , NE
cotransfection xxx NE
with xxx NE
a x NE
combination xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
and xxx NE
AP-1 XX-d protein
significantly xxx NE
augmented xxx NE
transcription xxx NE
from xxx NE
the xxx NE
GM-CSF XX-XXX DNA_B
promoter xxx DNA_E
containing xxx NE
the xxx NE
GM-kappa XX-xxx DNA_B
B/GC-box X/XX-xxx DNA_E
and xxx NE
the xxx NE
CLE0 XXXd DNA
( ( NE
AP-1 XX-d NE
/NF-AT /XX-XX NE
) ) NE
. . NE

Expression Xxxx NE
of xx NE
a x NE
constitutively xxx NE
active xxx NE
calcineurin xxx protein
( ( NE
CN XX protein
) ) NE
, , NE
a x NE
Ca2+ Xxd+ NE
/calmodulin-dependent /xxx-xxx NE
protein xxx NE
phosphatase xxx NE
, , NE
potentiated xxx NE
by xx NE
two xxx NE
fold xxx NE
the xxx NE
transcriptional xxx NE
activation xxx NE
by xx NE
NF-kappa XX-xxx NE
B X NE
/AP-1 /XX-d NE
. . NE

Both Xxxx NE
constitutively xxx NE
active xxx NE
forms xxx NE
of xx NE
CN XX protein
and xxx NE
protein xxx protein_B
kinase xxx protein_M
C X protein_E
( ( NE
PKC XXX protein
) ) NE
synergistically xxx NE
activated xxx NE
transcription xxx NE
from xxx NE
the xxx NE
GM-CSF XX-XXX DNA_B
promoter xxx DNA_E
. . NE

These Xxxx NE
results xxx NE
suggest xxx NE
that xxx NE
cooperation xxx NE
among xxx NE
NF-kappa XX-xxx DNA_B
B-binding X-xxx DNA_M
sequence xxx DNA_M
and xxx DNA_M
AP-1-binding XX-d-xxx DNA_M
sequence xxx DNA_M
and xxx DNA_M
NF-AT-binding XX-XX-xxx DNA_M
sequence xxx DNA_E
is xx NE
required xxx NE
for xxx NE
induction xxx NE
of xx NE
the xxx NE
GM-CSF XX-XXX DNA_B
gene xxx DNA_E
through xxx NE
PKC- XXX- NE
signaling xxx NE
pathway xxx NE
and xxx NE
Ca2+- Xxd+- NE
signaling xxx NE
pathway xxx NE

Nonpituitary Xxxx NE
human xxx NE
prolactin xxx NE
gene xxx NE
transcription xxx NE
is xx NE
independent xxx NE
of xx NE
Pit-1 Xxx-d protein
and xxx NE
differentially xxx NE
controlled xxx NE
in xx NE
lymphocytes xxx cell_type
and xxx NE
in xx NE
endometrial xxx NE
stroma xxx NE
. . NE

Expression Xxxx NE
of xx NE
the xxx NE
human xxx DNA_B
PRL XXX DNA_M
(hPRL) (xXXX) DNA_M
gene xxx DNA_E
in xx NE
extrapituitary xxx NE
sites xxx NE
such xxx NE
as xx NE
the xxx NE
uterus xxx NE
(decidualized (xxx NE
endometrial xxx NE
stroma xxx NE
and xxx NE
myometrium xxx NE
) ) NE
and xxx NE
cells xxx NE
of xx NE
the xxx NE
hematopoietic xxx cell_type_B
lineage xxx cell_type_E
is xx NE
directed xxx NE
by xx NE
an xx NE
alternative xxx DNA_B
promoter xxx DNA_E
which xxx NE
is xx NE
located xxx NE
approximately xxx NE
6 d DNA_B
kilobases xxx DNA_M
(kb) (xx) DNA_M
upstream xxx DNA_E
of xx NE
the xxx NE
pituitary-specific xxx-xxx DNA_B
start xxx DNA_M
site xxx DNA_E
. . NE

In Xx NE
order xxx NE
to xx NE
delineate xxx NE
the xxx NE
tissue-specific xxx-xxx NE
mechanisms xxx NE
governing xxx NE
the xxx NE
control xxx NE
of xx NE
nonpituitary xxx NE
PRL XXX NE
gene xxx NE
expression xxx NE
, , NE
we xx NE
have xxx NE
cloned xxx NE
and xxx NE
sequenced xxx NE
3 d DNA_B
kb xx DNA_M
5'-flanking d'-xxx DNA_M
DNA XXX DNA_E
of xx NE
the xxx NE
upstream xxx NE
decidual/lymphoid xxx/xxx DNA_B
(dPRL) (xXXX) DNA_M
promoter xxx DNA_E
. . NE

Based Xxxx NE
on xx NE
sequence xxx NE
homology xxx NE
we xx NE
identified xxx NE
two xxx NE
binding xxx DNA_B
motifs xxx DNA_E
for xxx NE
Pit-1 Xxx-d protein
and xxx NE
seven xxx NE
half-sites xxx-xxx DNA
for xxx NE
glucocorticoid xxx NE
receptor/progesterone xxx/xxx NE
receptor xxx NE
( ( NE
PR XX NE
) ) NE
binding xxx NE
. . NE

We Xx NE
focused xxx NE
our xxx NE
studies xxx NE
on xx NE
the xxx NE
role xxx NE
of xx NE
Pit-1 Xxx-d protein
and xxx NE
of xx NE
PR XX protein
as xx NE
potential xxx NE
transcriptional xxx NE
regulators xxx NE
, , NE
since xxx NE
the xxx NE
POU XXX protein_B
domain xxx protein_M
protein xxx protein_E
Pit-1 Xxx-d protein
is xx NE
essential xxx NE
in xx NE
the xxx NE
control xxx NE
of xx NE
pituitary xxx NE
PRL XXX NE
expression xxx NE
, , NE
and xxx NE
progesterone xxx NE
induces xxx NE
decidual xxx NE
transformation xxx NE
of xx NE
the xxx NE
endometrial xxx NE
stroma xxx NE
, , NE
a x NE
differentiation xxx NE
process xxx NE
during xxx NE
which xxx NE
the xxx NE
decidual xxx NE
PRL XXX DNA_B
gene xxx DNA_E
is xx NE
activated xxx NE
. . NE

We Xx NE
demonstrate xxx NE
in xx NE
a x NE
variety xxx NE
of xx NE
cell xxx NE
types xxx NE
, , NE
including xxx NE
lymphocytes xxx cell_type
and xxx NE
endometrial xxx NE
stroma xxx NE
, , NE
that xxx NE
Pit-1 Xxx-d protein
is xx NE
not xxx NE
involved xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
dPRL xXXX DNA_B
promoter/reporter xxx/xxx DNA_M
gene xxx DNA_M
constructs xxx DNA_E
carrying xxx NE
3 d DNA_B
kb xx DNA_M
5'-flanking d'-xxx DNA_M
DNA XXX DNA_E
. . NE

Our Xxx NE
experiments xxx NE
also xxx NE
show xxx NE
that xxx NE
activated xxx NE
PR XX protein
does xxx NE
not xxx NE
confer xxx NE
direct xxx NE
transcriptional xxx NE
control xxx NE
on xx NE
the xxx NE
dPRL xXXX DNA_B
promoter xxx DNA_E
. . NE

When Xxxx NE
we xx NE
compared xxx NE
the xxx NE
activity xxx NE
of xx NE
the xxx NE
transfected xxx NE
dPRL xXXX DNA_B
promoter xxx DNA_E
in xx NE
PRL-secreting XXX-xxx cell_type_B
lymphoid xxx cell_type_M
cell xxx cell_type_M
and xxx cell_type_M
PRL-nonsecreting XXX-xxx cell_type_M
lymphoid xxx cell_type_M
cell xxx cell_type_E
of xx NE
the xxx NE
dPRL xXXX DNA_B
promoter xxx DNA_E
did xxx NE
not xxx NE
contain xxx NE
elements xxx NE
restricting xxx NE
expression xxx NE
to xx NE
only xxx NE
those xxx NE
lymphocytes xxx cell_type
that xxx NE
produce xxx NE
PRL XXX NE
but xxx NE
allowed xxx NE
expression xxx NE
of xx NE
fusion xxx NE
reporter xxx NE
genes xxx NE
irrespective xxx NE
of xx NE
the xxx NE
status xxx NE
of xx NE
the xxx NE
endogenous xxx NE
PRL XXX DNA_B
gene xxx DNA_E
. . NE

This Xxxx NE
was xxx NE
in xx NE
sharp xxx NE
contrast xxx NE
to xx NE
endometrial xxx NE
cells xxx NE
where xxx NE
3 d NE
kb xx NE
5'-flanking d'-xxx NE
DNA XXX NE
conferred xxx NE
strong xxx NE
transcriptional xxx NE
activation xxx NE
on xx NE
the xxx NE
dPRL xXXX DNA_B
promoter xxx DNA_E
in xx NE
decidualized xxx NE
endometrial xxx cell_type_B
stromal xxx cell_type_M
cells xxx cell_type_E
actively xxx NE
secreting xxx NE
PRL XXX protein
, , NE
but xxx NE
did xxx NE
not xxx NE
allow xxx NE
transcription xxx NE
in xx NE
undifferentiated xxx NE
non-PRL-secreting xxx-XXX-xxx cell_type_B
endometrial xxx cell_type_M
stromal xxx cell_type_M
cells xxx cell_type_E
. . NE

Activation Xxxx NE
of xx NE
the xxx NE
dPRL xXXX DNA_B
promoter xxx DNA_E
construct xxx NE
in xx NE
these xxx NE
undifferentiated xxx NE
cells xxx NE
could xxx NE
however xxx NE
be xx NE
induced xxx NE
by xx NE
the xxx NE
addition xxx NE
of xx NE
cAMP xXXX NE
, , NE
in xx NE
the xxx NE
absence xxx NE
of xx NE
progesterone xxx NE
, , NE
suggesting xxx NE
that xxx NE
a x NE
signal xxx NE
transduced xxx NE
through xxx NE
the xxx NE
cAMP xXXX NE
signaling xxx NE
pathway xxx NE
is xx NE
a x NE
primary xxx NE
inducer xxx NE
of xx NE
decidual xxx NE
PRL XXX NE
gene xxx NE
expression xxx NE
. . NE

Signals Xxxx NE
and xxx NE
nuclear xxx protein_B
factors xxx protein_E
that xxx NE
regulate xxx NE
the xxx NE
expression xxx NE
of xx NE
interleukin-4 xxx-d DNA_B
gene xxx DNA_M
and xxx DNA_M
interleukin-5 xxx-d DNA_M
gene xxx DNA_E
helper xxx NE
T X NE
cells xxx NE
. . NE

Mouse Xxxx cell_line_B
thymoma xxx cell_line_M
line xxx cell_line_M
EL-4 XX-d cell_line_M
cells xxx cell_line_E
produce xxx NE
cytokines xxx protein
such xxx NE
as xx NE
interleukin xxx protein_B
(IL)-2 (XX)-d protein_E
, , NE
IL-3 XX-d protein
, , NE
IL-4 XX-d protein
, , NE
IL-10 XX-dd protein
, , NE
and xxx NE
granulocyte-macrophage xxx-xxx protein_B
colony-stimulating xxx-xxx protein_M
factor xxx protein_E
in xx NE
response xxx NE
to xx NE
phorbol xxx NE
12-myristate dd-xxx NE
13-acetate dd-xxx NE
( ( NE
PMA XXX NE
) ) NE
. . NE

EL-4 XX-d cell_line_B
cells xxx cell_line_E
also xxx NE
produce xxx NE
low xxx NE
levels xxx NE
of xx NE
IL-5 XX-d protein
when xxx NE
stimulated xxx NE
by xx NE
PMA XXX NE
alone xxx NE
; ; NE
however xxx NE
, , NE
cAMP xXXX NE
greatly xxx NE
augments xxx NE
PMA XXX NE
-dependent -xxx NE
IL-5 XX-d NE
production xxx NE
. . NE

A X NE
transient xxx NE
transfection xxx NE
assay xxx NE
revealed xxx NE
that xxx NE
two xxx NE
signals xxx NE
, , NE
PMA XXX NE
and xxx NE
cAMP xXXX NE
, , NE
are xxx NE
required xxx NE
for xxx NE
optimal xxx NE
activation xxx NE
of xx NE
the xxx NE
IL-5 XX-d DNA_B
promoter xxx DNA_E
. . NE

In Xx NE
contrast xxx NE
, , NE
cAMP xXXX NE
almost xxx NE
completely xxx NE
inhibited xxx NE
the xxx NE
PMA XXX NE
-dependent -xxx NE
activation xxx NE
of xx NE
the xxx NE
endogenous xxx DNA_B
IL-2 XX-d DNA_M
gene xxx DNA_E
, , NE
as xx NE
well xxx NE
as xx NE
the xxx NE
transfected xxx NE
IL-2 XX-d DNA_B
promoter xxx DNA_E
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
the xxx NE
IL-5 XX-d DNA_B
gene xxx DNA_E
is xx NE
positively xxx NE
regulated xxx NE
by xx NE
cAMP xXXX NE
in xx NE
a x NE
manner xxx NE
opposite xxx NE
to xx NE
that xxx NE
for xxx NE
the xxx NE
IL-2 XX-d DNA_B
gene xxx DNA_E
. . NE

One Xxx NE
of xx NE
the xxx NE
nuclear xxx protein_B
factors xxx protein_E
( ( NE
NFs XXx protein
) ) NE
that xxx NE
regulates xxx NE
the xxx NE
response xxx NE
of xx NE
the xxx NE
IL-5 XX-d DNA_B
promoter xxx DNA_E
to xx NE
cAMP xXXX NE
and xxx NE
PMA XXX NE
has xxx NE
properties xxx NE
similar xxx NE
to xx NE
NF XX protein
for xxx NE
activated xxx cell_type_B
t x cell_type_M
cell xxx cell_type_E
. . NE

NF XX DNA_B
kappa xxx DNA_M
B X DNA_M
binding xxx DNA_M
site xxx DNA_M
and xxx DNA_M
the xxx DNA_M
NF-activated XX-xxx DNA_M
T X DNA_M
cell xxx DNA_M
binding xxx DNA_M
site xxx DNA_E
P X NE
sequence xxx NE
of xx NE
the xxx NE
IL-4 XX-d DNA_B
gene xxx DNA_E
, , NE
defined xxx NE
as xx NE
a x NE
responsive xxx DNA_B
element xxx DNA_E
for xxx NE
PMA XXX NE
and xxx NE
calcium xxx NE
ionophore xxx NE
( ( NE
A23187 Xddddd NE
) ) NE
, , NE
shares xxx NE
sequence xxx NE
similarity xxx NE
with xxx NE
the xxx NE
NF XX NE
kappa xxx NE
B X NE
and xxx NE
the xxx NE
NF-activated XX-xxx NE
T X NE
cell xxx NE
binding xxx NE
sites xxx NE
. . NE

We Xx NE
attempted xxx NE
to xx NE
determine xxx NE
whether xxx NE
NF(P) XX(X) protein
, , NE
a x NE
nuclear xxx NE
factor xxx NE
specific xxx NE
for xxx NE
the xxx NE
P X DNA_B
sequence xxx DNA_E
, , NE
is xx NE
related xxx NE
to xx NE
NF-kappa XX-xxx protein_B
B X protein_E
and xxx NE
nuclear xxx protein_B
factor xxx protein_M
for xxx protein_M
activated xxx protein_M
T X protein_M
cell xxx protein_E
( ( NE
NF-AT XX-XX protein
) ) NE
. . NE

In Xx NE
electromobility xxx NE
shift xxx NE
assays xxx NE
both xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
( ( NE
P65 Xdd protein
or xx NE
P65/P50 Xdd/Xdd protein_B
heterodimer xxx protein_E
) ) NE
and xxx NE
NF-AT XX-XX protein
bound xxx NE
to xx NE
the xxx NE
P X DNA_B
sequence xxx DNA_E
. . NE

However Xxxx NE
, , NE
sequence xxx NE
specificity xxx NE
of xx NE
NF-AT XX-XX protein
was xxx NE
more xxx NE
similar xxx NE
to xx NE
that xxx NE
of xx NE
NF(P) XX(X) protein
, , NE
and xxx NE
only xxx NE
a x NE
small xxx NE
amount xxx NE
of xx NE
P65 Xdd protein
was xxx NE
detected xxx NE
in xx NE
NF(P) XX(X) protein
. . NE

These Xxxx NE
results xxx NE
indicate xxx NE
that xxx NE
a x NE
component xxx NE
or xx NE
components xxx NE
of xx NE
NF-AT XX-XX protein
have xxx NE
the xxx NE
potential xxx NE
to xx NE
reconstitute xxx NE
NF(P) XX(X) protein
, , NE
whereas xxx NE
NF-kappa XX-xxx protein_B
B X protein_E
alone xxx NE
does xxx NE
not xxx NE
account xxx NE
for xxx NE
NF(P) XX(X) protein
in xx NE
Jurkat Xxxx NE
crude xxx NE
extract xxx NE
. . NE

Taken Xxxx NE
together xxx NE
, , NE
these xxx NE
results xxx NE
suggest xxx NE
that xxx NE
NF-AT-like XX-XX-xxx protein_B
factors xxx protein_E
are xxx NE
involved xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
IL-4 XX-d DNA_B
gene xxx DNA_M
and xxx DNA_M
IL-5 XX-d DNA_M
gene xxx DNA_E

Solution Xxxx NE
structure xxx NE
of xx NE
a x NE
POU-specific XXX-xxx protein_B
homeodomain xxx protein_E
: : NE
3D-NMR dX-XXX NE
studies xxx NE
of xx NE
human xxx NE
B-cell X-xxx NE
transcription xxx NE
factor xxx NE
Oct-2 Xxx-d NE
. . NE

The Xxx NE
POU XXX protein_B
DNA-binding XXX-xxx protein_M
motif xxx protein_E
defines xxx NE
a x NE
conserved xxx NE
family xxx NE
of xx NE
eukaryotic xxx protein_B
transcription xxx protein_M
factors xxx protein_E
involved xxx NE
in xx NE
regulation xxx NE
of xx NE
gene xxx NE
expression xxx NE
. . NE

This Xxxx NE
bipartite xxx protein_B
motif xxx protein_E
consists xxx NE
of xx NE
an xx NE
N-terminal X-xxx protein_B
POU-specific XXX-xxx protein_M
domain xxx protein_E
( ( NE
POUs XXXx protein
) ) NE
, , NE
a x NE
flexible xxx protein_B
linker xxx protein_E
, , NE
and xxx NE
a x NE
C-terminal X-xxx protein_B
POU-specific XXX-xxx protein_M
homeodomain xxx protein_E
( ( NE
POUHD XXXXX protein
) ) NE
. . NE

Here Xxxx NE
we xx NE
describe xxx NE
the xxx NE
solution xxx NE
structure xxx NE
of xx NE
a x NE
POU-specific XXX-xxx protein_B
homeodomain xxx protein_E
. . NE

An Xx NE
NMR XXX NE
model xxx NE
is xx NE
obtained xxx NE
from xxx NE
Oct-2 Xxx-d protein
, , NE
a x NE
human xxx protein_B
B-cell X-xxx protein_M
specific xxx protein_M
transcription xxx protein_M
factor xxx protein_E
which xxx NE
participates xxx NE
in xx NE
the xxx NE
regulation xxx NE
of xx NE
immunoglobulin xxx DNA_B
genes xxx DNA_E
. . NE

A X NE
fragment xxx NE
of xx NE
Oct-2 Xxx-d protein
containing xxx NE
POUHD XXXXX protein
and xxx NE
an xx NE
adjoining xxx NE
linker xxx NE
was xxx NE
expressed xxx NE
in xx NE
Escherichia Xxxx NE
coli xxx NE
and xxx NE
characterized xxx NE
by xx NE
three-dimensional xxx-xxx NE
nuclear xxx NE
magnetic xxx NE
resonance xxx NE
( ( NE
3D-NMR dX-XXX NE
) ) NE
spectroscopy xxx NE
. . NE

Complete Xxxx NE
1H dX NE
and xxx NE
15N ddX NE
resonance xxx NE
assignment xxx NE
of xx NE
the xxx NE
POUHD XXXXX protein_B
moiety xxx protein_E
is xx NE
presented xxx NE
. . NE

The Xxx NE
POUHD XXXXX NE
solution xxx NE
structure xxx NE
, , NE
as xx NE
calculated xxx NE
by xx NE
distance xxx NE
geometry xxx NE
and xxx NE
simulated xxx NE
annealing xxx NE
( ( NE
DG/SA XX/XX NE
) ) NE
, , NE
is xx NE
similar xxx NE
to xx NE
that xxx NE
of xx NE
canonical xxx protein_B
homeodomains xxx protein_E
. . NE

A X NE
salient xxx NE
difference xxx NE
between xxx NE
solution xxx protein_B
structure xxx protein_M
and xxx protein_M
crystal xxx protein_M
structure xxx protein_E
is xx NE
observed xxx NE
in xx NE
the xxx NE
C-terminal X-xxx protein_B
segment xxx protein_E
of xx NE
alpha-helix xxx-xxx protein_B
3 d protein_E
(the (xxx NE
HTH XXX protein_B
recognition xxx protein_M
helix xxx protein_E
) ) NE
, , NE
which xxx NE
is xx NE
not xxx NE
well xxx NE
ordered xxx NE
in xx NE
solution xxx NE
. . NE

Because Xxxx NE
this xxx NE
segment xxx NE
presumably xxx NE
folds xxx NE
upon xxx NE
specific xxx NE
DNA XXX NE
binding xxx NE
, , NE
its xxx NE
flexibility xxx NE
in xx NE
solution xxx NE
may xxx NE
reduce xxx NE
the xxx NE
intrinsic xxx NE
DNA XXX NE
affinity xxx NE
of xx NE
POUHD XXXXX protein
in xx NE
the xxx NE
absence xxx NE
of xx NE
POUs XXXx protein
. . NE

NF-kappa XX-xxx NE
B-dependent X-xxx NE
pathway xxx NE
and xxx NE
NF-kappa XX-xxx NE
B-independent X-xxx NE
pathway xxx NE
of xx NE
HIV XXX NE
activation xxx NE
in xx NE
a x NE
chronically xxx cell_line_B
infected xxx cell_line_M
T X cell_line_M
cell xxx cell_line_M
line xxx cell_line_E
. . NE

J X cell_line_B
delta xxx cell_line_M
K X cell_line_M
cells xxx cell_line_E
were xxx NE
isolated xxx NE
as xx NE
a x NE
chronically xxx cell_line_B
infected xxx cell_line_M
survivor xxx cell_line_M
cell xxx cell_line_M
line xxx cell_line_E
, , NE
following xxx NE
infection xxx NE
of xx NE
Jurkat Xxxx cell_line_B
CD4+ XXd+ cell_line_M
T X cell_line_M
cells xxx cell_line_E
with xxx NE
dl-NF xx-XX NE
, , NE
a x NE
mutated xxx NE
strain xxx NE
of xx NE
human xxx NE
immunodeficiency xxx NE
virus xxx NE
type xxx NE
1 d NE
( ( NE
HIV-1 XXX-d NE
) ) NE
containing xxx NE
a x NE
deletion xxx NE
of xx NE
the xxx NE
long xxx DNA_B
terminal xxx DNA_M
repeat xxx DNA_E
( ( NE
LTR XXX DNA
) ) NE
NF-kappa XX-xxx protein_B
B X protein_E
sites xxx NE
. . NE

J X cell_line_B
delta xxx cell_line_M
K X cell_line_M
cells xxx cell_line_E
exhibited xxx NE
very xxx NE
low xxx NE
levels xxx NE
of xx NE
constitutive xxx NE
HIV XXX NE
production xxx NE
. . NE

HIV-1 XXX-d NE
expression xxx NE
was xxx NE
activated xxx NE
from xxx NE
J X cell_line_B
delta xxx cell_line_M
K X cell_line_M
cells xxx cell_line_E
by xx NE
treatment xxx NE
with xxx NE
phorbol xxx NE
myristate xxx NE
acetate xxx NE
( ( NE
PMA XXX NE
) ) NE
, , NE
sodium xxx NE
butyrate xxx NE
( ( NE
NaB XxX NE
) ) NE
, , NE
or xx NE
hexamethylene xxx NE
bisacetamide xxx NE
( ( NE
HMBA XXXX NE
) ) NE
, , NE
but xxx NE
not xxx NE
tumor xxx protein_B
necrosis xxx protein_M
factor xxx protein_M
alpha xxx protein_E
( ( NE
TNF-alpha XXX-xxx protein
) ) NE
, , NE
confirming xxx NE
the xxx NE
role xxx NE
of xx NE
NF-kappa XX-xxx protein_B
B X protein_E
in xx NE
mediating xxx NE
TNF-alpha XXX-xxx protein
induction xxx NE
of xx NE
HIV XXX NE
transcription xxx NE
. . NE

The Xxx NE
strong xxx NE
induction xxx NE
of xx NE
HIV XXX NE
expression xxx NE
by xx NE
NaB XxX NE
or xx NE
HMBA XXXX NE
in xx NE
J X cell_line_B
delta xxx cell_line_M
K X cell_line_M
cells xxx cell_line_E
clearly xxx NE
demonstrates xxx NE
the xxx NE
existence xxx NE
of xx NE
NF-kappa XX-xxx NE
B X NE
-independent -xxx NE
mechanisms xxx NE
of xx NE
HIV XXX NE
activation xxx NE
in xx NE
chronically xxx NE
infected xxx NE
cells xxx NE
. . NE

J X cell_line_B
delta xxx cell_line_M
K X cell_line_M
cells xxx cell_line_E
may xxx NE
provide xxx NE
a x NE
useful xxx NE
model xxx NE
for xxx NE
characterizing xxx NE
NF-kappa XX-xxx NE
B X NE
-independent -xxx NE
transcriptional xxx NE
activation xxx NE
of xx NE
the xxx NE
HIV XXX NE
LTR XXX NE
. . NE

JNK XXX protein
is xx NE
involved xxx NE
in xx NE
signal xxx NE
integration xxx NE
during xxx NE
costimulation xxx NE
of xx NE
T X cell_type_B
lymphocytes xxx cell_type_E
. . NE

T X NE
lymphocyte xxx NE
activation xxx NE
and xxx NE
interleukin-2 xxx-d NE
( ( NE
IL-2 XX-d NE
) ) NE
production xxx NE
require xxx NE
at xx NE
least xxx NE
two xxx NE
signals xxx NE
, , NE
generated xxx NE
by xx NE
phorbol xxx NE
ester xxx NE
( ( NE
TPA XXX NE
) ) NE
and xxx NE
Ca2+ Xxd+ NE
ionophore xxx NE
or xx NE
costimulation xxx NE
of xx NE
the xxx NE
T X NE
cell xxx NE
receptor xxx NE
( ( NE
TCR XXX NE
) ) NE
and xxx NE
the xxx NE
CD28 XXdd NE
auxiliary xxx NE
receptor xxx NE
. . NE

We Xx NE
investigated xxx NE
how xxx NE
these xxx NE
stimuli xxx NE
affect xxx NE
mitogen xxx protein_B
activated xxx protein_M
protein xxx protein_M
(MAP) (XXX) protein_M
kinases xxx protein_E
. . NE

Full Xxxx NE
activation xxx NE
of xx NE
the xxx NE
MAP XXX protein_B
kinases xxx protein_E
that xxx NE
phosphorylate xxx NE
the xxx NE
Jun Xxx protein_B
activation xxx protein_M
domain xxx protein_E
, , NE
JNK1 XXXd protein
and xxx NE
JNK2 XXXd protein
, , NE
required xxx NE
costimulation xxx NE
of xx NE
T X cell_type_B
cells xxx cell_type_E
with xxx NE
either xxx NE
TPA XXX NE
and xxx NE
Ca2+ Xxd+ NE
ionophore xxx NE
or xx NE
antibodies xxx NE
to xx NE
TCR XXX protein
and xxx NE
CD28 XXdd protein
. . NE

Alone Xxxx NE
, , NE
each xxx NE
stimulus xxx NE
resulted xxx NE
in xx NE
little xxx NE
or xx NE
no xx NE
activation xxx NE
. . NE

Similar Xxxx NE
to xx NE
its xxx NE
effect xxx NE
on xx NE
IL-2 XX-d NE
induction xxx NE
, , NE
cyclosporin xxx NE
A X NE
( ( NE
CsA XxX NE
) ) NE
inhibited xxx NE
the xxx NE
synergistic xxx NE
activation xxx NE
of xx NE
JNK XXX protein
, , NE
and xxx NE
a x NE
competitive xxx NE
inhibitor xxx NE
of xx NE
Jun Xxx NE
phosphorylation xxx NE
by xx NE
JNK XXX protein
inhibited xxx NE
IL-2 XX-d NE
promoter xxx NE
activation xxx NE
. . NE

